<SEC-DOCUMENT>0001493152-20-015690.txt : 20200814
<SEC-HEADER>0001493152-20-015690.hdr.sgml : 20200814
<ACCEPTANCE-DATETIME>20200814084407
ACCESSION NUMBER:		0001493152-20-015690
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200814
DATE AS OF CHANGE:		20200814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celsion CORP
		CENTRAL INDEX KEY:			0000749647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				521256615
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15911
		FILM NUMBER:		201101577

	BUSINESS ADDRESS:	
		STREET 1:		997 LENOX DRIVE
		STREET 2:		SUITE 100
		CITY:			LAWRENCEVILLE
		STATE:			NJ
		ZIP:			08648
		BUSINESS PHONE:		(609) 896-9100

	MAIL ADDRESS:	
		STREET 1:		997 LENOX DRIVE
		STREET 2:		SUITE 100
		CITY:			LAWRENCEVILLE
		STATE:			NJ
		ZIP:			08648

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CELSION CORP
		DATE OF NAME CHANGE:	19980515

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEUNG LABORATORIES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUARTERLY
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the quarterly period ended June 30, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-15911</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>52-1256615</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                         or other jurisdiction of</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
        or organization)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                         Employer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
        Number)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>997
Lenox Drive, Suite 100,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lawrenceville</B>,
<B>NJ 08648</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(609)
896-9100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&rsquo;s
telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    symbol(s)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
                                         of each exchange on</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">which
        registered</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, par value $0.01 per share</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLSN</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports)
and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). Yes [X] No [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo;,
&ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act (Check One):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer [&nbsp;&nbsp;]</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company [X]</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [&nbsp;&nbsp;] No [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 13, 2020, Celsion Corporation had 33,232,380 shares of common stock, $0.01 par value per share, outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUARTERLY
REPORT ON</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page(s)</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_001">PART I: FINANCIAL INFORMATION</A></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Financial Statements (Unaudited)</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Condensed Consolidated Balance Sheets</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Condensed Consolidated Statements of Operations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Condensed Consolidated Statements of Comprehensive Loss</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Condensed Consolidated Statements of Cash Flows</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Condensed Consolidated Statements of Changes in Stockholders&rsquo; Equity</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Notes to the Condensed Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#B_001">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#B_002">Quantitative and Qualitative Disclosures about Market Risk</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">42</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#B_003">Controls and Procedures</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">42</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#B_004">PART II: OTHER INFORMATION</A></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#B_005">Legal Proceedings</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#B_006">Risk Factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">43</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#B_007">Unregistered Sales of Equity Securities and Use of Proceeds</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">66</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#B_008">Defaults Upon Senior Securities</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">67</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#B_009">Mine Safety Disclosures</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">67</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#B_010">Other Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">67</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#B_011">Exhibits</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">67</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#B_012">SIGNATURES</A></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report includes &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are
&ldquo;forward-looking statements&rdquo; for purposes of this Quarterly Report on Form 10-Q, including, without limitation, any
projections of earnings, revenue or other financial items, any statements of the plans and objectives of management for future
operations (including, but not limited to, pre-clinical development, clinical trials, manufacturing and commercialization), uncertainties
and assumptions regarding the impact of the COVID-19 pandemic on our business, operations, clinical trials, supply chain, strategy,
goals and anticipated timelines, any statements concerning proposed drug candidates, potential therapeutic benefits, or other
new products or services, any statements regarding future economic conditions or performance, any changes in the course of research
and development activities and in clinical trials, any possible changes in cost and timing of development and testing, capital
structure, financial condition, working capital needs and other financial items, any changes in approaches to medical treatment,
any introduction of new products by others, any possible licenses or acquisitions of other technologies, assets or businesses,
our ability to realize the full extent of the anticipated benefits of our acquisition of the assets of EGEN, Inc., including achieving
operational cost savings and synergies in light of any delays we may encounter in the integration process and additional unforeseen
expenses, any possible actions by customers, suppliers, partners, competitors and regulatory authorities, compliance with listing
standards of The Nasdaq Capital Market and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking
statements can be identified by the use of terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;estimates,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue,&rdquo; or the negative thereof
or other comparable terminology. Although we believe that our expectations are based on reasonable assumptions within the bounds
of our knowledge of our industry, business and operations, we cannot guarantee that actual results will not differ materially
from our expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks
and uncertainties, including, but not limited to, the risk factors set forth in Part II, Item 1A &ldquo;Risk Factors&rdquo; below
and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why
results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements,
except as required by law or applicable regulations. The discussion of risks and uncertainties set forth in this Quarterly Report
on Form 10-Q is not necessarily a complete or exhaustive list of all risks facing us at any particular point in time. We operate
in a highly competitive, highly regulated and rapidly changing environment and our business is in a state of evolution. Therefore,
it is likely that new risks will emerge, and that the nature and elements of existing risks will change, over time. It is not
possible for management to predict all such risk factors or changes therein, or to assess either the impact of all such risk factors
on our business or the extent to which any individual risk factor, combination of factors, or new or altered factors, may cause
results to differ materially from those contained in any forward-looking statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
where the context otherwise requires, in this Quarterly Report on Form 10-Q, the &ldquo;Company,&rdquo; &ldquo;Celsion,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to Celsion Corporation, a Delaware corporation and its wholly-owned
subsidiary CLSN Laboratories, Inc., also a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trademarks</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Celsion brand and product names, including but not limited to Celsion<SUP>&reg;</SUP> and ThermoDox<SUP>&reg;</SUP> contained
in this document are trademarks, registered trademarks or service marks of Celsion Corporation or its subsidiary in the United
States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies
that are the property of their respective owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>PART
I: FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_002"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
1. FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_003"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BALANCE
SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left; padding-left: 20pt">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">22,653,760</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">6,875,273</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Investment in debt securities - available for sale, at fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,791,868</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,985,886</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Accrued interest receivable on investment securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,369</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Advances and deposits on clinical programs and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,342,566</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,352,670</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Total current assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">26,796,060</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,235,198</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property
                                                                               and equipment (at cost, less accumulated depreciation of $3,174,681 and $3,096,681, respectively)</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">339,200</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">405,363</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Other assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Deferred tax asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,819,324</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">In-process research and development, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,736,491</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,736,491</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,976,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,976,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Operating lease right-of-use assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,244,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,431,640</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Other intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">227,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">340,976</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Deposits and other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">403,482</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">333,274</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Total other assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">19,587,700</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21,637,806</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">46,722,960</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">38,278,367</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
accompanying notes to the condensed consolidated financial statements</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BALANCE
SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left; padding-left: 20pt">Accounts payable &#9472; trade</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">2,402,142</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">2,862,949</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Other accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,507,683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,303,547</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Notes payable &ndash; current portion, net of deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,385,915</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,840,228</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Operating lease liability - current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">410,005</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">387,733</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Deferred revenue - current portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 30pt">Total current liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">9,205,745</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">7,894,457</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Earn-out milestone liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,015,279</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,717,709</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Note payable, net of deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,610,555</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,963,449</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Operating lease liability - non-current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">933,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,143,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Deferred revenue - non-current portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">750,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Total liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">22,514,798</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">23,719,332</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Preferred stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at June 30, 2020 and December 31, 2019)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Common stock - $0.01 par value (112,500,000 shares authorized; 33,229,714 and 23,256,152 shares issued at June 30, 2020 and December 31, 2019, respectively, and 33,229,380 and 23,255,818 shares outstanding at June 30, 2020 and December 31, 2019, respectively)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">332,297</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">232,562</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">324,869,780</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">304,885,663</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Accumulated other comprehensive gain</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,778</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(300,916,593</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(290,516,780</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 30pt">Total stockholders&rsquo; equity before treasury stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">24,293,350</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">14,644,223</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt">Treasury stock, at cost (334 shares at June 30, 2020 and December 31, 2019)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(85,188</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(85,188</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Total stockholders&rsquo; equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">24,208,162</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">14,559,035</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">46,722,960</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">38,278,367</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
accompanying notes to the condensed consolidated financial statements</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Licensing revenue</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">125,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">125,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">250,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">250,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,990,861</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,558,074</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,042,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,325,733</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,901,136</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,136,684</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,740,042</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,354,548</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,891,997</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,694,758</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,782,952</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,680,281</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,766,997</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,569,758</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,532,952</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,430,281</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other (expense) income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">(Loss) gain from change in valuation of earn-out milestone liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(256,296</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(127,061</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(297,570</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,002,939</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(400,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Investment income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109,269</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">258,393</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(340,602</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(349,448</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(679,967</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(700,195</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other (expense) income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,850</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,407</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total other (expense) income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(575,938</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(334,757</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(866,861</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,158,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,342,935</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,904,515</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,399,813</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,271,967</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss per common share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"> Basic
    and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.37</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.42</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Weighted average shares
    outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"> Basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,887,329</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,605,762</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,830,573</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,713,449</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
accompanying notes to the condensed consolidated financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF COMPREHENSIVE LOSS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive (loss) gain</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Changes in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; text-align: left">Realized (gains) losses on investment securities recognized in investment income, net</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(2,865</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(969</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(46,097</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(10,350</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Unrealized gains on investment securities, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,918</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,721</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,185</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">75,054</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in unrealized gains (losses) on available for sale securities, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,053</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,752</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(34,912</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,704</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,342,935</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,904,515</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,399,813</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,271,967</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,338,882</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,896,763</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,434,725</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,207,263</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
accompanying notes to the condensed consolidated financial statements</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(10,399,813</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(8,271,967</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">378,990</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">362,027</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of earn-out milestone liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">297,570</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,002,939</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify">Fair value of warrants issued in connection with amendment to modify <BR>the GEN-1 earn-out milestone payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Recognition of deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(250,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(250,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Stock-based compensation costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,030,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,308,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Shares issued in exchange for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred income tax asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,819,324</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">&nbsp;Amortization of deferred finance charges and debt discount associated with notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,793</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191,724</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Net changes in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Accrued interest on investment securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,503</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,636</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Advances, deposits and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(60,104</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(931,654</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(946,265</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,460</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash (used in) operating activities:</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(7,923,276</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,161,871</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Purchases of investment securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,940,894</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,279,686</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from sale and maturity of investment securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,900,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,837</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(262,728</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) investing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,147,269</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,642,414</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from sale of common stock equity, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,182,599</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,464,060</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock upon conversion of stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">371,895</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from Payroll Protection Program (PPP) loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,324,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Repayments on Payroll Protection Program (PPP) loans</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,324,750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">18,554,494</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> 4,464,060 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Increase (decrease) in cash and cash equivalents</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">15,778,487</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(7,340,225</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,875,273</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,353,543</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">22,653,760</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,013,318</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
accompanying notes to the condensed consolidated financial statements</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF CASH FLOWS (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Six Months Ended June 30,</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 64%; text-align: left; padding-left: 10pt">Interest paid</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(487,174</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(508,471</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for amounts included in measurement of lease liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Operating cash flows from lease payments</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">262,084</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">224,585</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-cash financing and investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">400,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Right of use assets obtained in exchange for lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Right of use assets</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &#9472;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,797,561</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Stock issued in lieu of cash bonus payments</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">498,632</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &#9472;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Realized and unrealized (gains) losses, net, on investment securities</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(34,912</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">64,704</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
accompanying notes to the condensed consolidated financial statements</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THREE
MONTHS ENDED JUNE 30, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> <B>Three Months Ended</B> </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paid in</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Treasury Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated Other Comprehensive</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"> <B>June 30, 2020</B> </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left"><B>Balance at April 1, 2020</B></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">29,257,101</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">292,574</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">311,570,995</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">334</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(85,188</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">3,813</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(295,573,658</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">16,208,536</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,342,935</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,342,935</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sale of equity through financing facilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,831,415</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,314</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,349,538</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,387,852</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of common stock upon exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,864</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,409</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">370,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">371,895</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Realized and unrealized gains and losses, net, on investments securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,053</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,053</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Stock-based compensation expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">578,761</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">578,761</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><B>Balance at June 30, 2020</B></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">33,229,380</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">332,297</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">324,869,780</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">334</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(85,188</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,866</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(300,916,593</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">24,208,162</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THREE
MONTHS ENDED JUNE 30, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three
                                         Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
                                         Stock</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paid
                                         in</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><B>Treasury Stock</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><B>Accumulated Other Comprehensive</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><B>Accumulated</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>June 30, 2019</B></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-weight: bold; text-align: left">Balance at April 1, 2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">19,662,020</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">196,624</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">297,231,041</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">334</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(85,188</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">86,824</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(276,032,699</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">21,396,602</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,904,515</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,904,515</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sale of equity through financing facilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,337,775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,695,798</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,709,176</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Realized and unrealized gains and losses, net, on investments securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,752</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,752</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">617,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">617,347</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Issuance of restricted stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,325</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,349</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><B>Balance at June 30, 2019</B></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,002,295</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">210,026</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">300,549,511</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">334</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(85,188</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">94,576</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(281,937,214</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,831,711</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
accompanying notes to the condensed consolidated financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_010"></A>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIX
MONTHS ENDED JUNE 30, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> <B>Six Months Ended</B> </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paid in</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Treasury Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated Other Comprehensive</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"> <B>June 30, 2020</B> </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 28%; font-weight: bold">Balance at January 1, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">23,255,818</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">232,562</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">304,885,663</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">334</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(85,188</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">42,778</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(290,516,780</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">14,559,035</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> (10,399,813 </TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> (10,399,813 </TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sale of equity through financing facilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,402,843</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94,027</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,088,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,182,599</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of common stock upon exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,864</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,409</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">370,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">371,895</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Realized and unrealized gains and losses, net, on investments securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(34,912</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(34,912</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,030,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,030,726</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Issuance of common stock in lieu of cash bonus</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">429,855</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,299</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">494,333</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">498,632</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Balance at June 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">33,229,380</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">332,297</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">324,869,780</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">334</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(85,188</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,866</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(300,916,593</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">24,208,162</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIX
MONTHS ENDED JUNE 30, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0"> <B>Six
                                 Months Ended</B> </P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paid in</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Treasury Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated Other Comprehensive</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"> <B>June 30, 2019</B> </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 28%; font-weight: bold">Balance at January 1, 2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">18,831,834</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">188,322</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">294,393,313</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">334</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(85,188</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">29,872</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(273,665,247</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">20,861,072</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,271,967</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,271,967</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sale of equity through financing facilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,159,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,599</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,442,461</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,464,060</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Realized and unrealized gains and losses, net, on investments securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,704</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,704</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,308,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,308,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Issuance of restricted stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">105</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,245</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,350</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Balance at June 30, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,002,295</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">210,026</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">300,549,511</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">334</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(85,188</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">94,576</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(281,937,214</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,831,711</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
accompanying notes to the condensed consolidated financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_011"></A>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO THE CONDENSED CONSOLIDATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(UNAUDITED)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
1. Business Description</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celsion
Corporation (&ldquo;Celsion&rdquo; and the &ldquo;Company&rdquo;) is a fully integrated development stage oncology drug company
focused on advancing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy
and RNA based therapies. Celsion is a fully integrated oncology company focused on developing a portfolio of innovative cancer
treatments, including immunotherapies, DNA-based therapies and directed chemotherapies. The Company&rsquo;s product pipeline includes
GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer and ThermoDox&reg;, a proprietary heat-activated
liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development
for other cancer indications. Celsion has two feasibility stage platform technologies for the development of novel nucleic acid-based
immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability
in nucleic acid cellular transfection.With these technologies we are working to develop and commercialize more efficient, effective
and targeted oncology therapies that maximize efficacy while minimizing side-effects common to cancer treatments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2. Basis of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly owned
subsidiary, CLSN Laboratories, Inc, have been prepared in accordance with generally accepted accounting principles in the United
States (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. All significant
intercompany balances and transactions have been eliminated in consolidation. Certain information and disclosures normally included
in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation,
have been included in the accompanying unaudited condensed consolidated financial statements. Operating results for the three-month
and six-month periods ended June 30, 2020 and 2019 are not necessarily indicative of the results that may be expected for any
other interim period(s) or for any full year. For further information, refer to the financial statements and notes thereto included
in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange
Commission (SEC) on March 25, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions
that affect the amounts reported in the Company&rsquo;s financial statements and accompanying notes. Actual results could differ
materially from those estimates. Events and conditions arising subsequent to the most recent balance sheet date have been evaluated
for their possible impact on the financial statements and accompanying notes. With the recent introduction of the COVID-19 pandemic
to the United States, the Company continues to monitor the impact of this pandemic on its financial condition and results of operations,
along with the valuation of its long-term assets, intangible assets, and goodwill. The effect of this matter could potentially
have an impact on the valuation of such assets in the future. The COVID-19 matter is discussed in more detail in Note 3 to the
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
3. Financial Condition and Business Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company&rsquo;s
research and development programs, clinical trials conducted in connection with the Company&rsquo;s product candidates, and applications
and submissions to the U.S. Food and Drug Administration. The Company has not generated significant revenue and has incurred significant
net losses in each year since our inception. As of June 30, 2020, the Company has incurred approximately $301 million of cumulative
net losses and we had approximately $25.5 million in cash, investment securities, and interest receivable. We have substantial
future capital requirements to continue our research and development activities and advance our product candidates through various
development stages. The Company believes these expenditures are essential for the commercialization of its technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects its operating losses to continue for the foreseeable future as it continues its product development efforts, and
when it undertakes marketing and sales activities. The Company&rsquo;s ability to achieve profitability is dependent upon its
ability to obtain governmental approvals, manufacture, and market and sell its new product candidates. There can be no assurance
that the Company will be able to commercialize its technology successfully or that profitability will ever be achieved. The operating
results of the Company have fluctuated significantly in the past.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>COVID-19
Pandemic</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2020, the World Health Organization (&ldquo;WHO&rdquo;) declared an outbreak of coronavirus, COVID-19, to be a &ldquo;Public
Health Emergency of International Concern,&rdquo; and the U.S. Department of Health and Human Services declared a public health
emergency to aid the U.S. healthcare community in responding to COVID-19. This virus has spread to over 100 countries, including
the United States. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19,
including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions
that prohibit many employees from going to work. Uncertainty with respect to the economic impacts of the pandemic has introduced
significant volatility in the financial markets. The Company did not observe significant impacts on its business or results of
operations for the three-month and six-month periods ended June 30, 2020 due to the global emergence of COVID-19. While the extent
to which COVID-19 impacts the Company&rsquo;s future results will depend on future developments, the pandemic and associated economic
impacts could result in a material impact to the Company&rsquo;s future financial condition, results of operations and cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions
and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the ongoing
COVID-19 pandemic. The disruptions caused by COVID-19 may also disrupt the clinical trials process and enrolment of patients.
This may delay commercialization efforts. The Company is currently monitoring its operating activities in light of these events
and it is reasonably possible that the virus could have a negative effect on the Company&rsquo;s financial condition and results
of operations. The specific impact, if any, is not readily determinable as of the date of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company&rsquo;s
control. These factors include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress of research activities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and scope of research programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress of preclinical and clinical development activities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress of the development efforts of parties with whom the Company has entered into research and development agreements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with additional clinical trials of product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to maintain current research and development licensing arrangements and to establish new research and development
    and licensing arrangements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to achieve milestones under licensing arrangements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of regulatory approvals.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2020, the Company announced that it has received a recommendation from the independent Data Monitoring Committee (DMC)
to consider stopping the global Phase III OPTIMA Study of ThermoDox<SUP>&reg;</SUP> in combination with radiofrequency ablation
(RFA) for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer. The recommendation was made following the
second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020. The DMC&rsquo;s analysis found that the pre-specified
boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903. The Company intends to follow
the advice of the DMC and will consider its options to either stop the study or continue to follow patients after a thorough review
of the data, and an evaluation of the probability of success. Timing for this decision is made less urgent by the fact that the
OPTIMA Study has been fully enrolled since August 2018 and that the vast majority of the trial expenses have already been incurred.
On August 4, 2020, the Company issued a press release announcing it will continue following patients for overall survival (&ldquo;OS&rdquo;),
noting that the unexpected and marginally crossed futility boundary, suggested by the Kaplan-Meier analysis at the second interim
analysis on July 9, 2020, may be associated with a data maturity issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2019 and 2018, the Company submitted applications to sell a portion of the Company&rsquo;s State of New Jersey net operating losses
as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the
program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these
benefits to other New Jersey-based companies. The Company received approval from the New Jersey Economic Development Authority
to sell $1.9 million of its State of New Jersey net operating losses recognizing a tax benefit for the year ended December 31,
2019 for the net proceeds (approximately $1.8 million). In early 2020, the Company entered into an agreement to sell these net
operating losses. In April of 2020, the Company completed the sale of its State of New Jersey net operating losses and received
$1.8 million in net proceeds. In 2018, the Company completed the sale of a portion of its State of New Jersey net operating losses
for calendar years 2011 - 2017 totalling approximately $11.1 million for net proceeds of approximately $10.4 million in December
2018. The proceeds of $10.4 million were reflected as a tax benefit for the year ended December 31, 2018. In June 2020, the Company
filed an application with the New Jersey Economic Development Authority to sell substantially all of its remaining State of New
Jersey net operating losses totalling $2.0 million available under the program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018, the Company entered into the Horizon Credit Agreement with Horizon Technology Finance Corporation (&ldquo;Horizon&rdquo;)
that provided $10 million in new capital (the &ldquo;Horizon Credit Agreement&rdquo;). The obligations under the Horizon Credit
Agreement are secured by a first-priority security interest in substantially all assets of Celsion other than intellectual property
assets. Payments under the loan agreement are interest only (calculated based on one-month LIBOR plus 7.625%) for the first twenty-four
(24) months through July 2020, followed by a 24-month amortization period of principal and interest starting on August 1, 2020
and ending through the scheduled maturity date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
$25.5 million in cash, investments, interest receivable and up to $2.0 million in potential proceeds from the sale of the 2019
State of New Jersey net operating losses, coupled with remaining availability under the Capital-on-Demand&trade; Sales Agreement
(the &ldquo;Capital on Demand Agreement&rdquo;) with JonesTrading Institutional Services LLC, the Company believes it has sufficient
capital resources to fund its operations through the end of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner
or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or
private sales of the Company&rsquo;s shares or debt, the sale of the Company&rsquo;s State of New Jersey net operating losses
and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into
common stock, the ownership interest of existing stockholders may be diluted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
4. New Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) and are adopted by us
as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements
will not have a material impact on the Company&rsquo;s condensed consolidated financial position, results of operations, and cash
flows, or do not apply to our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued Accounting Standards Update No. 2016-13, &ldquo;Financial Instruments &ndash; Credit Losses (Topic
326): Measurement of Credit Losses on Financial Instruments&rdquo;, which modifies the measurement of expected credit losses on
certain financial instruments. The Company will adopt ASU 2016-13 in its first quarter of 2021 utilizing the modified retrospective
transition method. Based on the composition of the Company&rsquo;s investment portfolio and current market conditions, the adoption
of ASU 2016-13 is not expected to have a material impact on its condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued ASU No. 2018-13, <I>Fair Value Measurement: Disclosure Framework &ndash; Changes to the Disclosure
Requirements for Fair Value Measurement</I>, which adds and modifies certain disclosure requirements for fair value measurements.
Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level
1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies
will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value
measurements, and related changes in unrealized gains and losses included in other comprehensive income. This update is effective
for annual periods beginning after December 15, 2019, and interim periods within those periods, and early adoption is permitted.
The adoption of this standard did not have an impact on the Company&rsquo;s condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740). The standard simplifies the accounting for incomes taxes
by removing certain exceptions to the general principles in Topic 740 related to the approach for intra-period tax allocation
and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for
transactions that result in a step-up in the tax basis of goodwill. The standard also improves consistent application of and simplifies
GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment is effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The Company is currently
evaluating the impact that the adoption of this standard will have on its condensed consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
5. Net Loss per Common Share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is calculated based upon the net loss available to common shareholders divided by the weighted average number of
common shares outstanding during the period. Diluted loss per share is calculated after adjusting the denominator of the basic
earnings per share computation for the effects of all dilutive potential common shares outstanding during the period. The dilutive
effects of preferred stock, options and warrants and their equivalents are computed using the treasury stock method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total number of shares of common stock issuable upon exercise of warrants, stock option grants and equity awards were 8,560,124
and 4,595,990 shares for the six-month periods ended June 30, 2020 and 2019, respectively. Warrants with an exercise price of
$0.01 (as more fully described in Note 13) exercisable for 200,000 shares of common stock were considered issued in calculating
basic loss per share. For the three-month and six-month periods ended June 30, 2020 and 2019, diluted loss per common share was
the same as basic loss per common share as the other warrants and equity awards that were convertible into shares of the Company&rsquo;s
common stock were excluded from the calculation of diluted loss per common share as their effect would have been anti-dilutive.
The Company did not pay any dividends during the six-month periods ended June 30, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
6. Investment in Debt Securities Available for Sale</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in debt securities available for sale with a fair value of $2,791,868 and $7,985,886 as of June 30, 2020 and December 31, 2019,
respectively, consist of corporate debt securities. These investments are valued at estimated fair value, with unrealized gains
and losses reported as a separate component of stockholders&rsquo; equity in accumulated other comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in debt securities available for sale are evaluated periodically to determine whether a decline in their value is other than temporary.
The term &ldquo;other than temporary&rdquo; is not intended to indicate a permanent decline in value. Rather, it means that the
prospects for near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values
equal to, or greater than, the carrying value of the security. Management reviews criteria such as the magnitude and duration
of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. Once a decline
in value is determined to be other than temporary, the value of the security is reduced and a corresponding charge to earnings
is recognized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the cost, fair value and maturities of the Company&rsquo;s short-term investments is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Short-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; text-align: left; padding-bottom: 1.5pt">Investments in debt securities</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"> 2,784,002 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">2,791,868</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">7,943,108</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">7,985,886</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 2,784,002 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,791,868</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,943,108</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,985,886</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Short-term investment maturities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; padding-bottom: 1.5pt">Within 3 months</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"> 2,784,002 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">2,791,868</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">7,943,108</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">7,985,886</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 2,784,002 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,791,868</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,943,108</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,985,886</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the Company&rsquo;s investment securities gross unrealized gains (losses) and fair value by investment category
and length of time that individual securities have been in a continuous unrealized loss position at June 30, 2020 and December
31, 2019. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost
basis is other than temporary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Available for sale securities <FONT STYLE="font-style: normal; font-weight: normal">(all
    unrealized holding gains and losses are less than 12 months at date of measurement)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unrealized</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holding</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gains</B></FONT> </P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unrealized</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holding</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gains</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; text-align: left; padding-bottom: 1.5pt">Investments in debt securities with unrealized Gains</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">2,791,868</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"> 7,866 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"></TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">7,985,886</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">42,778</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,791,868</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 7,866 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,985,886</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">42,778</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
income, which includes net realized gains on sales of available for sale securities and investment income interest and dividends,
is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Interest and dividends accrued and paid</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">18,095</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">143,633</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Realized gains</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,865</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">969</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Investment income, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,960</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">144,602</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Interest and dividends accrued and paid</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">63,172</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">248,043</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Realized gains</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">46,097</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,350</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Investment income, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">109,269</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">258,393</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
7. Fair Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
Accounting Standards Codification (ASC) Section 820 &ldquo;Fair Value Measurements and Disclosures,&rdquo; establishes a three-level
hierarchy for fair value measurements which requires an entity to maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as
of the measurement date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted
prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Significant unobservable inputs that reflect a reporting entity&rsquo;s own assumptions that market participants would use
in pricing an asset or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents, accounts payable and other accrued liabilities are reflected in the condensed consolidated balance sheet
at their approximate estimated fair values primarily due to their short-term nature. The fair values of securities available for
sale are determined by relying on the securities&rsquo; relationship to other benchmark quoted securities and classified its investments
as Level 2 items at June 30, 2020 and December 31, 2019. There were no transfers of assets or liabilities between Level 1 and
Level 2 and no transfers in or out of Level 3 during the six-month period ended June 30, 2020 or during the year ended December
31, 2019. The changes in Level 3 liabilities were the result of changes in the fair value of the earn-out milestone liability
included in earnings and in-process R&amp;D. The earnout milestone liability is valued using a risk-adjusted assessment of the
probability of payment of each milestone, discounted to present value using an estimated time to achieve the milestone (see Note
13). The in-process R&amp;D is valued using a multi-period excess earnings method (see Note 8).</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities measured at fair value are summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Total Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Significant Other Observable Inputs (Level 2)</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Significant Unobservable Inputs (Level 3)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Recurring items as of June 30, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Corporate debt securities, available for sale</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,791,868</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;
</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,791,868</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &#9472; &nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Recurring items as of December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Corporate debt securities, available for sale</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,985,886</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472; </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,985,886</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;
&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Recurring items as of June 30, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Earn-out milestone liability (Note 13)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,015,279</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &#9472;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472; &nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,015,279</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Recurring items as of December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Earn-out milestone liability (Note 13)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,717,709</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;
&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,717,709</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
8. Intangible Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2014, we completed the acquisition of substantially all of the assets of EGEN, Inc., an Alabama corporation, which has changed
its company name to EGWU, Inc. after the closing of the acquisition (&ldquo;EGEN&rdquo;). We acquired all of EGEN&rsquo;s right,
title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks
and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment,
furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities
of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Acquired
In-process Research and Development</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
in-process research and development (IPR&amp;D) consists of EGEN&rsquo;s drug technology platforms: TheraPlas and TheraSilence.
The fair value of the IPR&amp;D drug technology platforms was estimated to be $24.2 million as of the acquisition date. As of
the closing of the acquisition, the IPR&amp;D was considered indefinite lived intangible assets and will not be amortized. IPR&amp;D
is reviewed for impairment at least annually as of our third quarter ended September 30, and whenever events or changes in circumstances
indicate that the carrying value of the assets might not be recoverable. The Company&rsquo;s IPR&amp;D consisted of three core
elements, its RNA delivery system, its glioblastoma multiforme cancer (GBM) product candidate and its ovarian cancer indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s ovarian cancer indication, with original value of $13.3 million, has not been impaired since its acquisition.
At September 30, 2019, the Company evaluated its IPR&amp;D of the ovarian cancer indication and concluded that it is not more
likely than not that the asset is impaired. As no other indicators of impairment existed during the fourth quarter of 2019, or
first half of 2020, no impairment charges were recorded during the six months ended June 30, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s GBM candidate, with original value of $9.4 million had cumulative impairments through 2018 of $7 million, with
remaining carrying value of $2.4 million at December 31, 2019 and March 31, 2020, On September 30, 2019, the Company evaluated
its IPR&amp;D of the (GBM) product candidate and concluded that it is not more likely than not that the asset is further impaired.
As no other indicators of impairment existed during the fourth quarter of 2019 and in the first half of 2020, no impairment charges
were recorded during the six months ended June 30, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s RNA delivery system, with an initial value of $1.5, million was previously fully impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Covenants
Not to Compete</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the EGEN Purchase Agreement, EGEN provided certain covenants (&ldquo;Covenant Not To Compete&rdquo;) to the Company whereby
EGEN agreed, during the period ending on the seventh anniversary of the closing date of the acquisition on June 20, 2014, not
to enter into any business, directly or indirectly, which competes with the business of the Company nor will it contact, solicit
or approach any of the employees of the Company for purposes of offering employment. The Covenant Not to Compete which was valued
at approximately $1.6 million at the date of the EGEN acquisition has a definitive life and is amortized on a straight-line basis
over its life of 7 years. The Company recognized amortization expense of $56,829 in each of the three-month periods ended June
30, 2020 and 2019. The Company recognized amortization expense of $113,658 in each of the six-month periods ended June 30, 2020
and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Covenant Not to Compete was $227,318, net of $1,363,896 accumulated amortization as of June 30, 2020 and
$340,976, net of $1,250,238 accumulated amortization, as of December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a schedule of future amortization amounts during the remaining life of the Covenant Not to Compete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">227,318</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2022 and thereafter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9472;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">227,318</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Goodwill</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price exceeded the estimated fair value of the net assets acquired by approximately $2.0 million which was recorded as
Goodwill. Goodwill represents the difference between the total purchase price for the net assets purchased from EGEN and the aggregate
fair values of tangible and intangible assets acquired, less liabilities assumed. Goodwill is reviewed for impairment at least
annually as of our third quarter ended September 30 or sooner if we believe indicators of impairment exist. As of June 30, 2020,
we concluded that the Company&rsquo;s fair value exceeded its carrying value therefore &ldquo;it is not more likely than not&rdquo;
that the Goodwill was impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 3, on July 13, 2020, the Company announced that it has received a recommendation from the DMC to consider stopping
the global Phase III OPTIMA Study of ThermoDox&reg; in combination with RFA for the treatment of hepatocellular carcinoma (HCC),
or primary liver cancer. This event will be incorporated in the Company&rsquo;s assessment of the carrying value of goodwill and
intangible assets as of the date the information was available, which is the third quarter of 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of the net fair value of the assets acquired in the EGEN asset acquisition for the three-month period ended June
30, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">IPR&amp;D</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Goodwill</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Covenant Not To Compete</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">For the six-months ended June 30, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: left">Balance at January 1, 2020, net</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">15,736,491</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1,976,101</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">340,976</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(113,658</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Balance at June 30, 2020, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,736,491</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,976,101</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">227,318</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
9. Other Accrued Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accrued liabilities at June 30, 2020 and December 31, 2019 include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Amounts due to contract research organizations and other contractual agreements</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">284,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">475,440</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued payroll and related benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,054,272</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,604,541</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204,155</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,411</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,411</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,507,683</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,303,547</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
10. Notes and Loans Payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Horizon
Credit Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2018, the Company entered the Horizon Credit Agreement. The Company drew down $10 million upon closing of the Horizon
Credit Agreement on June 27, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three-month period ended June 30, 2020, the Company incurred $243,299 in interest expense and amortized $96,727 as interest
expense for debt discounts and end of term charges in connection with the Horizon Credit Agreement. During the three-month period
ended June 30, 2019, the Company incurred $255,182 in interest expense and amortized $94,266 as interest expense for debt discounts
and end of term charges in connection with the Horizon Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six-month period ended June 30, 2020, the Company incurred $486,597 in interest expense and amortized $192,793 as interest
expense for debt discounts and end of term charges in connection with the Horizon Credit Agreement. During the six-month period
ended June 30, 2019, the Company incurred $508,471 in interest expense and amortized $191,724 as interest expense for debt discounts
and end of term charges in connection with the Horizon Credit Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a schedule of future principal payments, net of unamortized debt discounts and amortized end of term charges, due on the Horizon
Credit Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">4,583,336</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">416,664</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2024 and thereafter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Subtotal of future principal payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Unamortized debt issuance costs, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,530</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,996,470</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Paycheck
Protection Program</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 23, 2020, we entered into a loan agreement with Silicon Valley Bank (the &ldquo;April PPP Loan&rdquo;), pursuant to the
Paycheck Protection Program (the &ldquo;PPP&rdquo;), established pursuant to the recently enacted Coronavirus Aid, Relief, and
Economic Security Act (the &ldquo;CARES Act&rdquo;) and administered by the U.S. Small Business Administration (&ldquo;SBA&rdquo;).
We thereafter received proceeds of $632,220 under the April PPP Loan. The April PPP Loan application required Celsion to certify
that there was economic uncertainty surrounding the Company and that, as such, the April PPP Loan was necessary to support our
ongoing operations. Celsion made this certification in good faith after analyzing, among other things, its financial situation
and access to alternative forms of capital, and believed that the Company satisfied all eligibility criteria for the April PPP
Loan, and that our receipt of the April PPP Loan proceeds was consistent with the broad objectives of the PPP of the CARES Act.
The certification given with respect to the April PPP Loan did not contain any objective criteria and was subject to interpretation.
Considering subsequent guidance issued by the SBA in consultation with the U.S. Department of the Treasury at that time, out of
an abundance of caution we returned the proceeds of the PPP Loan in full on May 13, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shortly
after the April PPP Loan was repaid, the SBA provided further guidance with respect to these certifications providing a safe harbor
under which companies such as Celsion with PPP loans of less than $2 million will be deemed to have made these certifications
in good faith. Therefore, as the Company continued to believe it qualifies for a loan under the PPP, it reapplied for and eventually
received the new PPP Loan for $692,530 on May 26, 2020 (the &ldquo;May PPP Loan&rdquo;). The May PPP Loan was guaranteed by the
SBA and evidenced by a promissory note of the Company dated May 26, 2020 (the &ldquo;Note&rdquo;) in the principal amount of $692,530
payable to the lender. Pursuant to the terms of the Note, was payable in part or in full, at any time, without penalty.
On June 22, 2020, as disclosed in the Company&rsquo;s Current Report on Form 8-K filed on the same date, the Company commenced
an offering of 2,666,667 shares of its common stock which closed on June 24, 2020 (Note 11) and received net proceeds of approximately
$9.1 million. In light of the proceeds received from this equity offering, the Company elected to repay the May PPP Loan in full
(including interest accrued of $577) on June 24, 2020, terminating all obligations of the Company under the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
11. Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2018, the Company filed with the SEC a new $75 million shelf registration statement on Form S-3 (the &ldquo;2018 Shelf
Registration Statement&rdquo;) (File No. 333-227236) that allows the Company to issue any combination of common stock, preferred
stock or warrants to purchase common stock or preferred stock. This shelf registration was declared effective on October 12, 2018
and will expire three years from that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Aspire
Purchase Agreements </U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> On August 31, 2018, the Company entered
into a common stock purchase agreement (the &ldquo;2018 Aspire Purchase Agreement&rdquo;) with Aspire Capital Fund, LLC (&ldquo;Aspire
Capital&rdquo;) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital
was committed to purchase up to an aggregate of $15.0 million of shares of the Company&rsquo;s common stock over the 24-month
term of the 2019 Aspire Purchase Agreement. During 2018, the Company sold and issued an aggregate of 0.1 million shares under
the 2018 Aspire Purchase Agreement, receiving approximately $0.2 million. During 2019, the Company sold and issued an aggregate
of 3.3 million shares under the 2018 Aspire Purchase Agreement, receiving approximately $6.3 million. As a result of the Company
and Aspire entering into a new purchase agreement on October 28, 2019 (the &ldquo;2019 Aspire Purchase Agreement&rdquo;) discussed
in the next paragraph, the 2018 Aspire Purchase Agreement was terminated. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif"> The 2019 Aspire Purchase Agreement provided
that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase
up to an aggregate of $10.0 million of shares of the Company&rsquo;s common stock over the 24-month term of the 2019 Aspire Purchase
Agreement. During 2019, the Company sold and issued an aggregate of 0.5 million shares under the 2019 Aspire Purchase Agreement,
receiving approximately $0.7 million. During the first quarter of 2020 through March 5, 2020 when the Company delivered notice
to Aspire terminating the 2019 Aspire Purchase Agreement, the Company sold 1.0 million shares of common stock under the Aspire
Purchase Agreement, receiving approximately $1.6 million in additional gross proceeds.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Capital
on Demand<SUP>TM</SUP> Sales Agreement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 4, 2018, the Company entered into the Capital on Demand Agreement with JonesTrading, pursuant to which the Company may
offer and sell, from time to time, through JonesTrading shares of Common Stock having an aggregate offering price of up to $16.0
million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares will be issued pursuant to Celsion&rsquo;s previously filed and effective Registration Statement on Form S-3 (File No.
333-227236), the base prospectus dated October 12, 2018, filed as part of such Registration Statement, and the prospectus supplement
dated December 4, 2018, filed by Celsion with the Securities and Exchange Commission. During 2019, the Company sold and issued
an aggregate of 0.5 million shares under the Capital on Demand Agreement, receiving approximately $1.0 million in gross proceeds.
During 2020 through June 30, 2020, the Company sold and issued an aggregate of 1.2 million shares under the Capital on Demand
Agreement, receiving approximately $3.5 million in gross proceeds. The Company has not sold any shares under the Capital on Demand
Agreement subsequent to June 30, 2020 through the date of this Quarterly Report on Form 10Q. As of June 30, 2020, the Company
has approximately $11.5 million available under the Capital on Demand Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Registered
Direct Offering</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 27, 2020, we entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with several institutional
investors, pursuant to which we agreed to issue and sell, in a registered direct offering (the &ldquo;February 2020 Offering&rdquo;),
an aggregate of 4,571,428 shares (the &ldquo;Shares&rdquo;) of our common stock at an offering price of $1.05 per Share for gross
proceeds of approximately $4.8 million before the deduction of the Placement Agent fees and offering expenses. The Shares were
offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-227236). The Purchase Agreement contains
customary representations, warranties and agreements by the Company and customary conditions to closing. In a concurrent private
placement (the &ldquo;Private Placement&rdquo;), the Company agreed to issue to the investors that participated in the Offering,
for no additional consideration, warrants, to purchase up to 2,971,428 shares of Common Stock (the &ldquo;Original Warrants&rdquo;).
The Original Warrants were initially exercisable six months following their date of issue and were set to expire on the five-year
anniversary of such initial exercise date. The Original Warrants had an exercise price of $1.15 per share subject to adjustment
as provided therein. On March 12, 2020, the Company entered into private exchange agreements (the &ldquo;Exchange Agreements&rdquo;)
with holders of the Original Warrants. Pursuant to the Exchange Agreements, in return for a higher exercise price of $1.24 per
share of Common Stock, the Company issued new warrants to the Investors to purchase up to 3,200,000 shares of Common Stock (the
&ldquo;Exchange Warrants&rdquo;) in exchange for the Original Warrants. The Exchange Warrants, like the Original Warrants, are
initially exercisable six months following their issuance (the &ldquo;Initial Exercise Date&rdquo;) and expire on the five-year
anniversary of their Initial Exercise Date. Other than having a higher exercise price, different issue date, Initial Exercise
Date and expiration date, the terms of the Exchange Warrants are identical to those of the Original Warrants. On July 31, 2020,
the Company filed a Form S-3 Registration Statement to register the shares of Common Stock issuable under the Exchange Warrants.</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Underwritten
Offering</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2020, the Company entered into an underwriting agreement (the &ldquo;Underwriting Agreement&rdquo;) with Oppenheimer
&amp; Co. Inc. (the &ldquo;Underwriter&rdquo;), relating to the issuance and sale (the &ldquo;Underwritten Offering&rdquo;) of
2,666,667 shares of the Company&rsquo;s common stock. Pursuant to the terms of the Underwriting Agreement, the Underwriter agreed
to purchase the shares at a price of $3.4875 per share. The Underwriter offered the shares at a public offering price of $3.75
per share, reflecting an underwriting discount equal to $0.2625, or 7.0% of the public offering price. The net proceeds to the
Company from the Underwritten Offering, after deducting the underwriting discount and estimated offering expenses payable by the
Company, were approximately $9.1 million. The Underwritten Offering closed on June 24, 2020 and was made pursuant to the Company&rsquo;s
effective shelf registration statement on Form S-3 (File No. 333-227236) filed with the Securities and Exchange Commission on
September 7, 2018, and declared effective on October 12, 2018, including the base prospectus dated October 12, 2018 included therein
and the related prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriter including for liabilities under the Securities Act, other obligations
of the parties, and termination provisions. Pursuant to the Underwriting Agreement, until December 31, 2020, the Underwriter shall
have a right of first refusal to act as sole underwriter, initial purchaser, placement/selling agent, or arranger, as the case
may be, on any new financing for the Company (excluding equipment lease financings, loans or grants from governmental authorities
or in connection with government programs and financings relating to or sales of tax attributes) during such period. The Underwriter
shall have the sole right to determine whether or not any other broker dealer shall have the right to participate in any such
offering and the economic terms of any such participation. Pursuant to the Underwriting Agreement, subject to certain exceptions,
the Company and certain of the Company&rsquo;s executive officers and directors have agreed that, without the prior written consent
of the Underwriter and subject to certain negotiated exceptions, they will not, for a period of 60 days, in either case, following
the date of the final prospectus supplement, sell or otherwise dispose of any of the Company&rsquo;s securities held by them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
12. Stock-Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted
stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the 2018 Annual Stockholders Meeting of the Company held on May 15, 2018, the Company&rsquo;s stockholders approved the Celsion
Corporation 2018 Stock Incentive Plan (the &ldquo;2018 Plan&rdquo;). The 2018 Plan, as adopted, permits the granting of 2,700,000
shares of Celsion common stock as equity awards in the form of incentive stock options, nonqualified stock options, restricted
stock, restricted stock units, stock appreciation rights, other stock awards, performance awards, or in any combination of the
foregoing. At the 2019 Annual Stockholders Meeting of the Company held on May 14, 2019, stockholders approved an amendment to
the 2018 Plan whereby the Company increased the number of shares of common stock available by 1,200,000 to a total of 3,900,000
under the 2018 Plan, as amended. Prior to the adoption of the 2018 Plan, the Company had maintained the Celsion Corporation 2007
Stock Incentive Plan (the &ldquo;2007 Plan&rdquo;). At the 2020 Annual Stockholders Meeting of the Company held on June 15, 2020,
stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares
of common stock available by 2,500,000 to a total of 6,400,000 under the 2018 Plan, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the adoption of the 2018 Plan, the Company had maintained the Celsion Corporation 2007 Stock Incentive Plan (the &ldquo;2007
Plan&rdquo;). The 2007 Plan permitted the granting of 688,531 shares of Celsion common stock as equity awards in the form of incentive
stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, phantom stock,
performance awards, or in any combination of the foregoing. The 2018 Plan replaced the 2007 Plan although the 2007 Plan remains
in effect for awards previously granted under the 2007 Plan. Under the terms of the 2018 Plan, any shares subject to an award
under the 2007 Plan which are not delivered because of the expiration, forfeiture, termination or cash settlement of the award
will become available for grant under the 2018 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued stock awards to employees and directors in the form of stock options and restricted stock. Options are generally
granted with strike prices equal to the fair market value of a share of Celsion common stock on the date of grant. Incentive stock
options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying
shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning
more than 10% of the outstanding stock of Celsion must be at least 110% of such fair market value on the date of grant. Only officers
and key employees may receive incentive stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
and restricted stock awards vest upon terms determined by the Compensation Committee of the Board of Directors and are subject
to accelerated vesting in the event of a change of control or certain terminations of employment. The Company issues new shares
to satisfy its obligations from the exercise of options or the grant of restricted stock awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 19, 2019, the Compensation Committee of the Board of Directors approved the grant of (i) inducement stock options (the
&ldquo;Inducement Option Grants&rdquo;) to purchase a total of 140,004 shares of Celsion common stock, and (ii) inducement restricted
stock awards (the &ldquo;Inducement Stock Grants&rdquo;) totalling 13,000 shares of Celsion common stock to two new employees
collectively. Each award has a grant date of the date of grant. Each Inducement Option Grant has an exercise price per share equal
to $2.18 which represents the closing price of Celsion&rsquo;s common stock as reported by the Nasdaq Capital Market on the date
of grant. Each Inducement Option Grant will vest over three years, with one-third vesting on the one-year anniversary of the employee&rsquo;s
first day of employment with the Company and one-third vesting on the second and third anniversaries thereafter, subject to the
new employee&rsquo;s continued service relationship with the Company on each such date. Each Inducement Option Grant has a ten-year
term and is subject to the terms and conditions of the applicable stock option agreement. Each Inducement Stock Grant will vest
on the one-year anniversary of the employee&rsquo;s first day of employment with the Company and is subject to the new employee&rsquo;s
continued service relationship with the Company through such date and is subject to the terms and conditions of the applicable
restricted stock agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option awards and restricted stock grants for the six-months ended June 30, 2020 is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Restricted Stock Awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-vested</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair Value</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Terms of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Awards</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in years)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Equity awards outstanding at January 1, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,332,142</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.63</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.59</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Equity awards granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">644,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">429,855</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(140,864</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.64</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vested and issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(429,855</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Equity awards forfeited, cancelled or expired</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(110,002</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">2.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Equity awards outstanding at June 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,725,276</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">2.76</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,750</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.59</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.3</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Aggregate intrinsic value of outstanding equity awards at June 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,494,924</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,875</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Equity awards exercisable at June 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,194,777</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">2.86</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.8</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Aggregate intrinsic value of equity awards exercisable at June 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,733,421</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2020, there was a total of 6,510,174 shares of Celsion common stock reserved for issuance under the 2018 Plan which
were comprised of 4,594,022 shares of Celsion common stock subject to equity awards previously granted under the 2018 Plan and
2007 Plan and 1,916,152 shares of Celsion common stock available for future issuance under the 2018 Plan. As of June 30, 2020,
there was a total of 140,004 shares of Celsion common stock subject to outstanding inducement awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
compensation cost related to stock options and restricted stock awards amounted to $578,761 and $622,696 for the three-month periods
ended June 30, 2020 and 2019, respectively. Of these amounts, $200,186 and $239,406 was charged to research and development during
the three-month periods ended June 30, 2020 and 2019, respectively, and $378,575 and $383,290 was charged to general and administrative
expenses during the three-month periods ended June 30, 2020 and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
compensation cost related to stock options and restricted stock awards amounted to $1,030,726 and $1,313,842 for the six-month
periods ended June 30, 2020 and 2019, respectively. Of these amounts, $378,122 and $479,794 was charged to research and development
during the six-month periods ended June 30, 2020 and 2019, respectively, and $652,604 and $834,048 was charged to general and
administrative expenses during the six-month periods ended June 30, 2020 and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2020, there was $2.4 million of total unrecognized compensation cost related to non-vested stock-based compensation
arrangements. That cost is expected to be recognized over a weighted-average period of 1.5 years. The weighted average grant date
fair values of the stock options granted was $3.10 and $1.88 during the six-month periods ended June 30, 2020 and 2019, respectively.
In connection with the Company&rsquo;s annual 2019 bonus program, the Company issued 429,855 shares of common stock from the 2018
Stock Incentive Plan in lieu of paying cash for 50% of the annual bonus awards. These amounts were fully accrued for in the consolidated
financial statements for the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company received gross proceeds of $371,895 from the issuance of 140,864 shares of common stock upon exercise of stock
option awards under the 2018 Plan. No options were exercised in 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes
model was originally developed for use in estimating the fair value of traded options, which have different characteristics from
Celsion&rsquo;s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value
estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes
option pricing model:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font-size: 11pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD COLSPAN="5" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six
                                         Months Ended June 30, </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font-size: 11pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Risk-free interest rate</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">0.71% to 1.33 </TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">2.42%-2.65</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.4% to 104.2  </TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101.3%-106.2</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.5 to 10.0  </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.5 to 9.3 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
volatilities utilized in the model are based on historical volatility of the Company&rsquo;s stock price. The risk-free interest
rate is derived from values assigned to U.S. Treasury bonds with terms that approximate the expected option lives in effect at
the time of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
13. Earn-out Milestone Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Amended Asset Purchase Agreement entered by and between Company and EGWU, Inc in March 2019, payment of the earnout milestone
liability related to the Ovarian Cancer Indication of $12.4 million was modified. The Company has the option to make a $7.0 million
payment within 10 business days of achieving the milestone; or make a payment of $12.4 million in cash, common stock of the Company,
or a combination of either, within one year of achieving the milestone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2020, March 31, 2020, and December 31, 2019, the Company fair valued the earn-out milestone liability at $6.0 million,
$5.8 million and $5.7 million, respectively and recognized a non-cash charge of $0.2 and $0.3 million for the three-month and
six-month periods ended June 30, 2020, respectively. In assessing the earnout milestone liability at June 30, 2020 and March 31,
2020, the Company fair valued each of the two payment options per the Amended Asset Purchase Agreement and weighted them at 80%
and 20% probability for the $7.0 million and the $12.4 million payments, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2019, March 31, 2019, and December 31, 2018, the Company fair valued the earn-out milestone liability at $13.1 million,
$5.8 million and $8.9 million, respectively and recognized a non-cash charge of $0.1 million and a non-cash benefit of $3.0 million
during the three-month and six-month periods ended June 30, 2019, respectively. In assessing the earnout milestone liability at
June 30, 2019 and March 31, 2019, the Company fair valued each of the two payment options per the Amended Asset Purchase Agreement
and weighted them at 80% and 20% probability for the $7.0 million and the $12.4 million payments, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the changes in the earn-out milestone liability for the six-month period ended June 30, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%">Balance at January 1, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(5,717,709</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Non-cash loss from the change in fair value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(297,570</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance at June 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,015,279</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a schedule of the Company&rsquo;s risk-adjustment assessment of each milestone:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Date</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Risk-adjustment Assessment <BR>of Achieving each Milestone</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Discount Rate</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">Estimated Time <BR>to Achieve</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; text-align: justify">June 30, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">80</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">9</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.54 to 1.54 years</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">March 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.04 to 2.04 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12 to 2.12 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.75 to 1.75 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">March 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00 to 2.00 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">December 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
14. Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of all warrant activity for the six months ended June 30, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Warrants</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issued</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise Price</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">Warrants outstanding at December 31, 2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">626,098</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">1.87</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Warrants issued during the six months ended June 30, 2020 (see Note 11)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,200,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.24</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Warrants outstanding at June 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,826,098</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.34</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Aggregate intrinsic value of outstanding warrants at June 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,096,322</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Schedule of weighted average exercise price and remaining contractual terms at June 30, 2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants provided to EGWU, Inc. (Note 13)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All other warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Number of warrants issued</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">200,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">3,626,098</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average exercise prise</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.42</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average contractual terms remaining</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No expiration</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
15. Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains a lease, as amended, for its 10,870 square foot premises located in Lawrenceville, New Jersey which is currently
set to expire September 1, 2023. Also, the Company maintains a lease for an 11,500 square foot premises located in Huntsville
Alabama, which is currently set to expire in January 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
adopted ASC Topic 842 on January 1, 2019 using the modified retrospective transition method for all lease arrangements at the
beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC 842, while
prior period amounts were not adjusted and continue to be reported in accordance with our historic accounting under Topic 840,
Leases. The standard had a material impact on our Condensed Consolidated Balance Sheet but had no impact on our condensed consolidated
net earnings and cash flows. The most significant impact of adopting ASC Topic 842 was the recognition of the right-of-use (ROU)
asset and lease liabilities for operating leases, which are presented in the following three-line items on the Consolidated Condensed
Balance Sheet: (i) operating lease right-of-use asset; (ii) current operating lease liabilities; and (iii) operating lease liabilities.
Therefore, on date of adoption of ASC Topic 842, the Company recognized a ROU asset of $1.4 million, operating lease liabilities,
current and non-current collectively, of $1.5 million and reduced other liabilities by approximately $0.1 million. We elected
the package of practical expedients for leases that commenced before the effective date of ASC Topic 842 whereby we elected to
not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any
expired or existing leases; and (iii) initial direct costs for any existing leases. In addition, we have lease agreements with
lease and non-lease components, and we have elected the practical expedient for all underlying asset classes and account for them
as a single lease component. We have no finance leases. We determine if an arrangement is a lease at inception. We have operating
leases for office space and research and development facilities. Neither of our leases include options to renew; however, one
contains an option for early termination. We considered the option of early termination in measurement of right-of-use assets
and lease liabilities, and we determined it is not reasonably certain to be terminated. In connection with the 2<SUP>nd</SUP>
Lease Amendment for the New Jersey office lease in January 2019, the Company considered this as one modified lease and not as
two separate leases. Therefore, in January 2019, the Company determined this lease was an operating lease and remeasured the ROU
asset and lease liability. Therefore, the Company increased the ROU asset and operating lease liabilities by $0.4 million to $1.8
million and $1.9 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a table of the lease payments and maturity of our operating lease liabilities as of June 30, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>year ending</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December 31,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%">Remainder of 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">263,726</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">530,734</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">535,579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 233,116 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2024 and thereafter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Subtotal future lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,563,155</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less imputed interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(219,931</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total lease liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,343,224</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Weighted average remaining life</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 years</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average discount rate</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.98</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three-month and six-month periods ending June 30, 2020, operating lease expense was $130,595 and $261,190, respectively and
cash paid for operating leases included in operating cash flows was $131,452 and $262,084, respectively. For the three-month and
six-month periods ending June 30, 2019, operating lease expense was $130,595 and $261,190, respectively and cash paid for operating
leases included in operating cash flows was $118,415 and 224,585, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
16. Technology Development and Licensing Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2012, the Company entered into a long-term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun)
for the production of ThermoDox<SUP>&reg;</SUP> in the China territory. In accordance with the terms of the agreement, Hisun will
be responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer,
registration and bioequivalence studies, technical transfer costs, Celsion consultative support costs and the purchase of any
necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture of ThermoDox<SUP>&reg;</SUP>.
Celsion will repay Hisun for the aggregate amount of these development costs and fees commencing on the successful completion
of three registration batches of ThermoDox<SUP>&reg;</SUP>. Hisun is also obligated to certain performance requirements under
the agreement. The agreement will initially be limited to a percentage of the production requirements of ThermoDox<SUP>&reg;</SUP>
in the China territory with Hisun retaining an option for additional global supply after local regulatory approval in the China
territory. In addition, Hisun will collaborate with Celsion around the regulatory approval activities for ThermoDox<SUP>&reg;
</SUP>with the China State Food and Drug Administration (CHINA FDA). During the first quarter of 2015, Hisun completed the successful
manufacture of three registration batches of ThermoDox<SUP>&reg;</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 18, 2013, we entered into a technology development contract with Hisun, pursuant to which Hisun paid us a non-refundable
research and development fee of $5 million to support our development of ThermoDox<SUP>&reg;</SUP> in mainland China, Hong Kong
and Macau (the China territory). Following our announcement on January 31, 2013 that the HEAT study failed to meet its primary
endpoint, Celsion and Hisun have agreed that the Technology Development Contract entered into on January 18, 2013 will remain
in effect while the parties continue to collaborate and are evaluating the next steps in relation to ThermoDox<SUP>&reg;</SUP>
, which include the sub-group analysis of patients in the Phase III HEAT Study for the hepatocellular carcinoma clinical indication
and other activities to further the development of ThermoDox<SUP>&reg;</SUP> for the Greater China market. The $5.0 million received
as a non-refundable payment from Hisun in the first quarter 2013 has been recorded to deferred revenue and will continue to be
amortized over the 10 -year term of the agreement, until such time as the parties find a mutually acceptable path forward on the
development of ThermoDox<SUP>&reg;</SUP> based on findings of the ongoing post-study analysis of the HEAT Study data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 19, 2013, the Company and Hisun entered into a Memorandum of Understanding to pursue ongoing cooperation for the continued
clinical development of ThermoDox <SUP>&reg;</SUP> as well as the technology transfer relating to the commercial manufacture of
ThermoDox<SUP>&reg;</SUP> for the China territory. This expanded level of cooperation includes development of the next generation
liposomal formulation with the goal of creating safer, more efficacious versions of marketed cancer chemotherapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the key provisions of the Celsion-Hisun Memorandum of Understanding are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hisun
    will provide the Company with internal resources necessary to complete the technology transfer of the Company&rsquo;s proprietary
    manufacturing process and the production of registration batches for the China territory;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hisun
    will coordinate with the Company around the clinical and regulatory approval activities for ThermoDox<SUP>&reg;</SUP> as well
    as other liposomal formations with the CHINA FDA; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hisun
    will be granted a right of first offer for a commercial license to ThermoDox<SUP>&reg;</SUP> for the sale and distribution
    of ThermoDox<SUP>&reg; </SUP>in the China territory.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2016, we signed a Technology Transfer, Manufacturing and Commercial Supply Agreement (&ldquo;GEN-1 Agreement&rdquo;)
with Hisun to pursue an expanded partnership for the technology transfer relating to the clinical and commercial manufacture and
supply of GEN-1, Celsion&rsquo;s proprietary gene mediated, IL- 12 immunotherapy, for the greater China territory, with the option
to expand into other countries in the rest of the world after all necessary regulatory approvals are in effect. The GEN- 1 Agreement
will help to support supply for both ongoing and planned clinical studies in the U.S., and for potential future studies of GEN-
1 in China. GEN- 1 is currently being evaluated by Celsion in first line ovarian cancer patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
provisions of the GEN-1 Agreement are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    GEN-1 Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with the Company&rsquo;s
    current suppliers;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">once
    approved, the cost structure for GEN-1 will support rapid market adoption and significant gross margins across global markets;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celsion
    will provide Hisun a certain percentage of China&rsquo;s commercial unit demand, and separately of global commercial unit
    demand, subject to regulatory approval;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hisun
    and Celsion will commence technology transfer activities relating to the manufacture of GEN-1, including all studies required
    by CHINA FDA for site approval; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hisun
    will collaborate with Celsion around the regulatory approval activities for GEN-1 with the CHINA FDA. A local China partner
    affords Celsion access to accelerated CHINA FDA review and potential regulatory exclusivity for the approved indication.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the Hisun arrangement in accordance with ASC 606 and determined that its performance obligations under the agreement
include the non-exclusive, royalty-free license, research and development services to be provided by the Company, and its obligation
to serve on a joint committee. The Company concluded that the license was not distinct since its value is closely tied to the
ongoing research and development activities. As such, the license and the research and development services are bundled as a single
performance obligation. Since the provision of the license and research and development services are considered a single performance
obligation, the $5,000,000 upfront payment is being recognized as revenue ratably through 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
17. Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2019, a purported stockholder of the Company filed a derivative and putative class action lawsuit against the Company
and certain officers and directors (the &ldquo;Shareholder Action&rdquo;). The Company is a defendant in this derivative and putative
class action lawsuit in the Superior Court of New Jersey, Chancery Division, filed by a shareholder against the Company (as both
a class action defendant and nominal defendant), and certain of its officers and directors (the &ldquo;Individual Defendants&rdquo;),
with the caption O&rsquo;Connor v. Braun et al., Docket No. MER-C-000068-19 (the &ldquo;Shareholder Action&rdquo;). The Shareholder
Action alleges breaches of the defendants&rsquo; fiduciary duties based on allegations that the defendants omitted or made improper
statements when seeking shareholder approval of the 2018 Stock Incentive Plan. The Shareholder Action seeks, among other things,
any damages sustained by the Company as a result of the defendants&rsquo; alleged wrongdoing, a declaratory judgment against all
defendants invalidating the 2018 Stock Incentive Plan and declaring any awards made under the Plan invalid, rescinded, and subject
to disgorgement, an order disgorging the equity awards granted to the Individual Defendants under the 2018 Stock Incentive Plan,
and attorneys&rsquo; fees and costs. Without admitting the validity of any of the claims asserted in the Shareholder Action, or
any liability with respect thereto, and expressly denying all allegations of wrongdoing, fault, liability, or damage against the
Company and the Individual Defendants arising out of any of the conduct, statements, acts or omissions alleged, or that could
have been alleged, in the Shareholder Action, the Company and the Individual Defendants have concluded that it is desirable that
the claims be settled on the terms and subject to the conditions set forth in the Settlement Agreement. The Company and the Individual
Defendants are entering into the Settlement Agreement for settlement purposes only and solely to avoid the cost and disruption
of further litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2020, the Company, the Individual Defendants, and the plaintiff (the &ldquo;Parties&rdquo;) entered into a Settlement
Agreement and Release (the &ldquo;Settlement Agreement&rdquo;), which memorializes the terms of the Parties&rsquo; settlement
of the Shareholder Action (the &ldquo;Settlement&rdquo;). The Settlement calls for repricing of certain stock options and payment
of plaintiff legal fees of $187,500. On July 24, 2020, the Court issued an order approving the Parties&rsquo; proposed form
of notice to shareholders regarding the Settlement. A hearing to determine whether the Court should issue a final order approving
the proposed Settlement has been scheduled for September 8, 2020. On August 3, 2020, the Company filed notice of the Settlement
Agreement on Form 8-K as filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
18. Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2020, the Company announced that it has received a recommendation from the DMC to consider stopping the global Phase
III OPTIMA Study of ThermoDox<SUP>&reg;</SUP> in combination with RFA for the treatment of HCC, or primary liver cancer. The recommendation
was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020. The DMC analysis found
that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903. The Company
intends to follow the advice of the DMC and will consider its options either to stop the study or continue to follow patients
after a thorough review of the data, and an evaluation of the probability of success. Timing for this decision is made less urgent
by the fact that the OPTIMA Study has been fully enrolled since August 2018 and that the vast majority of the trial expenses have
already been incurred. On August 4, 2020, the Company issued a press release announcing it will continue following patients for
overall survival (&ldquo;OS&rdquo;), noting that the unexpected and marginally crossed futility boundary, suggested by the Kaplan-Meier
analysis at the second interim analysis on July 9, 2020, may be associated with a data maturity issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_001"></A>Item
2. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Statements
and terms such as &ldquo;expect&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;estimate&rdquo;, &ldquo;plan&rdquo;, &ldquo;believe&rdquo;
and words of similar import regarding our expectations as to the development and effectiveness of our technologies, the potential
demand for our products, and other aspects of our present and future business operations, constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Although we believe that our expectations are based
on reasonable assumptions within the bounds of our knowledge of our industry, business and operations, we cannot guarantee that
actual results will not differ materially from our expectations. In evaluating such forward-looking statements, readers should
specifically consider the various factors contained in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended
December 31, 2019, filed with the SEC on March 25, 2020, which factors include, without limitation, plans and objectives of management
for future operations or programs or proposed new products or services; changes in the course of research and development activities
and in clinical trials; possible changes in cost and timing of development and testing; possible changes in capital structure,
financial condition, working capital needs and other financial items; changes in approaches to medical treatment; clinical trial
analysis and future plans relating thereto; our ability to realize the full extent of the anticipated benefits of our acquisition
of substantially all of the assets of EGEN, Inc., including achieving operational cost savings and synergies in light of any delays
we may encounter in the integration process and additional unforeseen expenses; introduction of new products by others; possible
licenses or acquisitions of other technologies, assets or businesses; and possible actions by customers, suppliers, partners,
competitors and regulatory authorities. These and other risks and uncertainties could cause actual results to differ materially
from those indicated by forward-looking statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
discussion of risks and uncertainties set forth in this Quarterly Report on Form 10-Q and in our most recent Annual Report on
Form 10-K, as well as in other filings with the SEC, is not a complete or exhaustive list of all risks facing the Company at any
particular point in time. We operate in a highly competitive, highly regulated and rapidly changing environment and our business
is constantly evolving. Therefore, it is likely that new risks will emerge, and that the nature and elements of existing risks
will change, over time. It is not possible for management to predict all such risk factors or changes therein, or to assess either
the impact of all such risk factors on our business or the extent to which any individual risk factor, combination of factors,
or new or altered factors, may cause results to differ materially from those contained in any forward-looking statement. We disclaim
any obligation to revise or update any forward-looking statement that may be made from time to time by us or on our behalf.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strategic
and Clinical Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celsion
is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including immunotherapies,
DNA-based therapies and directed chemotherapies. The Company&rsquo;s product pipeline includes GEN-1, a DNA-based immunotherapy
for the localized treatment of ovarian cancer and ThermoDox&reg;, a proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications.
Celsion has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular
transfection. With these technologies we are working to develop and commercialize more efficient, effective and targeted oncology
therapies that maximize efficacy while minimizing side effects common to cancer treatments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>ThermoDox&reg;</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThermoDox&reg;
is being evaluated in a Phase III clinical trial for primary liver cancer, which we call the OPTIMA Study, which was initiated
in 2014. ThermoDox&reg; is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment
of a wide range of cancers. Localized heat at hyperthermia temperatures (greater than 40&deg; Celsius) releases the encapsulated
doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in and around the targeted
tumor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
OPTIMA Study.</I></B> The OPTIMA Study represents an evaluation of ThermoDox&reg; in combination with a first line therapy, RFA,
for newly diagnosed, intermediate stage HCC patients. HCC incidence globally is approximately 755,000 new cases per year and is
the third largest cancer indication globally. Approximately 30% of newly diagnosed patients can be addressed with RFA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2014, we announced that the United States Food and Drug Administration (the &ldquo;FDA&rdquo;) provided clearance
for the OPTIMA Study, which is a pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox&reg;, in combination with
standardized RFA, for the treatment of primary liver cancer. The trial design of the OPTIMA Study is based on the comprehensive
analysis of data from an earlier clinical trial called the HEAT Study (the &ldquo;HEAT Study&rdquo;). The OPTIMA Study is supported
by a hypothesis developed from an overall survival analysis of a large subgroup of patients from the HEAT Study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-hoc
data analysis from our earlier Phase III HEAT Study suggest that ThermoDox&reg; may substantially improve OS, when compared to
the control group, in patients if their lesions undergo a 45-minute RFA procedure standardized for a lesion greater than 3 cm
in diameter. Data from nine OS sweeps have been conducted since the top line progression free survival (&ldquo;PFS&rdquo;) data
from the HEAT Study were announced in January 2013, with each data set demonstrating substantial improvement in clinical benefit
over the control group with statistical significance. On August 15, 2016, we announced updated results from its final retrospective
OS analysis of the data from the HEAT Study. These results demonstrated that in a large, well bounded, subgroup of patients with
a single lesion (n=285, 41% of the HEAT Study patients), treatment with a combination of ThermoDox&reg; and optimized RFA provided
an average 54% risk improvement in OS compared to optimized RFA alone. The Hazard Ratio (&ldquo;HR&rdquo;) at this analysis is
0.65 (95% CI 0.45 - 0.94) with a p-value of 0.02. Median OS for the ThermoDox&reg; group has been reached which translates into
a two-year survival benefit over the optimized RFA group (projected to be greater than 80 months for the ThermoDox&reg; plus optimized
RFA group compared to less than 60 months projection for the optimized RFA only group).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
this information should be viewed with caution since it is based on a retrospective analysis of a subgroup, we also conducted
additional analyses that further strengthen the evidence for the HEAT Study subgroup. We commissioned an independent computational
model at the University of South Carolina Medical School. The results unequivocally indicate that longer RFA heating times correlate
with significant increases in doxorubicin concentration around the RFA treated tissue. In addition, we conducted a prospective
preclinical study in 22 pigs using two different manufacturers of RFA and human equivalent doses of ThermoDox&reg; that clearly
support the relationship between increased heating duration and doxorubicin concentrations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
OPTIMA Study was designed with extensive input from globally recognized HCC researchers and expert clinicians and after receiving
formal written feedback from the FDA. The OPTIMA Study was designed to enroll up to 550 patients globally at approximately 65
clinical sites in the U.S., Canada, European Union (EU), China and other countries in the Asia-Pacific region and will evaluate
ThermoDox&reg; in combination with standardized RFA, which will require a minimum of 45 minutes across all investigators and clinical
sites for treating lesions three to seven centimeters, versus standardized RFA alone. The primary endpoint for this clinical trial
is overall survival (&ldquo;OS&rdquo;), and the secondary endpoints are progression free survival and safety. The statistical
plan calls for two interim efficacy analyses by an independent Data Monitoring Committee (&ldquo;DMC&rdquo;). The Company completed
enrollment of 556 patients in the Phase III OPTIMA Study in August 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2018, we announced that the DMC for the OPTIMA Study completed its last scheduled review of all patients enrolled
in the trial and unanimously recommended that the OPTIMA Study continue according to protocol to its final data readout. The DMC&rsquo;s
recommendation was based on the Committee&rsquo;s assessment of safety and data integrity of all patients randomized in the trial
as of October 4, 2018. The DMC reviewed study data at regular intervals throughout the patient enrollment period, with the primary
responsibilities of ensuring the safety of all patients enrolled in the study, the quality of the data collected, and the continued
scientific validity of the study design. As part of its review of all 556 patients enrolled into the trial, the DMC evaluated
a quality matrix relating to the total clinical data set, confirming the timely collection of data, that all data are current
as well as other data collection and quality criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 5, 2019, the Company announced that the prescribed number of OS events had been reached for the first prespecified interim
analysis of the OPTIMA Phase III Study. Following preparation of the data, the first interim analysis was conducted by the DMC
on November 1, 2019. This timeline was consistent with the Company&rsquo;s stated expectations and is necessary to provide a full
and comprehensive data set that may represent the potential for a successful trial outcome. In accordance with the statistical
plan, this initial interim analysis has a target of 118 events, or 60% of the total number required for the final analysis. At
the time of the data cutoff, the Company received reports of 128 events. The hazard ratio for success at 128 events is approximately
0.63, which represents a 37% reduction in the risk of death compared with RFA alone and is consistent with the 0.65 hazard ratio
that was observed in the prospective HEAT Study subgroup, which demonstrated a two-year overall survival advantage and a median
time to death of more than seven and a half years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 13, 2019, the Company announced that results from an independent analysis of the Company&rsquo;s ThermoDox<I><SUP>&reg;
</SUP></I>HEAT Study conducted by the National Institutes of Health (NIH) were published in the peer-reviewed publication, <I>Journal
of Vascular and Interventional Radiology</I>. The analysis was conducted by the intramural research program of the NIH and the
NIH Center for Interventional Oncology (CIO), with the full data set from the Company&rsquo;s HEAT Study. The analysis evaluated
the full data set to determine if there was a correlation between baseline tumor volume and radiofrequency ablation (RFA) heating
time (minutes/tumor volume in milliliters), with or without ThermoDox<SUP>&reg;</SUP> treatment, for patients with HCC. The NIH
analysis was conducted under the direction of Dr. Bradford Wood, MD, Director, NIH Center for Interventional Oncology and Chief,
NIH Clinical Center Interventional Radiology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
article titled, &ldquo;<I>RFA Duration Per Tumor Volume May Correlate With Overall Survival in Solitary Hepatocellular Carcinoma
Patients Treated With RFA Plus Lyso-thermosensitive Liposomal Doxorubicin</I>,&rdquo; discussed the NIH analysis of results from
437 patients in the HEAT Study (all patients with a single lesion representing 62.4% of the study population). The key finding
was that increased RFA heating time per tumor volume significantly improved overall survival (OS) in patients with single-lesion
HCC who were treated with RFA plus ThermoDox<SUP>&reg;</SUP>, compared to patients treated with RFA alone. A one-unit increase
in RFA duration per tumor volume was shown to result in about a 20% improvement in OS for patients administered ThermoDox<SUP>&reg;</SUP>,
compared to RFA alone. The authors conclude that increasing RFA heating time in combination with ThermoDox<SUP>&reg;</SUP> significantly
improves OS and establishes an improvement of over two years versus the control arm when the heating time per milliliter of tumor
is greater than 2.5 minutes. This finding is consistent with the Company&rsquo;s own results, which defined the optimized RFA
procedure as a 45-minute treatment for tumors with a diameter of 3 centimeters. Thus, the NIH analysis lends support to the hypothesis
underpinning the OPTIMA Study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 4, 2019, the Company announced that the DMC unanimously recommended the OPTIMA Study continue according to protocol.
The recommendation was based on a review of blinded safety and data integrity from 556 patients enrolled in the Company&rsquo;s
multinational, double-blind, placebo-controlled pivotal Phase III OPTIMA Study. The DMC&rsquo;s pre-planned interim efficacy review
followed 128 patient events, or deaths, which occurred in August 2019. Data presented demonstrated that PFS and OS data appear
to be tracking with patient data observed at a similar point in the Company&rsquo;s subgroup of patients followed prospectively
in the earlier Phase III HEAT Study, upon which the OPTIMA Study is based.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
data review demonstrated the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    OPTIMA Study patient demographics and risk factors are consistent with what the Company observed in the HEAT Study subgroup
    with all data quality metrics meeting expectations.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
    PFS for the OPTIMA Study reached 17 months as of August 2019. These blinded data compare favorably with 16 months median PFS
    for all 285 patients in the HEAT Study subgroup of patients treated with RFA &gt;45 minutes. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
    OS for the OPTIMA Study has not been reached as of August 5, 2019, however median OS appears to be consistent with the HEAT
    Study subgroup of patients treated with RFA &gt;45 minutes and followed prospectively for overall survival. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    OPTIMA Study has lost only 4 patients to follow-up from the initiation of the trial in September 2014 through August 2019
    while the trial design allows for 3% risk for loss per year, which at this point would have exceeded 60 patients.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unblinded
PFS and OS were tracking similarly to the subgroup of patients who received more than 45 minutes of RFA in our HEAT Study and
followed prospectively for more than three years. This subgroup in the HEAT Study demonstrated a 2-year overall survival advantage
and a median time to death of more than 7 &frac12; years. This tracking appears to bode well for success at the second of two
pre-planned interim efficacy analysis, which is intended after a minimum of 158 patient deaths and is projected to occur during
the second quarter of 2020. The hazard ratio for success at 158 events is 0.70. This is below the hazard ratio of 0.65 observed
in the HEAT Study subgroup of patients treated with RFA &gt; 45 minutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 15, 2020, the Company announced that the prescribed minimum number of events of 158 patient deaths had been reached for
the second pre-specified interim analysis of the OPTIMA Phase III Study. The hazard ratio for success at 158 deaths is 0.70, which
represents a 30% reduction in the risk of death compared with RFA alone. On July 13, 2020, the Company announced that it has received
a recommendation from the DMC to consider stopping the global OPTIMA Study. The recommendation was made following the second pre-planned
interim safety and efficacy analysis by the DMC on July 9, 2020. The DMC analysis found that the pre-specified boundary for stopping
the trial for futility of 0.900 was crossed with an actual value of 0.903. However, the 2-sided p-value of 0.524 for this analysis
provides uncertainty, subsequently, the DMC has left the final decision of whether or not to stop the OPTIMA Study to Celsion.
There were no safety concerns noted during the interim analysis. The Company intends to follow the advice of the DMC and will
consider our options either to stop the study or continue to follow patients after a thorough review of the data, and an evaluation
of our probability of success. Timing for this decision is made less urgent by the fact that the OPTIMA Study has been fully enrolled
since August 2018 and that the vast majority of the trial expenses have already been incurred. <FONT STYLE="background-color: white">On
August 4, 2020, the Company issued a press release announcing it will continue following patients for overall survival (&ldquo;OS&rdquo;),
noting that the unexpected and marginally crossed futility boundary, suggested by the Kaplan-Meier analysis at the second interim
analysis on July 9, 2020, may be associated with a data maturity issue.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
HEAT Study</I></B><I>.</I> On January 31, 2013, the Company announced that the HEAT Study, ThermoDox&reg; in combination with
RFA, did not meet the primary endpoint, PFS, in the Phase III clinical trial enrolling 701 patients with primary liver cancer.
This determination was made after conferring with the HEAT Study independent DMC, that the HEAT Study did not meet the goal of
demonstrating a clinically meaningful improvement in progression free survival. In the trial, ThermoDox&reg; was well-tolerated
with no unexpected serious adverse events. Following the announcement of the HEAT Study results, we continued to follow patients
for OS, the secondary endpoint of the HEAT Study. We have conducted a comprehensive analysis of the data from the HEAT Study to
assess the future strategic value and development strategy for ThermoDox&reg;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GEN-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEN-1
is a DNA-based immunotherapeutic product candidate for the localized treatment of ovarian cancer by intraperitoneally administering
an Interleukin-12 (&ldquo;IL-12&rdquo;) plasmid formulated with our proprietary TheraPlas delivery system. In this DNA-based approach,
the immunotherapy is combined with a standard chemotherapy drug, which can potentially achieve better clinical outcomes than with
chemotherapy alone. We believe that increases in IL-12 concentrations at tumours sites for several days after a single administration
could create a potent immune environment against tumor activity and that a direct killing of the tumor with concomitant use of
cytotoxic chemotherapy could result in a more robust and durable antitumor response than chemotherapy alone. We believe the rationale
for local therapy with GEN-1 is based on the following.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loco-regional
    production of the potent cytokine IL-12 avoids toxicities and poor pharmacokinetics associated with systemic delivery of recombinant
    IL-12;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persistent
    local delivery of IL-12 lasts up to one week and dosing can be repeated; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ideal
    for long-term maintenance therapy.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>GEN-I
OVATION Study.</I></B> In February 2015, we announced that the FDA accepted, without objection, the Phase I dose-escalation clinical
trial of GEN-1 in combination with the standard of care in neoadjuvant ovarian cancer (the &ldquo;OVATION Study&rdquo;). On September
30, 2015, we announced enrollment of the first patient in the OVATION Study. The OVATION Study was designed to (i) identify a
safe, tolerable and potentially therapeutically active dose of GEN-1 by recruiting and maximizing an immune response; (ii) to
enroll three to six patients per dose level and will evaluate safety and efficacy and (iii) attempt to define an optimal dose
for a follow-on Phase I/II study. In addition, the OVATION Study establishes a unique opportunity to assess how cytokine-based
compounds such as GEN-1, directly affect ovarian cancer cells and the tumor microenvironment in newly diagnosed patients. The
study was designed to characterize the nature of the immune response triggered by GEN-1 at various levels of the patients&rsquo;
immune system, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infiltration
    of cancer fighting T-cell lymphocytes into primary tumor and tumor microenvironment including peritoneal cavity, which is
    the primary site of metastasis of ovarian cancer;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in local and systemic levels of immuno-stimulatory and immunosuppressive cytokines associated with tumor suppression and growth,
    respectively; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expression
    profile of a comprehensive panel of immune related genes in pre-treatment and GEN-1-treated tumor tissue.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
initiated the OVATION Study at four clinical sites at the University of Alabama at Birmingham, Oklahoma University Medical Center,
Washington University in St. Louis and the Medical College of Wisconsin. During 2016 and 2017, we announced data from the first
fourteen patients in the OVATION Study, who completed treatment. On October 3, 2017, we announced final clinical and translational
research data from the OVATION Study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
translational research findings from all evaluable patients are consistent with the earlier reports from partial analysis of the
data and are summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    intraperitoneal treatment of GEN-1 in conjunction with neoadjuvant chemotherapy resulted in dose dependent increases in IL-12
    and Interferon-gamma (IFN-&gamma;) levels that were predominantly in the peritoneal fluid compartment with little to no changes
    observed in the patients&rsquo; systemic circulation. These and other post-treatment changes including decreases in VEGF levels
    in peritoneal fluid are consistent with an IL-12 based immune mechanism;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consistent
    with the previous partial reports, the effects observed in the IHC analysis were pronounced decreases in the density of immunosuppressive
    T-cell signals (Foxp3, PD-1, PDL-1, IDO-1) and increases in CD8+ cells in the tumor microenvironment;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ratio of CD8+ cells to immunosuppressive cells was increased in approximately 75% of patients suggesting an overall shift
    in the tumor microenvironment from immunosuppressive to pro-immune stimulatory following treatment with GEN-1. An increase
    in CD8+ to immunosuppressive T-cell populations is a leading indicator and believed to be a good predictor of improved overall
    survival; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analysis
    of peritoneal fluid by cell sorting, not reported before, shows a treatment-related decrease in the percentage of immunosuppressive
    T-cell (Foxp3+), which is consistent with the reduction of Foxp3+ T-cells in the primary tumor tissue, and a shift in tumor
    na&iuml;ve CD8+ cell population to more efficient tumor killing memory effector CD8+ cells.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also reported positive clinical data from the first fourteen patients who completed treatment in the OVATION Study. GEN-1
plus standard chemotherapy produced positive clinical results, with no dose limiting toxicities and positive dose dependent efficacy
signals which correlate well with positive surgical outcomes as summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
    the fourteen patients treated in the entire study, two patients demonstrated a complete response, ten patients demonstrated
    a partial response and two patients demonstrated stable disease, as measured by RECIST criteria. This translates to a 100%
    disease control rate and an 86% objective response rate (&ldquo;ORR&rdquo;). Of the five patients treated in the highest dose
    cohort, there was a 100% ORR with one complete response and four partial responses;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourteen
    patients had successful resections of their tumors, with nine patients (64%) having a complete tumor resection (&ldquo;R0&rdquo;),
    which indicates a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed.
    Seven out of eight (88%) patients in the highest two dose cohorts experienced a R0 surgical resection. All five patients treated
    at the highest dose cohort experienced a R0 surgical resection; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    patients experienced a clinically significant decrease in their CA-125 protein levels as of their most recent study visit.
    CA-125 is used to monitor certain cancers during and after treatment. CA-125 is present in greater concentrations in ovarian
    cancer cells than in other cells.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 2, 2019, the Company announced final PFS results from the OVATION Study. Median PFS in patients treated per protocol (n=14)
was 21 months and was 17.1 months for the intent-to-treat population (n=18) for all dose cohorts, including three patients who
dropped out of the study after 13 days or less, and two patients who did not receive full NAC and GEN-1 cycles. Under the current
standard of care, in women with Stage III/IV ovarian cancer undergoing NAC, the disease progresses within about 12 months on average.
The results from the OVATION Study support continued evaluation of GEN-1 based on promising tumor response, as reported in the
PFS data, and the ability for surgeons to completely remove visible tumor at debulking surgery. GEN-1 was well tolerated, and
no dose-limiting toxicities were detected. Intraperitoneal administration of GEN-1 was feasible with broad patient acceptance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>GEN-1
OVATION 2 Study.</I></B> The Company held an Advisory Board Meeting on September 27, 2017 with the clinical investigators and
scientific experts including those from Roswell Park Cancer Institute, Vanderbilt University Medical School, and M.D. Anderson
Cancer Center to review and finalize clinical, translational research and safety data from the Phase IB OVATION Study in order
to determine the next steps forward for our GEN-1 immunotherapy program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2017, the Company filed its Phase I/II clinical trial protocol with the FDA for GEN-1 for the localized treatment
of ovarian cancer. The protocol is designed with a single dose escalation phase to 100 mg/m&sup2; to identify a safe and tolerable
dose of GEN-1 while maximizing an immune response. The Phase I portion of the study will be followed by a continuation at the
selected dose in 130 patients randomized Phase II study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the OVATION 2 Study, patients in the GEN-1 treatment arm will receive GEN-1 plus chemotherapy pre- and post-interval debulking
surgery. The OVATION 2 Study will include up to 130 patients with Stage III/IV ovarian cancer, with 12 to 15 patients in the Phase
I portion and up to 118 patients in Phase II. The study is powered to show a 33% improvement in the primary endpoint, PFS, when
comparing GEN-1 with neoadjuvant + adjuvant chemotherapy versus neoadjuvant + adjuvant chemotherapy alone. The PFS primary analysis
will be conducted after at least 80 events have been observed or after all patients have been followed for at least 16 months,
whichever is later.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 5, 2019, the Company announced that the independent Data Safety Monitoring Board (DSMB) completed its safety review of
data from the first eight patients enrolled in the ongoing Phase I/II OVATION 2 Study. Based on the DSMB&rsquo;s recommendation,
the study will continue as planned and the Company will proceed with completing enrollment in the Phase I portion of the trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the Company announced highly encouraging initial clinical data from the first 15 patients enrolled in the ongoing
Phase I/II OVATION 2 Study for patients newly diagnosed with Stage III and IV ovarian cancer. The OVATION 2 Study combines GEN-1,
the Company&rsquo;s IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy (NACT). Following NACT,
patients undergo interval debulking surgery (IDS), followed by three additional cycles of chemotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEN-1
plus standard NACT produced positive dose-dependent efficacy results, with no dose-limiting toxicities, which correlates well
with successful surgical outcomes as summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
    the 15 patients treated in the Phase I portion of the OVATION 2 Study, nine patients were treated with GEN-1 at a dose of
    100 mg/m&sup2; plus NACT and six patients were treated with NACT only. All 15 patients had successful resections of their
    tumors, with seven out of nine patients (78%) in the GEN-1 treatment arm having an R0 resection, which indicates a microscopically
    margin-negative resection in which no gross or microscopic tumor remains in the tumor bed. Only three out of six patients
    (50%) in the NACT only treatment arm had a R0 resection.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    combining these results with the surgical resection rates observed in the Company&rsquo;s prior Phase Ib dose-escalation trial
    (the OVATION 1 Study), a population of patients with inclusion criteria identical to the OVATION 2 Study, the data reflect
    the strong dose-dependent efficacy of adding GEN-1 to the current standard of care NACT:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">% of Patients<BR>
 with <BR> R0 Resections</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">0, 36, 47 mg/m&sup2; of GEN-1 plus NACT</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">n=12</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">42</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">61, 79, 100 mg/m&sup2; of GEN-1 plus NACT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">n=17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for the 0, 36,
    47 mg/m&sup2; dose GEN-1 patients were comparable, as expected, to the higher (61, 79, 100 mg/m&sup2;) dose GEN-1 patients,
    with both groups demonstrating an approximate 80% ORR.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 23, 2020, the Company announced that the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
Medicines Agency (EMA) Committee for Orphan Medicinal Products <FONT STYLE="background-color: white">(COMP) has recommended that
GEN-1 be designated as an orphan medicinal product for the treatment of ovarian cancer. GEN-1, designed using </FONT>Celsion&rsquo;s
<FONT STYLE="background-color: white">proprietary TheraPlas platform technology, is an IL-12 DNA plasmid vector encased in a non-viral
nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. GEN-1
previously received orphan designation from the </FONT>FDA <FONT STYLE="background-color: white">and is currently being evaluated
in a Phase I/II clinical trial (the OVATION 2 Study) for the treatment of newly diagnosed patients with Stage III and IV ovarian
cancer.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 26, 2020, the Company announced </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with Medidata,
a Dassault Syst&egrave;mes company, that examining matched patient data provided by Medidata in a synthetic control arm (SCA)
with results from the Company&rsquo;s completed Phase Ib dose-escalating OVATION I Study with GEN-1 in Stage III/IV ovarian cancer
patients showed positive results in progression-free survival (PFS). The hazard ratio (HR) was 0.53 in the intent-to-treat (ITT)
group, showing strong signals of efficacy. GEN-1, designed using Celsion&rsquo;s proprietary TheraPlas platform technology, is
an IL-12 DNA plasmid vector encased in a non-viral nanoparticle delivery system, which enables cell transfection followed by persistent,
local secretion of the IL-12 protein. Celsion believes these data may warrant consideration of strategies to accelerate the clinical
development program for GEN-1 in newly diagnosed, advanced ovarian cancer patients by the FDA. In its March 2019 discussion with
Celsion, the FDA noted that preliminary findings from the Phase Ib OVATION I Study were exciting but lacked a control group to
evaluate GEN-1&rsquo;s independent impact on impressive tumor response, surgical results and PFS. The FDA encouraged the Company
to continue its GEN-1 development program and consult with FDA with new findings that may have a bearing on designations such
as Fast Track and Breakthrough Therapy. <FONT STYLE="background-color: white">SCAs have the potential to revolutionize clinical
trials in certain oncology indications and some other diseases where a randomized control is not ethical or practical. SCAs are
formed by carefully selecting control patients from historical clinical trials to match the demographic and disease characteristics
of the patients treated with the new investigational product. SCAs have been shown to mimic the results of traditional randomized
controls so that the treatment effects of an investigational product can be visible by comparison to the SCA. SCAs can help advance
the scientific validity of single arm trials, and in certain indications, reduce time and cost, and expose fewer patients to placebos
or existing standard-of-care treatments that might not be effective for them.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
July 27, 2020, the Company announced the randomization of the first two patients in the Phase II portion of the Phase I/II OVATION
2 Study with GEN-1 in advanced ovarian cancer. The Company anticipates completing enrolment of up to 118 patients in the third
quarter of 2021. Because this is an open-label study, the Company intends to provide clinical updates throughout the course of
treatment including response rates and surgical resection scores.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>TheraPlas
Technology Platform.</I></B> TheraPlas is a technology platform for the delivery of DNA and messenger RNA (&ldquo;mRNA&rdquo;)
therapeutics via synthetic non-viral carriers and is capable of providing cell transfection for double-stranded DNA plasmids and
large therapeutic RNA segments such as mRNA. There are two components of the TheraPlas system, a plasmid DNA or mRNA payload encoding
a therapeutic protein and a delivery system. The delivery system is designed to protect the DNA/RNA from degradation and promote
trafficking into cells and through intracellular compartments. We designed the delivery system of TheraPlas by chemically modifying
the low molecular weight polymer to improve its gene transfer activity without increasing toxicity. We believe TheraPlas is a
viable alternative to current approaches to gene delivery due to several distinguishing characteristics, including enhanced molecular
versatility that allows for complex modifications to improve activity and safety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Technology
Development and Licensing Agreements.</I></B> Our current efforts and resources are applied on the development and commercialization
of cancer drugs including tumor-targeting chemotherapy treatments using focused heat energy in combination with heat-activated
drug delivery systems, immunotherapies and RNA-based therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2016, we signed the GEN-1 Agreement with Hisun to pursue an expanded partnership for the technology transfer relating
to the clinical and commercial manufacture and supply of GEN-1, Celsion&rsquo;s proprietary gene mediated, IL-12 immunotherapy,
for the China territory, with the option to expand into other countries in the rest of the world after all necessary regulatory
approvals are obtained. The GEN-1 Agreement will help to support supply for both ongoing and planned clinical studies in the U.S.
and for potential future studies of GEN-1 in China. GEN-1 is currently being evaluated by Celsion in first line ovarian cancer
patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2012, Celsion and Hisun signed a long-term commercial supply agreement for the production of ThermoDox&reg;. Hisun is one
the largest manufacturers of chemotherapy agents globally, including doxorubicin. In July 2013, the ThermoDox&reg; collaboration
was expanded to focus on next generation liposomal formulation development with the goal of creating safer, more efficacious versions
of marketed cancer chemotherapeutics. During 2015, Hisun successfully completed the manufacture of three registration batches
for ThermoDox&reg; and has obtained regulatory approvals to supply ThermoDox&reg; to participating clinical trial sites in all
of the countries of South East Asia and North America, as well as to the European Union countries allowing for early access to
ThermoDox&reg;. The future manufacturing of clinical and commercial supplies by Hisun will result in a cost structure allowing
Celsion to profitably access all global markets, including third world countries, and help accelerate the Company&rsquo;s product
development program in China for ThermoDox&reg; in primary liver cancer and other approved indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Business
Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a clinical stage biopharmaceutical company, our business and our ability to execute our strategy to achieve our corporate goals
are subject to numerous risks and uncertainties. Material risks and uncertainties relating to our business and our industry are
described in &ldquo;Part II, Item 1A. Risk Factors&rdquo; in this Quarterly Report on Form 10-Q.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company&rsquo;s
research and development programs, clinical trials conducted in connection with the Company&rsquo;s product candidates, and applications
and submissions to the FDA. The Company has not generated significant revenue and have incurred significant net losses in each
year since our inception. As of June 30, 2020, the Company has incurred approximately $301 million of cumulative net losses and
we had approximately $25.5 million in cash, investment securities, and interest receivable. We have substantial future capital
requirements to continue our research and development activities and advance our product candidates through various development
stages. The Company believes these expenditures are essential for the commercialization of its technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects its operating losses to continue for the foreseeable future as it continues its product development efforts, and
when it undertakes marketing and sales activities. The Company&rsquo;s ability to achieve profitability is dependent upon its
ability to obtain governmental approvals, manufacture, and market and sell its new product candidates. There can be no assurance
that the Company will be able to commercialize its technology successfully or that profitability will ever be achieved. The operating
results of the Company have fluctuated significantly in the past.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>COVID-19
Pandemic</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2020, the WHO declared an outbreak of coronavirus, COVID-19, to be a &ldquo;Public Health Emergency of International Concern,&rdquo;
and the U.S. Department of Health and Human Services declared a public health emergency to aid the U.S. healthcare community in
responding to COVID-19. This virus has spread to over 100 countries, including the United States. Governments and businesses around
the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place
orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work.
Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets.
The Company did not observe significant impacts on its business or results of operations for the thus far in 2020 due to the global
emergence of COVID-19. While the extent to which COVID-19 impacts the Company&rsquo;s future results will depend on future developments,
the pandemic and associated economic impacts could result in a material impact to the Company&rsquo;s future financial condition,
results of operations and cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions
and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the ongoing
COVID-19 pandemic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disruptions caused by COVID-19 may also disrupt the clinical trials process and enrolment of patients. This may delay commercialization
efforts. The Company is currently monitoring its operating activities in light of these events and it is reasonably possible that
the virus could have a negative effect on the Company&rsquo;s financial condition and results of operations, the specific impact
is not readily determinable as of the date of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company&rsquo;s
control. These factors include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress of research activities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and scope of research programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress of preclinical and clinical development activities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress of the development efforts of parties with whom the Company has entered into research and development agreements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with additional clinical trials of product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to maintain current research and development licensing arrangements and to establish new research and development
    and licensing arrangements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to achieve milestones under licensing arrangements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of regulatory approvals.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2020, the Company announced that it has received a recommendation from the DMC to consider stopping the global Phase
III OPTIMA Study of ThermoDox<SUP>&reg;</SUP> in combination with RFA for the treatment of HCC, or primary liver cancer. The recommendation
was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020. The DMC analysis found
that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903. The Company
<FONT STYLE="background-color: white">intends to follow the advice of the DMC and will consider its options either to stop the
study or continue to follow patients after a thorough review of the data, and an evaluation of the probability of success. Timing
for this decision is made less urgent by the fact that the OPTIMA Study has been fully enrolled since </FONT>August 2018 <FONT STYLE="background-color: white">and
that the vast majority of the trial expenses have already been incurred. On August 4, 2020, the Company issued a press release
announcing it will continue following patients for overall survival (&ldquo;OS&rdquo;), noting that the unexpected and marginally
crossed futility boundary, suggested by the Kaplan-Meier analysis at the second interim analysis on July 9, 2020, may be associated
with a data maturity issue.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2019 and 2018, the Company submitted applications to sell a portion of the Company&rsquo;s State of New Jersey net operating losses
as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the
program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these
benefits to other New Jersey-based companies. As more fully discussed in Note 9, the Company received approval from the New Jersey
Economic Development Authority to sell $1.9 million of its State of New Jersey net operating losses recognizing a tax benefit
for the year ended December 31, 2019 for the net proceeds (approximately $1.8 million). In early 2020, the Company entered into
an agreement to sell these net operating losses. In April of 2020, the Company completed the sale of its State of New Jersey net
operating losses and received $1.8 million in net proceeds. In 2018, the Company completed the sale of a portion of its State
of New Jersey net operating losses for calendar years 2011 - 2017 totalling approximately $11.1 million for net proceeds of approximately
$10.4 million in December 2018. The proceeds of $10.4 million were reflected as a tax benefit for the year ended December 31,
2018. In June 2020, the Company filed an application with the New Jersey Economic Development Authority to sell substantially
all of its remaining State of New Jersey net operating losses totalling $2.0 million available under the program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018, the Company entered into the Horizon Credit Agreement with Horizon that provided $10 million in new capital. The obligations
under the Horizon Credit Agreement are secured by a first-priority security interest in substantially all assets of Celsion other
than intellectual property assets. Payments under the loan agreement are interest only (calculated based on one-month LIBOR plus
7.625%) for the first twenty-four (24) months after through July 2020, closing, followed by a 24-month amortization period of
principal and interest starting on August 1, 2020 and ending through the scheduled maturity date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
$25.5 million in cash, investments, interest receivable and up to $2.0 million in potential proceeds from the sale of the 2019
State of New Jersey net operating losses, coupled with remaining availability under the Capital-on-Demand Equity Facility with
JonesTrading Institutional Services LLC, the Company believes it has sufficient capital resources to fund its operations through
the end of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner
or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or
private sales of the Company&rsquo;s shares or debt, the sale of the Company&rsquo;s State of New Jersey net operating losses
and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into
common stock, the ownership interest of existing stockholders may be diluted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financing
Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Equity,
Debt and Other Forms of Financing</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
more fully discussed in Note 3 of the Financial Statement included in this Quarterly Report, during the fourth quarter of 2018
and 2020, the Company received eligibility from the New Jersey Economic Development Authority to sell $11.1 million and $1.9 million,
respectively, of its unused New Jersey net operating losses under the Technology Business Tax Certificate Program, and after selling
these net operating losses, received $10.4 million and $1.8 million of non-dilutive funding in the fourth quarter of 2018 and
second quarter of 2020, respectively. In June 2020, the Company filed an application with the New Jersey Economic Development
Authority to sell substantially all the remaining $2.0 million of its State of New Jersey net operating losses available under
the program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 23, 2020, we entered into the April PPP Loan, pursuant to the CARES Act and administered by the SBA. We thereafter received
proceeds of $632,220 under the April PPP Loan. The April PPP Loan application required Celsion to certify that there was economic
uncertainty surrounding the Company and that, as such, the April PPP Loan was necessary to support our ongoing operations. Celsion
made this certification in good faith after analysing, among other things, its financial situation and access to alternative forms
of capital, and believed that the Company satisfied all eligibility criteria for the April PPP Loan, and that our receipt of the
April PPP Loan proceeds was consistent with the broad objectives of the PPP of the CARES Act. The certification given with respect
to the April PPP Loan does not contain any objective criteria and is subject to interpretation. Considering subsequent guidance
issued by the U.S. Small Business Administration in consultation with the U.S. Department of the Treasury at that time, out of
an abundance of caution we returned the proceeds of the PPP Loan in full on May 13, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shortly
after the April PPP Loan was repaid, the SBA provided further guidance with respect to these certifications providing a safe harbor
under which companies such as Celsion with PPP loans of less than $2 million will be deemed to have made these certifications
in good faith. Therefore, as the Company continued to believe it qualifies for a loan under the PPP, it reapplied for and eventually
received the May PPP Loan for $692,530 on May 26, 2020. The May PPP Loan is guaranteed by the SBA and evidenced the Note in the
principal amount of $692,530 payable to the lender. Pursuant to the terms of the Note, it may be prepaid in part or in
full, at any time, without penalty. On June 22, 2020, as disclosed in the Company&rsquo;s Current Report on Form 8-K filed on
the same date, the Company commenced an offering of 2,666,667 shares of its common stock which closed on June 24, 2020 (Note 11)
and received net proceeds of approximately $9.1 million. In light of the proceeds received from this equity offering, the Company
elected to repay the May PPP Loan in full (including interest accrued of $577), on June 24, 2020, terminating all obligations
of the Company under the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018, the Company entered into the Horizon Credit Agreement with Horizon that provided $10 million in new capital. The obligations
under the Horizon Credit Agreement are secured by a first-priority security interest in substantially all assets of Celsion other
than intellectual property assets. Payments under the loan agreement are interest only (calculated based on one-month LIBOR plus
7.625%) for the first twenty-four (24) months after through July 2020, closing, followed by a 24-month amortization period of
principal and interest starting on August 1, 2020 and ending through the scheduled maturity date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2019 and thus far in 2020, we issued a total of 13.8 million shares of common stock in the following equity transactions raising
approximately $27.8 million in gross proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.4in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2020, the Company entered into an underwriting agreement (the &ldquo;Underwriting Agreement&rdquo;) with Oppenheimer
&amp; Co. Inc. (the &ldquo;Underwriter&rdquo;), relating to the issuance and sale (the &ldquo;Underwritten Offering&rdquo;) of
2.7 shares of the Company&rsquo;s common stock. Pursuant to the terms of the Underwriting Agreement, the Underwriter agreed to
purchase the shares at a price of $3.4875 per share. The Underwriter offered the shares at a public offering price of $3.75 per
share, reflecting an underwriting discount equal to $0.2625, or 7.0% of the public offering price. The net proceeds to the Company
from the Underwritten Offering, after deducting the underwriting discount and estimated offering expenses payable by the Company,
are approximately $9.1 million. The Underwritten Offering closed on June 24, 2020 and was made pursuant to the Company&rsquo;s
effective shelf registration statement on Form S-3 (File No. 333- 227236) filed with the Securities and Exchange Commission on
September 7, 2018, and declared effective on October 12, 2018, including the base prospectus dated October 12, 2018 included therein
and the related prospectus supplement.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.4in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 27, 2020, we entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with several institutional
    investors, pursuant to which we agreed to issue and sell, in a registered direct offering (the &ldquo;February 2020 Offering&rdquo;),
    an aggregate of 4.6 million shares (the &ldquo;Shares&rdquo;) of our common stock at an offering price of $1.05 per share
    for gross proceeds of approximately $4.8 million before the deduction of the Placement Agent fees and offering expenses. The
    Shares were offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-227236). The Purchase Agreement
    contains customary representations, warranties and agreements by the Company and customary conditions to closing. In a concurrent
    private placement (the &ldquo;Private Placement&rdquo;), the Company agreed to issue to the investors that participated in
    the Offering, for no additional consideration, warrants, to purchase up to 3.0 million shares of Common Stock (the &ldquo;Original
    Warrants&rdquo;). The Original Warrants were initially exercisable six months following their and were set to expire on the
    five-year anniversary of such initial exercise date. The Warrants had an exercise price of $1.15 per share subject to adjustment
    as provided therein. On March 12, 2020 the Company entered into private exchange agreements (the &ldquo;Exchange Agreements&rdquo;)
    with holders the Warrants. Pursuant to the Exchange Agreements, in return for a higher exercise price of $1.24 per share of
    Common Stock, the Company issued new warrants to the Investors to purchase up to 3.2 million shares of Common Stock (the &ldquo;Exchange
    Warrants&rdquo;) in exchange for the Original Warrants. The Exchange Warrants, like the Original Warrants, are initially exercisable
    six months following their issuance (the &ldquo;Initial Exercise Date&rdquo;) and expire on the five-year anniversary of their
    Initial Exercise Date. Other than having a higher exercise price, different issue date, Initial Exercise Date and expiration
    date, the terms of the Exchange Warrants are identical to those of the Original Warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.4in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                         August 31, 2018, the Company entered into the 2018 Aspire Purchase Agreement with Aspire
                                         Capital Fund LLC (&ldquo;Aspire Capital&rdquo;) which provides that, upon the terms and
                                         subject to the conditions and limitations set forth therein, Aspire Capital was
                                         committed to purchase up to an aggregate of $15.0 million of shares of the Company&rsquo;s
                                         common stock over the 24-month term of the 2018 Aspire Purchase Agreement. On October
                                         12, 2018, the Company filed with the SEC a prospectus supplement to the 2018 Shelf Registration
                                         Statement registering all of the shares of common stock that may be offered to Aspire
                                         Capital from time to time. The timing and amount of sales of the Company&rsquo;s common
                                         stock to Aspire Capital. Aspire Capital has no right to require any sales by the Company
                                         but is obligated to make purchases from the Company as directed by the Company in accordance
                                         with the Purchase Agreement. There were no limitations on use of proceeds, financial
                                         or business covenants, restrictions on future funding, rights of first refusal, participation
                                         rights, penalties or liquidated damages in the Purchase Agreement. In consideration for
                                         entering into the Purchase Agreement, concurrently with the execution of the Purchase
                                         Agreement in 2018, the Company issued to Aspire Capital 164,835 Commitment Shares. The
                                         2018 Aspire Purchase Agreement could be terminated by the Company at any time, at
                                         its discretion, without any cost to the Company. During 2019 the Company sold and issued
                                         an aggregate of 3.3 million shares under the Purchase Agreement, receiving approximately
                                         $6.3 million. All proceeds from the Company received under the 2018 Aspire Purchase Agreement
                                         were used for working capital and general corporate purposes. As a result of the Company
                                         and Aspire Capital entering into a new purchase agreement on October 28, 2019 discussed
                                         in the next paragraph, the 2018 Aspire Purchase Agreement was terminated. The Company
                                         sold a total of 3.4 million shares receiving $6.5 million under the 2018 Aspire Agreement
                                         during 2018 through its termination in 2019.</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                         October 28, 2019, Company entered into the 2019 Aspire Purchase Agreement with Aspire
                                         Capital. The terms and conditions pursuant to the 2019 Aspire Purchase Agreement were
                                         substantially similar to the 2018 Aspire Purchase Agreement. Pursuant to the new
                                         2019 Aspire Purchase Agreement, Aspire Capital was committed to purchase up to
                                         an aggregate of $10.0 million of shares of the Company&rsquo;s common stock over the
                                         24-month term of the 2019 Aspire Purchase Agreement. Concurrently with entering into
                                         the 2019 Aspire Purchase Agreement, the Company also entered into a registration rights
                                         agreement with Aspire Capital (the &ldquo;Registration Rights Agreement&rdquo;), in which
                                         the Company agreed to file one or more registration statements, as permissible and necessary
                                         to register under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
                                         registering the sale of the shares of the Company&rsquo;s common stock that have been
                                         and may be issued to Aspire Capital under the 2019 Aspire Purchase Agreement. In consideration
                                         for entering into the 2019 Aspire Purchase Agreement, the Company issued to Aspire Capital
                                         an additional 0.1 million Commitment Shares. On November 8, 2019, the Company filed with
                                         the SEC a Registration Statement on Form S-1 registering all the shares of common stock
                                         that may be offered to Aspire Capital from time to time under the 2019 Aspire Purchase
                                         Agreement. During 2019, the Company sold 0.5 million shares of common stock under the
                                         2019 Aspire Purchase Agreement, receiving approximately $0.7 million in gross proceeds.
                                         On March 5, 2020, the Company delivered notice to Aspire Capital terminating the 2019
                                         Aspire Purchase Agreement effective as of March 6, 2020. During the first quarter of
                                         2020 though the date of termination, the Company sold 1.0 million shares of common stock
                                         under the 2019 Aspire Purchase Agreement and received $1.6 million in gross proceeds.</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 4, 2018, the Company entered into a new Capital on Demand<SUP>TM</SUP> Sales Agreement (the &ldquo;Capital on Demand
    Agreement&rdquo;) with JonesTrading Institutional Services LLC, as sales agent (&ldquo;JonesTrading&rdquo;), pursuant to which
    the Company may offer and sell, from time to time, through JonesTrading shares of common stock having an aggregate offering
    price of up to $16.0 million. The Company intends to use the net proceeds from the offering, if any, for general corporate
    purposes, including research and development activities, capital expenditures and working capital. The Company is not obligated
    to sell any Common Stock under the Capital on Demand Agreement and, subject to the terms and conditions of the Capital on
    Demand Agreement, JonesTrading will use commercially reasonable efforts, consistent with its normal trading and sales practices
    and applicable state and federal law, rules and regulations and the rules of The Nasdaq Capital Market, to sell common stock
    from time to time based upon Celsion&rsquo;s instructions, including any price, time or size limits or other customary parameters
    or conditions the Company may impose. Under the Capital on Demand Agreement, JonesTrading may sell common stock by any method
    deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule 415 promulgated under the Securities Act of 1933,
    as amended. The Capital on Demand Agreement will terminate upon the earlier of (i) the sale of all shares of our common stock
    subject to the Sales Agreement, and (ii) the termination of the Capital on Demand Agreement by JonesTrading or Celsion. The
    Capital on Demand Agreement may be terminated by JonesTrading or the Company at any time upon 10 days&rsquo; notice to the
    other party, or by JonesTrading at any time in certain circumstances, including the occurrence of a material adverse change
    in the Company. During 2019 and
    in 2020 thus far, the Company sold 0.5 million and 1.2 million shares of common stock under the Capital on Demand Agreement,
    respectively, receiving gross proceeds of approximately $1.0 million and $3.5 million. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting policies are more fully described in Note 1 to our consolidated financial statements included in our 2019
Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 25, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued Accounting Standard Update No. 2016-13, &ldquo;Financial Instruments &ndash; Credit Losses (Topic 326):
Measurement of Credit Losses on Financial Instruments&rdquo;, which modifies the measurement of expected credit losses on certain
financial instruments. The Company will adopt ASU 2016-13 in its first quarter of 2021 utilizing the modified retrospective transition
method. Based on the composition of the Company&rsquo;s investment portfolio and current market conditions, the adoption of ASU
2016-13 is not expected to have a material impact on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued ASU No. 2018-13, <I>Fair Value Measurement: Disclosure Framework &ndash; Changes to the Disclosure
Requirements for Fair Value Measurement</I>, which adds and modifies certain disclosure requirements for fair value measurements.
Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level
1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies
will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value
measurements, and related changes in unrealized gains and losses included in other comprehensive income. This update is effective
for annual periods beginning after December 15, 2019, and interim periods within those periods, and early adoption is permitted.
The adoption of this standard did not have an impact on the Company&rsquo;s financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740). The standard simplifies the accounting for incomes taxes
by removing certain exceptions to the general principles in Topic 740 related to the approach for intra-period tax allocation
and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for
transactions that result in a step-up in the tax basis of goodwill. The standard also improves consistent application of and simplifies
GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment is effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The Company is currently
evaluating the impact that the adoption of this standard will have on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a clinical stage biopharmaceutical company, our business and our ability to execute our strategy to achieve our corporate goals
are subject to numerous risks and uncertainties. Material risks and uncertainties relating to our business and our industry are
described in &ldquo;Item 1A. Risk Factors&rdquo; under &ldquo;Part II: Other Information&rdquo; included herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL
REVIEW FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2020 AND 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended June 30, 2020 our net loss was $5.1 million compared to a net loss of $2.4 million for the same three-month
period of 2019. For the six months ended June 30, 2020 our net loss was $10.4 million compared to a net loss of $8.3 million for
the same three-month period of 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
$25.5 million in cash, investments, interest receivable and income tax receivable at June 30, 2020, coupled with future sales
of the Company&rsquo;s State of New Jersey net operating losses well as the remaining availability under the Capital on Demand
Equity Agreement, the Company believes it has sufficient capital resources to fund its operations through the end of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(In thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change Increase (Decrease)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Licensing Revenue:</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">125</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">125</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Clinical Research</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,481</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,327</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(846</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36.4</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Chemistry, Manufacturing and Controls</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,510</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,231</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">279</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">22.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,991</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(567</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15.9</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,901</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,137</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(236</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">(11.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,892</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,695</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(803</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">(14.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Loss from operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,767</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,570</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">803</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">14.4</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(In thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change Increase (Decrease)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Licensing Revenue:</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">250</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">250</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Clinical Research</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,299</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,107</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(808</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19.7</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Chemistry, Manufacturing and Controls</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,744</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,218</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">526</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">23.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,325</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(282</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4.5</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,740</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,355</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(615</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">(14.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,783</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,680</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(897</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">(8.4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Loss from operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,533</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,430</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">897</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">8.6</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of the Three Months Ended June 30, 2020 and 2019</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Licensing
Revenue</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2013, we entered a technology development contract with Hisun, pursuant to which Hisun paid us a non-refundable technology
transfer fee of $5.0 million to support our development of ThermoDox&reg; in the China territory. The $5.0 million received as
a non-refundable payment from Hisun in the second quarter 2013 has been recorded to deferred revenue and will be amortized over
the ten-year term of the agreement; therefore, we recorded deferred revenue of $125,000 in each of the second quarters of 2020
and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Research
and Development Expenses</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development (&ldquo;R&amp;D&rdquo;) expenses decreased by $0.6 million to $3.0 million in the second quarter of 2020 from
$3.6 million in the same period of 2019. Costs associated with the OPTIMA Study decreased to $0.6 million in the second quarter
of 2020 compared to $1.2 million in the same period of 2019. Costs associated the OVATION 2 Study increased to $0.2 million in
the second quarter of 2020 compared to $0.1 million in the same period of 2019. Regulatory costs were $0.3 million in the second
quarter of 2020 compared to $0.4 million in the same period of 2019. Other clinical costs were consistent at $0.5 million in the
second quarter of 2020 compared to $0.6 million in the same period of 2019. Costs associated with the development of GEN-1 to
support the OVATION 2 Study were $0.7 million in the second quarter of 2020 compared to $0.8 million in the same period of 2019.
Production costs associated with the development of ThermoDox&reg; increased to $0.8 million in the second quarter of 2020 compared
to $0.4 million in the same period of 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>General
and Administrative Expenses</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses decreased to $1.9 million in the second quarter of 2020 compared to $2.1 million in the same period
of 2019. This decrease is primarily attributable to lower professional fees in the second quarter of 2020 when compared to the
same period of 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Change
in Earn-out Milestone Liability and Warrant Expense</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total aggregate purchase price for the acquisition of assets from EGEN included potential future earn-out payments contingent
upon achievement of certain milestones. The difference between the aggregate $30.4 million in future earn-out payments and the
$13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company&rsquo;s risk-adjusted
assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. These milestone
payments are fair valued at the end of each quarter and any change in their value is recognized in the condensed consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2019, the Company and EGWU, Inc, entered into the Amended Asset Purchase Agreement discussed in Note 8. Pursuant to
the Amended Asset Purchase Agreement, payment of the earnout milestone liability related to the Ovarian Cancer Indication of $12.4
million has been modified. The Company has the option to make the payment as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$7.0
    million in cash within 10 business days of achieving the milestone; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$12.4
    million in cash, common stock of the Company, or a combination of either, within one year of achieving the milestone.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provided EGWU, Inc. 200,000 warrants to purchase common stock at a strike price of $0.01 per warrant share as consideration
for entering into the amended agreement. These warrant shares have no expiration and were fair valued at $2.00 using the closing
price of a share of Celsion stock on the date of issuance offset by the exercise price and recorded as an expense in the income
statement and were classified as equity on the balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2020, and March 31, 2020, the Company fair valued the earn-out milestone liability at $6.0 million and $5.8 million,
respectively and recognized a non-cash charge of $0.2 million during the second quarter of 2020. In assessing the earnout milestone
liability at June 30, 2020, the Company fair valued each of the two payment options per the Amended Asset Purchase Agreement and
weighted them at 80% and 20% probability for the $7.0 million and the $12.4 million payments, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2019, and March 31, 2019, the Company fair valued the earn-out milestone liability at $5.9 million and $5.8 million,
respectively and recognized a non-cash charge of $0.1 million during the second quarter of 2019. In assessing the earnout milestone
liability at June 30, 2019, the Company the fair valued each of the two payment options per the Amended Asset Purchase Agreement
and weighted them at 80% and 20% probability for the $7.0 million and the $12.4 million payments, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Investment
income and interest expense</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company realized $0.1 million of investment income from its short-term investments during the second quarter of 2019. Investment
income was insignificant in the second quarter of 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Horizon Credit Agreement, the Company incurred $0.7 million in interest expense in each of the second quarters
of 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of the Six Months Ended June 30, 2020 and 2019</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Licensing
Revenue</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2013, we entered a technology development contract with Hisun, pursuant to which Hisun paid us a non-refundable technology
transfer fee of $5.0 million to support our development of ThermoDox&reg; in the China territory. The $5.0 million received as
a non-refundable payment from Hisun in the second quarter 2013 has been recorded to deferred revenue and will be amortized over
the ten-year term of the agreement; therefore, we recorded deferred revenue of $250,000 in each of the first halves of 2020 and
2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Research
and Development Expenses</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
expenses decreased by $0.3 million to $6.0 million in the first half of 2020 from $6.3 million in the same period of 2019. Costs
associated with the OPTIMA Study decreased to $1.3 million in the first half of 2020 compared to $2.1 million in the same period
of 2019. Costs associated the OVATION 2 Study increased to $0.5 million in the first half of 2020 compared to $0.2 million in
the same six-month period of 2019. Regulatory costs were $0.4 million in the first half of 2020 compared to $0.6 million in the
same period of 2019. Other clinical costs were consistent at $1.1 million in the first half of 2020 compared to $1.2 million in
the same period of 2019. Costs associated with the development of GEN-1 to support the OVATION 2 Study were $1.6 million in the
first half of 2020 compared to $1.5 million in the same period of 2019. Production costs associated with the development of ThermoDox&reg;
increased to $1.1 million in the first half of 2020 compared to $0.7 million in the same period of 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>General
and Administrative Expenses</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses decreased to $3.7 million in the first half of 2020 compared to $4.4 million in the same period of
2019. This decrease is primarily attributable to lower personnel costs and professional fees in the first six months of 2020 when
compared to the same period of 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Change
in Earn-out Milestone Liability and Warrant Expense</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total aggregate purchase price for the acquisition of assets from EGEN included potential future earn-out payments contingent
upon achievement of certain milestones. The difference between the aggregate $30.4 million in future earn-out payments and the
$13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company&rsquo;s risk-adjusted
assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. These milestone
payments are fair valued at the end of each quarter and any change in their value is recognized in the condensed consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2019, the Company and EGWU, Inc, entered into the Amended Asset Purchase Agreement discussed in Note 8. Pursuant to
the Amended Asset Purchase Agreement, payment of the earnout milestone liability related to the Ovarian Cancer Indication of $12.4
million has been modified. The Company has the option to make the payment as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$7.0
    million in cash within 10 business days of achieving the milestone; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$12.4
    million in cash, common stock of the Company, or a combination of either, within one year of achieving the milestone.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provided EGWU, Inc. 200,000 warrants to purchase common stock at a strike price of $0.01 per warrant share as consideration
for entering into the amended agreement. These warrant shares have no expiration and were fair valued at $2.00 using the closing
price of a share of Celsion stock on the date of issuance offset by the exercise price and recorded as an expense in the income
statement and were classified as equity on the balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2020, and December 31, 2019, the Company fair valued the earn-out milestone liability at $6.0 million and $5.7 million,
respectively and recognized a non-cash charge of $0.3 million during the first half of 2020. In assessing the earnout milestone
liability at June 30, 2020, the Company fair valued each of the two payment options per the Amended Asset Purchase Agreement and
weighted them at 80% and 20% probability for the $7.0 million and the $12.4 million payments, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2019, and December 31, 2018, the Company fair valued the earn-out milestone liability at $5.9 million and $8.8 million,
respectively and recognized a non-cash benefit of $3.0 million during the first half of 2019. In assessing the earnout milestone
liability at June 30, 2019, the Company the fair valued each of the two payment options per the Amended Asset Purchase Agreement
and weighted them at 80% and 20% probability for the $7.0 million and the $12.4 million payments, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Investment
income and interest expense</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company realized $0.1 million and $0.3 million of investment income from its short-term investments during the first half of 2020
and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Horizon Credit Agreement,
the Company incurred $0.7 million in interest expense in each of the first halves of 2020 and 2019.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Condition, Liquidity and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception we have incurred significant losses and negative cash flows from operations. We have financed our operations primarily
through the net proceeds from the sales of equity, credit facilities and amounts received under our product licensing agreement
with Yakult and our technology development agreement with Hisun. The process of developing and commercializing ThermoDox<SUP>&reg;</SUP>,
GEN-1 and other product candidates and technologies requires significant research and development work and clinical trial studies,
as well as significant manufacturing and process development efforts. We expect these activities, together with our general and
administrative expenses to result in significant operating losses for the foreseeable future. Our expenses have significantly
and regularly exceeded our revenue, and we had an accumulated deficit of $301 million at June 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2020 we had total current assets of $26.8 million (including cash, cash equivalents and short-term investments and related
interest receivable on short-term investments of $25.5 million) and current liabilities of $9.2 million, resulting in net working
capital of $17.6 million. At December 31, 2019 we had total current assets of $16.2 million (including cash, cash equivalents,
short-term investment, interest receivable of $14.9 million) and current liabilities of $7.9 million, resulting in net working
capital of $8.3 million. We have substantial future capital requirements to continue our research and development activities and
advance our product candidates through various development stages. The Company believes these expenditures are essential for the
commercialization of its technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the first six months of 2020 was $7.9 million. Net cash provided by investing activities
was $5.1 million during the first six months of 2020. Net cash provided by financing activities was $18.6 million during the first
six months of 2020 from net proceeds received through the sale of our common stock. The Company also received $1.3 million from
two PPP Loans in 2020 pursuant to the CARES Act which have been paid back in full as of June 30, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to seek additional capital through further public or private equity offerings, debt financing, additional strategic alliance
and licensing arrangements, collaborative arrangements, potential sales of our net operating losses, or some combination of these
financing alternatives. If we raise additional funds through the issuance of equity securities, the percentage ownership of our
stockholders could be significantly diluted, and the newly issued equity securities may have rights, preferences, or privileges
senior to those of the holders of our common stock. If we raise funds through the issuance of debt securities, those securities
may have rights, preferences, and privileges senior to those of our common stock. If we seek strategic alliances, licenses, or
other alternative arrangements, such as arrangements with collaborative partners or others, we may need to relinquish rights to
certain of our existing or future technologies, product candidates, or products we would otherwise seek to develop or commercialize
on our own, or to license the rights to our technologies, product candidates, or products on terms that are not favorable to us.
The overall status of the economic climate could also result in the terms of any equity offering, debt financing, or alliance,
license, or other arrangement being even less favorable to us and our stockholders than if the overall economic climate were stronger.
We also will continue to look for government sponsored research collaborations and grants to help offset future anticipated losses
from operations and, to a lesser extent, interest income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
adequate funds are not available through either the capital markets, strategic alliances, collaborators, or sales of our net operating
losses, we may be required to delay or, reduce the scope of, or terminate our research, development, clinical programs, manufacturing,
or commercialization efforts, or effect additional changes to our facilities or personnel, or obtain funds through other arrangements
that may require us to relinquish some of our assets or rights to certain of our existing or future technologies, product candidates,
or products on terms not favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements and Contractual Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_002"></A>Item
3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objective of our investment activities is to preserve our capital until it is required to fund operations while at the
same time maximizing the income, we receive from our investments without significantly increasing risk. Our cash flow and earnings
are subject to fluctuations due to changes in interest rates in our investment portfolio. We maintain a portfolio of various issuers,
types, and maturities. These securities are classified as available-for-sale and, consequently, are recorded on the condensed
consolidated balance sheet at fair value with unrealized gains or losses reported as a component of accumulated other comprehensive
loss included in stockholders&rsquo; equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: #FAF9F8">Except
as discussed herein, the information required in this Item 3 is not significantly different from the information set forth in
&ldquo;Item 7A. Quantitative and Qualitative Disclosures About Market Risk&rdquo; in our 2019 Form 10-K and is therefore not presented
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_003"></A>Item
4. CONTROLS AND PROCEDURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have carried out an evaluation, under the supervision and with the participation of management, including our principal executive
officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures,
as that term is defined in Rule 13a-15(e) under the Exchange Act of 1934. Based on that evaluation, our principal executive officer
and principal financial officer have concluded that, as of June 30, 2020, which is the end of the period covered by this report,
our disclosure controls and procedures are effective at the reasonable assurance level in alerting them in a timely manner to
material information required to be included in our periodic reports with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting identified in connection with the evaluation that occurred during
the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, including our chief executive officer and chief financial officer, does not expect that our disclosure controls and
procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter
how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system
are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include
the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes.
Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management
override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential
future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with
the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements
due to error or fraud may occur and not be detected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_004"></A>PART
II: OTHER INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_005"></A>Item
1. Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2019, a purported stockholder of the Company filed a derivative and putative class action lawsuit against the Company
and certain officers and directors (the &ldquo;Shareholder Action&rdquo;). The Company is a defendant in this derivative and putative
class action lawsuit in the Superior Court of New Jersey, Chancery Division, filed by a shareholder against the Company (as both
a class action defendant and nominal defendant), and certain of its officers and directors (the &ldquo;Individual Defendants&rdquo;),
with the caption O&rsquo;Connor v. Braun et al., Docket No. MER-C-000068-19 (the &ldquo;Shareholder Action&rdquo;). The Shareholder
Action alleges breaches of the defendants&rsquo; fiduciary duties based on allegations that the defendants omitted or made improper
statements when seeking shareholder approval of the 2018 Stock Incentive Plan. The Shareholder Action seeks, among other things,
any damages sustained by the Company as a result of the defendants&rsquo; alleged wrongdoing, a declaratory judgment against all
defendants invalidating the 2018 Stock Incentive Plan and declaring any awards made under the Plan invalid, rescinded, and subject
to disgorgement, an order disgorging the equity awards granted to the Individual Defendants under the 2018 Stock Incentive Plan,
and attorneys&rsquo; fees and costs. Without admitting the validity of any of the claims asserted in the Shareholder Action, or
any liability with respect thereto, and expressly denying all allegations of wrongdoing, fault, liability, or damage against the
Company and the Individual Defendants arising out of any of the conduct, statements, acts or omissions alleged, or that could
have been alleged, in the Shareholder Action, the Company and the Individual Defendants have concluded that it is desirable that
the claims be settled on the terms and subject to the conditions set forth in the Settlement Agreement. The Company and the Individual
Defendants are entering into the Settlement Agreement for settlement purposes only and solely to avoid the cost and disruption
of further litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2020, the Company, the Individual Defendants, and the plaintiff (the &ldquo;Parties&rdquo;) entered into a Settlement
Agreement and Release (the &ldquo;Settlement Agreement&rdquo;), which memorializes the terms of the Parties&rsquo; settlement
of the Shareholder Action (the &ldquo;Settlement&rdquo;). The Settlement calls for repricing of certain stock options and payment
of plaintiff legal fees of $187,500. On July 24, 2020, the Court issued an order approving the Parties&rsquo; proposed form
of notice to shareholders regarding the Settlement. A hearing to determine whether the Court should issue a final order approving
the proposed Settlement has been scheduled for September 8, 2020. On August 3, 2020, the Company filed notice of the Settlement
Agreement on Form 8-K as filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_006"></A>Item
1A. Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the risk factors, uncertainties and assumptions that we believe are most relevant to our business. These
are factors that, individually or in the aggregate, we think could cause our actual results to differ significantly from expected
or historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the
Exchange Act of 1934 and Section 27A of the Securities Act of 1933. Additional risks that we currently believe are immaterial
may also impair our business operations. Investors should carefully consider the risks described below before making an investment
decision and understand that it is not possible to predict or identify all such factors. Consequently, investors should not consider
the following to be a complete discussion of all potential risks or uncertainties that may impact our business. Moreover, we operate
in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the
impact of all of these factors on our business, financial condition or results of operations. We undertake no obligation to publicly
update forward-looking statements, whether as a result of new information, future events, or otherwise. The description provided
in this Item 1A includes any material changes to and supersedes the description of the risk factors associated with our business
previously disclosed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed on March 25,
2020 with the SEC. In assessing these risks, investors should also refer to the other information contained or incorporated by
reference in this Quarterly Report and our other filings made from time to time with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISKS
RELATED TO OUR BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
have a history of significant losses from operations and expect to continue to incur significant losses for the foreseeable future.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, our expenses have substantially exceeded our revenue, resulting in continuing losses and an accumulated deficit
of $301 million at June 30, 2020. For the year ended December 31, 2019 and the six months ended June 30, 2020, we incurred net
losses of $16.9 million and $10.4 million, respectively. We currently have no product revenue and do not expect to generate any
product revenue for the foreseeable future. Because we are committed to continuing our product research, development, clinical
trial and commercialization programs, we will continue to incur significant operating losses unless and until we complete the
development of ThermoDox&reg;, GEN-1 and other new product candidates and these product candidates have been clinically tested,
approved by the United States Food and Drug Administration (FDA) and successfully marketed. The amount of future losses is uncertain.
Our ability to achieve profitability, if ever, will depend on, among other things, us or our collaborators successfully developing
product candidates, obtaining regulatory approvals to market and commercialize product candidates, manufacturing any approved
products on commercially reasonable terms, delays or setbacks we may experience associated with our preclinical studies, clinical
trials, third parties, or supply chain due to the COVID-19 pandemic, establishing a sales and marketing organization or suitable
third-party alternatives for any approved product and raising sufficient funds to finance business activities. If we or our collaborators
are unable to develop and commercialize one or more of our product candidates or if sales revenue from any product candidate that
receives approval is insufficient, we will not achieve profitability, which could have a material adverse effect on our business,
financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
do not expect to generate revenue for the foreseeable future.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have devoted our resources to developing a new generation of products and will not be able to market these products until we have
completed clinical trials and obtain all necessary governmental approvals. ThermoDox&reg; and the product candidates we purchased
in our acquisition of EGEN, including GEN-1, are still in various stages of development and trials and cannot be marketed until
we have completed clinical testing and obtained necessary governmental approval. Following our announcement on January 31, 2013
that the HEAT Study failed to meet its primary endpoint of progression free survival, we continued to follow the patients enrolled
in the HEAT Study to the secondary endpoint, overall survival. Based on the overall survival data from the post-hoc analysis of
results from the HEAT Study, we launched a pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox&reg; in combination
with RFA in primary liver cancer, known as the OPTIMA Study, in the first half of 2014. GEN-1 is currently in an early stage of
clinical development for the treatment of ovarian cancer. We conducted a Phase I dose-escalation clinical trial of GEN-1 in combination
with the standard of care in neo-adjuvant ovarian cancer starting in the second half of 2015 and completing enrollment in 2017.
We also expanded our ovarian cancer development program to include a Phase I/II dose escalating trial evaluating GEN-1 in ovarian
cancer patients. Our delivery technology platforms, TheraPlas and TheraSilence, are in preclinical stages of development. Accordingly,
our revenue sources are, and will remain, extremely limited until our product candidates are clinically tested, approved by the
FDA or foreign regulatory agencies and successfully marketed. We cannot guarantee that any of our product candidates will be approved
by the FDA or any foreign regulatory agency or marketed, successfully or otherwise, at any time in the foreseeable future or at
all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Drug
development is an inherently uncertain process with a high risk of failure at every stage of development. Our lead drug candidate
failed to meet its primary endpoint in our earlier Phase III clinical trial.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2013, we announced that ThermoDox&reg; in combination with RFA failed to meet the primary endpoint of the Phase III
clinical trial for primary liver cancer, known as the HEAT study. We have not completed our final analysis of the data and do
not know the extent to which, if any, the failure of ThermoDox&reg; to meet its primary endpoint in the Phase III trial could
impact our other ongoing studies of ThermoDox&reg; including a pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox&reg;
in combination with RFA in primary liver cancer, known as the OPTIMA study, which we launched in the first half of 2014. The trial
design of the OPTIMA study is based on the overall survival data from the post-hoc analysis of results from the HEAT study. We
completed a Phase I dose-escalation clinical trial of GEN-1 in combination with the standard of care in neo-adjuvant ovarian cancer
in the third quarter of 2017 and expanded our clinical development program for GEN-1 into a follow-on Phase I/II trial for newly
diagnosed ovarian cancer in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2020, the Company announced that it has received a recommendation from the DMC to consider stopping the global Phase
III OPTIMA Study of ThermoDox<SUP>&reg;</SUP> in combination with RFA for the treatment of HCC, or primary liver cancer. The recommendation
was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020. The DMC analysis found
that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903. The Company
<FONT STYLE="background-color: white">intends to follow the advice of the DMC and will consider its options either to stop the
study or continue to follow patients after a thorough review of the data, and an evaluation of the probability of success. Timing
for this decision is made less urgent by the fact that the OPTIMA Study has been fully enrolled since </FONT>August 2018 <FONT STYLE="background-color: white">and
that the vast majority of the trial expenses have already been incurred. On August 4, 2020, the Company issued a press release
announcing it will continue following patients for overall survival (&ldquo;OS&rdquo;), noting that the unexpected and marginally
crossed futility boundary, suggested by the Kaplan-Meier analysis at the second interim analysis on July 9, 2020, may be associated
with a data maturity issue.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
testing and clinical trials are long, expensive and highly uncertain processes and failure can unexpectedly occur at any stage
of clinical development, as evidenced by the failure of ThermoDox&reg; to meet its primary endpoint in the HEAT study. Drug development
is inherently risky and clinical trials take us several years to complete. The start or end of a clinical trial is often delayed
or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower
than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparator drug or required
prior therapy, clinical outcomes including insufficient efficacy, safety concerns, or our own financial constraints. The results
from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in
later phase clinical trials of the product candidate. We, the FDA or other applicable regulatory authorities may suspend clinical
trials of a product candidate at any time for various reasons, including a belief that subjects participating in such trials are
being exposed to unacceptable health risks or adverse side effects. We may not have the financial resources to continue development
of, or to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay
or prevent regulatory approval of, or our ability to commercialize, product candidates. The failure of one or more of our drug
candidates or development programs could have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
will need to raise additional capital to fund our planned future operations, and we may be unable to secure such capital without
dilutive financing transactions. If we are not able to raise additional capital, we may not be able to complete the development,
testing and commercialization of our product candidates.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated significant revenue and have incurred significant net losses in each year since our inception. For the year
ended December 31, 2019 and the six months ended June 30, 2020, we incurred net losses of $16.9 million and $10.4 million, respectively.
We have incurred approximately $301 million of cumulative net losses. As of June 30, 2020, cash, cash equivalents and short-term
investments and related interest receivable on short-term investments of $25.5 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have substantial future capital requirements to continue our research and development activities and advance our product candidates
through various development stages. For example, ThermoDox&reg; is currently being evaluated in a Phase III clinical trial in
combination with RFA for the treatment of primary liver cancer and other preclinical studies. On July 13, 2020, the Company announced
that it has received a recommendation from the DMC to consider stopping the global Phase III OPTIMA Study of ThermoDox<SUP>&reg;
</SUP>in combination with RFA for the treatment of HCC, or primary liver cancer. The recommendation was made following the second
pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020. The DMC analysis found that the pre-specified boundary
for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903. The Company <FONT STYLE="background-color: white">intends
to follow the advice of the DMC and will consider its options either to stop the study or continue to follow patients after a
thorough review of the data, and an evaluation of the probability of success. Timing for this decision is made less urgent by
the fact that the OPTIMA Study has been fully enrolled since </FONT>August 2018 <FONT STYLE="background-color: white">and that
the vast majority of the trial expenses have already been incurred. On August 4, 2020, the Company issued a press release announcing
it will continue following patients for overall survival (&ldquo;OS&rdquo;), noting that the unexpected and marginally crossed
futility boundary, suggested by the Kaplan-Meier analysis at the second interim analysis on July 9, 2020, may be associated with
a data maturity issue.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed a Phase I dose-escalation clinical trial of GEN-1 in combination with the standard of care in neo-adjuvant ovarian cancer
in the third quarter of 2017 and expanded our clinical development program for GEN-1 into a follow-on Phase I/II trial for newly
diagnosed ovarian cancer in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
complete the development and commercialization of our product candidates, we will need to raise substantial amounts of additional
capital to fund our operations. Our future capital requirements will depend upon numerous unpredictable factors, including, without
limitation, the cost, timing, progress and outcomes of clinical studies and regulatory reviews of our proprietary drug candidates,
including any unforeseen delays or increased costs we may incur as a result of the COVID-19 pandemic or other causes, our efforts
to implement new collaborations, licenses and strategic transactions, general and administrative expenses, capital expenditures
and other unforeseen uses of cash. We do not have any committed sources of financing and cannot assure you that alternate funding
will be available in a timely manner, on acceptable terms or at all. We may need to pursue dilutive equity financings, such as
the issuance of shares of common stock, convertible debt or other convertible or exercisable securities. Such dilutive equity
financings could dilute the percentage ownership of our current common stockholders and could significantly lower the market value
of our common stock. In addition, a financing could result in the issuance of new securities that may have rights, preferences
or privileges senior to those of our existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain additional capital on a timely basis or on acceptable terms, we may be required to delay, reduce or terminate
our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo
corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others
that may require us to relinquish rights to some of our technologies, product candidates or potential markets or that could impose
onerous financial or other terms. Furthermore, if we cannot fund our ongoing development and other operating requirements, particularly
those associated with our obligations to conduct clinical trials under our licensing agreements, we will be in breach of these
licensing agreements and could therefore lose our license rights, which could have material adverse effects on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
we do not obtain or maintain FDA and foreign regulatory approvals for our drug candidates on a timely basis, or at all, or if
the terms of any approval impose significant restrictions or limitations on use, we will be unable to sell those products and
our business, results of operations and financial condition will be negatively affected.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain regulatory approvals from the FDA and foreign regulatory agencies, we must conduct clinical trials demonstrating that our
products are safe and effective. We may need to amend ongoing trials, or the FDA and/or foreign regulatory agencies may require
us to perform additional trials beyond those we planned. The testing and approval process require substantial time, effort and
resources, and generally takes a number of years to complete. The time to complete testing and obtaining approvals is uncertain,
and the FDA and foreign regulatory agencies have substantial discretion, at any phase of development, to terminate clinical studies,
require additional clinical studies or other testing, delay or withhold approval, and mandate product withdrawals, including recalls.
In addition, our drug candidates may have undesirable side effects or other unexpected characteristics that could cause us or
regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or
denial of regulatory approval by regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed.
The failure to obtain timely regulatory approval of product candidates, the imposition of marketing limitations, or a product
withdrawal would negatively impact our business, results of operations and financial condition. Even if we receive approval, we
will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional
expense and subject us to restrictions, withdrawal from the market, or penalties if we fail to comply with applicable regulatory
requirements or if we experience unanticipated problems with our product candidates, when and if approved. Finally, even if we
obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the
United States, given that we may be subject to additional or different regulatory burdens in other markets. This could limit our
ability to realize their full market potential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
industry is highly regulated by the FDA and comparable foreign regulatory agencies. We must comply with extensive, strictly enforced
regulatory requirements to develop, obtain, and maintain marketing approval for any of our product candidates.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securing
FDA or comparable foreign regulatory approval requires the submission of extensive preclinical and clinical data and supporting
information for each therapeutic indication to establish the product candidate&rsquo;s safety and efficacy for its intended use.
It takes years to complete the testing of a new drug or biological product and development delays and/or failure can occur at
any stage of testing. Any of our present and future clinical trials may be delayed, halted, not authorized, or approval of any
of our products may be delayed or may not be obtained due to any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">factors
    related to the COVID-19 pandemic, including regulators or institutional review boards, or IRBs, or ethics committees may not
    authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    preclinical test or clinical trial may fail to produce safety and efficacy results satisfactory to the FDA or comparable foreign
    regulatory authorities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
    and clinical data can be interpreted in different ways, which could delay, limit or prevent marketing approval;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or inconclusive results from a preclinical test or clinical trial or adverse events during a clinical trial could cause a
    preclinical study or clinical trial to be repeated or a development program to be terminated, even if other studies relating
    to the development program are ongoing or have been completed and were successful;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities can place a clinical hold on a trial if, among other reasons, it finds that
    subjects enrolled in the trial are or would be exposed to an unreasonable and significant risk of illness or injury;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    facilities that we utilize, or the processes or facilities of third-party vendors, including without limitation the contract
    manufacturers who will be manufacturing drug substance and drug product for us or any potential collaborators, may not satisfactorily
    complete inspections by the FDA or comparable foreign regulatory authorities; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may encounter delays or rejections based on changes in FDA policies or the policies of comparable foreign regulatory authorities
    during the period in which we develop a product candidate, or the period required for review of any final marketing approval
    before we are able to market any product candidate.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, information generated during the clinical trial process is susceptible to varying interpretations that could delay,
limit, or prevent marketing approval at any stage of the approval process. Moreover, early positive preclinical or clinical trial
results may not be replicated in later clinical trials. As more product candidates within a particular class of drugs proceed
through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory
authorities may increase or change. Failure to demonstrate adequately the quality, safety, and efficacy of any of our product
candidates would delay or prevent marketing approval of the applicable product candidate. We cannot assure you that if clinical
trials are completed, either we or our potential collaborators will submit applications for required authorizations to manufacture
or market potential products or that any such application will be reviewed and approved by appropriate regulatory authorities
in a timely manner, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Separately,
in response to the COVID-19 global pandemic, on March 10, 2020, the FDA announced its intention to postpone most inspections of
foreign manufacturing facilities and products through at least April 2020, though no set end date has been determined. On March
18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities.
Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19
pandemic and provide guidance regarding the conduct of clinical trials, which guidance continues to evolve. In April 2020, the
FDA stated that its New Drug Program was continuing to meet program user fee performance goals, but due to many agency staff working
on COVID-19 activities, it was possible that the FDA would not be able to sustain that level of performance indefinitely. If global
health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews
or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory
submissions, which could have a material adverse effect on our business</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business, including our preclinical studies and
clinical trials.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2020, the World Health Organization declared COVID-19 a global pandemic, and the U.S. Department of Health and Human Services
declared a public health emergency to aid the U.S. healthcare community in responding to COVID-19. This virus continues to spread
globally and, as of June 2020, has spread to over 100 countries, including the United States. Governments and businesses around
the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place
orders, quarantines, and significant restrictions on travel, as well as restrictions that prohibit many employees from going to
work. Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial
markets. The Company did not observe significant impacts on its business or results of operations for the three months ended June
30, 2020 due to the global emergence of COVID-19. While the extent to which COVID-19 impacts the Company&rsquo;s future results
will depend on future developments, the pandemic and associated economic impacts could result in a material impact to the Company&rsquo;s
future financial condition, results of operations and cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions
and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the ongoing
COVID-19 pandemic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disruptions caused by COVID-19 may also disrupt preclinical studies, the clinical trials process and enrollment of patients. This
may delay commercialization efforts. The Company is currently monitoring its operating activities in light of these events and
it is reasonably possible that the virus could have a negative effect on the Company&rsquo;s financial condition and results of
operations, the specific impact is not readily determinable as of the date of this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While,
as of the date of this report, we have not experienced any material disruptions to the execution of the clinical trials and the
research and development activities that we currently have underway, as a result of the pandemic we may experience disruptions
that could severely impact research and development timelines and outcomes, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in enrolling patients in our clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical
    site staff;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical
    trial sites and hospital staff supporting the conduct of our clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended
    by federal, state or foreign governments, employers and others or interruption of clinical trial subject visits and study
    procedures (such as procedures that are deemed non-essential under law, regulation or institutional policies), which may impact
    the integrity of subject data and clinical study endpoints;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing
    shortages, production slowdowns or stoppages and disruptions in delivery systems;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruptions
    in preclinical studies due to restricted or limited operations at our contracted research facilities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs we may incur as a result of the impact of the COVID-19 pandemic, including the costs of mitigation efforts;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deterioration
    of worldwide credit and financial markets that could limit our ability to obtain external financing to fund our operations
    and capital expenditures;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investment-related
    risks, including difficulties in liquidating investments due to current market conditions and adverse investment performance;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    on employee resources that would otherwise be focused on the conduct of our research and development activities, including
    because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;
    or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruptions
    or limitations of the types described affecting our service providers and collaboration partners, including contract research
    organizations running clinical trials and collaboration partners sponsoring clinical trials in which we are supplying our
    product candidates or otherwise participating.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
addition, the trading prices for common stock of other biopharmaceutical companies have been highly volatile as a result of the
COVID-19 pandemic.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The COVID-19 pandemic continues
to rapidly evolve. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend
on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread
of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries,
business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to diagnose,
contain and treat the disease. If we or any of the third parties with whom we engage were to experience shutdowns or other business
disruptions, our ability to conduct our business and development activities in the manner and on the timelines presently planned
could be materially and negatively impacted. There can be no assurance that any such disruptions or delays will not materially
adversely impact our business, results of operations, access to financial resources and our financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
gene-based products for therapeutic applications are subject to extensive regulation by the FDA and comparable agencies in other
countries. The precise regulatory requirements with which we will have to comply, now and in the future, are uncertain due to
the novelty of the gene-based products we are developing.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory approval process for novel product candidates such as ours can be significantly more expensive and take longer than
for other, better known or more extensively studied product candidates. Limited data exist regarding the safety and efficacy of
DNA-based therapeutics compared with conventional therapeutics, and government regulation of DNA-based therapeutics is evolving.
Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future.
The FDA has established the Office of Cellular, Tissue and Gene Therapies within its Center for Biologics Evaluation and Research
(CBER), to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies
Advisory Committee to advise CBER in its review. It is difficult to determine how long it will take or how much it will cost to
obtain regulatory approvals for our product candidates in either the U.S. or the European Union or how long it will take to commercialize
our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
events or the perception of adverse events in the field of gene therapy generally, or with respect to our product candidates specifically,
may have a particularly negative impact on public perception of gene therapy and result in greater governmental regulation, including
future bans or stricter standards imposed on gene-based therapy clinical trials, stricter labeling requirements and other regulatory
delays in the testing or approval of our potential products. For example, if we were to engage an NIH-funded institution to conduct
a clinical trial, we may be subject to review by the NIH Office of Biotechnology Activities&rsquo; Recombinant DNA Advisory Committee
(the RAC). If undertaken, RAC can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and
details and approved its initiation. Conversely, the FDA can put an investigational new drug (IND) application on a clinical hold
even if the RAC has provided a favorable review or an exemption from in-depth, public review. Such committee and advisory group
reviews and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies,
increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization
of our product candidates or lead to significant post-approval limitations or restrictions. Any increased scrutiny could delay
or increase the costs of our product development efforts or clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our products receive regulatory approval, they may still face future development and regulatory difficulties. Government regulators
may impose significant restrictions on a product&rsquo;s indicated uses or marketing or impose ongoing requirements for potentially
costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Serious
adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development
or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities
to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations
on the use of our product candidates thereby limiting the commercial potential of such product candidate.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we continue our development of our product candidates and initiate clinical trials of our additional product candidates, serious
adverse events, undesirable side effects or unexpected characteristics may emerge causing us to abandon these product candidates
or limit their development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects
or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our product candidates initially show promise in these early clinical trials, the side effects of drugs are frequently only
detectable after they are tested in large, Phase 3 clinical trials or, in some cases, after they are made available to patients
on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects
were caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions
and be taking other medications. If serious adverse or unexpected side effects are identified during development and are determined
to be attributed to our product candidate, we may be required to develop a Risk Evaluation and Mitigation Strategy (REMS) to mitigate
those serious safety risks, which could impose significant distribution and use restrictions on our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, drug-related side effects could also affect subject recruitment or the ability of enrolled subjects to complete the
trial, result in potential product liability claims, reputational harm, withdrawal of approvals, a requirement to include additional
warnings on the label or to create a medication guide outlining the risks of such side effects for distribution to patients. It
can also result in patient harm, liability lawsuits, and reputational harm. Any of these occurrences could prevent us from achieving
or maintaining market acceptance and may harm our business, financial condition and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise
adversely affected.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical
trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients
who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patient eligibility and exclusion criteria defined in the protocol;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size of the patient population required for analysis of the trial&rsquo;s primary endpoints and the process for identifying
    patients;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in our research programs resulting from factors related to the COVID-19 pandemic;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness or availability of patients to participate in our trials; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proximity of patients to trial sites;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    design of the trial;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to recruit clinical trial investigators with the appropriate competencies and experience;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&rsquo;
    and patients&rsquo; perceptions as to the potential advantages and risks of the product candidate being studied in relation
    to other available therapies, including any new products that may be approved for the indications we are investigating;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of competing commercially available therapies and other competing drug candidates&rsquo; clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain patient informed consents; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that patients enrolled in clinical trials will drop out of the trials before completion.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic
areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some
patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors.
Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same
clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical
trials in such clinical trial site. Certain of our planned clinical trials may also involve invasive procedures, which may lead
some patients to drop out of trials to avoid these follow-up procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
timely enrollment in clinical trials is reliant on clinical trial sites which may be adversely affected by global health matters,
including, among other things, pandemics. For example, our clinical trial sites may be located in regions currently being affected
by the COVID-19 coronavirus. Some factors from the COVID-19 coronavirus outbreak that we believe may adversely affect enrollment
in our trials include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of healthcare resources away from the conduct of clinical trial matters to focus on pandemic concerns, including
    the attention of infectious disease physicians serving as our clinical trial investigators, hospitals serving as our clinical
    trial sites and hospital staff supporting the conduct of our clinical trials; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    who would otherwise be candidates for enrollment in our clinical trials, may become infected with the COVID-19 coronavirus,
    which may kill some patients and render others too ill to participate, limiting the available pool of participants for our
    trials; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    on travel that interrupt key trial activities, such as clinical trial site initiations and monitoring;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    in global shipping affecting the transport of clinical trial materials, such as investigational drug product and comparator
    drugs used in our trials; and </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee
    furlough days that delay necessary interactions with local regulators, ethics committees and other important agencies and
    contractors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other factors arising from the COVID-19 coronavirus could worsen in countries that are already afflicted with the virus or
could continue to spread to additional countries, each of which may further adversely impact our clinical trials. The global outbreak
of the COVID-19 coronavirus continues to evolve and the conduct of our trials may continue to be adversely affected, despite efforts
to mitigate this impact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
may not successfully engage in future strategic transactions, which could adversely affect our ability to develop and commercialize
product candidates, impact our cash position, increase our expense and present significant distractions to our management.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may consider strategic alternatives intended to further the development of our business, which may include acquiring
businesses, technologies or products, out- or in-licensing product candidates or technologies or entering into a business combination
with another company. Any strategic transaction may require us to incur non-recurring or other charges, increase our near- and
long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These
transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our
business and diversion of our management&rsquo;s time and attention in order to manage a collaboration or develop acquired products,
product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction
consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill
or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the
operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers
of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired
business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of
the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material
adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter any
strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product
candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strategic
transactions, such as acquisitions, partnerships and collaborations, including the EGEN asset acquisition, involve numerous risks,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of markets for the products of acquired businesses, technologies or product lines to develop as expected;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainties
    in identifying and pursuing acquisition targets;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    challenges in achieving strategic objectives, cost savings and other benefits expected from acquisitions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that the financial returns on acquisitions will not support the expenditures incurred to acquire such businesses or the
    capital expenditures needed to develop such businesses;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in assimilating the acquired businesses, technologies or product lines;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure to successfully manage additional business locations, including the additional infrastructure and resources necessary
    to support and integrate such locations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    existence of unknown product defects related to acquired businesses, technologies or product lines that may not be identified
    due to the inherent limitations involved in the due diligence process of an acquisition;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of management&rsquo;s attention from other business concerns;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    associated with entering markets or conducting operations with which we have no or limited direct prior experience;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    associated with assuming the legal obligations of acquired businesses, technologies or product lines;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    related to the effect that internal control processes of acquired businesses might have on our financial reporting and management&rsquo;s
    report on our internal control over financial reporting;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential loss of key employees related to acquired businesses, technologies or product lines; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    incurrence of significant exit charges if products or technologies acquired in business combinations are unsuccessful.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never realize the perceived benefits of the EGEN asset acquisition or potential future transactions. We cannot assure you
that we will be successful in overcoming problems encountered in connection with any transactions, and our inability to do so
could significantly harm our business, results of operations and financial condition. These transactions could dilute a stockholder&rsquo;s
investment in us and cause us to incur debt, contingent liabilities and amortization/impairment charges related to intangible
assets, all of which could materially and adversely affect our business, results of operations and financial condition. In addition,
our effective tax rate for future periods could be negatively impacted by the EGEN asset acquisition or potential future transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
business depends on license agreements with third parties to permit us to use patented technologies. The loss of any of our rights
under these agreements could impair our ability to develop and market our products.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, in a substantial part, on our ability to maintain our rights under license agreements granting us rights
to use patented technologies. For instance, we are party to license agreements with Duke University, under which we have exclusive
rights to commercialize medical treatment products and procedures based on Duke&rsquo;s thermo-sensitive liposome technology.
The Duke University license agreement contains a license fee, royalty and/or research support provisions, testing and regulatory
milestones, and other performance requirements that we must meet by certain deadlines. If we breach any provisions of the license
and research agreements, we may lose our ability to use the subject technology, as well as compensation for our efforts in developing
or exploiting the technology. Any such loss of rights and access to technology could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we cannot guarantee that any patent or other technology rights licensed to us by others will not be challenged or circumvented
successfully by third parties, or that the rights granted will provide adequate protection. We may be required to alter any of
our potential products or processes or enter into a license and pay licensing fees to a third party or cease certain activities.
There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at
all, or that we could develop or otherwise obtain alternate technology. If a license is not available on commercially reasonable
terms or at all, our business, results of operations, and financial condition could be significantly harmed, and we may be prevented
from developing and commercializing the product. Litigation, which could result in substantial costs, may also be necessary to
enforce any patents issued to or licensed by us or to determine the scope and validity of another&rsquo;s claimed proprietary
rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual
property protection.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual
issues. We own various U.S. and international patents and have pending U.S. and international patent applications that cover various
aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court
of law through the entire patent term. Even for patents that are held valid and enforceable, the legal process associated with
obtaining such a judgment is time consuming and costly. Additionally, issued patents can be subject to opposition, interferences
or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially
in a form that renders the patent without commercially relevant or broad coverage). Further, our competitors may be able to circumvent
and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization
of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a short period of protection,
if any, following the commercialization of products encompassed by our patents. We may have to participate in interference proceedings
declared by the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed patent applications, and plan to file additional patent applications, covering various aspects of our technologies
and our proprietary product candidates. There can be no assurance that the patent applications for which we apply would actually
issue as patents or do so with commercially relevant or broad coverage. The coverage claimed in a patent application can be significantly
reduced before the patent is issued. The scope of our claim coverage can be critical to our ability to enter into licensing transactions
with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in
scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor
of inventions covered by our patents or patent applications. In addition, there is no guarantee that we will be the first to file
a patent application directed to an invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant
liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the
technology in dispute. In those instances where we seek an intellectual property license from another, we may not be able to obtain
the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our
technologies or products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of
such rights could harm our business, results of operations and financial condition.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secrets and confidential information that we seek to protect, in part, by confidentiality agreements with our corporate
partners, collaborators, employees and consultants. We cannot assure you that these agreements are adequate to protect our trade
secrets and confidential information or will not be breached or, if breached, we will have adequate remedies. Furthermore, others
may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade
secrets or disclose such technology. Any loss of trade secret protection or other unpatented proprietary rights could harm our
business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
products may infringe patent rights of others, which may require costly litigation and, if we are not successful, could cause
us to pay substantial damages or limit our ability to commercialize our products.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends on our ability to operate without infringing the patents and other proprietary rights of third parties.
There may be third party patents that relate to our products and technology. We may unintentionally infringe upon valid patent
rights of third parties. Although we currently are not involved in any material litigation involving patents, a third-party patent
holder may assert a claim of patent infringement against us in the future. Alternatively, we may initiate litigation against the
third-party patent holder to request that a court declare that we are not infringing the third party&rsquo;s patent and/or that
the third party&rsquo;s patent is invalid or unenforceable. If a claim of infringement is asserted against us and is successful,
and therefore we are found to infringe, we could be required to pay damages for infringement, including treble damages if it is
determined that we knew or became aware of such a patent and we failed to exercise due care in determining whether or not we infringed
the patent. If we have supplied infringing products to third parties or have licensed third parties to manufacture, use or market
infringing products, we may be obligated to indemnify these third parties for damages they may be required to pay to the patent
holder and for any losses they may sustain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can also be prevented from selling or commercializing any of our products that use the infringing technology in the future, unless
we obtain a license from such third party. A license may not be available from such third party on commercially reasonable terms
or may not be available at all. Any modification to include a non-infringing technology may not be possible, or if possible, may
be difficult or time-consuming to develop, and require revalidation, which could delay our ability to commercialize our products.
Any infringement action asserted against us, even if we are ultimately successful in defending against such action, would likely
delay the regulatory approval process of our products, harm our competitive position, be expensive and require the time and attention
of our key management and technical personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
rely on third parties to conduct all of our clinical trials. If these third parties are unable to carry out their contractual
duties in a manner that is consistent with our expectations, comply with budgets and other financial obligations or meet expected
deadlines, we may not receive certain development milestone payments or be able to obtain regulatory approval for or commercialize
our product candidates in a timely or cost-effective manner.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not independently conduct clinical trials for our drug candidates. We rely, and expect to continue to rely, on third-party
clinical investigators, clinical research organizations (CROs), clinical data management organizations and consultants to design,
conduct, supervise and monitor our clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we do not conduct our own clinical trials, we must rely on the efforts of others and have reduced control over aspects of these
activities, including, the timing of such trials, the costs associated with such trials and the procedures that are followed for
such trials. We do not expect to significantly increase our personnel in the foreseeable future and may continue to rely on third
parties to conduct all of our future clinical trials. If we cannot contract with acceptable third parties on commercially reasonable
terms or at all, if these third parties are unable to carry out their contractual duties or obligations in a manner that is consistent
with our expectations or meet expected deadlines, if they do not carry out the trials in accordance with budgeted amounts, if
the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols
or for other reasons, or if they fail to maintain compliance with applicable government regulations and standards, our clinical
trials may be extended, delayed or terminated or may become significantly more expensive, we may not receive development milestone
payments when expected or at all, and we may not be able to obtain regulatory approval for or successfully commercialize our product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
our reliance on third parties to conduct our clinical trials, we are ultimately responsible for ensuring that each of our clinical
trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires
clinical trials to be conducted in accordance with good clinical practices for conducting, recording and reporting the results
of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of clinical trial participants are protected. We also are required to register ongoing clinical trials and post the results of
completed clinical trials on a government-sponsored database, <B><I>ClinicalTrials.gov</I></B>, within certain timeframes. Failure
to do so can result in fines, adverse publicity and civil and criminal sanctions. Our reliance on third parties that we do not
control does not relieve us of these responsibilities and requirements. If we or a third party we rely on fails to meet these
requirements, we may not be able to obtain, or may be delayed in obtaining, marketing authorizations for our drug candidates and
will not be able to, or may be delayed in our efforts to, successfully commercialize our drug candidates. This could have a material
adverse effect on our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Because
we rely on third party manufacturing and supply partners, our supply of research and development, preclinical and clinical development
materials may become limited or interrupted or may not be of satisfactory quantity or quality.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research
and development, preclinical and clinical trial drug supplies. We do not own manufacturing facilities or supply sources for such
components and materials. There can be no assurance that our supply of research and development, preclinical and clinical development
drugs and other materials will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality
or continue to be available at acceptable prices. Suppliers and manufacturers must meet applicable manufacturing requirements
and undergo rigorous facility and process validation tests required by FDA and foreign regulatory authorities in order to comply
with regulatory standards, such as current Good Manufacturing Practices. In the event that any of our suppliers or manufacturers
fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if
our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture
the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another
third party, which we may not be able to do on reasonable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
business is subject to numerous and evolving state, federal and foreign regulations and we may not be able to secure the government
approvals needed to develop and market our products.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling
of our products, are all subject to extensive regulation by the FDA and foreign regulatory agencies. Pre-clinical testing and
clinical trial requirements and the regulatory approval process typically take years and require the expenditure of substantial
resources. Additional government regulation may be established that could prevent or delay regulatory approval of our product
candidates. Delays or rejections in obtaining regulatory approvals would adversely affect our ability to commercialize any product
candidates and our ability to generate product revenue or royalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and foreign regulatory agencies require that the safety and efficacy of product candidates be supported through adequate and
well-controlled clinical trials. If the results of pivotal clinical trials do not establish the safety and efficacy of our product
candidates to the satisfaction of the FDA and other foreign regulatory agencies, we will not receive the approvals necessary to
market such product candidates. Even if regulatory approval of a product candidate is granted, the approval may include significant
limitations on the indicated uses for which the product may be marketed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the periodic inspection of our clinical trials, facilities, procedures and operations and/or the testing of our
products by the FDA to determine whether our systems and processes, or those of our vendors and suppliers, are in compliance with
FDA regulations. Following such inspections, the FDA may issue notices on Form 483 and warning letters that could cause us to
modify certain activities identified during the inspection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with the FDA and other governmental regulations can result in fines, unanticipated compliance expenditures, recall or
seizure of products, total or partial suspension of production and/or distribution, suspension of the FDA&rsquo;s review of product
applications, enforcement actions, injunctions and criminal prosecution. Under certain circumstances, the FDA also has the authority
to revoke previously granted product approvals. Although we have internal compliance programs, if these programs do not meet regulatory
agency standards or if our compliance is deemed deficient in any significant way, it could have a material adverse effect on the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to recordkeeping and reporting regulations. These regulations require, among other things, the reporting to the
FDA of adverse events alleged to have been associated with the use of a product or in connection with certain product failures.
Labeling and promotional activities also are regulated by the FDA. We must also comply with record keeping requirements as well
as requirements to report certain adverse events involving our products. The FDA can impose other post-marketing controls on us
as well as our products including, but not limited to, restrictions on sale and use, through the approval process, regulations
and otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states in which we do or may do business, or in which our products may be sold, if at all, impose licensing, labeling or certification
requirements that are in addition to those imposed by the FDA. There can be no assurance that one or more states will not impose
regulations or requirements that have a material adverse effect on our ability to sell our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
many of the foreign countries in which we may do business or in which our products may be sold, we will be subject to regulation
by national governments and supranational agencies as well as by local agencies affecting, among other things, product standards,
packaging requirements, labeling requirements, import restrictions, tariff regulations, duties and tax requirements. There can
be no assurance that one or more countries or agencies will not impose regulations or requirements that could have a material
adverse effect on our ability to sell our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
have obtained Orphan Drug Designation for ThermoDox&reg; and may seek Orphan Drug Designation for other product candidates, but
we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential
for market exclusivity.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThermoDox&reg;
has been granted orphan drug designation for primary liver cancer in both the U.S. and Europe. As part of our business strategy,
we may seek Orphan Drug Designation for other product candidates, but we may be unsuccessful. Regulatory authorities in some jurisdictions,
including the U.S. and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan
Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which
is generally defined as a patient population of fewer than 200,000 individuals annually in the U.S., or a patient population greater
than 200,000 in the U.S. where there is no reasonable expectation that the cost of developing the drug will be recovered from
sales in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
though we have obtained Orphan Drug Designation for ThermoDox&reg; and may obtain such designation for other product candidates
in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated
indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights
in the U.S. may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost
if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure
sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain
orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different
drugs with different active moieties can be approved for the same condition. Even after an orphan product is approved, the FDA
can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later
drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development
time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition,
while we may seek Orphan Drug Designation for other product candidates, we may never receive such designations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fast
Track designation may not actually lead to a faster development or regulatory review or approval process.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThermoDox&reg;
has received U.S. FDA Fast Track Designation. However, we may not experience a faster development process, review, or approval
compared to conventional FDA procedures. The FDA may withdraw our Fast Track designation if the FDA believes that the designation
is no longer supported by data from our clinical or pivotal development program. Our Fast Track designation does not guarantee
that we will qualify for or be able to take advantage of the FDA&rsquo;s expedited review procedures or that any application that
we may submit to the FDA for regulatory approval will be accepted for filing or ultimately approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud
and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual
damages, reputational harm and diminished profits and future earnings.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and
prescription of biopharmaceutical products. Arrangements with third-party payors and customers can expose biopharmaceutical manufacturers
to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback
Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through
which such companies sell, market and distribute biopharmaceutical products. In particular, the research of our product candidates,
as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the
healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices.
These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring
and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these
laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The applicable
federal, state and foreign healthcare laws and regulations laws that may affect our ability to operate include, but are not limited
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering
    or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash
    or in kind, to induce or reward, or in return for, either the referral of an individual, or the purchase, lease, order or
    recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal
    healthcare program, such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating the statute
    without actual knowledge of the statute or specific intent to violate it. In addition, a claim submitted for payment to any
    federal health care program that includes items or services that were made as a result of a violation of the federal Anti-Kickback
    Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA. The Anti-Kickback Statute
    has been interpreted to apply to arrangements between biopharmaceutical manufacturers on the one hand and prescribers, purchasers,
    and formulary managers, among others, on the other. There are a number of statutory exceptions and regulatory safe harbors
    protecting some common activities from prosecution;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal civil and criminal false claims laws, including the FCA, and civil monetary penalty laws which prohibit, among other
    things, individuals or entities from knowingly presenting, or causing to be presented, false, fictious or fraudulent claims
    for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs; knowingly making, using or causing
    to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit
    money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing or
    concealing an obligation to pay money to the federal government. A claim that includes items or services resulting from a
    violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA. Manufacturers can be
    held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &ldquo;cause&rdquo;
    the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &ldquo;whistleblower&rdquo;
    to bring qui tam actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes
    that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program
    or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by,
    or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and
    knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially
    false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare
    matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual
    knowledge of the statute or specific intent to violate it;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective
    implementing regulations, which impose, among other things, requirements relating to the privacy, security and transmission
    of individually identifiable health information on certain covered healthcare providers, health plans, and healthcare clearinghouses,
    known as covered entities, as well as their respective &ldquo;business associates,&rdquo; those independent contractors or
    agents of covered entities that perform services for covered entities that involve the creation, use, receipt, maintenance
    or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties,
    amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general
    new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek
    attorneys&rsquo; fees and costs associated with pursuing federal civil actions; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which require some manufacturers
    of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s
    Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers
    of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching
    hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective
    January 1, 2022, these reporting obligations will extend to include transfers of value made in the previous year to certain
    non-physician providers such as physician assistants and nurse practitioners;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially
    harm consumers; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing
    arrangements and claims involving healthcare items or services reimbursed by third-party payors, including private insurers,
    and may be broader in scope than their federal equivalents; state and foreign laws that require biopharmaceutical companies
    to comply with the biopharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance
    promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential
    referral sources; state and foreign laws that require drug manufacturers to report information related to payments and other
    transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state and local laws
    that require the registration of biopharmaceutical sales representatives; and state and foreign laws governing the privacy
    and security of health information in certain circumstances, many of which differ from each other in significant ways and
    often are not preempted by HIPAA, thus complicating compliance efforts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping,
licensing, storage and security requirements intended to prevent the unauthorized sale of biopharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare
reform, especially in light of the lack of applicable precedent and regulations. Ensuring business arrangements comply with applicable
healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming
and can divert a company&rsquo;s attention from the business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current
or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations.
If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative
penalties, damages, fines, disgorgement, imprisonment, reputational harm, possible exclusion from participation in federal and
state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional
reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations
of non-compliance with these laws. Further, if any of the physicians or other healthcare providers or entities with whom we expect
to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs. Any action for violation of these laws, even if successfully
defended, could cause a biopharmaceutical manufacturer to incur significant legal expenses and divert management&rsquo;s attention
from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially
affect business in an adverse way.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ongoing
legislative and regulatory changes affecting the healthcare industry could have a material adverse effect on our business.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Political,
economic and regulatory influences are subjecting the healthcare industry to potential fundamental changes that could substantially
affect our results of operations by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications
to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example,
in March 2010, the ACA was passed, which substantially changed the way health care is financed by both governmental and private
insurers, and significantly impacted the U.S. biopharmaceutical industry. The ACA, among other things, addressed a new methodology
by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate
Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees
and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program,
in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019)
point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period,
as a condition for the manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its enactment, some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject
to judicial, congressional, and executive challenges. As a result, there have been delays in the implementation of, and action
taken to repeal or replace, certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders designed
to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance
mandated by the ACA. The first Executive Order, singed on January 20, 2017 directs federal agencies with authorities and responsibilities
under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose
a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals
or medical devices. The second Executive Order, signed on October 13, 2017 terminates the cost-sharing subsidies that reimburse
insurers under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies,
but their request for a restraining order was denied by a federal judge in California on October 25, 2017. The loss of the cost
share reduction payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA.
Further, on June 14, 2018, U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to
pay more than $12 billion in ACA risk corridor payments to third-party payors who argued were owed to them. On December 10, 2019,
the U.S. Supreme Court heard arguments in <I>Moda Health Plan, Inc. v. United States.</I> On April 27, 2020, the U.S. Supreme
Court held that the ACA requires the federal government to compensate insurers for significant losses their health plans incurred
during the first three years of the ACA&rsquo;s marketplaces, and that insurers can sue for nonpayment in the Court of Federal
Claims. The effects of this decision on third-party payors, the viability of the ACA marketplace, providers, and potentially our
business, are still uncertain. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify
certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&rsquo;s individual
mandate to carry health insurance, delaying the implementation of certain ACA-mandated fees, and increasing the point-of-sale
discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. On December 14, 2018, a U.S. District
Court Judge in the Northern District of Texas ruled that the ACA is unconstitutional in its entirety because the &ldquo;individual
mandate&rdquo; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Additionally, on December 18, 2019, the
U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and
remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On
March 2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, and has allotted
one hour for oral arguments, which are expected to occur in the fall. We cannot predict what effect further changes to the ACA
would have on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011,
among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked
with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach
required goals, thereby triggering the legislation&rsquo;s automatic reduction to several government programs, including aggregate
reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due
to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, or BBA, will remain in effect
through 2030, unless additional congressional action is taken. The BBA also amended the ACA, effective January 1, 2019, by increasing
the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage
gap in most Medicare drug plans, commonly referred to as the &ldquo;donut hole&rdquo;. However, pursuant to the CARES Act, these
reductions will be suspended from May 1, 2020 through December 31, 2020 due to the COVID-19 pandemic and extend the reductions
by one year, through 2030, in order to offset the added expense of the 2020 suspension. On January 2, 2013, the American Taxpayer
Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers,
including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government
to recover overpayments to providers from three to five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may
cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they
may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest
in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional
inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug
pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for drugs. Several states have adopted price transparency
requirements and those as well as any future federal price transparency requirements that may be implemented in the future could
have a negative effect on our business. Additionally, we expect to experience pricing pressures in connection with the sale of
any future approved product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance
organizations, cost containment initiatives and additional legislative changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the federal level, the Trump administration&rsquo;s budget for fiscal year 2021 includes a $135 billion allowance to support legislative
proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient
access to lower-cost generic and biosimilar drugs. On March 10, 2020, the U.S. government sent &ldquo;principles&rdquo; for drug
pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy
expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical
price increases. The Trump administration previously released a &ldquo;Blueprint&rdquo; to lower drug prices and reduce out of
pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power
of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out
of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services, or HHS, has solicited feedback
on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final
rule that would allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs
beginning January 1, 2020. This final rule codified CMS&rsquo;s policy change that was effective January 1, 2019. Although a number
of these and other measures may require additional authorization to become effective, Congress and the Trump administration have
each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. For example,
the Lower Drug Costs Now Act of 2019 was introduced in the House of Representatives on September 19, 2019 and would require HHS
to directly negotiate drug prices with manufacturers. The Lower Drugs Costs Now Act of 2019 has passed out of the House and was
delivered to the Senate on December 16, 2019. However, it is unclear whether this bill will make it through both chambers and
be signed into law, and if enacted, what effect it would have on our business. Individual states in the United States have also
increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price
or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. At the state level,
legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the state level, legislatures are increasingly passing legislation and implementing regulations designed to control biopharmaceutical
and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict what healthcare reform initiatives may be adopted in the future. Further, federal and state legislative and regulatory
developments are likely, and we expect ongoing initiatives in the United States to increase pressure on drug pricing. Such reforms
could have an adverse effect on anticipated revenues from and any product candidates that we may successfully develop and for
which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
may fail to comply with evolving European and other privacy laws.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we conduct clinical trials in the European Economic Area (&ldquo;EEA&rdquo;), we are subject to additional European data-privacy
laws. The General Data Protection Regulation, (EU) 2016/679 (&ldquo;GDPR&rdquo;) became effective on May 25, 2018 and deals with
the processing of personal data and on the free movement of such data. The GDPR imposes a broad range of strict requirements on
companies subject to the GDPR, including requirements relating to having legal bases for processing personal information relating
to identifiable individuals and transferring such information outside the EEA, including to the United States, providing details
to those individuals regarding the processing of their personal information, keeping personal information secure, having data
processing agreements with third parties who process personal information, responding to individuals&rsquo; requests to exercise
their rights in respect of their personal information, reporting security breaches involving personal data to the competent national
data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments,
and record-keeping. The GDPR increases substantially the penalties to which we could be subject in the event of any non-compliance,
including fines of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses,
or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious offenses. Given the limited enforcement
of the GDPR to date, we face uncertainty as to the exact interpretation of the new requirements on our trials and we may be unsuccessful
in implementing all measures required by data protection authorities or courts in interpretation of the new law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, national laws of member states of the EU are in the process of being adapted to the requirements under the GDPR, thereby
implementing national laws which may partially deviate from the GDPR and impose different obligations from country to country,
so that we do not expect to operate in a uniform legal landscape in the EEA. Also, as it relates to processing and transfer of
genetic data, the GDPR specifically allows national laws to impose additional and more specific requirements or restrictions,
and European laws have historically differed quite substantially in this field, leading to additional uncertainty. Further, the
impact of the impending &ldquo;Brexit&rdquo;, (whereby the United Kingdom is planning to leave the EEA in March of 2019), either
with or without a &ldquo;deal&rdquo; is uncertain and cannot be predicted at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we continue to conduct clinical trials in the EEA, we must also ensure that we maintain adequate safeguards to enable
the transfer of personal data outside of the EEA, in particular to the United States, in compliance with European data protection
laws. We expect that we will continue to face uncertainty as to whether our efforts to comply with our obligations under European
privacy laws will be sufficient. If we are investigated by a European data protection authority, we may face fines and other penalties.
Anype1 such investigation or charges by European data protection authorities could have a negative effect on our existing business
and on our ability to attract and retain new clients or pharmaceutical partners. We may also experience hesitancy, reluctance,
or refusal by European or multi-national clients or pharmaceutical partners to continue to use our products and solutions due
to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on
them by certain data protection authorities in interpretation of current law, including the GDPR. Such clients or pharmaceutical
partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain, or
otherwise objectionable and therefore decide not to do business with us. Any of the foregoing could materially harm our business,
prospects, financial condition and results of operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
success of our products may be harmed if the government, private health insurers and other third-party payers do not provide sufficient
coverage or reimbursement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize our new cancer treatment systems successfully will depend in part on the extent to which reimbursement
for the costs of such products and related treatments will be available from third-party payors, which include government authorities
such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers, and other
organizations. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse
all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs,
such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Patients are unlikely to use our product
candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. The reimbursement
status of newly approved medical products is subject to significant uncertainty We cannot be sure that coverage and reimbursement
will be available for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement
will be available for any product that we may develop. Further, due to the COVID-19 pandemic, millions of individuals have lost
or will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our product candidates
even if there is adequate coverage and reimbursement from third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities and other third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. In
the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare
&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to
what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial
degree. No uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage
and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party
payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the
payor will pay for the product once coverage is approved. Coverage and reimbursement by a third-party payor may depend upon a
number of factors, including the third-party payor&rsquo;s determination that use of a product is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    covered benefit under its health plan;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe,
    effective and medically necessary;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
    for the specific patient;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective;
    and </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
    experimental nor investigational.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the
costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts
to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically
necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once
the product is approved and have a material adverse effect on sales, our operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government,
private health insurers and other third-party payors are increasingly attempting to contain healthcare costs by limiting both
coverage and the level of reimbursement for new therapeutic products approved for marketing by the FDA. For example, Congress
passed the ACA in 2010 which enacted a number of reforms to expand access to health insurance while also reducing or constraining
the growth of healthcare spending, enhancing remedies against fraud and abuse, adding new transparency requirements for healthcare
industries, and imposing new taxes on fees on healthcare industry participants, among other policy reforms. Federal agencies,
Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth
of health care costs, including price controls, price disclosures, restrictions on reimbursement and other fundamental changes
to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal
debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential
targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare
delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage
or reimbursement of, our product candidates hold the potential to severely limit market opportunities of such products. Accordingly,
even if coverage and reimbursement are provided by government, private health insurers and third-party payors for uses of our
products, market acceptance of these products would be adversely affected if the reimbursement available proves to be unprofitable
for health care providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
products may not achieve sufficient acceptance by the medical community to sustain our business.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our products will depend upon their acceptance by the medical community and third-party payors as clinically
useful, cost effective and safe. Any of our drug candidates or similar product candidates being investigated by our competitors
may prove not to be effective in trial or in practice, cause adverse events or other undesirable side effects. Our testing and
clinical practice may not confirm the safety and efficacy of our product candidates or even if further testing and clinical practice
produce positive results, the medical community may view these new forms of treatment as effective and desirable or our efforts
to market our new products may fail. Market acceptance depends upon physicians and hospitals obtaining adequate reimbursement
rates from third-party payors to make our products commercially viable. Any of these factors could have an adverse effect on our
business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly
smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is very difficult to predict the commercial potential of product candidates due to important factors such as safety and efficacy
compared to other available treatments, including potential generic drug alternatives with similar efficacy profiles, changing
standards of care, third party payor reimbursement standards, patient and physician preferences, the availability of competitive
alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability
of generic versions of our successful product candidates following approval by government health authorities based on the expiration
of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due
to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and
negatively impact the revenue potential for such drug candidate and would adversely affect our business, financial condition and
results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Several
of our current clinical trials are being conducted outside the United States, and the FDA may not accept data from trials conducted
in foreign locations.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
of our current clinical trials are being conducted outside the United States. Although the FDA may accept data from clinical trials
conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. For example,
the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles.
The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population
and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical
trials conducted outside of the United States must be representative of the population for whom we intend to label the product
in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the
data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. We
cannot assure you that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept
the data from such clinical trials, it would likely result in the need for additional trials, which would be costly and time-consuming
and delay or permanently halt our development of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
have no internal sales or marketing capability. If we are unable to create sales, marketing and distribution capabilities or enter
into alliances with others possessing such capabilities to perform these functions, we will not be able to commercialize our products
successfully.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no sales, marketing or distribution capabilities. We intend to market our products, if and when such products are
approved for commercialization by the FDA and foreign regulatory agencies, either directly or through other strategic alliances
and distribution arrangements with third parties. If we decide to market our products directly, we will need to commit significant
financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution,
administration and compliance capabilities. If we rely on third parties with such capabilities to market our products, we will
need to establish and maintain partnership arrangements, and there can be no assurance that we will be able to enter into third-party
marketing or distribution arrangements on acceptable terms or at all. To the extent that we do enter into such arrangements, we
will be dependent on our marketing and distribution partners. In entering into third-party marketing or distribution arrangements,
we expect to incur significant additional expenses and there can be no assurance that such third parties will establish adequate
sales and distribution capabilities or be successful in gaining market acceptance for our products and services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Technologies
for the treatment of cancer are subject to rapid change, and the development of treatment strategies that are more effective than
our technologies could render our technologies obsolete.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
methods for treating cancer currently are, and in the future, are expected to be, the subject of extensive research and development.
Many possible treatments that are being researched, if successfully developed, may not require, or may supplant, the use of our
technologies. The successful development and acceptance of any one or more of these alternative forms of treatment could render
our technology obsolete as a cancer treatment method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
may not be able to hire or retain key officers or employees that we need to implement our business strategy and develop our product
candidates and business, including those purchased in the EGEN asset acquisition.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends significantly on the continued contributions of our executive officers, scientific and technical personnel and
consultants, including those retained in the EGEN asset acquisition, and on our ability to attract additional personnel as we
seek to implement our business strategy and develop our product candidates and businesses. Our operations associated with the
EGEN asset acquisition are located in Huntsville, Alabama. Key employees may depart if we fail to successfully manage this additional
business location or in relation to any uncertainties or difficulties of integration with Celsion. We cannot guarantee that we
will retain key employees to the same extent that we and EGEN retained each of our own employees in the past, which could have
a negative impact on our business, results of operations and financial condition. Our integration of EGEN and ability to operate
in the fields we acquired from EGEN may be more difficult if we lose key employees. Additionally, during our operating history,
we have assigned many essential responsibilities to a relatively small number of individuals. However, as our business and the
demands on our key employees expand, we have been, and will continue to be, required to recruit additional qualified employees.
The competition for such qualified personnel is intense, and the loss of services of certain key personnel or our inability to
attract additional personnel to fill critical positions could adversely affect our business. Further, we do not carry &ldquo;key
man&rdquo; insurance on any of our personnel. Therefore, loss of the services of key personnel would not be ameliorated by the
receipt of the proceeds from such insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
success will depend in part on our ability to grow and diversify, which in turn will require that we manage and control our growth
effectively.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy contemplates growth and diversification. Our ability to manage growth effectively will require that we continue
to expend funds to improve our operational, financial and management controls, reporting systems and procedures. In addition,
we must effectively expand, train and manage our employees. We will be unable to manage our business effectively if we are unable
to alleviate the strain on resources caused by growth in a timely and successful manner. There can be no assurance that we will
be able to manage our growth and a failure to do so could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
face intense competition and the failure to compete effectively could adversely affect our ability to develop and market our products.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are many companies and other institutions engaged in research and development of various technologies for cancer treatment products
that seek treatment outcomes similar to those that we are pursuing. We believe that the level of interest by others in investigating
the potential of possible competitive treatments and alternative technologies will continue and may increase. Potential competitors
engaged in all areas of cancer treatment research in the U.S. and other countries include, among others, major pharmaceutical,
specialized technology companies, and universities and other research institutions. Most of our current and potential competitors
have substantially greater financial, technical, human and other resources, and may also have far greater experience than do we,
both in pre-clinical testing and human clinical trials of new products and in obtaining FDA and other regulatory approvals. One
or more of these companies or institutions could succeed in developing products or other technologies that are more effective
than the products and technologies that we have been or are developing, or which would render our technology and products obsolete
and non-competitive. Furthermore, if we are permitted to commence commercial sales of any of our products, we will also be competing,
with respect to manufacturing efficiency and marketing, with companies having substantially greater resources and experience in
these areas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
may be subject to significant product liability claims and litigation.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to potential product liability risks inherent in the testing, manufacturing and marketing of human therapeutic
products. We presently have product liability insurance limited to $10 million per incident and $10 million annually. If we were
to be subject to a claim in excess of this coverage or to a claim not covered by our insurance and the claim succeeded, we would
be required to pay the claim with our own limited resources, which could have a severe adverse effect on our business. Whether
or not we are ultimately successful in any product liability litigation, such litigation would harm the business by diverting
the attention and resources of our management, consuming substantial amounts of our financial resources and by damaging our reputation.
Additionally, we may not be able to maintain our product liability insurance at an acceptable cost, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
or the third parties upon whom we depend may be adversely affected by earthquakes, global pandemics or other natural disasters
and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster, including earthquakes,
outbreak of disease or other natural disasters.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current operations are located in our facilities in Lawrenceville, New Jersey. Any unplanned event, such as flood, fire, explosion,
earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or manmade
accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our
third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly
on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these
facilities may result in increased costs, delays in the development of our product candidates or interruption of our business
operations. Earthquakes or other natural disasters could further disrupt our operations and have a material and adverse effect
on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event
occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure,
such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted
operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of
time. For example, in January 2020, the World Health Organization declared COVID-19 a global pandemic, and the U.S. Department
of Health and Human Services declared a public health emergency to aid the U.S. healthcare community in responding to COVID-19.
This virus continues to spread globally and, as of June 2020, has spread to over 100 countries, including the United States. Governments
and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited
to, shelter-in-place orders, quarantines, and significant restrictions on travel, as well as restrictions that prohibit many employees
from going to work. An outbreak of communicable diseases in China or elsewhere, or the perception that such an outbreak could
occur, and the measures taken by the governments of countries affected, could adversely affect our business, financial condition
or results of operations by limiting our ability to manufacture products within or outside China, forcing temporary closure of
facilities that we rely upon or increasing the costs associated with obtaining clinical supplies of our product candidates. Please
see the risk factor titled &ldquo;<I>The outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business,
including our preclinical studies and clinical trials</I>&rdquo; for additional information regarding the COVID-19 pandemic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar
event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans,
which, could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage
at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities,
we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or
the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident
or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which
could result in a material disruption of our product development programs.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants
are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and
electrical failures. Such events could cause interruptions of our operations. For instance, the loss of preclinical data or data
from any clinical trial involving our product candidates could result in delays in our development and regulatory filing efforts
and significantly increase our costs. To the extent that any disruption or privacy or security breach were to result in a loss
of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be subject to reputational
harm, monetary fines, civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and other forms
of liability and the development of our product candidates could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pandemics
such as the COVID-19 coronavirus could have an adverse impact on our developmental programs and our financial condition.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of the COVID-19 coronavirus was first identified in Wuhan, Hubei Province, China. Any outbreak of
contagious diseases, or other adverse public health developments, could have a material and adverse effect on our business operations.
These could include disruptions or restrictions on our ability to travel, pursue partnerships and other business transactions,
conduct clinical trials, make shipments of biologic materials, as well as be impacted by the temporary closure of the facilities
of suppliers and clinical trial sites. Any disruption of suppliers, clinical trial sites or access to patients would likely impact
our clinical trial enrollment progress and rates as well as our ability to access capital through the financial markets. The extent
to which the COVID-19 coronavirus impacts our business will depend on future developments, which are highly uncertain and cannot
be predicted, including new information which may emerge concerning the severity of the COVID-19 coronavirus and the actions to
contain the COVID-19 coronavirus or treat its impact, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISKS
RELATED TO OUR SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in
substantial losses for investors and subject us to securities class action litigation.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price for our common stock has been, and we expect it to continue to be, volatile. The price at which our common stock
trades depends upon a number of factors, including our historical and anticipated operating results, our financial situation,
announcements of technological innovations or new products by us or our competitors, our ability or inability to raise the additional
capital we may need and the terms on which we raise it, and general market and economic conditions. Some of these factors are
beyond our control. Broad market fluctuations may lower the market price of our common stock and affect the volume of trading
in our stock, regardless of our financial condition, results of operations, business or prospect. The closing price of our common
stock as reported on The Nasdaq Capital Market had a high price of $3.48 and a low price of $1.35 in the 52-week period ended
December 31, 2018, a high price of $2.47 and a low price of $1.08 in the 52-week period ended December 31, 2019, and a high price
of $5.26 and a low price of $0.72 from January 1, 2020 through August 13, 2020. Among the factors that may cause
the market price of our common stock to fluctuate are the risks described in this &ldquo;Risk Factors&rdquo; section and other
factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of preclinical and clinical studies of our product candidates or those of our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal developments in the U.S. and other countries, especially changes in laws and regulations applicable to our product
    candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and
    marketing terms;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introductions
    and announcements of new products by us or our competitors, and the timing of these introductions or announcements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant acquisitions or other strategic transactions or capital commitments;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in our quarterly operating results or the operating results of our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">variance
    in our financial performance from the expectations of investors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the estimation of the future size and growth rate of our markets;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles or changes in interpretations of existing principles, which could affect our financial results;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our products to achieve or maintain market acceptance or commercial success;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    and trends in the markets we serve;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in general economic, industry and market conditions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    of competitive products and services;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in market valuations or earnings of our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our pricing policies or the pricing policies of our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in legislation or regulatory policies, practices or actions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commencement or outcome of litigation involving our company, our general industry or both;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruitment
    or departure of key personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure, such as future issuances of securities or the incurrence of additional debt;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock,
    other comparable companies or our industry generally;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or expected sales of our common stock by our stockholders;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquisitions
    and financings, including the EGEN asset acquisition; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    trading volume of our common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock markets, in general, The Nasdaq Capital Market and the market for pharmaceutical companies in particular,
may experience a loss of investor confidence. Such loss of investor confidence may result in extreme price and volume fluctuations
in our common stock that are unrelated or disproportionate to the operating performance of our business, financial condition or
results of operations. These broad market and industry factors may materially harm the market price of our common stock and expose
us to securities class action litigation. Such litigation, even if unsuccessful, could be costly to defend and divert management&rsquo;s
attention and resources, which could further materially harm our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Future
sales of our common stock in the public market could cause our stock price to fall.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could
depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity
securities. As of August 13, 2020, we had 33,232,380 shares of common stock outstanding, all of which, other than shares held
by our directors and certain officers, were eligible for sale in the public market, subject in some cases to compliance with the
requirements of Rule 144, including the volume limitations and manner of sale requirements. In addition, all of the shares of
common stock issuable upon exercise of warrants will be freely tradable without restriction or further registration upon issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
stockholders may experience significant dilution as a result of future equity offerings or issuances and exercise of outstanding
options and warrants.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to raise additional capital or pursue strategic transactions, we may in the future offer, issue or sell additional shares
of our common stock or other securities convertible into or exchangeable for our common stock, including the issuance of common
stock in relation to the achievement, if any, of milestones triggering our payment of earn-out consideration in connection with
the EGEN asset acquisition. Our stockholders may experience significant dilution as a result of future equity offerings or issuances.
Investors purchasing shares or other securities in the future could have rights superior to existing stockholders. As of August
13, 2020, we have a significant number of securities convertible into, or allowing the purchase of, our common stock, including
3,826,098 shares of common stock issuable upon exercise of warrants outstanding, 4,665,526 </FONT> options to purchase shares
of our common stock and restricted stock awards outstanding, and 1,981,652 shares of common stock reserved for future issuance
under our stock incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
adverse capital and credit market conditions could affect our liquidity.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
capital and credit market conditions could affect our ability to meet liquidity needs, as well as our access to capital and cost
of capital. The capital and credit markets have experienced extreme volatility and disruption in recent years. Our results of
operations, financial condition, cash flows and capital position could be materially adversely affected by continued disruptions
in the capital and credit markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Changes
in tax law could adversely affect our financial condition and results of operations.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative
process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive
application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes
are likely to continue to occur in the future. For example, on March 27, 2020, President Trump signed into law the &ldquo;Coronavirus
Aid, Relief, and Economic Security Act&rdquo; or the CARES Act, which included certain changes in tax law intended to stimulate
the U.S. economy in light of the COVID-19 coronavirus outbreak, including temporary beneficial changes to the treatment of net
operating losses, interest deductibility limitations and payroll tax matters. Future changes in tax laws could have a material
adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their
legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
ability to use net operating losses to offset future taxable income are subject to certain limitations.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, the President of the United States signed into law the Tax Reform Act. The Tax Reform Act significantly changes
U.S. tax law by, among other things, lowering corporate income tax rates, implementing a quasi-territorial tax system, providing
a one-time transition toll charge on foreign earnings, creating a new limitation on the deductibility of interest expenses and
modifying the limitation on officer compensation. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from
a maximum of 35% to a flat 21% rate, effective January 1, 2018. Net operating losses generated after December 31, 2017 are not
subject to expiration, and generally <STRIKE>but</STRIKE> may not be carried back to prior taxable years except that, under the
CARES Act, net operating losses generated in 2018, 2019 and 2020 may be carried back five taxable years. Additionally, for taxable
years beginning after December 31, 2020, the deductibility of such federal net operating losses is limited to 80% of our taxable
income in any future taxable year. We currently have significant net operating losses (NOLs) that may be used to offset future
taxable income. In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the Code), a corporation that
undergoes an &ldquo;ownership change&rdquo; is subject to limitations on its ability to utilize its pre-change NOLs to offset
future taxable income. During 2018, 2017 and years prior, we performed analyses to determine if there were changes in ownership,
as defined by Section 382 of the Internal Revenue Code that would limit our ability to utilize certain net operating loss and
tax credit carry forwards. We determined we experienced ownership changes, as defined by Section 382, in connection with certain
common stock offerings in 2011, 2013, 2015, 2017 and 2018. As a result, the utilization of our federal tax net operating loss
carry forwards generated prior to the ownership changes is limited. Future changes in our stock ownership, some of which are outside
of our control, could result in an ownership change under Section 382 of the Code, which would significantly limit our ability
to utilize NOLs to offset future taxable income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
have never paid cash dividends on our common stock in the past and do not anticipate paying cash dividends on our common stock
in the foreseeable future.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock
in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and
growth of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the
foreseeable future for holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-takeover
provisions in our charter documents and Delaware law could prevent or delay a change in control.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation and bylaws may discourage, delay or prevent a merger or acquisition that a stockholder may consider
favorable by authorizing the issuance of &ldquo;blank check&rdquo; preferred stock. This preferred stock may be issued by our
Board of Directors on such terms as it determines, without further stockholder approval. Therefore, our Board of Directors may
issue such preferred stock on terms unfavorable to a potential bidder in the event that our Board of Directors opposes a merger
or acquisition. In addition, our Board of Directors may discourage such transactions by increasing the amount of time necessary
to obtain majority representation on our Board of Directors. Certain other provisions of our bylaws and of Delaware law may also
discourage, delay or prevent a third party from acquiring or merging with us, even if such action were beneficial to some, or
even a majority, of our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_007"></A>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_008"></A>Item
3. Defaults Upon Senior Securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_009"></A>Item
4. Mine Safety Disclosures.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_010"></A>Item
5. Other Information.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_011"></A>Item
6. Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex3-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated By-Laws of the Company, dated June 16, 2020.</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note of the Company, dated May 26, 2020, payable to Silicon Valley Bank.</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/749647/000149315219007203/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to the Celsion Corporation 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company, filed on May 15, 2020.</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/749647/000149315220011263/ex10-1.htm" STYLE="-sec-extract: exhibit">Second Amendment to the Celsion Corporation 2018 Stock Incentive Plan, incorporated by reference to the Current Report on Form 8-K of the Company, filed on June 16, 2020.</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/749647/000149315220011263/ex10-2.htm" STYLE="-sec-extract: exhibit">Settlement Agreement and Release, by and between the plaintiff to the shareholder action captioned <I>O&rsquo;Connor v. Braun</I>, et al., N.J. Super., Dkt. No. MERC-00068-19, William J. O&rsquo;Connor, derivatively on behalf of Celsion Corporation and individually on behalf of himself and all other similarly situated stockholders of Celsion Corporation and defendants, incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K of the Company, filed on June 16, 2020.</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/749647/000149315220011606/ex1-1.htm" STYLE="-sec-extract: exhibit">Underwriting Agreement, dated as of June 22, 2020, by and between Celsion Corporation and Oppenheimer &amp; Co. Inc., incorporated herein by reference to Exhibit 1.1 to the Current Report on Form 8-K of the Company, filed on June 22, 2020.</A></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex31-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex31-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex32-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following materials from the Company&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 formatted in
    XBRL (Extensible Business Reporting Language): (i) the unaudited Consolidated Balance Sheets, (ii) the unaudited Consolidated
    Statements of Operations, (iii) the unaudited Consolidated Statements of Comprehensive Loss, (iv) the unaudited Consolidated
    Statements of Cash Flows, (v) the unaudited Consolidated Statements of Change in Stockholders&rsquo; Equity (Deficit), and
    (vi) Notes to Consolidated Financial Statements.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    32.1 is being furnished and shall not be deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange
    Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated
    by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities
    Exchange Act, except as otherwise stated in such filing.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    information is filed herewith.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="B_012"></A>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    14, 2020</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CELSION
    CORPORATION</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael H. Tardugno</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    H. Tardugno</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    President and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Jeffrey W. Church</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    W. Church</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex3-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.1</B></FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPOSED
RESOLUTIONS TO BE ADOPTED BY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
BOARD OF DIRECTORS OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Approval
of Amendment to the Amended and Restated By-Laws</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,
</B>pursuant to article X of the Amended and Restated By-laws of the Company (the &ldquo;By-laws&rdquo;), the By-laws may be amended
or repealed by the Board of Directors by the affirmative vote of a majority of the directors then in office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS,
</B>The Board of Directors deems it advisable and in the best interests of the stockholders of the Company to approve, ratify
and confirm the adoption of an Amendment to the Amended and Restated By-laws substantially in the form attached hereto as Exhibit
A (the &ldquo;Amendment&rdquo;) to designate the United States District court for the District of New Jersey as the exclusive
jurisdiction for any litigation arising under the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE, BE IT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESOLVED:
</B>That adoption of the Amendment be, and hereby is, approved, confirmed and ratified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
TO THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BY-LAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&ldquo;Corporation&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IX</B> of the Amended and Restated By-laws of the Corporation (the &ldquo;By-laws&rdquo;), is hereby amended by adding a new section
9.8 to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
8</B>. <U>Exclusive Jurisdiction of Delaware Courts or the United States District Court for the District of New Jersey</U>. Unless
the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall
be the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on behalf of the Corporation,
(ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation
to the Corporation or the Corporation&rsquo;s stockholders, (iii) any action asserting a claim arising pursuant to any provision
of the Delaware General Corporation Law or the Certificate or By-laws, (iv) any action to interpret, apply, enforce or determine
the validity of the Certificate or By-laws, or (v) any action asserting a claim against the Corporation governed by the internal
affairs doctrine (the &ldquo;Delaware Forum Provision&rdquo;). The Delaware Forum Provision shall not apply to any claims arising
under the Exchange Act or the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). In addition, unless the Corporation
consents in writing to the selection of an alternative forum, the United States District Court for the District of New Jersey
shall be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act. Any person
or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have
notice of and consented to the provisions of this Section 9.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_001.jpg" ALT="" STYLE="height: 827; width: 670">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_002.jpg" ALT="" STYLE="height: 752; width: 670">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_003.jpg" ALT="" STYLE="height: 833; width: 670">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_004.jpg" ALT="" STYLE="height: 830; width: 670">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_005.jpg" ALT="" STYLE="height: 721; width: 670">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="text-align: center; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michael H. Tardugno, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this quarterly report on Form 10-Q of Celsion Corporation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
    procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined
    in Exchange Act Rules 13a-15(f) and 15d-15 (f)), for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
    internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Celsion
    Corporation</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    14, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael H. Tardugno</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    H. Tardugno</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Jeffrey W. Church, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this quarterly report on Form 10-Q of Celsion Corporation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
    procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined
    in Exchange Act Rules 13a-15(f) and 15d-15 (f)), for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
    internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Celsion
    Corporation</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    14, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Jeffrey W. Church</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    W. Church</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELSION
CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
1350 CERTIFICATIONS*</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &sect;1350), each of the undersigned hereby certifies
that, to the best of his knowledge, (i) the Quarterly Report on Form 10-Q for the period ended June 30, 2020 of Celsion Corporation
(the &ldquo;Company&rdquo;) filed with the Securities and Exchange Commission on the date hereof fully complies with the requirements
of Section 13(a) or 15(d) of the Exchange Act and (ii) the information contained in such report fairly presents, in all material
respects, the financial condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    14, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael H. Tardugno</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    H. Tardugno</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    President and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    14, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Jeffrey W. Church</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    W. Church</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission
and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the
Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained
in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex10-1_001.jpg
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0W VH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH^)]+UGPKHUQJFG^+[A(K==PM[X*ZM[;NN:S8/BQ?S^"%U"VTS[3J,<9:Y<
MK#%CN3ZG^Z*P-3TFPUBWU#4-0LH4E$MBZI*70A26&1M/>M"N OOB3#IFC:>K
M6PN=?O(%D^PPG[I(ZL?X17(V7Q8\06&KW[:Q:PW%E%;^8J6L9X8GY0&Z$8#<
M]/E- CVVBO*?^%PW,WAE=8M/#D\D<3!;IV?;&A+8 5OXCT/XUZ3;:M9W-XUE
M'.C7<<2RR1 Y*!NF: +M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M14V<Y&,"F:EK5^-0NHK:[T^VCMQA5N)%W2MW'7BM_3KLWVGP7+*JM(N2JL&
M/?D4I4I1BI,F%:,Y.*Z'C'B/P[HOA\RBPD^:R4+<WLYWEF;D1!,_O'/'!X Z
MUT&@?#V]UCPU<GQ+>N)M6:*XGCCC".@3.R,GIM V\8&#FNCLO FACQ)<:Z9Y
M[V0SF5(99@\,$N "RJ/XN!U_PKJ(+NVNMWV>XBFV_>\MPV/KBLS4Y_4O!=IJ
M/AI-!%P]M8JJC9 BKR#D'\ZRX(=(\&:Y::9!<78N-0(=Y'02-(1QEW//7^==
MLL\3RO$LJ-(F-Z!@2N>F1VJ%A837$<CBV>=&*QL=I8'N >N: +5%1?:8//\
M(\Z/SL9\O<-V/IUI)+NVAE6*6XB21_NHS@$_04 345&\\,<B1O+&KO\ =5F
M+?0=ZDH ***:[!$9ST4$G% #J*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!
M_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=
MD_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_
M(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?
MXT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT
M?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?V
MI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!
M_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=
MD_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_
M(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?
MXT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT
M 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7
M:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*
MI?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?
MVI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI
M!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_
M=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D
M_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(
M?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?X
MT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?
MVI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI
M!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_
M=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D
M_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(?XT 7:*I?VI!_=D_(?XT?VI!_=D_(
M?XT >6>)O FOZEXEO[RV6'R9I2R;BV<?@M=]X<TFYL/!L6FW2J9Q$RL%<J.<
M]\9'Y5J_VI!_=D_(?XT?VI!_=D_(?XUT5,3.I!0ELC"GAX4YN<=V<G\.O#-_
MX=TK4;>[M[2!)I<P1PJ"X4#'SN$7?ST)&?<U2^$WA;4?"^G7]OJ-I##)(R$2
M1XS)C=U_=J>,]RW6NY_M2#^[)^0_QH_M2#^[)^0_QKG-SD/ GAJ^\/7<T%[I
M.F^:@</J\1)GNRSE@6ROH>?F/(JEI_@_6K?QG%)(+7^S;?4+B_6<.WF/YHX3
M;MP,<\YKO/[4@_NR?D/\:/[4@_NR?D/\: /.]>\#ZG??$R+Q$B1/:130DIR)
M& &"0X7*X/8'![U8\9>%=4U/X@Z/K%K:PSVUL@5]^,J=V<C,;?H0?>N\_M2#
M^[)^0_QH_M2#^[)^0_QH XCX@^$M1\1ZU82VFGZ?>1I:S0G[:S!8G;&'&U3R
M,>HKK-,TB[LM)L[2749)9(($C>3GYBJ@$]>^*M_VI!_=D_(?XT?VI!_=D_(?
MXT 7:CN/^/:7_</\JDJ*Y_X]9?\ </\ *@#S+4OB/H^FWL\ M-4NX;5REU>6
MEH9(+=AU#O[=\9KJK:YAO+6*YMY%D@F0/&Z]&4C(->9Z/XHT_P &:1>>'];M
MKM]4%S<&*V%L[_;@[E@4(!4@@@')K'^)\][-J&D2WUM;VFC-9ADBU#[0(XIR
M>C?9B3O QC/'6CHOZZ?U^H[:L]IK.N=;M(4U 0^9>7%A&'FM;5=\O()"A?[Q
M X%>8+HC:WJ7@C3?$,S7@:QNO,:-YH_-4;=H)8*_3&<XSBJ%_I.B:/KGCZV6
MW:&^;3FELP3(<Q-'F0@GC[V.OX42TO\ /\!1U_#\3TR^\8VEC>:59-IVJ2W>
MHH)%@AMMSPH< M(,_* 3SUQ6KI.I?VMIZ7?V*\L]S,ODWD7ER#!(R5R>#C(]
MJ\QT_P /Z7=>-?"=S-:[ICH:W!;S&'[R,($. >P[=/6LBQ\G_A7OAS^UOM'_
M  C?VZZ_M/R-_3<^S=LYV;NOX535KK^MVOT%'5)^GY7/<ZK7U_::;;?:+VX2
M"+<%W.<98G  ]23VKRJ^O?#5MX(M;<V6K7'ANXORD<M]),L<4>,@J(_WC1YX
M4-SGGL*PIM-M9_AMJ4=U%,]KI>N*T2,)5,%NVS/R$E@-C$X.2,^M*V_R_-?Y
MCZ?UY_Y'O=-=UC1G=@J*,LQ. !7S_P", S>(H$BEM+?2S:0+H4MU]MRJ[1@Q
M>4#\^>N\9Z<5['>V&H:EX"FL))5;4;C3S$TB@J&D*8S\P!&3Z@&E+2+DAKXD
MF90^)NBF<,;/5ETTMM&JM9,+0G./O^F>^,5K:MXKL]*U;3],^RWUY=7WS(MG
M#Y@1,@%V.1A1D9/-<-)XPTV;P&?":6=X?$!L?L7]F&U?>'V[<DXV[>^<]*EB
M\*6,7Q)\-)>P>;=PZ2)))/,;F6+8JMP<<<^Q[U5ES6Z7^_1O]";OEOUM]VW^
M?](] US7;#P]8"[OW<*SB...-"[RN>BJHY)-9_A_QE8>(+R:Q6TU#3[^%!(U
MIJ%OY,I0\;@,G(S[U0\<++:7_A_7#!//9Z;=L]TD*%V560J'VCDA2>W/-)9^
M,+;Q.^I?\(S:33M'9-Y6IM 8XS)SMCRP#'GGIBIOHWZE6U2.RHKQ/PV+ ZSH
M']A'5!XF$R?V]]H\[_5[3O\ -W_+UQMQ[5072+==%&M127,6H_\ "3/;)/'<
M.OEQM)A@HS@9[G&:=M;?UNE]VI-_Z^3?Z'O=-D<11/(V<*I8X]J\<U&QAT;3
MOB/I-D95L8;>"2.)Y6DVLZDL<L2<D\FG^&QI@\66I\,C4<?V?*-;^T^=]_8-
MF_S/X\YQCC'2I>S:[?HW^GY%;.S_ *V_S/4- UNV\1Z);:M9I*D%P"468 ,,
M$CD D=O6K-U?VEE);QW-PD3W$@BA5CS(W7 '>O [XWG_  KCPEYHM_[$V3_:
M3=>?Y'F;SLW^1\_KCMFM"^TNT?PQX3U#Q*ZW=E'?O$UQ$+D*MLP)5<.!)C<
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M]60!SCMP^TC(R!4UMXK229X+O1]3L;@6S744,J1R-.BD [!$[Y(++P<'D46
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M<EU;V^G:5J&HM-;)=%K?RD$<;DA2PED0Y.#P 3Q0(/L\_P#SQD_[Y-'V>?\
MYXR?]\FB;Q9:P:LUD;*]:%+A+22]54\E)G VH?FWY^91D*0"1S6_1TN'D8'V
M>?\ YXR?]\FC[//_ ,\9/^^36_10!@?9Y_\ GC)_WR:/L\__ #QD_P"^36_1
M0!@?9Y_^>,G_ 'R:/L\__/&3_ODUOT4 8'V>?_GC)_WR:/L\_P#SQD_[Y-;]
M% &!]GG_ .>,G_?)H^SS_P#/&3_ODUOT4 8'V>?_ )XR?]\FC[//_P \9/\
MODUOT4 8'V>?_GC)_P!\FC[//_SQD_[Y-;]% &!]GG_YXR?]\FC[//\ \\9/
M^^36_10!@?9Y_P#GC)_WR:/L\_\ SQD_[Y-;]% &!]GG_P">,G_?)H^SS_\
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MZ[A_7Y?Y'FUWX8U34Q=M'IU]9VMW?V4\EO<7JFX#)+F602I(Q5=FW: ^1MX
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M$/O8?+A5.5+'KQZY>M^'[K4F::Z\-VUQKEQ9+#'J]NZ%+.0;B"!(P9 I;(9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9HKFM%EU*+Q%=Z?-JLFJ6T,"M--+%&AAG)_U:[% QMYP<L.,DYKI:0!1110
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M=1$?NP"RDE@ V"<9Q]UB2 #3;3QOI5_X@FT:US+-"ZQ2R+/!M1V4MMP9-[$
M'.U2,Y]#AZOY@UH/'@S2S9VUK(UQ)#;V+V*JS@;HW*DDD '<"@P1BGIX61C
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MXQJ*!K5)9T5Y,_P@9Y(/! SS5FZUO2K*Z-I=:G9PW(B,WD23JK[ "2VTG.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KD?&=NVH7NBZ>EE;7YDEED:RO6VVTRK&1\[;'Y
M!8$#:>1VQD==574-,L-6M3:ZE8VUY;DAC%<Q+(F1T.&!%)@>516]EJ>F7[:L
MHF&G:"KVDLX!:"57F5WB;)((9$ 8<X"^M=9XQBDO?!VF136=O=RRW=D'MKLX
MCD8R+E7^5L#U^4_2NBNM T:^-L;O2+"X-K_Q[F6V1_)Z?<R/EZ#IZ58O].L=
M4M&M-0L[>\MF(+0W$2R(2.1E2"*IO]/Z^8/4RO#.CKI4=Q_Q3NB:,\A&5TM]
MPD SRQ\J/IDXX/6O-Y-- LKJZ;P_I$"W&LW,7_"0*^;JU8W#A7*B+(P<*#OQ
MR,X&:]6TS0='T4R'2M)L+ RX\S[+;)%OQTSM SC)_.ISI]D;26T-G;FVF+&6
M$Q#8^XDMN7&#DDDYZYH3UOZ?F'V7'O\ \$X@:C?S>*K[1H+W^SHY[^7-Y#!%
MYGR6\#!/F4J6.XG+ G"X'08T[?59-4^'-Y>7]^;1C#<1-?V\9.U59D$RJ.>0
M W'KQ6]<Z'I%[;26UUI5C/!*XDDBEMT978  ,01@D  9]A5Q(HXXEB2-5C4;
M0BC  ],>E#VL%]4SS:!H?#%^Y:"PTMI=.FECN]+S+!< %/WLT&U3OR1M(8YW
M$$U''J^H7&N2:5>7=W<Q66HZ?)')>QPI+ER^01$  ORC (#<G/&*[ZU\/:+8
MK<K::/I]NMT"+@16R()0>N[ ^;J>M+:Z!HUB%%II%A;A-NT16R)C:25Q@=B2
M1Z9-%Q-75D<!>>,M4T^[6YM-0N-1@N;*[N8TFMHHH?W2Y7R@O[W'J6+ ]B.E
M+<7NH:9XGG5-<-U-<VMC";V2*+-NLLTF6PH"]_ER#U&=U=]!H&C6MRUS;Z18
M0SL[2-+';(K%V!!8D#.2"03[TD/AW1+>">"#1M/BAN%*31I:HJR*23A@!R,D
MGGU-):#[_P!?U^11\-7UW//K%A=7AO?[/NQ!'=,BJT@,:.0VT!=P+$' '3I7
M&^&O"\]SINFWT&C:+II27SWU.VD)NYU#$E&'E+][H<NW'KV]+L[&TTZU2UL;
M6"UMT^Y%!&$1?H!P*?#;PV\"P00QQ0J,+&BA5 ^@I-?D'D>4^"M;U:'P#N+-
M:G3;*"XAMPBOY]N&)=\XSE@KK@?=P#U-6M)\4>(=?O9].M=16.XF:;4+61($
M(%D5*PJ<J0<OCGK@'FO18]*TZ&-(XK"U1$B,"*L*@+&>J 8X4X''2FKI5G#&
M19P16<H@%O'-;Q(KQH/NJN01@9R 01[53>K?]?UL&[_K^NYD^&-<E\13WM_&
MY&GH(X(XBHXE"[I23UR"P0CL4-='5'2-)MM%TV.QM=Y12SL\A!:1V)9F8@#D
MDDGCO5ZAVZ"04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1VHHH8'!^'O%\^KW%MYWBKPQYLC-OTR* _:0 3E03<'YL#^Y^%7K7X
MAZ=<V27C:;J<%O+:->0O+&G[V-"-Y #D@KN!.<9'3-6-(T/Q!I5O!8C6=,EL
M(B1L_LR02E"2<;_/QGGKM_"C3_!Z6=GHUM+=^='IUC+9,/*V^<'" GJ=OW.G
M/6CH/34L7?BRRMIIH(X+FZG29+>..!5)FE9/,V*2P&0G)+$  ]:H/XWMTO8&
M>)X;0VL[SQR1_OXYHY8XQ'@$C.7(XSDXP<=:<?PWMQX6M-)N;R*_N+6Z:Z6X
MO[431RN05 DB+?, A Z@\ Y%2#X>6YMH(OM%M 8H9% L[%((UD:6.175%. %
M,0X.2>[4U:XNA=E\<6EO$RW&EZG%>K/% ;$I&9MTF?+/#E"IVGD-QCG&#A__
M  FEJZQQ0Z;J,VHL\B/IZ+'YT9CV[]Q+A, ,O(8YW#&<UE:MX2UJ=X+U=1BN
M-6DOK9Y+B.W$<4,46_&(V<DC+G(W9.>,=EO?AU%?LE[<S:?>:H9)))9+_31/
M;N7" XA+@K@1J =V1@Y)S2 O?\)I;C4)9"0=+&FQ7B,(V\UG>1D"8SUR ,8S
MDU=T+7KG5]4U2VGL)K(6GD@13JOF NI)R59E(Z8P:H-X%@*-&EV(D^PQ6J"&
MV2,(\<IE60*N% W$?* !Q[UIZ)HU[I]]J%]J&HQ7EQ>^7N\JV\E$V C"@LQY
MSGDT"?2QAV7BS4;G7%M7ETU)&N&B;2)%,5XD8<KYH9W D&!NPJ=#P3WL:9XQ
MO+O3);F7P[J4DRW=Q L-LL1^2)RNXL9-@/&,%@20=H(YJ5_"M_<26]O=ZT+G
M3+:Z6ZB22W)N0ROO53/OY4'C[F2.">N:=QX&NY=T2ZO UH;BYE-M/9F1"DS[
MV##S &8'< Q&,$@J>M'V?,K37^N__ )Y/B'I:QK/%9:E/:_98;N6XBA4K%%*
M6"LP+!C@J<A03Z \U--XXM8 (WTK5/M9O18BT"1F0R&,R*<[]NTJ.N[C/..<
M5+'P#]BT:?3O[2WB2PM[(/\ 9\8$+.0V-W.=^,<=/?%-U_PMJ<VL6U]I5RBR
MR:K'=N[Q!E@5;9HN5+ N"<< @_-[9JG:^FPEU)KGQ]8VL8N9(+M(HX)GGM3;
M@S(\<D<94D/C(+] "#U#>MS_ (3"V6.X633M0CO(IT@6R98_-E9QN3;ARN"
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MPZED7K@#"\Y'5UK1TFTN=.(L-L']G6]M$D#)$L;%QN#Y5<*!PN %4#)K&O/
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M1,P+.3R<1IA0<[1@<8![T?9N/JD6=,\5Q:AJ%_9W&F7NFO8QK)/)=O 8UW=
M6CD< XYP<8&#W%7?^$DT+[!'??VUIWV.0L$N/M2>6Q4$G#9P< $GZ&N4_LR_
MN/#1TR'0-2@FCGBO)I;Z6V/VYUE5W5C'*YW-@]0%' R!38O#VIWWB^SUN;2/
MLENVH?:'MY)(V>,+;/&)'VL5W%BH^4G@ GV=M;?U_7]/<3>E_P"OZ_KH=A-K
MVCV]M;7$^K6,4%T0+>5[A%68GH$).&S[5:2[MI+J2U2XB:XC57>(."ZJV=I(
MZ@'!P>^#7F;^$-<@D$JPW_E2)=6Q@L7M-RJ]Q(X+>>K#8RLN=OS# X/;T'2(
MYK.RM].D@N,6UM$GVB21'$A P1D8)(QR2J@Y&.X!T!Z.Q%+XALXKS[-LF<_:
MDM"ZJ-HE92V,Y[#&?J/?!=ZZ(+^ZL+?3KR]N[>&*=HH#$I99&91@NZC(V$G)
M';&:YU-/O1;W<$$7GWVGZT;_ ,EF"&:)V+#:3@9VL0,X&4P2*U]%MK^X\0ZA
MK5Y926"3V\-M%;3.C2 (TC%FV,RC)?@!CT[4EMK_ %HOUN4[*_\ 77_(BL_&
M<-SIC:C<:1J5E:E@D3S^2QFD+[ B+'(S%MW'( ]ZTM+UO^T;B6UGTZ^T^ZC0
M2&&[5,E"2 P:-F4\@\9R.X'%8D>AZDGA/3XDA3^T+&\^U+ [C#XD8[=PR 2K
M'!['%:$,NN:R9EDM[C0;7RP$<M!)=&3.21@R1A<#'.2<_P ..1?U]R_X)/\
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M'_/:/_OH4?:(/^>T?_?0H DHJ/[1!_SVC_[Z%'VB#_GM'_WT* )**C^T0?\
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MM$'_ #VC_P"^A1]H@_Y[1_\ ?0H DHJ/[1!_SVC_ .^A1]H@_P">T?\ WT*
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M;((FSZIC!_*IH=+T^WBMHH+"UBCM01;JD*J(@1@[0!\O!QQ4_P!H@_Y[1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !N4'."1VS@_D:D^SP?\\8_^^10!PD7@[P_!H0T6+38X]/$BR>4CL,LI!!+
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M.-S*" 2!UP"1S[B@#%HK?^SP?\\8_P#OD4R2.UAB>65(4C0%F=@ % ZDGL*
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M]\BC[/!_SQC_ .^10!@45O\ V>#_ )XQ_P#?(H^SP?\ /&/_ +Y% &!16_\
M9X/^>,?_ 'R*/L\'_/&/_OD4 8%%;_V>#_GC'_WR*/L\'_/&/_OD4 8%%;_V
M>#_GC'_WR*/L\'_/&/\ [Y% &!16_P#9X/\ GC'_ -\BC[/!_P \8_\ OD4
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M5_R+\G_7_>?^E,E=%110W<04444@"BBB@ HHHH **** "BBB@ HHHH ****
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MW4([R[N&B?4(M(FFN7'VD! 81][$F2" 6R6 !YZUZQ146TL7?6YY!8ZOK/\
M9%_)::G'*HM8S=F#4Y[V:%_,02/\\2B%@A?,8/&!A1@FM.Y;1&N_#UW8Z[?7
MEG%J$\<5S-?RLF]H&*HLA(\T;@ ,EN25SU6O3**IN_\ 7K_F3;I_73_(\?BU
MF[;0TEN]8O8];6PM7T>W6Z<?:V:)2Q,><3$N6#;L[1SQUK:M6O!?R:BVI7[2
MCQ$;01-<N8A"< IY>=N.X)&1V(KT:BFW=W_K<&KJQR.L1:G+X]L1I=Y9VLHT
MR;<UU:M.I'F1\ +(F#[Y/TK-?1;G2]7L-,@OKN5ELKZ_*0S/ DUP98V&51ON
MAG8!22,'!S7H%%3TM_77_,:WO_73_+\3R0:Q=BTB;0]8O[V1['?K&Z=IC:R>
M9$&(!SY3A3+\@ ^[G'%68KJ&[N;RSTG7M0N=,;4;&))DU"20A'!WJDN[<0>Y
M#9SWXX],NK9+NVDMY6E5)!M)BE:-A]&4A@?<$57TS2+/2(I([1)<R-ODDFG>
M:1STRSN2QXXY/ IWUO\ U_PPFM++^O\ @GG5YK,=MXMLH+#4+\31:HEG<1W.
MINQ6+& #!R-I/21\,<@[CFH].@NYK#3C)K6L,;S0Y[R<_;Y<F6-H]C*<_+C>
M<A<!N-V:]7HI=+=?Z_X<K2Y1T:>2YT+3YYFWRRVT;NQ[DJ"35ZBBG)W;9,59
M)!7(^+-1LM+\2>%[O4+RWL[99YPTUQ*L: F%@,DD"NNHI=4QM75CSCQ#X@L;
MR^NY_P#A(7ALA8K)I$NGWA"W-SN<,%V'$S A!Y9W#GI4D.I$^)L:_JM]8Z@@
MMOL5E;RL!.&C!D_=#(D&\L&)!V@ Y7K7H=% /4\1O]5&KPW]O97VH3VUWHEX
M\Z2ZF\TAG0*55HU^2%@"<HA&1D%<#G>_M0 N@U>=?#WVVWCGO%OG_=P&T##$
MV[*JS[<L&!YZ\YKU"BG?2Q3=T>5:<UUK.M16;:QJK:6+2^>UDCNY(VGC26(1
MN74AGQEL,3\PZY!.>T\)7D5_H]A=2WIFU.;3K:2YC-P3C<N0WEYPN3NY &<=
M\<=#13OI8BVMSSN36=#BB\8:3?7MH]Y/>2A+#S%,\N88]NV/.XDGI@=O:L^6
M_O[4R0ZAJMW#XCMY+6/3[*.X8"X0I'O/E [906,@9B#MQU&,UZI123M^'X!;
M]?Q/,;R]DG/B&,ZUJ,/B0?;([:P@N'VB((?*;RQD*, ,) %)8XW'I1>ZWI^O
MS74?]H7=SIT5A8R-+9L)5AE$[$R$'@[2J[^"< Y'%>G44EHOZ_K_ ()5]SR_
M^UI)O[6NK6_LK]RU@AU?2RT:2#[0!Y3 .REP"<E3R&P0.!5*[U>19K=O[<OE
MUMYKX7]F+Q]L06&8Q_N\X0#"E2 -WWN2,UZ[69;Z!I]OJ9U "YEN<L5:XNY9
MECSUV*[%4ST^4#CBAZZ?UU_S"_\ 7W?Y'/>%5N+75;*%]0O;E+O1H[F7[5</
M+F7*@L-Q.W(/(7 ]J[2BBFW=_P!=V1%65OZV04444B@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?Q;=:S
M'<Z9;:3'JQ25I&N)--BMV=55> 6N/W8R2/<XXKJ*S]3TN34#$\&J7VGRQY&^
MU9#N!QD%9%93T'.,CL1DTAF%;:G>:S=6MII&K.(ET[SIKF>!&=G=PJ%E 4!L
M)+P,#..".*R;G7]8LG?3H+R]U-)[\6=O?110?:"1$[R!056(E2@4,0 ,G/W3
M71?\(?91:7?V%I>7MFMXB1M-;R*)(U48PC%3C/S$DY.6/X-@\(I#IL5FVL:A
M+]F=7LYC';HUJP4KE D2KT8@A@PJM+B*%CK&HWBZ3I]OJ$GVUY;DW,EU;()$
M2(%=KJAVE@[Q@E" V"1@&J.HZMK>D3W=G%K,E^";:![J6&)3:SS3*FU0JA3A
M&+!6W$?+DG-='9^%;6Q:>6&\O/M,T#Q-<%DWAG8LT@^7 8DCMM&T8  JE:>!
MXK71Y=*?6]4N+5@"@E%N&CD#!Q*&6($ON .6+9/7-&E]0(;?^UY'U73I_$LT
M,>GSJ[7YMX?.:)HPV"2OE@AL\[.GH>:HV>H^(-7-A8MJDNGRFSN+LW$4$6^=
M5E"0EE=2%!4AF  /(Y%:=QX%BNK4QR:YJWG/="ZGN/W!:=@H50ZF+85  PNT
M#C/6K5WX5:\2V9]>U5+R&.2$WD8@626-R"48>5LQP,$*",=>M+I_79Z_E]P/
M?^O+_@D^D:G?:KX/L-3@B@:]NK2.79(Q6,,P!/0$X&2<57\*ZCJFI>%]+O+G
MR+BYF9A<R%O*  9AE%"G/0#!QQW]=NRLX-/L+>RMDV001K%&OHH&!5/3M%32
MM.L[&TN[E(;9RW.PF4$DE6)7IEOX<'@<]<MM<S:V_P""Q=$<Y)KGB"._\60O
M$CR65A'/86MHAD;<PEQSC+,2B\8P.@SR3;\.7VI&*XM;B749]518I'MM7:VB
M*1L2-RM;(1@[6X.3E<'&<UKOH-L^H:C>B>Y2:_@C@D,<NS8$W;2A'(/SGG/8
M5%:: ;4S3'5;Z:^F"(][*L/F[$8D)A8PFWEOX<_,><X(%;\!LHMJ.L'Q^FER
MO##ITNGS2Q+%\TA97C4.Q(P#\QPHR/7/01>'AJDGB74P^O7U_IED!;[;J*W&
M^<@,Q!CB0X4%1U.23Z5NOI,$FNP:N7D^T0VSVRJ"-A5V5B2,9SE!W]:=I>EP
M:3;2PP/(XEGEN&:0@DM(Y8] .,G ]@*%_7W_ .0/J<=J^L7X\2:M:QZMKL+6
MRQ?9;;3]+%Q$S%,X=_(?&3ZNO'IUJOIWB[6;'Q3J2>(98X["*SC(A55Q!<+
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M-K %2R<@':K!?;DYA3P-I$4&N0QM<H-9E\VX*R %#UPAQ\HSD]^6-&G]>O\
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MU\F6&"\H<,#Q]W]X<=^G)IJW4.YLT444@"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHYR1;RD'!"'!'TH
MDHK ^T3_ //:3_OHT?:)_P#GM)_WT: -^BL#[1/_ ,]I/^^C1]HG_P">TG_?
M1H WZ*P/M$__ #VD_P"^C1]HG_Y[2?\ ?1H WZ*P/M$__/:3_OHT?:)_^>TG
M_?1H WZ*P/M$_P#SVD_[Z-'VB?\ Y[2?]]&@#?HK ^T3_P#/:3_OHT?:)_\
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M2?\ ?1H WZ*P/M$__/:3_OHT?:)_^>TG_?1H WZ*P/M$_P#SVD_[Z-'VB?\
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M9)ZTDWP]TB>+6(7N=1^SZI*)Y(5N,)#*#NWQC'#9P><]!2Z?+]5_P2GO\_\
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M@D;1D9^E5-.\?:A/I'B26ZM;87MC=216$2!@LZF1HHMV2>3(A!QC\*.E^W_
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M*,!0. !3ZYR/QA UC]IDTG587=T2V@EA0/=%P2OED,5Y )(+ KCY@*A?QU:
MQ11:5J<]ZQF5[.-(_,A:(*75R7"]'4@AB#V)R,C\Q+R.IHK#T7Q39ZY<B*WM
MKN)9+9;N"6>,*L\3<;EP21@\88*?;'-;E-JPD[A1112&%%%% !1110 4444
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M$,&F6MW;VL?V4W$\TNESW@4%MHSY3J(UX8EF..*=M;=P_0VH?#.DV\;I';R
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MRMOPTDA3=R0"P)QNY->QU!=V=KJ%K):WMM#<V\@P\4T8=&'N#P:E:%6/)9+
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M(Z@L*]JHJ^;WN;^M[DJ-E8;&,1J#Z"G445()65@HHHH&%%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/&.H5U;.?7TIVDZ7>:=K&M3OY#VU[+'/$RN=X81)&59=N /D!!!/7H,<XO\
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M<-I @TJ&9(F,%K;*J">*0/'+M! XY!&.1CD8KH+?5["[U.\TV"Y5[RS"&>(
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M@>H(/!%0:?I>GZ3;?9M-L;6R@SN\JVA6-<^N% %6YW;?<CELDCA+/1-3GU>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=@N 2.03NR-N<U2E\:I:^(+N&[3R=-ATN&]4O"ZS[Y)&4(5/?A0%P#DU!8>
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MVI);=DS%(8_+8J&5AAEZ@@\\\&A>8/R&-XDU*35(]/M=",D\5O#<7T<EVJ-
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M?RVT)N&"L& +!,8.,$  8)J>3PI8R7IF6:XCMFF2XDL4*"%Y4V['/R[AC8O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ@@\UU\WA3PY<6<%I-H&E26UOGR87LXV2//7:I&!GVJ4>'=$%O%;C1]/\B$
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M8P,1[6 !;/4YKTBBBET2%UN%%%% !1110 4444 %%%% !1110 4444 %%%%
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MI97FAZ/>VM_?:MIDEA=V5Z?M$<Z-;^?)*KR1(W0G!P!G)VGBO4:*.EOE^?\
MF'_#F!X;L))/ >DV-^)HW-A%'*%<HX^09&000>W!S61X*33;7PC90W$ZVT<>
MHW:6Z?:#$'(FEPF 1O&T'Y3D<9QQ7;454I7;??\ S;$EMY'!>']5\.>)?$4$
MVD7^G1P6%K+;6EK;3HLSJQ7>WEJ<H@VC P.N>.*D\,6FFZ:GB>VEG-I9QZR
M':Z>,[C'"1F3<&)9CSD_-G!SFNYHI)V_KSN-Z_UZ_P"9YGIUU:M?Z?I)FB?7
M(/$-U<2P!P98XR93O8=0I1E )XY KJ-"7^TO$6L:Q+AO)F.GVHSD(B8WD>A9
MR<^R+Z5TE%"?]?=_E^(Y:_UZO]3BFL-6U#Q-XDM[+4+&VM9?)CF6>Q:9V!BP
M=K"50./56_I7,W\1\(^*KW5+"*:X.G6=G8%<EGDC='5,^I\Q8N?<UZW14I6M
M_7];L3U?]?UV.(^&VFC1[?7K#<7:+4_WCGJ[F"(LWXL2?QKMZ**INXDK!111
M2&%%%% !1110 4444 %%%% !1110 4444 %%%% !39-QC8(P5\':6&0#[CC-
M.HI/8#R:#7_%&FZ=!J4NIVMYY6BW-T86MI '=95 +'S3DC(Y],COQU.L>)M4
MM]:ETVP2RW;K)5:9&;:9GD#$@,,X" @<=_PTQX.T(*J_8W**DT81KB4KLE^^
MA4M@H>H4\#L!2VGA#1+&3S8;65I2T3F2:ZEE8F,DIEG8DXW'\..@%4FK),EI
MZM&'8^)]=-U9B]33FAEO+JP<0QNK%XED82@ECA3Y9&SDC.=QZ51A\6^*FTA;
MQUT?<^CC5@!!* H &Z(_/R3GA^-O]UNM=H- TP&,BVYBN)+E/WC<22!@[=>X
M=N.@SQ3!X;TE;5;46G[E;+[ %\Q_]1TV9SGMUZ^]%]//^OU+TYO+^OT.6_X2
M;5Y-7%EIZVD;W>J&VWW/FRB-19K+D+O'?L-H/L2359_'VKN(+:&VC%Y'%*]P
M8M.N;M9&29X@JK%DQAC&3N8G'3#5V<?AS2HKR.[2UQ/'.;A6\QN)#'Y6<9Q]
MP 8Z=^O-03>$=%G1$-K*FQI&!AN98V/F,7=6*L"REB25.5]J;:Z$KS.1_P"$
MAO?[>CNY6O88/MJR/9NS HO]GF0QE?\ >YQCKSUJ^?%NLV<-L][%82G4K%KJ
MS6!67R7S&%1R6.\?O5^8!>AXKID\.:1'<I<)9*LB2"5<,P 81>4/ESC&SY<8
MQ^-5(_!FAPV]S##:R()XC#N,\CF)"<[8]S'RP#@@+@9 XXI-H?\ 7]?UJ<4(
MM6GN["_34;P?;KQ[6*Y;4)59=@<M+Y _<[?W;87;P,$DFN@TSQ)KNMW5K!8)
MI\9BL;:[NOM"O^^\TL,1D'Y  C')#9R!@=:SY?AW=RRGS)]/E/G&1;AQ< KN
MSN_=+*$^8$[@,*Q.2O:NHF\)Z3=_97O8I+F:"-8C(963S5!R!(J$*XSR%8$#
ML*%:PF<[;>-=2OM6DCBLY6LC=36FV/3;G,80LOFFXQY1&Y?NC&,]<C%5]&\4
MZQ;VWA^.\*1V4]K:@W-U;32?:6=%W'SU)6-LG #K\Q[C-=>/#&D#4FOQ;/YQ
M8OM\^3R@Y&"XCW; YR?F SSUJ%/!VA1R6SI9NHMEC5(Q<2B-O+ "%TW;7*X&
M"P)&!0ME?^OZ_K8;UO8P;#Q%K%[ EKIHLXIH+9[N=KL2RB1?-D144E\@G8<L
M2V./E]*UGXXUK4(I]3@@L$TV"XLD,+QN9G6=(B?G#;05,O\ =.<8XZUU%QX0
MT.Z@@ADM) D(95\NXEC)5CN96*L"ZDG)5LCVJQ_PCFDB.YC%FJI<RQ32JKL
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M0*R1J<[0K+M88Z$$<<U2A\)Z-#9WEJ+:22&\B,$PGN9928R"-@9F)5>3A5(
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M#8#8)]JH6?@?5XQ*9I[4M)J,UX<W$LI"R6IBV[F7)(8_3'0#A:<DM;?UO_P
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MG_LZZOK&62]:]CEA="T#L@0J@92NP@8VL".>,8&&K6_KR_K[^XVUT_K?^O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *R?$KW2:!<BRO(+2Z?:D4D\
M@C4L6 V[N<%L[0<'DC@UK5!>6=MJ%I):7<*302C#QN,@BAC1P)OYM(MM6@(U
M6UECMEE2QU&[:XW8DVF6.=96?:<@%<C'' R<W'\6:R7MKZ)+ :=<ZA/9+"\3
M^<OE"7YBV[!RT73:, ]3VWH/">CP6]Q#Y$\RW"A)7N;N:9RH.0H=V+!<\X!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.$8ECE>Z'Y%^;T2*T_KY?\$T;WQ7+;:H\,>GB2S@FMX+B9IBLBM,0$V1[2&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#T-#T 6BO+OAPUSJ-A
M:7U[9^)+F8W$^=0DU=C;';(X&8C<9(  &/+Z_G5+2/'FKVNBZ98P+/>WK6US
M>222V=Q>/,%G9%B'E\J3C&]LA<#@YH![GKU%<C!X@UO5]9EM=+MK2V2TM[>:
MXAU".02.903L!!'E[0.I5LGC QFL!?$WB:QNKQ!=6-TUQXD7381+;.!#&4R2
M,2<XXXXZ'GGAVUM_6]A75K_UM<]-HKA+[QAJUF=4NE2S>RT6XAM;Q# XDN&8
M(6>,[R$ \P84ALXZCK52?QWK,&HWKF*P-A::[%I9C$3^:Z2!,-NWX!!;^Z<^
MW6A*[LOZ_JXWH>C45YUI7BC5;N==*L!;17ESJ5^BSW0FGC2.%\?=,F<G(& P
M4<X':MGQM=ZE:?#'6+IY!:ZC'8LQ>SE;"/CJC8!_'@TGHK_UT_S';WN7^OZT
M.LHKRS0M8DL];FDC&LVT6G:4USJ%CJE^US)<$@-&\0,D@ X<$@CJ 1Z6;/XC
M:J=%GOKC3'D#VT,UO+]@N+:%'E=4$3-(,28W*=ZX!&< 4[=/ZWL2GI?^MKGI
M5%<E?:OXATL6&GW1TR34-1O/L]M=10R")5$;.6>(MG(VD!0_/!R.E9G_  F6
MMW%WIFF6T=A'>S:E<Z?<S20NT8,4982(N\'!X^4L>XSWH2N[#>AZ!17EVM>)
MM:U$V\]O<1VEE!XE@TXI#OCED"OARS;L%6/\&.G4FNL\7:_=Z1'!;Z:\!OYT
MEDCBD@:9G5%R<*&0 = 69P!D=:5_=YOZVO\ D.VMOZWL=+17E?\ PLK6[JPN
M;ZTMM/BBM]!AU=HY8W=F9BVZ,$,,#"\'''H:3Q?XNUC4/#WB0Z7*EA#IMK;,
MS@NL[/*%?*.& 4 ''0Y]13L[V$M3U6BN8\;)KTO@V7_A'E:2_!C8QI*8WEC!
M!=5<<JQ&1D<^G-<9HGC#[3HMDD46KP7::[;VMU9:K<R-):[^=H<%7=>X\S=G
MN,8H2N[";]U2_KN>M45YU_PG.M23V-U%%IZZ?=ZXVEB)XW\Y%0N"^[> 22G3
M;P/7M%H'Q!U:[_L&XU5-.2UU6&[<^3&Z&$P9.XL6;*D#ICCU/2ETO_7<;5CT
MJBO)[WQ[KUSI/B"&)[:":+1AJ=E=QVCI\C$C 5W)/ X<A?79VK5U#QGK.D6G
MB!'%E/-I.CV]Y')Y+J))'WYW#>3M^4<9SUYIV8;_ -?UW/0Z*\]7QSJT5MXG
MU.YALS8:(BE88XG\R9FA1_O;\* 6_NG(/;'.UX1\0ZCK,EU#?VDJ^2D<D=U_
M9T]I'+N!RH6;DE<<D$@Y!XZ468KZ7.HHKR9)[RV\)^(/$T>I:F^I6.JW"PJ]
M],\3(LVT1>46*8(^7A<C/'-:=_XLUFPO/$36&G27'V:_MH79(Y;HP1-"K-(8
M?,&<$XPFWKDYYRNG]=D_U*MK;^MVOT/1J*X.P\9ZEKJZ19Z5)IOVV\@N)Y+B
M2&5HE$+JA3RR4=6)89!)VX/WN,U=5\3:EH?BO49KD>8T>CVA%HDS- L\D[)N
M' XR1EL X%.SO872YZ-17 ZCXM\0Z6FIV'V&+4-2L?L\C365H[((92P+^3YA
M9BNP_*'YX/'.':=XYNK]/#9C:RF_M"_FL[IDBE0KL1VX1\,C9494[L9X)ZT)
M7V_K^K ]#O**\WT;QOK^M:QIUA%'IL(N)+X2R- [[4MY0BX&\<D'GGJ<]L&W
MX7\<ZCXAU.(#3Y?L-T9Q&PT^X06WEDA=\S?NY-V#]W&T\<T@>AWM%5-,_M#^
MS8/[5^R_;]O[[[+N\K=_L[N<?6K= !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML<?F[^N[=C.?>O/]0T[5+VVEEA^VWFFO?12W,^IZ4[2W"")E*O:H(F=%;R^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!-O_'?_KT 9M%:7]E?]-O_ !W_ .O1_97_ $V_\=_^O0!FT5I?V5_TV_\
M'?\ Z]']E?\ 3;_QW_Z] &;16E_97_3;_P =_P#KT?V5_P!-O_'?_KT 9M%:
M7]E?]-O_ !W_ .O1_97_ $V_\=_^O0!FT5I?V5_TV_\ '?\ Z]']E?\ 3;_Q
MW_Z] &;16E_97_3;_P =_P#KT?V5_P!-O_'?_KT 9M%:7]E?]-O_ !W_ .O1
M_97_ $V_\=_^O0!HT45'<?\ 'M+_ +A_E0!)17!R>+_#,,KQ2>(M)21&*LC7
ML8*D=01NZUK^8GE>;O7R]N[?GC'KGTH\P.EHKD(M6TV=K98M0M)&NE+VX292
M9E'4IS\P'M5R@#HZ*YRB@#HZ*X?_ (2?P_\ ;#9_VYIGVH/Y9@^UQ[]V<;=N
M<Y]JU: .CHKE9KVTM[B"WFN88Y[@D0Q/( TA R=H/)P/2BUO+6^B,MI<PW$8
M8H7B<. PX(R.X]* .JHKG** .CHKG** .CHK@Y/%_AF&5XI/$6DI(C%61KV,
M%2.H(W=:V%974,I#*1D$'((H Z2BN<HH Z.BN<HH Z.BN<HH Z.BN<HH Z.B
MN<HH Z.BN<HH Z.BN<HH Z.BN<HH Z.BN<HH Z.BN<H)P,F@#HZ*X^SUG2]1
MGE@LM2L[F:$XDC@G5V3Z@'BKM '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1
MT5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE
M% '1T5SE% '1T5SE% '1T5SE% '1T5SE% '1T5SE4M0UG2]($9U+4K.R$F=A
MN9UCW8ZXW$9H ["BN&B\4>'YX9IH==TR2* !I72[C*Q@G +$'CGCFM4$,H((
M(/(([T =)17.44 ='17.44 ='17.44 ='17.44 ='17.44 ='17.44 ='17.
M44 ='17.44 ='17.44 ='17.44 ='17.44 ='17.44 ='17.44 ='17.44 =
M'17.44 ='17.44 ='17.44 ='4=Q_P >TO\ N'^525'<?\>TO^X?Y4 ?.WAS
MPYK>I1W]S9:+X-NK<ZE<#S=5M7><XD.1D#&/2NGU?4=>U'Q%K&E:=JEGIEGI
M-FCO%);"3[3O0GJ2"JC&,BM"X^%/@J[N9;F?1=TLKF1V^U3#+$Y)P']:TM1\
M#>&=6EM)+_2(9WM(Q%$S%N$ P%//S >^:35XV_K:PT[2O_6]S@_#UQ<A/ %G
M;O#$T^F76)FMTD>-@O!5F&1SV!&>]1^'M8\0Z9X)M&&L+/<ZKJK6D5Q=0 K:
M_.X9R<_.25X!Z9Q7I-KX6T:SETV2WL]CZ9&T5H?-<^6K<,.3S^.:@3P3X;CM
M;^U&DPF#4)?-N8V+,'?U&3\O7MBK;NV_ZWO^1*5E;^MFCD+SQ)XCT33O%&F7
M6JPWU]IEDES!J,=LL9!<GY73E<C''M7;>&H=7BTI9-9U-+^XF(E#1VXB6-2H
M^0 =<'/)YYJ"T\%>';#0[G1;73(XK"Y&)XU=]TGU?.[]:W8XUBB2-!A$ 51Z
M 4@_K^OQ/,/#V@:!J.C^++K5]-L9675+P&YFB7>BCGAR,C'UK+G\8>)+3PYX
M6TRS-^EW=:?Y\D]IIXO)F53A<(S <CDGW%=Q+\,O!UQJ<FHS:*DMU)*979YI
M&5F)R25+;>O;&*U=<\*Z'XCM(K75M.BN(H?]4,E"GL"I! X'&:71?+\$4]V_
M7\3@UU/4=7U_P!=ZK936=Z9KM9(YH3$QPF VT\C(P<4_1-<U&Q\.VFK"6&.Q
MBUJ:"_CBMXHU,3.4#G:HP58J21R<G.:[J/POHL+Z8T5A'&=,W?8Q&S*(MPPW
M .#GWS2Q>&='AT6ZT=+(?8+HNTT)=CN+G+').1SZ'CM3OV_K5,6]K_UH_P#-
M' ZKXWUV'PY_:=JTI&K:HUOI_D6JS/# H(#*G&]F*D@$]Z:WB[Q7'X!U"XG2
M\M-1MKN"&WN[[3A;M,CLH):,[ESR0<>W0UZ#=>&]'O=!31+FPBDTU$6-(&SA
M0HP,'.01ZYS56#P5X=M=$.C0:9''8&196C5W!9U(();.XG('4]J%;7Y?I_D_
MO$[O\?U_X'W&'>:MK/A#4-,FU[6DOM.N(YXYY/LR0A)0#(F .?NAEZ\\=ZW?
M!MUJ5_X5L[_5I=]U=@SXV!=B,247@#HN/>JWC3P[<^*K"#252U6Q:9)+B:1V
M\Q0ISA%"X)(R,EAC/0UTJ(L:*B !5& !V%"V=_Z_K\AO='B_ASPYK>I1W]S9
M:+X-NK<ZE<#S=5M7><XD.1D#&/2NL\0>)]1\+ZCJEI)(L@N+..32(]B@"7(C
M:,8'/S,C<YX)JW<?"GP5=W,MS/HNZ65S([?:IAEB<DX#^M;]QX=TFZ;36GLD
M=M,8-9DLV8B!@=^> .N>@I+9)_UHE^@/=O\ K>__  YY[XI\5>*--UBST&QE
MU"2ZM[&.XN9[+2TNWGD.005RH1,CJ!FKS:YXLUC5=!L+6Y&BSWVF23W27%F'
M,4BL!D*V"#GH"<8/(-=;KWA'0?$[0MK&FQW30_ZMBS(P]LJ02/8\5:AT'2[>
M]M;R&S2*:T@-M 4)58XSC*A0<=AVH]?ZW_X'W"?E_6W_  ?O/*[_ %7Q)KOA
M[PW)_;AM;K^VFL998K=<2NK$+(5SCC;]WH2?:MWQ'JGBW2==EN+C49K'0K=4
M(N(-+2ZCD&WYFEPX=.<_=&,=ZZF?P5X>N=%?1YM-5[!YS<&(RO\ ZPG)8-NR
M.2>AJ'4/A_X5U348]0O=&@EN4"C>68!L# W '#< =0::>W]=%^M_O&_Z^]_I
M8Z&"5)[>.:-U=)%#*Z]&!&014E(JA5"J % P .U+28+8**** "BBB@ HHHH
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M?#^GK8Z5:1VMLISL3)R?4D\D^YH77^NPWT_KN:%%%%( HHHH **** "BBB@
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M* "BBB@ HHHH **** "BBB@ HHHH **** .CI&4.I5AD$8-+2,P12S'  R:
M*_V"V_YY?^/&C[!;?\\O_'C1]OMO^>O_ (Z:/M]M_P ]?_'30 ?8+;_GE_X\
M:/L%M_SR_P#'C1]OMO\ GK_XZ:/M]M_SU_\ '30 ?8+;_GE_X\:/L%M_SR_\
M>-'V^V_YZ_\ CIH^WVW_ #U_\=- !]@MO^>7_CQH^P6W_/+_ ,>-'V^V_P">
MO_CIH^WVW_/7_P =- !]@MO^>7_CQH^P6W_/+_QXT?;[;_GK_P".FC[?;?\
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MC1]OMO\ GK_XZ:/M]M_SU_\ '30 ?8+;_GE_X\:/L%M_SR_\>-'V^V_YZ_\
MCIH^WVW_ #U_\=- !]@MO^>7_CQH^P6W_/+_ ,>-'V^V_P">O_CIH^WVW_/7
M_P =- !]@MO^>7_CQH^P6W_/+_QXT?;[;_GK_P".FC[?;?\ /7_QTT 'V"V_
MYY?^/&C[!;?\\O\ QXT?;[;_ )Z_^.FC[?;?\]?_ !TT 'V"V_YY?^/&C[!;
M?\\O_'C1]OMO^>O_ (Z:/M]M_P ]?_'30 ?8+;_GE_X\:/L%M_SR_P#'C1]O
MMO\ GK_XZ:/M]M_SU_\ '30 ?8+;_GE_X\:/L%M_SR_\>-'V^V_YZ_\ CIH^
MWVW_ #U_\=- !]@MO^>7_CQH^P6W_/+_ ,>-'V^V_P">O_CIH^WVW_/7_P =
M- !]@MO^>7_CQH^P6W_/+_QXT?;[;_GK_P".FC[?;?\ /7_QTT 'V"V_YY?^
M/&C[!;?\\O\ QXT?;[;_ )Z_^.FC[?;?\]?_ !TT 'V"V_YY?^/&C[!;?\\O
M_'C1]OMO^>O_ (Z:/M]M_P ]?_'30 ?8+;_GE_X\:/L%M_SR_P#'C1]OMO\
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M]M_SU_\ '30 ?8+;_GE_X\:/L%M_SR_\>-'V^V_YZ_\ CIH^WVW_ #U_\=-
M!]@MO^>7_CQH^P6W_/+_ ,>-'V^V_P">O_CIH^WVW_/7_P =- !]@MO^>7_C
MQH^P6W_/+_QXT?;[;_GK_P".FC[?;?\ /7_QTT 'V"V_YY?^/&C[!;?\\O\
MQXT?;[;_ )Z_^.FC[?;?\]?_ !TT 'V"V_YY?^/&C[!;?\\O_'C1]OMO^>O_
M (Z:/M]M_P ]?_'30 ?8+;_GE_X\:/L%M_SR_P#'C1]OMO\ GK_XZ:/M]M_S
MU_\ '30 ?8+;_GE_X\:/L%M_SR_\>-'V^V_YZ_\ CIH^WVW_ #U_\=- !]@M
MO^>7_CQH^P6W_/+_ ,>-'V^V_P">O_CIH^WVW_/7_P =- !]@MO^>7_CQH^P
M6W_/+_QXT?;[;_GK_P".FC[?;?\ /7_QTT 'V"V_YY?^/&C[!;?\\O\ QXT?
M;[;_ )Z_^.FC[?;?\]?_ !TT 6:CN/\ CVE_W#_*I*BNF"6DS,< 1L23VXH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* ,#[//_ ,\9/^^31]GG_P">,G_?)K?HH P/L\__ #QD_P"^31]GG_YXR?\
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M_?)K?HH P/L\_P#SQD_[Y-'V>?\ YXR?]\FM^B@# ^SS_P#/&3_ODT?9Y_\
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M0 %/"D,,L_KM!'I5F/QWX9ET/^VDU:,Z<)1"9MC_ "N>@88ROXBC^OO Z_\
MM2?^['^1_P :/[4G_NQ_D?\ &N8TGQ;H>N3+%IU\)G>$W"@Q.FZ,,4+ L!GY
M@15W3-5LM9T]+_3YO.MG+!)-C*&P2#C(!QD'FAZ ;7]J3_W8_P C_C1_:D_]
MV/\ (_XUY+8>+_'%SHLWB(V.@SZ1 \ID@C,J7!2-B"1DE<\9]ZZ[4?&WAW1]
M/LK[4=3CMX;U \&069P0#G"@G'(YZ4 ][?UH=9_:D_\ =C_(_P"-']J3_P!V
M/\C_ (UQ-YXID7Q5X?T^Q:UGL-4@FF,PRQ(105*D'&#GT-.\,>+(-6M+**\O
M;.34+OSFB^R13+$ZQO@X,@!R.,@_AQ3M_7X =I_:D_\ =C_(_P"-']J3_P!V
M/\C_ (URUSXPT"STRXU*XU*..SMYVMWE9&YD7JJC&6/^[GH:9)XV\.1:);ZR
MVJQ?V=<2"*.<*Q&\]B,97IWQBD!UG]J3_P!V/\C_ (T?VI/_ '8_R/\ C7,Z
M7XKT366(L+X2D6XN3F-T_=$D!OF XR#5RPU6UU728]2L)?-MI4+Q.49=P&><
M, >U#T5P6IM?VI/_ '8_R/\ C1_:D_\ =C_(_P"->,Z'X^\4:S%:S_VMX&MQ
M.^W[+/<RI<#YL8V;C\Q[?45Z*?$.E*FIN]V%&F?\?FY&'E?+N[CGCTSFAZ!U
ML=#_ &I/_=C_ "/^-']J3_W8_P C_C7):GXW\-Z-]C_M'58[<WBJ\*NC;BIZ
M$C&5'NV*75O&WAS0IEBU+58K=V@%P@*LV^,G *D [OH.?:@#K/[4G_NQ_D?\
M:/[4G_NQ_D?\:X/6/B5X<T>+29GNC-!J1S%+&C%50<%C@9X/&,9S5R;Q[X7M
M]<71I=8@6_9@OEE6P&/0%L;0?8G-.S%<[#^U)_[L?Y'_ !H_M2?^['^1_P :
MI44AEW^U)_[L?Y'_ !H_M2?^['^1_P :I44 7?[4G_NQ_D?\:/[4G_NQ_D?\
M:I44 7?[4G_NQ_D?\:/[4G_NQ_D?\:I44 7?[4G_ +L?Y'_&C^U)_P"['^1_
MQJE5'6M1&CZ)?:D86F%K \WEKU;:,XI-V5V-*[L;?]J3_P!V/\C_ (T?VI/_
M '8_R/\ C7FGA#Q?XAUVZAGN(-$NM,G0NSZ;=$RV?&0LJN<DG@?**NZ/\3?#
M>KVNJ70N_L\&GOB1YE890G"N..YR .OMS5-6$M=COO[4G_NQ_D?\:/[4G_NQ
M_D?\:X6;XD^&1X:O-=M;_P"UVUJ0KK'&P?>?NKM8 C)[GBM#1O%^C:XMB+2Z
MW37L#3Q1^6XRJG:W) '#<>_:E8+G5?VI/_=C_(_XT?VI/_=C_(_XUR5UXW\.
M66DMJ=SJ:16BSM;[VC?)D4X90N-QQCL*T='UK3M?T]+_ $N[2YMG. Z9&#Z$
M'D'V- &Y_:D_]V/\C_C1_:D_]V/\C_C5*B@"[_:D_P#=C_(_XT?VI/\ W8_R
M/^-4J* +O]J3_P!V/\C_ (T?VI/_ '8_R/\ C5*B@"[_ &I/_=C_ "/^-']J
M3_W8_P C_C5*B@"[_:D_]V/\C_C1_:D_]V/\C_C5*B@"[_:D_P#=C_(_XT?V
MI/\ W8_R/^-4J* +O]J3_P!V/\C_ (T?VI/_ '8_R/\ C5*B@"[_ &I/_=C_
M "/^-']J3_W8_P C_C5*B@"[_:D_]V/\C_C1_:D_]V/\C_C5*B@"[_:D_P#=
MC_(_XT?VI/\ W8_R/^-4J* +O]J3_P!V/\C_ (T?VI/_ '8_R/\ C5*B@"[_
M &I/_=C_ "/^-']J3_W8_P C_C5*B@"[_:D_]V/\C_C1_:D_]V/\C_C5*B@"
M[_:D_P#=C_(_XT?VI/\ W8_R/^-4J* +O]J3_P!V/\C_ (T?VI/_ '8_R/\
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M0]>E7M&US3/$.GK?Z5=I=6S$KO4$8([$'!!]B* -W^U)_P"['^1_QH_M2?\
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MV$6G:/#I]LN(X(!#&/8# K0;PU;O?K?O:V;7J+L6X,8,BKZ!L9Q[59_LN?\
MO1_F?\*7V>7^OZW^\.MSQ+PYHNNZ'IMI:S_"S3KVZ@8G[<][:B1CN)#<@G(X
M[]JZ/Q3X3U'5?$=N]E&HTW4EBCU?+C(6)MZ\9YR,H<9KTK^RY_[T?YG_  H_
MLN?^]'^9_P *=]4P[GC_ (T\%Z[=^*I=2TM=0N+2[MTMY(K'5%LC&%R/FW*P
M9,'H/4\5LZ3X4N]-\7:;<?9V:RM-#%FLKS+(5DW_ '<X4GCOM ^E>C_V7/\
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M574A>-IER-.%N;PQGR1<@F,MV#8.<5K_ -ES_P!Z/\S_ (4?V7/_ 'H_S/\
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M<YY KL/[+G_O1_F?\*/[+G_O1_F?\*$_Z^[_ "#^OS_S*5%7?[+G_O1_F?\
M"C^RY_[T?YG_  I 4J*N_P!ES_WH_P S_A1_9<_]Z/\ ,_X4 4J*N_V7/_>C
M_,_X4?V7/_>C_,_X4 4J*N_V7/\ WH_S/^%']ES_ -Z/\S_A0!2HJ[_9<_\
M>C_,_P"%']ES_P!Z/\S_ (4 4J*N_P!ES_WH_P S_A1_9<_]Z/\ ,_X4 4J*
MN_V7/_>C_,_X4?V7/_>C_,_X4 4J*N_V7/\ WH_S/^%']ES_ -Z/\S_A0!2H
MJ[_9<_\ >C_,_P"%']ES_P!Z/\S_ (4 4J*N_P!ES_WH_P S_A1_9<_]Z/\
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M5%7?[+G_ +T?YG_"C^RY_P"]'^9_PH I45=_LN?^]'^9_P */[+G_O1_F?\
M"@"E15W^RY_[T?YG_"C^RY_[T?YG_"@"E15W^RY_[T?YG_"C^RY_[T?YG_"@
M"E15W^RY_P"]'^9_PH_LN?\ O1_F?\* *5%7?[+G_O1_F?\ "C^RY_[T?YG_
M  H I45=_LN?^]'^9_PH_LN?^]'^9_PH I45=_LN?^]'^9_PH_LN?^]'^9_P
MH UJ**CG)%O*0<$(<$?2@"2BL#[1/_SVD_[Z-'VB?_GM)_WT: -^BL#[1/\
M\]I/^^C1]HG_ .>TG_?1H WZ*P/M$_\ SVD_[Z-'VB?_ )[2?]]&@#?HK ^T
M3_\ /:3_ +Z-'VB?_GM)_P!]&@#?HK ^T3_\]I/^^C1]HG_Y[2?]]&@#?HK
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M^BL#[1/_ ,]I/^^C1]HG_P">TG_?1H WZ*P/M$__ #VD_P"^C1]HG_Y[2?\
M?1H WZ*P/M$__/:3_OHT?:)_^>TG_?1H WZ*P/M$_P#SVD_[Z-'VB?\ Y[2?
M]]&@#?HK ^T3_P#/:3_OHT?:)_\ GM)_WT: -^BL#[1/_P ]I/\ OHT?:)_^
M>TG_ 'T: -^BL#[1/_SVD_[Z-'VB?_GM)_WT: -^BL#[1/\ \]I/^^C1]HG_
M .>TG_?1H WZ*P/M$_\ SVD_[Z-'VB?_ )[2?]]&@#?HK ^T3_\ /:3_ +Z-
M'VB?_GM)_P!]&@#?HK ^T3_\]I/^^C1]HG_Y[2?]]&@#?HK ^T3_ //:3_OH
MT?:)_P#GM)_WT: -^BL#[1/_ ,]I/^^C1]HG_P">TG_?1H WZ*P/M$__ #VD
M_P"^C1]HG_Y[2?\ ?1H WZ*P/M$__/:3_OHT?:)_^>TG_?1H WZ*P/M$_P#S
MVD_[Z-'VB?\ Y[2?]]&@#?HK ^T3_P#/:3_OHT?:)_\ GM)_WT: -^BL#[1/
M_P ]I/\ OHT?:)_^>TG_ 'T: -^BL#[1/_SVD_[Z-'VB?_GM)_WT: -^BL#[
M1/\ \]I/^^C1]HG_ .>TG_?1H WZ*P/M$_\ SVD_[Z-'VB?_ )[2?]]&@#?H
MK ^T3_\ /:3_ +Z-'VB?_GM)_P!]&@#?HK ^T3_\]I/^^C1]HG_Y[2?]]&@#
M?HK ^T3_ //:3_OHT?:)_P#GM)_WT: -^HKG_CUE_P!P_P JEJ.X_P"/:7_<
M/\J /#](\*Z?XUT>\U_6KBZ75&N;@0W'VET^PA'*J$4$ 8"@G(JQXQ\?R^$+
MC3M&MKRQ>X^RK-)>:DLK+(OW1@0J3N;!.>E;6I?#G1]1O9YQ=ZI:0W3E[JSM
M+MHX+ACU+I[]\8JSJW@?2]26S-O/?:5-:1>1%/ID_D.(O[A.#E:.B7];?U^H
M]+MG/_\ ">ZWK(\.+X=L].\W5K>>1Q>L^V)HR >5P2,Y[9/'2LNYU?Q/-/XZ
M@U<Z9=:?8V>&MAY@ S&64+@@X(SN.<YZ'%>@+X9LUU32]0-Q>//IT,D,1EF\
MS>'QDN6RQ/'K5._\#:=?ZEJEZUW?PG5+;[-=0Q3 1,,;0^T@_.!P">/:B76W
MG_P!1\_+_@G!3V.H:WXQ\'PO;Z<=-BTV.[AMVEG'EA0FX\-RP/"Y)&.N:2R\
M?)X9\ :0+.VTZQGO;BX">=Y[6\2HYRQ +N221P#U/85Z1;>%K&UU#3KU);@R
M6%D;&(,RX*''+<?>^4=,#VK-'P[TA=!M-+BNM0A-G*\MO>0SB.XB9R2V&4 8
M.<8Q3D][?UJW^5@CLK^7Y6_,Q+/XDWVL>']/;2;2REUB\O6L5+LXM@RKN,G(
M#[<8..O-6_ K7[^,O%YU.*WCO/,MA*MNY://E]5) .#UY%;-WX)T^^T*WTNY
MO=4E>WD\V&^>[9KE)/[PD/0\],8]JF\.^$K+PU<7T]K=7UQ+>E#,]W-YK$J,
M9R1G)SSDGVQ35KO^NW_!$[V2_KK_ , Y34?"NB^*?BKJ<.LV?VF.'38&C'FN
MFTEF&?E(JHOB^3P5X<UBVWFX2RU8V%C+>.[JJLH;YRH+$)STYZ"NJUKP';:S
MKCZNNM:WIUR\2PO_ &?="$,JDD9^4D]?6K#^"-%;PZ-$6.9(%E\]9EE/G+-G
M/F!^N_/>H6D;?UO?\BNMW_6G^9YYJOC9O%_PN\21SM:27-F80TMF)!%(K.I!
M42 ,.A!!]*W+K5+S3_$OB"XTO3[22^M-)MIM[B1FF4')3 ?'0'& #GKFNC?P
M/9S^&+K0;O5-8O(;H@R7%U=F6;@@@ L"H''85H6WARSM==NM75YFGN;9+9T<
M@IL3I@8SGGGFJ]/ZTM^8NB3_ *U,*7QUFXU*[MHHY=(T[3%NYI!G>\KC<B*<
MX'R\GCN*P?"_Q4GUJ^N+.X.F2RM:RW,'V-9AY109\N3S%&3CNIQQ79:-X,T?
M0]%O-)MX7EM+MW:99R&+!AC;G X P![5%I/@JUTA+F--6UJYAFB:%8;J]:2.
M%",81>G Z$Y-)];=OQU_X'W NE^_^7_!^_R.>L_&'BM?"]GXDU*TTA-.FD@,
MB0>89$A8E7<Y. 02I YXSFNFT#7;G6]8UM52'^S;&X6V@D4'=(X7,A)SC )
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M< .">#6]H?B#6UU?0M'U46+27>FO<RR0;R2RD!<%C_=//'7-7+3P%I5K;:G
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MJ&'..IZ$GIQUK?\ ".O7^KIJ%IJ]O;PZEIUQY$_V9B8GRH8,N>0,'H:P=3\
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M>T?_ 'T* *W]EP?WI/S'^%']EP?WI/S'^%6?M$'_ #VC_P"^A1]H@_Y[1_\
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M 'T* *W]EP?WI/S'^%']EP?WI/S'^%6?M$'_ #VC_P"^A1]H@_Y[1_\ ?0H
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MM$'_ #VC_P"^A1]H@_Y[1_\ ?0H K?V7!_>D_,?X4?V7!_>D_,?X59^T0?\
M/:/_ +Z%'VB#_GM'_P!]"@"M_9<']Z3\Q_A1_9<']Z3\Q_A5G[1!_P ]H_\
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MO_7D=QX@\3Z/X7MHKC6;S[-%*_EHWE.^6QG&%![5!X?\9Z!XIDGCT6_^U-
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU#::1IE@\SV>G6ENTYS,T,"H9#_M8'/XUUGV>#_GC'_WR*/L\'_/&/\ [Y%
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MIWUN)JX4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<IXV_P"/OPI_V'8O_14M=77*>-O^/OPI_P!AV+_T5+77@?\
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MPR.Y2;<9-C.JX.[H#@X(KK[CPIHMSIUU8/9;;6ZB2&6.*5X\QI]U05(*@9/
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MP_\ A"_"O_0LZ-_X 1?_ !-'_"%^%?\ H6=&_P# "+_XFMRBCZU7_P"?DO\
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MW82MPH;G**#^E>Q4[:7!Z2:_KK_D%%%%( HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5!*_S0H&"KG.1C<W(YYZUMT4[L"E;Z39VM]=WD$;I-=A?/(E;:Q4;0=N< X
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MX+'GKS5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"A9Z/96+[XH@S+)))$74$
MP[SEU0XR 3SC^F "XT/2;N"X@N-+LIH;F3S9XY+=&65^!N8$88\#D^@HHH F
MCTZRB:-H[.W1HHC#&5B4%(SC*#CA>!QTX%0/H.CR2VDKZ58M)9J%MG:W0F #
MLAQ\H^E%%%P);/3X;.:[F0NTMU+YLKN1DG  ''8  #_'-6Z** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-1_002.jpg
<TEXT>
begin 644 ex10-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 08 Z8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &M_:D']V3\A_C1_:D']V3\A_C6310!K?VI!_=D_(?XT?VI!_=D_(?XUDT4
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M@#6_M2#^[)^0_P :/[4@_NR?D/\ &LFB@#6_M2#^[)^0_P :/[4@_NR?D/\
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M$<%]9R2QQRI,J_,N'4Y4\8Z&K%QI\EU;R0217 21=I,;/&V/9E((/N#1T?\
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MJUUIY@2UET6*Q\QP#@K'&Y+'DC.T9SU-;=EX4BT[Q+X/-GHGDP'3IH]0=+;
M9C&O$Q Y).?O5ZE]GG_YXR?]\FC[//\ \\9/^^33O_7R:_45OZ^[_(\4L_#T
M$?@B:QOO"^LI<V&I/*S65A$YF^9]K!).)D"G'0XR,<5VOPY2_31[H7>CQZ;!
MY^;?_0EM)95P,M)$I(5L\>_H*[;[//\ \\9/^^31]GG_ .>,G_?)H3_K[O\
M(;U?]?UU(Z*D^SS_ //&3_ODT?9Y_P#GC)_WR:0$=%2?9Y_^>,G_ 'R:/L\_
M_/&3_ODT 1T5)]GG_P">,G_?)H^SS_\ /&3_ +Y- $=%2?9Y_P#GC)_WR:/L
M\_\ SQD_[Y- $=%2?9Y_^>,G_?)H^SS_ //&3_ODT 1T5)]GG_YXR?\ ?)H^
MSS_\\9/^^30!'14GV>?_ )XR?]\FC[//_P \9/\ ODT 1T5)]GG_ .>,G_?)
MH^SS_P#/&3_ODT <_P"+HC/X;NH?[%_MB.3"R68E\MG3/)4^HZCITZUY]X)T
M&XCU^XCTS3M>L_#4MM(EQ9:Y&%1G/0(A)R.>I]QFO8?L\_\ SQD_[Y-'V>?_
M )XR?]\FE;<&]#Q;3+>YTOP)86$G@>:X-O?,FH"33$F=NN)(D)^?J%W'H :C
M/AB\'@/5X)- N7>'6UNX;1K93)Y)*$A%4!3\N00G'45[;]GG_P">,G_?)H^S
MS_\ /&3_ +Y-5?K_ %T_R!]OZZ_Y_D>67$M_I/B2\N['PQJ<MKJND116T5O;
M*HMW4-\DGS 1X!''X"LF[T/RO!WA>:\T/6YKZVLS#L@TR*\1"3G;)#+R#P.0
M!]:]I^SS_P#/&3_ODT?9Y_\ GC)_WR:7]?G_ )A_7Y?Y'/>#EOE\+62ZCIUO
MI]P ?]&MXQ&JKDX^09"DCDC)P36[4GV>?_GC)_WR:/L\_P#SQD_[Y--N[N)*
MR(Z*D^SS_P#/&3_ODT?9Y_\ GC)_WR:0R.BI/L\__/&3_ODT?9Y_^>,G_?)H
M CHJ3[//_P \9/\ ODT?9Y_^>,G_ 'R: (Z*D^SS_P#/&3_ODT?9Y_\ GC)_
MWR: (Z*D^SS_ //&3_ODT?9Y_P#GC)_WR: (Z*D^SS_\\9/^^31]GG_YXR?]
M\F@".BI/L\__ #QD_P"^31]GG_YXR?\ ?)H CHJ3[//_ ,\9/^^31]GG_P">
M,G_?)H CHJ3[//\ \\9/^^31]GG_ .>,G_?)H CHJ3[//_SQD_[Y-'V>?_GC
M)_WR: (Z*D^SS_\ /&3_ +Y-'V>?_GC)_P!\F@".BI/L\_\ SQD_[Y-'V>?_
M )XR?]\F@".BI/L\_P#SQD_[Y-'V>?\ YXR?]\F@".BI/L\__/&3_ODT?9Y_
M^>,G_?)H Y3XB6MQ?> =7MK2WEN)Y(@$BB0NS'<.@')K-\:6%Y=:)X9CM[2>
M9X=3M'E6.,L44=2P'0#N37>_9Y_^>,G_ 'R:/L\__/&3_ODT+3[T_N'?]?Q/
M$]<\*37.D^-+L:%-+J3ZJC6<HM293'N3)C.,XZ\K6IJOA*[35_$-IH&F_8X[
MK0DCC:*+RXY)=YW+NQC<1QZ\\UZQ]GG_ .>,G_?)H^SS_P#/&3_ODT6TM_6U
MO^"#=W?^M[GC'@3PW?+=ZA->6NJQ0_8'M9K<Z/!8";..%9)/G;KAB/Q%3^#M
M*FBUQM/M_#,ZZ7]GDAN+C5](@MY@,8"K(G^M!QSD>Y)S7L'V>?\ YXR?]\FC
M[//_ ,\9/^^33;O]UOS_ ,Q+3^OZ['C6EV]WI7PZMK$^"IKB6"_V:A'+IJRM
M(N2?-C0_ZPX*J&/\JIGPW?-H=]9?V%>QP3^(+:=;9K4#$!49.(QL  X..!T-
M>X_9Y_\ GC)_WR:/L\__ #QD_P"^31?6_P#73_(/+^NO^9XY?^#(#=>/5B\.
MCRA;1G352S^7?Y9W&$ 8W9 SMYI-4C@A\9Z.VI^'+C6EA\/)YEJD"RR(V[&[
MRW(R1T]1FO9/L\__ #QD_P"^35,Z# =9&K_8Y/MX@^SB7YO]7G=C'3KWQFDN
MG]=&OU'W?];K_(Y[X>Z;>:5X2BM[RW:U9II98[9CDPQLY*H?H#74U)]GG_YX
MR?\ ?)H^SS_\\9/^^33;N2E8CHJ3[//_ ,\9/^^31]GG_P">,G_?)I#(Z*D^
MSS_\\9/^^31]GG_YXR?]\F@".BI/L\__ #QD_P"^31]GG_YXR?\ ?)H CHJ3
M[//_ ,\9/^^31]GG_P">,G_?)H CHJ3[//\ \\9/^^31]GG_ .>,G_?)H CH
MJ3[//_SQD_[Y-'V>?_GC)_WR: (Z*D^SS_\ /&3_ +Y-'V>?_GC)_P!\F@".
MBI/L\_\ SQD_[Y-'V>?_ )XR?]\F@".BI/L\_P#SQD_[Y-'V>?\ YXR?]\F@
M".BI/L\__/&3_ODT?9Y_^>,G_?)H CHJ3[//_P \9/\ ODT?9Y_^>,G_ 'R:
M (Z*D^SS_P#/&3_ODT?9Y_\ GC)_WR: -NW_ ./:+_<'\JDJ. $6\0(P0@R#
M]*DH **** "BBB@ HHHH **** *]_>1Z?I]S>RAFCMXFE<(,DA1DX]^*P=/\
M8&_TG^UCX?U:VTXVINUN)FMB&0+N&%69FR1TR![XK6UVVFO?#VI6MNF^::UE
MCC7(&6*D 9/'6N#T#0M0L_"?]E-X?\00WYTIK5I+G5DFMO,\O&%C^TL%!(P,
M(,9["DV[2M\OQ_X!22NK]_\ +_@G;VGB/2KJ'36-[!;S:E"LUK;3RJDLBD9X
M7/) /.,U8EUC3(=0^P2ZC9QWNSS/L[3J)-G][;G./>O,$\#:^)8HIAJ!@NK*
MPB=;:XMD2!H -PD9T=P ?F7R\Y.<XZUU-AI>H:?KVH13:''J$-YJ8OH[^66,
M)"NQ5Y!R_F+M(&%Q@CYAS5R2N[>9FF[*_D:EAXW\,ZC8+>PZW8+ [O&K2W")
MDH<'@GW!^C ]ZTUU;37U)M-74+1K]4WM:B93*%]2F<X]\5P6A>&-8@UGPVUY
MI;1Q:3/J'F3&6-E(E.8W4!LX()'(!!!R.AJ:U\-:PEW9V#VC!;;6I-3;53)'
MB2-F<[ ,[]Y#!#D 8'7M25OZ^7_#E/2_]=_^!]YV5OX@T:[N/LUKJUC<7&UF
M$,5RC.0IPQP#V((/H:AB\2Z2VG6-[<WUK9I>X$"W%U%\['^%65BK'_=)K@](
M\'ZY:1>&M]@(WM-4O[BYQ*GRQRB0(>&YSN7@9([T_0?#6M:'8Z:]WH(U3.C_
M -GS6330[87\PL=Q8X*," 2NX_*/E-"0V=SXC\0V_AK2A?W%O<7"M-' D5N%
M+L[L%7&YE'4CJ:CTSQ-!?7]U87-E=Z9>6L2SR0WAC_U3$@.&C=UQE2.N1CI6
M;X[T.]UWPM:V%G;9E%Y:R21PS>7L19%+;6RI& #C&#QQS7/WW@K6OLWBG2+8
MR30ZA CV6I7%SYDP .3;2,Y9RO7!P1ACFDNO]=O^#]UA=OZZ_P!?F=]'KND3
M:6VJ1:K8OIZ9W7:W"&)<=<OG'ZTDVNZ/;Z;'J,VJV,=C+CR[E[A!$^>F&)P<
M_6N#B\+ZR4_M1K;4IITU*WNY+.]N+7S+A8D*<")5B5N01ECG8,E:TYM-U--5
MT[7(O#86.*.ZC?2X)H=X:5E(E))6/<=IW88_>X+4W_7]?UY@CJ[C6=*M)H8;
MG4[.&6< Q)).JM("0 5!/.20..Y%4)_%^CQ:_8Z+'<K<WEW+)#BW='$+HF\B
M3YLJ<=.*YOPYX0U/2M>T.6ZC5X[/1YK9IE<$12/*K!%'!("Y .,8%4-$\+ZY
M9ZEX1@GTG$>BSW?VB^,T9$HD5MK* VX@DC.0#GVYH25TOZZB>S/1+[5]-TMH
M5U#4;2T:=MD0N)EC,C>BY(R?85&^O:/'>_8GU:Q6[\P1>0UP@?>1D+MSG..<
M>E<7\1-!U_6S?VUA:27%K<Z8T,7D2QPD3;B<2LS!BA&, 9&<Y&#FLR[\&Z])
M:>(-EAF>[U+3YX6\Z/+I$(]YSNXP5;@\GMFB.N_];#EIL=UK'B_1]%NK>TFN
M5FNYKF*V^SP.C21F0X5F4L"%]ZFUWQ#:Z"+-)89KBYO9O)MK:#8'E?!) +LJ
MC !ZD?F:X6]\+:Z)S:)I1N5_X26/5?MQFC \DL"1@L&W*.,8QCH3TKHOB%X=
MA\3:-#8W6AS:I!YA9C:W*0W$!Q@/'OPK=>06''KTI?93_KI_P1];?UN;%MX@
M@N3IZFUNK>2],BK%=!89$*#)!1F#-]4##OG'-/'B30FFDA&M:<98M_F(+I-R
M;!E\C/&T<GT[UPNB>$O$EHGAE=0FGG%C)>[YII5>6WBD0K$K$'YV'?;D#Z#-
M<CIT4NO0Z+H^F6J3W>FZ-J%G.R2IN+L@52RYW1[FZ"0*V<\<9H?6PHJ^_D>W
M6FMZ3?\ G?8]3LKCR%#R^3<(_EJ1D%L'@$<\UGWOC7PW8Z0NJOK5C)9/.MNL
MT,Z.ID)QMR#CCJ?0 DUQ+>$_$D&PV5E#&Z^%XK#]XT3+]H#@E-I)!.,X)!7-
M-'A3Q 8?$%R-.N2UUJ-A>P07%W&\L@B*&0$[RH;Y3@9"],'%59<UKZ?\&WY"
M3=K_ -;?YGI!UK2A&\AU.S"1RK"[&=<+(V-J$YX8Y&!U.1ZTQ-?T:4W CU:P
M<VREI]MRA\H D$MS\H!!'/<&O/M7\->(+B;5H+?2))([[6K34DF\^(!8U\O>
MI!;.Y=AZ#!'0GI4[>#=9?P)?6$4;6U\^M27^R.2/=+&+C>,$Y7)4# ;C( />
METO_ %T_+7[A]?Z_K_AST.WOK2\LEO;2XBN;9E+)+ X=6'L1P:YW2/'5IJL6
MGW#Z5J5C9ZBP2TN;D1%)6.<+\DC%2<'&X#\Z?X4TB[T_2]1:Z6]$][<O.4O9
MH7DR5"Y(A544G'1=P[YYKFM$T'7+GPOX:\/7VC7%@-,N8;BYN9IH61O+8L%C
M".S$DXZ@#&:$E?[O^#]P?9OZ_P# ^\[4>)M)2T>ZO+ZUL85N7M@]S=1 ,ZG&
M 0Y&>/NDAAW JW=:OIEC);QW>HVEN]R=L"RSJAE/HH)^;\*\SN?!NLBT,JV6
MHQWB:G?RPRZ?=P!UCF;C='(?+=&'4%@PP.#S6I::#K>F3I+>:':ZR;G2+>QD
MMXC%%!"\98L&5L 1G</N*WW?N]*%KO\ UH.6CT_K4ZV'Q+ITEUK$,LGV9=)=
M$N9KAE2,;D#@AL],$=<5-+K^C6^FQZE-JUA'828V73W*")L],.3@_G7%7?AC
M63KFJZDEEYD0U:UOH[994_TJ..$(RC) !#<C=MY4=.M5K[PEJT\$FH"SU*"Y
MEU*6\@BL+N%9K-7C5,%7/E/NP2PW<;N">:70'N>C'4;%94B-Y;B22(S(AE7+
M1C&7 SRHR.>G-5H_$.BRS00QZQI[RW"JT*+<H3*&SM*C/(.TXQUP?2N)3P[X
MAL7T&Y>PBNYH-(N-/N$M#%"L;N5*MMRJ[?EP=O0G@8JOX2\%ZU90RI>6_P!C
MF?PY!IR3B1&,<P,FX?*3TRIST]*;TO;S_7_@"73^NQZ##KFDW%O=7$&J64L%
MH2+F1+A&6$CJ'(.%QWS5U'26-9(V5T8!E93D$'H0:\X\,^&M6TRQNI;_ $R\
MOIH-)6P6SO+FU\FZ*Y.Q5CC^YV#2'.&.5[UZ':@BSA#0+;D1KF%2"(^/NC''
M'3BAI+829-1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"'R/M,'F1+FYBW*N^,!B>KKPVUL$<4S4/&LL,""WT6]%ZM[;V\UI/Y0=$E;
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MH****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ5S:ZA9VT\TD-K%:R%PDC*CRN6:)0=OS*I!R#@CI7H-UI>GWMA]@N[&VN+/
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MA;H+&$./=9&)_P"N===\,K2/3_ UM91$F.WN+J)2QR<+/(!G\JZ;^SK'?O\
ML=OO\[S]WE+GS,8W]/O8XSUQ4EO;06D7E6T$<,>YFV1H%&222<#N223[FA.T
M;>GX?TPMK]_X_P!(EHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH P/$/A2#Q#>6%VVIZEI]Q9"18I;"58V(DV[@25/]T?K6=_P@4O\
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MK_\  U/_ (W1_P (%+_T.?BO_P #4_\ C==A11_:&)_F_"/_ ,B'(CC_ /A
MI?\ H<_%?_@:G_QNC_A I?\ H<_%?_@:G_QNNPHH_M#$_P WX1_^1#D1Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15+6'2/1+YY
M+F2V1;=RT\2%GB&T_,  22.N!7G]CH5G]KMM+N;&QCCU6REC6\TF4A;T; 3)
M/&5R&!Y5]S<GKSR?U_7W!_7]?>>FT5YO?SSZ[X<U WJYFT73;F*XX(!NS&R$
MCZ)EA[2BD\,:>VD>)-#/]A:5I27=A(O_ !*I]WGD!&#3+Y2= #@_-@L1GGEI
M:V_KK_D#T5_ZZ?YGI-%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG5S82IG=*8FV3;CTX8C&.P-)'XVL7L[F]:QU&.QC3?#=-"#'<C=L C(8\EB
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH AO+87EE/;&66(2QLGF0N4=,C&58<@CL:Y>Y\&W6L937M5BO
M(DMI;:+R+3R)"LB[6,C%VWG'H%&><=,=#K-__96B7^H;"_V6WDFV@==JDX_2
MN!N-0UG1O$MK>"^N;NRM-(BGU"V9BPD5Y'WRJ.S+U '\(*CM0M[?UU'K:_\
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M'5T5+U;;!:'$7?PZM[OP[#I:W-M9,MW]I=M/L5MXV4KL>,1J> R$KDECSU.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% #9)%B0NYPHZFH/M]M_SU_\ '35?7KZWTS0[N^NW,=O
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M.FC[?;?\]?\ QTUBT4 ;7V^V_P">O_CIH^WVW_/7_P =-8M% &U]OMO^>O\
MXZ:/M]M_SU_\=-8M% &U]OMO^>O_ (Z:/M]M_P ]?_'36+10!M?;[;_GK_XZ
M:/M]M_SU_P#'37.WM]:Z;9RWE[/'!;1#<\DAP%%9.A^,_#WB19SI.IQW)@&Z
M1=C(RCUVL 2/<"@#N/M]M_SU_P#'31]OMO\ GK_XZ:YG2M5LM;TV'4=.F\ZT
MF!,<FUES@X/# 'J#5RC8#:^WVW_/7_QTT?;[;_GK_P".FL6@G R: -K[?;?\
M]?\ QTT?;[;_ )Z_^.FL..1)8UDC=71AD,IR#^-.H VOM]M_SU_\=-'V^V_Y
MZ_\ CIK%HH VOM]M_P ]?_'31]OMO^>O_CIK%HH VOM]M_SU_P#'31]OMO\
MGK_XZ:Q:* -K[?;?\]?_ !TT?;[;_GK_ ..FL6B@#:^WVW_/7_QTT?;[;_GK
M_P".FL6B@#:^WVW_ #U_\=-'V^V_YZ_^.FL6B@#:^WVW_/7_ ,=-'V^V_P">
MO_CIK%HH VOM]M_SU_\ '31]OMO^>O\ XZ:Q:* -K[?;?\]?_'31]OMO^>O_
M (Z:Q:* -K[?;?\ /7_QTT?;[;_GK_XZ:Q:* -K[?;?\]?\ QTT?;[;_ )Z_
M^.FL6B@#:^WVW_/7_P =-'V^V_YZ_P#CIK%HH VOM]M_SU_\=-'V^V_YZ_\
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MU_\ '36+10!M?;[;_GK_ ..FC[?;?\]?_'36+10!M?;[;_GK_P".FC[?;?\
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M"XQUY^M+/I.FW-R;FXT^UEG,9A,LD*LVP]5R1G:<].E$NMOZTL*.CN_ZUO\
MEH>9:+-K&F:MX*N9=>U*_.LVK_:8+F4-$,1!EVC P<G[QR3W-8OACQ1XFO\
MQ;:3R7,GFSWABN;6?6;<1B/<056U(#JRCN,DX]Z]I&F:>&M6%C; V@Q;'RE_
M<C&,)Q\O''%-32=-CU%M133[1;YQAKE85$A'H6QFJNN:_K^8K>[8\LM-8ETS
MQJDFI>)KK4#<7IACCTW5H98@&;"J]J5W+@8!*DG@\CN:OK$VD^,Y[W4/$]S<
M0+=A(K72]6AS$I( 1[1ERQ!)!()/3CN/44T72H]1;44TRS6^;[URL"B0_P#
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M%9W]J_\ 3'_Q[_ZU']J_],?_ ![_ .M0!HT5G?VK_P!,?_'O_K4?VK_TQ_\
M'O\ ZU &C16=_:O_ $Q_\>_^M1_:O_3'_P >_P#K4 :-%9W]J_\ 3'_Q[_ZU
M']J_],?_ ![_ .M0!HT5G?VK_P!,?_'O_K4?VK_TQ_\ 'O\ ZU &C16=_:O_
M $Q_\>_^M1_:O_3'_P >_P#K4 :-%9W]J_\ 3'_Q[_ZU']J_],?_ ![_ .M0
M!HT5G?VK_P!,?_'O_K4?VK_TQ_\ 'O\ ZU &C16=_:O_ $Q_\>_^M1_:O_3'
M_P >_P#K4 :-%9W]J_\ 3'_Q[_ZU']J_],?_ ![_ .M0!HT5G?VK_P!,?_'O
M_K4?VK_TQ_\ 'O\ ZU &C16=_:O_ $Q_\>_^M1_:O_3'_P >_P#K4 :-%9W]
MJ_\ 3'_Q[_ZU']J_],?_ ![_ .M0!HT5G?VK_P!,?_'O_K4?VK_TQ_\ 'O\
MZU &C16=_:O_ $Q_\>_^M1_:O_3'_P >_P#K4 :-%9W]J_\ 3'_Q[_ZU']J_
M],?_ ![_ .M0!HT5G?VK_P!,?_'O_K4?VK_TQ_\ 'O\ ZU &C16=_:O_ $Q_
M\>_^M1_:O_3'_P >_P#K4 :-%9W]J_\ 3'_Q[_ZU']J_],?_ ![_ .M0!HT5
MG?VK_P!,?_'O_K4?VK_TQ_\ 'O\ ZU &C16=_:O_ $Q_\>_^M1_:O_3'_P >
M_P#K4 :-%9W]J_\ 3'_Q[_ZU']J_],?_ ![_ .M0!HT5G?VK_P!,?_'O_K4?
MVK_TQ_\ 'O\ ZU &C16=_:O_ $Q_\>_^M1_:O_3'_P >_P#K4 :-%9W]J_\
M3'_Q[_ZU']J_],?_ ![_ .M0!HT5G?VK_P!,?_'O_K4?VK_TQ_\ 'O\ ZU &
MC16=_:O_ $Q_\>_^M1_:O_3'_P >_P#K4 :-%9W]J_\ 3'_Q[_ZU']J_],?_
M ![_ .M0!HT5G?VK_P!,?_'O_K4?VK_TQ_\ 'O\ ZU &C16=_:O_ $Q_\>_^
MM1_:O_3'_P >_P#K4 :-%9W]J_\ 3'_Q[_ZU']J_],?_ ![_ .M0!HT5G?VK
M_P!,?_'O_K4?VK_TQ_\ 'O\ ZU &C16=_:O_ $Q_\>_^M1_:O_3'_P >_P#K
M4 :-%9W]J_\ 3'_Q[_ZU']J_],?_ ![_ .M0!HT5G?VK_P!,?_'O_K4?VK_T
MQ_\ 'O\ ZU &C16=_:O_ $Q_\>_^M1_:O_3'_P >_P#K4 :-%9W]J_\ 3'_Q
M[_ZU']J_],?_ ![_ .M0!HT5G?VK_P!,?_'O_K4?VK_TQ_\ 'O\ ZU &C16=
M_:O_ $Q_\>_^M1_:O_3'_P >_P#K4 :-%9W]J_\ 3'_Q[_ZU']J_],?_ ![_
M .M0!HT5G?VK_P!,?_'O_K4?VK_TQ_\ 'O\ ZU &C16=_:O_ $Q_\>_^M1_:
MO_3'_P >_P#K4 :-%9W]J_\ 3'_Q[_ZU']J_],?_ ![_ .M0!HT4V-_,B1\8
MW '%.H **** "BBB@ HHHH **** *.L3?9](NI]N[RTWXSC..:\PM/B5;WOP
M_N/$\-@?-MF5)K)IL%26 'S;>A# @XKTS7U9] OD12S-"P  R2:^?]4\+:S;
M?#?39].TZY:YN;2*UU&R$+>80K[D?9C.Y2"#[-[41WL_+\Q]OG^1[#=:MIVG
MI"U_?6MIYQ C$\RIN)[#)&3534/%.C:7J]EI5Y?PQ7=YDQ(S@<=B2>F3P/4]
M*XCQ#IWV7Q7?7VJ^%+KQ!:WMI%#9-!;+-]G8 AE()^0$G.^JB>&KS2)O MQJ
M>BR:D]HDEO=&& 3M$6QY6X_W4SUZ#!Q32NU_7?\ R7EJ3LOE_E_P?/0],&LZ
M6=2.G#4K,WPZVPG7S?\ OG.?TJ.3Q%HD4DD<FLZ>CQE@ZM=("A7[V1GC&1GT
MS7E=W8ZCJ'B"UN#X1FL;NSUJ.6:XMM/C2-X2^ WF#+R'!!8C@<Y[5TWACPE:
M74OBJ35-("SWFHW$:3S08=H6 'R,1G:<GIP:2ORW_KI_G^!3M>W]=?\ ([AK
MZT2>"!KJ!9K@%H8S( T@ R2HZG ]*Y[Q3XJU#0]4TS3=+T/^U;N_$I2/[6L&
MW8 3RP(/!]1TKF_AW!?ZCKD]UJ8YT*W_ +'A).=[JV7?\5""G?$W38;W7_#T
MU_H&IZQID2W'VB'3X7=@2%VY*D8Y]QTH=KJW7\M;?H)=;]/ST.LTC7=1EMI9
MO$FD1:#B18X1+?QRB4MT (P <\8[ULF\MA=FT-Q"+D1^:8=XW[,XW;>N,\9K
MSW1-%T75O">M:+H_AK6="20"0?VC"Z%I<?*R%F;H5&>G:H+71O$&O^$_$FIW
M-K+::WJ4 M88)<JRQQK@KSTW-O/XBA]?Z_K7\ 7]?UZ'H5OK.EW<$\]MJ5G-
M#;Y$TD<ZLL6.3N(.!CWI(=:TJYF,,&IV<LHB$Q2.=6/EGD-@'[OOTKR#POX<
MU5+36YVMM3B8:5-:F!]$ALUE<KP%\MR9#GH=O/KVK7TWPH--O_ ,MKHC0.()
M!J,B6NTY,(XF('J2/FIV_K[_ /+\0Z7_ *Z?YG=:9XPT#5[.[O+35+8V]HY2
M:1Y54)C^(Y/"G!P3UQQ6I97]GJ-L+FQNX+J!C@2P2!U/XCBO)+;P[;Q>&-8T
MV\\+ZNDMMJ9G$EC8Q-YR;F,>T/Q*BCC;@_>&!76?#=+^.QOA<:,FG6GFK]G9
M[!+*:88P3)$A(!'KQGT%"L_N7Z">AV]%%%(84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 9/B37[;PSH5QJMU&\D<6T!$QEF8@ <\
M#D]:S=!\3ZKJ-Q-;ZKX9N=+D6'SXI/.6>"1?3S5&T-['MS5SQ=$9_#=U#_8O
M]L1R862S$OELZ9Y*GU'4=.G6O/O!&CWMGK]PVC6/B+3_  ^UK*);76$"#S3]
MT1KG/?K^&:5]_P"NG]?D-]/ZZGH>E^(K>Y\.VVKZD]GIZ3<'-['+&IW$ "4'
M:V<=OI5TZSI81W.I682.40.WGKA9#T0\\,<CCKS7CL-F=,T3P*-:T>6^BB^T
MQR:2\:F=G9OE80N1OQW] <TZ#2&U+PUK=C;:5*(6\31!K2)?,\N,;-P.W(P!
MUQP/I5M7;2_K5+];DIZ7?];_ .1[':ZG87RS-:7UM<+"Q24PRJXC8=0V#P?K
M53_A)M":QNKV/6+&6VM5W3R17"N(_K@G!]JXF31;C1O$GBIM%\.Q/:R:7$(+
M;[,%MYY!G*XX5CSR.OYUCZ/H,VH:Q>SIX9N+"TO=$E@\F?3X[=&G# _<087G
M&-YR<9Z5'2Z[?Y_Y%+?7O_E_G^!Z;I?B71]8M+.XL]0MV%X#Y*&50[$#)&W.
M<@=1U'>K+ZQI<:2N^I6:K%*()&:=0$D/1#SPW(XZUY9807FEZ/X,U6#PQJ:C
M2GEAO;6&R G=VC"F0)D;@2/O&F2Z1JFJ:!K*WFAWL9O/$D4QMGA)8PDID\9!
M&.I!(Z\U;2O9?UJE^3N3TN_ZW_R7WGJ;Z]H\5E'>R:M8I:RMLCG:Y0([9Q@-
MG!.0:OJP90RD$$9!'>O(?B)X6O8-:T^?3-/?^QXK5H4@L-'AO?)D+;B?)<@#
M/'S#T]Z]!\&:;/I'A'3K&YDG>2*/'[^)8W49)"E59@,# X)Z4EJFQO1I&]11
M12 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH Y+QEXKU?PM"]Y;>&_[0TZ*(/-=?;DB\LYQC802>W(]:;!XKUL:=;7
M6I>&X;!KB[B@CCEU6'YD<??!P,D?W.I[58^(EK<7W@'5[:TMY;B>2(!(HD+L
MQW#H!R:S?&EA>76B>&8[>TGF>'4[1Y5CC+%%'4L!T [DT1\^Z_$;_1_@=4=<
MTA;C[.=5L1/YOD^6;A-WF?W,9SN]NM36^H65V\R6UY;S- VR98Y58QMZ-@\'
MZUY!KGA2:YTGQI=C0II=2?54:SE%J3*8]R9,9QG'7E:U-5\)7::OXAM- TW[
M''=:$D<;11>7')+O.Y=V,;B./7GFE]F_];7!K6W];V/2;+5-/U)9&L;ZVNEB
M;;(8)E<(WH<'@U#%X@T:X2Y:#5K&5;4%K@QW"-Y0'4M@\=#UKRWP)X;OEN]0
MFO+758H?L#VLUN='@L!-G'"LDGSMUPQ'XBI_!VE31:XVGV_AF==+^SR0W%QJ
M^D06\P&,!5D3_6@XYR/<DYJFNW;_ #$N[[GH6E^+-#U?1GU:VU*W%DA(DEED
M5!'@_P 63\N>O.."*MKK>DO91WJZI9-:R.(TG%PA1F/ 4-G!/M7ENEV]WI7P
MZMK$^"IKB6"_V:A'+IJRM(N2?-C0_P"L."JAC_*J9\-WS:'?67]A7L<$_B"V
MG6V:U Q 5&3B,;  .#C@=#1:[LO+]/\ /\ VW\_U_P OQ/71KVCFW%P-6L3"
M9?)\S[2FWS/[F<XW>W6GW>L:782,EYJ5G;NL?FE9IU0A,XW<GIGC->6W_@R
MW7CU8O#H\H6T9TU4L_EW^6=QA &-V0,[>:35(X(?&>CMJ?ARXUI8?#R>9:I
MLLB-NQN\MR,D=/49I=OZZ-_I^([:O^NJ_P _P/78I8YXDEAD62-P&5T.0P]0
M1UI]<M\/=-O-*\)16]Y;M:LTTLL=LQR88V<E4/T!KJ:;5F2G<****0PHHHH
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M!B_8+G_GE_X\*/L%S_SR_P#'A6U10!B_8+G_ )Y?^/"C[!<_\\O_ !X5M44
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MEK8Z'I=X=+07FIAY+>UGOHX%$2GAVD? 7((('OBF]/Z_KL"U/1OM]S_SU_\
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MF6&:_CMXT (&/,< ,V2.,4OZ_/\ R8?U^7^9Z5]ON?\ GK_XZ*/M]S_SU_\
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M_:U]I5A>7Y66+[,K+=0E "49AE3U&X$CVKV#^RO^FW_CO_UZ/[*_Z;?^._\
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MAU22$ZQ+%*&2(?N3&  #D_."1R./2O0_[*_Z;?\ CO\ ]>C^RO\ IM_X[_\
M7I?U^7^2'O\ UZ_YL\UB^']Q]GU<76NO=7&J:>MG+,UJJ;2-V&55( &#C;[=
M:7QOI<G_  @D&CVD=Y<:C&(ELWMH&)$L97#%@"$'7EB.]>D_V5_TV_\ '?\
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MSEBR./7.,$?C6GX2\,Q>%-&^P1W+7#/*TTDFP1J7;KM1>$7T45U_]E?]-O\
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M?:X+ Y;]XP.[((XQ6?<^!G-_ILUGJEW \$T\]S>[T^T2R.@7=@H4/  QM
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MJPHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!A>*-7DT:'3KA6F$<E]'%,L,#3.R$-D!%4L>@Z#-9EOXLGO-=U=;*WN
MIK>ULK>2.VNK=K,^8[R!F)F53MPJY/(X. 3Q72WVG0Z@UHTK.IM9UN$V$#+
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MY'%=,HVJ .PQ1I86HM%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <AXJO-:CUJS@L!K,=@MM+-<SZ;%;,58,H7<UP", ;SA<
ML?2I4O;[7M0EBTO66MM/AM(&:Y6&-W=I,L2-PPIV;#D@CYC\OIKZGH[:E*KI
MJE_9C;LD2W9"LJ]P5=6 ^JX;WK,NO!%A/H\^EV]Y>V,$\ZS2&V,>6"JJB,AD
M8%,*HP0<@<YYH6P=3";Q#K3VMC8PS7]T]W/<>1>64, GGMXP,.!(!$"2WWB
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MC"[0K (%"@8^X%/'7DYJOX2M;EI%O[Z^O[<I(D4%TR,L =2K;6"AR2"1EF;
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M=0HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M',>)?%O]A:M8:;&-+$UW&\@;4=1^R)\I4!5.QRS$MTQV-6KO7+]=2;3M/TN.
M\NDMXY9";KRXXRY8 %MI./E8Y )Z?+SP[6;/4IKCS-/LM+F\V!K>22Y=HY8U
M)Y*L$;</]CY>1UK'C\/>(='T2Z@T>YM);^:2*-9KJ9EVV\<:IP0C?.=I/*D
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MS(.1D[<8X&#@9]YX2N+S^WO,DM\7M_;WMN&RPS$L6%<8Z%HSTSP:-+_UY?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAJ>N:1HHC.JZK8V ER(S=7"1;\=<;B,]13[G5]-LHC+=:C:01B/S=\LRJ-G
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MZN@(0KM0(, D8VX.3D')KHJ* .?G\*)<0VY.L:HM] [LE^)(S-\X 88*% I
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MCQR3S7144 96C:%'HSWLHO;N\GO)5EFENF0L6"!. JJ ,*. *U:** "BBB@
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M'Y?2G8+FM]HG_P">TG_?1H^T3_\ /:3_ +Z-1T4@)/M$_P#SVD_[Z-'VB?\
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MVD_[Z-1T4 2?:)_^>TG_ 'T:/M$__/:3_OHU'10!)]HG_P">TG_?1H^T3_\
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M N1CCK3/$>@?\)!\0]':*WN_L]JN=1D,+)#(J$/$H8@!SN_NDXYS7IWE:?\
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M?#VIZ6-9E,MY>K?)=/ I>.4;3DC(#99<]ASBO1/*T_\ Y[R?E_\ 6H\K3_\
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M_P">\GY?_6H\K3_^>\GY?_6H I45=\K3_P#GO)^7_P!:CRM/_P">\GY?_6H
MI45=\K3_ /GO)^7_ -:CRM/_ .>\GY?_ %J *5%7?*T__GO)^7_UJ/*T_P#Y
M[R?E_P#6H I45=\K3_\ GO)^7_UJ/*T__GO)^7_UJ *5%7?*T_\ Y[R?E_\
M6H\K3_\ GO)^7_UJ *5%7?*T_P#Y[R?E_P#6H\K3_P#GO)^7_P!:@"E15WRM
M/_Y[R?E_]:CRM/\ ^>\GY?\ UJ *5%7?*T__ )[R?E_]:CRM/_Y[R?E_]:@"
ME15WRM/_ .>\GY?_ %J/*T__ )[R?E_]:@"E15WRM/\ ^>\GY?\ UJ/*T_\
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M3\)>&8O"FC?8([EKAGE::238(U+MUVHO"+Z**ZKRM/\ ^>\GY?\ UJ/*T_\
MY[R?E_\ 6IWW$4J*N^5I_P#SWD_+_P"M1Y6G_P#/>3\O_K4@*5%7?*T__GO)
M^7_UJ/*T_P#Y[R?E_P#6H I45=\K3_\ GO)^7_UJ/*T__GO)^7_UJ *5%7?*
MT_\ Y[R?E_\ 6H\K3_\ GO)^7_UJ *5%7?*T_P#Y[R?E_P#6H\K3_P#GO)^7
M_P!:@"E15WRM/_Y[R?E_]:CRM/\ ^>\GY?\ UJ *5%7?*T__ )[R?E_]:CRM
M/_Y[R?E_]:@"E15WRM/_ .>\GY?_ %J/*T__ )[R?E_]:@"E15WRM/\ ^>\G
MY?\ UJ/*T_\ Y[R?E_\ 6H I45=\K3_^>\GY?_6H\K3_ /GO)^7_ -:@"E15
MWRM/_P">\GY?_6H\K3_^>\GY?_6H I45=\K3_P#GO)^7_P!:CRM/_P">\GY?
M_6H TK?_ (]HO]P?RJ2F1!1"@0Y7:,$^E/H **** "BBB@ HHHH **** *>K
M2K;Z5<3."5C7<0.N!S7F.F_$N#53;&U\+>*&@N&4)<?V>#%@G&XL&(Q[UZ1X
MA_Y%Z_\ ^N+?RKYV\%:OX2M+#1S=>.O$4%[&4W:>DTOV<-G[FT1D;3Z9[T1U
ME;T"6BOZGLFEZ]:ZO?:G:6\<RR:=.()C(  S8SE<$Y'/?%:E>,:P=3_L_P =
M?V6&+?VO%Y^W?GR=HW?<^;'KCG&:I^'EU8> _$+:+=6\EB1%Y<.EK=_NQN_>
M^69U!R5S]TGGTH6JOY('O\V>WW%Q#:6\EQ<2I%#$I=Y'. JCDDFDM[B*[MHK
MF!P\,J!T<=&4C(->1VVG>%-5\+>)+7PK!JT]B;#S&1C)]F\]<LNW?\YDR!G'
MRXQ532M&\.Z[/X'T^W21]-DLKHSQI)(F^4!=X))#8W9Z''X4TM;>GZ_Y";LK
M^OZ?YGME%>+^)X](BU[68O$8U,:DF%\/"#SL ",;?*V<;MW7-:!T(Z_XUTNR
M\2"624>'%:[C69H_,??@ABA&>3G'3-+=7_K9O]-2K=_ZV_ST/2[W4?L5U90?
M8KR?[5(8_,@BW)#QG=(<_*OO5VO%]!GFGT?X?&:5Y#'JL\:ESDA5W@#/L!BI
M+ Z0/%$AU?\ MK_A,QJ3;!:;\F#?\F-W[OR=O7/.,TTM;?UT_P R7I>_];_Y
M'IWB3Q#;>&-(;4KN"YGC$B1B.V0,[,QP, D9Y/K69HWCNSU;5H]-FTG6=*N9
ME9H%U*T\D38Y(4Y.2!S5/XII))X.5(9?*E:^M@DFW=L/F#!P>N/2LBUM-4T[
MQ]I\/BW5Y=2<)(='N1#'#"92N'5U49#XZ<D$>]*/G_6E_O&_Z^^QZ917@'A8
M:P_CZV,]S9V^N"[9KU'%Z;B2+<<JW!AV8/'0?=YK;L#I \42'5_[:_X3,:DV
MP6F_)@W_ "8W?N_)V]<\XS32O;S"6E_+_@_Y?D>R45XGXE%@=9UX:Y_:?_"3
M^>W]@^1Y^-FT;/*V_+U^]FMV#0H];^)<2ZZCRW-MHMM,Z+*R+YP<\G:1G!SP
M>*4=;?UTN$M+_P!>1WFOZY;>'-'EU.\29X8V12L(!;+,%'4@=3ZUI Y /K7S
M[KYTL:?K(U/^T?\ A+?M_P ^[SMGD><-G3]WY>,8SWQBO9_%MZNG^$-0N7LY
M[Q$A^:""1D9@< _,OS <Y)'8&C['-_6R"WO<O];FY17@U@-/M[/Q7'HF8](N
M=":>*,+,J,X)#,/-)9L=-W [=LUOZ3I,6@>+O"3Z<\XN-2TR4W;R3N_G,L2E
M<AB0 #T QBG;^OD_\A7_ *^[_,]'UO7+;08+6:ZCF=;FYCM4$0!(9S@$Y(XJ
M?5=4L]$TNXU&_E\JU@7<[8S^0'4YKPF(Z2(=)6;^TO\ A+/[8M_[4\[SL9\P
MXW9_=XQC;CFO9?&,=E+X4OXM1LKN\M'0++%9J&EQD?,H)'3K^'>D](W_ *Z?
MYE*W-;^MV5-$\=:?K=\UC]@U2PO/*,T<%_:F)ID'\2<G(K<TK4/[5TV&]^QW
M=GYH)\B[B\N5,''S+DXZ5Y-X-U2[7Q!_9VA^([W7] :WE-P;NV=3:$+\HWL.
M23V''M5"T^R_\(7X*&N_:O\ A&S]H%V(/,P9=Y\K?L^;&<XQWIV_3\W_ )$W
M_KY(]THKPQH(YO"^M01/=I$_B>%$:9F$RJ=@!)/S X]>?7FMZ""V\)^(O&%G
MI]I=SV*:;'<M9QW,A>21LAB'R6!/<CG\J7]?@G^H^MOZWL>J,RHA=V"JHR23
M@ 5#97MMJ-G'=V<RS6\HRDB=&'J/:O&/"MEI%]KE_9Z3"PT;4]&D+0+YZI+,
M& ;!D;<Q&0-PP.<>M0Z)<:-HGA;PCJT*R16]CJ3_ -JR>7*WE3&,J200?]D<
M<4[=_+\VOT_$5^W]:7_KT/=**\0U2ZBU?0/&EQ$)HX;C6+3871HWVDH <$ C
M(Y&14OQ(T=-!&DV%O#;Q>'%25Y!?273P^>S Y<Q$N6[C/')I=+OR_*X]W;U_
M.Q[57##XI:8)9R^BZ^MG!*\4M_\ 8MUNA4X)+*QXR/2M3P$M\G@VQ74+E;F7
M#;)56493<=O^M4/P,#D?GUK@]!\:Z'IWAS6]"DFEFU:6\O%CLH;>1VD+,V "
M%V_K1+1M;V!:I'J/]K1MJ5K:16MU+'<PF9;N./,"@= 7SP3G@=ZT*\MLM/N-
M,\4^%-/NI)%G@\/S1R.@+,A &<8SDCM]*Q_ <FG:?XO6STE5U6[D61;F_C%Y
M!)&P!^:>.4E#D^G<]/5M*]EY_@W_ )"3TOZ?BCVJLK0]?M?$$-W):1S(MK=2
M6K^:H&70X)&">*\Q\('11KM@;C^V_P#A-/M+C41%OP1EO];O^3RL8QMYZ8JJ
MF[_A'[W[5]J_L/\ X26Z_M3[-OW>3C^+9SLSC.*/Z_%#>_\ 79_Y'MM%>.V%
MO9W/AKQ/'I-_J%CX2;R?L4QBGEVD<R!5_P!9Y9. ?J:B\-FUO?!OBO3-"TY7
MM_L3%+NT>Y\F9R&^01S$E7]=I.?7I2>B?DK@MTO.Q[/17D>E>(K'7?%7@A+$
MRO\ 9;&XBF9H715D$2@J"P 8C'.,]JSM,T.6V^$-SK.B13G5[G=%-(LLA/D"
M<[E50>!@'[HSR:<E:_\ 76W_  0CK;Y?E?\ X![;17E7P@$OG:BUK=:>VE%%
M"P6(N_+27)R0;A>I'4 GH.*]5H:L).X4444AA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ;]O\ \>T7^X/Y5)4=O_Q[1?[@_E4E !11
M10 4444 %%%% !1110!6O_\ CRD_#^8K%KHZ* .<HKHZ* .<HKHZ* .<HKHZ
M* .<HKHZ* .<HKHZ* .<HKHZ* .<HKHZ* .<HKHZ* .<HKHZ* .<HKHZ* .<
MK"\2>%+'Q,MLUQ/=VMU:L6M[NRF\J6(GKAL'K7H%% '#^'_#UGX;T]K2S>>7
MS)#++-<2>9)*YZLS=R<5JUT=% '.45T=% '.45T=% '.45T=% '.45T=% '.
M45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=
M% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.
M45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=
M% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.
M45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% '.45T=% $=O_Q[
M1?[@_E4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex10-1_003.jpg
<TEXT>
begin 644 ex10-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0@ U$# 2(  A$! Q$!_\0
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M;BX8O.G'F.8\_.Q/5L$Y;KSR[".DAU[1[C3Y=0AU:QDLH<B6Y2X0QICKN8'
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MPHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ8BI1LE2I.5!Y&/:H8?"5I#?QS_;+U[>*=KI+)G3R5F.29,!0V<L3@MM!.0
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M<.C?97/8:*Y7PUX?T1]/GNX_#5KI9O5>WN;$01JK(KL '5<J3CKC(Y[BN/\
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M6UMY7&]%?SL>^457L+*#3=/M[&V4K!;QK%&I.<*HP!^56*3\@"BBB@ HHHH
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MCDY'M7?T4EI_7?<'K_7;8PO#'A6R\+VUTMO)+<75Y.UQ=W4Y'F32'N<  #T
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M,=ZH^/\ PA=>-_#YT:+5(;"VD=7F9K0S.Q4@KM.]0.1SD'/M75T4GJ"T./\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@O&6
MJW&E>+M%AE\63:-IE]'/YQ;[*J(R*I7#2QM@DGG)/MBN]KCM=@U63Q]H%[;:
M)>7-E8I.LUQ'+ %_>JH& T@8XP<\?3-'5?UW#H_Z[$VG:]8Z591W.H>*1J%G
M?W BL)YQ%OD;.TJOE(JL,C(('0\G%:4GBG2$LH[H3S2)(7"QPVLLDIV-M?\
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M9PZVLT7E'RVPRCM@UC7?@F"]6\,NL:IYUY9+93S!H@SQ@MSCR]H)#L.!CG(
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M>-9?WRQJ53.#\X8-@=<@]Z!? ?\ "<P:)>M=21:E!)+%#<M-,(,1^?LY+?\
M/08'0Y QC%>L453E>3?K^+3_ $$M%;T_"_\ F>6WG]B)/J%WX=NK2W\/R:3.
M=0DLI_)A6?*^4<H0%D/S XP<8SVJ+0M1T.WU3P%+;7]BMU>:<\-PZSJ7F_=J
M%5CG+8<$ 'H00/2O5Z*2?]??_G^ FK_UZ?Y'!>&)&T[Q1)IA_LS4?/#SM?6?
MR7*9Y'VI/4C@.3SC&T4SXG?\([YGAW^V_P"RM_\ :4?_ !^^7GR>=_WOX/NY
M[=,UZ!12[>0^_F>:WBZ%)JNL6/B!+2--D9T$G"@1>4,?9B.CA]WW/F^[VQ5"
M*.*]\6^%M-\2W*27]SH4L6H6LMT>7.P+E-V QR_( )(/IQZS133_ *^_\==?
M0'Y?UM_D<A\2;:(_#O4AF5%@B5D\N5U/! P=I^88['(-<_JG]C_;M0O-'NK>
M#3/[*N%U6>VN/*3S\IY6]U(Q+G<#SNQP>HKM?%>B77B+P]<:5;7L-G]HPLDL
MMN9OEZX #K@YQSD_2M6W69+:)+B1))E4!WC0HK-CDA220/;)^M2U=/S_ ,K
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M];W_ *\B6KJW]=5_7H>;)=6T'CWQ'::%=PF_;0XC;6OGYVRC?A50GY,#R_E
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M4B,BVRMHZ3+]X>6V\PY_Y:;LYV_-C':L#1[[3[>U^%YN+LVMRJ&%H;B5H?\
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MI00:I8V]M>:%YL[0W@C,KY)#EE8'=L.=V<XYSBO3J*FVEOZVM_P1];_UO?\
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MH **** "BBB@ HHHH **** "LRYUN*#51IT=M/<SB+SI1#L_=(<@$@L"<E2
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MH\8&#CGY@W/3 ZUUNNZ7-K/AC4-+\Z-)[NU>#S-I"AF4C.,YQGWI?9_KLO\
M@E*W.K[?\'_(Y9[V8^--#U-].U%;J?2;G=9&569BK1;< 2&)2<GG(ZC)[5MO
MXUT:+PU%KL\WV>WE<Q*EPZ1-YH)!C)9@@8%6'+8XZU272_$A\2Z1J4EMI7DV
MEA+;RJMY)NWOL/'[KD Q@9.,[N@Q@YEOX0\21>%K>&*YT^RUNPU":]M)$E>:
M%_,9R4DRBD B1EX!Z ^U5*W]>K_34E=/ZZ?YG4>&O%&F^*K*6YTZ3=Y,GE2I
MO1]C8!QN1F1N".58BL\>(]#L;KQ)?"UODEL/+^WO]FD)?"G:57J0 /O  8YR
M1S6MH*:ZNG ^(9=/>^)Y73T=8E'H-Y+$^_'TKFK[P]XBN)O%QCM]+V:Q L-N
M6O9 5PA3+CR>."6P">1COD3+3;M_D.-G:_=?<;EKXIM[K4(+(65[')<VAN[4
MR*@$ZC;N"_-D,-R_>"CG@D<URWA_4;'4?MWB/7-&N;:YL;Z=(;Z4Q[\"0QK
M/+D+'' VD;2>1D\UI1:+XB37/#]\UKI?EZ=826LRB^DRS-MY7]SR!Y8ZX^\?
M3FM9>$-:N/#.HZ3J7V"UEDOVU"UGM;AYPLIF\U0RM&G .!P>>>E5HGI_6O\
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MA_MJ!$5#/(HC?9L<LVPEO7.,MWQ6EK.@^()['1[W1[JQM-<TU#'LG+R6\R,
M&1B &P=JG(&1BCI]WZ_U\Q+_ #_2WZE#7_'$5]X&75="AN;I)[J.UD:!XLQ$
MRJK*3O .<E05+#D'..:OZ)?Z=I5YJ.F6'AB^TVX2W%^UH# %D!^7"!92BME3
MD?*"><\YIFN:1XJU?PG;64W]CS:F;F*>X999((4$<BN%3Y79L[<9..N?:K<F
MD:PWB6/6(TL5-QIXL[J)IW/DL&+!D.P>8,L1@[/7VH>E[?UI_F/=*_\ 6O\
MD9%YJ%MKNN> ]<M1<QQW<TI2.5R,*8)#\R!BN[WY/O45AJB>%[WQK>_8M0OK
M>WU!'=(9!(\:F!&9OWKCY02> >,\# X?I_A/Q'IUMX0MBVE7*Z+(QF<2R1$J
M4:,!1L;<0&SDE<D8P.M:-A;3:%J'B74O$4FE6FEZA.LBRM>'"@(L8#[T51D*
M#U/)QSU-.RO;S_- O/R_7_@&TFMF34K*R73;PFZM_M!E#1%(!Z/A\YR0/E#
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MOG>;MSY&<Y^7I[^U4K*7H_U_RU)>J?>WZ/\ 6QUD7B(2>(KK1FTN_BEMX/M
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M]:%H2_W0V(W#=#DC&.@!ZU<AU'Q'YD\-SHVF)(L!DB,6INZ%L@;7)@!3/)!
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M78:0P!HIO,\S>NV(#.[!PP9>.E=9126@'.7'@K3+V/4X[^6ZO$U*.-;A99
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MN^0N,^Y/K4FMZ->ZO<6JQZQ+::>NX7=I'"C?:E.,*78$J.H..H/:MD    8
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MIVXQG)Z5,U>+MY_EI^OW(<=)?=^?^5BIX,UI+;P9X5L_)GNKNYTZ.0K$R95
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MJ5DD9^2R+@C=CH>F>^!32U_KK_E9DW>G]=/\SHJ***D84444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH,0<-R%) W9X)Y Q70ZAX&%QI,4=CJT]AJT-U)>QZE'&K-YSYWDH>"I!QM]
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MN5"A22<'(Z#/%2/X?NM2BNK^35;2>^N;-K6VN8[0^3%"YR2$\S+$\9.X X&
M.[8_!T@\+:/I;ZBHOM(,;6E[';[0K(NT$H6.05)!&1G)QBCU\OUO^GXAOM_6
MB_6Y%<>+]4@M=5A&APOK.F1K<2V0O3LEA8,0\<GEY8_*1@HO(^F=1-7U&;[*
M\&G6MQ!)9_:93!>$L&(RJ(&0*P8]&++T/%/TO1&M;ZZU*_GBNM2NHTAEEBA,
M4>Q,[55"S$#+$G+'.?H*@\/^&?\ A&](NK*RNR[R22/"\Z%EA4D[(PH(RJC
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MB"RN@92>5!!##!_*LK4?!$]U90PVFI003'4UU.ZFDM#)YTJL"  )%VKP!W.
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M2?+(8 ?)M'S8QG%8;:D]EX)L;NYUB\B>T\1M 9IM0D!\D794K(Q;YU"<?/G
MJN76WR_&Q-]+_P!;-_H=_P"*M?/AC0)]5^PRWBQ%0T<;JN 3C))[9(Z GVK9
M4Y4'U%<E\3/WGPYU8H=P*(01SQO7FHQ;2)XP33;:^OIK"^T^66\0WDC&%LH$
M=&W;H]V7X4@<9 &*E:W_ *Z7&^G]=;'945Y]I-O++<IX3N;W4S=:=>-<S7!O
MYQ)-;\F,EP^2&+!2I./D? &!6OXV>2WCT2YAN;F!EU6VC8Q3O&K([@,' (#
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MAG3M;8S*E]")(X(H7FES_$ D8+'!ZD#BKZ>(-+ETI=3CO%DM'.U612S,V<;
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MN[:RA$UR=CI%N"[RKJV 3P"<=\"MRBET_KR_R0^M_P"NO^;.1F.KGQQ!J/\
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MJI2YFVR4K*P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 5R>O\
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M[CE<R3AMV[*D?)W0@'/H>>@Z'0M3_MGP_I^J>5Y9N[:.?R\YV[E!QG\:RO\
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M45FZR.@C9E"L92 1G!.#G_9KM-)TF#1[5X87DE>61IIII=NZ60]6.T!03CL
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M&#;DVQ@=54X8$<=.M5IS>7_!5OPN*-TE?^M&G^-BGJ?B3Q(M]/I^BZ4-1N;
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M9PC1Q,BI;A@7WB/("B3E<8Y(QM[TEU_KI<'_ %]YZ)16!X*744\)6*ZF9&N
M& ,I.\Q[CY>[/.[9MSGGUK?IM68(****0!1110 4444 %%%% !1110 4444
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MPB2/&26<>9@ !3D DCN,\4@.BHK/U35HM+^SH89;B>YD\N&"$H&<XR<%V5>
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M:;JOC4V_AG6[^STR[-]I;&*:TE,8:-B 0Q(<J5PP;@D]L9HM_7W?YH/Z_/\
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M_P#!_P @OOY&_H&D76E6KG4=4DU34)<>==R1)%NP, !%&%4<\>YYYK7KG/\
MA-M)BTV[O+_S-.>SF$%Q;WC)&\<C %06W;.000=VWWZU/X9\6:9XKM[B73Y,
MO;N$FC\V.0H2,CYHV9#D>C'\Z>XMC<HK#U/Q1;:9).#9WES#:D"\GMT4I;9
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MOLY=5M[(6=ZL-S/);07I5/)DF3=N3AMX(V-R5 ..#TKH*7F'D%%%% !1110
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M<\5O;Q+NDEF<*B#U)/ %<=X<T*TU#3M96.[%UHUUYMKI[1D%4@?E]C#J-[,
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M#V&!^=4[BVU+6/$D<-]I%O%I6G3+<V]VUP)'N)-A Q'M^0 L>2<G [&NB(#
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MLI;/S!3Y$2%=IXR#SC)P>-R/PKH\=[J-T;>6634EV7:SW,LL<J^A1F*@8X&
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MBY(P$%N&64' (,I&<\<BMZ'P9HEO-ILL4=Z&TQ=EIG4;@B-?3!?##MSG@ =
M!3+;P)X8M/$C^(;?1K>/57))G7=U/5@N=H8\\@9Y-4VG)OU_,F,;1MZ?D=%1
M114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53
MO=6TW3@QOM0M+4(GF-Y\RIA<@;CD],D#/O5RN$U.2QTKXJ17TEC([2:._F/:
MVC32,?-0#(0%CQQG!P/04=;?UL'2YV3ZC8QPQ3/>6ZQ3<QNTJ@/QG@YYXYJO
M/K^C6T%M/<:M81171 MY)+E%6;/382?FS[5YR^BRZ=<>$?/TJX>2'5[FZ_=6
M3R_9+:3S"J,RJ0O+)\N>OTS70M NB^(]7CO-*GN-,U""&&T^RV33(BJI#0LJ
M [!DELD!?F//%#VOZ_I_G^ ?U^?]?,ZN_P!4T_2K<7&HW]K9P$A1)<3+&I)Z
M#+$"DOM5T[3+5;J_U"UM+=B LL\RQH2>F"3BO.K9==\&1Z++J6B7^N6HTL6<
MJV$:S36TF_.-I(RI4JI.?X*77;:32[C2;O\ X1GQ#-HOV#[,EEI%U(EQ9MNR
M RQ2KN!! /S$+MZTW_7]?T@/1;S4K'3[+[9>7UM:VW&)YY51.>G)('/UKF?!
MWBDWME)%K>K6)OWU&YM;905A\\1MM_=H22>.>I//6JD-L=#U/P_=)H^HQZ+#
M8R01VRHUS+9RLRE2X4NQRN5R"VWD9P<UB:?8ZE9Z5#//HM_!%9^)Y;QD6#>S
M0,7 9$3+$#<.@]QD4):_UW_KY!T_KL_Z]3TF+6])FAN9HM3LI(K5REPZW"E8
M6'4.<_*1Z&DEUO2;>TFNYM4LH[:!_+EF>X0)&W]UF)P#R.#7F7B>SNKK2?'<
M4F@:C,+V>&6Q869E\QQ$@&U5RP(VGYL #ID'BM?Q;;O;2:1K-OHNKWNFB-Q=
M6^D-+;72NP0+)M1D=L!-I!Z CTI=+^GY7_X VM;>OZ?Y_@>A0S17,*302I+$
MXW(Z,&5AZ@CK7)>._$SZ/IPCTS5+*+4DG@\RV?:\IA>14)"[LC[WWB".,5K>
M%+6VM/#T"6>FWFG0.6E6VO92\REB22Y+,0223C<>OX5P6K6VIMX+O-&?1=0N
M=8CU1;EV2W)6=?M(82+)]PG9@8R" .0 ,T[>];T_-"6J^_\ )GI=UJVFV%S!
M;7FH6MO/<'$,4TRHTI]%!.3^%/?4;&.^6Q>\MUO&7>MN95$A7.,A<YQGO7FN
MMVK_ /"4ZA;ZWX9\2ZI9ZJ8VMWTR[E6)%V*IBF1)E1<$$[CG.>^*W+^VU'3/
M$*3Z2]U-]KFA^TZ=<6CRP,%"*9%GQB,A0#\Q.2O S0E>P/K8ZM]5TZ/4DTU]
M0M5OW7>EJTRB5E]0F<D?A2MJFGI<"V:_M5G+^6(S,NXMC.,9SG'./2N$TZXO
M(-5F\/:SX4U.\E_M-[VWU*"-3;$&0O&[R;@591A=N"<+T(XJ3PU8:>-6\8FZ
MT.5;.2^^T1+-I<@611$JNR*4^8D[^F2V3C.:72_E?\O\_P !];?UU+NK:SJ6
MEMX8\K6K6[MKO4#;7=P(5'F+AVX(.U<;"#P?J,5U5IJFGW]D;VSO[6YM!G,\
M,RO'QU^8''%>::=87)\$^$G72[U4TC4S-=6[V4B2)&!)RL;*&8?.OW0?;I5S
M6=(U*]BUO6-,L+LVMU-:3"Q4O:37(B.9&&"KHQ!4#.&_=C/6GLOZ_N_\'[F+
M^OQE_P #\#O[+5=.U*S-Y8W]K=6HSF:"9708Z_,#CBN;T?Q)-JOCV^LK;4[.
M]TA=/CN+<VH5@&+LC N"=QRIZ8ZXQQFN>AL_M_AVXU'2?#?B*T:2\MI+VWU:
M:1[B[BC<%E59)'. ,\'&[&.:V-):XNOB;=:I%I-]'I]SI44:W,UN81O5W)#*
M^&!P0,8[=ABA+7[_ ,OZL*^G]=RYK.O76E>.=)M9[ZV@T>>SN)IO,0+M:/;\
MS2$X"_-TP.G4YKH?[5TX:9_:9O[7[!L\S[5YR^5M_O;\XQ[YKF_$D$MMXRT'
M6WM+B>QM(+F*9K>!IW1GV;3L0%CT/(!QWKG-4T?4K"P.III>I7.GG5Y;UM,T
M^9X+E(GCVAD\ME.[=EMF?XSGFDMOZ[E/?[OR.H\3Z[<Q:9I&H:'J-J]K<:C;
M0R2(HF$L<D@4[&!P.O7!]L=:W;W5],TV:&&^U&TM99VVPI/.J&0^B@GD_2O/
M+Z.WA\(:?+I_A_Q!:+<:S;WDEO=13W5SA9%9Y' ,C+PO0G)QTS6M.DEKK'B.
MWU33;R^MM75#:216CS(R>6%\E\ ^7ALGY]H^;.>M-Z+[_P EH):O^N[U.KFU
MO2;>^-C/JEE%>+&9C;O<(L@0#);:3G;@'GIQ4<7B+0Y[:WN8M9T^2"XE\B"5
M+I"LLG]Q3G!;V'-<Y'IFJZ)HGA>Z:)[[5+"-+.Z$8W,Z2*%//HKA&)]%)JUX
M=TV]T[5[S3)8Y#I]K,;JVG((#F49*@^SF4X[!EIV5VOZ_JPKZ7_K^K_@=915
M:QO/ML4DGV:XM]DKQ;9TV%MK$;@.ZG&0>XJS4C"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K%;PZK>*T\0'4[[S4@-N+;$7D[#@D?<W]0#G=U]N*VJ*.MP\
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "N"\9>*]>\,^+= MU.G+H6J7"VTD\MN[20OZ9$@'S
M=CCCG@XY[VN0^)OAM_%'@/4+."-GO(E^T6H7[WFIR /<\C\:3=FGV&E?3N9B
M^+M>L_BS!X4U.;2A87,#7%M+%:R+))C/[LDRD!@ 3G!SCH,\:&N>(M7T30=1
MOVO=":8W7DZ>ETWV1& ;#!G>4AFP&Z;?NYQSBN>\3^&]>U#P[X5UJ&'/B6RO
M8)Y@J'@/M5P1UPH"Y]E-7/B_IMS-\,)-+TZSO+VX:6%4CMK=YG;:P8D[0<<
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MZJ-4M8(O+%T 5W$'D;3RN,XP>0,5D6OAN\TKXFW_ -CC7^P=:MQ=72=DGC8
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MXGTSQ9I*ZCIES%+&6(95<,R<G&X#E21@X//->>:'8:A=:Y\38TTW4(DU./\
MT)KBTDA28B-D.UG4#J1]>O2NM^&$%S:?#K1[.[M+FUN+>$QR1W$1C8,&/8X/
MX]#VI+:_DG]][B?ZO]+?F=?1110,**** "BBB@ HHHH **** "BBB@ HHHH
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M444 %%%'2@ HJE)>3.+*2QMA=6]PX\R42A1'&5)#X/WN0!@>N>U7: "BBB@
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M%<1+(N1T.""*KW6@:->VIM;O2+">W,GFF*6V1D+_ -[!&,\GGWI+3^O-/]+
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M(<8RQ YX]:ABT'1X(O*BTFQCC)<[$MT ^?[_ !C^+OZ]Z/Z_/_/\!6_K[O\
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M21GGBA/9>GZ_HP>O]>G^1;\-6I2REOWENF:_E:X"3W$D@C1B2BJ')V?*1D#
MSGT%<?9V*6>G^.Y['4;ZUO$NIV1UO'D*[8HWR%D+*#DXSC.#C(XQZ4    ,
M51N-%TJ[%R+G3+*87847 D@5O."_=WY'S8[9Z5,E=-+M;\AK=-][G&VSWMWK
M_A6";5;\VM]HLC3P+-L#.JQ_/N7#[CO/.[TQBLZVO;^/PSIFHG4KY[FWU[[
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M'S8R><G'-=!%XKN4NM--_I:VMEJA5+*<7.]M[*6594VC82 <8+C/I1V_KO\
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MS3XKK[+/-'/^]# A698PI#*I/)+*1@X![U#XJM;.Y\2S3:2;1M+\KSIF9,W
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MHEQI4]W<VT%PNV1[;9O*]Q\ZL!GZ9J]:PM;6D4#SR3M&@4RRA0SX[G: ,_0
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M)YBR,-S,0PRO'RC'?=TJ_J/A8ZIJ>G75S<6[?8I5E2;[*!<Y!!P)0P"J<$,
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M3"29?G"[<Y8>M2SZ/I=U9I9W&FV<UK& $AD@5D4#H I&!T'Y5<"JJ! H"@8
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M>+&]6"9S\P([>E<MK&A>('\/^*= M].^T_VG)-/;7IN$"8DQ\C@D,&'08!&
M.1TKL)[*ZO\ PI+83+%!=SV30LJN71'*8^]@$C/? K.7\-VW_P"!_F7&RFK[
M?\%?H9GA3Q'9W>DZ-8W%W*VHS6$4F9XW'G'8"Q5V&UR.^"2.]:G_  D.F'4D
MT_SY%FD)6-V@D$3L,Y592NQFX/R@D\'CBN<TS1-3NX/#=I>V$EBNA%2\S2QM
MY[+$8QY>TD[3N));:> ,>F5X8\,ZCI.N1V=[X(T*6.VD9X_$2M$)I!DE24V;
MS+CJ<@9R<^NLK.;[:_G_ )&<4U!=]#=\)ZB]IINM2:KJ<]PMMJLT"SW)!8@%
M0J@* ,Y. %')/3)K3'B[1CIMW?\ GW BL\?:8VLYA-$#W:(IY@'?.W&.>E<I
M;:)KUQ97DO\ 9<]I<P:]_:D$-Q-%MN8R?N91VP<9ZX&<?AT.FZ9<WWB6[UZ]
MLIK%)[%++['.\;.V'9BS;&9?X@!\QZGI4:V^7Z+]="M$_G^O^6I?B\3:7-J5
MIIZ/="YNX/M,"M9S*&CP"3N*;01D9!((R!CD5=T_4(-3M%NK83")B0/.@>%N
M#@_*X!_'%<:/#^O0Z9I\L4:?VCI-S]GM<R@B2UR4+,?4H58CUC'>NO7S[.2Q
ML[>T\RUV%9)O, \H*!M^7JV>G'2F[=/Z_I?B+7^OZ_I%VBBBD,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[6M"TSQ%IQT_5K1;JT+K
M(8G) )4Y'0COVJ]##';PI##&L<4:A41!@*!P !Z4^B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1/IT8SO%W+$SGCC:(G<8]R1TZ<YKS5/ 6O+HEMX5^SD01:U_:+:L94VM%O+
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MS;3TXIM*[2_K1_\  7S)N[7_ *Z?\%_(WH_B/X5EL[&[34I#;WUR;2WD^R3
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MN@>%;_5=/@MYYK6/S-EP[*NT=3P"2?;C/J*VXV+Q(QZD T=+@.HHHH ****
M"BBB@ HHHH **P/#.M7VKSZU#?P6\+V%^UL@@=F!4(C DD#)^;T']:WZ "BJ
MTWVW[;;>1]G^R?-]HW[M_3Y=F..O7-6: "BBB@ HHHH **** "BLO6]3?3TM
M(8=@N;ZX%M TBED1BK-N8 @D *>,C/3(ZU8TP:B+)1JIM6NPQ!>U#!&&>#AL
ME21U&3CU- %RBBB@ HHHZ4 %%5[*]M]1M$NK6020.3L<=&P2,CVXHO\ [;]@
MF_L[R/MFP^3]HSY>[MNV\X^E %BBJQOH%U"*P>1?M4D33",?W5(!/TRPJS0
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MG@FL?6=,M+G0O%0T2WMKGPXMK!<6:VZB2%+@%C(T(&0,+M)V\9SWS7KH
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M?$SQ#$=3MX@ND0O)')=C$14ONPK-A %V$@8 !![UZ%12>UO)K\+?@4GW\O\
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M(_A[1-2^PWMRBRH0MQ_I$ :W) (#(9 [=1]Q6JQ%X<N8_$-IJ7GQ>6UOMOT
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MJ5L2#>"S2&,L_#@Y(R=N..M7[;1-?7Q!X=O9K?3%@T^Q>UN-EY(S$OL&5!B
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M>..@YP3BF^(?"\NJZM;W]I!;6U[&R@:G'</%/'&,':55<2@G(VLP'/?%-O\
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M;:2WU!7,$T1((SLY!4CC'K4=_HOB*]UKPS?2G3)CIKR2W;B62+<SH4(C38W
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MH7=WQ@,[L68@=AEC@>E/I_7]=A&K1112&%%%% !1110 4444 %%%% !1110
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MD4-T+!AM&,-C'4'K5?QE?7FM>!?%UY]NDMK6S^T6:V8C3;)LP"SD@MDG.-I
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M?4&O-]5O+S5]&\):Y<7[F/4-6LY4LMB!(022 I W%L=<L1D< 5O6NK>(9?\
MA+H(VCO;NPN5CLTBC6+Y&C5\#<2"P#'DG!('04[63OTO^G^8=?N_-_Y'9UEZ
M_KMIX=TLWU]'<20[UC(@A,ARQP,XX ]R0/>N97Q@B:5:PF_O(;J6]BL9WU*V
M6*:U9E)RP 5"3@A6 VDD=<4WQ;;ZE:>!-9M]0U%;\++"UO,R*LOEF1/]8$55
MSG=@@#C'>E;^OFO\POI_7G_D=K:6=K86RV]E;0VT"_=BAC"*/H!Q4]<M<WE_
MJ_B:_P!%L]2FTS[!;0SB2**-VF:0OU#JPV#;CC!SGD5CQ^*]8N-&T?5;FUOX
MK+]ZM]-IMNLI$B.4!,;!F\HX8_(-PXY ')_7Y_Y!_7Z_J>@T5R$.I7EYXPBM
M;;699-.O=&-U$8XXL(^Y5$B$H3R#G#%A[5AZ=X@\0W<'@U&U50-4>YBN9#;)
MYC%%D*L#]T?=' 7J/3BG9WM_75?H*Z_KT3_4]+HKSV74/%^H:I>:;H]]8?:=
M),<4K7$XA\]C&K%WB\ASL))QL=.A%:6I:]>Z9XAC.I->6NE/'&L5S;0I-:EV
MQGS6VETYX#?*N#R<T6&]#KV8*I9B  ,DGM2US'Q#69O 6KF"[GM76 MOAV[B
M.XY!X/?'/O44L^H2ZY;^&8M8O('33_M;7_E0F:4[PH !C\O YSA.Z].M):_U
MY7"_]?.QUE%8/A/5KS5M+N/MP'VFTO)K-Y43:LOEL5#@=LC]<UA->:Q87FKZ
M'<Z]>2ZA<-$^E3M#;@B-SM. (P&*G.[(/RXQC-'7^O+_ ##U.[HKBQ=ZQJ5Q
MK5I::S/:2Z*4B5G@B;[4WE!R\H*?=.<839T//I7T/7]3US6=/9KRXMK;4]"^
MV?9Q''_H\NY5W(2F3U)^;</:C^OP;_0'IO\ UM_F=Y5:VO/M%S=P_9KB+[.X
M3?*FU9<J&RA[CG&?4&LCP1J%YJG@^PO+^<W%U('#RE54MAV .% '0#H!7-:G
MXB\16FE>,I$U"V\_2KN-;=_LG"QLB-MQN^]\^-Q)''3M3MK;^NG^8=+_ -=?
M\CT6BN9L;[4(?&\^E7%ZUU;RZ>MXH>-%\I]^TJNT [3U^8L1ZU'K5WJX\::3
MI=MJ2VUC?6UP7$=NIE5T PP9LC^(<;>W.<TNWG_P?\@77^NW^9LP:!HUMJ3Z
ME!I-A%?O]^YCMD65OJP&3T'>M&N%@US5#IUU8W&I[+FWU4V O$@4SW"; P,:
M!2ADY /R[1M8D =**^(?$7]BV+_;A'*NO?V=,UQ:H99(_,VC.P[%;'7 Y[8I
MK73T_'_AP>FK\_PO_D>D45P6H>)=3\-S:_:SW/\ :"V=M;W,%S<JL?E^;(R$
M2&-0-J[=V0N<9SG%0:A?>-=&\+ZYJ4^H::5BM#=6C^:+IP5Y8#;#"NTC&"0Q
M!ZYZ4NEQVUL>B5DZAK\=C=?9X[&]OG389Q9HKF!6)"LP+ D<'A0QXSBI-%CO
M?LIGO+\W7VA4DC4Q*GE H,J,=1G)YYYQ7$K->:'XC\;ZP=2OKM=/@CF%H4A"
MR_NF8*2(PV%[8(..N:'H[/\ JPE[RTZV_$](HKC/[1U?3-4T%Y-3;4;;66,3
MQO @$#^4T@>,H =GRD$,6.".?7.TW5/$]]X0U/6#K<"W5DU[%L^PJ8G,3D*V
M-VX'"$8W'[W.<<DO=3;Z?IH$?>M;K^IZ)17#6FI:S)JOAV!]6D,>L::\DH\B
M,>5(BH=\?R]3N.0VX>@%1V6NZI=Z!!%+JC1W/]IW-B\\4*M<S)&S@&--A3?\
MJEB5V@;CQ3::;7];V$G=7_K57.\9E498@#(')[TM>8M>:OKOA[0'N=5OK.Y7
M7'M)'B2$.X1Y%4N-K)N&P'CY<YXZ8]-4%452Q8@8+'&3[\46_KY)_J-Z.W]=
M5^@M%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N<UVVU+6
M-1CT9](MWT1Q'-/?2W )RK[O+6+:22=H^8D#!/<5T=4K_5],TKRO[1U&TL_.
M;9%]HG6/>WHNXC)]A1U#H-U31;#688X[Z OY3[XI(Y&BDB;IE'0AE..."*CE
M\/:7/H[Z5+:[K20[G4R-O9LYWE\[M^0#NSG(SFK%WJFGV"NUY?6UNJ1F5C-,
MJ!4! +')Z<CGWITNHV-OIYU":]MX[(('^T/*HCVGON)QCWH J6?AS2;'4SJ4
M%DGV]H1 UU(S22E!V+,23[^O>G:EH.G:K/%/=12">(;4F@GDAD"]UW(P)4_W
M2<>U8_@W6KW6+OQ EW>0745IJ'E6TD$85#$8T<8Y.?O=<G/MTJ2_\66,MYJN
MB:;JME'K-I;>8%D(D(;#'&S<"V ,G!XW#-$G97?:_P"H):V7H6]9\'^']?TB
M+2M3TJ":RA(,40RGED?W2I!'X&H[OP3X;O\ P[#H%SI%N^EP_P"J@&5V'U#
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MBE5GB)Z!@#E?QJ*;6])M]3BTR?5+*+4)0#':O<(LK@YQA"<GH>W:A;6_K^M
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M2$S"X%N\CM"LG/*QD[%R22< 9/)YJS9^&-*L+N^N;>.Y$M\XDN"]Y,X9AC!
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MY*^_2FC5;&XO+C3K74K-M1B3+0"57>/T+(#G'Y4/N"VL5M/\,:1I3$V=O)&
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M13^]5!\S;6+# !.&X'%8VI:/?2:9K>HVEG<_8KC5K*^@M!;LLNR-HS*XB(W
MG:3MQN..F37IM1O<01S10O-&LLN?+1F 9\<G [XIIV=U_6S_ $#^OS_S.4T8
MW4GQ"U>\_LV]2QN[&V\JYEB\M<H7RI#$,#\XXV\8.<5<\8PRP:?%KEHFZ\TE
MS<*HX,L>,21_\"7./]H+Z5M-J-BD5Q*U[;K';G;.YE4"(X!PQS\IP0>?6J.H
M^'[?5M4LK^>\OMEJ,BUBN62WE.00TB#[Y!'&>*.WD'>YS][97^G3:!JLUM-<
MPP333ZA#!&976253AU4?,VS)4  G!X'%9.I:/?2:9K>HVEG<_8KC5K*^@M!;
MLLNR-HS*XB(W G:3MQN..F37IM%"=G=?UL_T#U_K?_,\O\0Q37MUXPE?0M1N
M+*_T>%+=S9,X:5?,VKY>-^[+J?N_+@D[<5VWA6"*/PYISK:-;SFUBCF$D!BD
MW(NW#!@#P<XS^%;$DB0QM)*ZHBC+,QP /<T12QS1)+$ZR1NH974Y# ]"#W%"
MV_KS_P Q/^OP_P CS7Q';WMW/J:0Z;>P^5J]G<M'#:/)]J57B!E\P@K@*OW$
MP1MR>IJ>:ZN[77=4T?5_"6J:G;:I=K<6]W:1JT84*F%E?<OEE"O'/TKT6BA.
MUOZ[?Y(;U/*9;C4;3QKXBU./3-2N+!;BW:6T_LZ?_2E5!&6C;: Y1N0O(89/
M8&M2.XLV^(.HZJFDZBL4VCH#.='N%+R L2,^7DML*C'7MU&*]"HJ;:6_K56'
M?5O^NG^1YAX?%_8:/X-U"XT_46L]/LY+6[MOL4OG02D*%D\HKO8 !ERH/#<<
M9K2@T"[;1/$%Q;0-$)K\:CI=LT9C9&14;[IY7>ZMD8!^8Y&2:[VHH[F"662*
M.:-Y(B!(BL"4STR.U4Y-MO\ K=/\Q>O];_YLY".UU)_$45VMG.EKKD"M=JZX
M^S&,@J&'8M&2I]Q4.JK=77CV^@M(KV*270WM8KO['+Y*S%BP_>;=G3!Z^W7B
MNZHI-)Z>OX_Y7!::^GX6_P CROP[9R7T4T,/AGQ)I6O6EA) EWJ-[-+;1NR8
MQ$7E8,"0#PN!CKP*G(NKFX\#_9?#VI(VEW)CO$:V\OR?W+(3N;"LN3G<I(/N
M>*],)"J68@ <DGM3()X;F%9H)4EB;[KQL&4_0BGS:W_KK_F*VECQC6_$OA8:
MM=^%M6U.RB@_MG[5.;VVF:4'>&V%3$8RIY <N,*1Q6O<PVL1^("66BWJ1WEJ
MJV_DZ3,%G?RRC;,1X;+D<C.?O=!FNVL-(B6ZN!;Z_>W%JKLDMB9(71&/)!;9
MYF><X+]_2MX    8 J;>[;^ME_D5>TK^?ZW//;2X/_"4^$G2PU..--+EAED.
MFSJL;OY>T.2F%Y1NN,=3U&<SP[9!-8@TW6_#'B634;&9YO[0:[FDL&Y/[U09
M=N6!/R*A^]C&*]5HJF[N_K^=R4M+>GX*QX_:(+/P/:6]OHNJ0O%XB%P(8](N
M%981<EPVT1Y"^61_+KQ7=Z0)H?&6O>9:W*QW7V>6*8Q$1LHCVGYNF01C;UY'
M&*Z6BB_]?)+]!O7^O-O]3E-7:XTSQG;ZM<VMU=:6UBUL/LUL\[6\A<$G8@+$
M,,#(!QM&:YB_LKO2/"MI;/97[K)KZWL%O;64LQM[87 ?!$:MMPO.#ZX'3%>I
M44EI_7G?\P>O]>5B.-TNK97"MY<J [9(RIP1T*L 1]",UQVAZ;>P:M<:(X T
M_2&:6RER#Q*#Y:X_Z9@R#'ILKK[J$7%G-"TLD(D1E,D3[63(QD'L1ZU0\/:9
M9:5I*0V-W/>HQ+/=W%P9Y)FZ%F<]3P!Z#&.,4=_Z_JP=$<1;:??7?AO1M!>P
MNX-=TV]AEENY+9A&-LF9)5FQM;>N[@'<=V"!S2:W97XL/'VG1Z;>S7&HL)[3
MRH&9)5,,:</C;G<I&W.>^,5Z;13N_P"OE_D@_K\_\V>>Z?;0W?Q-EN9]"NH8
MKG1XHIFN+!MAF#;MKR %&(7 SN(XQG/%7?B;:K=Z!91KI\]Y.NHVTD8AM'G:
M,+(I=OE4[?EW<\9Z=\5VM%%]O+_.XK;_ -=+'G'B^!M/UVUU(:#KFH:1/;,C
M1:'++!-#*S[BS1QNA8/D9W="OO23R7/A2[TR[M_"FJWFB/IWV1;.V N+FS8O
MNPP+$D," 3N(&WK7I%%+R_K^M1W/,_$-M+IJZ'>IX<UZ71H;-K<V&DW4B75H
M25*Y$4@WC P1N(&.M.FT^QL=4\$O:>']2MDAFF+"2VEN9+>*1'&V20;]N78$
M@L<9ST''I5(PRI 8J2.H[4T[:_UU_P P:N>3V-E#<^%-?\.:;ILD=S/JUR+5
MHK0B&$K*,/O V)LQD D'C@&NST^.XMO'NK&6VN#%<VEMY<XC/EL4\P-EN@/(
MXZ\_6K/A?1K;2+.X:TU>YU*&[G>X,DS1,-[$[BIC11R?KCMBMVA.R_KLE^@G
MJWZ_K<Y773<Z?XNTW6);:YNM+CM9K>1;:!IGAD9D(?RT!8@A2N0#CZ$US6JV
M%UI_@+7(%LKUDU#4C-8V=O9R2/%&75N5124!VNW.,;L<'BO3Z*2T_KSO^@WK
M_7DU^I5CGBOM-\Y$N!%+&2%>)XI,8_NL RGZ@&N$BT[6O[+UGP_ \^HV TR6
M"UGN[,V\T3E<+%O("RJ0?O* !MP237HM%)J]_,<7:S['GMLU]=:]X4N;;2M2
M6*+3;BVFEEMC%]GD(C'S!]IQE3T!SVR*C\*WUPJZ=I.L^$=5BU'148MJ(A!M
MF.TAG1P=TA<9.T*3D\\\UZ-15.5W?^MV_P!2;:)=O^&/)[:5H_#?A_\ XE.K
M)/%KSW,R_P!E7&]$\QR6(V9QM=>>_([''K%%%'3^NR7Z!;^OFW^H4444AA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SM[XBOH_
M$SZ%9:.)9_L9NHYKBZ$44F&"D?*&8=>I7KVQR.BK@-5OA+\6+>ST[6+"VU$:
M4Z;)U$W)D5MIC#JV=H)'(X&>10M6EZ_D#T3?];FQ%XLFO=%@O+'3-UP\TL$L
M=S/Y45N\9(?S)0K8&5(!VG.1TJI;^/6O+;P_+;:0\HUB62!9!<IY4<B!\C<.
M6!V$@A>G/7BK+>#O)33!9WJK]DGEGF6Y@\Y+AY"2[E0RX?))4\@9/!KE]:M(
M_#5YX2TI]?M5NCJ\\\+W"*NU9$F(RFX%AN<+D$9R,8)IJS=F#\O,Z4^-A:V]
MY'J.GO#J=K<);&UMR]P)&==ZLA1-[+MR3\F1M/'%5)/B!<6WANZU2Z\.7T<E
MM/'"\95XD8.0 ZM,D;%<D _)D'L1S5J^\$#4=.NO/U.2+6+BXCNO[1MH]ABE
MC4*FQ"3A0,C:2<[CSS4%[X.UW4_"<FCZCXJ^V74TR/+=S:>JC8C!@J1HR@<@
M9)+=_;"7GY?I?]0?EY_K_P  ZFRN+R:&9KNR%NZ2,L:+,)/,0=&SQC/H>GZU
MS%KXZGN+"RU%]&:"SFU Z?+YER#+%)YAB!"J"K#<.?F&.VZNN19A;*KR1M.$
MP7"$*6QUVYSC/;/XUQ"^!=870(M,&O6.Z/4_[2\W^S'P6\WS=NWS^FXGG/3C
MKS35KZ^7YZ_@'3S_ .!_F:5_XMGMX;^^L],6[TO39'CO)A<;9 4 +F--I#A<
MD'+*<@XS3!KNK7'C5+6TMK2?23IJW2LMR5D<,W!"E-I/  !8#!)SVITOA"?=
MJ5M;:FD.F:JSO>VQMMS;G7#F)]PV;NIRK\YQBKQ\/O!KD&H:?=I;1QV7V,P-
M!O&U3E"#N&,<@CG(Z$'FE_7X/]=@?]?>OTO<S='\41W6@V<EAH\=M=WMS<0P
MV+2JBAT9][.R@@#*DDJ&Y/?K5BY\62V&D+/?Z5<0Z@]PULEI&LDPD< G<I1"
M[1X&=P3/M64GP^OAX?@L_P#A(/(U.SO);NRU"UM-GE-(6+*T;.P=<NPQD<8^
MIO7W@^_U+P[;6EYXDNWUFVF%Q!JRP1HT<@!'$:@+MP2"O<'DTW_7X;?B"W_K
MS_X!$OCQDT5;N\TM]/N&NQ:*+_S;:!F*[@WF21*P0],E!\W&.]=;;RO- LCH
MJ,>RON&.Q![@]:Q+31-6CT%K+4=<CU6\DSYD]Y8IY3#'"^4A48SSUR?6K?A[
M1(O#VCQZ?$X9%=WPB;$4LQ8JBY.U!G 7)P.YH[B,BY\9O!9OJZ:<LF@13-#+
M>"XQ*NU]C.(MN"@(Z[\XYVU-%XHO+KQ)J&CVNBNYL6MS)+)<HN^.4G+J!G@
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MK\>.+&ZGGB)NM*1)1*3MY!C>X<1E3U*(H/XU5M;?UY"V5STVBN0\82WD6O\
MA6.WU"ZMX+J_:">&%@JRJ8G;DXW9!4=".OTQSOB"\>UUT>'[KQC%HL-I:126
MMQJ4DN^X/S!G,JSQ!R" "KAAP#CFE_7W%'J-%</;RS:OK%QIU_JL["QL+>>"
M2UF:V^U,P;=-A&R5R -I)7U!R*S?#U_>7=WX(O+K4+MWU#3+C[5FX<1RL K
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M\Z/=(NP/OSG &T@XR3[9XKJ+:;[3:0S[=OF(K[<YQD9Q7G&I_P#(*^*/T/\
MZ2)6GJJ#17T/Q/)=7PL88TAOH5NY1"J,H"RF,-M.UL9XQAB3R :%MKY?BG^H
MY+73S_3_ #.YK%\4>(?^$:TI+\V,MVK3QPL$=5";V"ACD],D#@$\]*=X;LGM
M=,,\LEVTMV[7#)<W$DIB#'(0;V.T $# XR#7G/B6^CU'P)<ZW?W\R7:ZJD$L
M!N6$4"I= !#'G:"%4,6(W=\XXH2]Y)^7YI"Z??\ DV>O45PDUP==U3Q%#<:I
M=63:<L<MB;6[:(>48@PF(4[9 6W#Y@5^7&.M9_\ PE$=T-&M/%VH2:(MYI"7
M0D%TUFKW&?F!D4J00-IV[L?,<@XI?U^?^0?U^7^9Z717!6LK#QAH2?VW<7UK
M=:-<"6=;EEBN"C1@2!5;8&PS'<N.N<UAZ-JEU<V/AE8/$%Y(!KEU9748NO-+
M(#,RB1FR^0JKC+=#WX-5R]/ZW:_0/Z_"YZS17EM_->6GA[QFT6IZCNT2\WV+
M->2%D_=1OAF+9D7+'Y7+#'&*G\5:Q)-XF?2[OQ59>'HX[:*>V>Z\V,2L=VY@
MZ3Q X.!L;<. <<U/]?A<.MOZWL>EU')-'$\:2.%:5MB _P 1P3@?@"?PKA8$
MO;WQ3<Z?=Z[>W5JVB13YMY#;J9"Q4NGEX9<[0?O'J><<5F6X&N6?P[U#5;NZ
M-Q*KF25+N2'<1 S9.Q@,_+R>XR.A(II7?]>?^0GHK_ULG^IZC17&6=[?Z;XI
M\K5HKB2*_NG2SOK>\+P, &*Q/"3^[( /*@Y*Y)KLZ72X^M@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JBVBZ4VJ#5&TRR.H@8%V8%\W&
M,8WXST]ZO5Q_BOQ!!:ZWI6AS?VDL5X9&G:RMKDN5"' 62)<CYL$[3D #. :.
MJL'0Z-](TR34UU-].M&OT7:MT8%,H'H'QG'XTK:3IKZDNI-I]HU^J[!=&%3*
M%]-^,X_&LC1O$>@B&+3K;6Y+]HI7MO/E)D)=%WE6D"[<A>Y/.#U(-7+/Q/H]
M]>FTANF$VPRH)H7B$J#JT;.H$BCCE21S1Z!ZEN72-,N-1BU&;3K22^A&([EX
M%,B#V8C(_"F6NB:38W\]_::796]Y/GSKB*W1)),G)W,!D\\\UGQ>-?#L\-O/
M#J226]Q,8([A(W:'S <;3(!M7)X&2,]LUH:?K-CJD]U!:R2&:U8+-'+"\3+G
MH<. 2IP<,.#C@T RW%!#!O\ )B2/>Q=]B@;F/4G'4^]5[?2-,L[V>]MM.M(+
MNX_UT\4"K))_O,!D_C4$FOZ?%JL^F,\_VR&W-RT8M93NC& 2I"X<Y(&%).>U
M1P^)M*N-,M-1@FFEM[MML'EVTK.YS@_(%W #')(X[XH0%F]T72M2N(;B_P!,
MLKJ>#/E23P*[1YZ[21D?A3K[2--U0PG4-/M+LPMOB^T0K)Y;>JY!P?<59BE2
M:)9(VW(PR#ZT^@#.U72[:]A\[^S;&[O8$;[*;E0 C$8X?:Q3Z@&LKPUX:-KX
M0TK2=?L=.N9M/50FW]^@9?NNI=%(;\./6NFHH6@&;=^']%O[86UYH^GW, D,
MHBFMD==YSEL$8W')YZ\TZTT'1]/O)+RRTFQMKJ08>:&W1'8>A8#)K0HH III
M&F1ZF^I)IUHM^Z[6NE@42L/0OC)'XTPZ)I)NY;LZ79&YE*F2;[.F]ROW26QD
MX[>E7Z* *FH:7I^KVWV;4K&VO;?<&\JYA61<CH<,",U7@\.:':WT=];Z-IT-
MW&@C2>.U19%4#:%# 9 QQCTXK3HH I6VCZ997D]Y::=:075QS--% JO)_O,!
MD_C45UX=T.]CFCN]&T^=)I1-*LMJC"23&-[ CEL<9/-:5% %"XT/2+N*UBN=
M+LIH[0@VZ26Z,(2.FP$?+CVI]]I&F:GY/]H:=:7?D-OB^T0+)Y;>JY!P?<5<
MHH J7&EZ?=SPSW-A:S30MNBDDA5FC;&,J2.#]*L30Q7$+PS1I)%(I5T=058'
MJ"#U%/HH RW\,Z#);?9GT336@\L1>4UI&5V [@N,8P#SCIFDB\,:!!<VUS#H
M>F1SVJA;>5+2,-$!GA2!E1R>GJ:U:* *"Z)I*7<EVNEV0N97$DDPMTWNP! 8
MG&20">?>KLD<<T31RHKQN,,K#((]"*=10!3L])T[3K(V5EI]K;6ASF"&%40Y
MZ_*!CFHHO#^BPZ9)IL6D:?'82_ZRU6V01/WY3&#^5:-% &1'X5\.Q26TD>@:
M6CVO_'NRV<8,/)/R''R\DGCN:N6VEZ?97$UQ:V-M!//CS9(H55I,=-Q R<>]
M6Z* ,V/P]HD45W%'H^GI'>9^THML@$^>N\8^;\:A7PGX<3[-L\/Z4OV5MUOB
MSC'DG.<IQ\ISSQWK8HH IG2=-*W"G3[3%R^^<>2O[UL8RW'S''&34UK:V]C;
M1VUI;Q6]O&-J11($51Z #@5-10!3ETC3+C48M1FTZTDOH1B.Y>!3(@]F(R/P
MIEOH6D6=[/>VVE6,%W<9$T\5NBR2Y.3N8#)R?6K]% %.PTG3=*CDCT[3[2S2
M5M\BV\*QAV]2% R:2RT?3--69;'3K2U6=BTH@@5!(QZEL#D_6KM% &7_ ,(S
MH.^U?^Q--WV@Q;M]DCS",YPG'R\\\5/>:1IFHSP3WVG6ES-;G,,D\"NT9]5)
M&1^%7:* ,VX\.Z)=WS7USH^GS7C(8VN)+5&D*D;2I8C.,$C'I5?_ (0_PS]G
MBM_^$<TCR8G,D<?V*/:C'&6 VX!.!S["MJB@"G)I.FS:A%J$NGVDE[$-L=RT
M*F1!Z!L9%1OH6D2SSSR:58O-.RO-(UNA:1E.5+'')! QGIBM"B@#,;PWH3W5
MS=-HNG-<72&.XE-JA>93U5SC+ X'!]*S;_0+R*&VTKP]%I&F:+*'6^1;8K)M
M;'^J"$*"1N!)Z<'FNEHH :B+'&J(H55   [ 5E3>%?#MQ>RWLV@:7+=2Y\R=
M[.-G?(P<L1DY'!]JUZ* V*=GI.FZ=9M9V.GVEK:MG=#!"J(<C!RH&.E0+X<T
M--,?3$T73ET^0[GM1:H(F.<Y*8P>>>E:=% &0GA7P['+;RIH&EK);+M@=;.,
M&(9)PIQ\HR2>/4U9TW1-*T5)$TK3+*Q60@NMK;K$&(Z$[0,U>HH I3Z1IEU=
M-=7&G6DUPT1A,TD"LYC/5,D9V^W2EFTG3;B6"6;3[262W(:%WA5C&0, J2..
M/2KE% !6=#H&C6T5U%!I-A%'=Y^THELBB;/7> /FS[UHT4 5=/TRPTFW^SZ=
M8VUG!G=Y5O$L:Y]<* .PI[65H]ZEZUK"UW&AC2<Q@NJGDJ&Z@' XJ>B@"E!I
M&F6M_-?V^G6D5Y/_ *VXC@59)/\ >8#)_&K%Q;6]W"T-S!'-$W!21 RG\#4M
M% &7/X:T&ZMK:WN-$TV:"UXMXI+1&6'_ ' 1A>@Z>E<?KWPUL/$/B:74-5\/
MZ7?I*0/M1U"XMI8T P!Y:*5<CU+#/M@5Z)11UN!AVW@_P_!&N_1[&XG\@027
M$]NLDLJ;=N&=@688&.2>*TK#3;#2K46NG65M9VX)816\2QH">IPH JU11<"D
MNCZ8FI/J2:=:+?NNQ[H0*)67T+XR1^-1V6@:-IL<\=AI%A:QW'^N6"V1!+_O
M #GJ>OK6C10!3LM*T[3;,V=AI]K:VISF""%40YZ_*!CFFVNC:58V,EC::99V
M]I)G?!% J1MGKE0,'-7J* ,U?#VB)>0WBZ/IZW4"+'%,+9 \:CHJMC( [ 5+
M/H^F75_#?W&G6DUY!Q%<20*TD?\ NL1D?A5VB@#+E\,Z!/=7%U-H>FR7%RI2
M>5[2,O*IQD,2,L.!P?2F+X4\.)]EVZ!I0^R'=;XLX_W)SNRG'R\\\=ZUZ*-@
M*?\ 9.FC4SJ8T^T_M KL-UY*^;M]-^,X]LTQ=#TA)FE72K%96F^T,XMT!,O3
M>3C[W)YZU?HH R&\*>'&%T&T#2C]K.ZXS9Q_OCG=E^/FYYY[U4OM%U"2XM-,
ML%TNT\-+&!<0) PE.&SL0 A%0C@\9ZXZY'144+0 JA)HFDRW<EW)I=D]S(%#
MS-;H7<*<C+8R<$ CTJ_10!2O-'TS4)X)[W3K2YFMSF&2:!7:,^JDCC\*=?Z7
MI^JPK#J-A:WD2L&5+B%9%!'0@,#S5NB@"K<Z9I]X+<75C;3_ &9P\'FQ*WE,
M.A7(^4^XJK<>&M"NWA>YT339G@8M$TEJC&,DY)7(X.>>*U** ,=O"7AIEN%;
MP]I)6Y8/.#91XE8'(+?+\QR2<GUJ>7P_HL]O:V\VD6$D%H0;:-[9"L)'38",
M+^%:-% &7-X:T&XO)KR?1--ENID,<LSVJ,\BD8*LQ&2,<8/:GPZ!HUM:16D&
MDV$5M#+YT4,=LBHDG]Y5 P&]QS6C10!432]/COS?I8VJWA78;A85$A7.<;L9
MQGM5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD]
M?CU-O&>@W=KHEY=VEF)O.GBE@4#S%"C >16.,9/'3IGI7644=4PZ6."TS0-4
MO]+\9V%Y97&F?VO<S/;RR21-\KQJ@/R.V.5/![&K4=AJ^K7.@R7^ER6$FBR&
M61UFC=;AO*9-L6UL[3NS\X7H!CT[.BFG;\/P5@>OX_B>7-I?B%O",EG_ ,(U
M??:6U[[<(O/ML^5]H\[.?-QG QC/7VYKIM*@U)?B!K-[/I%U!975K;QQ7#R0
ME2T>\GA7+#.\8X['IQGJZ*$[?UY)?H#UW_K6YS6H6.H1>.++5K>R:ZMFL9+.
M0I(BF)BZL&;<1E>"/ER?:L&P\,:@G@RPM=1TZ\BU&P>5[:32KY!.FYLCERJ<
MY.5)9?E'7MZ'12_K\;AUO_6UC'TE];@MM.M=3@6XE,#&ZNUD5=C@C:"H')8$
MY(X!!]16Q113;N 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK!<YPP(_,4/2+ET_X"?Y,$KM+O\ H[&K17!> /',.I^%] 76]1+:QJ,;E7>
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910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex10-1_004.jpg
<TEXT>
begin 644 ex10-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /# PD# 2(  A$! Q$!_\0
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M:Q;WA>9U6<%$#'><( #@E?N^O%6K+4++4K?[187=O=0[BOF02!UR.",@XR*
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MF,<9C96+.BG:"Q7()YZ]LC"UNUU-_!_B/0Y-(OKK5YKU[B.1+8LD\;3 HRR
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M@X.>O2DMDC\#:7JEYXBU2">TO;TRY@T^0%7E.-NT-(6!. .!^.:;LF^7S_\
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MQGMM[I6NOZZ/_@!K9_UV_P"":&O:^^BW.EP+I\UU_:%R+8.DBJL;$$C.3DY
M/0=N<51B\8A(=02^LA#>V=['8^1#-YBRR2!3'M8JO4.,Y Q@]<5:\1Z%?:U<
MZ5+::A;VJV%T+HK+:M,9& ( R)%P,,WKV].<MO ]Q=3ZT]]JL3C4+N*\@-O:
M&-[:6,*$(+.P; 1<C SSV.*2\_ZV_P""4_+^M_\ @%EO$VHQR:AIMSIMK;ZQ
M#9M=VZ"[,D$R XSOV!@0<9&SN,9K/T[Q'=MIOA!M:T:&>XU-T$=U',LB0N8B
MP<[E#!R-W"@@<C=6U;>'9I+J6_U>\AN[][0V:RV]OY*)&3DX4LYR3C)SC@8
MK-;P?J@L_#EM'K=MC195D!DL"?-"H8U'$HV_*3GKD\\#BFK=?+]?^ 2_\_R7
M_!-!?$=Y/<)+9:2;K2_M1M'N(YLRJX<HS"/;@QA@<G<#P3C%4+WQT8=7-K9Z
M-?7UM'/]GFF@M;AB&! )0K"8V .<YD4C!X-%GX,U'3-?FN-.\47=MHT\[7$N
MEBWC<&1CEMLK LJDY.!ZG!%*/!NIVOB2:^TOQ1=V.EW4YN+K35MHY [G[VQV
M&8PW4X&<DG(H72_];?\ !_ ;ZV_K^M#2T_Q&NI:Y?:? EL19R"*0?:<3J?5H
MBO"],'<<^E;M<_?>&?[0U^QU.>6US92&2-TM=MQGGY?-W?<P<%=O.!S5_1H]
M1BMIEU*\%VYG<Q2^0(3Y9.54KGMTSWP#26P/<Y+QYJ1U;PGXFLK;3K>[LK.V
MECNIII<%)1'O&Q-I#%<J225P>F2*T-(U>)=:TG2GTHB8Z,)X[\E"2H\L,B@9
M;J03G'0=>RZEX,GNTURUM=6^S6&LJYN86M][)(R!"R/N& 0!D$'/8BGV?A34
M+/Q!IFH#68YH+&P-CY<MG^]D4E26+JX4'*+CY.F>N<TX[?UV?ZA+^OO7_!)]
M&\60:KI-QJI%JEC"KNSQ7/F/&JC)$JE1L?KE><8ZU):ZE>ZG/]CU'0E33[RV
M:2.42B92N!E)EV@*2&Z N#@\^M?_ (0Z"XUFZU"^>U?[1:O:.MM;>2TR.!N\
MUMQWGCCA<9/6H?#_ (5US0EDAD\77&H6D<1CL;>YM(\0\84R,N'EQ]5_D0GJ
MOE_G_P  ?H9O@W5?[,\$Z!I]E;1S7UT)UMH&D\I $9B2S ':HX'"GDCBM*7Q
MQ%:Z3J,U]:QVM]IT\=O<PR7'[I&?&QC+MXC(8'<5SUXSQ4-AX'N['1]+A&KP
M_P!I:7+(]I>)9E4VOG<CQF0E@<]F7H.F.=BRT![5+Z=[B"74+]U>ZF-O^[?:
M@0*(]Q(4 =-Q/7FF_P"OP_X-Q+^OQ_X%B"]\1W=E+HNZPMI8=1NA;-+%>%@A
M*E@R?)\Z\,.2IZ<<UF7_ (\N-,M-;FN-%,C:7>QVI%O=!@RR!2KDLJD??4$
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MQ6[3?D 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"01B81Y"3 J 0S*0W7'0@"IM_7W_ .0K]?ZZ?YGI$<UTVH3PO:;+9$0Q7'F
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M6( S@]3VI=(U :KHUCJ(C\H74"3!,YV[E!QGOUKC!96L7C7Q7=/-<)/_ &?
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M1WOS\QRO)Y//N:YC0?%D-GJWB6?5-2OY;%;^"&V,UM(3#YD8(0JJ QC<V/F
M[ G-=5+XGT>WN]0MKB\^SR:?$L]R9XGC1(VSA@[ *PX(RI/(Q1YA;6Q/;Z#H
M]GJ$FH6NDV,%[(NU[B*W19&''!8#)' _*I+'2-,TQYGT_3K2T:9M\K6\"QF1
MO5L 9/UK!OO%GAN^LH4;79+19GMWBDBWQ/+O;<BJ2OS!MI! [9!Q5^Y\7Z%:
M2WT3WX>2PV_:D@B>4PY[L$!P!CD]N^*8&H]E:2+<*]K"PN1B<-&#YHQC#?WN
M..>U0:AHVEZO;QV^I:;9WL$9W)'<P+(JG&,@," <4R^UW3M.B@>>9W\\;HDM
MX7G=UXRP5 25&1DXP,C-2Z;JVG:Q;M<:9?VU["K;&>WE60*WH<'@\CBD%QL^
MB:5=36TUQIEE-+:C%N\ENK-#_N$CY?PI]UI6G7UQ#<7EA:W$T&?*DFA5VCSU
MVDC(S[5QNN>+#JWAGQ8FFR:EI]UI22;)Q:O'DH@;AG3;R3C ^;'(QD&NFTS7
M]/O)OL"7+&[BMUF<21NH9"!\ZLP <9ZE20#UIVNK_P!;7#;\CGO&/@6W\1R6
M2R:'I6HV=K&4BMYKJ6S,1)Y(>)6R, #;@#OFMC1O!^CZ3X?;15L(GTYV+FSG
M9KB),X^4>9DD9&?J3P*NVGB#3;W4#8PS2"XVEU$L$D8E48RT;,H$@&1RI(Y%
M3ZCJMII42R73R9<X2.&%Y9'QUVH@+-CO@<4MEZAN_0KW/AK0;R&VANM$TV>*
MU&+=);1&6$<<("/EZ#IZ5&_A/PY(;DOX?TIC='-P39QGSCG=\_'S<\\]Z>WB
M/2AID&H)<F6WGR(1!$\LDA&<A8U!8D8.1C(P<U"WB[1%L+6^^UNUM<SK;(Z6
M\C;92=H1P%S&<\?/C!XIZ@69/#NB365O92Z-I[VEL=T$#6J&.(^JKC"_A23^
M'-#N;TWL^C:=+=LAC,\EJC.4(VE=Q&<8)&/3BJ]SXOT*R?4EO+\6O]FA#=&X
MB>,('R%(+ !@2"!MS3QXHTAHW=)Y9-DJQ;([:5W9F4.-JA<L-ISD @#/H:6X
M;$T'AW1+:R%E!HVGQ6BRB801VJ*@D'1]H&-PP.>O%3C2]/%^+\6-K]M"E1<>
M2OF 'J-V,X-17>M65E:K<2M,ZMG:D%O)-(<'!(1%+8!ZG'%6;.\MM0M([JTF
M6:"091UZ&@"+3M-MM,BE2U@AA$LK3.L,8C4N>IP.YQR>YYIDVAZ3<3SSS:79
M233A1-(]NA:0*<KN)&3@@$9Z57/BC1UU%+%KIA*[F))#"XA:0'!02[=A?((V
M[L\=*Y_4M7@UKQI-X:DGUBV2&V21);*&XB(F9F&XR*NTJ HP6RA)(.<8 MU8
M.YOMX3\..;DOX?TIC='-P39QGSCG=\_'S<\\]ZL-H.CM;VENVDV)ALV#6T9M
MTVP$="@QA3]*DO=0M=)M4>[F<Y^1 L;222M@G"H@)9L G"CL:SW\7Z)'IB:B
MUW)]E:<6[,MM*3'(3@+(H7=&<D#Y@,9'K1Z!ZFO;VT%I"L-M#'#$OW4C4*H^
M@%5VTC3&U,:FVG6AU +L%T8%\T+Z;\9Q^-4[GQ7HEE<ZA!=WHMGT^-);DSQ/
M&BHQPK!F 5@2"/E)YXJUINM:?J_F?89S+Y:HS9C9>'7<I&X#((]*/,'YCKS1
MM+U!W>]TVSN6DC\IS- KEDSG:<CE<\XZ55C\*^'89;:6+0=+22T_X]V6SC!A
MY+?(<?+R2>.YID/BW0KB\:T@U&.65;@VK>6K,JRA2Q5F P#@'J>V.M2P:[IV
MH7<FGP7,T=R8RR%X'CWK_>C9UVR 9'*[AR,T>@>I.FBZ5%?3WT>F6:7=PNV:
M=8%$D@]&;&2/K2Z=H^F:/$T6F:=:6,;'+);0+$"?<*!7,^$-<%GX,AN-7O[F
MZF-Y<PJ[(TTTQ6:0 !$4ECM7HHX Z "KFH>.-+M-/TV]MQ=7<%]<BW1H+260
MH03N#*JE@PP1M(SGMP:=K;>7X_\ #A_7W?\ #&[>:98:BT+7MC;7+0.)(3/$
MKF-AT9<C@^XIDVCZ9<:>=/GTZSELCUMG@5H_^^2,52M=2TNX\1WR0:M))=P6
MT?VBS,AV6ZY+!BN/E8YYR<X XIUKXIT:[NFMH[LI((S,OG0O$LD8Y+HSJ ZC
MN5)%+H']?U]YH"PLUL?L*VD M-FS[.(QY>WTV],>U1P:1IMMIS:=!I]I%8LI
M4VT<*K$0>HV@8P?I5"T\7Z%?-9BUOQ,EZ[1V\J1.8G<9ROF8VAN#@$Y(Y&:N
M+JUG->RV,<DOG(=K.(7V!CV#E=A8>F21W%#!#'\.Z)):&TDT;3VMC&L1A:U0
MIL4Y5=N,8!Y [5$GA7P['+;RIH&EK);+M@=;.,&(9)PIQ\HR2>/4U@^$O$4%
MMIJ6>JZG<W%U)J5U:QSSQLVXK,RHK.J[%8@# .W/85I/XB\/V.IZS<SZ\!]C
MCB6\BDFS%:\MMP,8#-GD9R<#BF_Z_KY_U<+.]OZ_K0T+;PWH5E9W%G::+IT%
MK<\3PQ6J*DO^\H&&_&F2^%_#]Q9P6<VA:9):VY)AA>TC*1$]=JD8'X467B32
MM0OULK>Y<SO%YT8D@DC$J8!W(S* X&1G:3C/.*EU'6['2KJRMKMIUDO9/*@\
MNVDD5G]"RJ0O_ B.A]#1K< @\/Z-:W5Q=6^D6$-Q<@K/+';(KR@]0Q RP/O2
MOH6D26T%L^E6+06^WR8FMT*Q;?N[1C QVQTJK'XKTF6+49$:\8:=((KE?L$^
MY6., +LRW!!^4'@@]#5=]=TB#5=5N$U*ZN;FRLT:YL(0TGDKRP/E@9#G//?
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MO+F>.*VB0R/*[ *J@9))]*.EPW.8\5^%Y;Y8)M#TS25OC?075S/,Q@:01.&
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MU&2.UMM0M;NYN[>"7?+:.(YUVD;&*A@.1SP0>*LU/2W];6_(J]OZ\T_T//O
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M/IZ06%[96Z*9)U,J.A?Y2JY'\?)W=N,YKJ:**0!1110 4444 %%%% !1110
M4444 %%%% '/7VMZC;>,[+1X[:U:UNK.:=)&D;>9(RORD8PJ_,.>3UX'?&T_
MQ?K-QIVAZG=06"07]^UC-;Q*[,IWNJNKD@8!3D%>>N1TK>U#PT+_ ,0VNLC5
MK^VGM87ACBA$)C ?&XG=&QR<+W_A'OG,C\ 0Q:78V":_K BLKLWD38MMWF$E
MN?W." 2QZ?Q'VP+S_K7_ ""7E_6G^9'JGBK4M.UZ"$_8C;/?Q69M1&\DVU\
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M(HVDXV@$GG&!TII7_KRN#T7]=[&U-KM[%X^M-!-O;_8I[&2Y$P=C(61E4C&
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MNM7/B+P/XH^UZ9>V*V4LB1/YZ ,4(&/W;DGG)((V\XYIM6ER_P!;I?J+I?\
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M%H ;MK1$86X(SE@6!;CG"!CC''(JE<>+)#XET:PL-.GO;'4+5[H7<+Q;=H*
M'#.#@!P3QGD8!YPEJ,ZFBN8T?7M%_LZ]O-/M;R-6U!X7BDB999;@XR K'(S[
M[0,$\#FK \7Z=%I=Y?:BDVF"RE$-Q%>E$9';&T;@Q0@[AR&(YY(P< &_17)Z
M=\0]$U33[JYMF9Y;9TC>V2:&1RSG" .DC1G)_P!OCOBNFMIVN(M[V\L#=#'*
M!D'&>Q(/7L2*+!<FHKD]3^(OAW2M9&F7%Y'Y@E$,K+<0_NG.,!HRXD/4<JA
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M0>($F'E1)(IF$+@K*2F<[=FXY/&56NPJ!;*T6]>]6UA%VZ"-IQ&-[*.BENI
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MM!0#(8\'/M6GX+TO4=$\,V^FZFEJL\#. ;:9I%8%BV<LBD'G&,=NM=!13O\
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MT(]:NV-A;:;:K;6D7EQ*2<;BQ))R22<EB2<DDDDT^FH%FBBBD 4444 %%%%
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M6.1=ZE2JY)P-GO6U?:7-I>EZ?=:$NHZ9/!:B"+3YK5[Z.1&)(BEVEBI!ZMO
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MU\Q^SJI(8Y$7S,",%< 9XS3_ *_/_(/Z_"YM:I8_VGIEQ8_:I[43H4:6 )O
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M*2*&5[2Y\^)L^C;5)[=AUK1H:L&X4444 %%%% !1110 4444 %%%% !1110
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MS+,R@*&4N#L.  2 <X%)>^#=2'B)]4T3Q1=:3%=%#?6RVT<XG*@*&4OG8Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB\<9B5X9I(6,9ZHS(P+(>ZG(/I6G;6T%E:Q6UK"D,$2A(XXUPJJ.@ HZ>?\
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MJ0V:641MV@F95P[J6<R#@=&4<=#TKU#7_#NF>)]..GZO#+/:%MS1)<21!_\
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MIW@7P[I9M?L]C(ZVF#;)=74UPD!'>-9&8(?=0*W;B!+JVD@D,@212K&.1HV
M/HRD$'W!!JY._-;J[_A8A+9=E^MSR+X9R3P^"_',UK</;W$>J7CQRHJL48("
M#A@0>G<5!I?B_P 7W5CX$F&MH\^O>?#<":TCV+M)PX"@'<!VS@X'%>AZ=X \
M.:1:7]I8VMU#!?JRW,8U"X(DW=3R_#'^\,'WJ.'X<^%[<:8(K&Y0:6Q>R O[
MC$!)R=O[SO26ZO\ W?P5G]^A3UO\_P =ON. O/&GBBW^'?BZ[766_M#0]7-K
M!=_9X=TL8=5PZ[-O1NH Z"NGT[Q#K-G\0=)T6\OFO[35=+^UX:%$-O(HYP5
M^0^C9.>]5?&WP]BA\!ZUIOA/2KB:^U6:-YD:^9@S!PQ=C-)@'CDCDY'X=/X<
M\-6%I##J<FE36FJR6JV\OGS^9)$H&-B$.RHN1G"$#\:%W]/_ $FWYZCG;IY_
MFOTN>6Z)XIO/"_@6Z-A&QN+_ ,5368=0I:,,W)4.0N[ P-QQD\\5TGB?7_&.
MB_#76=2F:ZTV^LKE/L=Q.MK))/"S*/WBINC!^8_=QT'3D5UD'P]\+0:+=Z.N
MF%["[E\Z:*:XEES)_?!9B5;W!!JU?^#]$U70?[$OK>>XL,J6CDO)BS[>FY]^
MY@/0DC@>E+[-O3\$O\G]X1LG=[:_BW_G^!PS:[XJE\:MH46O;()M"34C*UI$
M7A<<$1_+C!./O[L<XJI;?$;7;GP5X,<B1]1UR>2":>U2(280D?()"(P[<?>X
MZ\=!7=_\(!X=%_\ ;OLUY]K^R_8_._M&YW>3MV[,^9TQ^O/7FA/A]X73P_#H
M8TPG3H)?.AC:XE+0OG.Y'+;DY]".I]:IM?UZO]&E\B;?U\E^NOS.0\0^(?&>
ME>'] FN99-,OIM;2QD5TMY?M%NQ.UG"[@K8 R%(YS[8EL_$NMW"_$339M3E9
M]%4M9W0CC65 8V;!PNTX*]<9KLM5\&:'K=I9VNHV]Q/%9R"6$F]F5@XX#E@X
M9F'8L211IW@W0M+O=1O+6TE\[4@1>&6ZEE$V?[RNQ'<CIT..E2]4UWO^EOR?
MWE)I.+[6_-_IH<%X8U'4M,^%/ANY77MLFH3HCFZ"M* [,"EOB,[I">1Y@8=<
MD#I73Q7K^I_##QO)<:C-'>Z1<SVT-U&D:2LBX^_M&W/)!*@>WK7?_P#"!>&?
M[,L-._LW_1=/G%Q:J9Y,Q."2"&W;L9)XSCVJQ:^#M LK34[2#3D6VU1V>\A+
MLR2LPP3M)P,^V*)^\I>?_ _X(H>[R^7_  ?^ >;&ZU'2=.^%\:ZE)<Q7LT*O
M'<VUN^P&-<!#Y892 2 0<X)R35_5_&NN+%XPUBWN_LL'AVY6WAL6B0I<]-QD
M)&[G/R[2O;.:[&;P#X<N(M+CDLIRNE$&R O9U\HC&#P_)& ,G/ QTJU?>$="
MU*_:]N[ 22NRM*HE=8YBOW3)&"%D([;@<54G=M^;_%JWY/[Q15M^R_6_WW7W
M'%:AXCUZ;Q\=/M=6GM+&X\/'45A\B%FAEZ#!9">W1L]_;!I_BGQ3K/PLT+7K
M9+B6XDD/]HMI\<9N/*4NI:)'!0MD+D8/&<>W87_@G0=2UF35[FVN#?R0&V:6
M.]GC_=$8* *X '/8=>>O-2:?X0T32=&32;"WG@LX]WEJEW-NCW?>V/OW+^!'
M4^II=/Z[M_DTOD/JOZZ)?GJ8PU2_U#2O#%WH_B>S\B>Z"W$M_$L<EX@SF-5P
M )."" !R.V,'M:QI_">@W,6FQ3:;$R:9-Y]H,G]V_P#>Z\G//.<GGK6S0[?U
M\A?U^84444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<1XY\)6=U);^
M*+32;6YUC2Y!<;7B4FYC4?,AR.6QRI/0@8JUI>F:+XIU"W\8RZ;;R,8E^P2S
M0#S G42'(SDGIGH!QC)H0/0ZVBN3D\:/':PZNVG(?#\LPA%Z+C]XN7V!S'MQ
MY9..=^<'.VH+OQM?6FC^([TZ1;M+H=SY3Q"];;*FQ7W!O+X.''RXQGO32O\
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M@]O13N[W XZ+P3=136LG]KQE[;47O4E-G^\D#*Z[9&W_ #$!\!L#  &#55_
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M =F=H8,!\P&>Q)J!(9-$N/B!JVFM?2WMG(#"LEY-*O,",249RK$9)&02 ,#
MXKN5\)^'$^S;/#^E+]E;=;XLXQY)SG*<?*<\\=ZELO#FAZ;>R7MCHVG6MU("
M'G@M41V!.3E@,G)JVTVVO/\ %I_\#YB6GX?A?_/\#FT\VS\0Z(-(U.]N[35H
M9FN?,NC.% 0,LR;RVSYB!A<+\PXKFE;59?A-?:[_ ,)%K"ZA;I=IYBSC$@6=
M@,@K@'"XRN" 2!CC'IMMH>D627*6NEV4"W63<"*W11-GKOP/FS[U /"WAX:<
M=.&@Z7]A+^8;;[''Y9;^]MQC/O2O_7SO^6@+^ON_IF ;:1O&YTQM0U$VE[I)
MN)D%Y(#YBNJAD(.8^&Y";167I^I3ZQX=\/VES?7LMW<07#M%#<M;M*L;;1(\
MZL&4+QG&2Q;D$ UV7_"*^'1,LPT#2_-6+R5?[''N$>W;L!Q]W;QCICBG0>%_
M#]K'%';Z%ID20R^=&L=I&H23&-X '#8&,CFE_7XO_/\  2T_KR7^5S@,+KVB
M^ ;G4[VY>X-ZT<LL5[)&<^3+U9"O/RCYN#C/J<WK_5]5TEO&TL%]=70M1;/
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M>M[:"SMTM[:"."%!A(XD"JH]@.!3OI_7]?\ # _Z_#^OF>?IKVFZAK=[#?\
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MF,]*Y230?$L'A"_L&T4W%Q/KOVV-+:YC)\K[0)26WLH'"X !).1G'.".^O\
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MFKX=\.:A/9ZA9WG@G1/#=PUI);#4K!HB\Q9<;D5%!5>_S-GCIZ+IIV_S_P"
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M//YUSD6GZTMCX8U)-*N%N=(B:"XTZ2:$/*IC"%D8.4R"!C+#@G.*%N_E^O\
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MBETM_77_ #8?U^7^2.0OOAWIE]I.F68U#5;:XTR(0VVH6MUY5RJ8 *[@,8(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2W:0;A&?O8==W!.,8P>3FLJR\9)X:E^(FKW.F637-A>11E[5'C-TQ^5-^YV
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M52>,O&J +C:%VH&& ,?>^N:Z>BA: <U/X&TB^L]6M]2\Z^.J[1=2S%5<A/N
M;%4#;V.,^I-:>B:.=%TZ*S.I7U^L2A$DO&0N%'0955!^I!/O6E10!DWNA"YO
M)KRVU&^L+N5$C:6V=3\JDD#9(K)W/.W//6I](T>TT2R-M9JP5Y&FD=SEI)&.
M6=CW)/\ G%7Z* ,G0_#>F^'3?G3H3']NNGNIL_WVZX]![5E:AX&2^\5KXD77
M]7M;](3;Q>0+<I'&>2H#Q-GGG)R?>NKHH#N8?AWPIIWAHWDMJT\]Y>R>9=W=
MS)OEF;L6. !U/  'M4FN^&=-\0BV>\21+FTD\VUNH'*2P-ZJP_4'(/<5L44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%?
M$'2RGAK7=:34=4ANH+%FMQ;:A/ D9520=B.%8Y[D'M5_3K*R\.Z;_;,VHZB8
M/LBM.MU?3W*YX.Y1(S8/487KFK'C/3=1UKPIJ&E:8EJT]Y"T!:YF:-45@1N^
M5&)(XXP/K4=YH5UK?@LZ1J!AM+MHE4/;RM*D;H048$JA/*@D8'I[T+1/Y?\
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M:^#_ !'9VOAFV,FE7":3>R73MYLD1*LK@(!M;<?G)W?+T QWIV5[=/\ @O\
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M0I-;-=[BB@D8""W#+*#@$&4C.>.15[0+_4]?MK'7K76D^R3NR7-B\:!(AE@
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MS3%!R[GJ2>I_I3[35],O[F>VL]1M+F>W.)HH9U=HS_M '(_&D_MK2A<0V_\
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MPXC,[B(L,8+1[MC$;002#@CBJA\(:&68_8VPUS]K"?:)-BRYSN5=V%R220
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MH:9]N,_@5DT?4B+&WDMKO?;F/R6\I4)._;D CJ,Y'W<UZ/136G]>O^;$U?\
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M'E-&5$BX]'/E\?[_ *UV=9&C>'K?19;J9+N_O)[ERS2WMRTS*N20BYX5!DX
M_6G?WK_U_77Y"^S;^OZ_S.1OK2Z&G>*="O=.N[F]U.>:6QN([9GCD#(/+W2
M%8RF /F*_=!&:OK;WNF>,(I;J"ZNO/T5+07$,#.K3(S%@Q PF<Y!; /K78QW
M,$TLL44T;R0L%E56!*$@$!AV."#SZU+4VTM_6UBKZ_UW3_0\BTFRFC/P[6]\
M/ZA%<V*R1W+O8,_EH8V4;G0,%4L1PQ!'4@5ZU##%;PI#!&D44:A41%"JH'0
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M31QSQRPQR"4*) Y W*&VX(7.>PQFK,5M!#\6IY8H8TDFT8-*ZH 7(EP"Q[\
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M3MP.N*T++3K_ $Z^L+:#4))=,M[,0/#-#N=F'"R&7.<\8*X]^*- &>(-;O\
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M$$\#--M_!>HVL7AF*+6K<QZ&<CS+$DS#88\9$@V_*3Z\\].*OW>;3:_X:_\
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MA2_U74+;5=&\03:+JD41@>>.W29)HR<[6C;@X.<'/&31T7]=%^MQ]7\_S?Z
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M+J$H98A<*I5V+99=A/#$C'-;VA+<ZGXS\11RZS?S6UE<VTUJ$G"H%:,L4PH
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M:2Y^S1-*88V4,P R<%B!TK@_$FHW*:C/J%CJ%VWV35[:U9_M30PPJS1J\7E
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M$TTZ>&WBU-I'Y0;UV8QGWQ6I10!EP^&]"M[Q+R'1=.CNDC$2S):HKJ@7:%#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'I3)/"VIR:_HFIR:XD_]F1R(WGV>9)S)@.2RNJKP!@!>/?I27G_6_P#P!O\
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MY>.F,XYZUG7'A[7SXJN-;LM:TV(RVZVRPS:9))M0,6&2)URV2>< >U+2Z?\
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M8?ATFMZ5%KFAWVE3NR17<#PLZ=5##&14]$_Z_I[EJW-KM_7Y&1=^*;JTUL6
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M8%;>E)?7OC'Q/#-JNHRII]S;RVT0F"*,QEC&0H *DG'(SP.<C-']?@G^H/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'AXZ=K=RUK;W$R)'<+($,4N<HP8\ Y&!]<4Y)K[[?E_F*,D_NO\ G_D6K?Q
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M>0">VE66(D@.O0D$@_J#4I(52S$  9)/:O%_#]W;:1\)_":)K%Y:S:C<Q1M
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M_$,1W3P*94'H'(R/SJ[10!DW/A?P]>W<UW=:%ID]S,-LLTMI&SN,8PS$9(P
M.:D3P]HL>FG34T?3UL#G-J+9!$<G)^3&.H!Z5I44 -1$C14C5411A548 'H*
M=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%96H^)M TBY%M
MJ>N:;93E0XBN;N.-MIZ'#$''!I^F>(=%UJ22/2M8T^_>,;G6UN4E*CU(4G%
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M .3@<<$5*Z?U_7F-]?Z_KR(CKOB"[\6:AHEI;Z=;_9K:WN8WG9Y"RNQ#!@N
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MX<!(T;[P9L@+_#@9/.X9XZ.P\(6>GM!&MW>2V-K();2QE=#%;L,XVX4.0,G
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M_P!:O^O0+:V7]:?Y_B>ET5S_ (7L[25+GQ!'91P7&K.)R_E!9#%@",,<9^Z
MV#W8UPVOV^EVL/Q&TR:VM4ENH%O+>U,2YE/D\RJN.2'!)8=#R:'H[/\ K8<5
MS;'K-1SSQ6T$D\TBQQ1J7=V. H'))KSG6KE8(M+UV-M/ND6R2---U)&@G+8/
M-N2-PE89&W;DX'(KL/$UO'J/@W5(9;42B6RD(@DC#'=L) QSR#C\:4_=BVNE
MPA[S2[V-6WG2ZMHKB//ERH'7/H1D5+7F$3Z#!;^'4O(-.3PA+I[;RT2K:?:C
ML(,G&S)&[!/\6>]=1X(BN(-.OXRS'3EOI1IQ9B3]GXQ@GG;NW;?;&.,5;5F_
MZZV_X/H0G=)_UM_7S.GHK@M;TB#0/$LFHZ=I-LYUZ(V,Y6W4XG.2KMQ]UANW
M>NU<U5ETWP]I&NOHNOVMC!H:6<*Z4+A56'S<OYFTG@3$E3D?,>W>I6W]?UZ%
M,]'HKRS3HVT[4_!VHZ^(XI7@N[1KNY&'="1Y$<C-R6*]CSG/>M_X:&WCT34;
M2V@:".WU2[58_(:)%4RL5"Y !&,=.G2G;?\ KK_P0?\ 7X_Y':5@:9K5]=>+
M]9TBYM[>."RB@E@>)V9G$F_EL@ 'Y.@S]3VX#7)M+N/'-U8>)-5UBPU)KD'2
MA:V,<N^,JN/)D\AW0Y!#88#.?6M'4-39_%/C:#2+M)-572K;RX8)5,VY?,WA
M1S\X##MP67/6DMK^3_3\@>]O3\STVFNZ11M)(P5%!9F)P !WKR;PY+IEUIFO
MWO@O5-6N]5%E(LEM+8QVR+/C(W;(8U:7/&<D^M7]"NO!WB2WU'^Q;.<736+P
MZA9O9.B,^,_OMR[7E!&,Y+<GK1+1-]E_G^ +5KU_R/1;.[AO[*"\MVW0SQK)
M&WJI&0?RJ>O&XW\/6VF_#F.":TME>8"XACE\I)/W!\PN@(#'>%!8@D'C/45N
MW-GH%EKE[I'B*&UATZ."!-$%RWR* I!$3-TE#?W3NQMQTJIKE;MY_A_GT%%W
M2;\OQ/1ZK7OV[RH_L'V?S/-3S//W8\O/SXQ_%C..V>M>6Z;) ?$WAFT\47L3
M7LNASK>6MW<Y#?,A3?&QQN*;B<CG!SG'%)=9T=OA[H<K:Q;*MIX@6.+%Z%18
MUNC@$!L%1'M(SD!<$8ZT*.O]=[ ]OZ[7_KY'M%%>77^K: _BN]TSQ/%=0ZO)
M=J^CW,-M)([1;4*^0ZJVWD'=T!R<\57\43V,NKWMY'Y,5_8:M9[Y;D[KJ*,M
M$K>5C!CA()Y)(8E^.:45>WG_ %^%]1]_Z[_Y'9G7M5/B?6=)2SLB+6QCNK0M
M,P\PL6&'.WY>4/0-QW[5?\+:M-KWA;3=5N(XXY;N!962/.U2>PS7,?VWI47Q
M,USS=2M(RFBP[Q),JE-K2,V03Q@,I.>@(K(TG2K#6/A=X<UJSM;._P!2T:*.
M:([5D)V<O%GL2,X!Z-@]10K6N_+\W_P!M:V7]:)GJM%<EI5WHNF6[>)+N."Q
MEUVY0)*T.UW#?+"K$#.2 #ST+&N@U;2;'7-,GT[4K:.YM9EVO'(H(]C]1U![
M4FFA)IEVBO/-!TLWBQV<VEVHO/#$4EM;R-;J%:<@%'3CCY C''&7]JS=-%G=
M0>'Y=,$2^+4N(4U=>EP5P1-]H Y*X!P6XSMV]J=M;+^K_P!:]A/1:_U_73N>
MJT5XU?)I5EX2U33C;0+<Z=XC6>.TB@W26\;7"%65%!*@H3@@<@X'I7<_$6>T
M_P"%<:Q-<7+6R&T9HG,S0,9,90=0<DX&T]>A':D_AYOZV3_7\"U&\N7^M['6
M45Y=%<>&7\:Z+$+K3'AU#1)#=H9D*W./+V>8,_/@"3&<\!O2LW3;W2I_"_AK
M4_M-E)#I.O21O=!U86D!>4*"W\"8\OT&-O;%5RZ_UW:(OI?^MKGL=5[V^M]/
MBCDN9 BR2I"F?XG9@J@?B:\YLK>UNKKQQIUA,FGK->PSI,;0_9VS'&3NX"LK
M'.X9R0Q/?-5K]].U?PA;'4-)TC[)8:Q:H9K4":R>/<@9XR1A4VG:PZ#!&3S2
M2O;Y?B.6E_F>KT5EZG;1W'ANXM;6X^PQR6_EQ2I'@1 C ^7C@<<<<>E<%_:-
M_'X.U:UT^TM5-@T(>Z\/8:.:+?\ O1$A4JLH4-E,,.1R<TNX=CU&BO$+B?PI
M_P *\U^]T37]0EMI!&N)HEL85F#9VJL<42LQ!.X#=G'/:NE.HV%MXVU&'PY=
MV!O;O0?.CBAF5C<7 )*,0#EVVD'/4K[4/1?UVN"U=OZW2_4ZG7-=O=+\1>'[
M"&WMWM=2N'AEE=VWH5C9QM4#'\/4G\*Z&O(UN-#;5?!%YIL?F7?VTC49(H6>
M82^0RGSP!NW[C_%T'H*ZSXA0VRV.D:C<11;;'5;:5KAU'[B/> S;OX1TR?SJ
MK6LO.WXH5^OE_F=A17F*0V=YKGC.RT^>.Q%V;6=;C[*6MY#@%MY "L&)&><D
M,3TYKI_!&H"]TJ=%L[&%+>41+)ILF^TF 5<-$<# [$#@$$9-2M4-G3T5Y3XT
MGL9]2UB91!'J&FS6T@ENOFN(TRA9K<#!CC(ZOD@G<,>L6IW7ARYU;QZMU?VD
MP6QAE1+FZW^7(%?E59OE(8IC&-I88P32OI?^NX[>];T_R/6Z*P]#OGU+P397
M=E<QW,\EBI24.'5I-F.2/]KK^->>^"9_#]YK'G2:SK4>NP6[?VK;3VD=OM^3
M#&:9(4+ =5+.3T(JFK2<>W_!_KYDQ=XJ7<]>HKQ&QO\ P]!X0T&]&I60N8=?
M>%;I[L&583.V\>86W;2A4GGD$$]<UN?VOHFG7?CFPM;J)+:/R9/LVGS(C(64
M+*X SM 8C>V..<T-?U]S_7\ _K\6OT/3;CS_ +-+]F\O[1L/E^;G;NQQG'.,
M^E8.H:UJFG:YX<L)+>S:+47>*YE5VW*ZQ,^$7'W<KU)S[=ZX57TNRM/&EL+F
MPL["33H+J!=-D:W@4E9 &5E(!)95!88#<#'KH-K6E;_AJ?[3L_F/'[]>?]&9
M/7^_\OUXZTXKWE\OQYO\@;T?S_3_ #/1;Z^M].MOM%U((X]ZH"3U9F"J![DD
M"K%<?\2K2RN?":O?VT$T$%[:R.9HPRQIYR!V.>@VELGT)SQ65=KH!UZ^LO$4
M5E%IQ@@&B><H2-5"D$0YP%E#?W?FQMQ4]+_UM<IK;^NMCT6BL3P@-2'A#2QK
M!<W_ )"^:7^][;O]K&,^^:YG0$C@\07&B7,6D:M#>)))+=6Z@3A6' NX^0<C
M@,3SC&T4VM;"OI<] .<'')[9K \(:[>:_IEU<7UO!!/!>S6I2!RR_NVV]2 3
MT/.!]*YWP_HVGQ:E<^$9M"MC9Z5<F_AD:!2C*^3$>GWP2XSUQ&/6L%+*S.DZ
MS9".)/%J:K<SZ:AXN8]TV5D7^(1D=2/E(SFA:OU_S7_!^2![>G^3_P"!]Y[!
M17EVM:IHB>*M1TKQA#=0WDTL9T:ZAMI)6";%SY#(K%'#AB<8ZC/%0>,+BQN+
M[5IU6*+4--EM9!+>?-<Q)E"Q@ P8X\=6R06W#'JEK;^NW^8/2YZQ7/\ BC7+
MW0WT?[+;V\L5YJ$5I,TKL&0.>J@#D]>I&/>N5TM-(U;XE>)XEN(KN6.*TN((
MWN68I,F\G W97!VY48 SC'-8=Q=Z9)HWAR[DBW^(X]6MCJXCA9[E'!8L)% +
M[0<[1@C'W>*<5=Q^7XNW]?():)_/\KGKL/VW[9<^?]G^R_+]GV;M_3YM^>.O
M3%6:\>UZ_P!%C3XDV_\ ;$:N(8W1?[18.)0A^4'?D#>0-@XR<8YQ6A%<>&7\
M:Z+$+K3'AU#1)#=H9D*W./+V>8,_/@"3&<\!O2DM5?\ K9O] >E_Z[?YGJ-8
M7C'6+W0/"M_JNGP6\\UK'YFRX=E7:.IX!)/MQGU%>;6%[IEWX:\+S_V@LL%G
MKTMNPBNB8XX=TI5653C:%5",CA>G!JUKC:=8^$/&LNF36D'AR>VC6R\IU6!Y
MRI\SROX<'Y/N\%L]\T[:_P!?W?SO^8+^OQ7Z'K4;%XD8]2 :=7DWC34](DU>
MR/B#5+N#P_=6<36%S:6D5W"\V6W?>AEP^"I4KCC-3I_PCT?CS2["\U/[5$V@
MRQRQZK<Y9U!C*^9&V "4#,05!(&2.."WZ_A?_(2V7HOT_P SU*BO&-/UC0;?
MPUX3U#^T]/6[AU=K87#7";T@#N"FXG(384XZ8*GN*GNY]+NO',UGX@U76;/7
M%OBVG);6,;B2+(*>3+Y#.JD8##>!G=GC-"5W;^NG^?X,+Z7_ *ZK]/Q1[!5?
M[=;_ -HBP$@-SY7G%!U"9QD_4_R->.ZK=Z%_8OQ!E_M&UFN+2_$MF\MV)7AD
M\M,&,LQ*G?O QZ$#IBNJ<:%)\08=6>WM+B6?1A-:W,42R22L&.6C8#EMI'(/
M0^E+I?\ K:XWO;^MTOU/0.E9QO9M1TM+K19+:0O(-KSYV,@?#D;>^ V.V<5Y
MOX9_LV3Q/H\MNMF;74M+N(IU0>9)<.IC_P"/EP LDF"V05ROS<D&J,HT#2_A
M3IS1O:Z?/'J4 F\M_L^Z43@.) " Y"!LALX SV!IVUMZ?G8/3^M&SV>BO.-2
MDT>\UO6X/$[6Y>01R:)+*<$Q^6,&W;_GIOW$[/FY7MBJ-M+ WBSPS:>*+R!K
M^70)5O[6YN<HS_NR-T9.W)&\GCG!ZXX$K_UY/_+4/Z_+_,]5JI?7K6JHD,)G
MN93MBB#;<^I)[*.Y_F2 ?+M*N+;4? EC/;:OHCPZ9>W/^CZDZM:LBRMY:EL_
MNRJE"AYP"" >*ZIM9NH_#5QK,.G/#=QZ2\MO:DER&!;< >I&0AZ<C'%)Z?UY
M7!:M+^M[%YM0UB&_G1M4T&9XD5VTY4:.5 3@9D,AX)R 3&,UOVUPEU;1SH"%
M<9PPY![@^XZ5YL\ND#4/!^GB=9K91)J;7F0?MLRJ.%Q_K'+/OP,_=]N-;Q):
MM_8UE<O>:3";::2YEMM6P;:1BVXJS=$92PPW.#G@]FU;?^N@EKL=Q7/>(M=O
M='U30;>"WMY+?4;T6LTDCG>F5+#:H&#PIY)XXX-<UJHM(-/T+QV?#RB\LR$N
M(A&))A"_R95B,L5)#*>#M)Z9I?$NCV>EVGAVZ-A;VEN-7%YJ;Q1A$3=')N:0
M@#@$@;C[9HMJK]_Z_ >Z^1Z+17$>'I=.T6ZUR_LGB@\+'R&MC I,/FG(D:(*
M,;22G*\9S[UD^)M5T*'Q5?Z;XP@N42X6+^Q[J.VDE*_+AO***Q24-DY !QM]
M!2ZI?U_PX=STVBN U-]*D\4S6WBY8/[,ELX/[,;4,!/-^;S ">!-RO3YL=.]
M8=E)!'K?@NW\07Z_;9(;J-K>ZNCEX3N$.^-C]YE.,D9/(.>E']?G_E^(F[*_
M]=/\SUNBO$SJ7AZ#P;/<P:AIRR6'B()8R+.F;>(W .V,Y^53'NX'&W/:O4_$
MEY;Q^$=1N_,N'MS:LPDL7'F%2/O(W('7.?QHZ7_K9/\ 4JVMOZT=C9HKQFYF
MTRPM_%JQW6GV5E<Z+%<P#396AA,N91N#J0'8D("P W<*0>^MIVHZ/;^+O"YT
MV^L!<WNC2B39.I:X8"/RPQSEB"' SZ,!WIV_KY/_ "%_7Y?Y_@=AXHUR]T-]
M'^RV]O+%>:A%:3-*[!D#GJH Y/7J1CWKH*\9N+O3)-&\.7<D6_Q''JUL=7$<
M+/<HX+%A(H!?:#G:,$8^[Q7LU%K+Y_HA/XOZ[L****0PHHHH **** "BBB@
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MM #=M:(C"W!&<L"P+<<X0,<8XY%(#<HKA?$FN+?ZOX>L(=(N-6TG44DF81F
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MC.\$T0!5MQ(!4$=,<]>.E=7I&J6^M:/::I:AQ;W<2S1[QAMK#(R*NTW>^O\
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M6=6!).?F52.I&,=JZ&BB_P#7SO\ J*W]?*QQNIZ)XLL_$L^I>&;_ $I;6_\
M+-Y;ZE%(VQE&WS(]A&25 &TD#BG-H_B%?%.J:FD&FRPW&G)9Q%[QT=F0L=S
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MQ*9GB5(Q(LF.(VYRN,8[YSVK8ATS7H_&=_K)M=--O/I\=M&OVQ]^]"S<CRL
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M<3VNIFV5XH?+7:LL>,+D_J37;:?X9TC2YQ+9VK(5&(D:9W2$8QB-&8K&,?W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKAO
MB3X<T:Y\(^(=6N=,M+B_6P?R[B:%7>+:IQL)&5Y)/'K5VTT_P]X/T0:[;:9;
M6;"T1)!:0I&9B=NT$ #+%L $^M"V!G65%+<P0/$DTT<;3/LC#L 7;!.!GJ<
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M]<C&E)X>UB3Q99ZVVK6&V"U-J\ T]\NK%6<AO.X)*<<' /.[K73TA(52S$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex10-1_005.jpg
<TEXT>
begin 644 ex10-1_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -# P@# 2(  A$! Q$!_\0
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MBPBBD-[!.?*3#C=&$C8/C.=I*\]Z];K#O-,2UO9-2_X2"]T^!W#S1;X3$Y
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M3!KDKPZW?>&+6ZOK22X>SUBWN#+!9/%+<0*RDR& Y=6&2"O4[<@=!7HE%):
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M+R]1;["Q^W\Y)/[WY3G)!^8C)[<5H^*]$N?$6@RZ9;7L-F964O++;F;A2&P
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M>.@Y'.8Z??\ E_F-[_=^9F:;XO1[/PS%8:"T4.L0LT"K*B1P;4+!#CGH.RX
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MK&B>%-8U;3[,WW]K*8'@E\QMK;\C+*NSH!@$\ <]JZ_^PK[_ (34Z[_:%O\
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M\4GUL..ZOW_K]31M/$]S/JUE8S::D/\ :%BUW:O]IW$E=NY7&WY?OC!!;//
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[B6>X6/2WV7G^AS;HCC.=NS)7'.X C'.<4 ;E%,BD2:))8SE'4,IQU!Z4^@
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MW1U5Y$"LI"EB%S\V>2.E=%13;_._ZDI6^ZQPD?AV^O+_ ,3#5-*8V&H7,-Q
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MK7?@@@$'(/>L-_&?AR/3;S46U>V%G9S&WGF!)59, [!_>/(X&?2A-W^[\/\
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MRIWJV,@X)&#[BET7]=Q]7_78P;:YUJ3XCW\/V^U?3X=/@E6W%N=WS&0?*^_
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M3^RY^RN$EBR@Z>9E6^?KDCCI5^#P##;V6C6D>NZMY6D3&>WS]GR3@C#?NN0
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M4&5I8IO*V+M&%V[4!&!QR3[Y/-:5C9_8;;R/M-Q<?.[^9</O;YF+8SZ#.!Z
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MOWMW>HM0GT*74_'46I7UE--'I\,ACGNPXCF"."5#,=I5RN,8VDC&":ENRO\
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M<\.CK%<[P<[GE+MN;/4A5YKL:** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!P'CCPMXA\0>)_#VHZ;'I?V;1[C[1BYNY$
M>8G&5PL3!1\O7)Z]*32/!FM>%?&-U>Z"]A_8&I8DO-.FF=#!*?O/"0A!^AQG
MIQQCT"BA:?C^(/7?^K?\.SSKP=\.!X9U"X2YTW0KVW%RUQ::B\/^F1@G.PY3
MMSA@_'I7&^//#.H>$?ACJFFO+:S:;)JZ7-M,';SL/("4=2,<?W@QSZ"O=ZHZ
MGHNE:U'''JNF65^D9)1;J!90I]1N!Q0M&GVM^#3_ $'O>_G^*?\ F<OK7A/4
M;SQQI7B73I+0B"QDLYH[AV7A@<,N%.<$]#C/K7)1_#'Q1%X T/P\KZ.UQINJ
M?;FE-U*$=02P _=9!)8CVP.N>/7X((;:"."WB2*&-0B1QJ%55'   X J2FG;
M;^M;_F);:_UI;\CB8?#6MI\6)?%#IIW]GRZ>MD4%PYF7!W;L>7@\\8W=.<]J
MHW?PZ+_$*^U]]/T35K'4HT$\.IQ9>W=0%#1_(P(('(.WZUZ)12OMY!W\_P!#
M@I_!.I6OB?7=0TJ2Q-KK=BMO,D[,A@=$*J4"J0RD=LC'OTK>\%Z!<^%_"5AH
MMU=173VB%!+'&4!&21P2>>>OZ5OT4+^OQ_S8/5W_ *Z+]$>2ZS\._%&HGQNL
M1T=4\0O"82UU+F)8S_$/*ZD#MT/KUK7U'PAXHU.*RM);[3TTZ/1WLY;7>[*+
MDIM$OW1O '3.,>F>:]#HI6TM_6S7ZCOK?^MT_P!$>5W?P^\1OX#\*:%"=*:Z
MT:\CN9FDN9%1]A) 4B(GG=SD#&.]=/XP\,7VNSZ#J=@]NFHZ1="Y2*=V$4@(
MPR%@"1[-M/TYKK:*IMMW\[_,E*RMY6^1Q_AOPGJ&D^*_$6M7MW:R1:RT;&VC
MC8F,HNT?,3R,$_P\^W2L(?"J2+PN=*@OUCF@U@7]C*,C[-$),A!QUVL_MD^E
M>FT4)VM\OP=Q_P!?A8Y?Q'HFM:A?:(FF7=M%I5M*3?6LI9?/0#"C(!R >JG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <QXG\0ZSH-I
MJ%_;:+:75A8V_G2237[0N^ 20BB)@<#')(Z^U5-1\2^);'PY?:I)H6FIY-D;
MN(KJ$DJ,!@E6_<J0<'('?U'6IOB9>6MG\.M<^U7,,'G6DD47FR!=[E3A5SU)
M]!53Q+J^FO\ !_4+Q-0M7MI-,>))EF4HSE-H4$'!.[C'K0MG\BHJ\HI]?^ =
MG;R&6VBD; +H&./<5)7ESW^GV_C"&/P]>V O[_P_*RB.=2;F8;#$6P<NV-V"
M<G /84SX>3:!?Z_]HL=5UI]9CA(U"SN;&. *Q SY[I F]@1P2Q/7WJK:_?\
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M16SO+AK5)WA"A)0Q4*REMX)*D#"GT.#Q6MI6MQ:I<7MK]FN+6ZLI DT,^S<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BFR.L4;2.P5%!9B>P%5]-U&TU?3;?4+"83VEP@D
MBD (W*>^#R/QH M445E:'XDTKQ&ET^E7+3"TG-O.&A>,I(.JD.H.: -6BBB@
M HHHH **R;OQ)I5CX@LM#N;AX]1OE9K:,P2%9 H).'"[<@#IG/3U%:U'F 45
ME:_XCTOPOIW]H:O/)!:;@IE6WDE"D]-VQ3M';)P,\5IQR++&LB'*L P/J#0
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M-W;C:1[YKK_AP?\ BV_AW_KPB_\ 0:NWOA#0M1OI[RZL=\]Q!]GG(E=1-'C
M#J& ?'8L"1VK1T[3;'2+&.QTZTAM;6/.R&% JKDY/ ]Z2TC;T_"_^8WK^/Y+
M_(X/POKOB/Q=>W>IV6I6\%M9:N]G-ITL2[?LZ=6W!=_FG.1\P7MBLBX\?:['
MHNJ>*5GQ!9ZU_9T>E>4A5XPZJ26V[_,.2>&Q[&O18/"VC6NLW&K6]H8;NY(,
MYCF=4E(_B:,-L9O<C-,D\(:%+JG]HO8 SF43E?-?RFE'20Q9V%_]HKGWHCI:
M_E^E_OL_2XGK>W];V^ZZ^XXC7_$/B&W\>>(-,M=:F@L[?P^VHPQ_9X6,4H.!
M@E,D<<AL]3TXP[_A*?$M_P"!/#6O(+M;:>%GU2?2X8GGC[*ZQR*P*Y!+ #/3
M%=;?>!?#VI:M=ZI=6MPUY=P&VGD6]G3?$1@IA7 "^P'O4]KX0T6RT:+2;6WN
M(;.%2L:I>3!D4G)4/OW!21TSCM2Z6_K=_HU]P^O]=E^J?WG':SXSU*76O#^A
MZ'/=W8OM.-Z;RSCMQ+/@?+@3$1@'!+#K@X&*2_U_Q;#XB\"V5Y<'3)]52:/4
M;1$AE4.BYW*V&()SGAB.G'7/97_@_0=22P6XT]5.GX%F]O(\#P#&,*\95@/;
M.*34?!^B:KJ5AJ%W;3M=V&?LLB7<T?EYZD!7 )/<GD]Z>E_G^&O^:^X%^GX_
MUJ>8W?BO7=4^"WBJ[GU*5;[3KV6S6YB5$>6,.H^;"X!PQ&5 KU+PI;RV_A/3
M(Y;R>Y8VL;"28(& *C &U5&!VXSZDU5L? ?AO3M'O])M]/8V&H$M<PRW,LHD
M8]6^=B03ZC!X'I6U86%OIEC#96B%((4"(&=G( &!EF))X]31W^7X*S_'475?
M/\7='CGA[Q#JVBZ)\0O$DFH7=_/8ZC-#';S",QL5VJCMA0PP,< A< \=ZZW1
M?$&KVGC/2]"O[YM234M+^W-*T2(T#@C(&Q1^[/;.3GN:Z>U\+:)9RZE)!I\:
M_P!IL7NT)9DE)&"=A)49[X SWI=)\,:1HEP]Q8VK+.Z"/S99GE94'1%+L2J#
MLHP/:A=+]E^5OSU'+6]O/\U^EU\SF_B+K6LZ+J'A7^R;\P+?:K':7$31(Z2(
MWKE2P/'8CJ:S_$?B'Q+H&IZ+X?>YEN[G5KRY9;FSC@698%Y1%$NV/?R 2W8'
MJ:['7O"FC^)9+.358)I6LY/-MS'=2P^6_P#>&QEY&.#U':I=:\-Z3XAMX(=4
MM//%NXDA<2,DD3#HRNI#*?H:2V^?X!U^7XG%:AXK\265MX7TG4X_[*U/5[Y[
M::YQ$[1QJ?E8 %D#L"O!R <\4>(?$7B?PU;Z#HUU.+O4-3OI(/M=E'$)3"O*
MX$NV,2D$9R-O7 KM-2\,Z/K&F1Z=J-G]HMXV#H7D?S%<=&$F=X;_ &LY]Z9J
M/A31=6TN+3M0LS<P0NLD;232&57'1A+NW[O?=FC_ #_ /\OQU_KY'G?BW6?%
M%GX8T";58OLEVVNQVS13Q6TWGPEB4D8 .JO@#[A&#G';&K=ZQKNC_$JXT6^U
MJY?3]4L7DTK$,"^7.#@IGR\L1QC.1@\@UU.K>#-"URRM+34K>XGAM'$L6;V9
M6#@8#%@X+,/5B36E<:38W=W8W=Q;B2XL&9K:1B28RR[2>O.0>^::\^[^ZUOO
MNKATT[?C>_Y:' :_XD\0VGBZR\):;)?75RFF&[>Y@2U$L\F[: PEVH$X);:
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M=7?;3\W_ )_@*ST^?XI?Y'-ZAXK\265MX7TG4X_[*U/5[Y[::YQ$[1QJ?E8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFNSV&@^#]-GL%6UO[)8H+A9LN)%CW8*;<!2JG!W$^H%-*Z_KS_R&U;^O)/\
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M[7&T4LLMN9L(00=H#K@^Y)^E-F\/G4O"AT35[B.<O$(VFMHC%C!^5E5F?!&
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M/EV=E%<6JQW!B\E]CM\NS:<94<'.>^>*[NQL+/3+5;6PM(+2W7[L4$8C0?0
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M^I6][:74FLBQGN[:>.Z:YM[PH!\R*23&1E3L "\G&:T/#FHZ)J$[7.C>*SJ
MGLRT]D]X;A@_!\S:6)BQR"H"KR.!75VVEZ?97$UQ:V-M!//CS9(H55I,=-Q
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ME]X-T$O]D&IW]]?FYU!H9!&J-*WS,N_[P48 '4XK;\217TWAZ\CTZVAN;IE
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MW/$^X+NQW!5AGN #WK/UN#4)?&OAVZMM+N+BSM1-Y]PDD05/,4*.&<,<8R<
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M+F,;C#/!)"Y7.-RAU!9?]H9'O7,:AX;U:^'BRRCB$*ZA/%=6MRTB[&*I&-C
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MA^O];G252U35]/T6V2XU*[BMHGD$2,Y^\YZ*!U)/H*S_  A?3ZCX2L9YG+W
M1HGD<<LR,4W'IG.W-<89]9N?A[K4^J7UM=M_:;1Q^7;M$1LNMO)+MD<#  &
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M7EOX7U2>PG2"ZBMI)(Y'CWA2%)Z9'IZ_GTKEH1JGV_P;YMS:RWC6=P1,(&1
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M_8%MXE5\D;]P._Y<8 _B':M75M MM5-I*)[BSN[,DVUU:E0\61@C# J01U#
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M"W=1'<_+MRV5)4XXRA4\#GBMZBD!@VWA:WM?$W]MPWUVK"V6T6U B$*1+R%
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M^O'6O6:*<7:WR_"_^8FKW^?Z?Y')_$BVFNO!DZ0Q22E;FVD81@DA5F0L>/0
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M&-QZ9]JI>'M#\7:)>KICZEI4_AJ$MY+-#)]L"9RL><[,#INY.!T])73^N_\
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MNUW;N3&[2N=-%)YL8?8Z9S\KC!%<LWQ&\.KK\>D"\C:5YOLXD2XA(\[=MV%
M_F Y&,E-OO6SX?T^YTO1+>RO+M[J:/</,=RY +$JNX\MM! W'DXR:Y_1M$\7
M:+JQLH=2TJ7PT)7EC\V*0W<89BWE@@[,#. QR<=J/M6Z!]DL0>.HKBZELTT'
M5_MT5R+>2T/D>:H(SYA'F_ZO'\6:OZGXHMM,DGS9WES#:D"\GMT4I;9 (W98
M,>"#A Q /(%8U[H?B:2[@URU334UQ+@QL&O9! ]GGB,_NLD]#TX;G)'RT2Z%
MXNT_Q)<WVA7^D+8ZDZ37L%_')(T$@0*3$4*[@0H^]CI0NE_ZV_KUT&^O]?U^
MJ&QR#3_B/K]U%%<W(_LBWG,*2[BQWR [ [!5R%'&0*U+7QC9W?\ 8#)97HAU
MR,O;2L(]J'87VN-^0=H/0$>]11:+JW_";:AJ4R6?]GW-A'9JZW#&;*ECN*>6
M%Y+D8W<8]\#+L?"6OV]IX6MVN--B_L&4C>/,E\^+RS'G&%VL0W3) /<]*%:R
M3_KXO^ $NK7]:+_@G2V?B"&^MIKJ*TNS:(&*3JBR"8+U*!&9O8 @$]A6-9>*
M--T[PYI%QI6C:E+IMY-Y,.SRP8F:0J-_F2 C+9]??' IUGX8NM.\0S:GI]K9
MV2O$YEA@NY!'>RL.KQ[-L9!YWKN8YY]TT?PO?#X?2>'=6^S13E)$26TG9P"6
M+*X)12"&/IV!S2\_3\]0>]OZV-6^\36FEF^?489;.TM-@-Y-)$L4C-C"J=^0
M<D?>"CWQS7*ZWXJTGQA\/?$PL9I$FLK1WD2*Z0LAVED.^"1E(.WH&/H1VK9N
MO#6JW?@ZWLFU14UV&1+K[:$RAN%.[[O=.JX]*KW.E^,M5\$:KIVKR:')J=Y"
MUO&MJ98H$5A@LS,&8GG. H';WH:W14'[T6:%IX@%MJ&D:*^F7Q-U:AX[L>5Y
M!VH"PR7W9''&W/?H"1I:3JO]JQ7$HL;JV2&9X09_+/F[20678S<9!'.#[5S/
MB)D_L+3--FO[&S\3Q&*2QACG$C>:#MRH(5F0@L&.T<$^E=?8VB6%A!:1$E84
M" L>6QW/N>M5+6[\W_7Z&<=$EY(Y:T\7>']/TVXOK>TU"*&;53:R VLFXW#$
M DJ>4!) YQST'(SNZ9KL.I:A?6!MKFUN[,J7BG"Y9&SM<%688.T]<$8Y KC9
M_"WBF72;VU%MHPDN-:34U/\ :$N HD5]I_<=?D _'/;!Z'3-+UB#QMJNJW4-
MBME>6T,2>5<N\@,>[JIC P=Y_BXQWSPHVMK_ %HOUNBGY?UJ_P!+$OB3QCI/
MA?RTOIH_/E4ND!N(8690<$@RNBG&>F<^U8FHWUCK7B'P-K6GSR2P7,\PC82,
M$9?(D/*9QG(ZXS[U?\2:+XD_MJ'6O"M[IT5V8/LUS;ZBCF&5 Q93E.0RDM]<
MTNIZ1X@O-5\-78&FSG3YFFNW:5X=Q9&0B- C\#=D9;MCOFB.Z;[_ .82V:7;
M_(1OB-X='B"/1Q>1-+)-]G$BW$)'F[MNPH'\P'(QDIM]ZOGQ3;?;X8!9WIM9
MIC;QWP1?),H)&S[V_JI&[;MSWK)T;1/%VBZN;*+4M*E\-"5Y8_-BD-W&&8MY
M8(.S S@,<G':DT/0O%NA:H;&'4M*E\-B5Y4,L,ANT#,6\L8(3 )/S')]J2Z7
M!];!!X^^SZ5K6J:OH^H6MI873P@HL<NX*=N,(Y(.>26PHSU-;$GB:)#Y2Z;J
M#W;.R06NQ%><*H8NA9@NW##DD<\=>*P-8\*:[=>&?$6CVATYAJ5U)+#)+.Z;
M5<ACNPC8(((P,YSG(Q@ZVI:-JDM]I.M6(M!J=C"\,EM+,PAE1]NY?,"Y!!52
M#L/ICT%MKY?E_F#WT\_ST_ #XYTI+2WF>&^626\%B\'V8F2"8X^63&0.H.<D
M'/&:6Y\3Z=/I6MKJ%C?1+IZF.\MC%OD*,N0RB(ME2ISD'(YSC%8^H^$M8=?M
M-G'I[WMSJT.IW:RW3I&GEA0L:$1L6X7J0/7'833Z#XBDN_%<BVVE[-6@6*WS
M>R97:A3+_N>."3QGD8[Y"E\+^?Y+];H<?B7;3\W^EC777K6TTNQ73M.O;O?:
M)/%:VX3>D.!@L7<+WZ;LG!QG%:VGW\&IZ=;WUJ6:">,2)N4J<'U!Y!]C7$R>
M&O%UD-*U'1+K2(-4@L4L+NVNS)+;2HARKJRJK!ASQ@=<=LGN+-;I+*);R6*6
MZ"_O'B0HA;OM!)('U)-7*UWZ_P"?_ (C>R]/Z_$\_L-0L]6UG7-2\0Z)=0II
M%[NM[V9HMUJ%CC/EJ8Y"^6))PH*MNP2>E=5!XIMVO);.\T_4+&Y6%YXXIXU=
MIXUZM'Y;-GJ/EX;D<5S\/A+6K^T\266J)86L6JW/VN&:UNWF:&11&%!5HT!
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M7;:YT_29]/U*X6<6AW%2?+12&)7KN7.[!)SG@U/?^NW_  2CK+:=KB+>]O+
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M#D$'RD+;8\@G[@%+IGAC2-)TVXTZUMG-I<EFFBN)Y)PY;.[/F,W7)SZUKT4
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M6DERKI(Q;:XC#,C*21R ",'-=U126C#I8Y/Q1IE[J;Z+K-E:N]QI-[]H%LQ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ6CX2U/4-3NM2W:E#J.DV[K%:7BP /<_*K,WF(P1@"2ORH!QUZT[?U]W^?\
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M)&6V(3DY*@=3ZUKT4 8-UX-T2]TV;3[B&Z>UFN?M<BF^G!,N<YW!\@9 .T'
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M ,77/">A^)-*BTW6; 7MK$04$LCEU(XR'SNSZG//>I(_#.DP:5!IEK;R6MI
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNY07!W'Y@2IQQWH6KM_77_(.C?\ 73_,[JBBB@ HHHH **** "BBB@ HHHH
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M7\&VZ6,]W;:5;31W-VDD016D   #.&(7!_AZ8QD\5VVL6,.IZ5/9W%NUQ#*
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MWA 0RB/@CYCNY)XXJGXK\5:IH0FN(ELHXK:*.5K:2-II;@,<, 4;]T%_O,K
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MJY.?O'&,T;;_ -:I?J&^B_K?_(]3HKR6:\GC\(>);[2O'UOJ!CL3<(FGL[M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(!W')DV[0H"GYB0"> 2014NF:OI-OX:MKV'4Y[VR<D0W#[I99SN/"@#<YX.
M <@<4>8=;&[16&?&/A]---_+J<<,"S"!O/5HW64]$*, P;O@C-6;?Q!IEU->
MQ1W)5[)0\XEC:/:ASAQN W(<'##(.#S0!IT54L=2MM1C+V_G #G;- \38R0#
MM< X.#@XYJIJOB;2=$DV7]RZ$*'D*022")22 TA12(UX/S-@<'GB@#6HJA-K
M-C!>):O)(96C\S]W"[JJ]BS*"JYP<;B,X.,XJ[)(D4;22.J(H+,S'  '4DT
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MW\-Z7XKC@L_LT]G>-&GEOO+[XFD4@#YB".I 7TKH;?3-3T?6M/U&UT. VSV
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MF\Z%GN7<+PA#[=ORG&XJ<XR!737=_;6/D?:9=GGRK#'\I.YST''3IWJS1O\
MUY6_4/Z_K[CS*PTO7[?0O!EK)X=O?-TR\,ET!/;?(H1UR/WO.=X/'8'VSMV6
MA:A8^)#_ &:+^STN?S'O(9YXY+<LP/,(R71]V"1PN">,UV5%-N_]=P_K\6_U
M/,O"7AW4M$OX[:\\!Z)NL%/EZ[;M")KG X*IM#"1AP2S*,DFDM=,\00^&-!M
M&\-WWVBSU@W<R">VXC\QWSGS<'(?&/4'VSZ=11?^OG<35_Z[JQSVB65]8^)/
M$#S6I%K>W$=Q#<>8I!'E(A7&=P(*'J,8(P370T44A[NX4444 %%%% !1110
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MX(W2-(C,QP6'4=?IB"?P#ILGB5];AO\ 5K1YG$ES:6MZT=O<N!C,B#KP!GD
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MO2TMKFUN-12SFDD<@J#)Y9* ##'(/4CUYZ5@:;'H]UXETF?PHMJ8)8YEUF.
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MY:)%&N3GD@'D#O0E<'H=S17FU_%X=B^(>OPZ^\#6MQ86K+'?2ET,A:480,2
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MR,<'([XJ5KJ-Z:&E;6T5G:PVT"!(84$:(!PJ@8 J6L>^\0"P\06&DR:;>O\
M;<B*[4Q>2& )*G+AL@#. ISVS@X@'BJ'$P;3KY9%NFM+>,F(M=R*"3Y>'(P-
MIR6*XQSC!HWU"UM#?HKEY_'%G;:?-<RZ=J"R6US';W=L5C$ML9" K-\^UE.1
MRA;K['&G;:[%<^(KW1#:W,5Q:PI/YDFSRY$<D KAB>JD<@=*+ :M%<-XA=K3
MXG>'[F**ZN'>QN\V\4GWRNS&%9@@/S'DXZ\FM"?QS:Q:;#>II.IS*UU]CGC5
M8E>UF+!0LN^0 <L.02.<YP1D6J_KO8'I_7E<Z=U+H5#LA/\ $N,C\Z(XUBC6
M-!A% 51Z 51AU4S:W<:8+"Z @B61KHF/RB6Z*,-NW=>J]NO(SRWB[5?[*\16
M\NNOJ,'ASR1LNK&66-8KC<<^<8B&V[<8S\O7/:CMY@=S17#^(M)N-7\%?;-,
MUS4+FXM]US;7%E?/%]ICW;O+)C*JV5&T'''4=ZOWR6GB71M$BLKZ_BANC'/'
M-:WLL4GE*N6W,K!FR,*<YY8'KS3M_7]?UH!U-%>:ZLEA9_$*>TO;KQ*UFVFQ
MS+%8W6H2A9/,92V(6)7@#K@?C6Q\.]3GU.QU,F^EN[&&]:*S-TV;E(P!\LH/
MS [LXW?-C!-):K^N]@>G]>5SLJ*Y+4=2N-5\=)X7AGFM;:&Q-[=R0ML>3<VQ
M$5ARH^\21@\#!%:]EHSZ=>Q-;7]X]DL3JUO<W#SDL2"&#N2_&",$D<\8H6UP
M?8UJ*XK7-7O[+Q+8:HD[C18+H:=<QAL(S2X'FGUVOY:^V7H^(_DV]AI=[/J-
MW8Q+J,$,TL.H2VR>4[ /N*.HZ#J>G8BCHF#TN=K17"^%;F2;Q=>Q:-J%SJ/A
M<6BD7$UR]RJW.\@K'*Y+.-O7YB <=*@T#0(=1UGQ-!<:EKA2TOQ%;[=:NQY:
MF&-L8\S!^9B><_E3M^5P/0:*Y'P?JU\VL:]X<U*Z>\GTF6/R[MU56EBD7<N[
M: -PY!( SP:J:Y:X^)N@K]LU-(;BWN9IH(K^=8W:/R]G[M7V]SP!@YY!I=5Y
M_P##_H'?R_X'^9W-%<K%X]TV:R@OELM2%E+=FR:=X GE2[M@#H2'Y;CA3@]<
M5)=^.-/TZVU::^L]0MWTL*\\/DB1S&V=KKY;,-IVGDD8QSBC^OR_S0'345AP
M>(+:]U,:3/9WMI)<P-+;O,%47" #<49&)4C<.&VMWQ7,^%M?TWPM\/XIM0N0
MB?;KN*$37"JTC":3"[Y6 S@=68?6G;>_]:V#T_K2YZ%17)P?$70KG2K;4(3<
MS1SWBV)6",3>7*2!AF0LF/F'(8@]LFK$GC&")-3#:3J7GZ;AKF +%N6,C(D!
MW[2N 3C.[@_+FD]/Z_KN!TE%<QK?C[0M"CMFN+J-WN(EG2/[1#$QB;H_[UTR
M/89/M4D?C73+FYL[:PAO+V6]LC?6PA@PLL8QP'<JN[D<$C&><9% '1T5QU[X
MX<P:#<:7I%Y=QZE=O;NJM$KQ,@?<A#.!NRA'7& >>F="]\7V=C?FW>SO7ACN
M([6>[C5#'!*^W:K MO.=Z\JI'/)ZT[/^OZ\P_K^ON.AHKD_^$IE?5O$-G?:-
M?+I^G1J&FC"2;P5R?E1B^2#P O0<XZ59L==TVU\/:-_9=G=2I=VJO8V,>WS3
M&$!ZNP48!&2S=2.<FDMK_P!=?\@ZV_K^M3HZ*YH^.=*2TMYGAOEDEO!8O!]F
M)D@F./EDQD#J#G)!SQFK$7BNR,.IM<P7-I+IKJD\,X3=\P!0@JQ4ALC'/UQ1
M_7]?>@-VBJUC=O>6XDDM)[5R 3'-M)&1GJC,I_ FN=\8:K%)HNL:;#;7UP\=
MHYGFM'V"V)0LI9MRMV'"Y.#R,&E)\J;'%<SL=76!/H5]+XUM=>74+=;>"U>V
M-J;5B[*Q5B?,\S .57^'IGZC-\+^((X-.\/Z*UE=M<2Z,EU%*/+\N0(J!E!+
MY#99>H YZU/;^/=-GM]+?['J*2:E/+;0PM "1)&6#*S*Q0'*G'S<]?6KE'EE
MZ?\ !7Z,B+YHW[_\.=517+1^(-(G\0V[2Z;J<.J+IDEP!+;."D.Y2R8&0SYV
M\+N/'7GF6Q\:Z??G27CM;U+7524MKF6-50N QV$;MP)"D@[<=LYXI6_K[_\
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M+$EF52221_",8[U?U+1=*UF../5=,L[Y(SN1;J!90I]0&!P:NJJHBHBA548
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>12
<FILENAME>clsn-20200630.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CLSN %2D 20200630 10Q Q2 DFN.xfr; Date: 2020%2D08%2D14T04:09:48Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80060006 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:CLSN="http://celsion.com/20200630">
    <link:schemaRef xlink:href="clsn-20200630.xsd" xlink:type="simple" />
    <xbrli:context id="From2020-01-01to2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-17to2013-01-18_custom_HisunMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">CLSN:HisunMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-17</xbrli:startDate>
        <xbrli:endDate>2013-01-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-26to2018-06-27_custom_HorizonCreditAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:HorizonCreditAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-26</xbrli:startDate>
        <xbrli:endDate>2018-06-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-12-30to2016-12-31_custom_IPRAndDDrugTechnologyPlatformsMember_custom_OvarianCancerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLSN:IPRAndDDrugTechnologyPlatformsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CLSN:OvarianCancerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-12-30</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_TwoThousandEighteenAspirePurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:TwoThousandEighteenAspirePurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-02to2018-12-04_custom_CapitalOnDemandTMSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:CapitalOnDemandTMSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-02</xbrli:startDate>
        <xbrli:endDate>2018-12-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_EGENIncMember_custom_GlioblastomaMultiformeBrainCancerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CLSN:GlioblastomaMultiformeBrainCancerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_TwoThousandEighteenAspirePurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:TwoThousandEighteenAspirePurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_CapitalOnDemandAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:CapitalOnDemandAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_NJMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CLSN:NJMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_EGENIncMember_custom_GlioblastomaMultiformeBrainCancerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CLSN:GlioblastomaMultiformeBrainCancerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_IPRAndDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLSN:IPRAndDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_AspirePurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:AspirePurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-19_custom_InducementOptionGrantsMember_custom_TwoNewEmployeesMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:InducementOptionGrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLSN:TwoNewEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-19_custom_InducementOptionGrantsMember_custom_TwoNewEmployeesMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:InducementOptionGrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLSN:TwoNewEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-18to2019-02-19_custom_InducementOptionGrantsMember_custom_FiveNewEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:InducementOptionGrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLSN:FiveNewEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-18</xbrli:startDate>
        <xbrli:endDate>2019-02-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-30to2019-01-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-30</xbrli:startDate>
        <xbrli:endDate>2019-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_TwoThousandNineteenAspirePurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:TwoThousandNineteenAspirePurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-30to2018-08-31_custom_TwoThousandNineteenAspirePurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:TwoThousandNineteenAspirePurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-30</xbrli:startDate>
        <xbrli:endDate>2018-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-01-18_custom_HisunMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">CLSN:HisunMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-01-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_NJMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CLSN:NJMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ShortTermInvestmentsMember_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-09-01to2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-09-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-05_us-gaap_SubsequentEventMember_custom_TwoThousandNineteenAspirePurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:TwoThousandNineteenAspirePurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-26to2020-02-27_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-26</xbrli:startDate>
        <xbrli:endDate>2020-02-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-27_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-27_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_OriginalWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLSN:OriginalWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-12_us-gaap_SubsequentEventMember_custom_PrivateExchangeAgreementsMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:PrivateExchangeAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-04-30_custom_NJMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CLSN:NJMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-01to2018-06-30_custom_HorizonCreditAgreementMember_custom_HorizonTechnologyFinanceCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:HorizonCreditAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLSN:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_HorizonCreditAgreementMember_custom_HorizonTechnologyFinanceCorporationMember_us-gaap_LondonInterbankOfferedRateLIBORMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:HorizonCreditAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLSN:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_ShortTermInvestmentsMember_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_EGENIncMember_custom_IPRAndDDrugTechnologyPlatformsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLSN:IPRAndDDrugTechnologyPlatformsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_IPRAndDDrugTechnologyPlatformsMember_custom_OvarianCancerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLSN:IPRAndDDrugTechnologyPlatformsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CLSN:OvarianCancerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_IPRAndDDrugTechnologyPlatformsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLSN:IPRAndDDrugTechnologyPlatformsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_custom_EGENIncMember_custom_GlioblastomaMultiformeBrainCancerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CLSN:GlioblastomaMultiformeBrainCancerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_EGENIncMember_custom_RNADeliverySystemMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CLSN:RNADeliverySystemMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_EGENIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_IPRAndDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLSN:IPRAndDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_IPRAndDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLSN:IPRAndDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_HorizonCreditAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLSN:HorizonCreditAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_HorizonCreditAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLSN:HorizonCreditAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_CapitalOnDemandAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:CapitalOnDemandAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_TwoThousandAndEighteenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_TwoThousandAndEighteenStockIncentivePlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_TwoThousandAndEighteenStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_TwoThousandSevenStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:TwoThousandSevenStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_EquityStockAwardsMember_custom_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EquityStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">CLSN:GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_TwoThousandAndEighteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:TwoThousandAndEighteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_InducementAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:InducementAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_NonVestedStockBasedCompensationArrangementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:NonVestedStockBasedCompensationArrangementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_NonVestedStockBasedCompensationArrangementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:NonVestedStockBasedCompensationArrangementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_NonVestedStockBasedCompensationArrangementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:NonVestedStockBasedCompensationArrangementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_TwoThousandNineteenBonusProgramMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:TwoThousandNineteenBonusProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_TwoThousandNineteenBonusProgramMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:TwoThousandNineteenBonusProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_FairValueEarnoutMilestoneLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_FairValueEarnoutMilestoneLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_FairValueEarnoutMilestoneLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_FairValueEarnoutMilestoneLiabilityMember_custom_PaymentOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">CLSN:PaymentOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_AmendedAssetPurchaseAgreementOptionPaymentOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:AmendedAssetPurchaseAgreementOptionPaymentOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_FairValueEarnoutMilestoneLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_FairValueEarnoutMilestoneLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_FairValueEarnoutMilestoneLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_FairValueEarnoutMilestoneLiabilityMember_custom_PaymentOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">CLSN:PaymentOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_custom_AmendedAssetPurchaseAgreementOptionPaymentOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:AmendedAssetPurchaseAgreementOptionPaymentOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_EGWUIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLSN:EGWUIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_AllOtherWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:AllOtherWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AccountingStandardsUpdate201602Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-08-08_custom_HisunMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">CLSN:HisunMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-01to2020-06-30_custom_NJMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CLSN:NJMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CLSN:EGENIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_custom_HorizonCreditAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLSN:HorizonCreditAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_custom_HorizonCreditAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLSN:HorizonCreditAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-22to2020-04-23_custom_AprilPaycheckProtectionProgramLoanMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:AprilPaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CLSN:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-22</xbrli:startDate>
        <xbrli:endDate>2020-04-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-23_custom_PaycheckProtectionProgramLoansMember_custom_SiliconValleyBankMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:PaycheckProtectionProgramLoansMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CLSN:SiliconValleyBankMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-25to2020-05-26_custom_MayPaycheckProtectionProgramLoanMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:MayPaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CLSN:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-25</xbrli:startDate>
        <xbrli:endDate>2020-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-26_custom_MayPaycheckProtectionProgramLoanMember_custom_SiliconValleyBankMember_us-gaap_NotesPayableToBanksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:MayPaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CLSN:SiliconValleyBankMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-21to2020-06-22_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-21</xbrli:startDate>
        <xbrli:endDate>2020-06-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_CapitalOnDemandAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:CapitalOnDemandAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-21to2020-06-22_custom_UnderwritingAgreementMember_custom_UnderwrittenOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLSN:UnderwrittenOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-21</xbrli:startDate>
        <xbrli:endDate>2020-06-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-22_custom_UnderwritingAgreementMember_custom_UnderwrittenOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLSN:UnderwrittenOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-15_custom_TwoThousandAndEighteenStockIncentivePlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-15_custom_TwoThousandAndEighteenStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLSN:EmployeeStockOptionAndRestrictedStockAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_us-gaap_CommonStockMember_custom_TwoThousandAndEighteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLSN:TwoThousandAndEighteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_FairValueEarnoutMilestoneLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_FairValueEarnoutMilestoneLiabilityMember_custom_PaymentOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">CLSN:PaymentOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_custom_AmendedAssetPurchaseAgreementOptionPaymentTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:AmendedAssetPurchaseAgreementOptionPaymentTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_FairValueEarnoutMilestoneLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_FairValueEarnoutMilestoneLiabilityMember_custom_PaymentOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">CLSN:PaymentOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_custom_AmendedAssetPurchaseAgreementOptionPaymentTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:AmendedAssetPurchaseAgreementOptionPaymentTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-01to2019-03-31_custom_EGWUIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLSN:EGWUIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-01to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_custom_FairValueEarnoutMilestoneLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_custom_FairValueEarnoutMilestoneLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLSN:FairValueEarnoutMilestoneLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_LawrencevilleNewJerseyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CLSN:LawrencevilleNewJerseyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_LawrencevilleNewJerseyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CLSN:LawrencevilleNewJerseyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_HuntsvilleAlabamaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CLSN:HuntsvilleAlabamaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-06-30_custom_HuntsvilleAlabamaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CLSN:HuntsvilleAlabamaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-22to2020-04-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-22</xbrli:startDate>
        <xbrli:endDate>2020-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percentage">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">2791868</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" decimals="0">7985886</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2019-12-31_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" decimals="0">7985886</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">7985886</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" decimals="0">7985886</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2019-12-31_us-gaap_ShortTermInvestmentsMember_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" decimals="0">7985886</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2020-06-30_us-gaap_ShortTermInvestmentsMember_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" decimals="0">2791868</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2020-06-30_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" decimals="0">2791868</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" decimals="0">2791868</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" decimals="0">2791868</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">227318</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-12-31_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">340976</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">340976</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-12-31_custom_IPRAndDMember" unitRef="USD" decimals="0">15736491</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-12-31_us-gaap_GoodwillMember" unitRef="USD" decimals="0">1976101</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-12-31_custom_AspirePurchaseAgreementsMember" unitRef="USD" decimals="0">340976</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember" unitRef="USD" decimals="0">227318</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-06-30_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">227318</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-06-30_custom_IPRAndDMember" unitRef="USD" decimals="0">15736491</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-06-30_us-gaap_GoodwillMember" unitRef="USD" decimals="0">1976101</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">6015279</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">5717709</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2019-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">5717709</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">5717709</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">6015279</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2020-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">6015279</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <CLSN:CashInvestmentSecuritiesAndInterestReceivable contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">25500000</CLSN:CashInvestmentSecuritiesAndInterestReceivable>
    <CLSN:NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards contextRef="From2020-01-01to2020-06-30" unitRef="Shares" decimals="INF">8560124</CLSN:NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards>
    <CLSN:NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards contextRef="From2019-01-01to2019-06-30" unitRef="Shares" decimals="INF">4595990</CLSN:NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards>
    <CLSN:DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">2784002</CLSN:DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost>
    <CLSN:DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">7943108</CLSN:DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost>
    <CLSN:DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">2791868</CLSN:DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue>
    <CLSN:DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">7985886</CLSN:DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">2791868</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">7985886</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <CLSN:AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">7866</CLSN:AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss>
    <CLSN:AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">42778</CLSN:AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss>
    <us-gaap:AssetImpairmentCharges contextRef="From2016-12-30to2016-12-31_custom_IPRAndDDrugTechnologyPlatformsMember_custom_OvarianCancerMember" unitRef="USD" decimals="0">13300000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="From2018-01-01to2018-12-31_custom_EGENIncMember_custom_GlioblastomaMultiformeBrainCancerMember" unitRef="USD" decimals="0">9400000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="From2019-01-01to2019-12-31_custom_EGENIncMember_custom_GlioblastomaMultiformeBrainCancerMember" unitRef="USD" decimals="0">7000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="From2020-01-01to2020-06-30_custom_IPRAndDDrugTechnologyPlatformsMember_custom_OvarianCancerMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AssetImpairmentCharges contextRef="From2019-01-01to2019-06-30_custom_IPRAndDDrugTechnologyPlatformsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AssetImpairmentCharges contextRef="From2020-01-01to2020-03-31_custom_EGENIncMember_custom_GlioblastomaMultiformeBrainCancerMember" unitRef="USD" decimals="0">2400000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="From2020-01-01to2020-06-30_custom_EGENIncMember_custom_RNADeliverySystemMember" unitRef="USD" decimals="0">1500000</us-gaap:AssetImpairmentCharges>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-01to2020-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2020-01-01to2020-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember" unitRef="USD" decimals="0">1600000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-12-31_custom_AspirePurchaseAgreementsMember" unitRef="USD" decimals="0">1250238</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember" unitRef="USD" decimals="0">1363896</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2020-02-27_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_OriginalWarrantsMember" unitRef="Shares" decimals="INF">2971428</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2020-03-12_us-gaap_SubsequentEventMember_custom_PrivateExchangeAgreementsMember_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-06-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-02-27_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_OriginalWarrantsMember" unitRef="USDPShares" decimals="INF">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-12_us-gaap_SubsequentEventMember_custom_PrivateExchangeAgreementsMember_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2020-06-30_custom_TwoThousandAndEighteenStockIncentivePlanMember" unitRef="Shares" decimals="INF">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember" unitRef="USD" decimals="0">1030726</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-01-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember" unitRef="USD" decimals="0">1313842</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">378122</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-01-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">479794</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">652604</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-01-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">834048</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-04-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember" unitRef="USD" decimals="0">578761</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-04-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember" unitRef="USD" decimals="0">622696</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-04-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">200186</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-04-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">239406</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-04-01to2020-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">378575</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-04-01to2019-06-30_custom_EmployeeStockOptionAndRestrictedStockAwardsMember_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">383290</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-01-01to2020-06-30_custom_NonVestedStockBasedCompensationArrangementsMember">P1Y6M0D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">4332142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">4725276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2020-06-30_custom_TwoThousandAndEighteenStockIncentivePlanMember_srt_MinimumMember" unitRef="Shares" decimals="INF">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2020-06-30_custom_TwoThousandAndEighteenStockIncentivePlanMember_srt_MaximumMember" unitRef="Shares" decimals="INF">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2020-06-15_custom_TwoThousandAndEighteenStockIncentivePlanMember_srt_MinimumMember" unitRef="Shares" decimals="INF">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2020-06-15_custom_TwoThousandAndEighteenStockIncentivePlanMember_srt_MaximumMember" unitRef="Shares" decimals="INF">6400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2020-01-01to2020-06-30_custom_TwoThousandSevenStockIncentivePlanMember" unitRef="Shares" decimals="INF">688531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2020-01-01to2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">644000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2020-01-01to2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">110002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">5494924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">3194777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">3733421</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-02-18to2019-02-19_custom_InducementOptionGrantsMember_custom_FiveNewEmployeesMember" unitRef="USDPShares" decimals="INF">2.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30_custom_NonVestedStockBasedCompensationArrangementsMember" unitRef="USDPShares" decimals="INF">3.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-06-30_custom_NonVestedStockBasedCompensationArrangementsMember" unitRef="USDPShares" decimals="INF">1.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember">P8Y3M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2020-01-01to2020-06-30" unitRef="Percentage" decimals="INF">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2019-01-01to2019-06-30" unitRef="Percentage" decimals="INF">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-01-01to2018-12-31_custom_TwoThousandEighteenAspirePurchaseAgreementsMember" unitRef="Shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-01-01to2019-12-31_custom_TwoThousandEighteenAspirePurchaseAgreementsMember" unitRef="Shares" decimals="INF">3300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-01-01to2019-12-31_custom_CapitalOnDemandAgreementMember" unitRef="Shares" decimals="INF">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-01-01to2019-12-31_custom_TwoThousandNineteenAspirePurchaseAgreementsMember" unitRef="Shares" decimals="INF">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-03-05_us-gaap_SubsequentEventMember_custom_TwoThousandNineteenAspirePurchaseAgreementsMember" unitRef="Shares" decimals="INF">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-02-26to2020-02-27_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">4571428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-06-21to2020-06-22_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-06-30_custom_CapitalOnDemandAgreementMember" unitRef="Shares" decimals="INF">1200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-06-21to2020-06-22_custom_UnderwritingAgreementMember_custom_UnderwrittenOfferingMember" unitRef="Shares" decimals="INF">2666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">18182599</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-01-01to2018-12-31_custom_TwoThousandEighteenAspirePurchaseAgreementsMember" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-01-01to2019-12-31_custom_TwoThousandEighteenAspirePurchaseAgreementsMember" unitRef="USD" decimals="0">6300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-01-01to2019-12-31_custom_CapitalOnDemandAgreementMember" unitRef="USD" decimals="0">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-01-01to2019-12-31_custom_TwoThousandNineteenAspirePurchaseAgreementsMember" unitRef="USD" decimals="0">700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-01-01to2020-03-05_us-gaap_SubsequentEventMember_custom_TwoThousandNineteenAspirePurchaseAgreementsMember" unitRef="USD" decimals="0">1600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-02-26to2020-02-27_custom_SecuritiesPurchaseAgreementMember_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">4800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">4464060</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-06-21to2020-06-22_us-gaap_CommonStockMember" unitRef="USD" decimals="0">9100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-01-01to2020-06-30_custom_CapitalOnDemandAgreementMember" unitRef="USD" decimals="0">3500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-06-21to2020-06-22_custom_UnderwritingAgreementMember_custom_UnderwrittenOfferingMember" unitRef="USD" decimals="0">9100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShortTermInvestments contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">2784002</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="AsOf2019-12-31_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" decimals="0">7943108</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">7943108</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="AsOf2020-06-30_us-gaap_CorporateDebtSecuritiesMember" unitRef="USD" decimals="0">2784002</us-gaap:ShortTermInvestments>
    <CLSN:AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">2784002</CLSN:AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent>
    <CLSN:AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">7943108</CLSN:AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent>
    <CLSN:AggregateOfferingPrices contextRef="From2018-12-02to2018-12-04_custom_CapitalOnDemandTMSalesAgreementMember" unitRef="USD" decimals="0">16000000</CLSN:AggregateOfferingPrices>
    <us-gaap:SharesIssued contextRef="AsOf2019-02-19_custom_InducementOptionGrantsMember_custom_TwoNewEmployeesMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">140004</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2019-02-19_custom_InducementOptionGrantsMember_custom_TwoNewEmployeesMember_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">13000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2020-06-30_custom_TwoThousandNineteenBonusProgramMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">429855</us-gaap:SharesIssued>
    <CLSN:AggregateOfferingPriceAdditions contextRef="From2019-01-01to2019-12-31_custom_TwoThousandNineteenAspirePurchaseAgreementsMember" unitRef="USD" decimals="0">10000000</CLSN:AggregateOfferingPriceAdditions>
    <CLSN:AggregateOfferingPriceAdditions contextRef="From2018-08-30to2018-08-31_custom_TwoThousandNineteenAspirePurchaseAgreementsMember" unitRef="USD" decimals="0">15000000</CLSN:AggregateOfferingPriceAdditions>
    <CLSN:AggregateOfferingPriceTerm contextRef="From2019-01-01to2019-12-31_custom_TwoThousandNineteenAspirePurchaseAgreementsMember">P24M</CLSN:AggregateOfferingPriceTerm>
    <CLSN:AggregateOfferingPriceTerm contextRef="From2018-08-30to2018-08-31_custom_TwoThousandNineteenAspirePurchaseAgreementsMember">P24M</CLSN:AggregateOfferingPriceTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2020-01-01to2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" xsi:nil="true" />
    <CLSN:TaxBenefitsOfEarningsBeforeDepreciationAndAmortization contextRef="From2019-01-01to2019-12-31_custom_NJMember" unitRef="USD" decimals="0">1900000</CLSN:TaxBenefitsOfEarningsBeforeDepreciationAndAmortization>
    <CLSN:TaxBenefitsOfEarningsBeforeDepreciationAndAmortization contextRef="From2018-01-01to2018-12-31_custom_NJMember" unitRef="USD" decimals="0">10400000</CLSN:TaxBenefitsOfEarningsBeforeDepreciationAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2020-01-01to2020-06-30_custom_IPRAndDMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2020-01-01to2020-06-30_us-gaap_GoodwillMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2020-01-01to2020-06-30_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">113658</us-gaap:AmortizationOfIntangibleAssets>
    <CLSN:AggregateValueAvailableForIssuance contextRef="AsOf2020-06-30_custom_CapitalOnDemandAgreementMember" unitRef="USD" decimals="0">11500000</CLSN:AggregateValueAvailableForIssuance>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired contextRef="From2020-01-01to2020-06-30_custom_EGENIncMember_custom_IPRAndDDrugTechnologyPlatformsMember" unitRef="USD" decimals="0">24200000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="From2020-01-01to2020-06-30_custom_EGENIncMember" unitRef="USD" decimals="0">2000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2019-02-18to2019-02-19_custom_InducementOptionGrantsMember_custom_FiveNewEmployeesMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2020-01-01to2020-06-30" unitRef="Percentage" decimals="INF">1.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2019-01-01to2019-06-30" unitRef="Percentage" decimals="INF">1.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2020-01-01to2020-06-30" unitRef="Percentage" decimals="INF">1.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2019-01-01to2019-06-30" unitRef="Percentage" decimals="INF">1.062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <CLSN:DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">-2791868</CLSN:DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months>
    <CLSN:DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-7985886</CLSN:DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-06-30_custom_TwoThousandAndEighteenStockIncentivePlanMember" unitRef="Shares" decimals="INF">6510174</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-06-30_custom_EquityStockAwardsMember_custom_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" unitRef="Shares" decimals="INF">4594022</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-06-30_custom_TwoThousandAndEighteenPlanMember" unitRef="Shares" decimals="INF">1916152</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-06-30_custom_InducementAwardsMember" unitRef="Shares" decimals="INF">140004</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <CLSN:NetProceedsFromSaleOfNetOperatingLosses contextRef="From2019-01-01to2019-12-31_custom_NJMember" unitRef="USD" decimals="0">1800000</CLSN:NetProceedsFromSaleOfNetOperatingLosses>
    <CLSN:NetProceedsFromSaleOfNetOperatingLosses contextRef="From2018-01-01to2018-12-31_custom_NJMember" unitRef="USD" decimals="0">11100000</CLSN:NetProceedsFromSaleOfNetOperatingLosses>
    <CLSN:NetProceedsFromSaleOfNetOperatingLosses contextRef="From2020-04-01to2020-04-30_custom_NJMember" unitRef="USD" decimals="0">1800000</CLSN:NetProceedsFromSaleOfNetOperatingLosses>
    <CLSN:NetProceedsFromSaleOfNetOperatingLosses contextRef="From2020-06-01to2020-06-30_custom_NJMember" unitRef="USD" decimals="0">2000000</CLSN:NetProceedsFromSaleOfNetOperatingLosses>
    <CLSN:NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare contextRef="From2020-01-01to2020-06-30" unitRef="Shares" decimals="INF">200000</CLSN:NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2018-06-26to2018-06-27_custom_HorizonCreditAgreementMember" unitRef="USD" decimals="0">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2018-06-30_custom_HorizonCreditAgreementMember_custom_HorizonTechnologyFinanceCorporationMember_us-gaap_LondonInterbankOfferedRateLIBORMember" unitRef="Percentage" decimals="INF">0.07625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt contextRef="From2020-01-01to2020-06-30_custom_HorizonCreditAgreementMember" unitRef="USD" decimals="0">486597</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2019-01-01to2019-06-30_custom_HorizonCreditAgreementMember" unitRef="USD" decimals="0">508471</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-04-01to2020-06-30_custom_HorizonCreditAgreementMember" unitRef="USD" decimals="0">243299</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2019-04-01to2019-06-30_custom_HorizonCreditAgreementMember" unitRef="USD" decimals="0">255182</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2020-01-01to2020-06-30_custom_HorizonCreditAgreementMember" unitRef="USD" decimals="0">192793</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2019-01-01to2019-06-30_custom_HorizonCreditAgreementMember" unitRef="USD" decimals="0">191724</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2020-04-01to2020-06-30_custom_HorizonCreditAgreementMember" unitRef="USD" decimals="0">96727</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2019-04-01to2019-06-30_custom_HorizonCreditAgreementMember" unitRef="USD" decimals="0">94266</us-gaap:AmortizationOfFinancingCosts>
    <CLSN:ShelfRegistrationStatementAmount contextRef="From2018-09-01to2018-09-30" unitRef="USD" decimals="0">75000000</CLSN:ShelfRegistrationStatementAmount>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2020-02-27_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember" unitRef="USDPShares" decimals="INF">1.05</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2020-06-22_custom_UnderwritingAgreementMember_custom_UnderwrittenOfferingMember" unitRef="USDPShares" decimals="INF">3.75</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-02-27_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_custom_OriginalWarrantsMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-03-12_us-gaap_SubsequentEventMember_custom_PrivateExchangeAgreementsMember_us-gaap_WarrantMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2020-06-30_custom_NonVestedStockBasedCompensationArrangementsMember" unitRef="USD" decimals="0">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-05-26_custom_MayPaycheckProtectionProgramLoanMember_custom_SiliconValleyBankMember_us-gaap_NotesPayableToBanksMember" unitRef="USD" decimals="0">692530</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromContributedCapital contextRef="From2018-06-01to2018-06-30_custom_HorizonCreditAgreementMember_custom_HorizonTechnologyFinanceCorporationMember" unitRef="USD" decimals="0">10000000</us-gaap:ProceedsFromContributedCapital>
    <CLSN:StockOptionsStrikePriceDescription contextRef="From2020-01-01to2020-06-30_custom_TwoThousandSevenStockIncentivePlanMember">Options are generally granted with strike prices equal to the fair market value of a share of Celsion common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of Celsion must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options.</CLSN:StockOptionsStrikePriceDescription>
    <CLSN:AnnualBonusAwardsPercentage contextRef="From2020-01-01to2020-06-30_custom_TwoThousandNineteenBonusProgramMember_us-gaap_CommonStockMember" unitRef="Percentage" decimals="INF">0.50</CLSN:AnnualBonusAwardsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">8750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2020-06-30_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">8750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember" unitRef="USDPShares" decimals="INF">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-06-30_us-gaap_RestrictedStockMember" unitRef="USDPShares" decimals="INF">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">429855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember" unitRef="USDPShares" decimals="INF">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2020-06-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">7875</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember" unitRef="USDPShares" decimals="INF">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">429855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">10000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2020-04-23_custom_PaycheckProtectionProgramLoansMember_custom_SiliconValleyBankMember_srt_MaximumMember" unitRef="USD" decimals="0">2000000</us-gaap:DebtInstrumentCarryingAmount>
    <CLSN:DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">7866</CLSN:DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain>
    <CLSN:DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">42778</CLSN:DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 1. Business Description&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Celsion Corporation (&amp;#8220;Celsion&amp;#8221;&#13;and the &amp;#8220;Company&amp;#8221;) is a fully integrated development stage oncology drug company focused on advancing a portfolio&#13;of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA based therapies. Celsion&#13;is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including immunotherapies,&#13;DNA-based therapies and directed chemotherapies. The Company&amp;#8217;s product pipeline includes GEN-1, a DNA-based immunotherapy&#13;for the localized treatment of ovarian cancer and ThermoDox&amp;#174;, a proprietary heat-activated liposomal encapsulation of doxorubicin,&#13;currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications.&#13;Celsion has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other&#13;anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular&#13;transfection.With these technologies we are working to develop and commercialize more efficient, effective and targeted oncology&#13;therapies that maximize efficacy while minimizing side-effects common to cancer treatments.&lt;/p&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2. Basis of Presentation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated&#13;financial statements, which include the accounts of the Company and its wholly owned subsidiary, CLSN Laboratories, Inc, have been&#13;prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial information&#13;and with the instructions to Form 10-Q and Article 10 of Regulation S-X. All significant intercompany balances and transactions&#13;have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in&#13;accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the opinion of management, all adjustments,&#13;consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying&#13;unaudited condensed consolidated financial statements. Operating results for the three-month and six-month periods ended June 30,&#13;2020 and 2019 are not necessarily indicative of the results that may be expected for any other interim period(s) or for any full&#13;year. For further information, refer to the financial statements and notes thereto included in the Company&amp;#8217;s Annual Report&#13;on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) on March 25, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in&#13;conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amounts reported in the&#13;Company&amp;#8217;s financial statements and accompanying notes. Actual results could differ materially from those estimates. Events&#13;and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial&#13;statements and accompanying notes. With the recent introduction of the COVID-19 pandemic to the United States, the Company continues&#13;to monitor the impact of this pandemic on its financial condition and results of operations, along with the valuation of its long-term&#13;assets, intangible assets, and goodwill. The effect of this matter could potentially have an impact on the valuation of such assets&#13;in the future. The COVID-19 matter is discussed in more detail in Note 3 to the financial statements.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 3. Financial Condition and Business&#13;Plan&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Since inception, the Company has incurred substantial&#13;operating losses, principally from expenses associated with the Company&amp;#8217;s research and development programs, clinical trials&#13;conducted in connection with the Company&amp;#8217;s product candidates, and applications and submissions to the U.S. Food and Drug&#13;Administration. The Company has not generated significant revenue and has incurred significant net losses in each year since our&#13;inception. As of June 30, 2020, the Company has incurred approximately $301 million of cumulative net losses and we had approximately&#13;$25.5 million in cash, investment securities, and interest receivable. We have substantial future capital requirements to continue&#13;our research and development activities and advance our product candidates through various development stages. The Company believes&#13;these expenditures are essential for the commercialization of its technologies.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expects its operating losses to&#13;continue for the foreseeable future as it continues its product development efforts, and when it undertakes marketing and sales&#13;activities. The Company&amp;#8217;s ability to achieve profitability is dependent upon its ability to obtain governmental approvals,&#13;manufacture, and market and sell its new product candidates. There can be no assurance that the Company will be able to commercialize&#13;its technology successfully or that profitability will ever be achieved. The operating results of the Company have fluctuated significantly&#13;in the past.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;COVID-19 Pandemic&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2020, the World Health Organization&#13;(&amp;#8220;WHO&amp;#8221;) declared an outbreak of coronavirus, COVID-19, to be a &amp;#8220;Public Health Emergency of International Concern,&amp;#8221;&#13;and the U.S. Department of Health and Human Services declared a public health emergency to aid the U.S. healthcare community in&#13;responding to COVID-19. This virus has spread to over 100 countries, including the United States. Governments and businesses around&#13;the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place&#13;orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work.&#13;Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets.&#13;The Company did not observe significant impacts on its business or results of operations for the three-month and six-month periods&#13;ended June 30, 2020 due to the global emergence of COVID-19. While the extent to which COVID-19 impacts the Company&amp;#8217;s future&#13;results will depend on future developments, the pandemic and associated economic impacts could result in a material impact to the&#13;Company&amp;#8217;s future financial condition, results of operations and cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s ability to raise additional&#13;capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility&#13;in, financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. The disruptions caused by&#13;COVID-19 may also disrupt the clinical trials process and enrolment of patients. This may delay commercialization efforts. The&#13;Company is currently monitoring its operating activities in light of these events and it is reasonably possible that the virus&#13;could have a negative effect on the Company&amp;#8217;s financial condition and results of operations. The specific impact, if any,&#13;is not readily determinable as of the date of these financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The actual amount of funds the Company will&#13;need to operate is subject to many factors, some of which are beyond the Company&amp;#8217;s control. These factors include the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;the progress of research activities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;the number and scope of research programs;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;the progress of preclinical and clinical development activities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;the progress of the development efforts of parties with whom the Company has entered into research and development agreements;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;the costs associated with additional clinical trials of product candidates;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;the ability to achieve milestones under licensing arrangements;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;the costs and timing of regulatory approvals.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 13, 2020, the Company announced that&#13;it has received a recommendation from the independent Data Monitoring Committee (DMC) to consider stopping the global Phase III&#13;OPTIMA Study of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt; in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular&#13;carcinoma (HCC), or primary liver cancer. The recommendation was made following the second pre-planned interim safety and efficacy&#13;analysis by the DMC on July 9, 2020. The DMC&amp;#8217;s analysis found that the pre-specified boundary for stopping the trial for&#13;futility of 0.900 was crossed with an actual value of 0.903. The Company intends to follow the advice of the DMC and will consider&#13;its options to either stop the study or continue to follow patients after a thorough review of the data, and an evaluation of the&#13;probability of success. Timing for this decision is made less urgent by the fact that the OPTIMA Study has been fully enrolled&#13;since August 2018 and that the vast majority of the trial expenses have already been incurred. On August 4, 2020, the Company issued&#13;a press release announcing it will continue following patients for overall survival (&amp;#8220;OS&amp;#8221;), noting that the unexpected&#13;and marginally crossed futility boundary, suggested by the Kaplan-Meier analysis at the second interim analysis on July 9, 2020,&#13;may be associated with a data maturity issue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During 2019 and 2018, the Company submitted&#13;applications to sell a portion of the Company&amp;#8217;s State of New Jersey net operating losses as part of the Technology Business&#13;Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies&#13;with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies.&#13;The Company received approval from the New Jersey Economic Development Authority to sell $1.9 million of its State of New Jersey&#13;net operating losses recognizing a tax benefit for the year ended December 31, 2019 for the net proceeds (approximately $1.8 million).&#13;In early 2020, the Company entered into an agreement to sell these net operating losses. In April of 2020, the Company completed&#13;the sale of its State of New Jersey net operating losses and received $1.8 million in net proceeds. In 2018, the Company completed&#13;the sale of a portion of its State of New Jersey net operating losses for calendar years 2011 - 2017 totalling approximately $11.1&#13;million for net proceeds of approximately $10.4 million in December 2018. The proceeds of $10.4 million were reflected as a tax&#13;benefit for the year ended December 31, 2018. In June 2020, the Company filed an application with the New Jersey Economic Development&#13;Authority to sell substantially all of its remaining State of New Jersey net operating losses totalling $2.0 million available&#13;under the program.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2018, the Company entered into the&#13;Horizon Credit Agreement with Horizon Technology Finance Corporation (&amp;#8220;Horizon&amp;#8221;) that provided $10 million in new capital&#13;(the &amp;#8220;Horizon Credit Agreement&amp;#8221;). The obligations under the Horizon Credit Agreement are secured by a first-priority&#13;security interest in substantially all assets of Celsion other than intellectual property assets. Payments under the loan agreement&#13;are interest only (calculated based on one-month LIBOR plus 7.625%) for the first twenty-four (24) months through July 2020, followed&#13;by a 24-month amortization period of principal and interest starting on August 1, 2020 and ending through the scheduled maturity&#13;date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With $25.5 million in cash, investments, interest&#13;receivable and up to $2.0 million in potential proceeds from the sale of the 2019 State of New Jersey net operating losses, coupled&#13;with remaining availability under the Capital-on-Demand&amp;#8482; Sales Agreement (the &amp;#8220;Capital on Demand Agreement&amp;#8221;)&#13;with JonesTrading Institutional Services LLC, the Company believes it has sufficient capital resources to fund its operations through&#13;the end of 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has based its estimates on assumptions&#13;that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates.&#13;Potential sources of financing include strategic relationships, public or private sales of the Company&amp;#8217;s shares or debt,&#13;the sale of the Company&amp;#8217;s State of New Jersey net operating losses and other sources. If the Company raises funds by selling&#13;additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders&#13;may be diluted.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 4. New Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From time to time, new accounting pronouncements&#13;are issued by the Financial Accounting Standards Board (FASB) and are adopted by us as of the specified effective date. Unless&#13;otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material impact on&#13;the Company&amp;#8217;s condensed consolidated financial position, results of operations, and cash flows, or do not apply to our operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, the FASB issued Accounting Standards&#13;Update No. 2016-13, &amp;#8220;Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&amp;#8221;,&#13;which modifies the measurement of expected credit losses on certain financial instruments. The Company will adopt ASU 2016-13 in&#13;its first quarter of 2021 utilizing the modified retrospective transition method. Based on the composition of the Company&amp;#8217;s&#13;investment portfolio and current market conditions, the adoption of ASU 2016-13 is not expected to have a material impact on its&#13;condensed consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2018, the FASB issued ASU No. 2018-13,&#13;&lt;i&gt;Fair Value Measurement: Disclosure Framework &amp;#8211; Changes to the Disclosure Requirements for Fair Value Measurement&lt;/i&gt;,&#13;which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer&#13;be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation&#13;processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average&#13;of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and&#13;losses included in other comprehensive income. This update is effective for annual periods beginning after December 15, 2019, and&#13;interim periods within those periods, and early adoption is permitted. The adoption of this standard did not have an impact on&#13;the Company&amp;#8217;s condensed consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2019, the FASB issued ASU No.&#13;2019-12, Income Taxes (Topic 740). The standard simplifies the accounting for incomes taxes by removing certain exceptions to&#13;the general principles in Topic 740 related to the approach for intra-period tax allocation and the recognition of deferred tax&#13;liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up&#13;in the tax basis of goodwill. The standard also improves consistent application of and simplifies GAAP for other areas of Topic&#13;740 by clarifying and amending existing guidance. The amendment is effective for fiscal years, and interim periods within those&#13;fiscal years, beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact that&#13;the adoption of this standard will have on its condensed consolidated financial statements.&lt;/p&gt;</us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 5. Net Loss per Common Share&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic loss per share is calculated based upon&#13;the net loss available to common shareholders divided by the weighted average number of common shares outstanding during the period.&#13;Diluted loss per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects&#13;of all dilutive potential common shares outstanding during the period. The dilutive effects of preferred stock, options and warrants&#13;and their equivalents are computed using the treasury stock method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The total number of shares of common stock&#13;issuable upon exercise of warrants, stock option grants and equity awards were 8,560,124 and 4,595,990 shares for the six-month&#13;periods ended June 30, 2020 and 2019, respectively. Warrants with an exercise price of $0.01 (as more fully described in Note&#13;13) exercisable for 200,000 shares of common stock were considered issued in calculating basic loss per share. For the three-month&#13;and six-month periods ended June 30, 2020 and 2019, diluted loss per common share was the same as basic loss per common share&#13;as the other warrants and equity awards that were convertible into shares of the Company&amp;#8217;s common stock were excluded from&#13;the calculation of diluted loss per common share as their effect would have been anti-dilutive. The Company did not pay any dividends&#13;during the six-month periods ended June 30, 2020 and 2019.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 6. Investment in Debt Securities Available&#13;for Sale&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Investments in debt securities available for&#13;sale with a fair value of $2,791,868 and $7,985,886 as of June 30, 2020 and December 31, 2019, respectively, consist of corporate&#13;debt securities. These investments are valued at estimated fair value, with unrealized gains and losses reported as a separate&#13;component of stockholders&amp;#8217; equity in accumulated other comprehensive loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Investments in debt securities available for&#13;sale are evaluated periodically to determine whether a decline in their value is other than temporary. The term &amp;#8220;other than&#13;temporary&amp;#8221; is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery&#13;of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the&#13;carrying value of the security. Management reviews criteria such as the magnitude and duration of the decline, as well as the reasons&#13;for the decline, to predict whether the loss in value is other than temporary. Once a decline in value is determined to be other&#13;than temporary, the value of the security is reduced and a corresponding charge to earnings is recognized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the cost, fair value and maturities&#13;of the Company&amp;#8217;s short-term investments is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Short-term investments&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 48%; padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Investments in debt securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,784,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,943,108&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,784,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,943,108&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Short-term investment maturities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 48%; padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Within 3 months&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,784,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,943,108&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,784,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,943,108&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the Company&amp;#8217;s&#13;investment securities gross unrealized gains (losses) and fair value by investment category and length of time that individual&#13;securities have been in a continuous unrealized loss position at June 30, 2020 and December 31, 2019. The Company has reviewed&#13;individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Available for sale securities &lt;/b&gt;(all unrealized holding gains and losses are less than 12 months at date of measurement)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Holding&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Holding&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 48%; padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Investments in debt securities with unrealized Gains&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,866&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;42,778&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,866&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;42,778&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Investment income, which includes net realized&#13;gains on sales of available for sale securities and investment income interest and dividends, is summarized as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 66%"&gt;&lt;font style="font-size: 10pt"&gt;Interest and dividends accrued and paid&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18,095&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;143,633&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Realized gains&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,865&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;969&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Investment income, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;20,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;144,602&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 66%"&gt;&lt;font style="font-size: 10pt"&gt;Interest and dividends accrued and paid&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;63,172&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;248,043&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Realized gains&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;46,097&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,350&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Investment income, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;109,269&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;258,393&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the cost, fair value and maturities&#13;of the Company&amp;#8217;s short-term investments is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Short-term investments&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 48%; padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Investments in debt securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,784,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,943,108&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,784,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,943,108&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Short-term investment maturities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 48%; padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Within 3 months&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,784,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,943,108&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,784,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,943,108&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the Company&amp;#8217;s&#13;investment securities gross unrealized gains (losses) and fair value by investment category and length of time that individual&#13;securities have been in a continuous unrealized loss position at June 30, 2020 and December 31, 2019. The Company has reviewed&#13;individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Available for sale securities &lt;/b&gt;(all unrealized holding gains and losses are less than 12 months at date of measurement)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Holding&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Holding&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 48%; padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Investments in debt securities with unrealized Gains&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,866&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;42,778&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,866&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;42,778&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:InvestmentIncomeTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Investment income, which includes net realized&#13;gains on sales of available for sale securities and investment income interest and dividends, is summarized as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 66%"&gt;&lt;font style="font-size: 10pt"&gt;Interest and dividends accrued and paid&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18,095&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;143,633&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Realized gains&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,865&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;969&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Investment income, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;20,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;144,602&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 66%"&gt;&lt;font style="font-size: 10pt"&gt;Interest and dividends accrued and paid&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;63,172&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;248,043&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Realized gains&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;46,097&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,350&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Investment income, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;109,269&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;258,393&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:InvestmentIncomeTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">-300916593</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-290516780</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:InvestmentIncomeNonoperating contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">109269</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">258393</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">20960</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">144602</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">46097</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">10350</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">2865</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">969</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">63172</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">248043</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">18095</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">143633</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 7. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FASB Accounting Standards Codification (ASC)&#13;Section 820 &amp;#8220;Fair Value Measurements and Disclosures,&amp;#8221; establishes a three-level hierarchy for fair value measurements&#13;which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair&#13;value. The three levels of inputs that may be used to measure fair value are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Level 1: Quoted prices (unadjusted)&#13;or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Level 2: Significant other observable&#13;inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not&#13;active; or other inputs that are observable or can be corroborated by observable market data; and&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Level 3: Significant unobservable&#13;inputs that reflect a reporting entity&amp;#8217;s own assumptions that market participants would use in pricing an asset or liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents, accounts payable&#13;and other accrued liabilities are reflected in the condensed consolidated balance sheet at their approximate estimated fair values&#13;primarily due to their short-term nature. The fair values of securities available for sale are determined by relying on the securities&amp;#8217;&#13;relationship to other benchmark quoted securities and classified its investments as Level 2 items at June 30, 2020 and December&#13;31, 2019. There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during&#13;the six-month period ended June 30, 2020 or during the year ended December 31, 2019. The changes in Level 3 liabilities were the&#13;result of changes in the fair value of the earn-out milestone liability included in earnings and in-process R&amp;#38;D. The earnout&#13;milestone liability is valued using a risk-adjusted assessment of the probability of payment of each milestone, discounted to present&#13;value using an estimated time to achieve the milestone (see Note 13). The in-process R&amp;#38;D is valued using a multi-period excess&#13;earnings method (see Note 8).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Assets and liabilities measured at fair value&#13;are summarized below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Significant Other Observable Inputs (Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Significant Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Recurring items as of June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 48%; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Corporate debt securities, available for sale&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Recurring items as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Corporate debt securities, available for sale&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Liabilities:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Recurring items as of June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Earn-out milestone liability (Note 13)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,015,279&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,015,279&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Recurring items as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Earn-out milestone liability (Note 13)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,717,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,717,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 8. Intangible Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2014, we completed the acquisition&#13;of substantially all of the assets of EGEN, Inc., an Alabama corporation, which has changed its company name to EGWU, Inc. after&#13;the closing of the acquisition (&amp;#8220;EGEN&amp;#8221;). We acquired all of EGEN&amp;#8217;s right, title and interest in and to substantially&#13;all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical&#13;data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible&#13;personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising&#13;out of the acquired contracts and other assets relating to periods after the closing date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Acquired In-process Research and Development&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Acquired in-process research and development&#13;(IPR&amp;#38;D) consists of EGEN&amp;#8217;s drug technology platforms: TheraPlas and TheraSilence. The fair value of the IPR&amp;#38;D drug&#13;technology platforms was estimated to be $24.2 million as of the acquisition date. As of the closing of the acquisition, the IPR&amp;#38;D&#13;was considered indefinite lived intangible assets and will not be amortized. IPR&amp;#38;D is reviewed for impairment at least annually&#13;as of our third quarter ended September 30, and whenever events or changes in circumstances indicate that the carrying value of&#13;the assets might not be recoverable. The Company&amp;#8217;s IPR&amp;#38;D consisted of three core elements, its RNA delivery system, its&#13;glioblastoma multiforme cancer (GBM) product candidate and its ovarian cancer indication.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s ovarian cancer indication,&#13;with original value of $13.3 million, has not been impaired since its acquisition. At September 30, 2019, the Company evaluated&#13;its IPR&amp;#38;D of the ovarian cancer indication and concluded that it is not more likely than not that the asset is impaired. As&#13;no other indicators of impairment existed during the fourth quarter of 2019, or first half of 2020, no impairment charges were&#13;recorded during the six months ended June 30, 2020 and 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s GBM candidate, with original&#13;value of $9.4 million had cumulative impairments through 2018 of $7 million, with remaining carrying value of $2.4 million at December&#13;31, 2019 and March 31, 2020, On September 30, 2019, the Company evaluated its IPR&amp;#38;D of the (GBM) product candidate and concluded&#13;that it is not more likely than not that the asset is further impaired. As no other indicators of impairment existed during the&#13;fourth quarter of 2019 and in the first half of 2020, no impairment charges were recorded during the six months ended June 30,&#13;2020 and 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s RNA delivery system, with&#13;an initial value of $1.5, million was previously fully impaired.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Covenants Not to Compete&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the EGEN Purchase Agreement, EGEN&#13;provided certain covenants (&amp;#8220;Covenant Not To Compete&amp;#8221;) to the Company whereby EGEN agreed, during the period ending&#13;on the seventh anniversary of the closing date of the acquisition on June 20, 2014, not to enter into any business, directly or&#13;indirectly, which competes with the business of the Company nor will it contact, solicit or approach any of the employees of the&#13;Company for purposes of offering employment. The Covenant Not to Compete which was valued at approximately $1.6 million at the&#13;date of the EGEN acquisition has a definitive life and is amortized on a straight-line basis over its life of 7 years. The Company&#13;recognized amortization expense of $56,829 in each of the three-month periods ended June 30, 2020 and 2019. The Company recognized&#13;amortization expense of $113,658 in each of the six-month periods ended June 30, 2020 and 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying value of the Covenant Not to Compete&#13;was $227,318, net of $1,363,896 accumulated amortization as of June 30, 2020 and $340,976, net of $1,250,238 accumulated amortization,&#13;as of December 31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following is a schedule of future amortization&#13;amounts during the remaining life of the Covenant Not to Compete.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;227,318&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;2022 and thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;227,318&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The purchase price exceeded the estimated fair&#13;value of the net assets acquired by approximately $2.0 million which was recorded as Goodwill. Goodwill represents the difference&#13;between the total purchase price for the net assets purchased from EGEN and the aggregate fair values of tangible and intangible&#13;assets acquired, less liabilities assumed. Goodwill is reviewed for impairment at least annually as of our third quarter ended&#13;September 30 or sooner if we believe indicators of impairment exist. As of June 30, 2020, we concluded that the Company&amp;#8217;s&#13;fair value exceeded its carrying value therefore &amp;#8220;it is not more likely than not&amp;#8221; that the Goodwill was impaired.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As described in Note 3, on July 13, 2020, the&#13;Company announced that it has received a recommendation from the DMC to consider stopping the global Phase III OPTIMA Study of&#13;ThermoDox&amp;#174; in combination with RFA for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer. This event&#13;will be incorporated in the Company&amp;#8217;s assessment of the carrying value of goodwill and intangible assets as of the date the&#13;information was available, which is the third quarter of 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following is a summary of the net fair value&#13;of the assets acquired in the EGEN asset acquisition for the three-month period ended June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;IPR&amp;#38;D&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Covenant Not To Compete&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;For the six-months ended June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Balance at January 1, 2020, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,736,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,976,101&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;340,976&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(113,658&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Balance at June 30, 2020, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,736,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,976,101&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;227,318&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Assets and liabilities measured at fair value&#13;are summarized below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Significant Other Observable Inputs (Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Significant Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Recurring items as of June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 48%; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Corporate debt securities, available for sale&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,791,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Recurring items as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Corporate debt securities, available for sale&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,985,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Liabilities:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Recurring items as of June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Earn-out milestone liability (Note 13)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,015,279&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,015,279&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Recurring items as of December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Earn-out milestone liability (Note 13)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,717,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472; &amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,717,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following is a schedule of future amortization&#13;amounts during the remaining life of the Covenant Not to Compete.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;227,318&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;2022 and thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;227,318&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following is a summary of the net fair value&#13;of the assets acquired in the EGEN asset acquisition for the three-month period ended June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;IPR&amp;#38;D&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Covenant Not To Compete&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;For the six-months ended June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Balance at January 1, 2020, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,736,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,976,101&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;340,976&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(113,658&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Balance at June 30, 2020, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,736,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,976,101&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;227,318&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:AdjustmentForAmortization contextRef="From2020-01-01to2020-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember" unitRef="USD" decimals="0">113658</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="From2019-01-01to2019-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember" unitRef="USD" decimals="0">113658</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="From2020-04-01to2020-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember" unitRef="USD" decimals="0">56829</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="From2019-04-01to2019-06-30_custom_EGENIncMember_custom_PurchaseAgreementMember" unitRef="USD" decimals="0">56829</us-gaap:AdjustmentForAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2020-06-30_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">227318</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 9. Other Accrued Liabilities&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other accrued liabilities at June 30, 2020&#13;and December 31, 2019 include the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Amounts due to contract research organizations and other contractual agreements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;284,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;475,440&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued payroll and related benefits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,054,272&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,604,541&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued professional fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;204,155&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;19,411&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;19,411&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,507,683&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,303,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other accrued liabilities at June 30, 2020&#13;and December 31, 2019 include the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Amounts due to contract research organizations and other contractual agreements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;284,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;475,440&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued payroll and related benefits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,054,272&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,604,541&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued professional fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;150,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;204,155&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;19,411&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;19,411&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,507,683&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,303,547&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">1507683</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">2303547</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">19411</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">19411</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">150000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">204155</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">1054272</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1604541</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractualObligation contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">284000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">475440</us-gaap:ContractualObligation>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 10. Notes and Loans Payable&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Horizon Credit Agreement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 27, 2018, the Company entered the Horizon&#13;Credit Agreement. The Company drew down $10 million upon closing of the Horizon Credit Agreement on June 27, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three-month period ended June 30,&#13;2020, the Company incurred $243,299 in interest expense and amortized $96,727 as interest expense for debt discounts and end of&#13;term charges in connection with the Horizon Credit Agreement. During the three-month period ended June 30, 2019, the Company incurred&#13;$255,182 in interest expense and amortized $94,266 as interest expense for debt discounts and end of term charges in connection&#13;with the Horizon Credit Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six-month period ended June 30,&#13;2020, the Company incurred $486,597 in interest expense and amortized $192,793 as interest expense for debt discounts and end of&#13;term charges in connection with the Horizon Credit Agreement. During the six-month period ended June 30, 2019, the Company incurred&#13;$508,471 in interest expense and amortized $191,724 as interest expense for debt discounts and end of term charges in connection&#13;with the Horizon Credit Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following is a schedule of future principal&#13;payments, net of unamortized debt discounts and amortized end of term charges, due on the Horizon Credit Agreement:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,583,336&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,000,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;416,664&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;2024 and thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Subtotal of future principal payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,000,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Unamortized debt issuance costs, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(3,530&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,996,470&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Paycheck Protection Program&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On April 23, 2020,&#13;we entered into a loan agreement with Silicon Valley Bank (the &amp;#8220;April PPP Loan&amp;#8221;), pursuant to the Paycheck Protection&#13;Program (the &amp;#8220;PPP&amp;#8221;), established pursuant to the recently enacted Coronavirus Aid, Relief, and Economic Security Act&#13;(the &amp;#8220;CARES Act&amp;#8221;) and administered by the U.S. Small Business Administration (&amp;#8220;SBA&amp;#8221;). We thereafter received&#13;proceeds of $632,220 under the April PPP Loan. The April PPP Loan application required Celsion to certify that there was economic&#13;uncertainty surrounding the Company and that, as such, the April PPP Loan was necessary to support our ongoing operations. Celsion&#13;made this certification in good faith after analyzing, among other things, its financial situation and access to alternative forms&#13;of capital, and believed that the Company satisfied all eligibility criteria for the April PPP Loan, and that our receipt of the&#13;April PPP Loan proceeds was consistent with the broad objectives of the PPP of the CARES Act. The certification given with respect&#13;to the April PPP Loan did not contain any objective criteria and was subject to interpretation. Considering subsequent guidance&#13;issued by the SBA in consultation with the U.S. Department of the Treasury at that time, out of an abundance of caution we returned&#13;the proceeds of the PPP Loan in full on May 13, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Shortly after the April PPP Loan was repaid,&#13;the SBA provided further guidance with respect to these certifications providing a safe harbor under which companies such as Celsion&#13;with PPP loans of less than $2 million will be deemed to have made these certifications in good faith. Therefore, as the Company&#13;continued to believe it qualifies for a loan under the PPP, it reapplied for and eventually received the new PPP Loan for $692,530&#13;on May 26, 2020 (the &amp;#8220;May PPP Loan&amp;#8221;). The May PPP Loan was guaranteed by the SBA and evidenced by a promissory note&#13;of the Company dated May 26, 2020 (the &amp;#8220;Note&amp;#8221;) in the principal amount of $692,530 payable to the lender. Pursuant&#13;to the terms of the Note, was payable in part or in full, at any time, without penalty. On June 22, 2020, as disclosed in the&#13;Company&amp;#8217;s Current Report on Form 8-K filed on the same date, the Company commenced an offering of 2,666,667 shares of its&#13;common stock which closed on June 24, 2020 (Note 11) and received net proceeds of approximately $9.1 million. In light of the&#13;proceeds received from this equity offering, the Company elected to repay the May PPP Loan in full (including interest accrued&#13;of $577) on June 24, 2020, terminating all obligations of the Company under the Note.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following is a schedule of future principal&#13;payments, net of unamortized debt discounts and amortized end of term charges, due on the Horizon Credit Agreement:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of June 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,583,336&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,000,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;416,664&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;2024 and thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Subtotal of future principal payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,000,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Unamortized debt issuance costs, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(3,530&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,996,470&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:ProceedsFromLoans contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">1324750</us-gaap:ProceedsFromLoans>
    <us-gaap:ProceedsFromLoans contextRef="From2019-01-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromLoans contextRef="From2020-04-22to2020-04-23_custom_AprilPaycheckProtectionProgramLoanMember_custom_SiliconValleyBankMember" unitRef="USD" decimals="0">632220</us-gaap:ProceedsFromLoans>
    <us-gaap:ProceedsFromLoans contextRef="From2020-05-25to2020-05-26_custom_MayPaycheckProtectionProgramLoanMember_custom_SiliconValleyBankMember" unitRef="USD" decimals="0">692530</us-gaap:ProceedsFromLoans>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-04-22to2020-04-23_custom_AprilPaycheckProtectionProgramLoanMember_custom_SiliconValleyBankMember">2020-05-13</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-05-25to2020-05-26_custom_MayPaycheckProtectionProgramLoanMember_custom_SiliconValleyBankMember">2020-06-24</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LongTermDebt contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">9996470</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsNet contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">3530</us-gaap:DeferredFinanceCostsNet>
    <CLSN:LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter contextRef="AsOf2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">416664</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">5000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 11. Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2018, the Company filed with the&#13;SEC a new $75 million shelf registration statement on Form S-3 (the &amp;#8220;2018 Shelf Registration Statement&amp;#8221;) (File No.&#13;333-227236) that allows the Company to issue any combination of common stock, preferred stock or warrants to purchase common stock&#13;or preferred stock. This shelf registration was declared effective on October 12, 2018 and will expire three years from that date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Aspire Purchase Agreements&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 31, 2018, the Company entered into&#13;a common stock purchase agreement (the &amp;#8220;2018 Aspire Purchase Agreement&amp;#8221;) with Aspire Capital Fund, LLC (&amp;#8220;Aspire&#13;Capital&amp;#8221;) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital&#13;was committed to purchase up to an aggregate of $15.0 million of shares of the Company&amp;#8217;s common stock over the 24-month term&#13;of the 2019 Aspire Purchase Agreement. During 2018, the Company sold and issued an aggregate of 0.1 million shares under the 2018&#13;Aspire Purchase Agreement, receiving approximately $0.2 million. During 2019, the Company sold and issued an aggregate of 3.3 million&#13;shares under the 2018 Aspire Purchase Agreement, receiving approximately $6.3 million. As a result of the Company and Aspire entering&#13;into a new purchase agreement on October 28, 2019 (the &amp;#8220;2019 Aspire Purchase Agreement&amp;#8221;) discussed in the next paragraph,&#13;the 2018 Aspire Purchase Agreement was terminated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2019 Aspire Purchase Agreement provided&#13;that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase&#13;up to an aggregate of $10.0 million of shares of the Company&amp;#8217;s common stock over the 24-month term of the 2019 Aspire Purchase&#13;Agreement. During 2019, the Company sold and issued an aggregate of 0.5 million shares under the 2019 Aspire Purchase Agreement,&#13;receiving approximately $0.7 million. During the first quarter of 2020 through March 5, 2020 when the Company delivered notice&#13;to Aspire terminating the 2019 Aspire Purchase Agreement, the Company sold 1.0 million shares of common stock under the Aspire&#13;Purchase Agreement, receiving approximately $1.6 million in additional gross proceeds.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Capital on Demand&lt;sup&gt;TM&lt;/sup&gt; Sales&#13;Agreement&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 4, 2018, the Company entered into&#13;the Capital on Demand Agreement with JonesTrading, pursuant to which the Company may offer and sell, from time to time, through&#13;JonesTrading shares of Common Stock having an aggregate offering price of up to $16.0 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Shares will be issued pursuant to Celsion&amp;#8217;s&#13;previously filed and effective Registration Statement on Form S-3 (File No. 333-227236), the base prospectus dated October 12,&#13;2018, filed as part of such Registration Statement, and the prospectus supplement dated December 4, 2018, filed by Celsion with&#13;the Securities and Exchange Commission. During 2019, the Company sold and issued an aggregate of 0.5 million shares under the Capital&#13;on Demand Agreement, receiving approximately $1.0 million in gross proceeds. During 2020 through June 30, 2020, the Company sold&#13;and issued an aggregate of 1.2 million shares under the Capital on Demand Agreement, receiving approximately $3.5 million in gross&#13;proceeds. The Company has not sold any shares under the Capital on Demand Agreement subsequent to June 30, 2020 through the date&#13;of this Quarterly Report on Form 10Q. As of June 30, 2020, the Company has approximately $11.5 million available under the Capital&#13;on Demand Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Registered Direct Offering&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 27, 2020, we entered into a Securities&#13;Purchase Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;) with several institutional investors, pursuant to which we agreed to&#13;issue and sell, in a registered direct offering (the &amp;#8220;February 2020 Offering&amp;#8221;), an aggregate of 4,571,428 shares (the&#13;&amp;#8220;Shares&amp;#8221;) of our common stock at an offering price of $1.05 per Share for gross proceeds of approximately $4.8 million&#13;before the deduction of the Placement Agent fees and offering expenses. The Shares were offered by the Company pursuant to a registration&#13;statement on Form S-3 (File No. 333-227236). The Purchase Agreement contains customary representations, warranties and agreements&#13;by the Company and customary conditions to closing. In a concurrent private placement (the &amp;#8220;Private Placement&amp;#8221;), the&#13;Company agreed to issue to the investors that participated in the Offering, for no additional consideration, warrants, to purchase&#13;up to 2,971,428 shares of Common Stock (the &amp;#8220;Original Warrants&amp;#8221;). The Original Warrants were initially exercisable&#13;six months following their date of issue and were set to expire on the five-year anniversary of such initial exercise date. The&#13;Original Warrants had an exercise price of $1.15 per share subject to adjustment as provided therein. On March 12, 2020, the Company&#13;entered into private exchange agreements (the &amp;#8220;Exchange Agreements&amp;#8221;) with holders of the Original Warrants. Pursuant&#13;to the Exchange Agreements, in return for a higher exercise price of $1.24 per share of Common Stock, the Company issued new warrants&#13;to the Investors to purchase up to 3,200,000 shares of Common Stock (the &amp;#8220;Exchange Warrants&amp;#8221;) in exchange for the Original&#13;Warrants. The Exchange Warrants, like the Original Warrants, are initially exercisable six months following their issuance (the&#13;&amp;#8220;Initial Exercise Date&amp;#8221;) and expire on the five-year anniversary of their Initial Exercise Date. Other than having&#13;a higher exercise price, different issue date, Initial Exercise Date and expiration date, the terms of the Exchange Warrants are&#13;identical to those of the Original Warrants. On July 31, 2020, the Company filed a Form S-3 Registration Statement to register&#13;the shares of Common Stock issuable under the Exchange Warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Underwritten Offering&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 22, 2020, the Company entered into&#13;an underwriting agreement (the &amp;#8220;Underwriting Agreement&amp;#8221;) with Oppenheimer &amp;#38; Co. Inc. (the &amp;#8220;Underwriter&amp;#8221;),&#13;relating to the issuance and sale (the &amp;#8220;Underwritten Offering&amp;#8221;) of 2,666,667 shares of the Company&amp;#8217;s common stock.&#13;Pursuant to the terms of the Underwriting Agreement, the Underwriter agreed to purchase the shares at a price of $3.4875 per share.&#13;The Underwriter offered the shares at a public offering price of $3.75 per share, reflecting an underwriting discount equal to&#13;$0.2625, or 7.0% of the public offering price. The net proceeds to the Company from the Underwritten Offering, after deducting&#13;the underwriting discount and estimated offering expenses payable by the Company, were approximately $9.1 million. The Underwritten&#13;Offering closed on June 24, 2020 and was made pursuant to the Company&amp;#8217;s effective shelf registration statement on Form S-3&#13;(File No. 333-227236) filed with the Securities and Exchange Commission on September 7, 2018, and declared effective on October&#13;12, 2018, including the base prospectus dated October 12, 2018 included therein and the related prospectus supplement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Underwriting Agreement contains customary&#13;representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the&#13;Company and the Underwriter including for liabilities under the Securities Act, other obligations of the parties, and termination&#13;provisions. Pursuant to the Underwriting Agreement, until December 31, 2020, the Underwriter shall have a right of first refusal&#13;to act as sole underwriter, initial purchaser, placement/selling agent, or arranger, as the case may be, on any new financing&#13;for the Company (excluding equipment lease financings, loans or grants from governmental authorities or in connection with government&#13;programs and financings relating to or sales of tax attributes) during such period. The Underwriter shall have the sole right&#13;to determine whether or not any other broker dealer shall have the right to participate in any such offering and the economic&#13;terms of any such participation. Pursuant to the Underwriting Agreement, subject to certain exceptions, the Company and certain&#13;of the Company&amp;#8217;s executive officers and directors have agreed that, without the prior written consent of the Underwriter&#13;and subject to certain negotiated exceptions, they will not, for a period of 60 days, in either case, following the date of the&#13;final prospectus supplement, sell or otherwise dispose of any of the Company&amp;#8217;s securities held by them.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharePrice contextRef="AsOf2020-06-22_custom_UnderwritingAgreementMember_custom_UnderwrittenOfferingMember" unitRef="USDPShares" decimals="INF">3.4875</us-gaap:SharePrice>
    <CLSN:UnderwritingDiscountPricePerShare contextRef="From2020-06-21to2020-06-22_custom_UnderwritingAgreementMember_custom_UnderwrittenOfferingMember" unitRef="USDPShares" decimals="INF">0.2625</CLSN:UnderwritingDiscountPricePerShare>
    <CLSN:PercentageOfUnderwritingDiscountOnPublicOfferingPrice contextRef="From2020-06-21to2020-06-22_custom_UnderwritingAgreementMember_custom_UnderwrittenOfferingMember" unitRef="Percentage" decimals="INF">0.007</CLSN:PercentageOfUnderwritingDiscountOnPublicOfferingPrice>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 12. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has long-term compensation plans&#13;that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation&#13;rights, other stock awards, and performance awards.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At the 2018 Annual Stockholders Meeting of&#13;the Company held on May 15, 2018, the Company&amp;#8217;s stockholders approved the Celsion Corporation 2018 Stock Incentive Plan (the&#13;&amp;#8220;2018 Plan&amp;#8221;). The 2018 Plan, as adopted, permits the granting of 2,700,000 shares of Celsion common stock as equity&#13;awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation&#13;rights, other stock awards, performance awards, or in any combination of the foregoing. At the 2019 Annual Stockholders Meeting&#13;of the Company held on May 14, 2019, stockholders approved an amendment to the 2018 Plan whereby the Company increased the number&#13;of shares of common stock available by 1,200,000 to a total of 3,900,000 under the 2018 Plan, as amended. Prior to the adoption&#13;of the 2018 Plan, the Company had maintained the Celsion Corporation 2007 Stock Incentive Plan (the &amp;#8220;2007 Plan&amp;#8221;). At&#13;the 2020 Annual Stockholders Meeting of the Company held on June 15, 2020, stockholders approved an amendment to the 2018 Plan,&#13;as previously amended, whereby the Company increased the number of shares of common stock available by 2,500,000 to a total of&#13;6,400,000 under the 2018 Plan, as amended.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the adoption of the 2018 Plan, the&#13;Company had maintained the Celsion Corporation 2007 Stock Incentive Plan (the &amp;#8220;2007 Plan&amp;#8221;). The 2007 Plan permitted&#13;the granting of 688,531 shares of Celsion common stock as equity awards in the form of incentive stock options, nonqualified stock&#13;options, restricted stock, restricted stock units, stock appreciation rights, phantom stock, performance awards, or in any combination&#13;of the foregoing. The 2018 Plan replaced the 2007 Plan although the 2007 Plan remains in effect for awards previously granted under&#13;the 2007 Plan. Under the terms of the 2018 Plan, any shares subject to an award under the 2007 Plan which are not delivered because&#13;of the expiration, forfeiture, termination or cash settlement of the award will become available for grant under the 2018 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has issued stock awards to employees&#13;and directors in the form of stock options and restricted stock. Options are generally granted with strike prices equal to the&#13;fair market value of a share of Celsion common stock on the date of grant. Incentive stock options may be granted to purchase shares&#13;of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided&#13;that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock&#13;of Celsion must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive&#13;stock options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Option and restricted stock awards vest upon&#13;terms determined by the Compensation Committee of the Board of Directors and are subject to accelerated vesting in the event of&#13;a change of control or certain terminations of employment. The Company issues new shares to satisfy its obligations from the exercise&#13;of options or the grant of restricted stock awards.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 19, 2019, the Compensation Committee&#13;of the Board of Directors approved the grant of (i) inducement stock options (the &amp;#8220;Inducement Option Grants&amp;#8221;) to purchase&#13;a total of 140,004 shares of Celsion common stock, and (ii) inducement restricted stock awards (the &amp;#8220;Inducement Stock Grants&amp;#8221;)&#13;totalling 13,000 shares of Celsion common stock to two new employees collectively. Each award has a grant date of the date of grant.&#13;Each Inducement Option Grant has an exercise price per share equal to $2.18 which represents the closing price of Celsion&amp;#8217;s&#13;common stock as reported by the Nasdaq Capital Market on the date of grant. Each Inducement Option Grant will vest over three years,&#13;with one-third vesting on the one-year anniversary of the employee&amp;#8217;s first day of employment with the Company and one-third&#13;vesting on the second and third anniversaries thereafter, subject to the new employee&amp;#8217;s continued service relationship with&#13;the Company on each such date. Each Inducement Option Grant has a ten-year term and is subject to the terms and conditions of the&#13;applicable stock option agreement. Each Inducement Stock Grant will vest on the one-year anniversary of the employee&amp;#8217;s first&#13;day of employment with the Company and is subject to the new employee&amp;#8217;s continued service relationship with the Company through&#13;such date and is subject to the terms and conditions of the applicable restricted stock agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of stock option awards and restricted&#13;stock grants for the six-months ended June 30, 2020 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Restricted Stock Awards&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Non-vested&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Restricted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Stock&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Grant&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Terms of&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Equity&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Awards&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font-size: 10pt"&gt;Equity awards outstanding at January 1, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,332,142&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Equity awards granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;644,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;429,855&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Options exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(140,864&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested and issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(429,855&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Equity awards forfeited, cancelled or expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(110,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Equity awards outstanding at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,725,276&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Aggregate intrinsic value of outstanding equity awards at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,494,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,875&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Equity awards exercisable at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,194,777&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Aggregate intrinsic value of equity awards exercisable at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,733,421&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2020, there was a total of 6,510,174&#13;shares of Celsion common stock reserved for issuance under the 2018 Plan which were comprised of 4,594,022 shares of Celsion common&#13;stock subject to equity awards previously granted under the 2018 Plan and 2007 Plan and 1,916,152 shares of Celsion common stock&#13;available for future issuance under the 2018 Plan. As of June 30, 2020, there was a total of 140,004 shares of Celsion common stock&#13;subject to outstanding inducement awards.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Total compensation cost related to stock options&#13;and restricted stock awards amounted to $578,761 and $622,696 for the three-month periods ended June 30, 2020 and 2019, respectively.&#13;Of these amounts, $200,186 and $239,406 was charged to research and development during the three-month periods ended June 30, 2020&#13;and 2019, respectively, and $378,575 and $383,290 was charged to general and administrative expenses during the three-month periods&#13;ended June 30, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Total compensation cost related to stock options&#13;and restricted stock awards amounted to $1,030,726 and $1,313,842 for the six-month periods ended June 30, 2020 and 2019, respectively.&#13;Of these amounts, $378,122 and $479,794 was charged to research and development during the six-month periods ended June 30, 2020&#13;and 2019, respectively, and $652,604 and $834,048 was charged to general and administrative expenses during the six-month periods&#13;ended June 30, 2020 and 2019, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2020, there was $2.4 million&#13;of total unrecognized compensation cost related to non-vested stock-based compensation arrangements. That cost is expected to be&#13;recognized over a weighted-average period of 1.5 years. The weighted average grant date fair values of the stock options granted&#13;was $3.10 and $1.88 during the six-month periods ended June 30, 2020 and 2019, respectively. In connection with the Company&amp;#8217;s&#13;annual 2019 bonus program, the Company issued 429,855 shares of common stock from the 2018 Stock Incentive Plan in lieu of paying&#13;cash for 50% of the annual bonus awards. These amounts were fully accrued for in the consolidated financial statements for the&#13;year ended December 31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During 2020, the Company received gross proceeds&#13;of $371,895 from the issuance of 140,864 shares of common stock upon exercise of stock option awards under the 2018 Plan. No options&#13;were exercised in 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair values of stock options granted were&#13;estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for&#13;use in estimating the fair value of traded options, which have different characteristics from Celsion&amp;#8217;s stock options. The&#13;model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following&#13;assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Six Months Ended June 30, &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.71% to 1.33 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.42%-2.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;100.4% to 104.2 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;101.3%-106.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected life (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8.5 to 10.0 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.5 to 9.3 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Expected volatilities utilized in the model&#13;are based on historical volatility of the Company&amp;#8217;s stock price. The risk-free interest rate is derived from values assigned&#13;to U.S. Treasury bonds with terms that approximate the expected option lives in effect at the time of grant.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <CLSN:SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of stock option awards and restricted&#13;stock grants for the six-months ended June 30, 2020 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Restricted Stock Awards&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Non-vested&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Restricted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Stock&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Grant&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Terms of&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Equity&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Awards&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 40%"&gt;&lt;font style="font-size: 10pt"&gt;Equity awards outstanding at January 1, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,332,142&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Equity awards granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;644,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;429,855&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Options exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(140,864&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested and issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(429,855&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Equity awards forfeited, cancelled or expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(110,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Equity awards outstanding at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,725,276&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Aggregate intrinsic value of outstanding equity awards at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,494,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,875&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Equity awards exercisable at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,194,777&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Aggregate intrinsic value of equity awards exercisable at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,733,421&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</CLSN:SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company used the following assumptions&#13;for determining the fair value of options granted under the Black-Scholes option pricing model:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Six Months Ended June 30, &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.71% to 1.33 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.42%-2.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;100.4% to 104.2 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;101.3%-106.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected life (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8.5 to 10.0 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.5 to 9.3 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">371895</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2019-01-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember_custom_TwoThousandAndEighteenPlanMember" unitRef="USD" decimals="0">371895</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">140864</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">140864</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2019-01-01to2019-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember_custom_TwoThousandAndEighteenPlanMember" unitRef="Shares" decimals="INF">140864</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">140864</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <CLSN:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.64</CLSN:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2020-01-01to2020-06-30" unitRef="Percentage" decimals="INF">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2019-01-01to2019-06-30" unitRef="Percentage" decimals="INF">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2020-01-01to2020-06-30" unitRef="Percentage" decimals="INF">0.0133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2019-01-01to2019-06-30" unitRef="Percentage" decimals="INF">0.0265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-01to2019-06-30_srt_MinimumMember">P7Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-01to2019-06-30_srt_MaximumMember">P9Y3M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-01to2020-06-30_srt_MinimumMember">P8Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-01to2020-06-30_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <CLSN:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter contextRef="AsOf2020-06-30_us-gaap_NoncompeteAgreementsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="From2020-05-25to2020-05-26_custom_MayPaycheckProtectionProgramLoanMember_custom_SiliconValleyBankMember" unitRef="USD" decimals="0">577</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember" unitRef="Shares" xsi:nil="true" />
    <CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockMember" unitRef="USDPShares" xsi:nil="true" />
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-06-30">Celsion CORP</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-06-30">0000749647</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2020-01-01to2020-06-30">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-06-30">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-08-13" unitRef="Shares" decimals="INF">33232380</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-06-30">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">22653760</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">6875273</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccruedInvestmentIncomeReceivable contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">7866</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:AccruedInvestmentIncomeReceivable contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">21369</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:GrantsReceivableCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">1342566</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1352670</us-gaap:GrantsReceivableCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">26796060</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">16235198</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">339200</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">405363</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1819324</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">15736491</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">15736491</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">1976101</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1976101</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">1244308</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1431640</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-01-02" unitRef="USD" decimals="0">400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-06-30_us-gaap_AccountingStandardsUpdate201602Member" unitRef="USD" decimals="0">1400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">403482</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">333274</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">19587700</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">21637806</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">46722960</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">38278367</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">2402142</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">2862949</us-gaap:AccountsPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">4385915</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1840228</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">410005</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">387733</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">9205745</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">7894457</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">5610555</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">7963449</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">933219</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1143717</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">750000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1000000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">22514798</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">23719332</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockValue contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">332297</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">232562</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">324869780</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">304885663</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">7866</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">42778</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityBeforeTreasuryStock contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">24293350</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:StockholdersEquityBeforeTreasuryStock contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">14644223</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:TreasuryStockValue contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">85188</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">85188</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">24208162</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">188322</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">294393313</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_TreasuryStockMember" unitRef="USD" decimals="0">-85188</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">29872</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-273665247</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">14559035</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">232562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">304885663</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember" unitRef="USD" decimals="0">-85188</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">42778</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-290516780</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">18831711</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">20861072</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">21396602</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">332297</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">210026</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">324869780</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">300549511</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" decimals="0">-85188</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" decimals="0">-85188</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">7866</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">94576</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-300916593</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-281937214</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">292574</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">311570995</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" decimals="0">-85188</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">3813</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-295573658</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">196624</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">297231041</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_TreasuryStockMember" unitRef="USD" decimals="0">-85188</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">86824</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-276032699</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">16208536</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">46722960</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">38278367</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-06-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-06-30" unitRef="Shares" decimals="INF">100000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">100000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-06-30" unitRef="Shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-06-30" unitRef="Shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-06-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-06-30" unitRef="Shares" decimals="INF">112500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">112500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-06-30" unitRef="Shares" decimals="INF">33229714</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">23256152</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-06-30" unitRef="Shares" decimals="INF">33229380</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">23255818</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockShares contextRef="AsOf2020-06-30" unitRef="Shares" decimals="INF">334</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">334</us-gaap:TreasuryStockShares>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">6042910</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">6325733</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">2990861</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">3558074</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">3740042</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">4354548</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">1901136</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">2136684</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">9782952</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">10680281</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">4891997</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">5694758</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-9532952</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">-10430281</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">-4766997</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-5569758</us-gaap:OperatingIncomeLoss>
    <CLSN:GainLossFromChangeInEarnoutMilestoneLiability contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-297570</CLSN:GainLossFromChangeInEarnoutMilestoneLiability>
    <CLSN:GainLossFromChangeInEarnoutMilestoneLiability contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">3002939</CLSN:GainLossFromChangeInEarnoutMilestoneLiability>
    <CLSN:GainLossFromChangeInEarnoutMilestoneLiability contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">-256296</CLSN:GainLossFromChangeInEarnoutMilestoneLiability>
    <CLSN:GainLossFromChangeInEarnoutMilestoneLiability contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-127061</CLSN:GainLossFromChangeInEarnoutMilestoneLiability>
    <CLSN:FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <CLSN:FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">-400000</CLSN:FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments>
    <CLSN:FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments contextRef="From2020-04-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <CLSN:FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments contextRef="From2019-04-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestAndDebtExpense contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">679967</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">700195</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">340602</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">349448</us-gaap:InterestAndDebtExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">1407</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">-2823</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2020-04-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-2850</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-866861</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">2158314</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">-575938</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-334757</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-10399813</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">-8271967</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-10399813</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-8271967</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">-5342935</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-5904515</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-04-01to2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-04-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-5342935</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-5904515</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-06-30" unitRef="USDPShares" decimals="INF">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-06-30" unitRef="USDPShares" decimals="INF">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-04-01to2020-06-30" unitRef="USDPShares" decimals="INF">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-04-01to2019-06-30" unitRef="USDPShares" decimals="INF">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-06-30" unitRef="Shares" decimals="INF">27830573</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-06-30" unitRef="Shares" decimals="INF">19713449</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-04-01to2020-06-30" unitRef="Shares" decimals="INF">29887329</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-04-01to2019-06-30" unitRef="Shares" decimals="INF">20605762</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-46097</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">-10350</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">-2865</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-969</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">11185</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">75054</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">6918</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">8721</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-34912</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">64704</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">4053</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">7752</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-10434725</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">-8207263</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">-5338882</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-5896763</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">378990</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">362027</us-gaap:DepreciationDepletionAndAmortization>
    <CLSN:GainLossFromValuationOfEarnoutMilestoneLiability contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-297570</CLSN:GainLossFromValuationOfEarnoutMilestoneLiability>
    <CLSN:GainLossFromValuationOfEarnoutMilestoneLiability contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">3002939</CLSN:GainLossFromValuationOfEarnoutMilestoneLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">250000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">250000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">1030726</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">1308492</us-gaap:ShareBasedCompensation>
    <CLSN:SharesIssuedInExchangeForServices contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <CLSN:SharesIssuedInExchangeForServices contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">5350</CLSN:SharesIssuedInExchangeForServices>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">1819324</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <CLSN:AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">192793</CLSN:AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable>
    <CLSN:AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">191724</CLSN:AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable>
    <us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-13503</us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable>
    <us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">-2636</us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">60104</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">931654</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-946265</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">24460</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-7923276</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">-10161871</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">9940894</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">13279686</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">15100000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">11900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">11837</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">262728</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">5147269</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">-1642414</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForLoans contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">1324750</us-gaap:PaymentsForLoans>
    <us-gaap:PaymentsForLoans contextRef="From2019-01-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">18554494</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">4464060</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">15778487</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">-7340225</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">22653760</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">6875273</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">6013318</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">13353543</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">487174</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">508471</us-gaap:InterestPaidNet>
    <us-gaap:OperatingLeasePayments contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">261190</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">261190</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">130595</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">130595</us-gaap:OperatingLeasePayments>
    <CLSN:FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <CLSN:FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">400000</CLSN:FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments>
    <CLSN:RightOfUseAssetsObtainedInExchangeForLease contextRef="From2020-01-01to2020-06-30" unitRef="USD" xsi:nil="true" />
    <CLSN:RightOfUseAssetsObtainedInExchangeForLease contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">1797561</CLSN:RightOfUseAssetsObtainedInExchangeForLease>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-34912</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">64704</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-01-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-01-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-01-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-01-01to2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-01-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-01-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-34912</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-01-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">64704</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-01-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-01-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">4053</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">7752</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-04-01to2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-04-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">4053</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-04-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-04-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">7752</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">18831834</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_TreasuryStockMember" unitRef="Shares" decimals="INF">334</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">23255818</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember" unitRef="Shares" decimals="INF">334</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">33229380</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">21002295</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember" unitRef="Shares" decimals="INF">334</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-06-30_us-gaap_TreasuryStockMember" unitRef="Shares" decimals="INF">334</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">29257101</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_TreasuryStockMember" unitRef="Shares" decimals="INF">334</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">19662020</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_TreasuryStockMember" unitRef="Shares" decimals="INF">334</us-gaap:SharesOutstanding>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">18182599</CLSN:SaleOfEquityThroughEquityFinancingFacilities>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">4464060</CLSN:SaleOfEquityThroughEquityFinancingFacilities>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">94027</CLSN:SaleOfEquityThroughEquityFinancingFacilities>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-01-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">21599</CLSN:SaleOfEquityThroughEquityFinancingFacilities>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2020-01-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">18088572</CLSN:SaleOfEquityThroughEquityFinancingFacilities>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-01-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4442461</CLSN:SaleOfEquityThroughEquityFinancingFacilities>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2020-01-01to2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-01-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2020-01-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-01-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2020-01-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-01-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">2709176</CLSN:SaleOfEquityThroughEquityFinancingFacilities>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">13378</CLSN:SaleOfEquityThroughEquityFinancingFacilities>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2695798</CLSN:SaleOfEquityThroughEquityFinancingFacilities>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-04-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-04-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <CLSN:SaleOfEquityThroughEquityFinancingFacilities contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <CLSN:SaleOfEquityThroughEquityFinancingFacilitiesShares contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">9402843</CLSN:SaleOfEquityThroughEquityFinancingFacilitiesShares>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilitiesShares contextRef="From2019-01-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2159961</CLSN:SaleOfEquityThroughEquityFinancingFacilitiesShares>
    <CLSN:SaleOfEquityThroughEquityFinancingFacilitiesShares contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1337775</CLSN:SaleOfEquityThroughEquityFinancingFacilitiesShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2019-01-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">1030726</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">1308492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1030726</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1308492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-01-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-01-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">578761</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">617347</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">578761</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">617347</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">5350</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">105</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5245</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">5349</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">105</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5325</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-04-01to2019-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-04-01to2019-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2019-01-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">10500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">10500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">371895</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1409</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">370486</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">371895</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1409</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">370486</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-04-01to2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-04-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <CLSN:EarnoutMilestoneLiabilityDisclosureTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 13. Earn-out Milestone Liability&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the Amended Asset Purchase Agreement&#13;entered by and between Company and EGWU, Inc in March 2019, payment of the earnout milestone liability related to the Ovarian Cancer&#13;Indication of $12.4 million was modified. The Company has the option to make a $7.0 million payment within 10 business days of&#13;achieving the milestone; or make a payment of $12.4 million in cash, common stock of the Company, or a combination of either, within&#13;one year of achieving the milestone.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2020, March 31, 2020, and December&#13;31, 2019, the Company fair valued the earn-out milestone liability at $6.0 million, $5.8 million and $5.7 million, respectively&#13;and recognized a non-cash charge of $0.2 and $0.3 million for the three-month and six-month periods ended June 30, 2020, respectively.&#13;In assessing the earnout milestone liability at June 30, 2020 and March 31, 2020, the Company fair valued each of the two payment&#13;options per the Amended Asset Purchase Agreement and weighted them at 80% and 20% probability for the $7.0 million and the $12.4&#13;million payments, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2019, March 31, 2019, and December&#13;31, 2018, the Company fair valued the earn-out milestone liability at $13.1 million, $5.8 million and $8.9 million, respectively&#13;and recognized a non-cash charge of $0.1 million and a non-cash benefit of $3.0 million during the three-month and six-month periods&#13;ended June 30, 2019, respectively. In assessing the earnout milestone liability at June 30, 2019 and March 31, 2019, the Company&#13;fair valued each of the two payment options per the Amended Asset Purchase Agreement and weighted them at 80% and 20% probability&#13;for the $7.0 million and the $12.4 million payments, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a summary of the changes in&#13;the earn-out milestone liability for the six-month period ended June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;Balance at January 1, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,717,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Non-cash loss from the change in fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(297,570&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Balance at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(6,015,279&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a schedule of the Company&amp;#8217;s&#13;risk-adjustment assessment of each milestone:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;Date&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Risk-adjustment Assessment &lt;br /&gt;&#13;of Achieving each Milestone&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Discount Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Estimated Time &lt;br /&gt;&#13;to Achieve&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 47%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;0.54 to 1.54 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;1.04 to 2.04 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;1.12 to 2.12 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;0.75 to 1.75 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;1.00 to 2.00 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;1.25 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</CLSN:EarnoutMilestoneLiabilityDisclosureTextBlock>
    <CLSN:WarrantsTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 14. Warrants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Common Stock Warrants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following is a summary of all warrant activity&#13;for the six months ended June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number of Warrants&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Issued&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;626,098&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.87&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrants issued during the six months ended June 30, 2020 (see Note 11)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrants outstanding at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,826,098&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.34&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Aggregate intrinsic value of outstanding warrants at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,096,322&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Schedule of weighted average exercise price and remaining contractual terms at June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Warrants provided to EGWU, Inc. (Note 13)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;All other warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Number of warrants issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,626,098&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Weighted average exercise prise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Weighted average contractual terms remaining&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;No expiration&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.1 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</CLSN:WarrantsTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 15. Leases&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains a lease, as amended,&#13;for its 10,870 square foot premises located in Lawrenceville, New Jersey which is currently set to expire September 1, 2023. Also,&#13;the Company maintains a lease for an 11,500 square foot premises located in Huntsville Alabama, which is currently set to expire&#13;in January 2023.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We adopted ASC Topic 842 on January 1, 2019&#13;using the modified retrospective transition method for all lease arrangements at the beginning of the period of adoption. Results&#13;for reporting periods beginning January 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and continue&#13;to be reported in accordance with our historic accounting under Topic 840, Leases. The standard had a material impact on our Condensed&#13;Consolidated Balance Sheet but had no impact on our condensed consolidated net earnings and cash flows. The most significant impact&#13;of adopting ASC Topic 842 was the recognition of the right-of-use (ROU) asset and lease liabilities for operating leases, which&#13;are presented in the following three-line items on the Consolidated Condensed Balance Sheet: (i) operating lease right-of-use asset;&#13;(ii) current operating lease liabilities; and (iii) operating lease liabilities. Therefore, on date of adoption of ASC Topic 842,&#13;the Company recognized a ROU asset of $1.4 million, operating lease liabilities, current and non-current collectively, of $1.5&#13;million and reduced other liabilities by approximately $0.1 million. We elected the package of practical expedients for leases&#13;that commenced before the effective date of ASC Topic 842 whereby we elected to not reassess the following: (i) whether any expired&#13;or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct&#13;costs for any existing leases. In addition, we have lease agreements with lease and non-lease components, and we have elected the&#13;practical expedient for all underlying asset classes and account for them as a single lease component. We have no finance leases.&#13;We determine if an arrangement is a lease at inception. We have operating leases for office space and research and development&#13;facilities. Neither of our leases include options to renew; however, one contains an option for early termination. We considered&#13;the option of early termination in measurement of right-of-use assets and lease liabilities, and we determined it is not reasonably&#13;certain to be terminated. In connection with the 2&lt;sup&gt;nd&lt;/sup&gt; Lease Amendment for the New Jersey office lease in January 2019,&#13;the Company considered this as one modified lease and not as two separate leases. Therefore, in January 2019, the Company determined&#13;this lease was an operating lease and remeasured the ROU asset and lease liability. Therefore, the Company increased the ROU asset&#13;and operating lease liabilities by $0.4 million to $1.8 million and $1.9 million, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following is a table of the lease payments&#13;and maturity of our operating lease liabilities as of June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;year ending&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;Remainder of 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;263,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;530,734&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;535,579&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;233,116&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;2024 and thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Subtotal future lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,563,155&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Less imputed interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(219,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total lease liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,343,224&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average remaining life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.2 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average discount rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the three-month and six-month periods&#13;ending June 30, 2020, operating lease expense was $130,595 and $261,190, respectively and cash paid for operating leases included&#13;in operating cash flows was $131,452 and $262,084, respectively. For the three-month and six-month periods ending June 30, 2019,&#13;operating lease expense was $130,595 and $261,190, respectively and cash paid for operating leases included in operating cash&#13;flows was $118,415 and 224,585, respectively.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <CLSN:LicensingTransactionTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 16. Technology Development and Licensing&#13;Agreements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 7, 2012, the Company entered into a&#13;long-term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun) for the production of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt;&#13;in the China territory. In accordance with the terms of the agreement, Hisun will be responsible for providing all of the technical&#13;and regulatory support services, including the costs of all technical transfer, registration and bioequivalence studies, technical&#13;transfer costs, Celsion consultative support costs and the purchase of any necessary equipment and additional facility costs necessary&#13;to support capacity requirements for the manufacture of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt;. Celsion will repay Hisun for the aggregate&#13;amount of these development costs and fees commencing on the successful completion of three registration batches of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt;.&#13;Hisun is also obligated to certain performance requirements under the agreement. The agreement will initially be limited to a percentage&#13;of the production requirements of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt; in the China territory with Hisun retaining an option for additional&#13;global supply after local regulatory approval in the China territory. In addition, Hisun will collaborate with Celsion around the&#13;regulatory approval activities for ThermoDox&lt;sup&gt;&amp;#174; &lt;/sup&gt;with the China State Food and Drug Administration (CHINA FDA). During&#13;the first quarter of 2015, Hisun completed the successful manufacture of three registration batches of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt;.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 18, 2013, we entered into a technology&#13;development contract with Hisun, pursuant to which Hisun paid us a non-refundable research and development fee of $5 million to&#13;support our development of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt; in mainland China, Hong Kong and Macau (the China territory). Following our&#13;announcement on January 31, 2013 that the HEAT study failed to meet its primary endpoint, Celsion and Hisun have agreed that the&#13;Technology Development Contract entered into on January 18, 2013 will remain in effect while the parties continue to collaborate&#13;and are evaluating the next steps in relation to ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt; , which include the sub-group analysis of patients&#13;in the Phase III HEAT Study for the hepatocellular carcinoma clinical indication and other activities to further the development&#13;of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt; for the Greater China market. The $5.0 million received as a non-refundable payment from Hisun in&#13;the first quarter 2013 has been recorded to deferred revenue and will continue to be amortized over the 10 -year term of the agreement,&#13;until such time as the parties find a mutually acceptable path forward on the development of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt; based on&#13;findings of the ongoing post-study analysis of the HEAT Study data.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 19, 2013, the Company and Hisun entered&#13;into a Memorandum of Understanding to pursue ongoing cooperation for the continued clinical development of ThermoDox &lt;sup&gt;&amp;#174;&lt;/sup&gt;&#13;as well as the technology transfer relating to the commercial manufacture of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt; for the China territory.&#13;This expanded level of cooperation includes development of the next generation liposomal formulation with the goal of creating&#13;safer, more efficacious versions of marketed cancer chemotherapeutics.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Among the key provisions of the Celsion-Hisun&#13;Memorandum of Understanding are:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9679;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Hisun will provide the Company with internal resources necessary to complete the technology transfer of the Company&amp;#8217;s proprietary manufacturing process and the production of registration batches for the China territory;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9679;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Hisun will coordinate with the Company around the clinical and regulatory approval activities for ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt; as well as other liposomal formations with the CHINA FDA; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9679;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Hisun will be granted a right of first offer for a commercial license to ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt; for the sale and distribution of ThermoDox&lt;sup&gt;&amp;#174; &lt;/sup&gt;in the China territory.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 8, 2016, we signed a Technology Transfer,&#13;Manufacturing and Commercial Supply Agreement (&amp;#8220;GEN-1 Agreement&amp;#8221;) with Hisun to pursue an expanded partnership for&#13;the technology transfer relating to the clinical and commercial manufacture and supply of GEN-1, Celsion&amp;#8217;s proprietary gene&#13;mediated, IL- 12 immunotherapy, for the greater China territory, with the option to expand into other countries in the rest of&#13;the world after all necessary regulatory approvals are in effect. The GEN- 1 Agreement will help to support supply for both ongoing&#13;and planned clinical studies in the U.S., and for potential future studies of GEN- 1 in China. GEN- 1 is currently being evaluated&#13;by Celsion in first line ovarian cancer patients.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Key provisions of the GEN-1 Agreement are as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.9pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9679;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;the GEN-1 Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with the Company&amp;#8217;s current suppliers;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9679;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;once approved, the cost structure for GEN-1 will support rapid market adoption and significant gross margins across global markets;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9679;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Celsion will provide Hisun a certain percentage of China&amp;#8217;s commercial unit demand, and separately of global commercial unit demand, subject to regulatory approval;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9679;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Hisun and Celsion will commence technology transfer activities relating to the manufacture of GEN-1, including all studies required by CHINA FDA for site approval; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9679;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Hisun will collaborate with Celsion around the regulatory approval activities for GEN-1 with the CHINA FDA. A local China partner affords Celsion access to accelerated CHINA FDA review and potential regulatory exclusivity for the approved indication.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated the Hisun arrangement&#13;in accordance with ASC 606 and determined that its performance obligations under the agreement include the non-exclusive, royalty-free&#13;license, research and development services to be provided by the Company, and its obligation to serve on a joint committee. The&#13;Company concluded that the license was not distinct since its value is closely tied to the ongoing research and development activities.&#13;As such, the license and the research and development services are bundled as a single performance obligation. Since the provision&#13;of the license and research and development services are considered a single performance obligation, the $5,000,000 upfront payment&#13;is being recognized as revenue ratably through 2022.&lt;/p&gt;</CLSN:LicensingTransactionTextBlock>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 17. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 20, 2019, a purported stockholder&#13;of the Company filed a derivative and putative class action lawsuit against the Company and certain officers and directors (the&#13;&amp;#8220;Shareholder Action&amp;#8221;). The Company is a defendant in this derivative and putative class action lawsuit in the Superior&#13;Court of New Jersey, Chancery Division, filed by a shareholder against the Company (as both a class action defendant and nominal&#13;defendant), and certain of its officers and directors (the &amp;#8220;Individual Defendants&amp;#8221;), with the caption O&amp;#8217;Connor&#13;v. Braun et al., Docket No. MER-C-000068-19 (the &amp;#8220;Shareholder Action&amp;#8221;). The Shareholder Action alleges breaches of&#13;the defendants&amp;#8217; fiduciary duties based on allegations that the defendants omitted or made improper statements when seeking&#13;shareholder approval of the 2018 Stock Incentive Plan. The Shareholder Action seeks, among other things, any damages sustained&#13;by the Company as a result of the defendants&amp;#8217; alleged wrongdoing, a declaratory judgment against all defendants invalidating&#13;the 2018 Stock Incentive Plan and declaring any awards made under the Plan invalid, rescinded, and subject to disgorgement, an&#13;order disgorging the equity awards granted to the Individual Defendants under the 2018 Stock Incentive Plan, and attorneys&amp;#8217;&#13;fees and costs. Without admitting the validity of any of the claims asserted in the Shareholder Action, or any liability with respect&#13;thereto, and expressly denying all allegations of wrongdoing, fault, liability, or damage against the Company and the Individual&#13;Defendants arising out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Shareholder&#13;Action, the Company and the Individual Defendants have concluded that it is desirable that the claims be settled on the terms and&#13;subject to the conditions set forth in the Settlement Agreement. The Company and the Individual Defendants are entering into the&#13;Settlement Agreement for settlement purposes only and solely to avoid the cost and disruption of further litigation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 24, 2020, the Company, the Individual&#13;Defendants, and the plaintiff (the &amp;#8220;Parties&amp;#8221;) entered into a Settlement Agreement and Release (the &amp;#8220;Settlement&#13;Agreement&amp;#8221;), which memorializes the terms of the Parties&amp;#8217; settlement of the Shareholder Action (the &amp;#8220;Settlement&amp;#8221;).&#13;The Settlement calls for repricing of certain stock options and payment of plaintiff legal fees of $187,500. On July 24, 2020,&#13;the Court issued an order approving the Parties&amp;#8217; proposed form of notice to shareholders regarding the Settlement. A hearing&#13;to determine whether the Court should issue a final order approving the proposed Settlement has been scheduled for September 8,&#13;2020. On August 3, 2020, the Company filed notice of the Settlement Agreement on Form 8-K as filed with the SEC.&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 18. Subsequent Events&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 13, 2020, the Company announced that&#13;it has received a recommendation from the DMC to consider stopping the global Phase III OPTIMA Study of ThermoDox&lt;sup&gt;&amp;#174;&lt;/sup&gt;&#13;in combination with RFA for the treatment of HCC, or primary liver cancer. The recommendation was made following the second pre-planned&#13;interim safety and efficacy analysis by the DMC on July 9, 2020. The DMC analysis found that the pre-specified boundary for stopping&#13;the trial for futility of 0.900 was crossed with an actual value of 0.903. The Company intends to follow the advice of the DMC&#13;and will consider its options either to stop the study or continue to follow patients after a thorough review of the data, and&#13;an evaluation of the probability of success. Timing for this decision is made less urgent by the fact that the OPTIMA Study has&#13;been fully enrolled since August 2018 and that the vast majority of the trial expenses have already been incurred. On August 4,&#13;2020, the Company issued a press release announcing it will continue following patients for overall survival (&amp;#8220;OS&amp;#8221;),&#13;noting that the unexpected and marginally crossed futility boundary, suggested by the Kaplan-Meier analysis at the second interim&#13;analysis on July 9, 2020, may be associated with a data maturity issue.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <CLSN:ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a summary of the changes in&#13;the earn-out milestone liability for the six-month period ended June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;Balance at January 1, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,717,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Non-cash loss from the change in fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(297,570&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Balance at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(6,015,279&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</CLSN:ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock>
    <CLSN:ScheduleOfRiskadjustmentAssessmentTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a schedule of the Company&amp;#8217;s&#13;risk-adjustment assessment of each milestone:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;Date&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Risk-adjustment Assessment &lt;br /&gt;&#13;of Achieving each Milestone&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Discount Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Estimated Time &lt;br /&gt;&#13;to Achieve&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 47%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;0.54 to 1.54 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;1.04 to 2.04 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;1.12 to 2.12 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;0.75 to 1.75 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;1.00 to 2.00 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;1.25 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</CLSN:ScheduleOfRiskadjustmentAssessmentTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following is a summary of all warrant activity&#13;for the six months ended June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number of Warrants&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Issued&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;626,098&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.87&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrants issued during the six months ended June 30, 2020 (see Note 11)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrants outstanding at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,826,098&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.34&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Aggregate intrinsic value of outstanding warrants at June 30, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,096,322&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <CLSN:ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Schedule of weighted average exercise price and remaining contractual terms at June 30, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Warrants provided to EGWU, Inc. (Note 13)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;All other warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Number of warrants issued&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,626,098&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Weighted average exercise prise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Weighted average contractual terms remaining&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;No expiration&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.1 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</CLSN:ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following is a table of the lease payments&#13;and maturity of our operating lease liabilities as of June 30, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For the&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;year ending&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;Remainder of 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;263,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;530,734&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;535,579&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;233,116&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;2024 and thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Subtotal future lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,563,155&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Less imputed interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(219,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total lease liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,343,224&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average remaining life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.2 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average discount rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <CLSN:EarnoutMilestoneLiability1 contextRef="AsOf2020-06-30_custom_FairValueEarnoutMilestoneLiabilityMember" unitRef="USD" decimals="0">6000000</CLSN:EarnoutMilestoneLiability1>
    <CLSN:EarnoutMilestoneLiability1 contextRef="AsOf2019-12-31_custom_FairValueEarnoutMilestoneLiabilityMember" unitRef="USD" decimals="0">5700000</CLSN:EarnoutMilestoneLiability1>
    <CLSN:EarnoutMilestoneLiability1 contextRef="AsOf2019-06-30_custom_FairValueEarnoutMilestoneLiabilityMember" unitRef="USD" decimals="0">13100000</CLSN:EarnoutMilestoneLiability1>
    <CLSN:EarnoutMilestoneLiability1 contextRef="AsOf2018-12-31_custom_FairValueEarnoutMilestoneLiabilityMember" unitRef="USD" decimals="0">8900000</CLSN:EarnoutMilestoneLiability1>
    <CLSN:EarnoutMilestoneLiability1 contextRef="AsOf2020-03-31_custom_FairValueEarnoutMilestoneLiabilityMember" unitRef="USD" decimals="0">5800000</CLSN:EarnoutMilestoneLiability1>
    <CLSN:EarnoutMilestoneLiability1 contextRef="AsOf2019-03-31_custom_FairValueEarnoutMilestoneLiabilityMember" unitRef="USD" decimals="0">5800000</CLSN:EarnoutMilestoneLiability1>
    <CLSN:GainOnNoncashBenefit contextRef="From2020-01-01to2020-06-30_custom_FairValueEarnoutMilestoneLiabilityMember" unitRef="USD" decimals="0">300000</CLSN:GainOnNoncashBenefit>
    <CLSN:GainOnNoncashBenefit contextRef="From2019-01-01to2019-06-30_custom_FairValueEarnoutMilestoneLiabilityMember" unitRef="USD" decimals="0">3000000</CLSN:GainOnNoncashBenefit>
    <CLSN:GainOnNoncashBenefit contextRef="From2020-04-01to2020-06-30_custom_FairValueEarnoutMilestoneLiabilityMember" unitRef="USD" decimals="0">200000</CLSN:GainOnNoncashBenefit>
    <CLSN:GainOnNoncashBenefit contextRef="From2019-04-01to2019-06-30_custom_FairValueEarnoutMilestoneLiabilityMember" unitRef="USD" decimals="0">100000</CLSN:GainOnNoncashBenefit>
    <CLSN:RiskAdjustedAssessmentOfEachMilestone contextRef="AsOf2020-06-30_custom_FairValueEarnoutMilestoneLiabilityMember_custom_PaymentOptionOneMember" unitRef="Percentage" decimals="INF">0.80</CLSN:RiskAdjustedAssessmentOfEachMilestone>
    <CLSN:RiskAdjustedAssessmentOfEachMilestone contextRef="AsOf2019-06-30_custom_FairValueEarnoutMilestoneLiabilityMember_custom_PaymentOptionOneMember" unitRef="Percentage" decimals="INF">0.80</CLSN:RiskAdjustedAssessmentOfEachMilestone>
    <CLSN:RiskAdjustedAssessmentOfEachMilestone contextRef="AsOf2020-03-31_custom_FairValueEarnoutMilestoneLiabilityMember_custom_PaymentOptionTwoMember" unitRef="Percentage" decimals="INF">0.20</CLSN:RiskAdjustedAssessmentOfEachMilestone>
    <CLSN:RiskAdjustedAssessmentOfEachMilestone contextRef="AsOf2019-03-31_custom_FairValueEarnoutMilestoneLiabilityMember_custom_PaymentOptionTwoMember" unitRef="Percentage" decimals="INF">0.20</CLSN:RiskAdjustedAssessmentOfEachMilestone>
    <CLSN:GainLossFromChangeInFairValueOfEarnOutMilestoneLiability contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">-297570</CLSN:GainLossFromChangeInFairValueOfEarnOutMilestoneLiability>
    <CLSN:GainLossFromChangeInFairValueOfEarnOutMilestoneLiability contextRef="From2020-01-01to2020-06-30_custom_AmendedAssetPurchaseAgreementOptionPaymentOneMember" unitRef="USD" decimals="0">7000000</CLSN:GainLossFromChangeInFairValueOfEarnOutMilestoneLiability>
    <CLSN:GainLossFromChangeInFairValueOfEarnOutMilestoneLiability contextRef="From2019-01-01to2019-06-30_custom_AmendedAssetPurchaseAgreementOptionPaymentOneMember" unitRef="USD" decimals="0">7000000</CLSN:GainLossFromChangeInFairValueOfEarnOutMilestoneLiability>
    <CLSN:GainLossFromChangeInFairValueOfEarnOutMilestoneLiability contextRef="From2020-01-01to2020-03-31_custom_AmendedAssetPurchaseAgreementOptionPaymentTwoMember" unitRef="USD" decimals="0">12400000</CLSN:GainLossFromChangeInFairValueOfEarnOutMilestoneLiability>
    <CLSN:GainLossFromChangeInFairValueOfEarnOutMilestoneLiability contextRef="From2019-01-01to2019-03-31_custom_AmendedAssetPurchaseAgreementOptionPaymentTwoMember" unitRef="USD" decimals="0">12400000</CLSN:GainLossFromChangeInFairValueOfEarnOutMilestoneLiability>
    <CLSN:EarnoutMilestoneLiability contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">-6015279</CLSN:EarnoutMilestoneLiability>
    <CLSN:EarnoutMilestoneLiability contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-5717709</CLSN:EarnoutMilestoneLiability>
    <CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone contextRef="From2020-01-01to2020-06-30" unitRef="Percentage" decimals="INF">0.80</CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone>
    <CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">0.80</CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone>
    <CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone contextRef="From2019-01-01to2019-06-30" unitRef="Percentage" decimals="INF">0.80</CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone>
    <CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone contextRef="From2019-01-01to2019-12-31" unitRef="Percentage" decimals="INF">0.80</CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone>
    <CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone contextRef="From2020-01-01to2020-03-31" unitRef="Percentage" decimals="INF">0.80</CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone>
    <CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone contextRef="From2019-01-01to2019-03-31" unitRef="Percentage" decimals="INF">0.80</CLSN:RiskadjustmentAssessmentOfAchievingEachMilestone>
    <CLSN:DiscountRateOnMileStoneLiabilities contextRef="From2020-01-01to2020-06-30" unitRef="Percentage" decimals="INF">0.09</CLSN:DiscountRateOnMileStoneLiabilities>
    <CLSN:DiscountRateOnMileStoneLiabilities contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">0.09</CLSN:DiscountRateOnMileStoneLiabilities>
    <CLSN:DiscountRateOnMileStoneLiabilities contextRef="From2019-01-01to2019-06-30" unitRef="Percentage" decimals="INF">0.09</CLSN:DiscountRateOnMileStoneLiabilities>
    <CLSN:DiscountRateOnMileStoneLiabilities contextRef="From2019-01-01to2019-12-31" unitRef="Percentage" decimals="INF">0.09</CLSN:DiscountRateOnMileStoneLiabilities>
    <CLSN:DiscountRateOnMileStoneLiabilities contextRef="From2020-01-01to2020-03-31" unitRef="Percentage" decimals="INF">0.09</CLSN:DiscountRateOnMileStoneLiabilities>
    <CLSN:DiscountRateOnMileStoneLiabilities contextRef="From2019-01-01to2019-03-31" unitRef="Percentage" decimals="INF">0.09</CLSN:DiscountRateOnMileStoneLiabilities>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2018-01-01to2018-12-31">P1Y2M30D</CLSN:EstimatedTimeToAchieveMileStone>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2019-01-01to2019-12-31_srt_MinimumMember">P1Y1M13D</CLSN:EstimatedTimeToAchieveMileStone>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2019-01-01to2019-12-31_srt_MaximumMember">P2Y1M13D</CLSN:EstimatedTimeToAchieveMileStone>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2019-01-01to2019-03-31_srt_MinimumMember">P1Y</CLSN:EstimatedTimeToAchieveMileStone>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2019-01-01to2019-03-31_srt_MaximumMember">P2Y</CLSN:EstimatedTimeToAchieveMileStone>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2019-01-01to2019-06-30_srt_MinimumMember">P9M</CLSN:EstimatedTimeToAchieveMileStone>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2019-01-01to2019-06-30_srt_MaximumMember">P1Y9M0D</CLSN:EstimatedTimeToAchieveMileStone>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2020-01-01to2020-06-30_srt_MinimumMember">P0Y6M14D</CLSN:EstimatedTimeToAchieveMileStone>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2020-01-01to2020-06-30_srt_MaximumMember">P1Y6M14D</CLSN:EstimatedTimeToAchieveMileStone>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2020-01-01to2020-03-31_srt_MinimumMember">P1Y0M15D</CLSN:EstimatedTimeToAchieveMileStone>
    <CLSN:EstimatedTimeToAchieveMileStone contextRef="From2020-01-01to2020-03-31_srt_MaximumMember">P2Y0M15D</CLSN:EstimatedTimeToAchieveMileStone>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2020-06-30" unitRef="Shares" decimals="INF">3826098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">626098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2020-01-01to2020-06-30" unitRef="Shares" decimals="INF">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2020-01-01to2020-06-30_custom_EGWUIncMember" unitRef="Shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2020-01-01to2020-06-30_custom_AllOtherWarrantsMember" unitRef="Shares" decimals="INF">3626098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-06-30" unitRef="USDPShares" decimals="INF">1.34</CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">1.87</CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-06-30" unitRef="USDPShares" decimals="INF">1.24</CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
    <CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">9096322</CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue contextRef="From2020-01-01to2020-06-30_custom_EGWUIncMember" unitRef="USDPShares" decimals="INF">0.01</CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue>
    <CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue contextRef="From2020-01-01to2020-06-30_custom_AllOtherWarrantsMember" unitRef="USDPShares" decimals="INF">1.42</CLSN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2020-01-01to2020-06-30_custom_EGWUIncMember">P0Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2020-01-01to2020-06-30_custom_AllOtherWarrantsMember">P5Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:AreaOfLand contextRef="AsOf2020-06-30_custom_LawrencevilleNewJerseyMember" unitRef="Sqft" decimals="INF">10870</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="AsOf2020-06-30_custom_HuntsvilleAlabamaMember" unitRef="Sqft" decimals="INF">11500</us-gaap:AreaOfLand>
    <us-gaap:LeaseExpirationDate1 contextRef="From2020-01-01to2020-06-30_custom_LawrencevilleNewJerseyMember">2023-09-01</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1 contextRef="From2020-01-01to2020-06-30_custom_HuntsvilleAlabamaMember">2023-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">1343224</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-01-02" unitRef="USD" decimals="0">1900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-06-30_us-gaap_AccountingStandardsUpdate201602Member" unitRef="USD" decimals="0">1500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OtherLiabilities contextRef="AsOf2020-06-30_us-gaap_AccountingStandardsUpdate201602Member" unitRef="USD" decimals="0">100000</us-gaap:OtherLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="From2018-12-30to2019-01-02" unitRef="USD" decimals="0">1800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">262084</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="0">224858</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">131452</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">118415</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">263726</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">530734</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">535579</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">233116</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <CLSN:LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter contextRef="AsOf2020-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">1563155</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">219931</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-06-30">P3Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-06-30" unitRef="Percentage" decimals="INF">0.0998</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ProceedsFromLicenseFeesReceived contextRef="From2013-01-17to2013-01-18_custom_HisunMember" unitRef="USD" decimals="0">5000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:DeferredRevenue contextRef="AsOf2013-01-18_custom_HisunMember" unitRef="USD" decimals="0">5000000</us-gaap:DeferredRevenue>
    <CLSN:DeferredRevenueAmortizationPeriod contextRef="From2013-01-17to2013-01-18_custom_HisunMember">P10Y</CLSN:DeferredRevenueAmortizationPeriod>
    <CLSN:UpfrontPayment contextRef="AsOf2016-08-08_custom_HisunMember" unitRef="USD" decimals="0">5000000</CLSN:UpfrontPayment>
    <CLSN:StockIssuedInLieuOfCashBonusPayments contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">498632</CLSN:StockIssuedInLieuOfCashBonusPayments>
    <CLSN:StockIssuedInLieuOfCashBonusPayments contextRef="From2019-01-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <CLSN:IssuanceOfCommonStockInLieuOfCashBonus contextRef="From2020-01-01to2020-06-30" unitRef="USD" decimals="0">498632</CLSN:IssuanceOfCommonStockInLieuOfCashBonus>
    <CLSN:IssuanceOfCommonStockInLieuOfCashBonus contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4299</CLSN:IssuanceOfCommonStockInLieuOfCashBonus>
    <CLSN:IssuanceOfCommonStockInLieuOfCashBonus contextRef="From2020-01-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">494333</CLSN:IssuanceOfCommonStockInLieuOfCashBonus>
    <CLSN:IssuanceOfCommonStockInLieuOfCashBonus contextRef="From2020-01-01to2020-06-30_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <CLSN:IssuanceOfCommonStockInLieuOfCashBonus contextRef="From2020-01-01to2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <CLSN:IssuanceOfCommonStockInLieuOfCashBonus contextRef="From2020-01-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <CLSN:IssuanceOfCommonStockInLieuOfCashBonusShares contextRef="From2020-01-01to2020-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">429855</CLSN:IssuanceOfCommonStockInLieuOfCashBonusShares>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">4583336</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <CLSN:PaymentsForEarnoutMilestoneLiability contextRef="From2019-03-01to2019-03-31_custom_EGWUIncMember" unitRef="USD" decimals="0">12400000</CLSN:PaymentsForEarnoutMilestoneLiability>
    <CLSN:PaymentsForEarnoutMilestoneLiability contextRef="From2019-03-01to2019-03-31" unitRef="USD" decimals="0">7000000</CLSN:PaymentsForEarnoutMilestoneLiability>
    <CLSN:PaymentsForEarnoutMilestoneLiabilityInCash contextRef="From2019-03-01to2019-03-31" unitRef="USD" decimals="0">12400000</CLSN:PaymentsForEarnoutMilestoneLiabilityInCash>
    <us-gaap:LitigationSettlementExpense contextRef="From2020-04-22to2020-04-24" unitRef="USD" decimals="0">187500</us-gaap:LitigationSettlementExpense>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>clsn-20200630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CLSN %2D 20200630 10Q Q2 DFN.xfr; Date: 2020%2D08%2D14T04:09:48Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80060006 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaOEibP9z5Z86ekhvWB4bblqnywsXmNQOyzNw8Om8XUD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:CLSN="http://celsion.com/20200630" elementFormDefault="qualified" targetNamespace="http://celsion.com/20200630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://celsion.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
	  <link:definition>00000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/BusinessDescription" id="BusinessDescription">
	  <link:definition>00000008 - Disclosure - Business Description</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/BasisOfPresentation" id="BasisOfPresentation">
	  <link:definition>00000009 - Disclosure - Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/FinancialConditionAndBusinessPlan" id="FinancialConditionAndBusinessPlan">
	  <link:definition>00000010 - Disclosure - Financial Condition and Business Plan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/NewAccountingPronouncements" id="NewAccountingPronouncements">
	  <link:definition>00000011 - Disclosure - New Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
	  <link:definition>00000012 - Disclosure - Net Loss Per Common Share</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale" id="InvestmentInDebtSecuritiesAvailableForSale">
	  <link:definition>00000013 - Disclosure - Investment in Debt Securities Available for Sale</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000014 - Disclosure - Fair Value Measurements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000015 - Disclosure - Intangible Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/OtherAccruedLiabilities" id="OtherAccruedLiabilities">
	  <link:definition>00000016 - Disclosure - Other Accrued Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/NotesAndLoansPayable" id="NotesAndLoansPayable">
	  <link:definition>00000017 - Disclosure - Notes and Loans Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000018 - Disclosure - Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000019 - Disclosure - Stock-Based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Earn-outMilestoneLiability" id="Earn-outMilestoneLiability">
	  <link:definition>00000020 - Disclosure - Earn-out Milestone Liability</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Warrants" id="Warrants">
	  <link:definition>00000021 - Disclosure - Warrants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Leases" id="Leases">
	  <link:definition>00000022 - Disclosure - Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreements" id="TechnologyDevelopmentAndLicensingAgreements">
	  <link:definition>00000023 - Disclosure - Technology Development and Licensing Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000024 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000025 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleTables" id="InvestmentInDebtSecuritiesAvailableForSaleTables">
	  <link:definition>00000026 - Disclosure - Investment in Debt Securities Available for Sale (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>00000027 - Disclosure - Fair Value Measurements (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000028 - Disclosure - Intangible Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/OtherAccruedLiabilitiesTables" id="OtherAccruedLiabilitiesTables">
	  <link:definition>00000029 - Disclosure - Other Accrued Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/NotesAndLoansPayableTables" id="NotesAndLoansPayableTables">
	  <link:definition>00000030 - Disclosure - Notes and Loans Payable (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000031 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Earn-outMilestoneLiabilityTables" id="Earn-outMilestoneLiabilityTables">
	  <link:definition>00000032 - Disclosure - Earn-out Milestone Liability (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/WarrantsTables" id="WarrantsTables">
	  <link:definition>00000033 - Disclosure - Warrants (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000034 - Disclosure - Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/FinancialConditionAndBusinessPlanDetailsNarrative" id="FinancialConditionAndBusinessPlanDetailsNarrative">
	  <link:definition>00000035 - Disclosure - Financial Condition and Business Plan (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/NetLossPerCommonShareDetailsNarrative" id="NetLossPerCommonShareDetailsNarrative">
	  <link:definition>00000036 - Disclosure - Net Loss Per Common Share (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative" id="InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative">
	  <link:definition>00000037 - Disclosure - Investment in Debt Securities Available for Sale (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails" id="InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails">
	  <link:definition>00000038 - Disclosure - Investment in Debt Securities Available for Sale - Schedule of Cost, Fair Value and Maturities of Short Term Investments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails" id="InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails">
	  <link:definition>00000039 - Disclosure - Investment in Debt Securities Available for Sale - Summary of Investment Securities Gross Unrealized Gains (Losses) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails" id="InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails">
	  <link:definition>00000040 - Disclosure - Investment in Debt Securities Available for Sale - Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
	  <link:definition>00000041 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000042 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails" id="IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails">
	  <link:definition>00000043 - Disclosure - Intangible Assets - Schedule of Future Amortization Amounts During the Remaining Life (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails" id="IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails">
	  <link:definition>00000044 - Disclosure - Intangible Assets - Schedule of Fair Value of Assets Acquired (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails" id="OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails">
	  <link:definition>00000045 - Disclosure - Other Accrued Liabilities - Schedule of Other Accrued Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/NotesAndLoansPayableDetailsNarrative" id="NotesAndLoansPayableDetailsNarrative">
	  <link:definition>00000046 - Disclosure - Notes and Loans Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails" id="NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails">
	  <link:definition>00000047 - Disclosure - Notes and Loans Payable - Schedule of Future Principle Payments, Net of Unamortized Debt Discounts (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000048 - Disclosure - Stockholders' Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000049 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails" id="Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails">
	  <link:definition>00000050 - Disclosure - Stock-Based Compensation - Summary of Stock Option and Restricted Stock Awards (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" id="Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails">
	  <link:definition>00000051 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Options Granted (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Earn-outMilestoneLiabilityDetailsNarrative" id="Earn-outMilestoneLiabilityDetailsNarrative">
	  <link:definition>00000052 - Disclosure - Earn-out Milestone Liability (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails" id="Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails">
	  <link:definition>00000053 - Disclosure - Earn-out Milestone Liability - Schedule of Changes in Earn-out Milestone Liability (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails" id="Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails">
	  <link:definition>00000054 - Disclosure - Earn-out Milestone Liability - Schedule of Risk Adjustment Assessment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Warrants-SummaryOfWarrantActivityDetails" id="Warrants-SummaryOfWarrantActivityDetails">
	  <link:definition>00000055 - Disclosure - Warrants - Summary of Warrant Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails" id="Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails">
	  <link:definition>00000056 - Disclosure - Warrants - Schedule of Weighted Average Remaining Contractual Terms (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000057 - Disclosure - Leases (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails" id="Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails">
	  <link:definition>00000058 - Disclosure - Leases - Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative" id="TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative">
	  <link:definition>00000059 - Disclosure - Technology Development and Licensing Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celsion.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000060 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="clsn-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="clsn-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="clsn-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="clsn-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="CLSN_CashInvestmentSecuritiesAndInterestReceivable" name="CashInvestmentSecuritiesAndInterestReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards" name="NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" name="DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" name="DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" name="AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" name="AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AggregateOfferingPrices" name="AggregateOfferingPrices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AggregateOfferingPriceAdditions" name="AggregateOfferingPriceAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AggregateOfferingPriceTerm" name="AggregateOfferingPriceTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization" name="TaxBenefitsOfEarningsBeforeDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AggregateValueAvailableForIssuance" name="AggregateValueAvailableForIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" name="DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_NetProceedsFromSaleOfNetOperatingLosses" name="NetProceedsFromSaleOfNetOperatingLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare" name="NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ShelfRegistrationStatementAmount" name="ShelfRegistrationStatementAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_StockOptionsStrikePriceDescription" name="StockOptionsStrikePriceDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AnnualBonusAwardsPercentage" name="AnnualBonusAwardsPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" name="DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" name="LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_UnderwritingDiscountPricePerShare" name="UnderwritingDiscountPricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice" name="PercentageOfUnderwritingDiscountOnPublicOfferingPrice" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock" name="SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_GainLossFromChangeInEarnoutMilestoneLiability" name="GainLossFromChangeInEarnoutMilestoneLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" name="FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability" name="GainLossFromValuationOfEarnoutMilestoneLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SharesIssuedInExchangeForServices" name="SharesIssuedInExchangeForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" name="AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments" name="FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_RightOfUseAssetsObtainedInExchangeForLease" name="RightOfUseAssetsObtainedInExchangeForLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SaleOfEquityThroughEquityFinancingFacilities" name="SaleOfEquityThroughEquityFinancingFacilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares" name="SaleOfEquityThroughEquityFinancingFacilitiesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock" name="EarnoutMilestoneLiabilityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_WarrantsTextBlock" name="WarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_LicensingTransactionTextBlock" name="LicensingTransactionTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock" name="ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock" name="ScheduleOfRiskadjustmentAssessmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock" name="ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EarnoutMilestoneLiability1" name="EarnoutMilestoneLiability1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_GainOnNoncashBenefit" name="GainOnNoncashBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_RiskAdjustedAssessmentOfEachMilestone" name="RiskAdjustedAssessmentOfEachMilestone" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability" name="GainLossFromChangeInFairValueOfEarnOutMilestoneLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EarnoutMilestoneLiability" name="EarnoutMilestoneLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone" name="RiskadjustmentAssessmentOfAchievingEachMilestone" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_DiscountRateOnMileStoneLiabilities" name="DiscountRateOnMileStoneLiabilities" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EstimatedTimeToAchieveMileStone" name="EstimatedTimeToAchieveMileStone" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_DeferredRevenueAmortizationPeriod" name="DeferredRevenueAmortizationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_UpfrontPayment" name="UpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_StockIssuedInLieuOfCashBonusPayments" name="StockIssuedInLieuOfCashBonusPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_IssuanceOfCommonStockInLieuOfCashBonus" name="IssuanceOfCommonStockInLieuOfCashBonus" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares" name="IssuanceOfCommonStockInLieuOfCashBonusShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_PaymentsForEarnoutMilestoneLiability" name="PaymentsForEarnoutMilestoneLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_PaymentsForEarnoutMilestoneLiabilityInCash" name="PaymentsForEarnoutMilestoneLiabilityInCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EGENIncMember" name="EGENIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_IPRAndDDrugTechnologyPlatformsMember" name="IPRAndDDrugTechnologyPlatformsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_GlioblastomaMultiformeBrainCancerMember" name="GlioblastomaMultiformeBrainCancerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_OvarianCancerMember" name="OvarianCancerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_HerculesCreditAgreementMember" name="HerculesCreditAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SecondTrancheMember" name="SecondTrancheMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_HerculesMember" name="HerculesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_HerculesWarrantMember" name="HerculesWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_HerculesTechnologyGrowthCapitalIncMember" name="HerculesTechnologyGrowthCapitalIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TwoThousandAndSevenStockIncentivePlanMember" name="TwoThousandAndSevenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TwoThousandAndEighteenStockIncentivePlanMember" name="TwoThousandAndEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EquityStockAwardsMember" name="EquityStockAwardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FirstTrancheMember" name="FirstTrancheMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_LawrencevilleNewJerseyMember" name="LawrencevilleNewJerseyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EGENAssetPurchaseAgreementMember" name="EGENAssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_HuntsvilleAlabamaMember" name="HuntsvilleAlabamaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_HisunMember" name="HisunMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ReductionInWarrantsMember" name="ReductionInWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_OppenheimerAndCoIncMember" name="OppenheimerAndCoIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_InvestorWarrantMember" name="InvestorWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_October2017UnderwrittenOfferingMember" name="October2017UnderwrittenOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_July2017DirectOfferingMember" name="July2017DirectOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_PreFundedSeriesCCCWarrantsMember" name="PreFundedSeriesCCCWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SeriesAAAWarrantsMember" name="SeriesAAAWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SeriesBBBWarrantsMember" name="SeriesBBBWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SeriesDDDWarrantsMember" name="SeriesDDDWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_February142017PublicOfferingMember" name="February142017PublicOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SeriesAAWarrantMember" name="SeriesAAWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_PreFundedSeriesBBWarrantMember" name="PreFundedSeriesBBWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TwoThousandThirteenWarrants2014WarrantsAndJune2016WarrantsMember" name="TwoThousandThirteenWarrants2014WarrantsAndJune2016WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TwoThousandFifteenWarrantsMember" name="TwoThousandFifteenWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_May2015CommonStockOfferingMember" name="May2015CommonStockOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_JuneTwoThousandAndSixrteenWarrantsMember" name="JuneTwoThousandAndSixrteenWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_HorizonTechnologyFinanceCorporationMember" name="HorizonTechnologyFinanceCorporationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_HorizonCreditAgreementMember" name="HorizonCreditAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_HorizonWarrantMember" name="HorizonWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_InducementOptionGrantsMember" name="InducementOptionGrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FiveNewEmployeesMember" name="FiveNewEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ThreeNewEmployeesMember" name="ThreeNewEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_HisunAgreementMember" name="HisunAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_CommonStockSalesAgreementMember" name="CommonStockSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AspireCapitalFundLLCMember" name="AspireCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_InProcessResearchAndDevelopmentTwoMember" name="InProcessResearchAndDevelopmentTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TaxReformActMember" name="TaxReformActMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FederalIncomeTaxMember" name="FederalIncomeTaxMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_WarrantExchangeAgreementsMember" name="WarrantExchangeAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FebruaryFourteenTwoThousandAndSeventeenPublicOfferingMember" name="FebruaryFourteenTwoThousandAndSeventeenPublicOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ExerciseAgreementsMember" name="ExerciseAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember" name="TwoThousandEighteenAspirePurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_CapitalOnDemandTMSalesAgreementMember" name="CapitalOnDemandTMSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ATMAgreementMember" name="ATMAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EGENMember" name="EGENMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_DukeUniversityMember" name="DukeUniversityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_USFederalAndStateTaxMember" name="USFederalAndStateTaxMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_NJMember" name="NJMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_IPRAndDMember" name="IPRAndDMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_CapitalOnDemandAgreementMember" name="CapitalOnDemandAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AspirePurchaseAgreementsMember" name="AspirePurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_RecognizedNoncashBenefitMember" name="RecognizedNoncashBenefitMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TwoNewEmployeesMember" name="TwoNewEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_InducementAwardsMember" name="InducementAwardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AmendedAssetPurchaseAgreementMember" name="AmendedAssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_CertainBusinessDaysOfAchievingMilestoneMember" name="CertainBusinessDaysOfAchievingMilestoneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AchievingMilestoneWithInOneYearMember" name="AchievingMilestoneWithInOneYearMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FairValueEarnoutMilestoneLiabilityMember" name="FairValueEarnoutMilestoneLiabilityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember" name="AmendedAssetPurchaseAgreementOptionPaymentOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember" name="AmendedAssetPurchaseAgreementOptionPaymentTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_RecognizedNonCashChargeMember" name="RecognizedNonCashChargeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_OtherWarrantsMember" name="OtherWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EGWUIncMember" name="EGWUIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FirstLeaseAmendmentMember" name="FirstLeaseAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SecondLeaseAmendmentMember" name="SecondLeaseAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FirstYearMember" name="FirstYearMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_RevenueRatablyThroughTwentyTwentyTwoMember" name="RevenueRatablyThroughTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_FinalYearMember" name="FinalYearMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AllOtherWarrantsMember" name="AllOtherWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_GeneralAndAdministrativeExpensesMember" name="GeneralAndAdministrativeExpensesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AspirePurchaseAgreementMember" name="AspirePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember" name="TwoThousandNineteenAspirePurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AssetPurchaseAgreementMember" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_ControlledEquityOfferingSMSalesAgreementMember" name="ControlledEquityOfferingSMSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_OriginalWarrantsMember" name="OriginalWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_PrivateExchangeAgreementsMember" name="PrivateExchangeAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SixtyMonthLeaseMember" name="SixtyMonthLeaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_OperatingLeasesMember" name="OperatingLeasesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_RNADeliverySystemMember" name="RNADeliverySystemMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TwoThousandSevenStockIncentivePlanMember" name="TwoThousandSevenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" name="GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TwoThousandAndEighteenPlanMember" name="TwoThousandAndEighteenPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember" name="EmployeeStockOptionAndRestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_NonVestedStockBasedCompensationArrangementsMember" name="NonVestedStockBasedCompensationArrangementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TwoThousandNineteenBonusProgramMember" name="TwoThousandNineteenBonusProgramMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_PaymentOptionOneMember" name="PaymentOptionOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_PaymentOptionTwoMember" name="PaymentOptionTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_AprilPaycheckProtectionProgramLoanMember" name="AprilPaycheckProtectionProgramLoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_SiliconValleyBankMember" name="SiliconValleyBankMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_PaycheckProtectionProgramLoansMember" name="PaycheckProtectionProgramLoansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_MayPaycheckProtectionProgramLoanMember" name="MayPaycheckProtectionProgramLoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_UnderwrittenOfferingMember" name="UnderwrittenOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" name="RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_EarnoutMilestoneLiabilityAbstract" name="EarnoutMilestoneLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract" name="TechnologyDevelopmentAndLicensingAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CLSN_LeaseContractTypeAxis" name="LeaseContractTypeAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>clsn-20200630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CLSN %2D 20200630 10Q Q2 DFN.xfr; Date: 2020%2D08%2D14T04:09:48Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80060006 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celsion.com/role/DocumentAndEntityInformation" xlink:href="clsn-20200630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BalanceSheets" xlink:href="clsn-20200630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BalanceSheetsParenthetical" xlink:href="clsn-20200630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfOperations" xlink:href="clsn-20200630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfComprehensiveLoss" xlink:href="clsn-20200630.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfCashFlows" xlink:href="clsn-20200630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="clsn-20200630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BusinessDescription" xlink:href="clsn-20200630.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BasisOfPresentation" xlink:href="clsn-20200630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FinancialConditionAndBusinessPlan" xlink:href="clsn-20200630.xsd#FinancialConditionAndBusinessPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NewAccountingPronouncements" xlink:href="clsn-20200630.xsd#NewAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NetLossPerCommonShare" xlink:href="clsn-20200630.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FairValueMeasurements" xlink:href="clsn-20200630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssets" xlink:href="clsn-20200630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/OtherAccruedLiabilities" xlink:href="clsn-20200630.xsd#OtherAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayable" xlink:href="clsn-20200630.xsd#NotesAndLoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StockholdersEquity" xlink:href="clsn-20200630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensation" xlink:href="clsn-20200630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiability" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Warrants" xlink:href="clsn-20200630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Leases" xlink:href="clsn-20200630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreements" xlink:href="clsn-20200630.xsd#TechnologyDevelopmentAndLicensingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/CommitmentsAndContingencies" xlink:href="clsn-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/SubsequentEvents" xlink:href="clsn-20200630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleTables" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSaleTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FairValueMeasurementsTables" xlink:href="clsn-20200630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssetsTables" xlink:href="clsn-20200630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/OtherAccruedLiabilitiesTables" xlink:href="clsn-20200630.xsd#OtherAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayableTables" xlink:href="clsn-20200630.xsd#NotesAndLoansPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensationTables" xlink:href="clsn-20200630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiabilityTables" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/WarrantsTables" xlink:href="clsn-20200630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/LeasesTables" xlink:href="clsn-20200630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FinancialConditionAndBusinessPlanDetailsNarrative" xlink:href="clsn-20200630.xsd#FinancialConditionAndBusinessPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="clsn-20200630.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="clsn-20200630.xsd#FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssetsDetailsNarrative" xlink:href="clsn-20200630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails" xlink:href="clsn-20200630.xsd#IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails" xlink:href="clsn-20200630.xsd#IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails" xlink:href="clsn-20200630.xsd#OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayableDetailsNarrative" xlink:href="clsn-20200630.xsd#NotesAndLoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails" xlink:href="clsn-20200630.xsd#NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StockholdersEquityDetailsNarrative" xlink:href="clsn-20200630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="clsn-20200630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails" xlink:href="clsn-20200630.xsd#Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:href="clsn-20200630.xsd#Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiabilityDetailsNarrative" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Warrants-SummaryOfWarrantActivityDetails" xlink:href="clsn-20200630.xsd#Warrants-SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails" xlink:href="clsn-20200630.xsd#Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/LeasesDetailsNarrative" xlink:href="clsn-20200630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails" xlink:href="clsn-20200630.xsd#Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative" xlink:href="clsn-20200630.xsd#TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="clsn-20200630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="loc_us-gaapAccruedInvestmentIncomeReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccruedInvestmentIncomeReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapGrantsReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:label="loc_us-gaapStockholdersEquityBeforeTreasuryStock" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityBeforeTreasuryStock" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityBeforeTreasuryStock" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityBeforeTreasuryStock" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityBeforeTreasuryStock" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityBeforeTreasuryStock" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityBeforeTreasuryStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainLossFromChangeInEarnoutMilestoneLiability" xlink:label="loc_CLSNGainLossFromChangeInEarnoutMilestoneLiability" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_CLSNGainLossFromChangeInEarnoutMilestoneLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:label="loc_CLSNFairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_CLSNFairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainLossFromValuationOfEarnoutMilestoneLiability" xlink:label="loc_CLSNGainLossFromValuationOfEarnoutMilestoneLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CLSNGainLossFromValuationOfEarnoutMilestoneLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:label="loc_CLSNFairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CLSNFairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInvestmentIncomeReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" xlink:label="loc_CLSNAmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CLSNAmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SharesIssuedInExchangeForServices" xlink:label="loc_CLSNSharesIssuedInExchangeForServices" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CLSNSharesIssuedInExchangeForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaapPaymentsToAcquireAvailableForSaleSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireAvailableForSaleSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLoans" xlink:label="loc_us-gaapPaymentsForLoans" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForLoans" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/BusinessDescription" xlink:title="00000008 - Disclosure - Business Description" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/BasisOfPresentation" xlink:title="00000009 - Disclosure - Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/FinancialConditionAndBusinessPlan" xlink:title="00000010 - Disclosure - Financial Condition and Business Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/NewAccountingPronouncements" xlink:title="00000011 - Disclosure - New Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/NetLossPerCommonShare" xlink:title="00000012 - Disclosure - Net Loss Per Common Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale" xlink:title="00000013 - Disclosure - Investment in Debt Securities Available for Sale" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/FairValueMeasurements" xlink:title="00000014 - Disclosure - Fair Value Measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssets" xlink:title="00000015 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/OtherAccruedLiabilities" xlink:title="00000016 - Disclosure - Other Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayable" xlink:title="00000017 - Disclosure - Notes and Loans Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensation" xlink:title="00000019 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiability" xlink:title="00000020 - Disclosure - Earn-out Milestone Liability" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Warrants" xlink:title="00000021 - Disclosure - Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Leases" xlink:title="00000022 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreements" xlink:title="00000023 - Disclosure - Technology Development and Licensing Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/CommitmentsAndContingencies" xlink:title="00000024 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/SubsequentEvents" xlink:title="00000025 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleTables" xlink:title="00000026 - Disclosure - Investment in Debt Securities Available for Sale (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/FairValueMeasurementsTables" xlink:title="00000027 - Disclosure - Fair Value Measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssetsTables" xlink:title="00000028 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/OtherAccruedLiabilitiesTables" xlink:title="00000029 - Disclosure - Other Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayableTables" xlink:title="00000030 - Disclosure - Notes and Loans Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensationTables" xlink:title="00000031 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiabilityTables" xlink:title="00000032 - Disclosure - Earn-out Milestone Liability (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/WarrantsTables" xlink:title="00000033 - Disclosure - Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/LeasesTables" xlink:title="00000034 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/FinancialConditionAndBusinessPlanDetailsNarrative" xlink:title="00000035 - Disclosure - Financial Condition and Business Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="00000036 - Disclosure - Net Loss Per Common Share (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative" xlink:title="00000037 - Disclosure - Investment in Debt Securities Available for Sale (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails" xlink:title="00000038 - Disclosure - Investment in Debt Securities Available for Sale - Schedule of Cost, Fair Value and Maturities of Short Term Investments (Details)">
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" xlink:label="loc_CLSNAvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" xlink:label="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CLSNAvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" xlink:to="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" xlink:label="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails" xlink:title="00000039 - Disclosure - Investment in Debt Securities Available for Sale - Summary of Investment Securities Gross Unrealized Gains (Losses) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" xlink:label="loc_CLSNDebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="loc_CLSNDebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" xlink:label="loc_CLSNAvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" xlink:label="loc_CLSNDebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CLSNAvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" xlink:to="loc_CLSNDebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails" xlink:title="00000040 - Disclosure - Investment in Debt Securities Available for Sale - Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaapInvestmentIncomeInterestAndDividend" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInvestmentIncomeNonoperating" xlink:to="loc_us-gaapInvestmentIncomeInterestAndDividend" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="loc_us-gaapAvailableForSaleSecuritiesGrossRealizedGainLossNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInvestmentIncomeNonoperating" xlink:to="loc_us-gaapAvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000041 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000042 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails" xlink:title="00000043 - Disclosure - Intangible Assets - Schedule of Future Amortization Amounts During the Remaining Life (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" xlink:label="loc_CLSNFiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_CLSNFiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails" xlink:title="00000044 - Disclosure - Intangible Assets - Schedule of Fair Value of Assets Acquired (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails" xlink:title="00000045 - Disclosure - Other Accrued Liabilities - Schedule of Other Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayableDetailsNarrative" xlink:title="00000046 - Disclosure - Notes and Loans Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails" xlink:title="00000047 - Disclosure - Notes and Loans Payable - Schedule of Future Principle Payments, Net of Unamortized Debt Discounts (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" xlink:label="loc_CLSNLongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_CLSNLongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - Stockholders&apos; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000049 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails" xlink:title="00000050 - Disclosure - Stock-Based Compensation - Summary of Stock Option and Restricted Stock Awards (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:title="00000051 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Options Granted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiabilityDetailsNarrative" xlink:title="00000052 - Disclosure - Earn-out Milestone Liability (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails" xlink:title="00000053 - Disclosure - Earn-out Milestone Liability - Schedule of Changes in Earn-out Milestone Liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails" xlink:title="00000054 - Disclosure - Earn-out Milestone Liability - Schedule of Risk Adjustment Assessment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Warrants-SummaryOfWarrantActivityDetails" xlink:title="00000055 - Disclosure - Warrants - Summary of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails" xlink:title="00000056 - Disclosure - Warrants - Schedule of Weighted Average Remaining Contractual Terms (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/LeasesDetailsNarrative" xlink:title="00000057 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails" xlink:title="00000058 - Disclosure - Leases - Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" xlink:label="loc_CLSNLesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_CLSNLesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative" xlink:title="00000059 - Disclosure - Technology Development and Licensing Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celsion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000060 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>clsn-20200630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CLSN %2D 20200630 10Q Q2 DFN.xfr; Date: 2020%2D08%2D14T04:09:48Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80060006 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celsion.com/role/DocumentAndEntityInformation" xlink:href="clsn-20200630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BalanceSheets" xlink:href="clsn-20200630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BalanceSheetsParenthetical" xlink:href="clsn-20200630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfOperations" xlink:href="clsn-20200630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfComprehensiveLoss" xlink:href="clsn-20200630.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfCashFlows" xlink:href="clsn-20200630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="clsn-20200630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BusinessDescription" xlink:href="clsn-20200630.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BasisOfPresentation" xlink:href="clsn-20200630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FinancialConditionAndBusinessPlan" xlink:href="clsn-20200630.xsd#FinancialConditionAndBusinessPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NewAccountingPronouncements" xlink:href="clsn-20200630.xsd#NewAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NetLossPerCommonShare" xlink:href="clsn-20200630.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FairValueMeasurements" xlink:href="clsn-20200630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssets" xlink:href="clsn-20200630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/OtherAccruedLiabilities" xlink:href="clsn-20200630.xsd#OtherAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayable" xlink:href="clsn-20200630.xsd#NotesAndLoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StockholdersEquity" xlink:href="clsn-20200630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensation" xlink:href="clsn-20200630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiability" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Warrants" xlink:href="clsn-20200630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Leases" xlink:href="clsn-20200630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreements" xlink:href="clsn-20200630.xsd#TechnologyDevelopmentAndLicensingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/CommitmentsAndContingencies" xlink:href="clsn-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/SubsequentEvents" xlink:href="clsn-20200630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleTables" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSaleTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FairValueMeasurementsTables" xlink:href="clsn-20200630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssetsTables" xlink:href="clsn-20200630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/OtherAccruedLiabilitiesTables" xlink:href="clsn-20200630.xsd#OtherAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayableTables" xlink:href="clsn-20200630.xsd#NotesAndLoansPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensationTables" xlink:href="clsn-20200630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiabilityTables" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/WarrantsTables" xlink:href="clsn-20200630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/LeasesTables" xlink:href="clsn-20200630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FinancialConditionAndBusinessPlanDetailsNarrative" xlink:href="clsn-20200630.xsd#FinancialConditionAndBusinessPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="clsn-20200630.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="clsn-20200630.xsd#FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssetsDetailsNarrative" xlink:href="clsn-20200630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails" xlink:href="clsn-20200630.xsd#IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails" xlink:href="clsn-20200630.xsd#IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails" xlink:href="clsn-20200630.xsd#OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayableDetailsNarrative" xlink:href="clsn-20200630.xsd#NotesAndLoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails" xlink:href="clsn-20200630.xsd#NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StockholdersEquityDetailsNarrative" xlink:href="clsn-20200630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="clsn-20200630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails" xlink:href="clsn-20200630.xsd#Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:href="clsn-20200630.xsd#Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiabilityDetailsNarrative" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Warrants-SummaryOfWarrantActivityDetails" xlink:href="clsn-20200630.xsd#Warrants-SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails" xlink:href="clsn-20200630.xsd#Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/LeasesDetailsNarrative" xlink:href="clsn-20200630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails" xlink:href="clsn-20200630.xsd#Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative" xlink:href="clsn-20200630.xsd#TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="clsn-20200630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SaleOfEquityThroughEquityFinancingFacilities" xlink:label="loc_CLSNSaleOfEquityThroughEquityFinancingFacilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNSaleOfEquityThroughEquityFinancingFacilities_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares" xlink:label="loc_CLSNSaleOfEquityThroughEquityFinancingFacilitiesShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNSaleOfEquityThroughEquityFinancingFacilitiesShares_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IssuanceOfCommonStockInLieuOfCashBonus" xlink:label="loc_CLSNIssuanceOfCommonStockInLieuOfCashBonus_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNIssuanceOfCommonStockInLieuOfCashBonus_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares" xlink:label="loc_CLSNIssuanceOfCommonStockInLieuOfCashBonusShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNIssuanceOfCommonStockInLieuOfCashBonusShares_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/BusinessDescription" xlink:title="00000008 - Disclosure - Business Description" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/BasisOfPresentation" xlink:title="00000009 - Disclosure - Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/FinancialConditionAndBusinessPlan" xlink:title="00000010 - Disclosure - Financial Condition and Business Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/NewAccountingPronouncements" xlink:title="00000011 - Disclosure - New Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/NetLossPerCommonShare" xlink:title="00000012 - Disclosure - Net Loss Per Common Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale" xlink:title="00000013 - Disclosure - Investment in Debt Securities Available for Sale" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/FairValueMeasurements" xlink:title="00000014 - Disclosure - Fair Value Measurements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssets" xlink:title="00000015 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/OtherAccruedLiabilities" xlink:title="00000016 - Disclosure - Other Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayable" xlink:title="00000017 - Disclosure - Notes and Loans Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - Stockholders&apos; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensation" xlink:title="00000019 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiability" xlink:title="00000020 - Disclosure - Earn-out Milestone Liability" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Warrants" xlink:title="00000021 - Disclosure - Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Leases" xlink:title="00000022 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreements" xlink:title="00000023 - Disclosure - Technology Development and Licensing Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/CommitmentsAndContingencies" xlink:title="00000024 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/SubsequentEvents" xlink:title="00000025 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleTables" xlink:title="00000026 - Disclosure - Investment in Debt Securities Available for Sale (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/FairValueMeasurementsTables" xlink:title="00000027 - Disclosure - Fair Value Measurements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssetsTables" xlink:title="00000028 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/OtherAccruedLiabilitiesTables" xlink:title="00000029 - Disclosure - Other Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayableTables" xlink:title="00000030 - Disclosure - Notes and Loans Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensationTables" xlink:title="00000031 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiabilityTables" xlink:title="00000032 - Disclosure - Earn-out Milestone Liability (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/WarrantsTables" xlink:title="00000033 - Disclosure - Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/LeasesTables" xlink:title="00000034 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/FinancialConditionAndBusinessPlanDetailsNarrative" xlink:title="00000035 - Disclosure - Financial Condition and Business Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NJMember" xlink:label="loc_CLSNNJMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CLSNNJMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonCreditAgreementMember" xlink:label="loc_CLSNHorizonCreditAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNHorizonCreditAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonTechnologyFinanceCorporationMember" xlink:label="loc_CLSNHorizonTechnologyFinanceCorporationMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLSNHorizonTechnologyFinanceCorporationMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaapLondonInterbankOfferedRateLIBORMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapLondonInterbankOfferedRateLIBORMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CashInvestmentSecuritiesAndInterestReceivable" xlink:label="loc_CLSNCashInvestmentSecuritiesAndInterestReceivable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNCashInvestmentSecuritiesAndInterestReceivable_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization" xlink:label="loc_CLSNTaxBenefitsOfEarningsBeforeDepreciationAndAmortization_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNTaxBenefitsOfEarningsBeforeDepreciationAndAmortization_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NetProceedsFromSaleOfNetOperatingLosses" xlink:label="loc_CLSNNetProceedsFromSaleOfNetOperatingLosses_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNNetProceedsFromSaleOfNetOperatingLosses_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromContributedCapital_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="00000036 - Disclosure - Net Loss Per Common Share (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative" xlink:title="00000037 - Disclosure - Investment in Debt Securities Available for Sale (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaapShortTermInvestmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapShortTermInvestmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails" xlink:title="00000038 - Disclosure - Investment in Debt Securities Available for Sale - Schedule of Cost, Fair Value and Maturities of Short Term Investments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermInvestments_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" xlink:label="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" xlink:label="loc_CLSNAvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" xlink:label="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails" xlink:title="00000039 - Disclosure - Investment in Debt Securities Available for Sale - Summary of Investment Securities Gross Unrealized Gains (Losses) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails" xlink:title="00000040 - Disclosure - Investment in Debt Securities Available for Sale - Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000041 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent_170" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000042 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EGENIncMember" xlink:label="loc_CLSNEGENIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CLSNEGENIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IPRAndDDrugTechnologyPlatformsMember" xlink:label="loc_CLSNIPRAndDDrugTechnologyPlatformsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLSNIPRAndDDrugTechnologyPlatformsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_OvarianCancerMember" xlink:label="loc_CLSNOvarianCancerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CLSNOvarianCancerMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GlioblastomaMultiformeBrainCancerMember" xlink:label="loc_CLSNGlioblastomaMultiformeBrainCancerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CLSNGlioblastomaMultiformeBrainCancerMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RNADeliverySystemMember" xlink:label="loc_CLSNRNADeliverySystemMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CLSNRNADeliverySystemMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PurchaseAgreementMember" xlink:label="loc_CLSNPurchaseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNPurchaseAgreementMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AspirePurchaseAgreementsMember" xlink:label="loc_CLSNAspirePurchaseAgreementsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNAspirePurchaseAgreementsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="loc_us-gaapIndefinitelivedIntangibleAssetsAcquired_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefinitelivedIntangibleAssetsAcquired_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaapGoodwillAcquiredDuringPeriod_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwillAcquiredDuringPeriod_160" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails" xlink:title="00000043 - Disclosure - Intangible Assets - Schedule of Future Amortization Amounts During the Remaining Life (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaapNoncompeteAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapNoncompeteAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" xlink:label="loc_CLSNFiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNFiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_20" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails" xlink:title="00000044 - Disclosure - Intangible Assets - Schedule of Fair Value of Assets Acquired (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IPRAndDMember" xlink:label="loc_CLSNIPRAndDMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_CLSNIPRAndDMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaapGoodwillMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapGoodwillMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaapNoncompeteAgreementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapNoncompeteAgreementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails" xlink:title="00000045 - Disclosure - Other Accrued Liabilities - Schedule of Other Accrued Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayableDetailsNarrative" xlink:title="00000046 - Disclosure - Notes and Loans Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonCreditAgreementMember" xlink:label="loc_CLSNHorizonCreditAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNHorizonCreditAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AprilPaycheckProtectionProgramLoanMember" xlink:label="loc_CLSNAprilPaycheckProtectionProgramLoanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNAprilPaycheckProtectionProgramLoanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaycheckProtectionProgramLoansMember" xlink:label="loc_CLSNPaycheckProtectionProgramLoansMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNPaycheckProtectionProgramLoansMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_MayPaycheckProtectionProgramLoanMember" xlink:label="loc_CLSNMayPaycheckProtectionProgramLoanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNMayPaycheckProtectionProgramLoanMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonCreditAgreementMember" xlink:label="loc_CLSNHorizonCreditAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLSNHorizonCreditAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SiliconValleyBankMember" xlink:label="loc_CLSNSiliconValleyBankMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CLSNSiliconValleyBankMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_us-gaapNotesPayableToBanksMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapNotesPayableToBanksMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromLoans_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_110" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails" xlink:title="00000047 - Disclosure - Notes and Loans Payable - Schedule of Future Principle Payments, Net of Unamortized Debt Discounts (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - Stockholders&apos; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember" xlink:label="loc_CLSNTwoThousandNineteenAspirePurchaseAgreementsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNTwoThousandNineteenAspirePurchaseAgreementsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember" xlink:label="loc_CLSNTwoThousandEighteenAspirePurchaseAgreementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNTwoThousandEighteenAspirePurchaseAgreementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CapitalOnDemandTMSalesAgreementMember" xlink:label="loc_CLSNCapitalOnDemandTMSalesAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNCapitalOnDemandTMSalesAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CapitalOnDemandAgreementMember" xlink:label="loc_CLSNCapitalOnDemandAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNCapitalOnDemandAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SecuritiesPurchaseAgreementMember" xlink:label="loc_CLSNSecuritiesPurchaseAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNSecuritiesPurchaseAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PrivateExchangeAgreementsMember" xlink:label="loc_CLSNPrivateExchangeAgreementsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNPrivateExchangeAgreementsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UnderwritingAgreementMember" xlink:label="loc_CLSNUnderwritingAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNUnderwritingAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_OriginalWarrantsMember" xlink:label="loc_CLSNOriginalWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLSNOriginalWarrantsMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UnderwrittenOfferingMember" xlink:label="loc_CLSNUnderwrittenOfferingMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CLSNUnderwrittenOfferingMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShelfRegistrationStatementAmount" xlink:label="loc_CLSNShelfRegistrationStatementAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNShelfRegistrationStatementAmount_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateOfferingPriceAdditions" xlink:label="loc_CLSNAggregateOfferingPriceAdditions_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAggregateOfferingPriceAdditions_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateOfferingPriceTerm" xlink:label="loc_CLSNAggregateOfferingPriceTerm_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAggregateOfferingPriceTerm_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateOfferingPrices" xlink:label="loc_CLSNAggregateOfferingPrices_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAggregateOfferingPrices_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateValueAvailableForIssuance" xlink:label="loc_CLSNAggregateValueAvailableForIssuance_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAggregateValueAvailableForIssuance_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UnderwritingDiscountPricePerShare" xlink:label="loc_CLSNUnderwritingDiscountPricePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNUnderwritingDiscountPricePerShare_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice" xlink:label="loc_CLSNPercentageOfUnderwritingDiscountOnPublicOfferingPrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNPercentageOfUnderwritingDiscountOnPublicOfferingPrice_170" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000049 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandAndEighteenStockIncentivePlanMember" xlink:label="loc_CLSNTwoThousandAndEighteenStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNTwoThousandAndEighteenStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandSevenStockIncentivePlanMember" xlink:label="loc_CLSNTwoThousandSevenStockIncentivePlanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNTwoThousandSevenStockIncentivePlanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_InducementOptionGrantsMember" xlink:label="loc_CLSNInducementOptionGrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNInducementOptionGrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandAndEighteenPlanMember" xlink:label="loc_CLSNTwoThousandAndEighteenPlanMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNTwoThousandAndEighteenPlanMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandNineteenBonusProgramMember" xlink:label="loc_CLSNTwoThousandNineteenBonusProgramMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNTwoThousandNineteenBonusProgramMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoNewEmployeesMember" xlink:label="loc_CLSNTwoNewEmployeesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLSNTwoNewEmployeesMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FiveNewEmployeesMember" xlink:label="loc_CLSNFiveNewEmployeesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLSNFiveNewEmployeesMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EquityStockAwardsMember" xlink:label="loc_CLSNEquityStockAwardsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CLSNEquityStockAwardsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_InducementAwardsMember" xlink:label="loc_CLSNInducementAwardsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CLSNInducementAwardsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember" xlink:label="loc_CLSNEmployeeStockOptionAndRestrictedStockAwardsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CLSNEmployeeStockOptionAndRestrictedStockAwardsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" xlink:label="loc_CLSNGrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_CLSNGrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NonVestedStockBasedCompensationArrangementsMember" xlink:label="loc_CLSNNonVestedStockBasedCompensationArrangementsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNNonVestedStockBasedCompensationArrangementsMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_StockOptionsStrikePriceDescription" xlink:label="loc_CLSNStockOptionsStrikePriceDescription_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNStockOptionsStrikePriceDescription_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_320" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_320" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_320" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AnnualBonusAwardsPercentage" xlink:label="loc_CLSNAnnualBonusAwardsPercentage_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAnnualBonusAwardsPercentage_320" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_320" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_320" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails" xlink:title="00000050 - Disclosure - Stock-Based Compensation - Summary of Stock Option and Restricted Stock Awards (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice" xlink:label="loc_CLSNShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod" xlink:label="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_30" xlink:type="arc" order="36" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:title="00000051 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Options Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiabilityDetailsNarrative" xlink:title="00000052 - Disclosure - Earn-out Milestone Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EGWUIncMember" xlink:label="loc_CLSNEGWUIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLSNEGWUIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FairValueEarnoutMilestoneLiabilityMember" xlink:label="loc_CLSNFairValueEarnoutMilestoneLiabilityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNFairValueEarnoutMilestoneLiabilityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember" xlink:label="loc_CLSNAmendedAssetPurchaseAgreementOptionPaymentOneMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNAmendedAssetPurchaseAgreementOptionPaymentOneMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember" xlink:label="loc_CLSNAmendedAssetPurchaseAgreementOptionPaymentTwoMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNAmendedAssetPurchaseAgreementOptionPaymentTwoMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentOptionOneMember" xlink:label="loc_CLSNPaymentOptionOneMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_CLSNPaymentOptionOneMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentOptionTwoMember" xlink:label="loc_CLSNPaymentOptionTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_CLSNPaymentOptionTwoMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentsForEarnoutMilestoneLiability" xlink:label="loc_CLSNPaymentsForEarnoutMilestoneLiability_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNPaymentsForEarnoutMilestoneLiability_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentsForEarnoutMilestoneLiabilityInCash" xlink:label="loc_CLSNPaymentsForEarnoutMilestoneLiabilityInCash_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNPaymentsForEarnoutMilestoneLiabilityInCash_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiability1" xlink:label="loc_CLSNEarnoutMilestoneLiability1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNEarnoutMilestoneLiability1_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainOnNoncashBenefit" xlink:label="loc_CLSNGainOnNoncashBenefit_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNGainOnNoncashBenefit_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RiskAdjustedAssessmentOfEachMilestone" xlink:label="loc_CLSNRiskAdjustedAssessmentOfEachMilestone_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNRiskAdjustedAssessmentOfEachMilestone_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability" xlink:label="loc_CLSNGainLossFromChangeInFairValueOfEarnOutMilestoneLiability_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNGainLossFromChangeInFairValueOfEarnOutMilestoneLiability_210" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails" xlink:title="00000053 - Disclosure - Earn-out Milestone Liability - Schedule of Changes in Earn-out Milestone Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails" xlink:title="00000054 - Disclosure - Earn-out Milestone Liability - Schedule of Risk Adjustment Assessment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone" xlink:label="loc_CLSNRiskadjustmentAssessmentOfAchievingEachMilestone_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNRiskadjustmentAssessmentOfAchievingEachMilestone_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DiscountRateOnMileStoneLiabilities" xlink:label="loc_CLSNDiscountRateOnMileStoneLiabilities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNDiscountRateOnMileStoneLiabilities_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EstimatedTimeToAchieveMileStone" xlink:label="loc_CLSNEstimatedTimeToAchieveMileStone_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNEstimatedTimeToAchieveMileStone_170" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Warrants-SummaryOfWarrantActivityDetails" xlink:title="00000055 - Disclosure - Warrants - Summary of Warrant Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails" xlink:title="00000056 - Disclosure - Warrants - Schedule of Weighted Average Remaining Contractual Terms (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EGWUIncMember" xlink:label="loc_CLSNEGWUIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLSNEGWUIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AllOtherWarrantsMember" xlink:label="loc_CLSNAllOtherWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNAllOtherWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue" xlink:label="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/LeasesDetailsNarrative" xlink:title="00000057 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LawrencevilleNewJerseyMember" xlink:label="loc_CLSNLawrencevilleNewJerseyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CLSNLawrencevilleNewJerseyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HuntsvilleAlabamaMember" xlink:label="loc_CLSNHuntsvilleAlabamaMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CLSNHuntsvilleAlabamaMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201602Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201602Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilities_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseCost_120" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails" xlink:title="00000058 - Disclosure - Leases - Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative" xlink:title="00000059 - Disclosure - Technology Development and Licensing Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaapLegalEntityTypeOfCounterpartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="loc_us-gaapLegalEntityTypeOfCounterpartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HisunMember" xlink:label="loc_CLSNHisunMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" xlink:to="loc_CLSNHisunMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaapProceedsFromLicenseFeesReceived_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromLicenseFeesReceived_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DeferredRevenueAmortizationPeriod" xlink:label="loc_CLSNDeferredRevenueAmortizationPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNDeferredRevenueAmortizationPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UpfrontPayment" xlink:label="loc_CLSNUpfrontPayment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNUpfrontPayment_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celsion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000060 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>clsn-20200630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CLSN %2D 20200630 10Q Q2 DFN.xfr; Date: 2020%2D08%2D14T04:09:48Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80060006 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HisunMember" xlink:label="CLSN_HisunMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HisunMember" xlink:to="CLSN_HisunMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_HisunMember_lbl" xml:lang="en-US">Hisun [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonCreditAgreementMember" xlink:label="CLSN_HorizonCreditAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HorizonCreditAgreementMember" xlink:to="CLSN_HorizonCreditAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_HorizonCreditAgreementMember_lbl" xml:lang="en-US">Horizon Credit Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IPRAndDDrugTechnologyPlatformsMember" xlink:label="CLSN_IPRAndDDrugTechnologyPlatformsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_IPRAndDDrugTechnologyPlatformsMember" xlink:to="CLSN_IPRAndDDrugTechnologyPlatformsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_IPRAndDDrugTechnologyPlatformsMember_lbl" xml:lang="en-US">IPR&amp;D Drug Technology Platforms [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_OvarianCancerMember" xlink:label="CLSN_OvarianCancerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_OvarianCancerMember" xlink:to="CLSN_OvarianCancerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_OvarianCancerMember_lbl" xml:lang="en-US">Ovarian Cancer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Significant Other Observable Inputs (Level 2) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Significant Unobservable Inputs (Level 3) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember" xlink:label="CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember" xlink:to="CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember_lbl" xml:lang="en-US">2018 Aspire Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CapitalOnDemandTMSalesAgreementMember" xlink:label="CLSN_CapitalOnDemandTMSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_CapitalOnDemandTMSalesAgreementMember" xlink:to="CLSN_CapitalOnDemandTMSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_CapitalOnDemandTMSalesAgreementMember_lbl" xml:lang="en-US">Capital on DemandTM Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EGENIncMember" xlink:label="CLSN_EGENIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EGENIncMember" xlink:to="CLSN_EGENIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_EGENIncMember_lbl" xml:lang="en-US">EGEN Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GlioblastomaMultiformeBrainCancerMember" xlink:label="CLSN_GlioblastomaMultiformeBrainCancerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GlioblastomaMultiformeBrainCancerMember" xlink:to="CLSN_GlioblastomaMultiformeBrainCancerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_GlioblastomaMultiformeBrainCancerMember_lbl" xml:lang="en-US">Glioblastoma Multiforme Brain Cancer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CapitalOnDemandAgreementMember" xlink:label="CLSN_CapitalOnDemandAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_CapitalOnDemandAgreementMember" xlink:to="CLSN_CapitalOnDemandAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_CapitalOnDemandAgreementMember_lbl" xml:lang="en-US">Capital on Demand Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NJMember" xlink:label="CLSN_NJMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_NJMember" xlink:to="CLSN_NJMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_NJMember_lbl" xml:lang="en-US">New Jersey [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="us-gaap_NoncompeteAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncompeteAgreementsMember" xlink:to="us-gaap_NoncompeteAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncompeteAgreementsMember_lbl" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IPRAndDMember" xlink:label="CLSN_IPRAndDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_IPRAndDMember" xlink:to="CLSN_IPRAndDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_IPRAndDMember_lbl" xml:lang="en-US">IPR&amp;D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillMember" xlink:label="us-gaap_GoodwillMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillMember_lbl" xml:lang="en-US">Goodwill [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AspirePurchaseAgreementsMember" xlink:label="CLSN_AspirePurchaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AspirePurchaseAgreementsMember" xlink:to="CLSN_AspirePurchaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLSN_AspirePurchaseAgreementsMember_lbl" xml:lang="en-US">2018 Aspire Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_InducementOptionGrantsMember" xlink:label="CLSN_InducementOptionGrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_InducementOptionGrantsMember" xlink:to="CLSN_InducementOptionGrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_InducementOptionGrantsMember_lbl" xml:lang="en-US">Inducement Option Grants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoNewEmployeesMember" xlink:label="CLSN_TwoNewEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoNewEmployeesMember" xlink:to="CLSN_TwoNewEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_TwoNewEmployeesMember_lbl" xml:lang="en-US">Two New Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FiveNewEmployeesMember" xlink:label="CLSN_FiveNewEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FiveNewEmployeesMember" xlink:to="CLSN_FiveNewEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_FiveNewEmployeesMember_lbl" xml:lang="en-US">Five New Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember" xlink:label="CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember" xlink:to="CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember_lbl" xml:lang="en-US">2019 Aspire Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US">Short-term Investments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SecuritiesPurchaseAgreementMember" xlink:label="CLSN_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SecuritiesPurchaseAgreementMember" xlink:to="CLSN_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_OriginalWarrantsMember" xlink:label="CLSN_OriginalWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_OriginalWarrantsMember" xlink:to="CLSN_OriginalWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_OriginalWarrantsMember_lbl" xml:lang="en-US">Original Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PrivateExchangeAgreementsMember" xlink:label="CLSN_PrivateExchangeAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PrivateExchangeAgreementsMember" xlink:to="CLSN_PrivateExchangeAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_PrivateExchangeAgreementsMember_lbl" xml:lang="en-US">Private Exchange Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonTechnologyFinanceCorporationMember" xlink:label="CLSN_HorizonTechnologyFinanceCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HorizonTechnologyFinanceCorporationMember" xlink:to="CLSN_HorizonTechnologyFinanceCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_HorizonTechnologyFinanceCorporationMember_lbl" xml:lang="en-US">Horizon Technology Finance Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RNADeliverySystemMember" xlink:label="CLSN_RNADeliverySystemMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RNADeliverySystemMember" xlink:to="CLSN_RNADeliverySystemMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_RNADeliverySystemMember_lbl" xml:lang="en-US">RNA Delivery System [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PurchaseAgreementMember" xlink:label="CLSN_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PurchaseAgreementMember" xlink:to="CLSN_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandAndEighteenStockIncentivePlanMember" xlink:label="CLSN_TwoThousandAndEighteenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandAndEighteenStockIncentivePlanMember" xlink:to="CLSN_TwoThousandAndEighteenStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_TwoThousandAndEighteenStockIncentivePlanMember_lbl" xml:lang="en-US">2018 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandSevenStockIncentivePlanMember" xlink:label="CLSN_TwoThousandSevenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandSevenStockIncentivePlanMember" xlink:to="CLSN_TwoThousandSevenStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_TwoThousandSevenStockIncentivePlanMember_lbl" xml:lang="en-US">2007 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EquityStockAwardsMember" xlink:label="CLSN_EquityStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EquityStockAwardsMember" xlink:to="CLSN_EquityStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_EquityStockAwardsMember_lbl" xml:lang="en-US">Equity Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" xlink:label="CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" xlink:to="CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember_lbl" xml:lang="en-US">Granted Under 2018 Plan and 2007 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandAndEighteenPlanMember" xlink:label="CLSN_TwoThousandAndEighteenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandAndEighteenPlanMember" xlink:to="CLSN_TwoThousandAndEighteenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_TwoThousandAndEighteenPlanMember_lbl" xml:lang="en-US">2018 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_InducementAwardsMember" xlink:label="CLSN_InducementAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_InducementAwardsMember" xlink:to="CLSN_InducementAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_InducementAwardsMember_lbl" xml:lang="en-US">Inducement Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember" xlink:label="CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember" xlink:to="CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember_lbl" xml:lang="en-US">Stock Options and Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NonVestedStockBasedCompensationArrangementsMember" xlink:label="CLSN_NonVestedStockBasedCompensationArrangementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_NonVestedStockBasedCompensationArrangementsMember" xlink:to="CLSN_NonVestedStockBasedCompensationArrangementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_NonVestedStockBasedCompensationArrangementsMember_lbl" xml:lang="en-US">Non-Vested Stock-Based Compensation Arrangements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandNineteenBonusProgramMember" xlink:label="CLSN_TwoThousandNineteenBonusProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandNineteenBonusProgramMember" xlink:to="CLSN_TwoThousandNineteenBonusProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_TwoThousandNineteenBonusProgramMember_lbl" xml:lang="en-US">2019 Bonus Program [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_2_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FairValueEarnoutMilestoneLiabilityMember" xlink:label="CLSN_FairValueEarnoutMilestoneLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FairValueEarnoutMilestoneLiabilityMember" xlink:to="CLSN_FairValueEarnoutMilestoneLiabilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_FairValueEarnoutMilestoneLiabilityMember_lbl" xml:lang="en-US">Fair Value Earnout Milestone Liability [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentOptionOneMember" xlink:label="CLSN_PaymentOptionOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PaymentOptionOneMember" xlink:to="CLSN_PaymentOptionOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_PaymentOptionOneMember_lbl" xml:lang="en-US">Payment Option One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember" xlink:label="CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember" xlink:to="CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember_lbl" xml:lang="en-US">Amended Asset Purchase Agreement Option Payment 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EGWUIncMember" xlink:label="CLSN_EGWUIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EGWUIncMember" xlink:to="CLSN_EGWUIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_EGWUIncMember_lbl" xml:lang="en-US">EGWU, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AllOtherWarrantsMember" xlink:label="CLSN_AllOtherWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AllOtherWarrantsMember" xlink:to="CLSN_AllOtherWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AllOtherWarrantsMember_lbl" xml:lang="en-US">All Other Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AprilPaycheckProtectionProgramLoanMember" xlink:label="CLSN_AprilPaycheckProtectionProgramLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AprilPaycheckProtectionProgramLoanMember" xlink:to="CLSN_AprilPaycheckProtectionProgramLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AprilPaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US">April PPP Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SiliconValleyBankMember" xlink:label="CLSN_SiliconValleyBankMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SiliconValleyBankMember" xlink:to="CLSN_SiliconValleyBankMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_SiliconValleyBankMember_lbl" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaycheckProtectionProgramLoansMember" xlink:label="CLSN_PaycheckProtectionProgramLoansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PaycheckProtectionProgramLoansMember" xlink:to="CLSN_PaycheckProtectionProgramLoansMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_PaycheckProtectionProgramLoansMember_lbl" xml:lang="en-US">PPP Loans [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_MayPaycheckProtectionProgramLoanMember" xlink:label="CLSN_MayPaycheckProtectionProgramLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_MayPaycheckProtectionProgramLoanMember" xlink:to="CLSN_MayPaycheckProtectionProgramLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_MayPaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US">May PPP Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="us-gaap_NotesPayableToBanksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBanksMember" xlink:to="us-gaap_NotesPayableToBanksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableToBanksMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UnderwritingAgreementMember" xlink:label="CLSN_UnderwritingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_UnderwritingAgreementMember" xlink:to="CLSN_UnderwritingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UnderwrittenOfferingMember" xlink:label="CLSN_UnderwrittenOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_UnderwrittenOfferingMember" xlink:to="CLSN_UnderwrittenOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_UnderwrittenOfferingMember_lbl" xml:lang="en-US">Underwritten Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xml:lang="en-US">Additional Paid-In Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentOptionTwoMember" xlink:label="CLSN_PaymentOptionTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PaymentOptionTwoMember" xlink:to="CLSN_PaymentOptionTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_PaymentOptionTwoMember_lbl" xml:lang="en-US">Payment Option Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember" xlink:label="CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember" xlink:to="CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember_lbl" xml:lang="en-US">Amended Asset Purchase Agreement Option Payment 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LawrencevilleNewJerseyMember" xlink:label="CLSN_LawrencevilleNewJerseyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LawrencevilleNewJerseyMember" xlink:to="CLSN_LawrencevilleNewJerseyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_LawrencevilleNewJerseyMember_lbl" xml:lang="en-US">Lawrenceville, New Jersey [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HuntsvilleAlabamaMember" xlink:label="CLSN_HuntsvilleAlabamaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HuntsvilleAlabamaMember" xlink:to="CLSN_HuntsvilleAlabamaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_HuntsvilleAlabamaMember_lbl" xml:lang="en-US">Huntsville Alabama [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US">Investment in debt securities - available for sale, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInvestmentIncomeReceivable" xlink:to="us-gaap_AccruedInvestmentIncomeReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable_lbl" xml:lang="en-US">Accrued interest receivable on investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US">Advances and deposits on clinical programs and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment (at cost, less accumulated depreciation of $3,174,681 and $3,096,681, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">In-process research and development, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Other intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable - trade</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable - current portion, net of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US">Earn-out milestone liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, net of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability - non-current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue - non-current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at June 30, 2020 and December 31, 2019)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - $0.01 par value (112,500,000 shares authorized; 33,229,714 and 23,256,152 shares issued at June 30, 2020 and December 31, 2019, respectively, and 33,229,380 and 23,255,818 shares outstanding at June 30, 2020 and December 31, 2019, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive gain</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:label="us-gaap_StockholdersEquityBeforeTreasuryStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="us-gaap_StockholdersEquityBeforeTreasuryStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityBeforeTreasuryStock_lbl" xml:lang="en-US">Total stockholders' equity before treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, at cost (334 shares at June 30, 2020 and December 31, 2019)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Licensing revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other (expense) income:</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainLossFromChangeInEarnoutMilestoneLiability" xlink:label="CLSN_GainLossFromChangeInEarnoutMilestoneLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GainLossFromChangeInEarnoutMilestoneLiability" xlink:to="CLSN_GainLossFromChangeInEarnoutMilestoneLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_GainLossFromChangeInEarnoutMilestoneLiability_lbl" xml:lang="en-US">(Loss) gain from change in valuation of earn-out milestone liability</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:label="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:to="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments_lbl" xml:lang="en-US">Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US">Investment income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other (expense) income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (expense) income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per common share - Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average shares outstanding - Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Other comprehensive (loss) gain</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Changes in:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xml:lang="en-US">Realized (gains) losses on investment securities recognized in investment income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized gains on investment securities, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Change in unrealized (loss) gain, net, on available for sale securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainLossFromValuationOfEarnoutMilestoneLiability" xlink:label="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability" xlink:to="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability_lbl" xml:lang="en-US">Change in fair value of earn-out milestone liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:to="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments_2_lbl" xml:lang="en-US">Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Recognition of deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SharesIssuedInExchangeForServices" xlink:label="CLSN_SharesIssuedInExchangeForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SharesIssuedInExchangeForServices" xlink:to="CLSN_SharesIssuedInExchangeForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_SharesIssuedInExchangeForServices_lbl" xml:lang="en-US">Shares issued in exchange for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" xlink:label="CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" xlink:to="CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable_lbl" xml:lang="en-US">Amortization of deferred finance charges and debt discount associated with notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Net changes in:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_lbl" xml:lang="en-US">Accrued interest on investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Advances, deposits and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xml:lang="en-US">Purchases of investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from sale and maturity of investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock equity, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from issuance of common stock upon conversion of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Proceeds from Payroll Protection Program (PPP) loans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLoans" xlink:label="us-gaap_PaymentsForLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLoans" xlink:to="us-gaap_PaymentsForLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForLoans_lbl" xml:lang="en-US">Repayments on Payroll Protection Program (PPP) loans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="CLSN_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="CLSN_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash financing and investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments" xlink:label="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments" xlink:to="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments_lbl" xml:lang="en-US">Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:label="CLSN_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:to="CLSN_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Right of use assets obtained in exchange for lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RightOfUseAssetsObtainedInExchangeForLease" xlink:label="CLSN_RightOfUseAssetsObtainedInExchangeForLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RightOfUseAssetsObtainedInExchangeForLease" xlink:to="CLSN_RightOfUseAssetsObtainedInExchangeForLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_RightOfUseAssetsObtainedInExchangeForLease_lbl" xml:lang="en-US">Right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_StockIssuedInLieuOfCashBonusPayments" xlink:label="CLSN_StockIssuedInLieuOfCashBonusPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_StockIssuedInLieuOfCashBonusPayments" xlink:to="CLSN_StockIssuedInLieuOfCashBonusPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_StockIssuedInLieuOfCashBonusPayments_lbl" xml:lang="en-US">Stock issued in lieu of cash bonus payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Realized and unrealized (gains) losses, net, on investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SaleOfEquityThroughEquityFinancingFacilities" xlink:label="CLSN_SaleOfEquityThroughEquityFinancingFacilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SaleOfEquityThroughEquityFinancingFacilities" xlink:to="CLSN_SaleOfEquityThroughEquityFinancingFacilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_SaleOfEquityThroughEquityFinancingFacilities_lbl" xml:lang="en-US">Sale of equity through financing facilities</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares" xlink:label="CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares" xlink:to="CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares_lbl" xml:lang="en-US">Sale of equity through financing facilities, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IssuanceOfCommonStockInLieuOfCashBonus" xlink:label="CLSN_IssuanceOfCommonStockInLieuOfCashBonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_IssuanceOfCommonStockInLieuOfCashBonus" xlink:to="CLSN_IssuanceOfCommonStockInLieuOfCashBonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_IssuanceOfCommonStockInLieuOfCashBonus_lbl" xml:lang="en-US">Issuance of common stock in lieu of cash bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares" xlink:label="CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares" xlink:to="CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares_lbl" xml:lang="en-US">Issuance of common stock in lieu of cash bonus, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Common stock warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_lbl" xml:lang="en-US">Realized and unrealized gains and losses, net, on investments securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Business Description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Financial Condition and Business Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:label="us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:to="us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_lbl" xml:lang="en-US">New Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Investment in Debt Securities Available for Sale</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_lbl" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Other Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes and Loans Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiabilityAbstract" xlink:label="CLSN_EarnoutMilestoneLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EarnoutMilestoneLiabilityAbstract" xlink:to="CLSN_EarnoutMilestoneLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_EarnoutMilestoneLiabilityAbstract_lbl" xml:lang="en-US">Hercules Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock" xlink:label="CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock" xlink:to="CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock_lbl" xml:lang="en-US">Earn-out Milestone Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_WarrantsTextBlock" xlink:label="CLSN_WarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_WarrantsTextBlock" xlink:to="CLSN_WarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_WarrantsTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract" xlink:label="CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract" xlink:to="CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract_lbl" xml:lang="en-US">Technology Development And Licensing Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LicensingTransactionTextBlock" xlink:label="CLSN_LicensingTransactionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LicensingTransactionTextBlock" xlink:to="CLSN_LicensingTransactionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_LicensingTransactionTextBlock_lbl" xml:lang="en-US">Technology Development and Licensing Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xml:lang="en-US">Short-term Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of Cost, Fair Value and Maturities of Short Term Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US">Summary of Investment Securities Gross Unrealized Gains (Losses)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeTextBlock" xlink:label="us-gaap_InvestmentIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeTextBlock" xlink:to="us-gaap_InvestmentIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeTextBlock_lbl" xml:lang="en-US">Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Amortization Amounts During the Remaining Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:label="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:to="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Assets Acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Principle Payments, Net of Unamortized Debt Discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock" xlink:label="CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock" xlink:to="CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option and Restricted Stock Awards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions Used to Determine Fair Value of Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock" xlink:label="CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock" xlink:to="CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Earn-out Milestone Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock" xlink:label="CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock" xlink:to="CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Risk Adjustment Assessment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock" xlink:label="CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock" xlink:to="CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Contractual Terms</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_2_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Cumulated net losses</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CashInvestmentSecuritiesAndInterestReceivable" xlink:label="CLSN_CashInvestmentSecuritiesAndInterestReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_CashInvestmentSecuritiesAndInterestReceivable" xlink:to="CLSN_CashInvestmentSecuritiesAndInterestReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_CashInvestmentSecuritiesAndInterestReceivable_lbl" xml:lang="en-US">Cash, investment securities and interest receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization" xlink:label="CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization" xlink:to="CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization_lbl" xml:lang="en-US">Tax benefits of EDA</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NetProceedsFromSaleOfNetOperatingLosses" xlink:label="CLSN_NetProceedsFromSaleOfNetOperatingLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_NetProceedsFromSaleOfNetOperatingLosses" xlink:to="CLSN_NetProceedsFromSaleOfNetOperatingLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_NetProceedsFromSaleOfNetOperatingLosses_lbl" xml:lang="en-US">Net proceeds from sale of net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US">Proceeds from new capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument, interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards" xlink:label="CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards" xlink:to="CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards_lbl" xml:lang="en-US">Number of shares of common stock issuable upon exercise of warrants and equity awards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare" xlink:label="CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare" xlink:to="CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare_lbl" xml:lang="en-US">Number of shares of common stock issued in calculation basic loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2_lbl" xml:lang="en-US">Short-term investments - Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments - Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" xlink:label="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" xlink:to="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost_lbl" xml:lang="en-US">Short-term investment maturities - Within 3 months, cost</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" xlink:label="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" xlink:to="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent_lbl" xml:lang="en-US">Total, cost</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" xlink:label="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" xlink:to="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue_lbl" xml:lang="en-US">Short-term investment maturities - Within 3 months, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US">Total, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" xlink:label="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" xlink:to="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months_lbl" xml:lang="en-US">Investments in debt securities with unrealized Gains, Less than 12 months , Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3_lbl" xml:lang="en-US">Investment securities - available for sale, Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" xlink:label="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" xlink:to="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain_lbl" xml:lang="en-US">Investments in debt securities with unrealized Gains, Less than 12 months, Unrealized Holding Gains</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" xlink:label="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" xlink:to="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized Holding Gains</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xml:lang="en-US">Interest and dividends accrued and paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xml:lang="en-US">Realized gains</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InvestmentIncomeNonoperating_2_lbl" xml:lang="en-US">Investment income, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4_lbl" xml:lang="en-US">Investment securities, available for sale</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xml:lang="en-US">Indefinite lived intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset impairment charges, total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xml:lang="en-US">Goodwill, acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" xlink:label="CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" xlink:to="CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter_lbl" xml:lang="en-US">2022 and thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_4_lbl" xml:lang="en-US">Intangible assets, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_5_lbl" xml:lang="en-US">Intangible assets, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Amounts due to contract research organizations and other contractual agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_RangeAxis_2_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from lines of credit, total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense, debt, total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromLoans_2_lbl" xml:lang="en-US">Proceeds from loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Loan repayment date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Loan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Interest accrued on loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" xlink:label="CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" xlink:to="CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter_lbl" xml:lang="en-US">2024 and thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xml:lang="en-US">Subtotal of future principal payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Unamortized debt issuance costs, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShelfRegistrationStatementAmount" xlink:label="CLSN_ShelfRegistrationStatementAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShelfRegistrationStatementAmount" xlink:to="CLSN_ShelfRegistrationStatementAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ShelfRegistrationStatementAmount_lbl" xml:lang="en-US">Shelf registration statement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateOfferingPriceAdditions" xlink:label="CLSN_AggregateOfferingPriceAdditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AggregateOfferingPriceAdditions" xlink:to="CLSN_AggregateOfferingPriceAdditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AggregateOfferingPriceAdditions_lbl" xml:lang="en-US">Aggregate offering price, additions</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateOfferingPriceTerm" xlink:label="CLSN_AggregateOfferingPriceTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AggregateOfferingPriceTerm" xlink:to="CLSN_AggregateOfferingPriceTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AggregateOfferingPriceTerm_lbl" xml:lang="en-US">Aggregate offering price, term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issued during period, shares, new issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateOfferingPrices" xlink:label="CLSN_AggregateOfferingPrices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AggregateOfferingPrices" xlink:to="CLSN_AggregateOfferingPrices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AggregateOfferingPrices_lbl" xml:lang="en-US">Aggregate offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateValueAvailableForIssuance" xlink:label="CLSN_AggregateValueAvailableForIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AggregateValueAvailableForIssuance" xlink:to="CLSN_AggregateValueAvailableForIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AggregateValueAvailableForIssuance_lbl" xml:lang="en-US">Aggregate value available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Number of warrants to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Shares purchased, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UnderwritingDiscountPricePerShare" xlink:label="CLSN_UnderwritingDiscountPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_UnderwritingDiscountPricePerShare" xlink:to="CLSN_UnderwritingDiscountPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_UnderwritingDiscountPricePerShare_lbl" xml:lang="en-US">Underwriting discount price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice" xlink:label="CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice" xlink:to="CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice_lbl" xml:lang="en-US">Percentage of underwriting discount on public offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Equity awards, number of stock authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of equity awards available for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of stock options granted, during period</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_StockOptionsStrikePriceDescription" xlink:label="CLSN_StockOptionsStrikePriceDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_StockOptionsStrikePriceDescription" xlink:to="CLSN_StockOptionsStrikePriceDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_StockOptionsStrikePriceDescription_lbl" xml:lang="en-US">Stock options, strike price description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Inducement option grant, exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Option vested period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Stock based compensation cost expected to be recognized, weighted average period</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AnnualBonusAwardsPercentage" xlink:label="CLSN_AnnualBonusAwardsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AnnualBonusAwardsPercentage" xlink:to="CLSN_AnnualBonusAwardsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AnnualBonusAwardsPercentage_lbl" xml:lang="en-US">Annual bonus awards, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xml:lang="en-US">Gross proceeds from issuance of common stock upon exercise of stock option</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares of common stock issued upon exercise of stock option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number Outstanding, Outstanding, Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number Outstanding, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Number Outstanding, Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number Outstanding, Vested and issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number Outstanding, Forfeited, cancelled or expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number Outstanding, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice" xlink:label="CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice" xlink:to="CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited, cancelled or expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number Outstanding, Non-vested stock awards outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number Outstanding, Non-vested stock awards outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod_lbl" xml:lang="en-US">Number Outstanding, Non-vested stock awards outstanding, Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number Outstanding, Non-vested stock awards outstanding, Vested and issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number Outstanding, Non-vested stock awards outstanding, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number Outstanding, Non-vested stock awards outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Non-vested stock awards, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Non-vested stock awards, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Non-vested stock awards, Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Non-vested stock awards, Vested and issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Non-vested stock awards, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Non-vested stock awards, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Non-vested stock awards, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentsForEarnoutMilestoneLiability" xlink:label="CLSN_PaymentsForEarnoutMilestoneLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PaymentsForEarnoutMilestoneLiability" xlink:to="CLSN_PaymentsForEarnoutMilestoneLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_PaymentsForEarnoutMilestoneLiability_lbl" xml:lang="en-US">Payments for earnout milestone liability</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentsForEarnoutMilestoneLiabilityInCash" xlink:label="CLSN_PaymentsForEarnoutMilestoneLiabilityInCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PaymentsForEarnoutMilestoneLiabilityInCash" xlink:to="CLSN_PaymentsForEarnoutMilestoneLiabilityInCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_PaymentsForEarnoutMilestoneLiabilityInCash_lbl" xml:lang="en-US">Payments for earnout milestone liability in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiability1" xlink:label="CLSN_EarnoutMilestoneLiability1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EarnoutMilestoneLiability1" xlink:to="CLSN_EarnoutMilestoneLiability1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_EarnoutMilestoneLiability1_lbl" xml:lang="en-US">Earnout milestone liability</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainOnNoncashBenefit" xlink:label="CLSN_GainOnNoncashBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GainOnNoncashBenefit" xlink:to="CLSN_GainOnNoncashBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_GainOnNoncashBenefit_lbl" xml:lang="en-US">Gain on non-cash benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RiskAdjustedAssessmentOfEachMilestone" xlink:label="CLSN_RiskAdjustedAssessmentOfEachMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RiskAdjustedAssessmentOfEachMilestone" xlink:to="CLSN_RiskAdjustedAssessmentOfEachMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_RiskAdjustedAssessmentOfEachMilestone_lbl" xml:lang="en-US">Risk adjusted assessment of each milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability" xlink:label="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability" xlink:to="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability_lbl" xml:lang="en-US">Gain (loss) from change in fair value of earn out milestone liability</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiability" xlink:label="CLSN_EarnoutMilestoneLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EarnoutMilestoneLiability" xlink:to="CLSN_EarnoutMilestoneLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="CLSN_EarnoutMilestoneLiability_lbl" xml:lang="en-US">Earn-out liabilities, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability" xlink:to="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability_2_lbl" xml:lang="en-US">Non-cash loss from the change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EarnoutMilestoneLiability" xlink:to="CLSN_EarnoutMilestoneLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CLSN_EarnoutMilestoneLiability_2_lbl" xml:lang="en-US">Earn-out liabilities, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone" xlink:label="CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone" xlink:to="CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone_lbl" xml:lang="en-US">Risk-adjustment Assessment of achieving each Milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DiscountRateOnMileStoneLiabilities" xlink:label="CLSN_DiscountRateOnMileStoneLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DiscountRateOnMileStoneLiabilities" xlink:to="CLSN_DiscountRateOnMileStoneLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_DiscountRateOnMileStoneLiabilities_lbl" xml:lang="en-US">Discount Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EstimatedTimeToAchieveMileStone" xlink:label="CLSN_EstimatedTimeToAchieveMileStone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EstimatedTimeToAchieveMileStone" xlink:to="CLSN_EstimatedTimeToAchieveMileStone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_EstimatedTimeToAchieveMileStone_lbl" xml:lang="en-US">Estimated Time to Achieve</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants Issued, Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants Issued, Warrants Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants Issued, Warrants Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value of Outstanding Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Number of Warrants Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Contractual Terms Remaining (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">ROU asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Increased ROU asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_2_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" xlink:label="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" xlink:to="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter_lbl" xml:lang="en-US">2024 and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Subtotal future lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US">Non-refundable research and development fee</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DeferredRevenueAmortizationPeriod" xlink:label="CLSN_DeferredRevenueAmortizationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DeferredRevenueAmortizationPeriod" xlink:to="CLSN_DeferredRevenueAmortizationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_DeferredRevenueAmortizationPeriod_lbl" xml:lang="en-US">Deferred revenue amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UpfrontPayment" xlink:label="CLSN_UpfrontPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_UpfrontPayment" xlink:to="CLSN_UpfrontPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_UpfrontPayment_lbl" xml:lang="en-US">Upfront payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US">Payment of legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ATMAgreementMember" xlink:label="CLSN_ATMAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ATMAgreementMember" xlink:to="CLSN_ATMAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ATMAgreementMember_doc" xml:lang="en-US">Represents Controlled Equity Offering Sales Agreement (the &amp;amp;amp;amp;amp;amp;amp;amp;#8220;ATM Agreement&amp;amp;amp;amp;amp;amp;amp;amp;#8221;) with Cantor Fitzgerald &amp;amp;amp;amp;amp;amp;amp;amp;amp; Co., as sales agent.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AchievingMilestoneWithInOneYearMember" xlink:label="CLSN_AchievingMilestoneWithInOneYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AchievingMilestoneWithInOneYearMember" xlink:to="CLSN_AchievingMilestoneWithInOneYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AchievingMilestoneWithInOneYearMember_doc" xml:lang="en-US">Within One Year of Achieving Milestone [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AggregateOfferingPriceAdditions" xlink:to="CLSN_AggregateOfferingPriceAdditions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AggregateOfferingPriceAdditions_doc" xml:lang="en-US">Represents the additional aggregate offering price for shares of common stock that the Company may offer and sell through a sales agent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AggregateOfferingPriceTerm" xlink:to="CLSN_AggregateOfferingPriceTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AggregateOfferingPriceTerm_doc" xml:lang="en-US">Aggregate offering price, term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AggregateOfferingPrices" xlink:to="CLSN_AggregateOfferingPrices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AggregateOfferingPrices_doc" xml:lang="en-US">Aggregate offering price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AggregateValueAvailableForIssuance" xlink:to="CLSN_AggregateValueAvailableForIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AggregateValueAvailableForIssuance_doc" xml:lang="en-US">Aggregate value available for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AllOtherWarrantsMember" xlink:to="CLSN_AllOtherWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AllOtherWarrantsMember_doc" xml:lang="en-US">All Other Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AmendedAssetPurchaseAgreementMember" xlink:label="CLSN_AmendedAssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AmendedAssetPurchaseAgreementMember" xlink:to="CLSN_AmendedAssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AmendedAssetPurchaseAgreementMember_doc" xml:lang="en-US">Amended Asset Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember" xlink:to="CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember_doc" xml:lang="en-US">Amended Asset Purchase Agreement Option Payment 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember" xlink:to="CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember_doc" xml:lang="en-US">Amended Asset Purchase Agreement Option Payment 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AspireCapitalFundLLCMember" xlink:label="CLSN_AspireCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AspireCapitalFundLLCMember" xlink:to="CLSN_AspireCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AspireCapitalFundLLCMember_doc" xml:lang="en-US">Aspire Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AspirePurchaseAgreementMember" xlink:label="CLSN_AspirePurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AspirePurchaseAgreementMember" xlink:to="CLSN_AspirePurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AspirePurchaseAgreementMember_doc" xml:lang="en-US">Aspire Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AspirePurchaseAgreementsMember" xlink:to="CLSN_AspirePurchaseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AspirePurchaseAgreementsMember_doc" xml:lang="en-US">2018 Aspire Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AssetPurchaseAgreementMember" xlink:label="CLSN_AssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AssetPurchaseAgreementMember" xlink:to="CLSN_AssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AssetPurchaseAgreementMember_doc" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" xlink:to="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent_doc" xml:lang="en-US">The current amount of amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" xlink:to="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss_doc" xml:lang="en-US">Amount of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_CapitalOnDemandAgreementMember" xlink:to="CLSN_CapitalOnDemandAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_CapitalOnDemandAgreementMember_doc" xml:lang="en-US">Capital on Demand Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_CapitalOnDemandTMSalesAgreementMember" xlink:to="CLSN_CapitalOnDemandTMSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_CapitalOnDemandTMSalesAgreementMember_doc" xml:lang="en-US">Capital on DemandTM Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_CashInvestmentSecuritiesAndInterestReceivable" xlink:to="CLSN_CashInvestmentSecuritiesAndInterestReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_CashInvestmentSecuritiesAndInterestReceivable_doc" xml:lang="en-US">The amount of cash, investment securities and interest receivable.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CertainBusinessDaysOfAchievingMilestoneMember" xlink:label="CLSN_CertainBusinessDaysOfAchievingMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_CertainBusinessDaysOfAchievingMilestoneMember" xlink:to="CLSN_CertainBusinessDaysOfAchievingMilestoneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_CertainBusinessDaysOfAchievingMilestoneMember_doc" xml:lang="en-US">10 Business Days of Achieving Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CommonStockSalesAgreementMember" xlink:label="CLSN_CommonStockSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_CommonStockSalesAgreementMember" xlink:to="CLSN_CommonStockSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_CommonStockSalesAgreementMember_doc" xml:lang="en-US">Common Stock Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ControlledEquityOfferingSMSalesAgreementMember" xlink:label="CLSN_ControlledEquityOfferingSMSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ControlledEquityOfferingSMSalesAgreementMember" xlink:to="CLSN_ControlledEquityOfferingSMSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ControlledEquityOfferingSMSalesAgreementMember_doc" xml:lang="en-US">Controlled Equity Offering SM Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" xlink:to="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months_doc" xml:lang="en-US">Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) unrealized gain less than 12 months.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" xlink:to="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain_doc" xml:lang="en-US">Amount of accumulated unrealized gain on investment in debt security measured at fair value with change in other comprehensive income (available-for-sale), unrealized gain for less than 12 months.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" xlink:to="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost_doc" xml:lang="en-US">Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with single maturity date and allocated without single maturity date, maturing in next rolling three months.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" xlink:to="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue_doc" xml:lang="en-US">Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three months.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DukeUniversityMember" xlink:label="CLSN_DukeUniversityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DukeUniversityMember" xlink:to="CLSN_DukeUniversityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_DukeUniversityMember_doc" xml:lang="en-US">Duke University [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EGENAssetPurchaseAgreementMember" xlink:label="CLSN_EGENAssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EGENAssetPurchaseAgreementMember" xlink:to="CLSN_EGENAssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_EGENAssetPurchaseAgreementMember_doc" xml:lang="en-US">EGEN Asset Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EGENIncMember" xlink:to="CLSN_EGENIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_EGENIncMember_doc" xml:lang="en-US">Information pertaining to the business acquisition of EGEN, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EGENMember" xlink:label="CLSN_EGENMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EGENMember" xlink:to="CLSN_EGENMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_EGENMember_doc" xml:lang="en-US">EGEN Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EGWUIncMember" xlink:to="CLSN_EGWUIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_EGWUIncMember_doc" xml:lang="en-US">EGWU, Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EquityStockAwardsMember" xlink:to="CLSN_EquityStockAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_EquityStockAwardsMember_doc" xml:lang="en-US">Equity Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ExerciseAgreementsMember" xlink:label="CLSN_ExerciseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ExerciseAgreementsMember" xlink:to="CLSN_ExerciseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ExerciseAgreementsMember_doc" xml:lang="en-US">Exercise Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ExercisePriceOneMember" xlink:label="CLSN_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ExercisePriceOneMember" xlink:to="CLSN_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ExercisePriceTwoMember" xlink:label="CLSN_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ExercisePriceTwoMember" xlink:to="CLSN_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FairValueEarnoutMilestoneLiabilityMember" xlink:to="CLSN_FairValueEarnoutMilestoneLiabilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FairValueEarnoutMilestoneLiabilityMember_doc" xml:lang="en-US">Fair Value Earnout Milestone Liability [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_February142017PublicOfferingMember" xlink:label="CLSN_February142017PublicOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_February142017PublicOfferingMember" xlink:to="CLSN_February142017PublicOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_February142017PublicOfferingMember_doc" xml:lang="en-US">Represents the public offering on February 14, 2017.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FebruaryFourteenTwoThousandAndSeventeenPublicOfferingMember" xlink:label="CLSN_FebruaryFourteenTwoThousandAndSeventeenPublicOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FebruaryFourteenTwoThousandAndSeventeenPublicOfferingMember" xlink:to="CLSN_FebruaryFourteenTwoThousandAndSeventeenPublicOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FebruaryFourteenTwoThousandAndSeventeenPublicOfferingMember_doc" xml:lang="en-US">February 14, 2017 Public Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FederalIncomeTaxMember" xlink:label="CLSN_FederalIncomeTaxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FederalIncomeTaxMember" xlink:to="CLSN_FederalIncomeTaxMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FederalIncomeTaxMember_doc" xml:lang="en-US">Federal Income Tax [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FinalYearMember" xlink:label="CLSN_FinalYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FinalYearMember" xlink:to="CLSN_FinalYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FinalYearMember_doc" xml:lang="en-US">Final Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FirstLeaseAmendmentMember" xlink:label="CLSN_FirstLeaseAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FirstLeaseAmendmentMember" xlink:to="CLSN_FirstLeaseAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FirstLeaseAmendmentMember_doc" xml:lang="en-US">1st Lease Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FirstTrancheMember" xlink:label="CLSN_FirstTrancheMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FirstTrancheMember" xlink:to="CLSN_FirstTrancheMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FirstTrancheMember_doc" xml:lang="en-US">First Tranche [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FirstYearMember" xlink:label="CLSN_FirstYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FirstYearMember" xlink:to="CLSN_FirstYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FirstYearMember_doc" xml:lang="en-US">First Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FiveNewEmployeesMember" xlink:to="CLSN_FiveNewEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FiveNewEmployeesMember_doc" xml:lang="en-US">Five New Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GeneralAndAdministrativeExpensesMember" xlink:label="CLSN_GeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GeneralAndAdministrativeExpensesMember" xlink:to="CLSN_GeneralAndAdministrativeExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_GeneralAndAdministrativeExpensesMember_doc" xml:lang="en-US">General and Administrative Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GlioblastomaMultiformeBrainCancerMember" xlink:to="CLSN_GlioblastomaMultiformeBrainCancerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_GlioblastomaMultiformeBrainCancerMember_doc" xml:lang="en-US">Glioblastoma Multiforme Brain Cancer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HerculesCreditAgreementMember" xlink:label="CLSN_HerculesCreditAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HerculesCreditAgreementMember" xlink:to="CLSN_HerculesCreditAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_HerculesCreditAgreementMember_doc" xml:lang="en-US">Represents a loan agreement with Hercules Technology Growth Capital, Inc. (&amp;amp;amp;amp;amp;amp;amp;amp;#8220;Hercules&amp;amp;amp;amp;amp;amp;amp;amp;#8221;).</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HerculesMember" xlink:label="CLSN_HerculesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HerculesMember" xlink:to="CLSN_HerculesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_HerculesMember_doc" xml:lang="en-US">Represents Hercules Technology Growth Capital, Inc..</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HerculesTechnologyGrowthCapitalIncMember" xlink:label="CLSN_HerculesTechnologyGrowthCapitalIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HerculesTechnologyGrowthCapitalIncMember" xlink:to="CLSN_HerculesTechnologyGrowthCapitalIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_HerculesTechnologyGrowthCapitalIncMember_doc" xml:lang="en-US">Hercules Technology Growth Capital, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HerculesWarrantMember" xlink:label="CLSN_HerculesWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HerculesWarrantMember" xlink:to="CLSN_HerculesWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_HerculesWarrantMember_doc" xml:lang="en-US">Represents Hercules Technology Growth Capital, Inc..</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HisunAgreementMember" xlink:label="CLSN_HisunAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HisunAgreementMember" xlink:to="CLSN_HisunAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_HisunAgreementMember_doc" xml:lang="en-US">Hisun Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HisunMember" xlink:to="CLSN_HisunMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_HisunMember_doc" xml:lang="en-US">Hisun [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HorizonCreditAgreementMember" xlink:to="CLSN_HorizonCreditAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_HorizonCreditAgreementMember_doc" xml:lang="en-US">Horizon Credit Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HorizonTechnologyFinanceCorporationMember" xlink:to="CLSN_HorizonTechnologyFinanceCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_HorizonTechnologyFinanceCorporationMember_doc" xml:lang="en-US">Horizon Technology Finance Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonWarrantMember" xlink:label="CLSN_HorizonWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HorizonWarrantMember" xlink:to="CLSN_HorizonWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_HorizonWarrantMember_doc" xml:lang="en-US">Horizon Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_HuntsvilleAlabamaMember" xlink:to="CLSN_HuntsvilleAlabamaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_HuntsvilleAlabamaMember_doc" xml:lang="en-US">Huntsville Alabama [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_IPRAndDDrugTechnologyPlatformsMember" xlink:to="CLSN_IPRAndDDrugTechnologyPlatformsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_IPRAndDDrugTechnologyPlatformsMember_doc" xml:lang="en-US">IPR&amp;amp;amp;amp;amp;amp;amp;D Drug Technology Platforms [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_IPRAndDMember" xlink:to="CLSN_IPRAndDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_IPRAndDMember_doc" xml:lang="en-US">IPR&amp;amp;amp;amp;amp;amp;D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_InProcessResearchAndDevelopmentTwoMember" xlink:label="CLSN_InProcessResearchAndDevelopmentTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_InProcessResearchAndDevelopmentTwoMember" xlink:to="CLSN_InProcessResearchAndDevelopmentTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_InProcessResearchAndDevelopmentTwoMember_doc" xml:lang="en-US">In Process R and D - GBM Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_InducementAwardsMember" xlink:to="CLSN_InducementAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_InducementAwardsMember_doc" xml:lang="en-US">Inducement Awards [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_InducementOptionGrantsMember" xlink:to="CLSN_InducementOptionGrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_InducementOptionGrantsMember_doc" xml:lang="en-US">Inducement Option Grants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_InvestorWarrantMember" xlink:label="CLSN_InvestorWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_InvestorWarrantMember" xlink:to="CLSN_InvestorWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_InvestorWarrantMember_doc" xml:lang="en-US">Investor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_July2017DirectOfferingMember" xlink:label="CLSN_July2017DirectOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_July2017DirectOfferingMember" xlink:to="CLSN_July2017DirectOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_July2017DirectOfferingMember_doc" xml:lang="en-US">Represents the information pertaining to the direct offering agreement on July 6, 2017.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_JuneTwoThousandAndSixrteenWarrantsMember" xlink:label="CLSN_JuneTwoThousandAndSixrteenWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_JuneTwoThousandAndSixrteenWarrantsMember" xlink:to="CLSN_JuneTwoThousandAndSixrteenWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_JuneTwoThousandAndSixrteenWarrantsMember_doc" xml:lang="en-US">June 2016 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LawrencevilleNewJerseyMember" xlink:to="CLSN_LawrencevilleNewJerseyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_LawrencevilleNewJerseyMember_doc" xml:lang="en-US">Lawrenceville New Jersey [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LeaseContractTypeAxis" xlink:label="CLSN_LeaseContractTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LeaseContractTypeAxis" xlink:to="CLSN_LeaseContractTypeAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_LeaseContractTypeAxis_doc" xml:lang="en-US">Lease Contract Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LicenseAgreementMember" xlink:label="CLSN_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LicenseAgreementMember" xlink:to="CLSN_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LoanAgreementMember" xlink:label="CLSN_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LoanAgreementMember" xlink:to="CLSN_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_LoanAgreementMember_doc" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_May2015CommonStockOfferingMember" xlink:label="CLSN_May2015CommonStockOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_May2015CommonStockOfferingMember" xlink:to="CLSN_May2015CommonStockOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_May2015CommonStockOfferingMember_doc" xml:lang="en-US">Represents a securities purchase agreement with certain investors into which the entity entered in May 2015.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_NJMember" xlink:to="CLSN_NJMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_NJMember_doc" xml:lang="en-US">New Jersey [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_NetProceedsFromSaleOfNetOperatingLosses" xlink:to="CLSN_NetProceedsFromSaleOfNetOperatingLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_NetProceedsFromSaleOfNetOperatingLosses_doc" xml:lang="en-US">Net proceeds from sale of net operating losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards" xlink:to="CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards_doc" xml:lang="en-US">Represents the total number of Shares of common stock issuable upon exercise of warrants and equity awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare" xlink:to="CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare_doc" xml:lang="en-US">Number of shares of common stock issued in calculation basic loss per share.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_October2017UnderwrittenOfferingMember" xlink:label="CLSN_October2017UnderwrittenOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_October2017UnderwrittenOfferingMember" xlink:to="CLSN_October2017UnderwrittenOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_October2017UnderwrittenOfferingMember_doc" xml:lang="en-US">Represents the October 2017 Underwritten Offering.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_OperatingLeasesMember" xlink:label="CLSN_OperatingLeasesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_OperatingLeasesMember" xlink:to="CLSN_OperatingLeasesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_OperatingLeasesMember_doc" xml:lang="en-US">Operating Leases [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_OppenheimerAndCoIncMember" xlink:label="CLSN_OppenheimerAndCoIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_OppenheimerAndCoIncMember" xlink:to="CLSN_OppenheimerAndCoIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_OppenheimerAndCoIncMember_doc" xml:lang="en-US">Oppenheimer &amp;amp;amp;amp;amp;amp;amp; Co. Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_OriginalWarrantsMember" xlink:to="CLSN_OriginalWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_OriginalWarrantsMember_doc" xml:lang="en-US">Original Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_OtherWarrantsMember" xlink:label="CLSN_OtherWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_OtherWarrantsMember" xlink:to="CLSN_OtherWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_OtherWarrantsMember_doc" xml:lang="en-US">Other Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_OvarianCancerMember" xlink:to="CLSN_OvarianCancerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_OvarianCancerMember_doc" xml:lang="en-US">Ovarian Cancer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PreFundedSeriesBBWarrantMember" xlink:label="CLSN_PreFundedSeriesBBWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PreFundedSeriesBBWarrantMember" xlink:to="CLSN_PreFundedSeriesBBWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_PreFundedSeriesBBWarrantMember_doc" xml:lang="en-US">Information relating to Pre-Funded Series BB Warrant.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PreFundedSeriesCCCWarrantsMember" xlink:label="CLSN_PreFundedSeriesCCCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PreFundedSeriesCCCWarrantsMember" xlink:to="CLSN_PreFundedSeriesCCCWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_PreFundedSeriesCCCWarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to the Pre-Funded Series CCC Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PrivateExchangeAgreementsMember" xlink:to="CLSN_PrivateExchangeAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_PrivateExchangeAgreementsMember_doc" xml:lang="en-US">Private Exchange Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PurchaseAgreementMember" xlink:to="CLSN_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RecognizedNonCashChargeMember" xlink:label="CLSN_RecognizedNonCashChargeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RecognizedNonCashChargeMember" xlink:to="CLSN_RecognizedNonCashChargeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_RecognizedNonCashChargeMember_doc" xml:lang="en-US">Recognized Non-cash Charge [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RecognizedNoncashBenefitMember" xlink:label="CLSN_RecognizedNoncashBenefitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RecognizedNoncashBenefitMember" xlink:to="CLSN_RecognizedNoncashBenefitMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_RecognizedNoncashBenefitMember_doc" xml:lang="en-US">Recognized Non-cash Benefit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ReductionInWarrantsMember" xlink:label="CLSN_ReductionInWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ReductionInWarrantsMember" xlink:to="CLSN_ReductionInWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ReductionInWarrantsMember_doc" xml:lang="en-US">Reduction in Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RevenueRatablyThroughTwentyTwentyTwoMember" xlink:label="CLSN_RevenueRatablyThroughTwentyTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RevenueRatablyThroughTwentyTwentyTwoMember" xlink:to="CLSN_RevenueRatablyThroughTwentyTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_RevenueRatablyThroughTwentyTwentyTwoMember_doc" xml:lang="en-US">Revenue Ratably Through 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SecondLeaseAmendmentMember" xlink:label="CLSN_SecondLeaseAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SecondLeaseAmendmentMember" xlink:to="CLSN_SecondLeaseAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SecondLeaseAmendmentMember_doc" xml:lang="en-US">2nd Lease Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SecondTrancheMember" xlink:label="CLSN_SecondTrancheMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SecondTrancheMember" xlink:to="CLSN_SecondTrancheMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SecondTrancheMember_doc" xml:lang="en-US">Second Tranche [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SecuritiesPurchaseAgreementMember" xlink:to="CLSN_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SeriesAAAWarrantsMember" xlink:label="CLSN_SeriesAAAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SeriesAAAWarrantsMember" xlink:to="CLSN_SeriesAAAWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SeriesAAAWarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to the Series AAA Warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SeriesAAWarrantMember" xlink:label="CLSN_SeriesAAWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SeriesAAWarrantMember" xlink:to="CLSN_SeriesAAWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SeriesAAWarrantMember_doc" xml:lang="en-US">Information relating to Series AA warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SeriesBBBWarrantsMember" xlink:label="CLSN_SeriesBBBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SeriesBBBWarrantsMember" xlink:to="CLSN_SeriesBBBWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SeriesBBBWarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to the Series BBB Warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SeriesDDDWarrantsMember" xlink:label="CLSN_SeriesDDDWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SeriesDDDWarrantsMember" xlink:to="CLSN_SeriesDDDWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SeriesDDDWarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to Series DDD Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShelfRegistrationStatementAmount" xlink:to="CLSN_ShelfRegistrationStatementAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ShelfRegistrationStatementAmount_doc" xml:lang="en-US">Shelf Registration statement.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SixtyMonthLeaseMember" xlink:label="CLSN_SixtyMonthLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SixtyMonthLeaseMember" xlink:to="CLSN_SixtyMonthLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SixtyMonthLeaseMember_doc" xml:lang="en-US">60 Month Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization" xlink:to="CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization_doc" xml:lang="en-US">Tax benefits of EDA</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TaxReformActMember" xlink:label="CLSN_TaxReformActMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TaxReformActMember" xlink:to="CLSN_TaxReformActMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TaxReformActMember_doc" xml:lang="en-US">Tax Reform Act [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ThreeNewEmployeesMember" xlink:label="CLSN_ThreeNewEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ThreeNewEmployeesMember" xlink:to="CLSN_ThreeNewEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ThreeNewEmployeesMember_doc" xml:lang="en-US">Three New Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandAndEighteenStockIncentivePlanMember" xlink:to="CLSN_TwoThousandAndEighteenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TwoThousandAndEighteenStockIncentivePlanMember_doc" xml:lang="en-US">2018 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandAndSevenStockIncentivePlanMember" xlink:label="CLSN_TwoThousandAndSevenStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandAndSevenStockIncentivePlanMember" xlink:to="CLSN_TwoThousandAndSevenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TwoThousandAndSevenStockIncentivePlanMember_doc" xml:lang="en-US">2007 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember" xlink:to="CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember_doc" xml:lang="en-US">2018 Aspire Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandFifteenWarrantsMember" xlink:label="CLSN_TwoThousandFifteenWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandFifteenWarrantsMember" xlink:to="CLSN_TwoThousandFifteenWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TwoThousandFifteenWarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to the 2015 Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember" xlink:to="CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember_doc" xml:lang="en-US">2019 Aspire Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandThirteenWarrants2014WarrantsAndJune2016WarrantsMember" xlink:label="CLSN_TwoThousandThirteenWarrants2014WarrantsAndJune2016WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandThirteenWarrants2014WarrantsAndJune2016WarrantsMember" xlink:to="CLSN_TwoThousandThirteenWarrants2014WarrantsAndJune2016WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TwoThousandThirteenWarrants2014WarrantsAndJune2016WarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to the 2013 Warrants, 2014 Warrants, and June 2016 Warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_USFederalAndStateTaxMember" xlink:label="CLSN_USFederalAndStateTaxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_USFederalAndStateTaxMember" xlink:to="CLSN_USFederalAndStateTaxMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_USFederalAndStateTaxMember_doc" xml:lang="en-US">U.S. Federal and State Tax [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_UnderwritingAgreementMember" xlink:to="CLSN_UnderwritingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_UnderwritingAgreementMember_doc" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_WarrantExchangeAgreementsMember" xlink:label="CLSN_WarrantExchangeAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_WarrantExchangeAgreementsMember" xlink:to="CLSN_WarrantExchangeAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_WarrantExchangeAgreementsMember_doc" xml:lang="en-US">Warrant Exchange Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock" xlink:to="CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock_doc" xml:lang="en-US">Summary of stock option and restricted stock awards [Table text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RNADeliverySystemMember" xlink:to="CLSN_RNADeliverySystemMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_RNADeliverySystemMember_doc" xml:lang="en-US">RNA Delivery System [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" xlink:to="CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter_doc" xml:lang="en-US">2023 and thereafter.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandSevenStockIncentivePlanMember" xlink:to="CLSN_TwoThousandSevenStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TwoThousandSevenStockIncentivePlanMember_doc" xml:lang="en-US">2007 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_StockOptionsStrikePriceDescription" xlink:to="CLSN_StockOptionsStrikePriceDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_StockOptionsStrikePriceDescription_doc" xml:lang="en-US">Stock options, strike price description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoNewEmployeesMember" xlink:to="CLSN_TwoNewEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TwoNewEmployeesMember_doc" xml:lang="en-US">Two New Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" xlink:to="CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember_doc" xml:lang="en-US">Granted Under 2018 Plan and 2007 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandAndEighteenPlanMember" xlink:to="CLSN_TwoThousandAndEighteenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TwoThousandAndEighteenPlanMember_doc" xml:lang="en-US">2018 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember" xlink:to="CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember_doc" xml:lang="en-US">Stock Options and Restricted Stock Awards [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_NonVestedStockBasedCompensationArrangementsMember" xlink:to="CLSN_NonVestedStockBasedCompensationArrangementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_NonVestedStockBasedCompensationArrangementsMember_doc" xml:lang="en-US">Non-Vested Stock-Based Compensation Arrangements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_TwoThousandNineteenBonusProgramMember" xlink:to="CLSN_TwoThousandNineteenBonusProgramMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_TwoThousandNineteenBonusProgramMember_doc" xml:lang="en-US">2019 Bonus Program [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AnnualBonusAwardsPercentage" xlink:to="CLSN_AnnualBonusAwardsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AnnualBonusAwardsPercentage_doc" xml:lang="en-US">Annual bonus awards, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PaymentOptionOneMember" xlink:to="CLSN_PaymentOptionOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_PaymentOptionOneMember_doc" xml:lang="en-US">Payment Option One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PaymentOptionTwoMember" xlink:to="CLSN_PaymentOptionTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_PaymentOptionTwoMember_doc" xml:lang="en-US">Payment Option Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AprilPaycheckProtectionProgramLoanMember" xlink:to="CLSN_AprilPaycheckProtectionProgramLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AprilPaycheckProtectionProgramLoanMember_doc" xml:lang="en-US">April PPP Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SiliconValleyBankMember" xlink:to="CLSN_SiliconValleyBankMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SiliconValleyBankMember_doc" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PaycheckProtectionProgramLoansMember" xlink:to="CLSN_PaycheckProtectionProgramLoansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_PaycheckProtectionProgramLoansMember_doc" xml:lang="en-US">PPP Loans [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_MayPaycheckProtectionProgramLoanMember" xlink:to="CLSN_MayPaycheckProtectionProgramLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_MayPaycheckProtectionProgramLoanMember_doc" xml:lang="en-US">May PPP Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_UnderwrittenOfferingMember" xlink:to="CLSN_UnderwrittenOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_UnderwrittenOfferingMember_doc" xml:lang="en-US">Underwritten Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_UnderwritingDiscountPricePerShare" xlink:to="CLSN_UnderwritingDiscountPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_UnderwritingDiscountPricePerShare_doc" xml:lang="en-US">Underwriting discount price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice" xlink:to="CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice_doc" xml:lang="en-US">Percentage of underwriting discount on public offering price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice" xlink:to="CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted Average Exercise Price, Options exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" xlink:to="CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter_doc" xml:lang="en-US">Finite-lived intangible asset, expected amortization, year two, and after.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod_doc" xml:lang="en-US">Number Outstanding, Non-vested stock awards outstanding, Options exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted Average Grant Date Fair Value, Non-vested stock awards, Options exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GainLossFromChangeInEarnoutMilestoneLiability" xlink:to="CLSN_GainLossFromChangeInEarnoutMilestoneLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_GainLossFromChangeInEarnoutMilestoneLiability_doc" xml:lang="en-US">Gain (loss) from change in valuation of earn-out milestone liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:to="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments_doc" xml:lang="en-US">Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability" xlink:to="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability_doc" xml:lang="en-US">The amount recognized in earnings related to the change in fair value during the period of milestone liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SharesIssuedInExchangeForServices" xlink:to="CLSN_SharesIssuedInExchangeForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SharesIssuedInExchangeForServices_doc" xml:lang="en-US">Shares issued in exchange for services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" xlink:to="CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable_doc" xml:lang="en-US">Amortization of deferred finance charges and debt discount associated with note payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments" xlink:to="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments_doc" xml:lang="en-US">Fair value of warrants issued in connection with amendment to modify the related earn-out milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:to="CLSN_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_doc" xml:lang="en-US">Right of use assets obtained in exchange for lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RightOfUseAssetsObtainedInExchangeForLease" xlink:to="CLSN_RightOfUseAssetsObtainedInExchangeForLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_RightOfUseAssetsObtainedInExchangeForLease_doc" xml:lang="en-US">Right of use assets, obtained in exchange for lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SaleOfEquityThroughEquityFinancingFacilities" xlink:to="CLSN_SaleOfEquityThroughEquityFinancingFacilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SaleOfEquityThroughEquityFinancingFacilities_doc" xml:lang="en-US">Sale of equity through financing facilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares" xlink:to="CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares_doc" xml:lang="en-US">Sale of equity through financing facilities, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock" xlink:to="CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock_doc" xml:lang="en-US">The disclosure related to earn-out milestone liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_WarrantsTextBlock" xlink:to="CLSN_WarrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_WarrantsTextBlock_doc" xml:lang="en-US">Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LicensingTransactionTextBlock" xlink:to="CLSN_LicensingTransactionTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_LicensingTransactionTextBlock_doc" xml:lang="en-US">The entire disclosure for a contractual arrangement, in which the Company gave another party an exclusive license.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock" xlink:to="CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock_doc" xml:lang="en-US">The disclosure of transactions regarding the changes in earn-out liabilities during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock" xlink:to="CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock_doc" xml:lang="en-US">Schedule of risk-adjustment assessment [Table text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock" xlink:to="CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of weighted average remaining contractual terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EarnoutMilestoneLiability1" xlink:to="CLSN_EarnoutMilestoneLiability1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_EarnoutMilestoneLiability1_doc" xml:lang="en-US">Earnout milestone liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GainOnNoncashBenefit" xlink:to="CLSN_GainOnNoncashBenefit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_GainOnNoncashBenefit_doc" xml:lang="en-US">Gain on non-cash benefit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RiskAdjustedAssessmentOfEachMilestone" xlink:to="CLSN_RiskAdjustedAssessmentOfEachMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_RiskAdjustedAssessmentOfEachMilestone_doc" xml:lang="en-US">The percentage of risk-adjusted assessment of each milestone.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability" xlink:to="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability_doc" xml:lang="en-US">The amount of gain (loss) from the change in the fair value of earn-out milestone liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EarnoutMilestoneLiability" xlink:to="CLSN_EarnoutMilestoneLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_EarnoutMilestoneLiability_doc" xml:lang="en-US">Earn-out liabilities, beginning balance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone" xlink:to="CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone_doc" xml:lang="en-US">Risk-adjustment assessment of achieving each milestone.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DiscountRateOnMileStoneLiabilities" xlink:to="CLSN_DiscountRateOnMileStoneLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_DiscountRateOnMileStoneLiabilities_doc" xml:lang="en-US">Discount rate on milestone liabilites.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EstimatedTimeToAchieveMileStone" xlink:to="CLSN_EstimatedTimeToAchieveMileStone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_EstimatedTimeToAchieveMileStone_doc" xml:lang="en-US">Estimated time to achieve milestone liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue_doc" xml:lang="en-US">Weighted Average Exercise Price, Warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" xlink:to="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter_doc" xml:lang="en-US">Year four and there after.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DeferredRevenueAmortizationPeriod" xlink:to="CLSN_DeferredRevenueAmortizationPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_DeferredRevenueAmortizationPeriod_doc" xml:lang="en-US">The amortization period for deferred revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_UpfrontPayment" xlink:to="CLSN_UpfrontPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_UpfrontPayment_doc" xml:lang="en-US">Upfront payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_StockIssuedInLieuOfCashBonusPayments" xlink:to="CLSN_StockIssuedInLieuOfCashBonusPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_StockIssuedInLieuOfCashBonusPayments_doc" xml:lang="en-US">Stock issued in lieu of cash bonus payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_IssuanceOfCommonStockInLieuOfCashBonus" xlink:to="CLSN_IssuanceOfCommonStockInLieuOfCashBonus_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_IssuanceOfCommonStockInLieuOfCashBonus_doc" xml:lang="en-US">Issuance of common stock in lieu of cash bonus.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares" xlink:to="CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares_doc" xml:lang="en-US">Issuance of common stock in lieu of cash bonus, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PaymentsForEarnoutMilestoneLiability" xlink:to="CLSN_PaymentsForEarnoutMilestoneLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_PaymentsForEarnoutMilestoneLiability_doc" xml:lang="en-US">Payments for earnout milestone liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_PaymentsForEarnoutMilestoneLiabilityInCash" xlink:to="CLSN_PaymentsForEarnoutMilestoneLiabilityInCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLSN_PaymentsForEarnoutMilestoneLiabilityInCash_doc" xml:lang="en-US">Payments for earnout milestone liability in cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AspirePurchaseAgreementsMember" xlink:to="CLSN_AspirePurchaseAgreementsMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AspirePurchaseAgreementsMember_3_lbl" xml:lang="en-US">clsn_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsAmortizedCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="us-gaap_StockholdersEquityBeforeTreasuryStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityBeforeTreasuryStock_2_lbl" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_2_lbl" xml:lang="en-US">Interest and Debt Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_lbl" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability" xlink:to="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_GainLossFromValuationOfEarnoutMilestoneLiability_3_lbl" xml:lang="en-US">Loss from change in valuation of earn-out milestone liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Investment Income Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLoans" xlink:to="us-gaap_PaymentsForLoans_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLoans_2_lbl" xml:lang="en-US">Payments for Loans</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_2_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" xlink:to="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent_3_lbl" xml:lang="en-US">Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_2_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" xlink:to="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months_3_lbl" xml:lang="en-US">Less than 12 months, unrealized gains, fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" xlink:to="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss_3_lbl" xml:lang="en-US">Unrealized gains (losses)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_2_lbl" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_EarnoutMilestoneLiability" xlink:to="CLSN_EarnoutMilestoneLiability_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_EarnoutMilestoneLiability_4_lbl" xml:lang="en-US">EarnoutMilestoneLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">clsn_AmountOfTimeAfterEffectiveDateOfLicenseAgreementForRegistrationRightsToTakePlace</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">clsn_NumberOfTrademarkProtectionApplicationPendingForThermoDox</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" xlink:to="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter_3_lbl" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>clsn-20200630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CLSN %2D 20200630 10Q Q2 DFN.xfr; Date: 2020%2D08%2D14T04:09:48Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80060006 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celsion.com/role/DocumentAndEntityInformation" xlink:href="clsn-20200630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BalanceSheets" xlink:href="clsn-20200630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BalanceSheetsParenthetical" xlink:href="clsn-20200630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfOperations" xlink:href="clsn-20200630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfComprehensiveLoss" xlink:href="clsn-20200630.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfCashFlows" xlink:href="clsn-20200630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="clsn-20200630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BusinessDescription" xlink:href="clsn-20200630.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/BasisOfPresentation" xlink:href="clsn-20200630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FinancialConditionAndBusinessPlan" xlink:href="clsn-20200630.xsd#FinancialConditionAndBusinessPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NewAccountingPronouncements" xlink:href="clsn-20200630.xsd#NewAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NetLossPerCommonShare" xlink:href="clsn-20200630.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FairValueMeasurements" xlink:href="clsn-20200630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssets" xlink:href="clsn-20200630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/OtherAccruedLiabilities" xlink:href="clsn-20200630.xsd#OtherAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayable" xlink:href="clsn-20200630.xsd#NotesAndLoansPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StockholdersEquity" xlink:href="clsn-20200630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensation" xlink:href="clsn-20200630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiability" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Warrants" xlink:href="clsn-20200630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Leases" xlink:href="clsn-20200630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreements" xlink:href="clsn-20200630.xsd#TechnologyDevelopmentAndLicensingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/CommitmentsAndContingencies" xlink:href="clsn-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/SubsequentEvents" xlink:href="clsn-20200630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleTables" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSaleTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FairValueMeasurementsTables" xlink:href="clsn-20200630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssetsTables" xlink:href="clsn-20200630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/OtherAccruedLiabilitiesTables" xlink:href="clsn-20200630.xsd#OtherAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayableTables" xlink:href="clsn-20200630.xsd#NotesAndLoansPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensationTables" xlink:href="clsn-20200630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiabilityTables" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/WarrantsTables" xlink:href="clsn-20200630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/LeasesTables" xlink:href="clsn-20200630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FinancialConditionAndBusinessPlanDetailsNarrative" xlink:href="clsn-20200630.xsd#FinancialConditionAndBusinessPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="clsn-20200630.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails" xlink:href="clsn-20200630.xsd#InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="clsn-20200630.xsd#FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssetsDetailsNarrative" xlink:href="clsn-20200630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails" xlink:href="clsn-20200630.xsd#IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails" xlink:href="clsn-20200630.xsd#IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails" xlink:href="clsn-20200630.xsd#OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayableDetailsNarrative" xlink:href="clsn-20200630.xsd#NotesAndLoansPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails" xlink:href="clsn-20200630.xsd#NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/StockholdersEquityDetailsNarrative" xlink:href="clsn-20200630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="clsn-20200630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails" xlink:href="clsn-20200630.xsd#Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:href="clsn-20200630.xsd#Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiabilityDetailsNarrative" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails" xlink:href="clsn-20200630.xsd#Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Warrants-SummaryOfWarrantActivityDetails" xlink:href="clsn-20200630.xsd#Warrants-SummaryOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails" xlink:href="clsn-20200630.xsd#Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/LeasesDetailsNarrative" xlink:href="clsn-20200630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails" xlink:href="clsn-20200630.xsd#Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative" xlink:href="clsn-20200630.xsd#TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celsion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="clsn-20200630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="loc_us-gaapAccruedInvestmentIncomeReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccruedInvestmentIncomeReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapGrantsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:label="loc_us-gaapStockholdersEquityBeforeTreasuryStock" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityBeforeTreasuryStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaapTreasuryStockShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainLossFromChangeInEarnoutMilestoneLiability" xlink:label="loc_CLSNGainLossFromChangeInEarnoutMilestoneLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CLSNGainLossFromChangeInEarnoutMilestoneLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:label="loc_CLSNFairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_CLSNFairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainLossFromValuationOfEarnoutMilestoneLiability" xlink:label="loc_CLSNGainLossFromValuationOfEarnoutMilestoneLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CLSNGainLossFromValuationOfEarnoutMilestoneLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:label="loc_CLSNFairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CLSNFairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SharesIssuedInExchangeForServices" xlink:label="loc_CLSNSharesIssuedInExchangeForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CLSNSharesIssuedInExchangeForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" xlink:label="loc_CLSNAmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CLSNAmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInvestmentIncomeReceivable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaapPaymentsToAcquireAvailableForSaleSecurities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireAvailableForSaleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLoans" xlink:label="loc_us-gaapPaymentsForLoans" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForLoans" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:label="loc_CLSNCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_CLSNCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments" xlink:label="loc_CLSNFairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLSNFairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:label="loc_CLSNRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_CLSNRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RightOfUseAssetsObtainedInExchangeForLease" xlink:label="loc_CLSNRightOfUseAssetsObtainedInExchangeForLease" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:to="loc_CLSNRightOfUseAssetsObtainedInExchangeForLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_StockIssuedInLieuOfCashBonusPayments" xlink:label="loc_CLSNStockIssuedInLieuOfCashBonusPayments" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:to="loc_CLSNStockIssuedInLieuOfCashBonusPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SaleOfEquityThroughEquityFinancingFacilities" xlink:label="loc_CLSNSaleOfEquityThroughEquityFinancingFacilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNSaleOfEquityThroughEquityFinancingFacilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares" xlink:label="loc_CLSNSaleOfEquityThroughEquityFinancingFacilitiesShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNSaleOfEquityThroughEquityFinancingFacilitiesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IssuanceOfCommonStockInLieuOfCashBonus" xlink:label="loc_CLSNIssuanceOfCommonStockInLieuOfCashBonus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNIssuanceOfCommonStockInLieuOfCashBonus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares" xlink:label="loc_CLSNIssuanceOfCommonStockInLieuOfCashBonusShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNIssuanceOfCommonStockInLieuOfCashBonusShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/BusinessDescription" xlink:title="00000008 - Disclosure - Business Description">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/BasisOfPresentation" xlink:title="00000009 - Disclosure - Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/FinancialConditionAndBusinessPlan" xlink:title="00000010 - Disclosure - Financial Condition and Business Plan">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/NewAccountingPronouncements" xlink:title="00000011 - Disclosure - New Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:label="loc_us-gaapDescriptionOfNewAccountingPronouncementsNotYetAdopted" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapDescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/NetLossPerCommonShare" xlink:title="00000012 - Disclosure - Net Loss Per Common Share">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale" xlink:title="00000013 - Disclosure - Investment in Debt Securities Available for Sale">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/FairValueMeasurements" xlink:title="00000014 - Disclosure - Fair Value Measurements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="loc_us-gaapDerivativesAndFairValueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDerivativesAndFairValueTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssets" xlink:title="00000015 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/OtherAccruedLiabilities" xlink:title="00000016 - Disclosure - Other Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayable" xlink:title="00000017 - Disclosure - Notes and Loans Payable">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensation" xlink:title="00000019 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiability" xlink:title="00000020 - Disclosure - Earn-out Milestone Liability">
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiabilityAbstract" xlink:label="loc_CLSNEarnoutMilestoneLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock" xlink:label="loc_CLSNEarnoutMilestoneLiabilityDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNEarnoutMilestoneLiabilityAbstract" xlink:to="loc_CLSNEarnoutMilestoneLiabilityDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Warrants" xlink:title="00000021 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_WarrantsTextBlock" xlink:label="loc_CLSNWarrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_CLSNWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Leases" xlink:title="00000022 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreements" xlink:title="00000023 - Disclosure - Technology Development and Licensing Agreements">
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract" xlink:label="loc_CLSNTechnologyDevelopmentAndLicensingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LicensingTransactionTextBlock" xlink:label="loc_CLSNLicensingTransactionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNTechnologyDevelopmentAndLicensingAgreementsAbstract" xlink:to="loc_CLSNLicensingTransactionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/CommitmentsAndContingencies" xlink:title="00000024 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/SubsequentEvents" xlink:title="00000025 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleTables" xlink:title="00000026 - Disclosure - Investment in Debt Securities Available for Sale (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaapShortTermInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaapAvailableForSaleSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermInvestmentsAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermInvestmentsAbstract" xlink:to="loc_us-gaapScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeTextBlock" xlink:label="loc_us-gaapInvestmentIncomeTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermInvestmentsAbstract" xlink:to="loc_us-gaapInvestmentIncomeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/FairValueMeasurementsTables" xlink:title="00000027 - Disclosure - Fair Value Measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssetsTables" xlink:title="00000028 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:label="loc_us-gaapFiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="loc_us-gaapFiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/OtherAccruedLiabilitiesTables" xlink:title="00000029 - Disclosure - Other Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayableTables" xlink:title="00000030 - Disclosure - Notes and Loans Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensationTables" xlink:title="00000031 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock" xlink:label="loc_CLSNSummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CLSNSummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiabilityTables" xlink:title="00000032 - Disclosure - Earn-out Milestone Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiabilityAbstract" xlink:label="loc_CLSNEarnoutMilestoneLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock" xlink:label="loc_CLSNScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNEarnoutMilestoneLiabilityAbstract" xlink:to="loc_CLSNScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock" xlink:label="loc_CLSNScheduleOfRiskadjustmentAssessmentTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNEarnoutMilestoneLiabilityAbstract" xlink:to="loc_CLSNScheduleOfRiskadjustmentAssessmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/WarrantsTables" xlink:title="00000033 - Disclosure - Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock" xlink:label="loc_CLSNScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_CLSNScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/LeasesTables" xlink:title="00000034 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/FinancialConditionAndBusinessPlanDetailsNarrative" xlink:title="00000035 - Disclosure - Financial Condition and Business Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NJMember" xlink:label="loc_CLSNNJMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CLSNNJMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonCreditAgreementMember" xlink:label="loc_CLSNHorizonCreditAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNHorizonCreditAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonTechnologyFinanceCorporationMember" xlink:label="loc_CLSNHorizonTechnologyFinanceCorporationMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLSNHorizonTechnologyFinanceCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVariableRateAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaapLondonInterbankOfferedRateLIBORMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapLondonInterbankOfferedRateLIBORMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CashInvestmentSecuritiesAndInterestReceivable" xlink:label="loc_CLSNCashInvestmentSecuritiesAndInterestReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNCashInvestmentSecuritiesAndInterestReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization" xlink:label="loc_CLSNTaxBenefitsOfEarningsBeforeDepreciationAndAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNTaxBenefitsOfEarningsBeforeDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NetProceedsFromSaleOfNetOperatingLosses" xlink:label="loc_CLSNNetProceedsFromSaleOfNetOperatingLosses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNNetProceedsFromSaleOfNetOperatingLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromContributedCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="00000036 - Disclosure - Net Loss Per Common Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards" xlink:label="loc_CLSNNumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_CLSNNumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare" xlink:label="loc_CLSNNumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_CLSNNumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative" xlink:title="00000037 - Disclosure - Investment in Debt Securities Available for Sale (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaapShortTermInvestmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapShortTermInvestmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails" xlink:title="00000038 - Disclosure - Investment in Debt Securities Available for Sale - Schedule of Cost, Fair Value and Maturities of Short Term Investments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" xlink:label="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" xlink:label="loc_CLSNAvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" xlink:label="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNDebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails" xlink:title="00000039 - Disclosure - Investment in Debt Securities Available for Sale - Summary of Investment Securities Gross Unrealized Gains (Losses) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" xlink:label="loc_CLSNDebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CLSNDebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" xlink:label="loc_CLSNDebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CLSNDebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" xlink:label="loc_CLSNAvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CLSNAvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails" xlink:title="00000040 - Disclosure - Investment in Debt Securities Available for Sale - Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="loc_us-gaapInvestmentIncomeInterestAndDividend" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterestAndDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="loc_us-gaapAvailableForSaleSecuritiesGrossRealizedGainLossNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaapInvestmentIncomeNonoperating" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapInvestmentIncomeNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000041 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000042 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EGENIncMember" xlink:label="loc_CLSNEGENIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CLSNEGENIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IPRAndDDrugTechnologyPlatformsMember" xlink:label="loc_CLSNIPRAndDDrugTechnologyPlatformsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLSNIPRAndDDrugTechnologyPlatformsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_OvarianCancerMember" xlink:label="loc_CLSNOvarianCancerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CLSNOvarianCancerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GlioblastomaMultiformeBrainCancerMember" xlink:label="loc_CLSNGlioblastomaMultiformeBrainCancerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CLSNGlioblastomaMultiformeBrainCancerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RNADeliverySystemMember" xlink:label="loc_CLSNRNADeliverySystemMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CLSNRNADeliverySystemMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PurchaseAgreementMember" xlink:label="loc_CLSNPurchaseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AspirePurchaseAgreementsMember" xlink:label="loc_CLSNAspirePurchaseAgreementsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNAspirePurchaseAgreementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="loc_us-gaapIndefinitelivedIntangibleAssetsAcquired" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaapGoodwillAcquiredDuringPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwillAcquiredDuringPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails" xlink:title="00000043 - Disclosure - Intangible Assets - Schedule of Future Amortization Amounts During the Remaining Life (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaapNoncompeteAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapNoncompeteAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" xlink:label="loc_CLSNFiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNFiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails" xlink:title="00000044 - Disclosure - Intangible Assets - Schedule of Fair Value of Assets Acquired (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_IPRAndDMember" xlink:label="loc_CLSNIPRAndDMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_CLSNIPRAndDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaapGoodwillMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapGoodwillMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaapNoncompeteAgreementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapNoncompeteAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails" xlink:title="00000045 - Disclosure - Other Accrued Liabilities - Schedule of Other Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayableDetailsNarrative" xlink:title="00000046 - Disclosure - Notes and Loans Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonCreditAgreementMember" xlink:label="loc_CLSNHorizonCreditAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNHorizonCreditAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AprilPaycheckProtectionProgramLoanMember" xlink:label="loc_CLSNAprilPaycheckProtectionProgramLoanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNAprilPaycheckProtectionProgramLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaycheckProtectionProgramLoansMember" xlink:label="loc_CLSNPaycheckProtectionProgramLoansMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNPaycheckProtectionProgramLoansMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_MayPaycheckProtectionProgramLoanMember" xlink:label="loc_CLSNMayPaycheckProtectionProgramLoanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNMayPaycheckProtectionProgramLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HorizonCreditAgreementMember" xlink:label="loc_CLSNHorizonCreditAgreementMember_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLSNHorizonCreditAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SiliconValleyBankMember" xlink:label="loc_CLSNSiliconValleyBankMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CLSNSiliconValleyBankMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_us-gaapNotesPayableToBanksMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapNotesPayableToBanksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails" xlink:title="00000047 - Disclosure - Notes and Loans Payable - Schedule of Future Principle Payments, Net of Unamortized Debt Discounts (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" xlink:label="loc_CLSNLongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_CLSNLongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - Stockholders&apos; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember" xlink:label="loc_CLSNTwoThousandNineteenAspirePurchaseAgreementsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNTwoThousandNineteenAspirePurchaseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember" xlink:label="loc_CLSNTwoThousandEighteenAspirePurchaseAgreementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNTwoThousandEighteenAspirePurchaseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CapitalOnDemandTMSalesAgreementMember" xlink:label="loc_CLSNCapitalOnDemandTMSalesAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNCapitalOnDemandTMSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_CapitalOnDemandAgreementMember" xlink:label="loc_CLSNCapitalOnDemandAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNCapitalOnDemandAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_SecuritiesPurchaseAgreementMember" xlink:label="loc_CLSNSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PrivateExchangeAgreementsMember" xlink:label="loc_CLSNPrivateExchangeAgreementsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNPrivateExchangeAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UnderwritingAgreementMember" xlink:label="loc_CLSNUnderwritingAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_OriginalWarrantsMember" xlink:label="loc_CLSNOriginalWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLSNOriginalWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UnderwrittenOfferingMember" xlink:label="loc_CLSNUnderwrittenOfferingMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CLSNUnderwrittenOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShelfRegistrationStatementAmount" xlink:label="loc_CLSNShelfRegistrationStatementAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNShelfRegistrationStatementAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateOfferingPriceAdditions" xlink:label="loc_CLSNAggregateOfferingPriceAdditions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAggregateOfferingPriceAdditions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateOfferingPriceTerm" xlink:label="loc_CLSNAggregateOfferingPriceTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAggregateOfferingPriceTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateOfferingPrices" xlink:label="loc_CLSNAggregateOfferingPrices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAggregateOfferingPrices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AggregateValueAvailableForIssuance" xlink:label="loc_CLSNAggregateValueAvailableForIssuance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAggregateValueAvailableForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UnderwritingDiscountPricePerShare" xlink:label="loc_CLSNUnderwritingDiscountPricePerShare" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNUnderwritingDiscountPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice" xlink:label="loc_CLSNPercentageOfUnderwritingDiscountOnPublicOfferingPrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNPercentageOfUnderwritingDiscountOnPublicOfferingPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000049 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandAndEighteenStockIncentivePlanMember" xlink:label="loc_CLSNTwoThousandAndEighteenStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNTwoThousandAndEighteenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandSevenStockIncentivePlanMember" xlink:label="loc_CLSNTwoThousandSevenStockIncentivePlanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNTwoThousandSevenStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_InducementOptionGrantsMember" xlink:label="loc_CLSNInducementOptionGrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNInducementOptionGrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandAndEighteenPlanMember" xlink:label="loc_CLSNTwoThousandAndEighteenPlanMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNTwoThousandAndEighteenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoThousandNineteenBonusProgramMember" xlink:label="loc_CLSNTwoThousandNineteenBonusProgramMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNTwoThousandNineteenBonusProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TwoNewEmployeesMember" xlink:label="loc_CLSNTwoNewEmployeesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLSNTwoNewEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FiveNewEmployeesMember" xlink:label="loc_CLSNFiveNewEmployeesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLSNFiveNewEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EquityStockAwardsMember" xlink:label="loc_CLSNEquityStockAwardsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CLSNEquityStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_InducementAwardsMember" xlink:label="loc_CLSNInducementAwardsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CLSNInducementAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember" xlink:label="loc_CLSNEmployeeStockOptionAndRestrictedStockAwardsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CLSNEmployeeStockOptionAndRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" xlink:label="loc_CLSNGrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_CLSNGrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_NonVestedStockBasedCompensationArrangementsMember" xlink:label="loc_CLSNNonVestedStockBasedCompensationArrangementsMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNNonVestedStockBasedCompensationArrangementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_StockOptionsStrikePriceDescription" xlink:label="loc_CLSNStockOptionsStrikePriceDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNStockOptionsStrikePriceDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AnnualBonusAwardsPercentage" xlink:label="loc_CLSNAnnualBonusAwardsPercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNAnnualBonusAwardsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails" xlink:title="00000050 - Disclosure - Stock-Based Compensation - Summary of Stock Option and Restricted Stock Awards (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice" xlink:label="loc_CLSNShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod" xlink:label="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails" xlink:title="00000051 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Options Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiabilityDetailsNarrative" xlink:title="00000052 - Disclosure - Earn-out Milestone Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiabilityAbstract" xlink:label="loc_CLSNEarnoutMilestoneLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNEarnoutMilestoneLiabilityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EGWUIncMember" xlink:label="loc_CLSNEGWUIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLSNEGWUIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_FairValueEarnoutMilestoneLiabilityMember" xlink:label="loc_CLSNFairValueEarnoutMilestoneLiabilityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNFairValueEarnoutMilestoneLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember" xlink:label="loc_CLSNAmendedAssetPurchaseAgreementOptionPaymentOneMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNAmendedAssetPurchaseAgreementOptionPaymentOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember" xlink:label="loc_CLSNAmendedAssetPurchaseAgreementOptionPaymentTwoMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLSNAmendedAssetPurchaseAgreementOptionPaymentTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentOptionOneMember" xlink:label="loc_CLSNPaymentOptionOneMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_CLSNPaymentOptionOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentOptionTwoMember" xlink:label="loc_CLSNPaymentOptionTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_CLSNPaymentOptionTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentsForEarnoutMilestoneLiability" xlink:label="loc_CLSNPaymentsForEarnoutMilestoneLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNPaymentsForEarnoutMilestoneLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_PaymentsForEarnoutMilestoneLiabilityInCash" xlink:label="loc_CLSNPaymentsForEarnoutMilestoneLiabilityInCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNPaymentsForEarnoutMilestoneLiabilityInCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiability1" xlink:label="loc_CLSNEarnoutMilestoneLiability1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNEarnoutMilestoneLiability1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainOnNoncashBenefit" xlink:label="loc_CLSNGainOnNoncashBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNGainOnNoncashBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RiskAdjustedAssessmentOfEachMilestone" xlink:label="loc_CLSNRiskAdjustedAssessmentOfEachMilestone" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNRiskAdjustedAssessmentOfEachMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability" xlink:label="loc_CLSNGainLossFromChangeInFairValueOfEarnOutMilestoneLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNGainLossFromChangeInFairValueOfEarnOutMilestoneLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails" xlink:title="00000053 - Disclosure - Earn-out Milestone Liability - Schedule of Changes in Earn-out Milestone Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiabilityAbstract" xlink:label="loc_CLSNEarnoutMilestoneLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiability" xlink:label="loc_CLSNEarnoutMilestoneLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNEarnoutMilestoneLiabilityAbstract" xlink:to="loc_CLSNEarnoutMilestoneLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability" xlink:label="loc_CLSNGainLossFromChangeInFairValueOfEarnOutMilestoneLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNEarnoutMilestoneLiabilityAbstract" xlink:to="loc_CLSNGainLossFromChangeInFairValueOfEarnOutMilestoneLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiability" xlink:label="loc_CLSNEarnoutMilestoneLiability_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNEarnoutMilestoneLiabilityAbstract" xlink:to="loc_CLSNEarnoutMilestoneLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails" xlink:title="00000054 - Disclosure - Earn-out Milestone Liability - Schedule of Risk Adjustment Assessment (Details)">
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EarnoutMilestoneLiabilityAbstract" xlink:label="loc_CLSNEarnoutMilestoneLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNEarnoutMilestoneLiabilityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone" xlink:label="loc_CLSNRiskadjustmentAssessmentOfAchievingEachMilestone" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNRiskadjustmentAssessmentOfAchievingEachMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DiscountRateOnMileStoneLiabilities" xlink:label="loc_CLSNDiscountRateOnMileStoneLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNDiscountRateOnMileStoneLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EstimatedTimeToAchieveMileStone" xlink:label="loc_CLSNEstimatedTimeToAchieveMileStone" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNEstimatedTimeToAchieveMileStone" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Warrants-SummaryOfWarrantActivityDetails" xlink:title="00000055 - Disclosure - Warrants - Summary of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails" xlink:title="00000056 - Disclosure - Warrants - Schedule of Weighted Average Remaining Contractual Terms (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_EGWUIncMember" xlink:label="loc_CLSNEGWUIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLSNEGWUIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_AllOtherWarrantsMember" xlink:label="loc_CLSNAllOtherWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLSNAllOtherWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue" xlink:label="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/LeasesDetailsNarrative" xlink:title="00000057 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LawrencevilleNewJerseyMember" xlink:label="loc_CLSNLawrencevilleNewJerseyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CLSNLawrencevilleNewJerseyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HuntsvilleAlabamaMember" xlink:label="loc_CLSNHuntsvilleAlabamaMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CLSNHuntsvilleAlabamaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201602Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201602Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails" xlink:title="00000058 - Disclosure - Leases - Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" xlink:label="loc_CLSNLesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_CLSNLesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative" xlink:title="00000059 - Disclosure - Technology Development and Licensing Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract" xlink:label="loc_CLSNTechnologyDevelopmentAndLicensingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLSNTechnologyDevelopmentAndLicensingAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_HisunMember" xlink:label="loc_CLSNHisunMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLegalEntityTypeOfCounterpartyDomain" xlink:to="loc_CLSNHisunMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaapProceedsFromLicenseFeesReceived" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromLicenseFeesReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_DeferredRevenueAmortizationPeriod" xlink:label="loc_CLSNDeferredRevenueAmortizationPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNDeferredRevenueAmortizationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="clsn-20200630.xsd#CLSN_UpfrontPayment" xlink:label="loc_CLSNUpfrontPayment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLSNUpfrontPayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celsion.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000060 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399127179368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 13, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Celsion CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000749647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,232,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399128467832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,653,760<span></span>
</td>
<td class="nump">$ 6,875,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment in debt securities - available for sale, at fair value</a></td>
<td class="nump">2,791,868<span></span>
</td>
<td class="nump">7,985,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInvestmentIncomeReceivable', window );">Accrued interest receivable on investment securities</a></td>
<td class="nump">7,866<span></span>
</td>
<td class="nump">21,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Advances and deposits on clinical programs and other current assets</a></td>
<td class="nump">1,342,566<span></span>
</td>
<td class="nump">1,352,670<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">26,796,060<span></span>
</td>
<td class="nump">16,235,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment (at cost, less accumulated depreciation of $3,174,681 and $3,096,681, respectively)</a></td>
<td class="nump">339,200<span></span>
</td>
<td class="nump">405,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,819,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">In-process research and development, net</a></td>
<td class="nump">15,736,491<span></span>
</td>
<td class="nump">15,736,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,976,101<span></span>
</td>
<td class="nump">1,976,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">1,244,308<span></span>
</td>
<td class="nump">1,431,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">227,318<span></span>
</td>
<td class="nump">340,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">403,482<span></span>
</td>
<td class="nump">333,274<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">19,587,700<span></span>
</td>
<td class="nump">21,637,806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">46,722,960<span></span>
</td>
<td class="nump">38,278,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable - trade</a></td>
<td class="nump">2,402,142<span></span>
</td>
<td class="nump">2,862,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">1,507,683<span></span>
</td>
<td class="nump">2,303,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable - current portion, net of deferred financing costs</a></td>
<td class="nump">4,385,915<span></span>
</td>
<td class="nump">1,840,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current portion</a></td>
<td class="nump">410,005<span></span>
</td>
<td class="nump">387,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue - current portion</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,205,745<span></span>
</td>
<td class="nump">7,894,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Earn-out milestone liability</a></td>
<td class="nump">6,015,279<span></span>
</td>
<td class="nump">5,717,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, net of deferred financing costs</a></td>
<td class="nump">5,610,555<span></span>
</td>
<td class="nump">7,963,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - non-current portion</a></td>
<td class="nump">933,219<span></span>
</td>
<td class="nump">1,143,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue - non-current portion</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,514,798<span></span>
</td>
<td class="nump">23,719,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at June 30, 2020 and December 31, 2019)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.01 par value (112,500,000 shares authorized; 33,229,714 and 23,256,152 shares issued at June 30, 2020 and December 31, 2019, respectively, and 33,229,380 and 23,255,818 shares outstanding at June 30, 2020 and December 31, 2019, respectively)</a></td>
<td class="nump">332,297<span></span>
</td>
<td class="nump">232,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">324,869,780<span></span>
</td>
<td class="nump">304,885,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="nump">7,866<span></span>
</td>
<td class="nump">42,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(300,916,593)<span></span>
</td>
<td class="num">(290,516,780)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Total stockholders' equity before treasury stock</a></td>
<td class="nump">24,293,350<span></span>
</td>
<td class="nump">14,644,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost (334 shares at June 30, 2020 and December 31, 2019)</a></td>
<td class="num">(85,188)<span></span>
</td>
<td class="num">(85,188)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">24,208,162<span></span>
</td>
<td class="nump">14,559,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 46,722,960<span></span>
</td>
<td class="nump">$ 38,278,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399133929432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">112,500,000<span></span>
</td>
<td class="nump">112,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">33,229,714<span></span>
</td>
<td class="nump">23,256,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">33,229,380<span></span>
</td>
<td class="nump">23,255,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399126982760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Licensing revenue</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,990,861<span></span>
</td>
<td class="nump">3,558,074<span></span>
</td>
<td class="nump">6,042,910<span></span>
</td>
<td class="nump">6,325,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,901,136<span></span>
</td>
<td class="nump">2,136,684<span></span>
</td>
<td class="nump">3,740,042<span></span>
</td>
<td class="nump">4,354,548<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,891,997<span></span>
</td>
<td class="nump">5,694,758<span></span>
</td>
<td class="nump">9,782,952<span></span>
</td>
<td class="nump">10,680,281<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,766,997)<span></span>
</td>
<td class="num">(5,569,758)<span></span>
</td>
<td class="num">(9,532,952)<span></span>
</td>
<td class="num">(10,430,281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_GainLossFromChangeInEarnoutMilestoneLiability', window );">(Loss) gain from change in valuation of earn-out milestone liability</a></td>
<td class="num">(256,296)<span></span>
</td>
<td class="num">(127,061)<span></span>
</td>
<td class="num">(297,570)<span></span>
</td>
<td class="nump">3,002,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments', window );">Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Investment income</a></td>
<td class="nump">20,960<span></span>
</td>
<td class="nump">144,602<span></span>
</td>
<td class="nump">109,269<span></span>
</td>
<td class="nump">258,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expense</a></td>
<td class="num">(340,602)<span></span>
</td>
<td class="num">(349,448)<span></span>
</td>
<td class="num">(679,967)<span></span>
</td>
<td class="num">(700,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,850)<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
<td class="num">(2,823)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(575,938)<span></span>
</td>
<td class="num">(334,757)<span></span>
</td>
<td class="num">(866,861)<span></span>
</td>
<td class="nump">2,158,314<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,342,935)<span></span>
</td>
<td class="num">$ (5,904,515)<span></span>
</td>
<td class="num">$ (10,399,813)<span></span>
</td>
<td class="num">$ (8,271,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - Basic and diluted</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding - Basic and diluted</a></td>
<td class="nump">29,887,329<span></span>
</td>
<td class="nump">20,605,762<span></span>
</td>
<td class="nump">27,830,573<span></span>
</td>
<td class="nump">19,713,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_GainLossFromChangeInEarnoutMilestoneLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from change in valuation of earn-out milestone liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_GainLossFromChangeInEarnoutMilestoneLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399129508744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Realized (gains) losses on investment securities recognized in investment income, net</a></td>
<td class="num">$ (2,865)<span></span>
</td>
<td class="num">$ (969)<span></span>
</td>
<td class="num">$ (46,097)<span></span>
</td>
<td class="num">$ (10,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on investment securities, net</a></td>
<td class="nump">6,918<span></span>
</td>
<td class="nump">8,721<span></span>
</td>
<td class="nump">11,185<span></span>
</td>
<td class="nump">75,054<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized (loss) gain, net, on available for sale securities</a></td>
<td class="nump">4,053<span></span>
</td>
<td class="nump">7,752<span></span>
</td>
<td class="num">(34,912)<span></span>
</td>
<td class="nump">64,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,342,935)<span></span>
</td>
<td class="num">(5,904,515)<span></span>
</td>
<td class="num">(10,399,813)<span></span>
</td>
<td class="num">(8,271,967)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (5,338,882)<span></span>
</td>
<td class="num">$ (5,896,763)<span></span>
</td>
<td class="num">$ (10,434,725)<span></span>
</td>
<td class="num">$ (8,207,263)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399128597768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,342,935)<span></span>
</td>
<td class="num">$ (5,904,515)<span></span>
</td>
<td class="num">$ (10,399,813)<span></span>
</td>
<td class="num">$ (8,271,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,990<span></span>
</td>
<td class="nump">362,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_GainLossFromValuationOfEarnoutMilestoneLiability', window );">Change in fair value of earn-out milestone liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,570<span></span>
</td>
<td class="num">(3,002,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments', window );">Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,030,726<span></span>
</td>
<td class="nump">1,308,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_SharesIssuedInExchangeForServices', window );">Shares issued in exchange for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,819,324<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable', window );">Amortization of deferred finance charges and debt discount associated with notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,793<span></span>
</td>
<td class="nump">191,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable', window );">Accrued interest on investment securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,503<span></span>
</td>
<td class="nump">2,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Advances, deposits and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,104)<span></span>
</td>
<td class="num">(931,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(946,265)<span></span>
</td>
<td class="nump">24,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) operating activities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,923,276)<span></span>
</td>
<td class="num">(10,161,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of investment securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,940,894)<span></span>
</td>
<td class="num">(13,279,686)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturity of investment securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,837)<span></span>
</td>
<td class="num">(262,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,147,269<span></span>
</td>
<td class="num">(1,642,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock equity, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,182,599<span></span>
</td>
<td class="nump">4,464,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon conversion of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,895<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from Payroll Protection Program (PPP) loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,324,750<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLoans', window );">Repayments on Payroll Protection Program (PPP) loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,324,750)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,554,494<span></span>
</td>
<td class="nump">4,464,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,778,487<span></span>
</td>
<td class="num">(7,340,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,875,273<span></span>
</td>
<td class="nump">13,353,543<span></span>
</td>
<td class="nump">$ 13,353,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">22,653,760<span></span>
</td>
<td class="nump">6,013,318<span></span>
</td>
<td class="nump">22,653,760<span></span>
</td>
<td class="nump">6,013,318<span></span>
</td>
<td class="nump">$ 6,875,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(487,174)<span></span>
</td>
<td class="num">(508,471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from lease payments</a></td>
<td class="nump">130,595<span></span>
</td>
<td class="nump">130,595<span></span>
</td>
<td class="nump">261,190<span></span>
</td>
<td class="nump">261,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing and investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments', window );">Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_RightOfUseAssetsObtainedInExchangeForLease', window );">Right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,797,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_StockIssuedInLieuOfCashBonusPayments', window );">Stock issued in lieu of cash bonus payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Realized and unrealized (gains) losses, net, on investment securities</a></td>
<td class="nump">$ 4,053<span></span>
</td>
<td class="nump">$ 7,752<span></span>
</td>
<td class="num">$ (34,912)<span></span>
</td>
<td class="nump">$ 64,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of deferred finance charges and debt discount associated with note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyEarnoutMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with amendment to modify the related earn-out milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_FairValueOfWarrantsIssuedInConnectionWithAmendmentToModifyRelatedEarnoutMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_GainLossFromValuationOfEarnoutMilestoneLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognized in earnings related to the change in fair value during the period of milestone liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_GainLossFromValuationOfEarnoutMilestoneLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_RightOfUseAssetsObtainedInExchangeForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use assets, obtained in exchange for lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_RightOfUseAssetsObtainedInExchangeForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_SharesIssuedInExchangeForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued in exchange for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_SharesIssuedInExchangeForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_StockIssuedInLieuOfCashBonusPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued in lieu of cash bonus payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_StockIssuedInLieuOfCashBonusPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in investment income that has been earned but not yet received in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments for and related to principal collection on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399129554424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 188,322<span></span>
</td>
<td class="nump">$ 294,393,313<span></span>
</td>
<td class="num">$ (85,188)<span></span>
</td>
<td class="nump">$ 29,872<span></span>
</td>
<td class="num">$ (273,665,247)<span></span>
</td>
<td class="nump">$ 20,861,072<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">18,831,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,271,967)<span></span>
</td>
<td class="num">(8,271,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_SaleOfEquityThroughEquityFinancingFacilities', window );">Sale of equity through financing facilities</a></td>
<td class="nump">$ 21,599<span></span>
</td>
<td class="nump">4,442,461<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,464,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares', window );">Sale of equity through financing facilities, shares</a></td>
<td class="nump">2,159,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Common stock warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Realized and unrealized gains and losses, net, on investments securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">64,704<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">64,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,308,492<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,308,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">5,245<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock, shares</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 210,026<span></span>
</td>
<td class="nump">300,549,511<span></span>
</td>
<td class="num">$ (85,188)<span></span>
</td>
<td class="nump">94,576<span></span>
</td>
<td class="num">(281,937,214)<span></span>
</td>
<td class="nump">18,831,711<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2019</a></td>
<td class="nump">21,002,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 188,322<span></span>
</td>
<td class="nump">294,393,313<span></span>
</td>
<td class="num">$ (85,188)<span></span>
</td>
<td class="nump">29,872<span></span>
</td>
<td class="num">(273,665,247)<span></span>
</td>
<td class="nump">$ 20,861,072<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">18,831,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 232,562<span></span>
</td>
<td class="nump">304,885,663<span></span>
</td>
<td class="num">$ (85,188)<span></span>
</td>
<td class="nump">42,778<span></span>
</td>
<td class="num">(290,516,780)<span></span>
</td>
<td class="nump">$ 14,559,035<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">23,255,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 196,624<span></span>
</td>
<td class="nump">297,231,041<span></span>
</td>
<td class="num">$ (85,188)<span></span>
</td>
<td class="nump">86,824<span></span>
</td>
<td class="num">(276,032,699)<span></span>
</td>
<td class="nump">21,396,602<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2019</a></td>
<td class="nump">19,662,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,904,515)<span></span>
</td>
<td class="num">(5,904,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_SaleOfEquityThroughEquityFinancingFacilities', window );">Sale of equity through financing facilities</a></td>
<td class="nump">$ 13,378<span></span>
</td>
<td class="nump">2,695,798<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,709,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares', window );">Sale of equity through financing facilities, shares</a></td>
<td class="nump">1,337,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Realized and unrealized gains and losses, net, on investments securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,752<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">617,347<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">617,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of restricted stock</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">5,325<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock, shares</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 210,026<span></span>
</td>
<td class="nump">300,549,511<span></span>
</td>
<td class="num">$ (85,188)<span></span>
</td>
<td class="nump">94,576<span></span>
</td>
<td class="num">(281,937,214)<span></span>
</td>
<td class="nump">18,831,711<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2019</a></td>
<td class="nump">21,002,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 232,562<span></span>
</td>
<td class="nump">304,885,663<span></span>
</td>
<td class="num">$ (85,188)<span></span>
</td>
<td class="nump">42,778<span></span>
</td>
<td class="num">(290,516,780)<span></span>
</td>
<td class="nump">14,559,035<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">23,255,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,399,813)<span></span>
</td>
<td class="num">(10,399,813)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_SaleOfEquityThroughEquityFinancingFacilities', window );">Sale of equity through financing facilities</a></td>
<td class="nump">$ 94,027<span></span>
</td>
<td class="nump">18,088,572<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,182,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares', window );">Sale of equity through financing facilities, shares</a></td>
<td class="nump">9,402,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 1,409<span></span>
</td>
<td class="nump">370,486<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">371,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, shares</a></td>
<td class="nump">140,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_IssuanceOfCommonStockInLieuOfCashBonus', window );">Issuance of common stock in lieu of cash bonus</a></td>
<td class="nump">$ 4,299<span></span>
</td>
<td class="nump">494,333<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">498,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares', window );">Issuance of common stock in lieu of cash bonus, shares</a></td>
<td class="nump">429,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Realized and unrealized gains and losses, net, on investments securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(34,912)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(34,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,030,726<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,030,726<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 332,297<span></span>
</td>
<td class="nump">324,869,780<span></span>
</td>
<td class="num">$ (85,188)<span></span>
</td>
<td class="nump">7,866<span></span>
</td>
<td class="num">(300,916,593)<span></span>
</td>
<td class="nump">24,208,162<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="nump">33,229,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 292,574<span></span>
</td>
<td class="nump">311,570,995<span></span>
</td>
<td class="num">$ (85,188)<span></span>
</td>
<td class="nump">3,813<span></span>
</td>
<td class="num">(295,573,658)<span></span>
</td>
<td class="nump">16,208,536<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="nump">29,257,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,342,935)<span></span>
</td>
<td class="num">(5,342,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 1,409<span></span>
</td>
<td class="nump">370,486<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">371,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, shares</a></td>
<td class="nump">140,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Realized and unrealized gains and losses, net, on investments securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,053<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">578,761<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">578,761<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 332,297<span></span>
</td>
<td class="nump">$ 324,869,780<span></span>
</td>
<td class="num">$ (85,188)<span></span>
</td>
<td class="nump">$ 7,866<span></span>
</td>
<td class="num">$ (300,916,593)<span></span>
</td>
<td class="nump">$ 24,208,162<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="nump">33,229,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_IssuanceOfCommonStockInLieuOfCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in lieu of cash bonus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_IssuanceOfCommonStockInLieuOfCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in lieu of cash bonus, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_IssuanceOfCommonStockInLieuOfCashBonusShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_SaleOfEquityThroughEquityFinancingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of equity through financing facilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_SaleOfEquityThroughEquityFinancingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of equity through financing facilities, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_SaleOfEquityThroughEquityFinancingFacilitiesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399130994888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Business Description</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1. Business Description</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Celsion Corporation (&#8220;Celsion&#8221;
and the &#8220;Company&#8221;) is a fully integrated development stage oncology drug company focused on advancing a portfolio
of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA based therapies. Celsion
is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including immunotherapies,
DNA-based therapies and directed chemotherapies. The Company&#8217;s product pipeline includes GEN-1, a DNA-based immunotherapy
for the localized treatment of ovarian cancer and ThermoDox&#174;, a proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications.
Celsion has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular
transfection.With these technologies we are working to develop and commercialize more efficient, effective and targeted oncology
therapies that maximize efficacy while minimizing side-effects common to cancer treatments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132380680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2. Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements, which include the accounts of the Company and its wholly owned subsidiary, CLSN Laboratories, Inc, have been
prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial information
and with the instructions to Form 10-Q and Article 10 of Regulation S-X. All significant intercompany balances and transactions
have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in
accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the opinion of management, all adjustments,
consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying
unaudited condensed consolidated financial statements. Operating results for the three-month and six-month periods ended June 30,
2020 and 2019 are not necessarily indicative of the results that may be expected for any other interim period(s) or for any full
year. For further information, refer to the financial statements and notes thereto included in the Company&#8217;s Annual Report
on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) on March 25, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in
conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amounts reported in the
Company&#8217;s financial statements and accompanying notes. Actual results could differ materially from those estimates. Events
and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial
statements and accompanying notes. With the recent introduction of the COVID-19 pandemic to the United States, the Company continues
to monitor the impact of this pandemic on its financial condition and results of operations, along with the valuation of its long-term
assets, intangible assets, and goodwill. The effect of this matter could potentially have an impact on the valuation of such assets
in the future. The COVID-19 matter is discussed in more detail in Note 3 to the financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399133090056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Condition and Business Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Financial Condition and Business Plan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3. Financial Condition and Business
Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since inception, the Company has incurred substantial
operating losses, principally from expenses associated with the Company&#8217;s research and development programs, clinical trials
conducted in connection with the Company&#8217;s product candidates, and applications and submissions to the U.S. Food and Drug
Administration. The Company has not generated significant revenue and has incurred significant net losses in each year since our
inception. As of June 30, 2020, the Company has incurred approximately $301 million of cumulative net losses and we had approximately
$25.5 million in cash, investment securities, and interest receivable. We have substantial future capital requirements to continue
our research and development activities and advance our product candidates through various development stages. The Company believes
these expenditures are essential for the commercialization of its technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expects its operating losses to
continue for the foreseeable future as it continues its product development efforts, and when it undertakes marketing and sales
activities. The Company&#8217;s ability to achieve profitability is dependent upon its ability to obtain governmental approvals,
manufacture, and market and sell its new product candidates. There can be no assurance that the Company will be able to commercialize
its technology successfully or that profitability will ever be achieved. The operating results of the Company have fluctuated significantly
in the past.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>COVID-19 Pandemic</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2020, the World Health Organization
(&#8220;WHO&#8221;) declared an outbreak of coronavirus, COVID-19, to be a &#8220;Public Health Emergency of International Concern,&#8221;
and the U.S. Department of Health and Human Services declared a public health emergency to aid the U.S. healthcare community in
responding to COVID-19. This virus has spread to over 100 countries, including the United States. Governments and businesses around
the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place
orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work.
Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets.
The Company did not observe significant impacts on its business or results of operations for the three-month and six-month periods
ended June 30, 2020 due to the global emergence of COVID-19. While the extent to which COVID-19 impacts the Company&#8217;s future
results will depend on future developments, the pandemic and associated economic impacts could result in a material impact to the
Company&#8217;s future financial condition, results of operations and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s ability to raise additional
capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility
in, financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. The disruptions caused by
COVID-19 may also disrupt the clinical trials process and enrolment of patients. This may delay commercialization efforts. The
Company is currently monitoring its operating activities in light of these events and it is reasonably possible that the virus
could have a negative effect on the Company&#8217;s financial condition and results of operations. The specific impact, if any,
is not readily determinable as of the date of these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The actual amount of funds the Company will
need to operate is subject to many factors, some of which are beyond the Company&#8217;s control. These factors include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the progress of research activities;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the number and scope of research programs;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the progress of preclinical and clinical development activities;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the progress of the development efforts of parties with whom the Company has entered into research and development agreements;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the costs associated with additional clinical trials of product candidates;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the ability to achieve milestones under licensing arrangements;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the costs and timing of regulatory approvals.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 13, 2020, the Company announced that
it has received a recommendation from the independent Data Monitoring Committee (DMC) to consider stopping the global Phase III
OPTIMA Study of ThermoDox<sup>&#174;</sup> in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular
carcinoma (HCC), or primary liver cancer. The recommendation was made following the second pre-planned interim safety and efficacy
analysis by the DMC on July 9, 2020. The DMC&#8217;s analysis found that the pre-specified boundary for stopping the trial for
futility of 0.900 was crossed with an actual value of 0.903. The Company intends to follow the advice of the DMC and will consider
its options to either stop the study or continue to follow patients after a thorough review of the data, and an evaluation of the
probability of success. Timing for this decision is made less urgent by the fact that the OPTIMA Study has been fully enrolled
since August 2018 and that the vast majority of the trial expenses have already been incurred. On August 4, 2020, the Company issued
a press release announcing it will continue following patients for overall survival (&#8220;OS&#8221;), noting that the unexpected
and marginally crossed futility boundary, suggested by the Kaplan-Meier analysis at the second interim analysis on July 9, 2020,
may be associated with a data maturity issue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2019 and 2018, the Company submitted
applications to sell a portion of the Company&#8217;s State of New Jersey net operating losses as part of the Technology Business
Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies
with unused NOLs and unused research and development credits are allowed to sell these benefits to other New Jersey-based companies.
The Company received approval from the New Jersey Economic Development Authority to sell $1.9 million of its State of New Jersey
net operating losses recognizing a tax benefit for the year ended December 31, 2019 for the net proceeds (approximately $1.8 million).
In early 2020, the Company entered into an agreement to sell these net operating losses. In April of 2020, the Company completed
the sale of its State of New Jersey net operating losses and received $1.8 million in net proceeds. In 2018, the Company completed
the sale of a portion of its State of New Jersey net operating losses for calendar years 2011 - 2017 totalling approximately $11.1
million for net proceeds of approximately $10.4 million in December 2018. The proceeds of $10.4 million were reflected as a tax
benefit for the year ended December 31, 2018. In June 2020, the Company filed an application with the New Jersey Economic Development
Authority to sell substantially all of its remaining State of New Jersey net operating losses totalling $2.0 million available
under the program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the Company entered into the
Horizon Credit Agreement with Horizon Technology Finance Corporation (&#8220;Horizon&#8221;) that provided $10 million in new capital
(the &#8220;Horizon Credit Agreement&#8221;). The obligations under the Horizon Credit Agreement are secured by a first-priority
security interest in substantially all assets of Celsion other than intellectual property assets. Payments under the loan agreement
are interest only (calculated based on one-month LIBOR plus 7.625%) for the first twenty-four (24) months through July 2020, followed
by a 24-month amortization period of principal and interest starting on August 1, 2020 and ending through the scheduled maturity
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With $25.5 million in cash, investments, interest
receivable and up to $2.0 million in potential proceeds from the sale of the 2019 State of New Jersey net operating losses, coupled
with remaining availability under the Capital-on-Demand&#8482; Sales Agreement (the &#8220;Capital on Demand Agreement&#8221;)
with JonesTrading Institutional Services LLC, the Company believes it has sufficient capital resources to fund its operations through
the end of 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has based its estimates on assumptions
that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates.
Potential sources of financing include strategic relationships, public or private sales of the Company&#8217;s shares or debt,
the sale of the Company&#8217;s State of New Jersey net operating losses and other sources. If the Company raises funds by selling
additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders
may be diluted.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399136103032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4. New Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, new accounting pronouncements
are issued by the Financial Accounting Standards Board (FASB) and are adopted by us as of the specified effective date. Unless
otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material impact on
the Company&#8217;s condensed consolidated financial position, results of operations, and cash flows, or do not apply to our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the FASB issued Accounting Standards
Update No. 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;,
which modifies the measurement of expected credit losses on certain financial instruments. The Company will adopt ASU 2016-13 in
its first quarter of 2021 utilizing the modified retrospective transition method. Based on the composition of the Company&#8217;s
investment portfolio and current market conditions, the adoption of ASU 2016-13 is not expected to have a material impact on its
condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued ASU No. 2018-13,
<i>Fair Value Measurement: Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement</i>,
which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer
be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation
processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average
of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and
losses included in other comprehensive income. This update is effective for annual periods beginning after December 15, 2019, and
interim periods within those periods, and early adoption is permitted. The adoption of this standard did not have an impact on
the Company&#8217;s condensed consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, the FASB issued ASU No.
2019-12, Income Taxes (Topic 740). The standard simplifies the accounting for incomes taxes by removing certain exceptions to
the general principles in Topic 740 related to the approach for intra-period tax allocation and the recognition of deferred tax
liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up
in the tax basis of goodwill. The standard also improves consistent application of and simplifies GAAP for other areas of Topic
740 by clarifying and amending existing guidance. The amendment is effective for fiscal years, and interim periods within those
fiscal years, beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact that
the adoption of this standard will have on its condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399136017800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5. Net Loss per Common Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share is calculated based upon
the net loss available to common shareholders divided by the weighted average number of common shares outstanding during the period.
Diluted loss per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects
of all dilutive potential common shares outstanding during the period. The dilutive effects of preferred stock, options and warrants
and their equivalents are computed using the treasury stock method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total number of shares of common stock
issuable upon exercise of warrants, stock option grants and equity awards were 8,560,124 and 4,595,990 shares for the six-month
periods ended June 30, 2020 and 2019, respectively. Warrants with an exercise price of $0.01 (as more fully described in Note
13) exercisable for 200,000 shares of common stock were considered issued in calculating basic loss per share. For the three-month
and six-month periods ended June 30, 2020 and 2019, diluted loss per common share was the same as basic loss per common share
as the other warrants and equity awards that were convertible into shares of the Company&#8217;s common stock were excluded from
the calculation of diluted loss per common share as their effect would have been anti-dilutive. The Company did not pay any dividends
during the six-month periods ended June 30, 2020 and 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399159464200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Debt Securities Available for Sale<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investment in Debt Securities Available for Sale</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6. Investment in Debt Securities Available
for Sale</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investments in debt securities available for
sale with a fair value of $2,791,868 and $7,985,886 as of June 30, 2020 and December 31, 2019, respectively, consist of corporate
debt securities. These investments are valued at estimated fair value, with unrealized gains and losses reported as a separate
component of stockholders&#8217; equity in accumulated other comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investments in debt securities available for
sale are evaluated periodically to determine whether a decline in their value is other than temporary. The term &#8220;other than
temporary&#8221; is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near term recovery
of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the
carrying value of the security. Management reviews criteria such as the magnitude and duration of the decline, as well as the reasons
for the decline, to predict whether the loss in value is other than temporary. Once a decline in value is determined to be other
than temporary, the value of the security is reduced and a corresponding charge to earnings is recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the cost, fair value and maturities
of the Company&#8217;s short-term investments is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>June 30, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Cost</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Cost</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt"><b>Short-term investments</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Investments in debt securities</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">2,784,002</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,943,108</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,784,002</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,943,108</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>June 30, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Cost</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Cost</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt"><b>Short-term investment maturities</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Within 3 months</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">2,784,002</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,943,108</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,784,002</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,943,108</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the Company&#8217;s
investment securities gross unrealized gains (losses) and fair value by investment category and length of time that individual
securities have been in a continuous unrealized loss position at June 30, 2020 and December 31, 2019. The Company has reviewed
individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>June 30, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Available for sale securities </b>(all unrealized holding gains and losses are less than 12 months at date of measurement)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unrealized</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Holding</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Gains</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unrealized</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Holding</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Gains</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Investments in debt securities with unrealized Gains</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,866</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">42,778</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,866</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">42,778</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investment income, which includes net realized
gains on sales of available for sale securities and investment income interest and dividends, is summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>June 30,</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%"><font style="font-size: 10pt">Interest and dividends accrued and paid</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">18,095</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">143,633</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Realized gains</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,865</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">969</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Investment income, net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">20,960</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">144,602</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>June 30,</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%"><font style="font-size: 10pt">Interest and dividends accrued and paid</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">63,172</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">248,043</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Realized gains</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">46,097</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10,350</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Investment income, net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">109,269</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">258,393</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399145447896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 7. Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB Accounting Standards Codification (ASC)
Section 820 &#8220;Fair Value Measurements and Disclosures,&#8221; establishes a three-level hierarchy for fair value measurements
which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair
value. The three levels of inputs that may be used to measure fair value are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 1: Quoted prices (unadjusted)
or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 2: Significant other observable
inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not
active; or other inputs that are observable or can be corroborated by observable market data; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 3: Significant unobservable
inputs that reflect a reporting entity&#8217;s own assumptions that market participants would use in pricing an asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents, accounts payable
and other accrued liabilities are reflected in the condensed consolidated balance sheet at their approximate estimated fair values
primarily due to their short-term nature. The fair values of securities available for sale are determined by relying on the securities&#8217;
relationship to other benchmark quoted securities and classified its investments as Level 2 items at June 30, 2020 and December
31, 2019. There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during
the six-month period ended June 30, 2020 or during the year ended December 31, 2019. The changes in Level 3 liabilities were the
result of changes in the fair value of the earn-out milestone liability included in earnings and in-process R&#38;D. The earnout
milestone liability is valued using a risk-adjusted assessment of the probability of payment of each milestone, discounted to present
value using an estimated time to achieve the milestone (see Note 13). The in-process R&#38;D is valued using a multi-period excess
earnings method (see Note 8).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Assets and liabilities measured at fair value
are summarized below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Total Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Significant Other Observable Inputs (Level 2)</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Significant Unobservable Inputs (Level 3)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Assets:</font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Recurring items as of June 30, 2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 48%; padding-left: 10pt"><font style="font-size: 10pt">Corporate debt securities, available for sale</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">&#9472; </font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">&#9472; &#160;</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Recurring items as of December 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Corporate debt securities, available for sale</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472; </font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472; &#160;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Liabilities:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Recurring items as of June 30, 2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Earn-out milestone liability (Note 13)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">6,015,279</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472; &#160;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">6,015,279</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Recurring items as of December 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Earn-out milestone liability (Note 13)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5,717,709</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472; &#160;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5,717,709</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399140265224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8. Intangible Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2014, we completed the acquisition
of substantially all of the assets of EGEN, Inc., an Alabama corporation, which has changed its company name to EGWU, Inc. after
the closing of the acquisition (&#8220;EGEN&#8221;). We acquired all of EGEN&#8217;s right, title and interest in and to substantially
all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical
data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible
personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising
out of the acquired contracts and other assets relating to periods after the closing date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Acquired In-process Research and Development</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Acquired in-process research and development
(IPR&#38;D) consists of EGEN&#8217;s drug technology platforms: TheraPlas and TheraSilence. The fair value of the IPR&#38;D drug
technology platforms was estimated to be $24.2 million as of the acquisition date. As of the closing of the acquisition, the IPR&#38;D
was considered indefinite lived intangible assets and will not be amortized. IPR&#38;D is reviewed for impairment at least annually
as of our third quarter ended September 30, and whenever events or changes in circumstances indicate that the carrying value of
the assets might not be recoverable. The Company&#8217;s IPR&#38;D consisted of three core elements, its RNA delivery system, its
glioblastoma multiforme cancer (GBM) product candidate and its ovarian cancer indication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s ovarian cancer indication,
with original value of $13.3 million, has not been impaired since its acquisition. At September 30, 2019, the Company evaluated
its IPR&#38;D of the ovarian cancer indication and concluded that it is not more likely than not that the asset is impaired. As
no other indicators of impairment existed during the fourth quarter of 2019, or first half of 2020, no impairment charges were
recorded during the six months ended June 30, 2020 and 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s GBM candidate, with original
value of $9.4 million had cumulative impairments through 2018 of $7 million, with remaining carrying value of $2.4 million at December
31, 2019 and March 31, 2020, On September 30, 2019, the Company evaluated its IPR&#38;D of the (GBM) product candidate and concluded
that it is not more likely than not that the asset is further impaired. As no other indicators of impairment existed during the
fourth quarter of 2019 and in the first half of 2020, no impairment charges were recorded during the six months ended June 30,
2020 and 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s RNA delivery system, with
an initial value of $1.5, million was previously fully impaired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Covenants Not to Compete</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the EGEN Purchase Agreement, EGEN
provided certain covenants (&#8220;Covenant Not To Compete&#8221;) to the Company whereby EGEN agreed, during the period ending
on the seventh anniversary of the closing date of the acquisition on June 20, 2014, not to enter into any business, directly or
indirectly, which competes with the business of the Company nor will it contact, solicit or approach any of the employees of the
Company for purposes of offering employment. The Covenant Not to Compete which was valued at approximately $1.6 million at the
date of the EGEN acquisition has a definitive life and is amortized on a straight-line basis over its life of 7 years. The Company
recognized amortization expense of $56,829 in each of the three-month periods ended June 30, 2020 and 2019. The Company recognized
amortization expense of $113,658 in each of the six-month periods ended June 30, 2020 and 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying value of the Covenant Not to Compete
was $227,318, net of $1,363,896 accumulated amortization as of June 30, 2020 and $340,976, net of $1,250,238 accumulated amortization,
as of December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is a schedule of future amortization
amounts during the remaining life of the Covenant Not to Compete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended June 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">2021</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">227,318</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">2022 and thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#9472;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">227,318</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Goodwill</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The purchase price exceeded the estimated fair
value of the net assets acquired by approximately $2.0 million which was recorded as Goodwill. Goodwill represents the difference
between the total purchase price for the net assets purchased from EGEN and the aggregate fair values of tangible and intangible
assets acquired, less liabilities assumed. Goodwill is reviewed for impairment at least annually as of our third quarter ended
September 30 or sooner if we believe indicators of impairment exist. As of June 30, 2020, we concluded that the Company&#8217;s
fair value exceeded its carrying value therefore &#8220;it is not more likely than not&#8221; that the Goodwill was impaired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As described in Note 3, on July 13, 2020, the
Company announced that it has received a recommendation from the DMC to consider stopping the global Phase III OPTIMA Study of
ThermoDox&#174; in combination with RFA for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer. This event
will be incorporated in the Company&#8217;s assessment of the carrying value of goodwill and intangible assets as of the date the
information was available, which is the third quarter of 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is a summary of the net fair value
of the assets acquired in the EGEN asset acquisition for the three-month period ended June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">IPR&#38;D</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Goodwill</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Covenant Not To Compete</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt"><b>For the six-months ended June 30, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 58%"><font style="font-size: 10pt">Balance at January 1, 2020, net</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">15,736,491</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,976,101</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">340,976</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Amortization</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(113,658</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at June 30, 2020, net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,736,491</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,976,101</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">227,318</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399147199096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Other Accrued Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9. Other Accrued Liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other accrued liabilities at June 30, 2020
and December 31, 2019 include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>June 30, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Amounts due to contract research organizations and other contractual agreements</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">284,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">475,440</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Accrued payroll and related benefits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,054,272</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,604,541</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Accrued professional fees</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">150,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">204,155</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Other</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">19,411</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">19,411</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,507,683</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,303,547</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132402488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes and Loans Payable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes and Loans Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10. Notes and Loans Payable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Horizon Credit Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 27, 2018, the Company entered the Horizon
Credit Agreement. The Company drew down $10 million upon closing of the Horizon Credit Agreement on June 27, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three-month period ended June 30,
2020, the Company incurred $243,299 in interest expense and amortized $96,727 as interest expense for debt discounts and end of
term charges in connection with the Horizon Credit Agreement. During the three-month period ended June 30, 2019, the Company incurred
$255,182 in interest expense and amortized $94,266 as interest expense for debt discounts and end of term charges in connection
with the Horizon Credit Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six-month period ended June 30,
2020, the Company incurred $486,597 in interest expense and amortized $192,793 as interest expense for debt discounts and end of
term charges in connection with the Horizon Credit Agreement. During the six-month period ended June 30, 2019, the Company incurred
$508,471 in interest expense and amortized $191,724 as interest expense for debt discounts and end of term charges in connection
with the Horizon Credit Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is a schedule of future principal
payments, net of unamortized debt discounts and amortized end of term charges, due on the Horizon Credit Agreement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of June 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">2021</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">4,583,336</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5,000,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">416,664</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">2024 and thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Subtotal of future principal payments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">10,000,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Unamortized debt issuance costs, net</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,530</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,996,470</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Paycheck Protection Program</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On April 23, 2020,
we entered into a loan agreement with Silicon Valley Bank (the &#8220;April PPP Loan&#8221;), pursuant to the Paycheck Protection
Program (the &#8220;PPP&#8221;), established pursuant to the recently enacted Coronavirus Aid, Relief, and Economic Security Act
(the &#8220;CARES Act&#8221;) and administered by the U.S. Small Business Administration (&#8220;SBA&#8221;). We thereafter received
proceeds of $632,220 under the April PPP Loan. The April PPP Loan application required Celsion to certify that there was economic
uncertainty surrounding the Company and that, as such, the April PPP Loan was necessary to support our ongoing operations. Celsion
made this certification in good faith after analyzing, among other things, its financial situation and access to alternative forms
of capital, and believed that the Company satisfied all eligibility criteria for the April PPP Loan, and that our receipt of the
April PPP Loan proceeds was consistent with the broad objectives of the PPP of the CARES Act. The certification given with respect
to the April PPP Loan did not contain any objective criteria and was subject to interpretation. Considering subsequent guidance
issued by the SBA in consultation with the U.S. Department of the Treasury at that time, out of an abundance of caution we returned
the proceeds of the PPP Loan in full on May 13, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shortly after the April PPP Loan was repaid,
the SBA provided further guidance with respect to these certifications providing a safe harbor under which companies such as Celsion
with PPP loans of less than $2 million will be deemed to have made these certifications in good faith. Therefore, as the Company
continued to believe it qualifies for a loan under the PPP, it reapplied for and eventually received the new PPP Loan for $692,530
on May 26, 2020 (the &#8220;May PPP Loan&#8221;). The May PPP Loan was guaranteed by the SBA and evidenced by a promissory note
of the Company dated May 26, 2020 (the &#8220;Note&#8221;) in the principal amount of $692,530 payable to the lender. Pursuant
to the terms of the Note, was payable in part or in full, at any time, without penalty. On June 22, 2020, as disclosed in the
Company&#8217;s Current Report on Form 8-K filed on the same date, the Company commenced an offering of 2,666,667 shares of its
common stock which closed on June 24, 2020 (Note 11) and received net proceeds of approximately $9.1 million. In light of the
proceeds received from this equity offering, the Company elected to repay the May PPP Loan in full (including interest accrued
of $577) on June 24, 2020, terminating all obligations of the Company under the Note.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399135956584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 11. Stockholders&#8217; Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2018, the Company filed with the
SEC a new $75 million shelf registration statement on Form S-3 (the &#8220;2018 Shelf Registration Statement&#8221;) (File No.
333-227236) that allows the Company to issue any combination of common stock, preferred stock or warrants to purchase common stock
or preferred stock. This shelf registration was declared effective on October 12, 2018 and will expire three years from that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Aspire Purchase Agreements</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 31, 2018, the Company entered into
a common stock purchase agreement (the &#8220;2018 Aspire Purchase Agreement&#8221;) with Aspire Capital Fund, LLC (&#8220;Aspire
Capital&#8221;) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital
was committed to purchase up to an aggregate of $15.0 million of shares of the Company&#8217;s common stock over the 24-month term
of the 2019 Aspire Purchase Agreement. During 2018, the Company sold and issued an aggregate of 0.1 million shares under the 2018
Aspire Purchase Agreement, receiving approximately $0.2 million. During 2019, the Company sold and issued an aggregate of 3.3 million
shares under the 2018 Aspire Purchase Agreement, receiving approximately $6.3 million. As a result of the Company and Aspire entering
into a new purchase agreement on October 28, 2019 (the &#8220;2019 Aspire Purchase Agreement&#8221;) discussed in the next paragraph,
the 2018 Aspire Purchase Agreement was terminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2019 Aspire Purchase Agreement provided
that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase
up to an aggregate of $10.0 million of shares of the Company&#8217;s common stock over the 24-month term of the 2019 Aspire Purchase
Agreement. During 2019, the Company sold and issued an aggregate of 0.5 million shares under the 2019 Aspire Purchase Agreement,
receiving approximately $0.7 million. During the first quarter of 2020 through March 5, 2020 when the Company delivered notice
to Aspire terminating the 2019 Aspire Purchase Agreement, the Company sold 1.0 million shares of common stock under the Aspire
Purchase Agreement, receiving approximately $1.6 million in additional gross proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Capital on Demand<sup>TM</sup> Sales
Agreement</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 4, 2018, the Company entered into
the Capital on Demand Agreement with JonesTrading, pursuant to which the Company may offer and sell, from time to time, through
JonesTrading shares of Common Stock having an aggregate offering price of up to $16.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Shares will be issued pursuant to Celsion&#8217;s
previously filed and effective Registration Statement on Form S-3 (File No. 333-227236), the base prospectus dated October 12,
2018, filed as part of such Registration Statement, and the prospectus supplement dated December 4, 2018, filed by Celsion with
the Securities and Exchange Commission. During 2019, the Company sold and issued an aggregate of 0.5 million shares under the Capital
on Demand Agreement, receiving approximately $1.0 million in gross proceeds. During 2020 through June 30, 2020, the Company sold
and issued an aggregate of 1.2 million shares under the Capital on Demand Agreement, receiving approximately $3.5 million in gross
proceeds. The Company has not sold any shares under the Capital on Demand Agreement subsequent to June 30, 2020 through the date
of this Quarterly Report on Form 10Q. As of June 30, 2020, the Company has approximately $11.5 million available under the Capital
on Demand Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Registered Direct Offering</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 27, 2020, we entered into a Securities
Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with several institutional investors, pursuant to which we agreed to
issue and sell, in a registered direct offering (the &#8220;February 2020 Offering&#8221;), an aggregate of 4,571,428 shares (the
&#8220;Shares&#8221;) of our common stock at an offering price of $1.05 per Share for gross proceeds of approximately $4.8 million
before the deduction of the Placement Agent fees and offering expenses. The Shares were offered by the Company pursuant to a registration
statement on Form S-3 (File No. 333-227236). The Purchase Agreement contains customary representations, warranties and agreements
by the Company and customary conditions to closing. In a concurrent private placement (the &#8220;Private Placement&#8221;), the
Company agreed to issue to the investors that participated in the Offering, for no additional consideration, warrants, to purchase
up to 2,971,428 shares of Common Stock (the &#8220;Original Warrants&#8221;). The Original Warrants were initially exercisable
six months following their date of issue and were set to expire on the five-year anniversary of such initial exercise date. The
Original Warrants had an exercise price of $1.15 per share subject to adjustment as provided therein. On March 12, 2020, the Company
entered into private exchange agreements (the &#8220;Exchange Agreements&#8221;) with holders of the Original Warrants. Pursuant
to the Exchange Agreements, in return for a higher exercise price of $1.24 per share of Common Stock, the Company issued new warrants
to the Investors to purchase up to 3,200,000 shares of Common Stock (the &#8220;Exchange Warrants&#8221;) in exchange for the Original
Warrants. The Exchange Warrants, like the Original Warrants, are initially exercisable six months following their issuance (the
&#8220;Initial Exercise Date&#8221;) and expire on the five-year anniversary of their Initial Exercise Date. Other than having
a higher exercise price, different issue date, Initial Exercise Date and expiration date, the terms of the Exchange Warrants are
identical to those of the Original Warrants. On July 31, 2020, the Company filed a Form S-3 Registration Statement to register
the shares of Common Stock issuable under the Exchange Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Underwritten Offering</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 22, 2020, the Company entered into
an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Oppenheimer &#38; Co. Inc. (the &#8220;Underwriter&#8221;),
relating to the issuance and sale (the &#8220;Underwritten Offering&#8221;) of 2,666,667 shares of the Company&#8217;s common stock.
Pursuant to the terms of the Underwriting Agreement, the Underwriter agreed to purchase the shares at a price of $3.4875 per share.
The Underwriter offered the shares at a public offering price of $3.75 per share, reflecting an underwriting discount equal to
$0.2625, or 7.0% of the public offering price. The net proceeds to the Company from the Underwritten Offering, after deducting
the underwriting discount and estimated offering expenses payable by the Company, were approximately $9.1 million. The Underwritten
Offering closed on June 24, 2020 and was made pursuant to the Company&#8217;s effective shelf registration statement on Form S-3
(File No. 333-227236) filed with the Securities and Exchange Commission on September 7, 2018, and declared effective on October
12, 2018, including the base prospectus dated October 12, 2018 included therein and the related prospectus supplement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Underwriting Agreement contains customary
representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the
Company and the Underwriter including for liabilities under the Securities Act, other obligations of the parties, and termination
provisions. Pursuant to the Underwriting Agreement, until December 31, 2020, the Underwriter shall have a right of first refusal
to act as sole underwriter, initial purchaser, placement/selling agent, or arranger, as the case may be, on any new financing
for the Company (excluding equipment lease financings, loans or grants from governmental authorities or in connection with government
programs and financings relating to or sales of tax attributes) during such period. The Underwriter shall have the sole right
to determine whether or not any other broker dealer shall have the right to participate in any such offering and the economic
terms of any such participation. Pursuant to the Underwriting Agreement, subject to certain exceptions, the Company and certain
of the Company&#8217;s executive officers and directors have agreed that, without the prior written consent of the Underwriter
and subject to certain negotiated exceptions, they will not, for a period of 60 days, in either case, following the date of the
final prospectus supplement, sell or otherwise dispose of any of the Company&#8217;s securities held by them.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399135125480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 12. Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has long-term compensation plans
that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation
rights, other stock awards, and performance awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the 2018 Annual Stockholders Meeting of
the Company held on May 15, 2018, the Company&#8217;s stockholders approved the Celsion Corporation 2018 Stock Incentive Plan (the
&#8220;2018 Plan&#8221;). The 2018 Plan, as adopted, permits the granting of 2,700,000 shares of Celsion common stock as equity
awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation
rights, other stock awards, performance awards, or in any combination of the foregoing. At the 2019 Annual Stockholders Meeting
of the Company held on May 14, 2019, stockholders approved an amendment to the 2018 Plan whereby the Company increased the number
of shares of common stock available by 1,200,000 to a total of 3,900,000 under the 2018 Plan, as amended. Prior to the adoption
of the 2018 Plan, the Company had maintained the Celsion Corporation 2007 Stock Incentive Plan (the &#8220;2007 Plan&#8221;). At
the 2020 Annual Stockholders Meeting of the Company held on June 15, 2020, stockholders approved an amendment to the 2018 Plan,
as previously amended, whereby the Company increased the number of shares of common stock available by 2,500,000 to a total of
6,400,000 under the 2018 Plan, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the adoption of the 2018 Plan, the
Company had maintained the Celsion Corporation 2007 Stock Incentive Plan (the &#8220;2007 Plan&#8221;). The 2007 Plan permitted
the granting of 688,531 shares of Celsion common stock as equity awards in the form of incentive stock options, nonqualified stock
options, restricted stock, restricted stock units, stock appreciation rights, phantom stock, performance awards, or in any combination
of the foregoing. The 2018 Plan replaced the 2007 Plan although the 2007 Plan remains in effect for awards previously granted under
the 2007 Plan. Under the terms of the 2018 Plan, any shares subject to an award under the 2007 Plan which are not delivered because
of the expiration, forfeiture, termination or cash settlement of the award will become available for grant under the 2018 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued stock awards to employees
and directors in the form of stock options and restricted stock. Options are generally granted with strike prices equal to the
fair market value of a share of Celsion common stock on the date of grant. Incentive stock options may be granted to purchase shares
of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided
that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock
of Celsion must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive
stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Option and restricted stock awards vest upon
terms determined by the Compensation Committee of the Board of Directors and are subject to accelerated vesting in the event of
a change of control or certain terminations of employment. The Company issues new shares to satisfy its obligations from the exercise
of options or the grant of restricted stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 19, 2019, the Compensation Committee
of the Board of Directors approved the grant of (i) inducement stock options (the &#8220;Inducement Option Grants&#8221;) to purchase
a total of 140,004 shares of Celsion common stock, and (ii) inducement restricted stock awards (the &#8220;Inducement Stock Grants&#8221;)
totalling 13,000 shares of Celsion common stock to two new employees collectively. Each award has a grant date of the date of grant.
Each Inducement Option Grant has an exercise price per share equal to $2.18 which represents the closing price of Celsion&#8217;s
common stock as reported by the Nasdaq Capital Market on the date of grant. Each Inducement Option Grant will vest over three years,
with one-third vesting on the one-year anniversary of the employee&#8217;s first day of employment with the Company and one-third
vesting on the second and third anniversaries thereafter, subject to the new employee&#8217;s continued service relationship with
the Company on each such date. Each Inducement Option Grant has a ten-year term and is subject to the terms and conditions of the
applicable stock option agreement. Each Inducement Stock Grant will vest on the one-year anniversary of the employee&#8217;s first
day of employment with the Company and is subject to the new employee&#8217;s continued service relationship with the Company through
such date and is subject to the terms and conditions of the applicable restricted stock agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of stock option awards and restricted
stock grants for the six-months ended June 30, 2020 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Stock Options</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Restricted Stock Awards</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Outstanding</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Non-vested</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Restricted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Stock</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Outstanding</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Grant</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Date</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fair Value</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Terms of</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Equity</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Awards</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(in years)</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 40%"><font style="font-size: 10pt">Equity awards outstanding at January 1, 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 10pt">4,332,142</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 10pt">2.63</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 10pt">8,750</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 10pt">1.59</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Equity awards granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">644,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.52</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">429,855</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.16</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Options exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(140,864</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2.64</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Vested and issued</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(429,855</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.16</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Equity awards forfeited, cancelled or expired</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(110,002</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">2.21</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Equity awards outstanding at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,725,276</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">2.76</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8,750</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.59</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">8.3</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Aggregate intrinsic value of outstanding equity awards at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,494,924</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,875</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Equity awards exercisable at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,194,777</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">2.86</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.8</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Aggregate intrinsic value of equity awards exercisable at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,733,421</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2020, there was a total of 6,510,174
shares of Celsion common stock reserved for issuance under the 2018 Plan which were comprised of 4,594,022 shares of Celsion common
stock subject to equity awards previously granted under the 2018 Plan and 2007 Plan and 1,916,152 shares of Celsion common stock
available for future issuance under the 2018 Plan. As of June 30, 2020, there was a total of 140,004 shares of Celsion common stock
subject to outstanding inducement awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total compensation cost related to stock options
and restricted stock awards amounted to $578,761 and $622,696 for the three-month periods ended June 30, 2020 and 2019, respectively.
Of these amounts, $200,186 and $239,406 was charged to research and development during the three-month periods ended June 30, 2020
and 2019, respectively, and $378,575 and $383,290 was charged to general and administrative expenses during the three-month periods
ended June 30, 2020 and 2019, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total compensation cost related to stock options
and restricted stock awards amounted to $1,030,726 and $1,313,842 for the six-month periods ended June 30, 2020 and 2019, respectively.
Of these amounts, $378,122 and $479,794 was charged to research and development during the six-month periods ended June 30, 2020
and 2019, respectively, and $652,604 and $834,048 was charged to general and administrative expenses during the six-month periods
ended June 30, 2020 and 2019, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2020, there was $2.4 million
of total unrecognized compensation cost related to non-vested stock-based compensation arrangements. That cost is expected to be
recognized over a weighted-average period of 1.5 years. The weighted average grant date fair values of the stock options granted
was $3.10 and $1.88 during the six-month periods ended June 30, 2020 and 2019, respectively. In connection with the Company&#8217;s
annual 2019 bonus program, the Company issued 429,855 shares of common stock from the 2018 Stock Incentive Plan in lieu of paying
cash for 50% of the annual bonus awards. These amounts were fully accrued for in the consolidated financial statements for the
year ended December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2020, the Company received gross proceeds
of $371,895 from the issuance of 140,864 shares of common stock upon exercise of stock option awards under the 2018 Plan. No options
were exercised in 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair values of stock options granted were
estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for
use in estimating the fair value of traded options, which have different characteristics from Celsion&#8217;s stock options. The
model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following
assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Six Months Ended June 30, </b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">0.71% to 1.33 </font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">2.42%-2.65</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">100.4% to 104.2 </font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">101.3%-106.2</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expected life (in years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">8.5 to 10.0 </font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.5 to 9.3 </font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Expected volatilities utilized in the model
are based on historical volatility of the Company&#8217;s stock price. The risk-free interest rate is derived from values assigned
to U.S. Treasury bonds with terms that approximate the expected option lives in effect at the time of grant.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132480504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earn-out Milestone Liability<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_EarnoutMilestoneLiabilityAbstract', window );"><strong>Hercules Warrant [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock', window );">Earn-out Milestone Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 13. Earn-out Milestone Liability</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Amended Asset Purchase Agreement
entered by and between Company and EGWU, Inc in March 2019, payment of the earnout milestone liability related to the Ovarian Cancer
Indication of $12.4 million was modified. The Company has the option to make a $7.0 million payment within 10 business days of
achieving the milestone; or make a payment of $12.4 million in cash, common stock of the Company, or a combination of either, within
one year of achieving the milestone.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2020, March 31, 2020, and December
31, 2019, the Company fair valued the earn-out milestone liability at $6.0 million, $5.8 million and $5.7 million, respectively
and recognized a non-cash charge of $0.2 and $0.3 million for the three-month and six-month periods ended June 30, 2020, respectively.
In assessing the earnout milestone liability at June 30, 2020 and March 31, 2020, the Company fair valued each of the two payment
options per the Amended Asset Purchase Agreement and weighted them at 80% and 20% probability for the $7.0 million and the $12.4
million payments, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2019, March 31, 2019, and December
31, 2018, the Company fair valued the earn-out milestone liability at $13.1 million, $5.8 million and $8.9 million, respectively
and recognized a non-cash charge of $0.1 million and a non-cash benefit of $3.0 million during the three-month and six-month periods
ended June 30, 2019, respectively. In assessing the earnout milestone liability at June 30, 2019 and March 31, 2019, the Company
fair valued each of the two payment options per the Amended Asset Purchase Agreement and weighted them at 80% and 20% probability
for the $7.0 million and the $12.4 million payments, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of the changes in
the earn-out milestone liability for the six-month period ended June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">Balance at January 1, 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">(5,717,709</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Non-cash loss from the change in fair value</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(297,570</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(6,015,279</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a schedule of the Company&#8217;s
risk-adjustment assessment of each milestone:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">Date</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Risk-adjustment Assessment <br />
of Achieving each Milestone</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Discount Rate</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Estimated Time <br />
to Achieve</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 47%; text-align: justify"><font style="font-size: 10pt">June 30, 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">80</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">9</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><font style="font-size: 10pt">0.54 to 1.54 years</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">March 31, 2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">1.04 to 2.04 years</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">December 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">1.12 to 2.12 years</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">June 30, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">0.75 to 1.75 years</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">March 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">1.00 to 2.00 years</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">December 31, 2018</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">1.25 years</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_EarnoutMilestoneLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_EarnoutMilestoneLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure related to earn-out milestone liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_EarnoutMilestoneLiabilityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132284392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_WarrantsTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 14. Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is a summary of all warrant activity
for the six months ended June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of Warrants</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Issued</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Warrants outstanding at December 31, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">626,098</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">1.87</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Warrants issued during the six months ended June 30, 2020 (see Note 11)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3,200,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.24</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Warrants outstanding at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,826,098</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.34</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Aggregate intrinsic value of outstanding warrants at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,096,322</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Schedule of weighted average exercise price and remaining contractual terms at June 30, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Warrants provided to EGWU, Inc. (Note 13)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>All other warrants</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Number of warrants issued</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">200,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">3,626,098</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Weighted average exercise prise</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.01</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.42</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Weighted average contractual terms remaining</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">No expiration</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.1 years</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399135121288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 15. Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains a lease, as amended,
for its 10,870 square foot premises located in Lawrenceville, New Jersey which is currently set to expire September 1, 2023. Also,
the Company maintains a lease for an 11,500 square foot premises located in Huntsville Alabama, which is currently set to expire
in January 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We adopted ASC Topic 842 on January 1, 2019
using the modified retrospective transition method for all lease arrangements at the beginning of the period of adoption. Results
for reporting periods beginning January 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and continue
to be reported in accordance with our historic accounting under Topic 840, Leases. The standard had a material impact on our Condensed
Consolidated Balance Sheet but had no impact on our condensed consolidated net earnings and cash flows. The most significant impact
of adopting ASC Topic 842 was the recognition of the right-of-use (ROU) asset and lease liabilities for operating leases, which
are presented in the following three-line items on the Consolidated Condensed Balance Sheet: (i) operating lease right-of-use asset;
(ii) current operating lease liabilities; and (iii) operating lease liabilities. Therefore, on date of adoption of ASC Topic 842,
the Company recognized a ROU asset of $1.4 million, operating lease liabilities, current and non-current collectively, of $1.5
million and reduced other liabilities by approximately $0.1 million. We elected the package of practical expedients for leases
that commenced before the effective date of ASC Topic 842 whereby we elected to not reassess the following: (i) whether any expired
or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct
costs for any existing leases. In addition, we have lease agreements with lease and non-lease components, and we have elected the
practical expedient for all underlying asset classes and account for them as a single lease component. We have no finance leases.
We determine if an arrangement is a lease at inception. We have operating leases for office space and research and development
facilities. Neither of our leases include options to renew; however, one contains an option for early termination. We considered
the option of early termination in measurement of right-of-use assets and lease liabilities, and we determined it is not reasonably
certain to be terminated. In connection with the 2<sup>nd</sup> Lease Amendment for the New Jersey office lease in January 2019,
the Company considered this as one modified lease and not as two separate leases. Therefore, in January 2019, the Company determined
this lease was an operating lease and remeasured the ROU asset and lease liability. Therefore, the Company increased the ROU asset
and operating lease liabilities by $0.4 million to $1.8 million and $1.9 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is a table of the lease payments
and maturity of our operating lease liabilities as of June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>year ending</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">Remainder of 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">263,726</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">530,734</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">535,579</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">233,116</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">2024 and thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Subtotal future lease payments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,563,155</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Less imputed interest</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(219,931</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Total lease liabilities</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,343,224</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Weighted average remaining life</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3.2 years</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Weighted average discount rate</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9.98</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three-month and six-month periods
ending June 30, 2020, operating lease expense was $130,595 and $261,190, respectively and cash paid for operating leases included
in operating cash flows was $131,452 and $262,084, respectively. For the three-month and six-month periods ending June 30, 2019,
operating lease expense was $130,595 and $261,190, respectively and cash paid for operating leases included in operating cash
flows was $118,415 and 224,585, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399147204888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Technology Development and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract', window );"><strong>Technology Development And Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_LicensingTransactionTextBlock', window );">Technology Development and Licensing Agreements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 16. Technology Development and Licensing
Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 7, 2012, the Company entered into a
long-term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun) for the production of ThermoDox<sup>&#174;</sup>
in the China territory. In accordance with the terms of the agreement, Hisun will be responsible for providing all of the technical
and regulatory support services, including the costs of all technical transfer, registration and bioequivalence studies, technical
transfer costs, Celsion consultative support costs and the purchase of any necessary equipment and additional facility costs necessary
to support capacity requirements for the manufacture of ThermoDox<sup>&#174;</sup>. Celsion will repay Hisun for the aggregate
amount of these development costs and fees commencing on the successful completion of three registration batches of ThermoDox<sup>&#174;</sup>.
Hisun is also obligated to certain performance requirements under the agreement. The agreement will initially be limited to a percentage
of the production requirements of ThermoDox<sup>&#174;</sup> in the China territory with Hisun retaining an option for additional
global supply after local regulatory approval in the China territory. In addition, Hisun will collaborate with Celsion around the
regulatory approval activities for ThermoDox<sup>&#174; </sup>with the China State Food and Drug Administration (CHINA FDA). During
the first quarter of 2015, Hisun completed the successful manufacture of three registration batches of ThermoDox<sup>&#174;</sup>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 18, 2013, we entered into a technology
development contract with Hisun, pursuant to which Hisun paid us a non-refundable research and development fee of $5 million to
support our development of ThermoDox<sup>&#174;</sup> in mainland China, Hong Kong and Macau (the China territory). Following our
announcement on January 31, 2013 that the HEAT study failed to meet its primary endpoint, Celsion and Hisun have agreed that the
Technology Development Contract entered into on January 18, 2013 will remain in effect while the parties continue to collaborate
and are evaluating the next steps in relation to ThermoDox<sup>&#174;</sup> , which include the sub-group analysis of patients
in the Phase III HEAT Study for the hepatocellular carcinoma clinical indication and other activities to further the development
of ThermoDox<sup>&#174;</sup> for the Greater China market. The $5.0 million received as a non-refundable payment from Hisun in
the first quarter 2013 has been recorded to deferred revenue and will continue to be amortized over the 10 -year term of the agreement,
until such time as the parties find a mutually acceptable path forward on the development of ThermoDox<sup>&#174;</sup> based on
findings of the ongoing post-study analysis of the HEAT Study data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 19, 2013, the Company and Hisun entered
into a Memorandum of Understanding to pursue ongoing cooperation for the continued clinical development of ThermoDox <sup>&#174;</sup>
as well as the technology transfer relating to the commercial manufacture of ThermoDox<sup>&#174;</sup> for the China territory.
This expanded level of cooperation includes development of the next generation liposomal formulation with the goal of creating
safer, more efficacious versions of marketed cancer chemotherapeutics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Among the key provisions of the Celsion-Hisun
Memorandum of Understanding are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><font style="font-size: 10pt"><b>&#9679;</b></font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Hisun will provide the Company with internal resources necessary to complete the technology transfer of the Company&#8217;s proprietary manufacturing process and the production of registration batches for the China territory;</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt"><b>&#9679;</b></font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Hisun will coordinate with the Company around the clinical and regulatory approval activities for ThermoDox<sup>&#174;</sup> as well as other liposomal formations with the CHINA FDA; and</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt"><b>&#9679;</b></font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Hisun will be granted a right of first offer for a commercial license to ThermoDox<sup>&#174;</sup> for the sale and distribution of ThermoDox<sup>&#174; </sup>in the China territory.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 8, 2016, we signed a Technology Transfer,
Manufacturing and Commercial Supply Agreement (&#8220;GEN-1 Agreement&#8221;) with Hisun to pursue an expanded partnership for
the technology transfer relating to the clinical and commercial manufacture and supply of GEN-1, Celsion&#8217;s proprietary gene
mediated, IL- 12 immunotherapy, for the greater China territory, with the option to expand into other countries in the rest of
the world after all necessary regulatory approvals are in effect. The GEN- 1 Agreement will help to support supply for both ongoing
and planned clinical studies in the U.S., and for potential future studies of GEN- 1 in China. GEN- 1 is currently being evaluated
by Celsion in first line ovarian cancer patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Key provisions of the GEN-1 Agreement are as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9.9pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><font style="font-size: 10pt"><b>&#9679;</b></font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">the GEN-1 Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with the Company&#8217;s current suppliers;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt"><b>&#9679;</b></font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">once approved, the cost structure for GEN-1 will support rapid market adoption and significant gross margins across global markets;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt"><b>&#9679;</b></font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Celsion will provide Hisun a certain percentage of China&#8217;s commercial unit demand, and separately of global commercial unit demand, subject to regulatory approval;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt"><b>&#9679;</b></font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Hisun and Celsion will commence technology transfer activities relating to the manufacture of GEN-1, including all studies required by CHINA FDA for site approval; and</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt"><b>&#9679;</b></font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Hisun will collaborate with Celsion around the regulatory approval activities for GEN-1 with the CHINA FDA. A local China partner affords Celsion access to accelerated CHINA FDA review and potential regulatory exclusivity for the approved indication.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated the Hisun arrangement
in accordance with ASC 606 and determined that its performance obligations under the agreement include the non-exclusive, royalty-free
license, research and development services to be provided by the Company, and its obligation to serve on a joint committee. The
Company concluded that the license was not distinct since its value is closely tied to the ongoing research and development activities.
As such, the license and the research and development services are bundled as a single performance obligation. Since the provision
of the license and research and development services are considered a single performance obligation, the $5,000,000 upfront payment
is being recognized as revenue ratably through 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_LicensingTransactionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a contractual arrangement, in which the Company gave another party an exclusive license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_LicensingTransactionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_TechnologyDevelopmentAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399135121288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 17. Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 20, 2019, a purported stockholder
of the Company filed a derivative and putative class action lawsuit against the Company and certain officers and directors (the
&#8220;Shareholder Action&#8221;). The Company is a defendant in this derivative and putative class action lawsuit in the Superior
Court of New Jersey, Chancery Division, filed by a shareholder against the Company (as both a class action defendant and nominal
defendant), and certain of its officers and directors (the &#8220;Individual Defendants&#8221;), with the caption O&#8217;Connor
v. Braun et al., Docket No. MER-C-000068-19 (the &#8220;Shareholder Action&#8221;). The Shareholder Action alleges breaches of
the defendants&#8217; fiduciary duties based on allegations that the defendants omitted or made improper statements when seeking
shareholder approval of the 2018 Stock Incentive Plan. The Shareholder Action seeks, among other things, any damages sustained
by the Company as a result of the defendants&#8217; alleged wrongdoing, a declaratory judgment against all defendants invalidating
the 2018 Stock Incentive Plan and declaring any awards made under the Plan invalid, rescinded, and subject to disgorgement, an
order disgorging the equity awards granted to the Individual Defendants under the 2018 Stock Incentive Plan, and attorneys&#8217;
fees and costs. Without admitting the validity of any of the claims asserted in the Shareholder Action, or any liability with respect
thereto, and expressly denying all allegations of wrongdoing, fault, liability, or damage against the Company and the Individual
Defendants arising out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Shareholder
Action, the Company and the Individual Defendants have concluded that it is desirable that the claims be settled on the terms and
subject to the conditions set forth in the Settlement Agreement. The Company and the Individual Defendants are entering into the
Settlement Agreement for settlement purposes only and solely to avoid the cost and disruption of further litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2020, the Company, the Individual
Defendants, and the plaintiff (the &#8220;Parties&#8221;) entered into a Settlement Agreement and Release (the &#8220;Settlement
Agreement&#8221;), which memorializes the terms of the Parties&#8217; settlement of the Shareholder Action (the &#8220;Settlement&#8221;).
The Settlement calls for repricing of certain stock options and payment of plaintiff legal fees of $187,500. On July 24, 2020,
the Court issued an order approving the Parties&#8217; proposed form of notice to shareholders regarding the Settlement. A hearing
to determine whether the Court should issue a final order approving the proposed Settlement has been scheduled for September 8,
2020. On August 3, 2020, the Company filed notice of the Settlement Agreement on Form 8-K as filed with the SEC.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399144642744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 18. Subsequent Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 13, 2020, the Company announced that
it has received a recommendation from the DMC to consider stopping the global Phase III OPTIMA Study of ThermoDox<sup>&#174;</sup>
in combination with RFA for the treatment of HCC, or primary liver cancer. The recommendation was made following the second pre-planned
interim safety and efficacy analysis by the DMC on July 9, 2020. The DMC analysis found that the pre-specified boundary for stopping
the trial for futility of 0.900 was crossed with an actual value of 0.903. The Company intends to follow the advice of the DMC
and will consider its options either to stop the study or continue to follow patients after a thorough review of the data, and
an evaluation of the probability of success. Timing for this decision is made less urgent by the fact that the OPTIMA Study has
been fully enrolled since August 2018 and that the vast majority of the trial expenses have already been incurred. On August 4,
2020, the Company issued a press release announcing it will continue following patients for overall survival (&#8220;OS&#8221;),
noting that the unexpected and marginally crossed futility boundary, suggested by the Kaplan-Meier analysis at the second interim
analysis on July 9, 2020, may be associated with a data maturity issue.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399133091176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Debt Securities Available for Sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Schedule of Cost, Fair Value and Maturities of Short Term Investments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the cost, fair value and maturities
of the Company&#8217;s short-term investments is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>June 30, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Cost</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Cost</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt"><b>Short-term investments</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Investments in debt securities</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">2,784,002</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,943,108</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,784,002</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,943,108</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>June 30, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Cost</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Cost</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt"><b>Short-term investment maturities</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Within 3 months</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">2,784,002</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,943,108</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,784,002</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,943,108</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Summary of Investment Securities Gross Unrealized Gains (Losses)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the Company&#8217;s
investment securities gross unrealized gains (losses) and fair value by investment category and length of time that individual
securities have been in a continuous unrealized loss position at June 30, 2020 and December 31, 2019. The Company has reviewed
individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>June 30, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Available for sale securities </b>(all unrealized holding gains and losses are less than 12 months at date of measurement)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unrealized</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Holding</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Gains</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Unrealized</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Holding</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Gains</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Investments in debt securities with unrealized Gains</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,866</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: right"><font style="font-size: 10pt">42,778</font></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,866</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">42,778</font></td>
    <td style="padding-bottom: 2.5pt"></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeTextBlock', window );">Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investment income, which includes net realized
gains on sales of available for sale securities and investment income interest and dividends, is summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>June 30,</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%"><font style="font-size: 10pt">Interest and dividends accrued and paid</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">18,095</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">143,633</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Realized gains</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,865</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">969</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Investment income, net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">20,960</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">144,602</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>June 30,</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 66%"><font style="font-size: 10pt">Interest and dividends accrued and paid</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">63,172</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">248,043</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Realized gains</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">46,097</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10,350</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Investment income, net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">109,269</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">258,393</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132409720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Assets and liabilities measured at fair value
are summarized below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Total Fair Value</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Significant Other Observable Inputs (Level 2)</b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Significant Unobservable Inputs (Level 3)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Assets:</font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Recurring items as of June 30, 2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 48%; padding-left: 10pt"><font style="font-size: 10pt">Corporate debt securities, available for sale</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">&#9472; </font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2,791,868</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">&#9472; &#160;</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Recurring items as of December 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Corporate debt securities, available for sale</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472; </font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">7,985,886</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472; &#160;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Liabilities:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Recurring items as of June 30, 2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Earn-out milestone liability (Note 13)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">6,015,279</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472; &#160;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">6,015,279</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Recurring items as of December 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Earn-out milestone liability (Note 13)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5,717,709</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#9472; &#160;</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5,717,709</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399133830312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Amounts During the Remaining Life</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is a schedule of future amortization
amounts during the remaining life of the Covenant Not to Compete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended June 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">2021</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">227,318</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">2022 and thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#9472;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">227,318</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Schedule of Fair Value of Assets Acquired</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is a summary of the net fair value
of the assets acquired in the EGEN asset acquisition for the three-month period ended June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">IPR&#38;D</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Goodwill</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Covenant Not To Compete</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt"><b>For the six-months ended June 30, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 58%"><font style="font-size: 10pt">Balance at January 1, 2020, net</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">15,736,491</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,976,101</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">340,976</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Amortization</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(113,658</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at June 30, 2020, net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,736,491</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,976,101</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">227,318</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132351080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other accrued liabilities at June 30, 2020
and December 31, 2019 include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>June 30, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Amounts due to contract research organizations and other contractual agreements</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">284,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">475,440</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Accrued payroll and related benefits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,054,272</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,604,541</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Accrued professional fees</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">150,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">204,155</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Other</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">19,411</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">19,411</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,507,683</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,303,547</font></td>
    <td style="padding-bottom: 2.5pt"></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399140250696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes and Loans Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principle Payments, Net of Unamortized Debt Discounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is a schedule of future principal
payments, net of unamortized debt discounts and amortized end of term charges, due on the Horizon Credit Agreement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of June 30,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">2021</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">4,583,336</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5,000,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">416,664</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">2024 and thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Subtotal of future principal payments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">10,000,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Unamortized debt issuance costs, net</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,530</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,996,470</font></td>
    <td style="padding-bottom: 2.5pt"></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399136103032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock', window );">Summary of Stock Option and Restricted Stock Awards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of stock option awards and restricted
stock grants for the six-months ended June 30, 2020 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Stock Options</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Restricted Stock Awards</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Outstanding</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Non-vested</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Restricted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Stock</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Outstanding</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Grant</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Date</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fair Value</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Terms of</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Equity</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Awards</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(in years)</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 40%"><font style="font-size: 10pt">Equity awards outstanding at January 1, 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 10pt">4,332,142</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 10pt">2.63</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><font style="font-size: 10pt">8,750</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 9%; text-align: right"><font style="font-size: 10pt">1.59</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Equity awards granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">644,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.52</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">429,855</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.16</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Options exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(140,864</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2.64</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Vested and issued</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(429,855</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.16</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Equity awards forfeited, cancelled or expired</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(110,002</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">2.21</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Equity awards outstanding at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,725,276</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">2.76</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8,750</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.59</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">8.3</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Aggregate intrinsic value of outstanding equity awards at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,494,924</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7,875</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Equity awards exercisable at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,194,777</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">2.86</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.8</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Aggregate intrinsic value of equity awards exercisable at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,733,421</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value of Options Granted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company used the following assumptions
for determining the fair value of options granted under the Black-Scholes option pricing model:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="5" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Six Months Ended June 30, </b></font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">0.71% to 1.33 </font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">2.42%-2.65</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">100.4% to 104.2 </font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">101.3%-106.2</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expected life (in years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">8.5 to 10.0 </font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.5 to 9.3 </font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of stock option and restricted stock awards [Table text block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132159048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earn-out Milestone Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_EarnoutMilestoneLiabilityAbstract', window );"><strong>Hercules Warrant [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock', window );">Schedule of Changes in Earn-out Milestone Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of the changes in
the earn-out milestone liability for the six-month period ended June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">Balance at January 1, 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">(5,717,709</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Non-cash loss from the change in fair value</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(297,570</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(6,015,279</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock', window );">Schedule of Risk Adjustment Assessment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a schedule of the Company&#8217;s
risk-adjustment assessment of each milestone:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">Date</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Risk-adjustment Assessment <br />
of Achieving each Milestone</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Discount Rate</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Estimated Time <br />
to Achieve</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 47%; text-align: justify"><font style="font-size: 10pt">June 30, 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">80</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">9</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><font style="font-size: 10pt">0.54 to 1.54 years</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">March 31, 2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">1.04 to 2.04 years</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">December 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">1.12 to 2.12 years</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">June 30, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">0.75 to 1.75 years</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">March 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">1.00 to 2.00 years</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">December 31, 2018</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">1.25 years</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_EarnoutMilestoneLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_EarnoutMilestoneLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions regarding the changes in earn-out liabilities during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ScheduleOfChangesInEarnOutMilestoneLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of risk-adjustment assessment [Table text block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ScheduleOfRiskadjustmentAssessmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399135088776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is a summary of all warrant activity
for the six months ended June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of Warrants</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Issued</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Warrants outstanding at December 31, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">626,098</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">1.87</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Warrants issued during the six months ended June 30, 2020 (see Note 11)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3,200,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.24</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Warrants outstanding at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,826,098</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.34</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Aggregate intrinsic value of outstanding warrants at June 30, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,096,322</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock', window );">Schedule of Weighted Average Remaining Contractual Terms</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Schedule of weighted average exercise price and remaining contractual terms at June 30, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Warrants provided to EGWU, Inc. (Note 13)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>All other warrants</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Number of warrants issued</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">200,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">3,626,098</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Weighted average exercise prise</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.01</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.42</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Weighted average contractual terms remaining</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">No expiration</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.1 years</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ScheduleOfWeightedAverageRemainingContractualTermsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132467528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is a table of the lease payments
and maturity of our operating lease liabilities as of June 30, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>year ending</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">Remainder of 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">263,726</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">530,734</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">535,579</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">233,116</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">2024 and thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Subtotal future lease payments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,563,155</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Less imputed interest</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(219,931</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Total lease liabilities</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,343,224</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Weighted average remaining life</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3.2 years</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Weighted average discount rate</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9.98</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">%</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399128527832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Condition and Business Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Cumulated net losses</a></td>
<td class="num">$ (300,916,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (290,516,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_CashInvestmentSecuritiesAndInterestReceivable', window );">Cash, investment securities and interest receivable</a></td>
<td class="nump">25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_HorizonCreditAgreementMember', window );">Horizon Credit Agreement [Member] | Horizon Technology Finance Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from new capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_HorizonCreditAgreementMember', window );">Horizon Credit Agreement [Member] | Horizon Technology Finance Corporation [Member] | London Interbank Offered Rate (LIBOR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=CLSN_NJMember', window );">New Jersey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization', window );">Tax benefits of EDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_NetProceedsFromSaleOfNetOperatingLosses', window );">Net proceeds from sale of net operating losses</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_CashInvestmentSecuritiesAndInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, investment securities and interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_CashInvestmentSecuritiesAndInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_NetProceedsFromSaleOfNetOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from sale of net operating losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_NetProceedsFromSaleOfNetOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax benefits of EDA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_TaxBenefitsOfEarningsBeforeDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_HorizonCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_HorizonCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CLSN_HorizonTechnologyFinanceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CLSN_HorizonTechnologyFinanceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=CLSN_NJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=CLSN_NJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399131023432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards', window );">Number of shares of common stock issuable upon exercise of warrants and equity awards</a></td>
<td class="nump">8,560,124<span></span>
</td>
<td class="nump">4,595,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare', window );">Number of shares of common stock issued in calculation basic loss per share</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total number of Shares of common stock issuable upon exercise of warrants and equity awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued in calculation basic loss per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_NumberOfSharesOfCommonStockIssuedInCalculationBasicLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399135102232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment in Debt Securities Available for Sale (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments - Fair Value</a></td>
<td class="nump">$ 2,791,868<span></span>
</td>
<td class="nump">$ 7,985,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments - Fair Value</a></td>
<td class="nump">2,791,868<span></span>
</td>
<td class="nump">7,985,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments - Fair Value</a></td>
<td class="nump">$ 2,791,868<span></span>
</td>
<td class="nump">$ 7,985,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399128457112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment in Debt Securities Available for Sale - Schedule of Cost, Fair Value and Maturities of Short Term Investments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments - Cost</a></td>
<td class="nump">$ 2,784,002<span></span>
</td>
<td class="nump">$ 7,943,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments - Fair Value</a></td>
<td class="nump">2,791,868<span></span>
</td>
<td class="nump">7,985,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost', window );">Short-term investment maturities - Within 3 months, cost</a></td>
<td class="nump">2,784,002<span></span>
</td>
<td class="nump">7,943,108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent', window );">Total, cost</a></td>
<td class="nump">2,784,002<span></span>
</td>
<td class="nump">7,943,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue', window );">Short-term investment maturities - Within 3 months, fair value</a></td>
<td class="nump">2,791,868<span></span>
</td>
<td class="nump">7,985,886<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total, fair value</a></td>
<td class="nump">2,791,868<span></span>
</td>
<td class="nump">7,985,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments - Cost</a></td>
<td class="nump">2,784,002<span></span>
</td>
<td class="nump">7,943,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments - Fair Value</a></td>
<td class="nump">$ 2,791,868<span></span>
</td>
<td class="nump">$ 7,985,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with single maturity date and allocated without single maturity date, maturing in next rolling three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132096040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment in Debt Securities Available for Sale - Summary of Investment Securities Gross Unrealized Gains (Losses) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months', window );">Investments in debt securities with unrealized Gains, Less than 12 months , Fair Value</a></td>
<td class="nump">$ 2,791,868<span></span>
</td>
<td class="nump">$ 7,985,886<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities - available for sale, Fair Value</a></td>
<td class="nump">2,791,868<span></span>
</td>
<td class="nump">7,985,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain', window );">Investments in debt securities with unrealized Gains, Less than 12 months, Unrealized Holding Gains</a></td>
<td class="nump">7,866<span></span>
</td>
<td class="nump">42,778<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss', window );">Unrealized Holding Gains</a></td>
<td class="nump">$ 7,866<span></span>
</td>
<td class="nump">$ 42,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_AvailableforsaleSecuritiesDebtSecuritiesCurrentAccumulatedUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) unrealized gain less than 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized gain on investment in debt security measured at fair value with change in other comprehensive income (available-for-sale), unrealized gain for less than 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399145659240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Debt Securities Available for Sale - Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest and dividends accrued and paid</a></td>
<td class="nump">$ 18,095<span></span>
</td>
<td class="nump">$ 143,633<span></span>
</td>
<td class="nump">$ 63,172<span></span>
</td>
<td class="nump">$ 248,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Realized gains</a></td>
<td class="nump">2,865<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="nump">46,097<span></span>
</td>
<td class="nump">10,350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Investment income, net</a></td>
<td class="nump">$ 20,960<span></span>
</td>
<td class="nump">$ 144,602<span></span>
</td>
<td class="nump">$ 109,269<span></span>
</td>
<td class="nump">$ 258,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399128715320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available for sale</a></td>
<td class="nump">$ 2,791,868<span></span>
</td>
<td class="nump">$ 7,985,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Earn-out milestone liability</a></td>
<td class="nump">6,015,279<span></span>
</td>
<td class="nump">5,717,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available for sale</a></td>
<td class="nump">2,791,868<span></span>
</td>
<td class="nump">7,985,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Earn-out milestone liability</a></td>
<td class="nump">6,015,279<span></span>
</td>
<td class="nump">5,717,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Earn-out milestone liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Earn-out milestone liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Earn-out milestone liability</a></td>
<td class="nump">6,015,279<span></span>
</td>
<td class="nump">5,717,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available for sale</a></td>
<td class="nump">2,791,868<span></span>
</td>
<td class="nump">7,985,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member] | Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available for sale</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available for sale</a></td>
<td class="nump">2,791,868<span></span>
</td>
<td class="nump">7,985,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member] | Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investment securities, available for sale</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399129923384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_AspirePurchaseAgreementsMember', window );">2018 Aspire Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CLSN_IPRAndDDrugTechnologyPlatformsMember', window );">IPR&amp;D Drug Technology Platforms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CLSN_IPRAndDDrugTechnologyPlatformsMember', window );">IPR&amp;D Drug Technology Platforms [Member] | Ovarian Cancer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges, total</a></td>
<td class="nump">$ 13,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CLSN_EGENIncMember', window );">EGEN Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CLSN_EGENIncMember', window );">EGEN Inc [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,829<span></span>
</td>
<td class="nump">$ 113,658<span></span>
</td>
<td class="nump">$ 113,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,363,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CLSN_EGENIncMember', window );">EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CLSN_EGENIncMember', window );">EGEN Inc [Member] | RNA Delivery System [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=CLSN_EGENIncMember', window );">EGEN Inc [Member] | IPR&amp;D Drug Technology Platforms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Indefinite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_AspirePurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_AspirePurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CLSN_IPRAndDDrugTechnologyPlatformsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CLSN_IPRAndDDrugTechnologyPlatformsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=CLSN_OvarianCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=CLSN_OvarianCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=CLSN_EGENIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=CLSN_EGENIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=CLSN_GlioblastomaMultiformeBrainCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=CLSN_GlioblastomaMultiformeBrainCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=CLSN_RNADeliverySystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=CLSN_RNADeliverySystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132556728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Future Amortization Amounts During the Remaining Life (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 227,318<span></span>
</td>
<td class="nump">$ 340,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">227,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter', window );">2022 and thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 227,318<span></span>
</td>
<td class="nump">$ 340,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-lived intangible asset, expected amortization, year two, and after.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwoAndAfter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399056794648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Fair Value of Assets Acquired (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, beginning balance</a></td>
<td class="nump">$ 340,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, ending balance</a></td>
<td class="nump">227,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, beginning balance</a></td>
<td class="nump">340,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(113,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, ending balance</a></td>
<td class="nump">227,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=CLSN_IPRAndDMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, beginning balance</a></td>
<td class="nump">15,736,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, ending balance</a></td>
<td class="nump">15,736,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, beginning balance</a></td>
<td class="nump">1,976,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, ending balance</a></td>
<td class="nump">$ 1,976,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=CLSN_IPRAndDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=CLSN_IPRAndDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399134331672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accrued Liabilities - Schedule of Other Accrued Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Amounts due to contract research organizations and other contractual agreements</a></td>
<td class="nump">$ 284,000<span></span>
</td>
<td class="nump">$ 475,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related benefits</a></td>
<td class="nump">1,054,272<span></span>
</td>
<td class="nump">1,604,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">204,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">19,411<span></span>
</td>
<td class="nump">19,411<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,507,683<span></span>
</td>
<td class="nump">$ 2,303,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399129461000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes and Loans Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Apr. 23, 2020</div></th>
<th class="th"><div>Jun. 27, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,324,750<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,182,599<span></span>
</td>
<td class="nump">4,464,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="nump">2,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLSN_HorizonCreditAgreementMember', window );">Horizon Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,299<span></span>
</td>
<td class="nump">$ 255,182<span></span>
</td>
<td class="nump">486,597<span></span>
</td>
<td class="nump">508,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,727<span></span>
</td>
<td class="nump">$ 94,266<span></span>
</td>
<td class="nump">$ 192,793<span></span>
</td>
<td class="nump">$ 191,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_HorizonCreditAgreementMember', window );">Horizon Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_AprilPaycheckProtectionProgramLoanMember', window );">April PPP Loan [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 632,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan repayment date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 13,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_PaycheckProtectionProgramLoansMember', window );">PPP Loans [Member] | Silicon Valley Bank [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_MayPaycheckProtectionProgramLoanMember', window );">May PPP Loan [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan repayment date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 24,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Interest accrued on loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_MayPaycheckProtectionProgramLoanMember', window );">May PPP Loan [Member] | Silicon Valley Bank [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CLSN_HorizonCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CLSN_HorizonCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_HorizonCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_HorizonCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_AprilPaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_AprilPaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CLSN_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CLSN_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_PaycheckProtectionProgramLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_PaycheckProtectionProgramLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_MayPaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_MayPaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399133974872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes and Loans Payable - Schedule of Future Principle Payments, Net of Unamortized Debt Discounts (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 4,583,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">416,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter', window );">2024 and thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Subtotal of future principal payments</a></td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs, net</a></td>
<td class="num">(3,530)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 9,996,470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2023 and thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399055964488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2020</div></th>
<th class="th"><div>Feb. 27, 2020</div></th>
<th class="th"><div>Dec. 04, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Mar. 05, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 12, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ShelfRegistrationStatementAmount', window );">Shelf registration statement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,182,599<span></span>
</td>
<td class="nump">$ 4,464,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember', window );">2019 Aspire Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_AggregateOfferingPriceAdditions', window );">Aggregate offering price, additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_AggregateOfferingPriceTerm', window );">Aggregate offering price, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember', window );">2018 Aspire Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_CapitalOnDemandTMSalesAgreementMember', window );">Capital on DemandTM Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_AggregateOfferingPrices', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_CapitalOnDemandAgreementMember', window );">Capital on Demand Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_AggregateValueAvailableForIssuance', window );">Aggregate value available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,571,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Original Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,971,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_PrivateExchangeAgreementsMember', window );">Private Exchange Agreements [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Underwritten Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="nump">2,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares purchased, price per share</a></td>
<td class="nump">3.4875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_UnderwritingDiscountPricePerShare', window );">Underwriting discount price per share</a></td>
<td class="nump">$ 0.2625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice', window );">Percentage of underwriting discount on public offering price</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_AggregateOfferingPriceAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional aggregate offering price for shares of common stock that the Company may offer and sell through a sales agent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_AggregateOfferingPriceAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_AggregateOfferingPriceTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price, term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_AggregateOfferingPriceTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_AggregateOfferingPrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_AggregateOfferingPrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_AggregateValueAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value available for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_AggregateValueAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of underwriting discount on public offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_PercentageOfUnderwritingDiscountOnPublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ShelfRegistrationStatementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ShelfRegistrationStatementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_UnderwritingDiscountPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting discount price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_UnderwritingDiscountPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_TwoThousandNineteenAspirePurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_TwoThousandEighteenAspirePurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_CapitalOnDemandTMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_CapitalOnDemandTMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_CapitalOnDemandAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_CapitalOnDemandAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CLSN_OriginalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CLSN_OriginalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_PrivateExchangeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_PrivateExchangeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CLSN_UnderwrittenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CLSN_UnderwrittenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399056142952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 19, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Gross proceeds from issuance of common stock upon exercise of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,895<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares of common stock issued upon exercise of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_NonVestedStockBasedCompensationArrangementsMember', window );">Non-Vested Stock-Based Compensation Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Inducement option grant, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation cost expected to be recognized, weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CLSN_EquityStockAwardsMember', window );">Equity Stock Awards [Member] | Granted Under 2018 Plan and 2007 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,594,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,594,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CLSN_InducementAwardsMember', window );">Inducement Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember', window );">Stock Options and Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 578,761<span></span>
</td>
<td class="nump">$ 622,696<span></span>
</td>
<td class="nump">$ 1,030,726<span></span>
</td>
<td class="nump">$ 1,313,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember', window );">Stock Options and Restricted Stock Awards [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,186<span></span>
</td>
<td class="nump">239,406<span></span>
</td>
<td class="nump">378,122<span></span>
</td>
<td class="nump">479,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember', window );">Stock Options and Restricted Stock Awards [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,575<span></span>
</td>
<td class="nump">$ 383,290<span></span>
</td>
<td class="nump">$ 652,604<span></span>
</td>
<td class="nump">$ 834,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares of common stock issued upon exercise of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Equity awards, number of stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,510,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,510,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of equity awards available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of equity awards available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_TwoThousandSevenStockIncentivePlanMember', window );">2007 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of stock options granted, during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_StockOptionsStrikePriceDescription', window );">Stock options, strike price description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Options are generally granted with strike prices equal to the fair market value of a share of Celsion common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of Celsion must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_InducementOptionGrantsMember', window );">Inducement Option Grants [Member] | Two New Employees [Member] | Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_InducementOptionGrantsMember', window );">Inducement Option Grants [Member] | Two New Employees [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="nump">140,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_InducementOptionGrantsMember', window );">Inducement Option Grants [Member] | Five New Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Inducement option grant, exercise price per share</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vested period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_TwoThousandAndEighteenPlanMember', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_TwoThousandAndEighteenPlanMember', window );">2018 Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Gross proceeds from issuance of common stock upon exercise of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares of common stock issued upon exercise of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_TwoThousandNineteenBonusProgramMember', window );">2019 Bonus Program [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_AnnualBonusAwardsPercentage', window );">Annual bonus awards, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_AnnualBonusAwardsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual bonus awards, percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_AnnualBonusAwardsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_StockOptionsStrikePriceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options, strike price description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_StockOptionsStrikePriceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_NonVestedStockBasedCompensationArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_NonVestedStockBasedCompensationArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CLSN_EquityStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CLSN_EquityStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=CLSN_GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CLSN_InducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CLSN_InducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CLSN_EmployeeStockOptionAndRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLSN_TwoThousandAndEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLSN_TwoThousandAndEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLSN_TwoThousandSevenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLSN_TwoThousandSevenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLSN_InducementOptionGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLSN_InducementOptionGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CLSN_TwoNewEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CLSN_TwoNewEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CLSN_FiveNewEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CLSN_FiveNewEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLSN_TwoThousandAndEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLSN_TwoThousandAndEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLSN_TwoThousandNineteenBonusProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLSN_TwoThousandNineteenBonusProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399128633576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option and Restricted Stock Awards (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number Outstanding, Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, Outstanding, Beginning Balance</a></td>
<td class="nump">4,332,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number Outstanding, Granted</a></td>
<td class="nump">644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number Outstanding, Options exercised</a></td>
<td class="num">(140,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number Outstanding, Vested and issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number Outstanding, Forfeited, cancelled or expired</a></td>
<td class="num">(110,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number Outstanding, Ending Balance</a></td>
<td class="nump">4,725,276<span></span>
</td>
<td class="nump">4,332,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Outstanding, Exercisable</a></td>
<td class="nump">3,194,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning Balance</a></td>
<td class="nump">$ 2.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">3.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercised</a></td>
<td class="nump">2.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Vested and issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited, cancelled or expired</a></td>
<td class="nump">2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending Balance</a></td>
<td class="nump">2.76<span></span>
</td>
<td class="nump">$ 2.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">$ 5,494,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 3,733,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (years), Outstanding, Ending Balance</a></td>
<td class="text">8 years 3 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Exercisable</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number Outstanding, Non-vested stock awards outstanding, Beginning Balance</a></td>
<td class="nump">8,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number Outstanding, Non-vested stock awards outstanding, Granted</a></td>
<td class="nump">429,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod', window );">Number Outstanding, Non-vested stock awards outstanding, Options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number Outstanding, Non-vested stock awards outstanding, Vested and issued</a></td>
<td class="num">(429,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number Outstanding, Non-vested stock awards outstanding, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number Outstanding, Non-vested stock awards outstanding, Ending Balance</a></td>
<td class="nump">8,750<span></span>
</td>
<td class="nump">8,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Non-vested stock awards, Beginning Balance</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Non-vested stock awards, Granted</a></td>
<td class="nump">1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Non-vested stock awards, Options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Non-vested stock awards, Vested and issued</a></td>
<td class="nump">1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Non-vested stock awards, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Non-vested stock awards, Ending Balance</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Outstanding, Non-vested stock awards, Ending Balance</a></td>
<td class="nump">$ 7,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Outstanding, Non-vested stock awards outstanding, Options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Grant Date Fair Value, Non-vested stock awards, Options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciseInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399128491256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">2.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.33%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">100.40%<span></span>
</td>
<td class="nump">101.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">104.20%<span></span>
</td>
<td class="nump">106.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">9 years 3 months 19 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399127415336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earn-out Milestone Liability (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_PaymentsForEarnoutMilestoneLiability', window );">Payments for earnout milestone liability</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_PaymentsForEarnoutMilestoneLiabilityInCash', window );">Payments for earnout milestone liability in cash</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability', window );">Gain (loss) from change in fair value of earn out milestone liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (297,570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_FairValueEarnoutMilestoneLiabilityMember', window );">Fair Value Earnout Milestone Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_EarnoutMilestoneLiability1', window );">Earnout milestone liability</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_GainOnNoncashBenefit', window );">Gain on non-cash benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_FairValueEarnoutMilestoneLiabilityMember', window );">Fair Value Earnout Milestone Liability [Member] | Payment Option One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_RiskAdjustedAssessmentOfEachMilestone', window );">Risk adjusted assessment of each milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_FairValueEarnoutMilestoneLiabilityMember', window );">Fair Value Earnout Milestone Liability [Member] | Payment Option Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_RiskAdjustedAssessmentOfEachMilestone', window );">Risk adjusted assessment of each milestone</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember', window );">Amended Asset Purchase Agreement Option Payment 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability', window );">Gain (loss) from change in fair value of earn out milestone liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember', window );">Amended Asset Purchase Agreement Option Payment 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability', window );">Gain (loss) from change in fair value of earn out milestone liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CLSN_EGWUIncMember', window );">EGWU, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_PaymentsForEarnoutMilestoneLiability', window );">Payments for earnout milestone liability</a></td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_EarnoutMilestoneLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnout milestone liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_EarnoutMilestoneLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) from the change in the fair value of earn-out milestone liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_GainOnNoncashBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on non-cash benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_GainOnNoncashBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_PaymentsForEarnoutMilestoneLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for earnout milestone liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_PaymentsForEarnoutMilestoneLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_PaymentsForEarnoutMilestoneLiabilityInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for earnout milestone liability in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_PaymentsForEarnoutMilestoneLiabilityInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_RiskAdjustedAssessmentOfEachMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of risk-adjusted assessment of each milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_RiskAdjustedAssessmentOfEachMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_FairValueEarnoutMilestoneLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_FairValueEarnoutMilestoneLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=CLSN_PaymentOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=CLSN_PaymentOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=CLSN_PaymentOptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=CLSN_PaymentOptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_AmendedAssetPurchaseAgreementOptionPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLSN_AmendedAssetPurchaseAgreementOptionPaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CLSN_EGWUIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CLSN_EGWUIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399131048120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earn-out Milestone Liability - Schedule of Changes in Earn-out Milestone Liability (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_EarnoutMilestoneLiabilityAbstract', window );"><strong>Hercules Warrant [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_EarnoutMilestoneLiability', window );">Earn-out liabilities, beginning balance</a></td>
<td class="num">$ (5,717,709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability', window );">Non-cash loss from the change in fair value</a></td>
<td class="num">(297,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_EarnoutMilestoneLiability', window );">Earn-out liabilities, ending balance</a></td>
<td class="num">$ (6,015,279)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_EarnoutMilestoneLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earn-out liabilities, beginning balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_EarnoutMilestoneLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_EarnoutMilestoneLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_EarnoutMilestoneLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) from the change in the fair value of earn-out milestone liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_GainLossFromChangeInFairValueOfEarnOutMilestoneLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399056788328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earn-out Milestone Liability - Schedule of Risk Adjustment Assessment (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone', window );">Risk-adjustment Assessment of achieving each Milestone</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_DiscountRateOnMileStoneLiabilities', window );">Discount Rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_EstimatedTimeToAchieveMileStone', window );">Estimated Time to Achieve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_EstimatedTimeToAchieveMileStone', window );">Estimated Time to Achieve</a></td>
<td class="text">1 year 15 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">6 months 14 days<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">1 year 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_EstimatedTimeToAchieveMileStone', window );">Estimated Time to Achieve</a></td>
<td class="text">2 years 15 days<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year 6 months 14 days<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">2 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_DiscountRateOnMileStoneLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate on milestone liabilites.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_DiscountRateOnMileStoneLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_EstimatedTimeToAchieveMileStone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated time to achieve milestone liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_EstimatedTimeToAchieveMileStone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-adjustment assessment of achieving each milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_RiskadjustmentAssessmentOfAchievingEachMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399134330552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Summary of Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Issued, Warrants Outstanding, Beginning Balance | shares</a></td>
<td class="nump">626,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants Issued, Warrants Issued | shares</a></td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Issued, Warrants Outstanding, Ending Balance | shares</a></td>
<td class="nump">3,826,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 1.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants Issued | $ / shares</a></td>
<td class="nump">1.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Warrants Outstanding, Ending Balance | $ / shares</a></td>
<td class="nump">$ 1.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value of Outstanding Warrants | $</a></td>
<td class="nump">$ 9,096,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399127621928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Schedule of Weighted Average Remaining Contractual Terms (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants Issued</a></td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLSN_AllOtherWarrantsMember', window );">All Other Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants Issued</a></td>
<td class="nump">3,626,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Contractual Terms Remaining (in years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CLSN_EGWUIncMember', window );">EGWU, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants Issued</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Contractual Terms Remaining (in years)</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageIssuedDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLSN_AllOtherWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLSN_AllOtherWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CLSN_EGWUIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CLSN_EGWUIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399129830248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 02, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 1,244,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,244,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,431,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">1,343,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,343,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Increased ROU asset</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,595<span></span>
</td>
<td class="nump">$ 130,595<span></span>
</td>
<td class="nump">261,190<span></span>
</td>
<td class="nump">$ 261,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,452<span></span>
</td>
<td class="nump">$ 118,415<span></span>
</td>
<td class="nump">262,084<span></span>
</td>
<td class="nump">$ 224,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=CLSN_LawrencevilleNewJerseyMember', window );">Lawrenceville, New Jersey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=CLSN_HuntsvilleAlabamaMember', window );">Huntsville Alabama [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=CLSN_LawrencevilleNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=CLSN_LawrencevilleNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=CLSN_HuntsvilleAlabamaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=CLSN_HuntsvilleAlabamaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399134325496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 263,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">530,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">535,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">233,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter', window );">2024 and thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Subtotal future lease payments</a></td>
<td class="nump">1,563,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(219,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 1,343,224<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining life</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year four and there after.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399133865432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Technology Development and Licensing Agreements (Details Narrative) - Hisun [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 18, 2013</div></th>
<th class="th"><div>Aug. 08, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Non-refundable research and development fee</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_DeferredRevenueAmortizationPeriod', window );">Deferred revenue amortization period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CLSN_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_DeferredRevenueAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amortization period for deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_DeferredRevenueAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLSN_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLSN_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLSN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=CLSN_HisunMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=CLSN_HisunMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140399132153736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Apr. 24, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Payment of legal fees</a></td>
<td class="nump">$ 187,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MK80R"&#U,@1JNV1R#"HK2)[F9YA\NZS(DSQ/PYB2 Z8DBNE369H><E:U5AI
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M'!AR1(SD0JE<P*DKW=8[%X0IU[OS"5NIAQ29HW8"'O&]2C*6\H*<;>LUEJ<
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MEC"QF3B^\[+P0%>I-@MN-,[QBLR)_I[/),S<FB6A&>&*"HXD64Z<&_]ZZEN
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M 'Y?2]@J=#=F@OT'2M?_ U!+ P04    " "!10Y1K.@:O% *   "1@  &
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M1<TFU<D(1&K .AD@:601M&<^=!3S&45]J5YI!^L*%. [AKH"  D& @ )U14
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M!G2>.WK3VP4'./[<6OX+4$L#!!0    ( (%%#E'&BW"XW04  %P-   8
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MUQ@;M-Y/X%/'C'IA*$GJ0+MV*H_DO\\FV11^%!XJ2[2*1NL]Y8G/G=K0.<H
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M+Y<)N/8ET4Z"K>/MO;&!W@)Q6-+C"QT+T'YA*<^["1\P/.?67P!02P,$%
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M=)3L728]7"T?O/6NN)2L-A3*B8PDT(<!QPZ*PFC/ ^N+)"=I*G<,Q7I-9AL
M^RH$QH+-Y^"2M=(H@+"4:W@(R$*A3:/4^'BE2&5\S;FCM5I0'A,[;,N"D]TB
MB.4\RA2+7LD*/'$U!"%K"V)IS%;EJUT!L.-UX@#A.YEC\ODR-#"%B2-BK"!9
M(%,9)TPKELCD*E>N7)#GWJ($R7BDU?IJT$+>O<%\NY&".Q;%X8MX;Q^" <,
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M+'#1)LL"V%\9H&I?V,'VZG[])U!+ P04    " "!10Y1F4;)0%D*  #O&@
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RE66EOVS@:_JY?0;A!D0"J
MXR/W!>1H.QE,,T'2V6*QV ^T1%M$)5$EJ3C97[_/2XJ2G#C9=A8%4HDBW_-Y
M+_IDJ?1WDPEAV6.1E^9TD%E;'6UOFR03!3=#58D27^9*%]SB52^V3:4%3]VA
M(M^>C$9[VP67Y>#LQ*W=ZK,35=M<EN)6,U,7!==/%R)7R]/!>! 6[N0BL[2P
M?792\86X%_:OZE;C;;NEDLI"E$:JDFDQ/QV<CX\N=FB_V_ /*9:F]\Q(DYE2
MW^GE.CT=C$@@D8O$$@6._Q[$I<AS(@0Q?C0T!RU+.MA_#M0_.=VARXP;<:GR
M;S*UV>G@8,!2,>=U;N_4\C?1Z+-+]!*5&_>7+?W>W=T!2VIC5=$<A@2%+/W_
M_+&Q0^_ P>B5 Y/FP,3)[1DY*:^XY6<G6BV9IMV@1@].57<:PLF2G')O-;Y*
MG+-GUZ7EY4+.<L'.C1'6G&Q;D*6/VTE#XL*3F+Q"8H]]4:7-#/M8IB)=/;\-
M<5J9)D&FB\F;!'^ORR&;CF(V&4U&;]";MCI.';WIS^H8LQO ??.Z3/(ZE>6"
M?58J7<H\WV+_.I\9JX&5?[_!>*=EO.,8[_P_QGV3!,7DD:EX(DX'"#HC](,8
MG-TH*]C!D+V@CQ4&ZPE8;KP3LZ5@B2JJ7%B1,IL)Q,"/6AI)\1"I.2(1RO+2
M2I[G3PQ_&!;=/D\-;Q\_?[R)0389QHR7[#SG,UYPD-65TIP(@4TFDXQEW+ D
M@SS@)7&8.//RB96\$,PJ4/KVEZ?$^-P*'1&C)%>&'!#X=O*QS??O#B:3T3%)
MX!['QUM#]JW9I,&E$3AL&.\?&Z8I"F-FI851> E12O 2QN+!O4.2%;6C-]26
M+4 2;C)WW#T("/# <U$2E"IN_0-@DR)C(INZG0H4M6.?4PJJ><XJC62J[9.7
M$D<2N%LF/(]2Q"Y>\1%Y%*8K'0:Q(Y<),J#P)'&XD+1* E1(C=!T7NM2VEJ+
M&'+/L?O%1Y-! QPR=57E4O2E"_")0-FHLB<B@8OQ-)7>Q9=_W-^P/_B,?*ZT
M(V*0Q^&$(+.I1"+G$BNYY#.9XZ!8:THR='\+UY(@$*%BK," /-P:HB=SXR0M
M<L"/Z"FRBU2I\;AB?5S!KF+(S@.]Z_(#%$R$,>P.P<1UXKUZ)1Y0GIS1NLVR
MVZS[F]-N<[1Y?7OWGA?5\=46"6NDZ?#38C+5-<0425:J7"V>6 7)J9R:(_85
M&O';G'L%W=N]!+ 22(TW-N=2,T"M%L$V+4-'-EI'EBU!#Y"7*%K"(7XFV,9D
M9SA!!<ES5PS-NI!KK-5^>STZXU59(N+H]$^%-QT*(Z!MR=4/;J'-5(W_2%]*
MN:Q4EN3CA=)6_D>DPYZ*DDS_@$H,$E"-2:04J9V;N&6YX(AK7I:U#V0GMZH)
M 5*G[$?-->%!4%EB]Z*RHICAG2J+XYZ)$J[$A@<*8 ;Z/G\9RA6)U$E=4)Y(
MW$**.(4Z-@-C9QNN]1,9)W@GZF60@N([:*9%HL"&0WGOU$N?&5M\=/HV$(*X
MSN1:4 +7".E<%#[)4&:]NSD'",FP^HF9)^POW(=H =_. "8T#9P5Z$LDX8%D
MA1*:;7Z^^+)%$9[6B:7%5)+'?9HD SP@%I'DF^V-SO#V>K%?W1Y'2VDSV%,N
M).64%K\;X^EP&C 8NXKA;23*QK70'(A#$B-Y>G@#*NTS%Z+$'7H8-H+!CV!$
MD(_H=&?5!KZORNL3NW(9RA5*N%A: A])5Y #<OE=H$3B4^D66Q@XA]/6(#_%
M3U2J-OT[)DH[;/;@*QZ]G]-:AZ0X!W1AM@!;[/<J I=SJ8'TC.=SOSR!_N#1
MHP?D:D+N$O$7$>)TNDK=R$>HXOHT'Q"N3PA=EC,!L5OO:@"GPPL*?M^]4>?>
MP^%.FV$R#IO6 "&GMKLGJB%@JWJ1$;\#=VZ_PX0CK06-$[[N/HLRY+$>$SCA
M2B0.$]%T[#'A5/GBLK5?(F/]6?X\>MA:]+P5/"UVHK^'G3DY7N@5#+&_@Z%H
M/8::1LBC[)>@Q'X)2M%/0&EM\B*O1S /E0RYFC&&NW'K;JHR%14$51M8=%Y3
MV]H9[1)IMN2$L!LRLW*\T?NRVUJ;&A]HC12@ZDR+T-2@=5X@S_I^B3Y$\/&#
M3'NM3=+2#3UIX.08?6T9A38U\ G00J718O;D^7)BE\9]@_K^A8SI&B'O*./*
M$K4<)1G+8&1^7I<= -?4<=5. 7$S"93>((*:82K&BI%<LQIDT-] &%@PL;"F
MTA'AS;^%UC[QZAD?G<0MG S<@Z8EDI6KZH@!:M[0NZ'Q5.ABL8!OO()UN6ND
M6FT$)A3U)$0@%@5B5/&K&H.&\=_0WPIG,W^"7!8PUG-'S^]>>D*- U1*^<))
M\.A:(Z@+?.WULPFQ[UO5>ZQG6JI9G#7=#26V7,Z;"FJZ'H8\P!D-DM0(?*"A
MCNX.)!5-<@"@Y,Z!RSY[0FMI5H+%)?!%Z2@U-'VA$H\530,N,G;WXH/)(86U
M((,V KNFX8.+SK8M_NE\SSJ^T:M\Q^-IO+=[\)PQDL(OLWV9W>WKWG0]YL9D
MLA]/QP= M+!>G'BZ-XT/#O?@IJ;>/+>:;PQ?"K(QW1G%A_M[?6*3W5$\F1Z\
M2BQNVLQ0=E@H.T/V2>6Y6I(Z! 5&]V=IG3NUYC5-:"N$R, UY91>'NCJ7D#'
M&_881O\$</RERTH&'K,-UIB)7B=^[*44Y.>C]^\.=_8GQ]%799%JV[WM)8AS
M316R8Z7=3/F8(&DUMPC=:$'C2;3B/+)DZ/##((7,]RSJ)L-1E]3;(&UK#9Z#
M,,-.+"W<#8CO( 12%J4#&I6BF;!+ZB%= #BMGHE/F>29=&$'E-"J: *];*Y)
M%LC1"TH#W?SELU,[Q)3]F29ZIC'&=LJ-*U.N'Y=[ZOS*;,/>G&VB?FM#6=8H
M55*:F=,-T S%5E ']F8;$<:^E2AI;I!6&F/[LJ9'O2FU!8J[ EJ-;X?!.;5$
M31E]NU%JJFG'MC4=@66E5TJ%2;2<N4&3N=NQ:>RK(.@A7S7:](L+3(OX2WK]
M?N8A*-S RAT:"Q@H]4G$H82DN/IR25$8IEUD>555(8(7N9H!?K<.>]?7U^S/
MVZ_77\[9O:U3*G@1C?B%NE*/[]^-]W>.W:2IBAD::<?%%=B[3^<M8BVBUCHW
MP3F9J.# 1.0Y,I,F\R:RI%EO\[?+RRTW*0#O=+GNQF[=C#J4;&%GUT]$SH S
M@D.XPQ-M;_B\5R-8&Q.XKYUZV2(X934DVB30M@BI'Y\%^@O_6T+HZ/@#ESE-
MQZ'=D*8I97VD-\WJRS3K?TWHYY\.CM'JQ1[OKG9ZU=UUX?T:W]K^12U=5]..
MHFY6:!'Z2H,8?6I(M]5R;9F,+GA.GJ-$\#M'"H!^[2A#&FZP\6Z\/]V+=PXI
MVX]=%1N/Z+FI:=%YOP)^P+_-4+BW5LBOQOO_(!Y*Q;J[\>W>CQ"%P 1!/[70
MK1"JG/\]HEUM?\TY]S]B=-O]3T&8WC!:(H&*.8Z.AON[ W]E&EX0<NXGC9FR
M5A7N,1,<T4@;\'VND .:%V+0_L9U]E]02P,$%     @ @44.4<_-,@[% @
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MTX6_W$@4*L,+\'ZE865SPQMTWRK/_@U02P,$%     @ @44.41.!;<8Q#
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M_&N-<&<E\61E!(T[DV82)LUZIG2J!C4$AB/1#4>;!D0[#)CV?&"K 6/IM,.
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M7AQ?E)H*(^K1IRW)P1D!-':'&F[86 !?>(E'&["N0DIJ,(2^F;NM_<;"'7J
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M.DK<1ZFM(J^:H?)NS=9 63^!NBQ+<6:HH"0OE=\O"CO"I$[,MIW- !(9=UA
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MC29GIP'H;JQW"ZMJ/TK7RM)@]I];N@E1.P/ZOU&4VW[A' QWZ_)_4$L#!!0
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MORLA<],2YO7]K?AJ6IV)LV4JS*,D!Y&<1YW3S490#+7)=:&A8Y6WQK6*!X(
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M<H;O_9;O_?-\WS/,N6J<*^:=%$J1#QP[2LF^0$[>82=1Y/6ON'SBFCD?<5;
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M\:%MAP7^LP%I#/#WA1!Z-S$!VO]*D[\!4$L#!!0    ( (%%#E%PH0\8. ,
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M"*A9&M3/&'Q8LQZ_R\R5*BLF7W_\;IK$DY_,0).F4_:FB76:G >RK'BKYVQ
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MO[HWT_)2V(74CG,J&-KO^?EBFPG4&&2JT/4S0SQ#PG+)0QNM=^#SPAAZ,7R
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M**/>"8G2S=AK-E:5?G*LE*4YY)<Y?2E0.P<Z7RMEMQL7H/OV)'\ 4$L#!!0
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MPX+F'._%YBL4AKJ&+Q9<V2O9%+&>0^)<H4@+L%:0LFQ[IZ]%(O8 ?N< ("@
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M^\-AN%MPT @.]@K^%Y;!=O-LL]QVVL72;0U ^_A\8VIE1X[ )>&\XR')5-5
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MBB0+BH.W9%&5%!$K\@D+^19HSGY#1CX*I1#SF5M'9=9[\"UVRC/2BG_%4U$
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M8<+).#/*/F4VSTP^4J;@&^4IP@-2G2JT&AD-'V!F9TR<<@2Y@#+J FZT1AM
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MMDP5NGP4C,$\H_I$/ZYTQ%8=MX5B$'&%V#/,:9*=P42R4&=(<46SMJ<H;B;
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M9G3)A-X ZRL.KI<W^F1>O:^:_ U02P,$%     @ @44.4<28^G>V @  !0<
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M2B*A0F#Y[X',29JJ2)+'MSKHH)E3 0_?[Z._*1<O%[/$G,QI^B6)Q>9\$ Y
M3%:X2,4GNGM+Z@7Y*EY$4U[^!;MJ;" '1P47-*O!DD&6Y-5__%AOQ $ >AT
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M7<IW]Y8$MK#?SG0/PGT?:@"US0!Z.M70G[Y"1TJRI%?V:PBS3^S(JNBQ9AW
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MXLN2XD;Q5?Z=PI0KQ9/\<LDHS)&: )[/.5>[&_WI0_5]S_7_ 5!+ P04
M" "!10Y1J-[3YV4%  "Z&P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6RU65UOHS@4_2M6M ^MU 9L""15$JE)9W9GI,Y4[4[G8;4/+G$25,!9VVG:
M?[\V4$P;,+BS^Y+PX7M][K5]CB^>'BA[Y%M"!'A.DXS/!ELA=A>.PZ,M23$?
MTAW)Y)LU92D6\I9M'+YC!*]RHS1QD.L&3HKC;#"?YL]NV'Q*]R*),W+# -^G
M*68O"Y+0PVP !Z\/;N/-5J@'SGRZPQMR1\2/W0V3=T[E916G).,QS0 CZ]G@
M$EXLO4 9Y"WN8W+@M6N@0GF@]%'=?%G-!JY"1!(2">4"R[\GLB1)HCQ)'/^4
M3@=5G\JP?OWJ_7,>O SF 7.RI,G/>"6VL\%X %9DC?>)N*6'/T@9T$CYBVC"
M\U]P*-NZ Q#MN:!I:2P1I'%6_./G,A$U S1J,4"E 7IG (,6 Z\T\/) "V1Y
M6%=8X/F4T0-@JK7TIB[RW.36,IHX4\-X)YA\&TL[,;\3-'H\7\A$K,"2IG)V
M<)SG]QS<%2,+Z!KDK<#W79'Y; 5N"1<LCH2T*MY='C!;<7!R102.$WXJ[7_<
M78&3WTZGCI X56].5&):%)A0"Z8 7--,;#GXE*W(JL%^:;:'R.# D0FJLH1>
ML[1 1H]?]]D0>.X90"YRFP"9S:](),VA,H<3 QRO&C0O]^>W^/NV3Q\( ]_W
M@@LY&G&V.2L'AP/R3%@4\^:\&=TJQKC@.QR1V4!2 B?LB0SFP(#7K_#Z1KSU
MZ</!7]=$P?_;X'A4.1[9)Z)^LR";.,OD)5C@!&<1:9J-11^CO ]%>T]SW_,0
M]-'4>6H %U3@ FMPOS.<B<:Q601'* +?=UVW&418@0C_EZFR"(_@G$/?'0=^
M,YYQA6=LC>=>DHDD$L4K,>?[9CQ&M_93=U+AG5CCE?JQ)K&$? 8B-:>21**G
M3.9S%[-F]).&;$(YN"U3#+J:OEUK?)_R?].,+YV^F?(A&J$PJ/"41-O0T+0V
M8$UWH#WP8D+BAZ09-3P"X\&)'X9A"QBDP2 CF)^YVLM1O'PB3.Y>7I$0<"-5
MCGR$5,H>PQI8- R\%J2:^:&9^CN1&ABF=*W&5"=P.&H;2LWNT$SOW=GK0SAE
M)V_0R8RU\ W4$@'-&M&)KA?]F#NQYQ^H502:9:03_P?HJ.SR7:X1;,FU%AMH
M5AN[==2#I\(FG,<L%=JL-2U5T*Q5G=%T\=6X =8X:(&E%0F:)>ERLV%D@P4!
M7S*Y"9<5503N<;+_0'J+CH(:P)$_\2>H9=$A+4O(+$L&C!U)*QW7,7FAY_EM
MDQ-IQ4%FQ3FJ67IL1)&6$&0I(;=$5=%J!):R&&&R7MWC!/Q)6 I.7@AF_-1Z
MO#H@C$'N%W@@+<H?. $K_,)-\6GA09;"TR>^KK$V=QF6\4RJ>,:=\6C10F;1
M:MI_?*/9^5.A!CR?(;BH:JFU^I>=U[<JXW#4LI='6LN0?;W3"[1A5X :RA\T
M&8]&+6"U<"'[^J<7V%[;!7/G]H*,M,@A^Y*J5UR]-AJHH? RCH>6,V1?>O7"
M76TP&O'^QX49TCJ([$NS7O'T(-KC>NW-\BT_^G2T>OMM1VNG9];.(Z;-%R^X
M4FKZ&<?L54A;8NW)4"6(^N8$#D>3%O!:9#VSR/XR> -3E5V_V0W"(6S94'E:
MNCU+Z;;%W(NPS"#L%XI7^UIH*=VV\?4B+J^ANC2,CA9JS[*ZM$5OI"]SYQ\8
M%:WEGF5=:AM7-XV5"%K7>/E1N*/5V_BT_'MF^>];IOQ*?,%1K1!*!GZ'W*F=
MCJ2$;?)#(PXBNL]$<5!2/:T.IB[SXQA'-R].M:XQD]3*04+6TM0=AC)UK#@H
M*FX$W>5G+0]4")KFEUN"5X2I!O+]FE+Q>J,ZJ([KYO\"4$L#!!0    ( (%%
M#E%0YEY4& ,  +0*   9    >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;*U6
M:V_:,!3]*U:D2IW4)DYX5X!4:+N'A%85M?LP[8,A%[!P8F8[!?[];">DT 7#
MJGTA?MQS?,^QL6]WS<52+@ 4VB0LE3UOH=3J)@CD= $)D3Y?0:IG9EPD1.FN
MF =R)8#$%I2P(,*X&22$IEZ_:\<>1;_+,\5H"H\"R2Q)B-@.@/%USPN]W< 3
MG2^4&0CZW169PQC4\^I1Z%Y0LL0T@512GB(!LYYW&]X,0PNP$2\4UG*OC8R4
M">=+T_D:]SQL,@(&4V4HB/Z\PA 8,TPZC]\%J5>N:8#[[1W[@Q6OQ4R(A"%G
M/VBL%CVO[:$89B1CZHFOOT AJ&'XIIQ)^XO612SVT#23BB<%6&>0T#3_DDUA
MQ!X@;!T!1 4@>@>(&D< M0)0LT+SS*RL.Z)(OROX&@D3K=E,PWICT5H-3<TV
MCI70LU3C5'^L^'1Y/=!&Q&C($WTZ)+'^7J.Q/C)QQ@#Q&;J5>I]79D*B9Q.K
M.+H#!4*G!.B!4(%>",ML[/<B[K,@J=*AESJ04"8_=0.E,S;K!M,BNT&>770D
MNR8:\50M)+I/8X@/\8%66LJ-=G('D9/P6Y;ZJ(:O4(0C7)'/\&QXV'&D4RO=
MKUF^^A&^)RJ7US,!@*BV2H!42! %5V:G:9(E58ZY&;'?"B^JA+EAD5^/+AR"
MZJ6@^@<%D<TQ06[&T*_5*@6Y89'?;+@$-4I!#2?/_6:E+QQ]BE\YTW\,1M76
MN3MNMA!COXXKY9P":A_> P\$-4M!S0\(.KX[;K80U_VH6M I8/-OX(&@5BFH
M=9Z@F+[2&-(8;2FPN$J+FPC[N%K)/\,.=+1+'6TGSR@_5.CG")()B%\.RDY)
MV3G/&D9G@"YIBK9 1/5%[&9JYTC41(F]D*ML<C.TG P'\D+\]GAAMV?YN3W'
MLW#O10S_FVLGJ$*<8ZOL.@'M%'[5"K]0V$$QV5;Z%NR]_PF(N2V+))KR+%7Y
MVUB.EJ77K2TXWHT/3$EFZXHWFKR>&Q$QI_I19S#3E/J5T?>5R$NDO*/XRE89
M$ZYTS6*;"UU6@C !>G[&N=IUS )EH=K_ U!+ P04    " "!10Y1,@F0-TL$
M  #\$P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6RU6&UOXC@0_BL6
MNI-::=O$X26A B1:WEI==U%[W?UPN@\F&,@UL5G;E*UT/WYM)R10C,G2;3^4
MQ)EGYIGQ3&;BUIJR9[[ 6( ?24QXN[(08GGE.#Q<X 3Q2[K$1#Z9498@(6_9
MW.%+AM%4@Y+8\5RWX20H(I5.2Z^-6:=%5R*."!XSP%=)@MCK-8[INEV!E<W"
M0S1?"+7@=%I+-,>/6#PMQTS>.;F6:91@PB-* ,.S=J4+K^Y@H !:XFN$UWSK
M&BA7)I0^JYO;:;OB*D8XQJ%0*I#\><$W.(Z5)LGC>Z:TDMM4P.WKC?:!=EXZ
M,T$<W]#X6S05BW8EJ( IGJ%5+![H>H0SA^I*7TACKO^#=2KK2^%PQ05-,K!D
MD$0D_44_LD!L :0>,\#+ %Y90#4#5-\":@< M0Q0*PNH9X!Z64 C S3*^N!G
M +^LA2 #!&4!S0S0+ N [F;G7)U!Z9;K?.DA@3HM1M> *7FI3UWHI--XF281
M4?7Q*)A\&DF<Z/01(Q>R;L!]%&-ICV#P5X0F41R)5W#6PP)%,0>?$6-()?(Y
MN !/CSUP]L=YRQ'2OM+BA)FMZ]26=\ 6!/>4B 4'?3+%4P/^QHZO'L,/[?B&
M!>_(N.7!\S;!N_:L"N\1NP15^ EX+FR:_+'#[U9$PET%]UP#O%?:NA'>+VW=
M2'[P/M^'[_-]]#[RMW9X#X=6\G?EX8$ECZIY$5:UOMH!?6/T*EN.X$#V.X!E
M1:J"3/*"C#<%:2JY5'-#:U;-\*7CN_JOY;P8*-5R2K7?0@E$!(2(+TS44@OU
M+6K0JUFXU7-N=2NWH6S[X"RFG)^#&:,)"!>(S+&B,D,1 R\H7F% 9YHW*!_+
M87TOEA=>TZ_[!_@V<KX-*]^!(O55D^IGD32];?^YQ\D$LW\M">7G%GVKQ?ZO
MY9"_YW<]V-VG]'6V+]=P#7*]DOKZ^W*P"@V"@Y(*A_Y>QAD)CLH:OC48]@UR
M=_MR0=.2Z4&^C\'Q3)=3)*'D0E49F&""9Y$P]9I@CX)GBOF^F,GQX;Y8U13(
M0V('_&[F?C=_9\6 _T'VO@)?EGKL_B+E2M03=(LQR;4R>HCX,T#3_^1,AJ<
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MEK69L2BM@SDOA=!;PP88IG;V"U!+ P04    " "!10Y18A*2)TX#  " #@
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M&<H2$9B:()_O*!7GCEJ@*#K'_P!02P,$%     @ @44.40?[R[+U @  R @
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M[?MX04&V0GVM]'1XXYOC@A\E3DG=^'7:"1AC]\?945'0W1=*,LZPG?S1#:,
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" "!10Y1R?6A;><$  #K)P  #P   'AL+W=O<FMB;V]K+GAM;,6:WU/;.!"
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MYA7J][0H;(UF,2N,HS7XN6AR3>A!DG9AULL5]CNS^ !>@\-P5A7&<KZ6#F)
MRBQC9K5<FGOPH=6T,CA,%D',H:@=WG;PXC3&I-PR9I;+A51.W$I=@_@&TM?N
M]6VFK#)FULHE#F"S:GY4G'H/?3#*)&-FE7P/:WSP<)BX&I/S3,FV6%7]44Q9
M9,RLD2LLLGV;7F96&APG\E&V!,]XE#_&S *9!UO<K:TNP?D_Q/FO&HO8F(TR
MR)A9(2W;,8JD=7"%/?E7A36ED3&S1\ZE,\>V#N*;TIACK(&G!S".84)))&&6
MR _IG.PGDH3R1<+LBQDFM][@3,AI![,<;J!8&ZOMZA'-< _:;I[F<S/L(<:D
MY)"PSSRJ2K4.ZS()EBU-20!8Q/1C22DB85;$O%YX^%4W\3N_?^&NA%)$PJP(
ML@+H38D22A0)LRCV5 #BZ*;Q12^:E# 29F&\J@1V@.]B0DH;";,V]I8$'6F,
M2=DC8;;'GL+@C?N=4@))F06R3\);SAB3\DK*[!7*Q8@:8U+"29F%L]/Q6X,F
M)=>VF!73>?E-+$HJ*;-4R*EZ?V&04DS*K)B]LV!Q= 9!QIB48E)FQ= FC-?=
M4DHQ*;MB*,QXY2VE/),R>X;&S&-,RC,ILV=HS$F\;$UY)F/VS+[RYUC,L?<R
MQJ0\DS%[YHWRIQGA2GMQA;D]QJ0\D[&O>KW$W,:QQA:[C#$IZV3,UB$Q>^D]
M(_=4F"VTOZ)L<6-,RD(9MX7V593=$QIC4A;*#K,B]M9(IRR4'6!E+!KL,29E
MH>Q BV1;U!B3LE#&;*&]F'C7ZZJ*]R4I"^6'FNUT#V>,25DH/^ALYRS&I"R4
M,UN(Q#R.WSW(*0OES!8B,?M[YI2%<F8+/<T=NR$CW6.SO;IM[>UDY>3>/K.%
M8LSGBD/\ +5:AUYZSRD+Y<P6VDUXX^I--B\:Q7/?G!)0SBR@+6$_C&UCH\Q>
MRJ0$E#,+B%Q#[X\>2D YLX#(-71Q%+]S0@EHT@IHN'NYK(2E,E!>X4]X;"^D
M+JZ=:/YT&]]9WNQ0+6NMOV+;=X,53[E[5VWWGMWG_P!02P,$%     @ @44.
M49@;6I[[ 0  RR,  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:
M2VZC0!2%X:U8+"#E^R))*\ZH)YE&V0!RR@_%-HBBE63W;3D#YZ >]"2J,T(%
MXO*//A#P\)P/W;3O3V6W'\KBXW@XE56SFZ;A5TIEO<O'KMST0SZ=CVSZ\=A-
MY^6X34.W?NNV.>ERV:;Q^XSF\>'[S,7+YY#_9V*_V>S7^7>__G/,I^D?@]-[
M/[Z57<Y3LWCIQFV>5DWZ.%QWEW39R,UY<K-X>ETUX].K-*EVD$*0U@\R"++Z
M00Y!7C\H("CJ![40U-8/NH6@V_I!=Q!T5S_H'H+NZP?)$F5<$B3-L";06I!K
M(?!:$&PA$%N0;"$P6Q!M(5!;D&TA<%L0;B&06Y!N(;!;$&\AT%M1;R706U%O
M)=!;9P_;!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ
M;01Z&^IM!'H;ZFT$>MOL90F!WH9Z&X'>AGH;@=Z&>AN!WH9Z&X'>AGH;@=Z&
M>AN!WHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>/GO93:"WH]Y.H+>CWDZ@MZ/>3J"W
MH]Y.H+>CWDZ@=Z#>0:!WH-Y!H'>@WD&@=Z#>0:!WH-Y!H'?,/E82Z!VH=Q#H
M':AW$.@=J'<0Z!VH=Q#HW:+>[4_J7:;/0R[7GJ\U7O\GJ9[.Y^;KY2_+KYUX
MOV@O."?X=^?Q+U!+ P04    " "!10Y1=-+&8MX!  !:(P  $P   %M#;VYT
M96YT7U1Y<&5S72YX;6S-VEU/PC 4!N"_0G9K6.D7?@2X46_5"_] W0ZPL*U-
M6Q#^O=T $XT2#2:^-UNVMN<]:Y/G:I/GG:,PV#9U&Z;9,D9WPU@HEM28D%M'
M;1J96]^8F![]@CE3K,R"F!B-QJRP;:0V#F-7(YM-[FANUG4<W&_3ZU#9=IIY
MJD,VN-U/[+*FF7&NK@H3TSC;M.6GE.$A(4\K^SEA6;EPD29D[,N$;N3[@,.Z
MQPUY7Y4T>#(^/I@FS6+;FH6XJRGDITM\T:.=SZN"2ENLF[0D#\Z3*<.2*#9U
MOB]Z<3HYIAVF_96?G=^7.1689CYYZT(Z,4^_CSL>2;=ZZ%(A\K$Z_8GOB:GT
MV=]'W6F75/XP.VWOJ_6K_CP"ZV_G[_'',WZO_\L^!$@?$J0/!=*'!NEC#-+'
M)4@?5R!]7(/TP4<HC:"(RE%(Y2BF<A14.8JJ'(55CN(J1X&5H\@J4&05*+(*
M%%D%BJP"15:!(JM D56@R"I09!4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR
M2A19)8JL"D56A2*K0I%5H<BJ4&15*+(J%%D5BJP*15:%(JM&D56CR*I19-4H
MLFH4636*K!I%5HTBJT:15:/(.OY/65^L7?WUWQ[=/6],U1[S6?]+S>P-4$L!
M A0#%     @ @44.40=!36*!    L0   !               ( !     &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "!10Y1?N>&XN\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "!
M10Y1F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( (%%#E&U8$<GG@,  /\,   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "!
M10Y1#@EA_O '   K(   &               @('B"P  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ @44.45YU+I@# P  A@H  !@
M         ("!"!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( (%%#E$L4B&ZJ 4  %,5   8              " @4$7  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "!10Y1*T2>>'T#  #G"@
M&               @($?'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ @44.4190_4>Q"   K"0  !@              ("!TB   'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (%%#E&LZ!J\4 H
M  )&   8              " @;DI  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " "!10Y1B&9%B#0$  !Z"0  &               @($_
M-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ @44.4<:+
M<+C=!0  7 T  !@              ("!J3@  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( (%%#E%0HT5AT0T  "LD   9
M  " @;P^  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M@44.4:<[O]^B!0  \ P  !D              ("!Q$P  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " "!10Y1"$"O/"@$  #:"0  &0
M            @(&=4@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( (%%#E'2ZE#P(@8  %@0   9              " @?Q6  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ @44.48V)1GM?!@
MQ@\  !D              ("!55T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " "!10Y1F4;)0%D*  #O&@  &0              @('K
M8P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( (%%#E'/
MS3(.Q0(  /L%   9              " @7MN  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ @44.45^:;5 Z"   MQ0  !D
M     ("!=W$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (%%#E'UJ6L+3 <  '81   9              "
M@9F<  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ @44.
M4<('8NB5!P  !1,  !D              ("!'*0  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " "!10Y1?N%JT'@&   !$   &0
M        @('HJP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( (%%#E&+O?WA4@(  /\$   9              " @9>R  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ @44.49SRRNR[!   -PT
M !D              ("!(+4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " "!10Y1<*$/&#@#  "@!P  &0              @($2N@
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (%%#E&+4L_>
M2P,  )X'   9              " @8&]  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ @44.4;F5+8W  @  V 4  !D
M ("! \$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "!
M10Y1#4B+I,L"  #E!0  &0              @('ZPP  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( (%%#E%_!+=$BP0  &0*   9
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M970S-2YX;6Q02P$"% ,4    " "!10Y1<'G^SZH"  "'!@  &0
M    @('AV0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M (%%#E'1M XQ6P(  (D&   9              " @<+<  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ @44.4>?/C.CE @  S0D  !D
M             ("!5-\  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " "!10Y1UD(_G+ "  !A!P  &0              @(%PX@  >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (%%#E'9>T+Q'@,
M  <)   9              " @5?E  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ @44.4?:&<.G0 P  EA(  !D              ("!
MK.@  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "!10Y1
M3^*B%GT$  !N$P  &0              @(&S[   >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( (%%#E$"MC7Z<P(  "\&   9
M      " @6?Q  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ @44.4=H1(^X) P  Q0H  !D              ("!$?0  'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "!10Y1-N_WZ\,"  !2!P
M&0              @(%1]P  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( (%%#E$M^0$WH00  +L2   9              " @4OZ  !X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ @44.4<28^G>V
M @  !0<  !D              ("!(_\  'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " "!10Y1J%PD&>@%  "!'   &0
M@($0 @$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( (%%
M#E&6-)H5VP<  .LC   9              " @2\( 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ @44.4:C>T^=E!0  NAL  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( (%%#E$'^\NR]0(  ,@(   9
M  " @> C 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M@44.4>ON>OW* @  B @  !D              ("!#"<! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " "!10Y1R9S62=8#   <#P  &0
M            @($-*@$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( (%%#E'_<HN;,P,  $T)   9              " @1HN 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ @44.44J2_Z98 @
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M96QS+RYR96QS4$L! A0#%     @ @44.4<GUH6WG!   ZR<   \
M     ( !D#D! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( (%%#E&8&UJ>
M^P$  ,LC   :              "  :0^ 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( (%%#E%TTL9BW@$  %HC   3
M  "  ==  0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !$ $0 DQ(  .9"
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>220</ContextCount>
  <ElementCount>368</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Business Description</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/BusinessDescription</Role>
      <ShortName>Business Description</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Financial Condition and Business Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/FinancialConditionAndBusinessPlan</Role>
      <ShortName>Financial Condition and Business Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/NewAccountingPronouncements</Role>
      <ShortName>New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Investment in Debt Securities Available for Sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale</Role>
      <ShortName>Investment in Debt Securities Available for Sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Other Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/OtherAccruedLiabilities</Role>
      <ShortName>Other Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Notes and Loans Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://celsion.com/role/NotesAndLoansPayable</Role>
      <ShortName>Notes and Loans Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Earn-out Milestone Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Earn-outMilestoneLiability</Role>
      <ShortName>Earn-out Milestone Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Technology Development and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreements</Role>
      <ShortName>Technology Development and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Investment in Debt Securities Available for Sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleTables</Role>
      <ShortName>Investment in Debt Securities Available for Sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celsion.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celsion.com/role/IntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Other Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/OtherAccruedLiabilitiesTables</Role>
      <ShortName>Other Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celsion.com/role/OtherAccruedLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Notes and Loans Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://celsion.com/role/NotesAndLoansPayableTables</Role>
      <ShortName>Notes and Loans Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celsion.com/role/NotesAndLoansPayable</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celsion.com/role/Stock-basedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Earn-out Milestone Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Earn-outMilestoneLiabilityTables</Role>
      <ShortName>Earn-out Milestone Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celsion.com/role/Earn-outMilestoneLiability</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celsion.com/role/Warrants</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celsion.com/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Financial Condition and Business Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/FinancialConditionAndBusinessPlanDetailsNarrative</Role>
      <ShortName>Financial Condition and Business Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/FinancialConditionAndBusinessPlan</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Net Loss Per Common Share (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/NetLossPerCommonShareDetailsNarrative</Role>
      <ShortName>Net Loss Per Common Share (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/NetLossPerCommonShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Investment in Debt Securities Available for Sale (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleDetailsNarrative</Role>
      <ShortName>Investment in Debt Securities Available for Sale (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSaleTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Investment in Debt Securities Available for Sale - Schedule of Cost, Fair Value and Maturities of Short Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-ScheduleOfCostFairValueAndMaturitiesOfShortTermInvestmentsDetails</Role>
      <ShortName>Investment in Debt Securities Available for Sale - Schedule of Cost, Fair Value and Maturities of Short Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Investment in Debt Securities Available for Sale - Summary of Investment Securities Gross Unrealized Gains (Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfInvestmentSecuritiesGrossUnrealizedGainsLossesDetails</Role>
      <ShortName>Investment in Debt Securities Available for Sale - Summary of Investment Securities Gross Unrealized Gains (Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Investment in Debt Securities Available for Sale - Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/InvestmentInDebtSecuritiesAvailableForSale-SummaryOfNetRealizedLossesOnSalesOfAvailableForSaleSecuritiesAndInvestmentIncomeInterestAndDividendsDetails</Role>
      <ShortName>Investment in Debt Securities Available for Sale - Summary of Net Realized Losses On Sales of Available for Sale Securities and Investment Income Interest and Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/FairValueMeasurements-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/IntangibleAssetsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Intangible Assets - Schedule of Future Amortization Amounts During the Remaining Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/IntangibleAssets-ScheduleOfFutureAmortizationAmountsDuringRemainingLifeDetails</Role>
      <ShortName>Intangible Assets - Schedule of Future Amortization Amounts During the Remaining Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Intangible Assets - Schedule of Fair Value of Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/IntangibleAssets-ScheduleOfFairValueOfAssetsAcquiredDetails</Role>
      <ShortName>Intangible Assets - Schedule of Fair Value of Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Other Accrued Liabilities - Schedule of Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/OtherAccruedLiabilities-ScheduleOfOtherAccruedLiabilitiesDetails</Role>
      <ShortName>Other Accrued Liabilities - Schedule of Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Notes and Loans Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://celsion.com/role/NotesAndLoansPayableDetailsNarrative</Role>
      <ShortName>Notes and Loans Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/NotesAndLoansPayableTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Notes and Loans Payable - Schedule of Future Principle Payments, Net of Unamortized Debt Discounts (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://celsion.com/role/NotesAndLoansPayable-ScheduleOfFuturePrinciplePaymentsNetOfUnamortizedDebtDiscountsDetails</Role>
      <ShortName>Notes and Loans Payable - Schedule of Future Principle Payments, Net of Unamortized Debt Discounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Stockholders' Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders' Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/StockholdersEquity</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Stock-Based Compensation - Summary of Stock Option and Restricted Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Stock-basedCompensation-SummaryOfStockOptionAndRestrictedStockAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option and Restricted Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Stock-basedCompensation-ScheduleOfAssumptionsUsedToDetermineFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Earn-out Milestone Liability (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Earn-outMilestoneLiabilityDetailsNarrative</Role>
      <ShortName>Earn-out Milestone Liability (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/Earn-outMilestoneLiabilityTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Earn-out Milestone Liability - Schedule of Changes in Earn-out Milestone Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfChangesInEarn-outMilestoneLiabilityDetails</Role>
      <ShortName>Earn-out Milestone Liability - Schedule of Changes in Earn-out Milestone Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Earn-out Milestone Liability - Schedule of Risk Adjustment Assessment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Earn-outMilestoneLiability-ScheduleOfRiskAdjustmentAssessmentDetails</Role>
      <ShortName>Earn-out Milestone Liability - Schedule of Risk Adjustment Assessment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Warrants - Summary of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Warrants-SummaryOfWarrantActivityDetails</Role>
      <ShortName>Warrants - Summary of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Warrants - Schedule of Weighted Average Remaining Contractual Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Warrants-ScheduleOfWeightedAverageRemainingContractualTermsDetails</Role>
      <ShortName>Warrants - Schedule of Weighted Average Remaining Contractual Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/LeasesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Leases - Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/Leases-ScheduleOfLeasePaymentsAndMaturityOfOurOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Lease Payments and Maturity of Our Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Technology Development and Licensing Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreementsDetailsNarrative</Role>
      <ShortName>Technology Development and Licensing Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/TechnologyDevelopmentAndLicensingAgreements</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="clsn-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celsion.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celsion.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>clsn-20200630.xml</File>
    <File>clsn-20200630.xsd</File>
    <File>clsn-20200630_cal.xml</File>
    <File>clsn-20200630_def.xml</File>
    <File>clsn-20200630_lab.xml</File>
    <File>clsn-20200630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001493152-20-015690-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-20-015690-xbrl.zip
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MS7&$F8^S?__>)T=3S</Q$FFF:&,7&CL;8Z <ULG>-SN6>U=;B0@<)/VI1:=
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M[T29(I)1T[^5P&5>X(M K5<ZI1296K(3"SP684\BOA=Q8PUG/?IJU?O(2K9
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MQR5Y3!*M)*E@BK-K!D[9^T>IZ*!-G&"SL"Q<)L@M!>B2(4ITYP,Y28&J&+A
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M!&*"?99*QB#R71O;BI4 ]@$\/?=E,,*&1B5 ?S)Q9(,OT<Y0*!?! *L'GJN
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MT.W3#:7OIO\'V@W,[MY8L#C*M6@O]5ZQ@\;;;]CQPZB\TXS:*:,>X=?V +@
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MS7;M(&35S'EE[&"M7 -OL+5CYF3H_T$SJFNF,1;UR+@;S/_\U7MT61G'729
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M6_!.S7I6X6E4371*G4ZS5&]M*IY%OQS9RP#M$,DP1R2E[LUI?\2 D_>^%XK
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M"R9,*([0PQEH+-LR7(]7XX#4&$B+^-4)[HCC"TD+?8<4IY3-Q&<AO178CZB
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M@%3$QS 5"EJ.15[ $KD/B>'*+PE/\.%?FITJ'=C((G*AKC:Y4,_MZ?AEEK?
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M(>JK E'32<UJDF(6U!BE:@^_@!W(LI/V_(X]MD-1P1" #S7P?&[:?&8#L=.
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M+6 U-_U(6DHGI)5\778F=,Y"/N4M ;9E 9GQ\E_PA^D[,5Y<2)8XT]/G+OM
M!/Z%2I9F>%*<9&'&3Z1K29$ K&-GG;1I]1<&6EG_6!IE<!^1%I8)#M?(GW\B
MP7*6HG+%="E-\_<.'IA(6($]%Z"1X^+S7IS&CZZ3"C.D$#^0O<,9KW2FB$GP
M A@JCE+H@VF6K/-&=?Z0UZ$+ @8V^IVOO%Z(N?811D"N#S#2DE#RC80S-Z+Y
M091(W&\*#6E$Z0AP/*@;4N5**P 3EJ=K88@&H.</+3S6,P<[] R?6^!S/D8
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M2)5\) Q/_B&Z,S,U 5+<F@4GZ,]?B3MR'DM9VKZ/P0%9>RF?".'7EN:)"3I
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M@8>@J>LT67H_=/6:K_U(9,E^(7G/,XMZ ,H-ND@G-N@:S9^3[-,>W'EJ4/4
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M[S1].,*5//S!DQTI"VP [Q)GJ-S" @(^.!%=,*"\A,LO[+^(8BO?64,U^;X
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MX2,-!WCL!_!BA @7,T4B)N#X3SDE<&B!V *?S01ADT?8"M+M42@*KBU1&%1
M>L\TY822*$4!80*)"U(Q*V-!;1L%M9.78$S 0.F&;@_R;^[ZE)?Y02D4\&N'
MH$M&!<(<S0U)3[$2)GY*^!=\F^LDL6Q>$C'Q-)_CHP>^%XFGCXC0RGG\AT.
M18)E,D9I;L\2%O_,9H>Q%UU!P;BOMW)(,OD%"!!8CCR]4QZ")U@M1(% !!DA
MEL3X-(0&=@9N8F>T$^A1Z+L.$80IC5RC;:ES7T$YNJ"C'XEH7;TN]J)BB9V0
M08)H$,L4M8*+ A_\'U8*-@,_'5F!*5<! 0Z) [($F'UD5AP@A^2'0-.X0;2B
M9I//@JG\7TRKLO$X"Y(2C&R]\IMB,&?L0&VZ+C]3G,$Z2!H1Q7MB#\GL@)V^
MZ=B>B"SM$$6+ERIY(<;S.V8&,:7HXH# CFP'5*;TCK-BFC^RL6MB8C(5\NM7
M\YP!1=X9Z VO);\&4Z^PSA;]@&(<!'<Z( @N$A1!;B24MFDDU"NQO7,UDNR)
MF9M##*5BKE*"<U"*JQ!'!''1L.T.[/49>Z?BR7:?U:M&GEY'4=L')F$WQE[V
M!PD=MDEH/E0/H)&KB K!:9U^]OX66F4FUA<:_':8G7,:A57T5CHV!I8^?L'O
M?W#MAWK_:N$U -2J53H-^1B>K. ZFK_ '>XZS(%9>D#24?"&<;27H1O&0-/*
MBJX^:+!FA8UP62,Q'!6\ICDH_XIB^Q46*9YUC**^</+7U5T<Q+:GS%?@OJTY
M=\?*X]K ! -%,\UCY_)WBOBQ1^9Q+G%T%Q;P;1Q?/U;LH0$8GT3QB?=WH>VM
MKDT'4Z.L]=>.E#[V@:^W5(JLA7IZ3&T=^%9=4J4V,$;&0#]5>W>E5OJ0VMUU
MCXM\WE]:\N*Y\],DYMV)S\-J8QE.3/@:F+!BXX(\$SIBSF;8?,[F*^E8,!VV
MV:R@Q(:;FQ 7$-V+'S?-GU%XKA)MC40C#)'[C?^+)[Y1.-@K1_:Y;SV'!Y,L
M?/YV_)T&GS.G)GN,U<?:0)NJV8?8-/5K:;M.8=*52$MP1!)E^H$T9TSLIPU&
MIB[VTP?J9)1[^%5*'UI9/[!XK-_CH96U [-D#NG0VF0PTMA^8%<.S(FY\;'[
M;S^62[C.=(7^Z,[@=/"A6\R\M&EB1(]3L\=#Y9;,'GS0 O?/RF6:!4,QE!R&
MHO$\232B.'I%>=S7OO+)?E8L2M9Z-B^#OBRR6$.@V!00+P"9BWDB++LMG&&N
M5[1:+I&:!1)9MLS_>R#_<FT@UG^XT<I7;A[L<&'/R(HE85T$0^5C[ R5M_37
M/R39,LLP<%8SD1F$&2.+X#+XAAC@B38<5=:(H4K\E$L%>H 'U[<QFR=TXR!\
M9CEFN619RONT-H8G0B3@#SC$3Z[GL93;:(F9.)A @%"RDFF:+(95OG.^%) :
MGBS)H C)_<JS<7^*H" $C43"1Z"[:,#96F0XLPPYWK(Z68EE.,\QW0K6<J.8
MU;Y0\KUS _+OE?MH>YAA")0!B^&Z63#$ FR#@7)!O A7P,2BE1?;- ]1 ,>
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M/ Z57T(;T\X 6&\X4"Z!D.#OGX.A\NG]E[.+,Q!MZGARIDW7P"ASJ^N?0:>
MW&/CUY#8//L\>9IPUHX#X,*5."MP:>&:G!7K&<LS$-E:7)4G2B]=1 FHKJ0M
MKQ<VJ'1W@0\S!(UNL#%X8^H'XH,2('\E*5SRM0L[DW,4L-Y$^8K<AF,6T?X#
M&KSQ;'_C<7%E;&E,<YT"GOR*&9,#6I;CV L;L1$!P]M)[]ZL<<!484BG&@A
MBC'%<.LH3Z")[AU4W0/*34">(3-0_[5R[IGFY@2-/IJ$,=>'TV)7>[G^8..I
MN3+%Y=D['\"*2:810W=J7=$/\[6IL31SZ6P1_J*6!"? 0+D/PGM>QF5S;8ZQ
M=O$KD2Z-[F2<;"=>G[G=4L@A$C@;#\0 LF/ E4^>9=RR=P[">XK3./50^1W8
M+%AA1! )38!&3\E;[R)*^)4!EEP<71J!Q2&-&EBGF8'"6ZTGG9<9/_-:4'$M
M(8D#!B_YA@,,(@][0/O/PO.6F0/'"$HT,;>!E ;I^G1'1HH;Y7X6KQ0(";=
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M0+$6]+T$Q0K41R4XAKQ7LW!UR L.P0=Z1\>]-\<*/&:]F>LN4Y2IR^X%Z:1
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MP:U+=AM3;\XG5.G]<T5)ZHNM<SY<N12[6OWKBZQS_#./2F/>[9R*;J)&XYN
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MSG$W#\VVB/1T>S2I;CM*QSPMQSFY[7V%);4I#-A"S62-7IM!]33Y:EI-ZDK
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MRFL]5G*4A*U(CI2\^.I;$81?U/EIPD.P60KO] GO0U'-MIJFDZ[+.(4I@,=
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M55ZM+&<N43K^@4E/^.;_ %!+ P04    " "!10Y1KRTA' PO  "T%@, %0
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M#T2P1_':$%1565M.7;615C!LJ=$#'LX:I]9M1YK?D(^H[3'\(W?!.!RGIGU
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M:FB!Q$%2<*!S']5;1VV%+/##=E+\,B=LRP6.?.(RXD)Y G;[--I O@9^3;B
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M17M#-6UW[O42;';5WL8:V'\P+!L<7 _,\)RNC_80C7,28"7 FU_!*0S7;_X
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M:X#W;D?K'E<(Y&FU^*%+)&J'@*F/"ZG9;TY6[X5+)BD331Y ]BSHN+U>G-'
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MUGMKM@?J+-BL)__ETR_!0V!M"&MMJ@Z=H9;- 8.*W+] XH [ZF9U1!=/CA]
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M$KEC]^(YF^.V2+-#>HE/S]F:?=WD6^(J0XXB2,C.T^C1S@'+D@4GB\F<<NR
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M.EG[./(?(W1)DGL_4M*J/](PFNKCA&_=/B,_S1,8Z-). \F5;KCFF#(]25/
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M(]1031Y3;IRJ\2+_$47\*[_2-HTF;PY&6R&7.S3'[-MQQC(-NDGL;MFDM*X
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M,)+S[P9,O#80= 9U-H9"8^QDK V-A&<W0.G.Z']1XJ/J!X7*V+%8&RJ8)-Q
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MO-5"5H]L;Y=1RLY)_IA-'DF>?2+L/3,2!RB!3':=,2Q/\D'UH57U2E>4]NW
M#7JJV;V$Q/3' .WF$^]8@'=-"T!'\+9#>(TQ7%B8RQQ/]N9)DI#DC-"C"J]>
MH;540T:Q^C;Y9A&:SB2HWI#L'RB;A&25R2Z]>@[GS!(.Q[SU)/D><G1A/F?L
MWN:6W^BP&UMV@.^>R>_;,SGS6&>/]O:*[E[1WV):71G#34GBI*AGK+B'S>S
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M<2 JM-Y41EGG$>$$XL>-*-JN!7!#J"HX%M39#=PT]%,$IHQ))\):.S<SFYV
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M['\>_131W_Q_4$L! A0#%     @ @44.49;(!R)BRP  /N,) !$
M     ( !     &-L<VXM,C R,# V,S N>&UL4$L! A0#%     @ @44.499=
M.B)^&   @PL! !$              ( !D<L  &-L<VXM,C R,# V,S N>'-D
M4$L! A0#%     @ @44.46U94->Q%P  Q!X! !4              ( !/N0
M &-L<VXM,C R,# V,S!?8V%L+GAM;%!+ 0(4 Q0    ( (%%#E&O+2$<#"\
M +06 P 5              "  2+\  !C;'-N+3(P,C P-C,P7V1E9BYX;6Q0
M2P$"% ,4    " "!10Y1"K8G,/)V  "#G08 %0              @ %A*P$
M8VQS;BTR,#(P,#8S,%]L86(N>&UL4$L! A0#%     @ @44.40@/9KQ61@
MH9L$ !4              ( !AJ(! &-L<VXM,C R,# V,S!?<')E+GAM;%!+
4!08     !@ & (H!   /Z0$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
